0001437749-21-020980.txt : 20210825 0001437749-21-020980.hdr.sgml : 20210825 20210825164635 ACCESSION NUMBER: 0001437749-21-020980 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210825 DATE AS OF CHANGE: 20210825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 211207471 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 10-K 1 tech20200630b_10k.htm FORM 10-K tech20210630_10k.htm
0000842023 BIO-TECHNE Corp false --06-30 FY 2021 1,229 775 0 0 5,000,000 5,000,000 0 0 0 0 0.01 0.01 100,000,000 100,000,000 38,955,484 38,955,484 38,453,046 38,453,046 57.4 15 5 1.28 1.28 279,381 0.6 10 3 1.4 2,239 0 0 0 0 Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired. Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5. Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2021 and June 30, 2020 was $6.6 million and $6.6 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.4 million as of June 30, 2021. The fair value of the warrant as of June 30, 2020 was $8.0 million Total cash paid for the Company's operating leases during the year ended June 30, 2021 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity. Finished goods inventory of $5,456 and $4,646 is included within other long-term assets in the June 30, 2021 and June 30, 2020 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date. Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year. Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company had deferred tax benefits of $1,908 and $4,058 included in the accumulated other comprehensive income loss as of June 30, 2021 and June 30, 2020, respectively. Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence. $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021. The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded. 00008420232020-07-012021-06-30 iso4217:USD 00008420232020-12-31 xbrli:shares 00008420232021-08-20 thunderdome:item 00008420232019-07-012020-06-30 00008420232018-07-012019-06-30 iso4217:USDxbrli:shares 00008420232021-06-30 00008420232020-06-30 0000842023us-gaap:CommonStockMember2018-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2018-06-30 0000842023us-gaap:RetainedEarningsMember2018-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 0000842023us-gaap:NoncontrollingInterestMember2018-06-30 00008420232018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:CommonStockMember2018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:NoncontrollingInterestMember2018-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-06-30 0000842023us-gaap:CommonStockMember2018-07-012019-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2018-07-012019-06-30 0000842023us-gaap:RetainedEarningsMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-07-012019-06-30 0000842023us-gaap:NoncontrollingInterestMember2018-07-012019-06-30 0000842023us-gaap:CommonStockMember2019-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2019-06-30 0000842023us-gaap:RetainedEarningsMember2019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30 0000842023us-gaap:NoncontrollingInterestMember2019-06-30 00008420232019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:CommonStockMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:NoncontrollingInterestMember2019-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-06-30 0000842023us-gaap:CommonStockMember2019-07-012020-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2019-07-012020-06-30 0000842023us-gaap:RetainedEarningsMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012020-06-30 0000842023us-gaap:NoncontrollingInterestMember2019-07-012020-06-30 0000842023us-gaap:CommonStockMember2020-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2020-06-30 0000842023us-gaap:RetainedEarningsMember2020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 0000842023us-gaap:NoncontrollingInterestMember2020-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:CommonStockMember2020-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2020-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2020-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:NoncontrollingInterestMember2020-06-30 0000842023srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-06-30 0000842023us-gaap:CommonStockMember2020-07-012021-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2020-07-012021-06-30 0000842023us-gaap:RetainedEarningsMember2020-07-012021-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012021-06-30 0000842023us-gaap:NoncontrollingInterestMember2020-07-012021-06-30 0000842023us-gaap:CommonStockMember2021-06-30 0000842023us-gaap:AdditionalPaidInCapitalMember2021-06-30 0000842023us-gaap:RetainedEarningsMember2021-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-30 0000842023us-gaap:NoncontrollingInterestMember2021-06-30 utr:Y 0000842023us-gaap:EquipmentMembersrt:MinimumMember2020-07-012021-06-30 0000842023us-gaap:EquipmentMembersrt:MaximumMember2020-07-012021-06-30 0000842023tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMembersrt:MinimumMember2020-07-012021-06-30 0000842023tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMembersrt:MaximumMember2020-07-012021-06-30 0000842023srt:MinimumMember2020-07-012021-06-30 0000842023srt:MaximumMember2020-07-012021-06-30 0000842023us-gaap:TradeNamesMember2020-07-012021-06-30 0000842023us-gaap:TradeNamesMember2021-06-30 0000842023us-gaap:TradeNamesMember2019-07-012020-06-30 0000842023us-gaap:TradeNamesMember2020-06-30 0000842023us-gaap:AccountingStandardsUpdate201602Member2019-07-01 0000842023us-gaap:AccountingStandardsUpdate201613Member2020-07-01 0000842023tech:ConsumablesMember2020-07-012021-06-30 0000842023tech:ConsumablesMember2019-07-012020-06-30 0000842023tech:ConsumablesMember2018-07-012019-06-30 0000842023tech:InstrumentsMember2020-07-012021-06-30 0000842023tech:InstrumentsMember2019-07-012020-06-30 0000842023tech:InstrumentsMember2018-07-012019-06-30 0000842023us-gaap:ServiceMember2020-07-012021-06-30 0000842023us-gaap:ServiceMember2019-07-012020-06-30 0000842023us-gaap:ServiceMember2018-07-012019-06-30 0000842023tech:ProductAndServicesMember2020-07-012021-06-30 0000842023tech:ProductAndServicesMember2019-07-012020-06-30 0000842023tech:ProductAndServicesMember2018-07-012019-06-30 0000842023us-gaap:RoyaltyMember2020-07-012021-06-30 0000842023us-gaap:RoyaltyMember2019-07-012020-06-30 0000842023us-gaap:RoyaltyMember2018-07-012019-06-30 0000842023country:US2020-07-012021-06-30 0000842023country:US2019-07-012020-06-30 0000842023country:US2018-07-012019-06-30 0000842023tech:EMEAExcludingUKMember2020-07-012021-06-30 0000842023tech:EMEAExcludingUKMember2019-07-012020-06-30 0000842023tech:EMEAExcludingUKMember2018-07-012019-06-30 0000842023country:GB2020-07-012021-06-30 0000842023country:GB2019-07-012020-06-30 0000842023country:GB2018-07-012019-06-30 0000842023tech:APACExcludingGreaterChinaMember2020-07-012021-06-30 0000842023tech:APACExcludingGreaterChinaMember2019-07-012020-06-30 0000842023tech:APACExcludingGreaterChinaMember2018-07-012019-06-30 0000842023country:CN2020-07-012021-06-30 0000842023country:CN2019-07-012020-06-30 0000842023country:CN2018-07-012019-06-30 0000842023tech:RestOfWorldMember2020-07-012021-06-30 0000842023tech:RestOfWorldMember2019-07-012020-06-30 0000842023tech:RestOfWorldMember2018-07-012019-06-30 0000842023tech:ChemoCentryxIncCCXIMember2021-06-30 0000842023tech:ChemoCentryxIncCCXIMember2020-06-30 0000842023tech:ChemoCentryxIncCCXIMember2021-06-30 0000842023tech:ChemoCentryxIncCCXIMember2020-06-30 0000842023us-gaap:OtherNoncurrentAssetsMember2021-06-30 0000842023us-gaap:OtherNoncurrentAssetsMember2020-06-30 0000842023us-gaap:LandMember2021-06-30 0000842023us-gaap:LandMember2020-06-30 0000842023us-gaap:BuildingAndBuildingImprovementsMember2021-06-30 0000842023us-gaap:BuildingAndBuildingImprovementsMember2020-06-30 0000842023us-gaap:MachineryAndEquipmentMember2021-06-30 0000842023us-gaap:MachineryAndEquipmentMember2020-06-30 0000842023us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2020-07-012021-06-30 0000842023us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2020-07-012021-06-30 0000842023us-gaap:DevelopedTechnologyRightsMember2021-06-30 0000842023us-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023us-gaap:TradeNamesMembersrt:MinimumMember2020-07-012021-06-30 0000842023us-gaap:TradeNamesMembersrt:MaximumMember2020-07-012021-06-30 0000842023us-gaap:CustomerRelationshipsMembersrt:MinimumMember2020-07-012021-06-30 0000842023us-gaap:CustomerRelationshipsMembersrt:MaximumMember2020-07-012021-06-30 0000842023us-gaap:CustomerRelationshipsMember2021-06-30 0000842023us-gaap:CustomerRelationshipsMember2020-06-30 0000842023us-gaap:PatentsMember2020-07-012021-06-30 0000842023us-gaap:PatentsMember2021-06-30 0000842023us-gaap:PatentsMember2020-06-30 0000842023us-gaap:OtherIntangibleAssetsMembersrt:MinimumMember2020-07-012021-06-30 0000842023us-gaap:OtherIntangibleAssetsMembersrt:MaximumMember2020-07-012021-06-30 0000842023us-gaap:OtherIntangibleAssetsMember2021-06-30 0000842023us-gaap:OtherIntangibleAssetsMember2020-06-30 0000842023us-gaap:InProcessResearchAndDevelopmentMember2021-06-30 0000842023us-gaap:InProcessResearchAndDevelopmentMember2020-06-30 0000842023us-gaap:PatentedTechnologyMember2020-07-012020-09-30 0000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2020-07-012021-06-30 0000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2019-07-012020-06-30 0000842023us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2018-07-012019-06-30 0000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012021-06-30 0000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012020-06-30 0000842023tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2018-07-012019-06-30 0000842023tech:ProteinSciencesMember2019-06-30 0000842023tech:DiagnosticsAndGenomicsMember2019-06-30 0000842023tech:ProteinSciencesMember2019-07-012020-06-30 0000842023tech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023tech:ProteinSciencesMember2020-06-30 0000842023tech:DiagnosticsAndGenomicsMember2020-06-30 0000842023tech:ProteinSciencesMember2020-07-012021-06-30 0000842023tech:DiagnosticsAndGenomicsMember2020-07-012021-06-30 0000842023tech:ProteinSciencesMember2021-06-30 0000842023tech:DiagnosticsAndGenomicsMember2021-06-30 0000842023us-gaap:PatentedTechnologyMember2020-07-012021-06-30 xbrli:pure 0000842023tech:ChangzhouEminenceBiotechnologyMember2020-10-20 0000842023tech:ChangzhouEminenceBiotechnologyMember2020-10-202020-10-20 0000842023tech:ChangzhouEminenceBiotechnologyMember2021-04-022021-04-02 0000842023tech:ChangzhouEminenceBiotechnologyMember2021-04-02 0000842023tech:ChangzhouEminenceBiotechnologyMember2021-06-30 0000842023tech:ChangzhouEminenceBiotechnologyMemberus-gaap:DevelopedTechnologyRightsMember2020-10-20 0000842023tech:ChangzhouEminenceBiotechnologyMemberus-gaap:DevelopedTechnologyRightsMember2021-06-30 0000842023tech:ChangzhouEminenceBiotechnologyMemberus-gaap:CustomerRelationshipsMember2020-10-20 0000842023tech:ChangzhouEminenceBiotechnologyMemberus-gaap:CustomerRelationshipsMember2021-06-30 0000842023tech:ChangzhouEminenceBiotechnologyMember2020-10-212021-06-30 0000842023tech:ChangzhouEminenceBiotechnologyMemberus-gaap:DevelopedTechnologyRightsMember2020-10-202020-10-20 0000842023tech:ChangzhouEminenceBiotechnologyMemberus-gaap:CustomerRelationshipsMember2020-10-202020-10-20 0000842023tech:AcquisitionOfAsuragenIncMember2021-04-062021-04-06 0000842023tech:AcquisitionOfAsuragenIncMember2021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:DevelopedTechnologyRightsMember2021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:InProcessResearchAndDevelopmentMember2021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:CustomerRelationshipsMember2021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:TradeNamesMember2021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:NoncompeteAgreementsMember2021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:DevelopedTechnologyRightsMember2021-04-062021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:CustomerRelationshipsMember2021-04-062021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:TradeNamesMember2021-04-062021-04-06 0000842023tech:AcquisitionOfAsuragenIncMemberus-gaap:NoncompeteAgreementsMember2021-04-062021-04-06 0000842023tech:QTHoldingsCorporationMember2018-07-022018-07-02 0000842023tech:QTHoldingsCorporationMember2018-07-02 0000842023tech:QTHoldingsCorporationMemberus-gaap:DevelopedTechnologyRightsMember2018-07-022018-07-02 0000842023tech:ExosomeDiagnosticsIncMember2018-08-012018-08-01 0000842023tech:ExosomeDiagnosticsIncMember2018-08-01 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:DevelopedTechnologyRightsMember2018-08-012018-08-01 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:TradeNamesMember2018-08-012018-08-01 0000842023tech:BMoGenMember2018-08-012018-08-01 0000842023tech:BMoGenMember2019-06-042019-06-04 0000842023tech:BMoGenMember2019-06-04 0000842023tech:BMoGenMember2019-07-012020-06-30 0000842023tech:BMoGenMemberus-gaap:DevelopedTechnologyRightsMember2019-06-042019-06-04 0000842023tech:BMoGenMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMember2020-06-30 0000842023tech:QTHoldingsCorporationMember2020-06-30 0000842023tech:BMoGenMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:QTHoldingsCorporationMemberus-gaap:DevelopedTechnologyRightsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:TradeNamesMember2020-06-30 0000842023tech:BMoGenMemberus-gaap:CustomerRelationshipsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMemberus-gaap:CustomerRelationshipsMember2020-06-30 0000842023tech:ExosomeDiagnosticsIncMember2019-07-012020-06-30 0000842023tech:QTHoldingsCorporationMember2019-07-012020-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023us-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-06-30 0000842023tech:CCXIMember2021-06-30 0000842023tech:CCXIMember2020-06-30 0000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2018-10-31 0000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2020-10-012020-10-31 0000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMembersrt:ScenarioForecastMember2021-10-012021-10-31 0000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMembersrt:ScenarioForecastMember2022-10-012022-10-31 0000842023us-gaap:OtherNoncurrentLiabilitiesMembertech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2020-06-30 0000842023us-gaap:OtherNoncurrentLiabilitiesMembertech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2020-12-31 0000842023us-gaap:OtherCurrentLiabilitiesMembertech:ForwardStartingSwapMemberus-gaap:NondesignatedMember2021-06-30 0000842023us-gaap:OtherNoncurrentLiabilitiesMembertech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2021-06-30 0000842023tech:NewForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2021-05-31 0000842023us-gaap:OtherNoncurrentAssetsMembertech:NewForwardStartingSwapMemberus-gaap:CashFlowHedgingMember2021-06-30 0000842023us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012021-06-30 0000842023us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012020-06-30 0000842023tech:AcquisitionOfAsuragenIncMember2021-06-30 0000842023tech:QTHoldingsCorporationMember2021-06-30 0000842023tech:BMoGenMember2021-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2020-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2019-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2020-07-012021-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2019-07-012020-06-30 0000842023us-gaap:FairValueInputsLevel3Membertech:ContingentConsiderationMember2021-06-30 0000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2018-08-01 0000842023tech:CreditAgreementMembertech:TermLoanMember2018-08-01 0000842023us-gaap:RevolvingCreditFacilityMembertech:CreditAgreementMember2018-08-012018-08-01 0000842023tech:CreditAgreementMembertech:TermLoanMember2018-08-012018-08-01 0000842023tech:CreditAgreementMember2021-06-30 0000842023tech:CreditAgreementMember2020-06-30 utr:sqft 0000842023srt:MaximumMember2021-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2018-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedTranslationAdjustmentMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201802Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedTranslationAdjustmentMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-30 0000842023us-gaap:AccountingStandardsUpdate201601Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2018-07-012019-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2019-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2019-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2019-07-012020-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2020-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2020-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-07-012021-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012021-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2020-07-012021-06-30 0000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-06-30 0000842023us-gaap:AccumulatedTranslationAdjustmentMember2021-06-30 0000842023us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2021-06-30 0000842023us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012021-06-30 0000842023tech:ChangzhouEminenceBiotechnologyMember2020-07-012021-06-30 0000842023tech:EquityIncentivePlan2010Member2010-06-30 0000842023tech:The2020EquityIncentivePlanMember2020-10-31 0000842023tech:The2020EquityIncentivePlanMember2020-10-012020-10-31 0000842023tech:The2020EquityIncentivePlanMember2021-06-30 0000842023tech:The2020EquityIncentivePlanMembersrt:MaximumMember2009-07-012010-06-30 0000842023srt:MinimumMember2019-07-012020-06-30 0000842023srt:MaximumMember2019-07-012020-06-30 0000842023srt:MinimumMember2018-07-012019-06-30 0000842023srt:MaximumMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockMember2018-06-30 0000842023us-gaap:RestrictedStockMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockMember2019-06-30 0000842023us-gaap:RestrictedStockMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockMember2020-06-30 0000842023us-gaap:RestrictedStockMember2020-07-012021-06-30 0000842023us-gaap:RestrictedStockMember2021-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2018-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2019-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2020-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2020-07-012021-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2021-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMember2017-07-012018-06-30 0000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012021-06-30 0000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012020-06-30 0000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-07-012019-06-30 0000842023us-gaap:CostOfSalesMember2019-07-012020-06-30 0000842023tech:EmployeeStockPurchasePlan2014Member2014-10-30 0000842023tech:EmployeeStockPurchasePlan2014Member2020-07-012021-06-30 0000842023tech:EmployeeStockPurchasePlan2014Member2019-07-012020-06-30 0000842023tech:EmployeeStockPurchasePlan2014Member2018-07-012019-06-30 0000842023tech:USProfitSharingAndSavingsPlanMember2020-07-012021-06-30 0000842023tech:USProfitSharingAndSavingsPlanMember2019-07-012020-06-30 0000842023tech:USProfitSharingAndSavingsPlanMember2018-07-012019-06-30 0000842023tech:GBProfitSharingAndSavingsPlanMember2020-07-012021-06-30 0000842023tech:GBProfitSharingAndSavingsPlanMember2019-07-012020-06-30 0000842023tech:GBProfitSharingAndSavingsPlanMember2018-07-012019-06-30 0000842023tech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2020-07-012021-06-30 0000842023us-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2020-07-012021-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2020-07-012021-06-30 0000842023tech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2019-07-012020-06-30 0000842023tech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2018-07-012019-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2019-07-012020-06-30 0000842023us-gaap:RestrictedStockUnitsRSUMembertech:PerformanceIncentiveProgramsMembersrt:ExecutiveOfficerMember2018-07-012019-06-30 0000842023us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-06-30 0000842023us-gaap:StateAndLocalJurisdictionMember2021-06-30 0000842023us-gaap:ForeignCountryMember2021-06-30 0000842023tech:OperatingLossCarryforwardsMember2021-06-30 0000842023tech:TaxCreditCarryforwardsMember2021-06-30 00008420232017-06-30 00008420232017-07-012018-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:ProteinSciencesMember2020-07-012021-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:ProteinSciencesMember2019-07-012020-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:ProteinSciencesMember2018-07-012019-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:DiagnosticsAndGenomicsMember2020-07-012021-06-30 0000842023us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMembertech:DiagnosticsAndGenomicsMember2018-07-012019-06-30 0000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2020-07-012021-06-30 0000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2019-07-012020-06-30 0000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2018-07-012019-06-30 0000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2020-07-012021-06-30 0000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndGenomicsMember2018-07-012019-06-30 0000842023us-gaap:IntersegmentEliminationMember2020-07-012021-06-30 0000842023us-gaap:IntersegmentEliminationMember2019-07-012020-06-30 0000842023us-gaap:IntersegmentEliminationMember2018-07-012019-06-30 0000842023us-gaap:OperatingSegmentsMember2020-07-012021-06-30 0000842023us-gaap:OperatingSegmentsMember2019-07-012020-06-30 0000842023us-gaap:OperatingSegmentsMember2018-07-012019-06-30 0000842023us-gaap:CorporateNonSegmentMember2020-07-012021-06-30 0000842023us-gaap:CorporateNonSegmentMember2019-07-012020-06-30 0000842023us-gaap:CorporateNonSegmentMember2018-07-012019-06-30 0000842023tech:ConsumablesMembertech:ProteinSciencesMember2020-07-012021-06-30 0000842023tech:ConsumablesMembertech:ProteinSciencesMember2019-07-012020-06-30 0000842023tech:ConsumablesMembertech:ProteinSciencesMember2018-07-012019-06-30 0000842023tech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2020-07-012021-06-30 0000842023tech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2019-07-012020-06-30 0000842023tech:ConsumablesMembertech:DiagnosticsAndGenomicsMember2018-07-012019-06-30 0000842023tech:UnitedStatesAndCanadaMember2021-06-30 0000842023tech:UnitedStatesAndCanadaMember2020-06-30 0000842023srt:EuropeMember2021-06-30 0000842023srt:EuropeMember2020-06-30 0000842023srt:AsiaMember2021-06-30 0000842023srt:AsiaMember2020-06-30
 
 
 
 

 

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 10-K

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended June 30, 2021, or

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period

from                      to                    

 

Commission file number 0-17272

 

 

 

BIO-TECHNE CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Minnesota

 

41-1427402

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

  

614 McKinley Place N.E.

Minneapolis, MN 55413

 

(612) 379-8854

(Address of principal executive offices) (Zip Code)

 

(Registrant's telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

TECH

The NASDAQ Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ☒  No ☐

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   Yes ☐  No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒  No ☐

 

1
Table of Contents

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

 Large accelerated filer

☒

Accelerated filer

☐

    

 Non-accelerated filer

☐

Smaller reporting company

☐

    
  

Emerging growth company

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes ☐  No ☒

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☒  No ☐

 

As of December 31, 2020 the aggregate market value of the Common Stock held by non-affiliates of the Registrant was $12.4 billion based upon the closing sale price as reported on The Nasdaq Stock Market ($317.55 per share). Shares of Common Stock held by each officer and director and by each person who owns 5% or more of the outstanding Common Stock have been excluded.

 

As of August 20, 2021, 39,079,539 shares of the Company’s Common Stock ($0.01 par value) were outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the Company’s Proxy Statement for its 2021 Annual Meeting of Shareholders are incorporated by reference into Part III.

 

 

2
Table of Contents

 

 

TABLE OF CONTENTS

 

   

Page

PART I
     

Item 1.

Business

1
     

Item 1A.

Risk Factors

9
     

Item 1B.

Unresolved Staff Comments

17
     

Item 2.

Properties

17
     

Item 3.

Legal Proceedings

17
     

Item 4.

Mine Safety Disclosures

17
     

PART II
     

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

18
     

Item 6.

Selected Financial Data

20
     

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

21
     

Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

33
     

Item 8.

Financial Statements and Supplementary Data

34
     

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

69
     

Item 9A.

Controls and Procedures

69
     

Item 9B.

Other Information

70
     

PART III
     

Item 10.

Directors, Executive Officers

71
     

Item 11.

Executive Compensation

71
     

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

71
     

Item 13.

Certain Relationships and Related Transactions, and Director Independence

71
     

Item 14.

Principal Accounting Fees and Services

71
     

PART IV
 

Item 15.

Exhibits, Financial Statement Schedules

72
     
 

SIGNATURES

74

 

3
 

 

In this Annual Report, the terms “Bio-Techne” or the “Company” refer to Bio-Techne Corporation, Bio-Techne Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Bio-Techne Corporation, as the context requires.

 

FORWARD-LOOKING INFORMATION AND CAUTIONARY STATEMENTS

 

Certain statements included or incorporated by reference in this Annual Report, in other documents we file with or furnish to the Securities and Exchange Commission (“SEC”), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are “forward-looking statements” within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, pricing, tax rates, tax provisions, cash flows, our liquidity position or other projected financial measures; management’s plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, new product and service developments, competitive strengths or market position, acquisitions and the integration thereof, strategic opportunities, dividends and executive compensation; growth, declines and other trends in markets we sell into; new or modified laws, regulations and accounting pronouncements; future regulatory approvals and the timing and conditionality thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future foreign currency exchange rates and fluctuations in those rates; the potential or anticipated direct or indirect impact of COVID-19 on our business, results of operations and/or financial condition; general economic and capital markets conditions; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Bio-Techne intends or believes will or may occur in the future. Terminology such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the risks and uncertainties set forth below and under “Item 1A. Risk Factors” in this Annual Report.

 

Forward-looking statements are not guaranties of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call, materials or other communication in which they are made. Except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

 

Investment in our securities involves risk and uncertainty and you should carefully consider all information in this Annual Report on Form 10-K prior to making an investment decision regarding our securities. Below is a summary of material risks and uncertainties we face, which are discussed more fully in “Item 1A. Risk Factors”:

 

Business and Strategic Risks

 

 

●

Conditions in the global economy, the particular markets we serve and the financial markets brought about by material global crises may adversely affect our business and financial statements.

 

 

●

U.S. and international political, economic, compliance and business factors, including the United Kingdom’s recent withdrawal from the European Union, can negatively impact our operations and financial results.

 

 

●

The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce healthcare costs or increase their predictability, all of which may adversely affect our business and financial results.

 

Acquisition and Investment Risks

 

 

●

Our inability to complete acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.

 

 

●

Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial statements.

 

 

●

We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets, or other investments may become impaired, which could negatively impact our financial statements or stock price.

 

4
 

 

Operational Risks

 

 

●

Our success will be dependent on recruiting and retaining highly qualified personnel and creating and maintaining a culture that includes the employees joining through acquisition.

 

 

●

Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customers’ needs.  Our growth can also be negatively impacted if our customers do not grow as anticipated.  

 

 

●

We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive.

 

 

●

A significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity, and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.  

 

 

●

If we suffer a loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.

 

 

●

The manufacture of many of our products is a complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial statements could suffer.

 

 

●

If we cannot adjust our manufacturing capacity or purchases required for our manufacturing activities to reflect changes in market conditions or customer demand, our business and financial statements may suffer.  In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.

 

 

●

The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations.  Our business could be adversely affected by disruptions at our sites.

 

 

●

Defects, unanticipated use of or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial statements.  

 

 

●

Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.

 

Intellectual Property Risks

 

 

●

We are dependent on maintaining our intellectual property rights. If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.  

 

 

●

We may be involved in disputes to determine the scope, coverage and validity of others' proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business.

 

Financial and Tax Risks

 

 

●

We have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future. The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy.

 

 

●

Our business and financial statements can be adversely affected by foreign currency exchange rates, changes in our tax rates and tax liabilities and assessments (including as a result of changes in tax laws).

 

 

●

Dividends on our common stock could be reduced or eliminated in the future.

 

Legal, Regulatory, Compliance and Reputational Risks 

 

 

●

Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results.  

 

 

●

Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, particularly in China, can have an adverse effect on our business and financial statements.

 

 

●

Our business and financial statements can be impaired by improper conduct of any of our employees, agents, or business partners.

 

 

●

Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial statements.

 

 

●

Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Company’s reputation and have a material adverse effect upon the Company’s business, a risk that has been elevated with the acquisition of Exosome Diagnostics, whose laboratory testing service is a healthcare provider that obtains and uses protected health information.

 

 

5
 

 

 

PART I

 

ITEM 1. BUSINESS

 

OVERVIEW

 

Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. With our broad product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Genomics segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.    

 

We are a Minnesota corporation with our global headquarters in Minneapolis, Minnesota. We were founded forty-five years ago, in 1976, as Research and Diagnostic Systems, Inc. We became a publicly traded company in 1985 through a merger with Techne Corporation, now Bio-Techne Corporation. Our common stock is listed on the NASDAQ under the symbol “TECH.” We operate globally, with offices in many locations throughout North America, Europe and Asia. Today, our product lines extend to over 350,000 products, most of which we manufacture ourselves in multiple locations in North America, as well as the U.K. and China.

 

Our historical focus was on providing high quality proteins, antibodies and immunoassays to the life science research market and hematology controls to the diagnostics market. Over the last eight years, we have been implementing a disciplined strategy to accelerate growth in part by acquiring businesses and product portfolios that leveraged and diversified our existing product lines, filled portfolio gaps with differentiated high growth businesses, and expanded our geographic scope. From fiscal years 2013 through 2021 we have acquired or made investments in seventeen companies that have expanded the product offerings and geographic footprint of both operating segments. Recognizing the importance of an integrated, global approach to meeting our mission and accomplishing our strategies, we have maintained many of the brands of the companies we have acquired, but unified under a single global brand -- Bio-Techne. 

 

We are committed to providing the life sciences community with innovative, high-quality scientific tools that allow our customers to make extraordinary discoveries. We intend to build on Bio-Techne’s past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to enter the diagnostics and other adjacent markets. Our strategies include:

 

Continued innovation in core products. Through collaborations with key opinion leaders, participation in scientific discussions and societies, and leveraging our internal talent we expect to be able to convert our continued significant investment in our research and development activities to be first-to-market with quality products that are at the leading edge of life science researchers’ needs.

 

Market and geographic expansion. We will continue to expand our sales staff and distribution channels globally in order to increase our global presence and make it easier for customers to transact with us. We will also leverage our existing portfolio to expand our product offerings into novel research fields and further into diagnostics and therapeutics markets.

 

Culture development and talent recruitment and retention. As we continue to grow both organically and through acquisition, we are intentionally fostering an “EPIC” culture based on the ideals of Empowerment, Passion, Innovation and Collaboration.  We strive to recruit, train and retain the most talented staff, who will live out these EPIC ideals and implement our strategies effectively.

 

Targeted acquisitions and investments. We will continue to leverage our strong balance sheet to gain access to new and differentiated technologies and products that improve our competitiveness in the current market, meet customers’ expanding workflow needs and allow us to enter adjacent markets. 

 

 

 

6
 

 

PROTEIN SCIENCES SEGMENT

 

Protein Sciences Segment Products and Markets

 

The Protein Sciences segment is the larger of our two segments, representing about 75% of our net sales in fiscal 2021. It is comprised of two divisions with complementary product offerings serving many of the same customers – the Reagent Solutions division and the Analytical Solutions division.

 

The Reagent Solutions division consists of specialized proteins, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera and cell selection technologies traditionally used by researchers to further their life science experimental activities and by companies developing next generation diagnostics and therapeutics, including companies developing cell and gene-based therapeutics. Key product brands include R&D Systems, Tocris Biosciences and Novus Biologicals. Our combined chemical and biological reagents portfolio provides high quality tools that customers can use in solving complex biological pathways and glean knowledge that may lead to a more complete understanding of biological processes, and, ultimately, to the development of novel therapeutic strategies to address different pathologies.  With the 2019 acquisitions of Quad Technologies, which has novel Quickgel™ technologies for cell separation and activation, and B-MoGen Technologies, which has a non-viral, transposon-based technology for gene editing called TcBuster, we have expanded our product offerings for the cell and gene therapy market. Through a collaborative marketing venture with two other companies, we have leveraged these and other products we have or are developing to provide a more complete offering for the cell and gene therapy market.

 

The Analytical Solutions division includes manual and automated protein analysis instruments and immunoassays that are used in quantifying proteins in a variety of biological fluids. Products in this division include traditional manual plate-based immunoassays, fully automated multiplex immunoassays on various instrument platforms, and automated western blotting and isoelectric focusing analysis of complex protein samples. Key product brands include R&D Systems and ProteinSimple. A number of our products have been demonstrated to have the potential to serve as predictive biomarkers and therapeutic targets for a variety of human diseases and conditions including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. Immunoassays can also be useful in clinical diagnostics. In fact, we have received Food and Drug Administration (FDA) marketing clearance for a few of our immunoassays for use as in vitro diagnostic devices. In response to the COVID-19 pandemic, we partnered with Mount Sinai Hospital and its commercial entity, Kantaro Biosciences, to rapidly develop and commercialize an immunoassay kit intended to test for antibodies to COVID-19, which has received regulatory clearance in several jurisdictions, including an Emergency Use Authorization from the FDA.

 

Protein Sciences Segment Customers and Distribution Methods

 

Our customers for this segment include researchers in academia, government and industry (chiefly pharmaceutical and biotech companies), as well as diagnostic/companion diagnostic and therapeutic customers, especially customers engaged in the development of cell and gene based therapies. Our biologics line of products in the Analytical Solutions division is used primarily by production and quality control departments at biotech and pharmaceutical companies. We sell our products directly to customers who are primarily located in North America, Europe and China, as well as through a distribution agreement with Fisher Scientific. We also sell through third party distributors in China, Japan, certain eastern European countries and the rest of the world. Our sales are widely distributed, and no single end-user customer accounted for more than 10% of the Protein Sciences segment's net sales during fiscal 2021, 2020 or 2019.

 

DIAGNOSTICS AND GENOMICS SEGMENT

 

The Diagnostics and Genomics segment, representing about 25% of our net revenues in fiscal 2021, is focused primarily on the diagnostics market and includes diagnostics reagents, genomics, our Exosome acquisition, and our Asuragen acquisition.

 

Diagnostics and Genomics Segment Products

 

The Diagnostic Reagents division consists of regulated products traditionally used as calibrators and controls in the clinical setting. Also included are instrument and process control products for hematology, blood chemistry, blood gases, coagulation controls and reagents used in various diagnostic applications. Often we manufacture these reagents on a custom basis, tailored to a customer's specific diagnostic assay technology. We supply these reagents in various formats including liquid, frozen, or in lyophilized form. Most of these products are sold on an Original Equipment Manufacturer (OEM) basis to instrument manufacturers, with most products being FDA-cleared.

 

The Genomics division includes products using nucleic acid (RNA or DNA) analysis that can be used for diagnostic or research applications. Key product brands include Advanced Cell Diagnostics, or ACD, Exosome Diagnostics, and Asuragen. ACD products are aimed at tissue biopsy and spatial analysis.  Exosome Diagnostics focuses on exosome-based liquid biopsy techniques that analyze genes or their transcripts. The first commercialized test from Exosome Diagnostics is a urine-based assay for early detection of high-grade prostate cancer used as an aid in deciding the need for an initial biopsy.  Our most recent acquisition is Asuragen, which makes and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research.

 

7
 

 

Diagnostics and Genomics Segment Customers and Distribution Methods

 

The majority of Diagnostic Reagents Division's sales are through OEM agreements, but we sell some of our diagnostics reagents products directly to customers and, in Europe and Asia, also through distributors. The customers for the ACD research products include researchers in academia as well as investigators in pharmaceutical and biotech companies. We sell our products directly to those customers who are primarily located in North America, Europe and China, and through distributors elsewhere. In addition to being useful research tools, our DNA and RNA in situ hybridization assays have diagnostics applications as well, and several are cleared or currently under review by the FDA in partnership with diagnostics instrument manufacturers and pharmaceutical companies. In the United States, we offer test services to physicians using our lab-developed non-invasive urine-based assay for prostate cancer detection.  Our diagnostic laboratory is certified under and regulated by the State of Massachusetts pursuant to the Clinical Laboratory Improvement Amendments, or CLIA. Customers are physicians prescribing such tests for their patients.  Finally, the Asuragen products are sold primarily to laboratories for use in lab-developed tests or in kit form as regulated diagnostic tests. 

 

No customers accounted for 10% or more of the reporting segment's consolidated net sales during fiscal years 2021, 2020 or 2019.

 

MANUFACTURING AND MATERIALS

 

Our manufacturing operations use a wide variety of raw materials and components, including electronic components, chemicals and biological materials.  No single supplier is material, although for some components that require particular specifications or regulatory or other qualifications there may be a single supplier or a limited number of suppliers that can readily provide such components. We utilize a number of techniques to address potential disruption in and other risks relating to our supply chain, including in certain cases the use of safety stock, alternative materials and qualification of multiple supply sources.  

 

The majority of our products are shipped within one day of receipt of the customers' orders, other than our instruments and related cartridges, which are typically shipped within one to two weeks of receipt of an order.  There was no significant backlog of orders for our products as of the date of this Annual Report on Form 10-K or as of a comparable date for fiscal 2021.  For additional discussion of risks relating to supply chain and manufacturing, refer to “Item 1A. Risk Factors.”  

 

COMPETITION

 

Although our segments both generally operate in highly competitive markets, it is difficult to determine our competitive position, either in the aggregate or by segment, since none of our competitors offer all of the same product and service lines or serve all of the same markets as the Company, or any of its segments, does. Because of the range of the products and services we sell, we encounter a wide variety of competitors, including a number of large, global companies or divisions of such companies with substantial capabilities and resources, as well a number of smaller, niche competitors with specialized product offerings.  We have increased competition in a number of our markets as a result of the entry of new companies into certain markets, the entry of competitors based in low-cost manufacturing locations, and increasing consolidation in particular markets. The number of competitors varies by product line. Key competitive factors vary among the Company’s businesses, but include the specific factors noted above with respect to each particular business and typically also include price, quality and safety, performance, delivery speed, application expertise, service and support, technology and innovation, distribution network, breadth of product, service and software offerings and brand name recognition.  We believe our competitive position is strong due to the unique aspects of many of our products and our product quality.   For a discussion of risks related to competition, refer to “Item 1A. Risk Factors.”

 

SEASONALITY OF BUSINESS

 

Bio-Techne believes there is some seasonality as a result of vacation and academic schedules of its worldwide customer base, particularly for the Protein Sciences segment. A majority of Diagnostics Reagents division products are manufactured in large bulk lots and sold on a schedule set by the customer. Consequently, sales for that segment can be unpredictable, and not necessarily based on seasonality. As a result, we can experience material and sometimes unpredictable fluctuations in our revenue from the Diagnostics and Genomics segment.

 

RESEARCH AND DEVELOPMENT

 

Bio-Techne is engaged in continuous research and development in all of our major product lines. We believe that our future success depends, to a large extent, on our ability to keep pace with changing technologies and market needs. In response to the global pandemic that emerged in early 2020, we diverted some of our development resources to new and existing products to meet the needs associated with COVID-19, including a major effort by the development teams in our Protein Sciences Segment to develop a diagnostic immunoassay for testing antibodies to COVID-19. That immunoassay product has thus far had limited sales.  However, there is no assurance that any of the products in the research and development phase can be successfully completed or, if completed, can be successfully introduced into the marketplace.

 

8
 

 

HUMAN CAPITAL

 

Through its subsidiaries, Bio-Techne employed approximately 2,600 full-time and part-time employees as of June 30, 2021, of whom approximately 2,000 were employed in the United States and approximately 600 outside the United States. None of the United States employees are unionized. Outside the United States, the Company has government-mandated collective bargaining arrangements or work councils in certain countries. 

 

Bio-Techne is committed to attracting, developing, engaging and retaining the best people possible from around the world to sustain and grow our leadership position in life sciences tools and diagnostics. Our human capital strategy spans multiple key dimensions, including the following:

 

Culture and Governance

 

Our commitment to our people is reflected in our four EPIC values of Empowerment, Passion, Innovation and Collaboration. Those four values (together with their 12 supporting EPIC behaviors) are the backbone for the way we approach the leadership and direction of our work force.  Employees are empowered to realize their potential. Our culture supports and encourages a collaborative approach to working with each other and with our customers. We encourage innovation to continually improve our products, services and processes, and our passion for science and the missions of our customers is our guiding light. 

 

Our EPIC values are embedded in our culture and practices. By way of example, our performance management system and annual review processes incorporate our EPIC values.  Each employee is measured against the behaviors and attributes that support those values. To further amplify our desired behaviours, we have an annual employee recognition program in which we ask for nominations and recognize winning individuals and teams form across our business who have best demonstrated our EPIC values during the previous year.    

 

Bio-Techne’s Board of Directors reviews management succession planning annually, and its Executive Compensation Committee reviews the Company’s human capital strategy periodically in connection with significant initiatives and acquisitions, as well as part of its oversight of our executive and equity compensation programs. At the management level, our Vice President of Human Resources, who reports directly to our President and CEO, is responsible for the development and execution of the Company’s human capital strategy.

 

Engagement; Diversity and Belonging

 

Our engagement strategy focuses on developing the best workplace and best people leaders to meet our employees’ needs. We believe that strong employee engagement helps enable higher retention and better business performance. We assess our engagement performance through regular consultation with our managers and more formally via an annual engagement survey that assesses our employees’ overall experience.

 

This feedback informs and shapes our future employee-focused initiatives.  These initiatives in the past have resulted in changes in programs and policies, including expansion of our management and leadership development programs, addition of a parental leave program, expansion of our incentive programs to include annual cash bonuses to all professional employees and above, introduction of flexible working and expanding the breadth of our Diversity & Belonging Council and Employee Resource Groups (ERGs).

 

We believe a diverse workforce and culture of inclusion is essential to drive innovation, fuel growth and help ensure our technologies and products effectively serve a global customer base. The Company’s executive-sponsored Diversity and Belonging initiative is focused on providing a welcoming working environment for all employees, continued education, broadening our candidate pools, and implementing and sustaining programs. Our ERGs, coordinated under the guidance of our executive-sponsored Employee Resource Group Council, offer mentorship, support and engagement to help our employees, including those from underrepresented groups, succeed and thrive. As of June 30, 2021, we had 8 ERGs operating globally. Furthermore, as of June 30, 2021, 50% of our total employee population was female, and 44% of our managerial employees were female.  In the United States, 33% of our total employee population identified as nonwhite and 28% of our managerial employees identified as nonwhite.

 

Talent Development and Learning and Development

 

Bio-Techne invests in people development in the belief that growing and promoting employees from within the Company creates a more sustainable organization. High potential and promotable employees are identified through our annual Talent Management program, and are then equipped with a personal development and career advancement plan. These plans involve training and development from internal and external programs, together with mentoring and coaching.

 

Our global Learning and Development program delivers a wide range of initiatives including a validated suite of compliance training, soft skills, technical skills, business skills, interpersonal skills and career skills. Many of these programs are assigned to individuals specifically, but in addition, there is an expansive menu available to employees in order to accelerate their own development. As a company that regularly acquires other businesses, we believe it is important for employees to be trained in the skills and mindsets that enable them to respond positively to change. This initiative allows individuals to deal with change easily and reduces the need to run large scale change management programs.

 

Community

 

The Company believes in giving back and in supporting the local communities in which we live and work. Most sites or departments engage in local charitable causes and activities. In some of our sites, employees are encouraged to give through regular payroll deductions and through the annual campaign week where employee contributions are matched by the Company. United States employees receive a paid day off to participate in local opportunities to give back to the community.

 

9
 


INTELLECTUAL PROPERTY

Our success depends in part upon our ability to protect our core technologies and intellectual property. To accomplish this, we rely on a combination of intellectual property rights, including patents, trade secrets and trademarks, as well as customary contractual protections in our terms and conditions and other sales-related documentation.

 

As of June 30, 2021, we had rights to approximately 350 granted patents and approximately 250 pending patent applications.  In particular, products in the Analytical Solutions and Genomics divisions are protected primarily through pending patent applications and issued patents. In addition, certain of our products are covered by licenses from third parties to supplement our own patent portfolio.  Patent protection, if granted, generally has a life of 20 years from the date of the patent application or patent grant. We cannot provide assurance that any of our pending patent applications will result in the grant of a patent, whether the examination process will require us to narrow our claims, and whether our claims will provide adequate coverage of our competitors' products or services.

 

In addition to pursuing patents on our products, we also preserve much of our innovation as trade secrets, particularly in the Reagent Solutions division of our Protein Sciences segment. We have taken steps to protect our intellectual property and proprietary technology, in part by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors. See the description of risks associated with the Company's intellectual property in “Item 1A.  Risk Factors.”

 

We can give no assurance that Bio-Techne's products do not infringe upon patents or proprietary rights owned or claimed by others. Bio-Techne has not conducted a patent infringement study for each of its products. Where we have been contacted by patent holders with certain intellectual property rights, Bio-Techne typically has entered into licensing agreements with patent holders under which it has the exclusive and/or non-exclusive right to use patented technology as well as the right to manufacture and sell certain patented products to the research and/or diagnostics markets.

 

10
Table of Contents

 

LAWS AND REGULATIONS

 

Our operations, and some of the products we offer, are subject to a number of complex laws and regulations governing the production, marketing, handling, transportation and distribution of our products and services.  The following sections describe certain significant regulations pertinent to the Company. These are not the only laws and regulations applicable to the Company’s business.  For a description of risks related to laws and regulations to which we are subject, refer to Item 1.A. Risk Factors.”

 

Medical Device Regulations 

 

A number of our products are classified as medical devices and are subject to restrictions under domestic and foreign laws, rules, regulations, self-regulatory codes and orders, including but not limited to the U.S. Food, Drug and Cosmetic Act (the “FDCA”).  The FDCA requires these products, when sold in the United States, to be safe and effective for their intended uses and to comply with the regulations administered by the U.S. Food and Drug Administration (“FDA”).  The FDA regulates the design, development, testing, manufacture, advertising, labeling, packaging, marketing, distribution, import and export and record keeping for such products.  Many medical device products are also regulated by comparable agencies in non-U.S. countries in which they are produced or sold.

 

Any medical devices we manufacture and distribute are subject to pervasive and continuing regulation by the FDA and certain state and non-U.S. agencies.  As a medical device manufacturer, our manufacturing facilities are subject to inspection on a routine basis by the FDA.  We are required to adhere to the Current Good Manufacturing Practices (“GMP”) requirements, as set forth in the Quality Systems Regulation (“QSR”), which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the design and manufacturing process.

 

We must also comply with post-market surveillance regulations, including medical device reporting, or MDR, requirements which require that we review and report to the FDA any incident in which our products may have caused or contributed to a death or serious injury.  We must also report any incident in which our product has malfunctioned if that malfunction would likely cause or contribute to a death or serious injury it if were to recur.

 

Labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission.  Medical devices approved or cleared by the FDA may not be promoted for unapproved or uncleared uses, otherwise known as “off-label” promotion.  The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

 

In the European Union (“EU”), our products are subject to the medical device laws of the various member states, which are currently based on a Directive of the European Commission.  However, the EU has adopted the In Vitro Diagnostic Regulation (the “EU IVDR”), which imposes stricter requirements for the marketing and sale of in vitro diagnostic medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance.  Manufacturers of currently approved in vitro diagnostics medical devices have until May 2022 to meet the EU IVDR.  Complying with EU IVDR, the regulation applicable to the Company, requires material modifications to our quality management systems, additional resources in certain functions, updates to technical files and additional clinical data in some cases, among other changes.

 

One of our products under our Exosome Diagnostics brand is offered as a test by a certified laboratory under CLIA. Our Asuragen business also maintains a CLIA certification. Consequently, we must comply with state licensing regulations applicable to laboratories regulated under CLIA, governing laboratory practices and procedures.

 

Other Healthcare Laws

 

Several of the products sold in our Diagnostics and Genomics segment are subject to various health care related laws regulating fraud and abuse, research and development, pricing and sales and marketing practices, and the privacy and security of health information, including, among others:

 

 

●

U.S. federal regulations regarding quality and cost by the U.S. Department of Health and Human Services (“HHS”), including the Centers for Medicare & Medicaid Services (“CMS”), as well as comparable state and non-U.S. agencies responsible for reimbursement and regulation of healthcare goods and services, including laws and regulations related to kickbacks, false claims, self-referrals and healthcare fraud.

 

 

●

U.S. Federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback or bribe), directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made in whole or in part under a federal health care program, such as Medicare or Medicaid.

 

 

●

Comparable laws and regulations similar to, and in some cases more stringent than, the U.S. federal regulations discussed above and below, including the UK Bribery Act and similar anti-bribery laws.

 

 

●

The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which prohibits knowingly and willfully (1) executing, or attempting to execute, a scheme to defraud any health care benefit program, including private payors, or (2) falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, also restricts the use and disclosure of patient identifiable health information, mandates the adoption of standards relating to the privacy and security of patient identifiable health information and requires the reporting of certain security breaches with respect to such information.

 

 

●

The False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program, knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly makes a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government.

 

 

●

The Open Payments Act requires manufacturers of medical devices covered under Medicare to, in certain circumstances,   record payments and other transfers of value to a broad range of healthcare providers and teaching hospitals and to report this data as well as ownership and investment interests held by the physicians described above and their immediate family members to HHS for subsequent public disclosure, as well as similar reporting requirements in some states and in other countries.

 

For a discussion of risks related to regulation by the FDA and comparable agencies of other countries, and the other regulatory regimes referenced above, please refer to section entitled “Item 1A. Risk Factors.”

 

11
 

 

Data Privacy and Security Laws

 

As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business.  In addition to the U.S. HIPAA privacy and security rules mentioned above, which impact some parts of our business, individual states also regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal  privacy.  In particular, a broad privacy law in California, the California Consumer Privacy Act (“CCPA”), came into effect in January 2020.  The CCPA has some of the same features as the GDPR (discussed below), and has already prompted several other states to follow with similar laws.  The EU General Data Protection Regulation that became effective in May 2018 (“GDPR”) has imposed significantly stricter requirements in how we collect, transmit, process and retain personal data, including, among other things, in certain circumstances a requirement for almost immediate notice of data breaches to supervisory authorities and prompt notice to data subjects with significant fines for non-compliance.  Several other countries such as China and Russia have passed, and other countries are considering passing, laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions.  For a discussion of risks related to improper disclosure of private information particularly as a result of cyber security incidents, please refer to section entitled “Item 1A. Risk Factors.”

 

Environmental Health and Safety Laws

 

We are also subject to various environmental health and safety laws and regulations both within and outside the U.S. Like other companies in our industry, our manufacturing and research activities involve the use and transportation of substances regulated under environmental health and safety laws including those relating to the transportation of hazardous materials.

 

Other Laws and Regulations Governing Our Sales, Marketing and Shipping Activities.

 

We are subject to the U.S. Foreign Corrupt Practices Act and various other similar anti-corruption and anti-bribery acts, which are particularly relevant to our operations in countries where the customers are government entities or are controlled by government officials.  Both we directly, and indirectly through our distributors, must comply with such laws when interacting with those entities.

 

As Bio-Techne’s businesses also include export and import activities, we are subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury.  Other nations’ governments have implemented similar export/import control and economic sanction regulations, which may affect the Company’s operations or transactions subject to their jurisdictions.

 

In addition, under U.S. laws and regulations, U.S. companies and their subsidiaries and affiliates outside the United States are prohibited from participating or agreeing to participate in unsanctioned foreign boycotts in connection with certain business activities, including the sale, purchase, transfer, shipping or financing of goods or services within the United States or between the United States and countries outside of the United States. If we, or certain third parties through which we sell or provide goods or services, violate anti-boycott laws and regulations, we may be subject to civil or criminal enforcement action and varying degrees of liability.

 

We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts could harm our business by a reduction in revenue associated with these customers. We have agreements relating to the sale of our products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

 

For a discussion of risks related to the above-referenced regulations, particularly with respect to our international operations, please refer to section entitled “Item 1A. Risk Factors.”

 

12
Table of Contents

 

INVESTOR INFORMATION

 

We are subject to the information requirements of the Securities Exchange Act of 1934 (the Exchange Act). Therefore, we file periodic reports, proxy statements, and other information with the Securities and Exchange Commission (SEC). The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically.

 

Financial and other information about us is available on our web site (https://investors.bio-techne.com/). We make available on our web site copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically or otherwise furnishing it to the SEC.

 

EXECUTIVE OFFICERS OF THE REGISTRANT

 

Currently, the names, ages, positions and periods of service of each executive officer of the Company are as follows:

 

Name

  

Age

  

Position

  

Officer Since
             

Charles Kummeth

  

61

  

President, Chief Executive Officer and Director

  

2013

James Hippel

  

50

  

Executive Vice President and Chief Financial Officer

  

2014

David Eansor

  

60

  

President, Protein Sciences

  

2014

Kim Kelderman

  

54

  

President, Diagnostics and Genomics

  

2018

Brenda Furlow

  

63

  

Executive Vice President, General Counsel and Corporate Secretary

  

2014

 

Set forth below is information regarding the business experience of each executive officer. There are no family relationships among any of the officers named, nor is there any arrangement or understanding pursuant to which any person was selected as an officer.

 

Charles Kummeth has been President and Chief Executive Officer of the Company since April 1, 2013. Prior to joining the Company, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. from September 2011. He was President of that company's Laboratory Consumables Division from 2009 to September 2011. Prior to Thermo Fisher, Mr. Kummeth served in various roles at 3M Corporation, most recently as the Vice President of the company's Medical Division from 2006 to 2008.

 

James Hippel has been Chief Financial Officer of the Company since April 1, 2014. Prior to joining the Company, Mr. Hippel served as Senior Vice President and Chief Financial Officer for Mirion Technologies, Inc., a global company that provided radiation detection and identification products. Prior to Mirion, Mr. Hippel served as Vice President, Finance at Thermo Fisher Scientific, Inc., leading finance operations for its Mass Spectrometry & Chromatography division and its Laboratory Consumables division. In addition, Mr. Hippel's experience includes nine years of progressive financial leadership at Honeywell International, within its Aerospace Segment. Mr. Hippel started his career with KPMG LLP.

 

David Eansor has been President of the Protein Sciences segment since July 1, 2018. Prior to that, he served as Senior Vice President, Biotechnology Division and as Senior Vice President, Novus Biologicals since the Company completed its acquisition of Novus on July 2, 2014. From January 2013 until the date of the acquisition, Mr. Eansor was the Senior Vice President of Corporate Development of Novus Biologicals. Prior to joining Novus Biologicals, Mr. Eansor was the President of the Bioscience Division of Thermo Fisher Scientific. Mr. Eansor was promoted to Division President in early 2010 after 5 years as President of Thermo Fisher's Life Science Research business.

 

Kim Kelderman joined Bio-Techne on April 30, 2018 as President, Diagnostics and Genomics. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. For the last three years, Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Kim served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes “Vacutainer” business.

 

Brenda Furlow joined the Company as General Counsel and Corporate Secretary on August 4, 2014. Prior to joining Bio-Techne, Ms. Furlow served as general counsel to emerging growth technology companies. Ms. Furlow was General Counsel for TomoTherapy, a global, publicly traded company that manufactured and sold radiation therapy equipment, from 2007 to 2011. From 1998 to 2007, Ms. Furlow served as General Counsel for Promega Corporation, a global life sciences company.

 

13
Table of Contents
 

 

ITEM 1A. RISK FACTORS

 

Set forth below are risks and uncertainties we believe are material to our investors. You should refer to the explanation of the qualifications and limitations on forward-looking statements in the section titled Information Relating to Forward-Looking Statements at the beginning of this Annual Report on Form 10-K.

 

Economic and Industry Risks

 

Conditions in the global economy, the particular markets we serve and the financial markets brought about by material global crises may adversely affect our business and financial statements.

 

Our global operations expose us to risks associated with many types of crises, whether political, social, economic, climate or otherwise.  In particular, given our industry, we have exposure to public health crises, including epidemics and pandemics such as COVID-19. Most recently, COVID-19 has had, and likely will continue to have, an adverse impact on our employees, operations, supply chains, and sales and distribution systems, including as a result of impacts associated with protective health measures that we, other businesses and governments are taking or might have to take again in the future. For example, as the world has grappled with the COVID-19 pandemic, many governments issued “stay-at-home” orders which restricted business and personal activities, and many employers required employees to work from home and cease all travel. While many of these travel and activity restrictions have been partially or fully lifted in certain countries where the pandemic has been controlled, they may be reinstituted in the future and jurisdictions may continue to close borders, impose prolonged quarantines and further restrict travel and other activities. 

 

In the past eighteen months, we have introduced new products or modified existing products to serve the research and healthcare markets as they address the global pandemic through novel diagnostic and therapeutic products. The direct impact of COVID-19 and the preventive and precautionary measures implemented as a result thereof have adversely affected, and are expected to continue to adversely affect, certain elements of our Company (including to a different degree our operations, commercial organizations, supply chains and distribution systems) and the future impact may be material, though the impact on our different businesses and the different elements of our businesses varies (please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for a discussion of how COVID-19 impacted our results of operations and financial position in fiscal 2021). Without limiting the foregoing, we have experienced and/or may in the future experience:

 

 

●

adverse impacts on customer orders and purchases and unpredictable reductions in demand for many of our products;

 

 

●

constraints on the movement of our products through the supply chain;

 

 

●

adverse impacts on our collections of accounts receivable, including delays in collections and increases in uncollectible receivables;

 

 

●

supply chain capacity constraints and price increases, including with respect to freight services;

 

 

●

failure of COVID-19 related products to be adopted in the market as anticipated;

 

 

●

adverse impacts on our workforce and/or key employees;

 

 

●

unpredictable increases in demand for certain products; and

 

 

●

increased cybersecurity attack activity.

 

Any of these developments may adversely affect our business and financial statements.

 

14
 

 

U.S. and international political, economic, compliance and business factors, including the United Kingdom’s recent withdrawal from the European Union, can negatively impact our operations and financial results.

 

Changes, potential changes or uncertainties in U.S. social, political, regulatory and economic conditions or laws and policies governing foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate, or governing the health care system, can adversely affect our business and financial statements. For example, the current U.S. administration has continued to keep in place many of the significant tariff increases for goods imported into the United States, particularly from China, imposed by the prior administration. Congress and the U.S. administration is also considering significant changes to healthcare in the United States, including government negotiation/regulation of drug prices paid by government programs.

 

Additionally, the UK’s exit from the European Union at the end of calendar year 2020 has created political and economic uncertainty, particularly in the UK and the EU, and has disrupted the free flow of goods and people between the UK and the EU.  In addition, our business could be negatively affected by new trade agreements between the UK and other countries, including the United States, and by the possible imposition of trade or other regulatory barriers in the UK. Any of these factors have affected and could continue to adversely affect customer demand, our relationships with customers and suppliers, and our business and financial results, particularly since our European headquarters and primary shipping facilities have been located in the UK. Additionally, attracting and retaining qualified employees who are citizens of EU countries to our UK facilities may be more difficult given the uncertainties resulting from the UK's withdrawal.

 

We engage in business globally, with approximately 46% of our sales revenue in fiscal 2021 coming from outside the U.S. In addition, one of our strategies is to expand geographically, particularly in China, India and in developing countries, both through distribution and through direct operations. This subjects us to a number of risks, including international economic, political, and labor conditions; currency fluctuations; tax laws (including U.S. taxes on foreign subsidiaries); increased financial accounting and reporting burdens and complexities; unexpected changes in, or impositions of, legislative or regulatory requirements; failure of laws to protect intellectual property rights adequately; inadequate local infrastructure and difficulties in managing and staffing international operations; delays resulting from difficulty in obtaining export licenses for certain technology; tariffs, quotas and other trade barriers and restrictions; transportation delays; operating in locations with a higher incidence of corruption and fraudulent business practices; and other factors beyond our control, including terrorism, war, natural disasters, climate change and diseases.

 

The application of laws and regulations impacting global transactions is often unclear and may at times conflict. Compliance with these laws and regulations may involve significant costs or require changes in our business practices that result in reduced revenue and profitability. Non-compliance could also result in fines, damages, criminal sanctions, prohibited business conduct, and damage to our reputation. We incur additional legal compliance costs associated with our global operations and could become subject to legal penalties in foreign countries if we do not comply with local laws and regulations, which may be substantially different from those in the U.S.

 

We continue to expand our operations in countries with developing economies, where it may be common to engage in business practices that are prohibited by U.S. regulations applicable to the Company, such as the Foreign Corrupt Practices Act. Although we implement policies and procedures designed to ensure compliance with these laws, there can be no assurance that all of our employees, contractors, and agents, as well as those companies to which we outsource certain aspects of our business operations, including those based in foreign countries where practices which violate such U.S. laws may be customary, will comply with our internal policies. Any such non-compliance, even if prohibited by our internal policies, could have an adverse effect on our business and result in significant fines or penalties.

 

The healthcare and life sciences industries that we serve face constant pressures and changes in an effort to reduce or increase the predictability of healthcare costs, all of which may adversely affect our business and financial results.

 

Our Protein Sciences segment products are sold primarily to research scientists at pharmaceutical and biotechnology companies and at university and government research institutions. In addition to the impacts described above relating to COVID-19, research and development spending by our customers and the availability of government research funding can fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities, general economic conditions and institutional and governmental budgetary policies. We carry essentially no backlog of orders and changes in the level of orders received and filled daily can cause fluctuations in quarterly revenues and earnings.

 

Our Genomics and Diagnostics segment products are intended primarily for the medical diagnostics market, which relies largely on government healthcare-related policies and funding. Changes in government reimbursement for certain diagnostic tests or reductions in overall healthcare spending could negatively impact us directly or our customers and, correspondingly, our sales to them. For example, our Exosome Diagnostics business develops and sells novel exosome-based diagnostic tests.  While we received public payer coverage for certain uses, we are currently seeking expanded coverage from public payors as well as coverage decisions regarding reimbursement from additional private payers. However, the process and timeline for obtaining coverage decisions is uncertain and difficult to predict. Further, reimbursement reductions due to changes in policy regarding coverage of tests or other requirements for payment (such as prior authorization, diagnosis code and other claims edits, or a physician or qualified practitioner’s signature on test requisitions) may be implemented from time to time. All of these payor actions and changes may have a material adverse effect on revenue and earnings associated with our diagnostics products. 

 

15
 

 

Acquisition and Investment Risks

 

Our inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.

 

We routinely explore acquiring other businesses and assets, and have completed seventeen acquisitions and investments in the last nine years.  Our ability to grow revenues, earnings and cash flow at or above our historic rates depends in part upon our ability to identify and successfully acquire and integrate businesses at appropriate prices and realize anticipated synergies, and to make appropriate investments that support our long-term strategy. We may not be able to consummate acquisitions at rates similar to the past, which could adversely impact our growth rate and our stock price. Promising acquisitions and investments are difficult to identify and complete for a number of reasons, including high valuations, competition among prospective buyers or investors, the availability of affordable funding in the capital markets and the need to satisfy applicable closing conditions and obtain applicable antitrust and other regulatory approvals on acceptable terms. Changes in accounting or regulatory requirements or instability in the credit markets could also adversely impact our ability to consummate acquisitions and investments.

 

Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial statements.

 

As part of our business strategy we acquire businesses, make investments and enter into joint ventures and other strategic relationships in the ordinary course, and we also from time to time complete more significant transactions. We joined with two partners to establish a collaborative marketing venture, ScaleReady LLC, to address the needs of the rapidly expanding cell and gene therapy market.  While we believe this joint venture provides a competitive advantage in addressing this market, we may have interests that diverge from those of our joint venture partners, and we may not be able to direct or influence the management and operations of the joint venture in the manner we believe is most appropriate, exposing us to additional risk.  More generally, acquisitions, investments, joint ventures and strategic relationships involve a number of additional financial, accounting, managerial, operational, legal, compliance and other risks and challenges, including but not limited to the following, any of which could adversely affect our business and our financial statements:

 

 

●

businesses, technologies, services and products that we acquire or invest in sometimes under-perform relative to our expectations and the price that we paid, fail to perform in accordance with our anticipated timetable or fail to achieve and/or sustain profitability;

 

 

●

we from time to time incur or assume significant debt in connection with our acquisitions and investments, which can result in increased borrowing costs and interest expense and diminish our future access to the capital markets;

 

 

●

acquisitions, investments, joint ventures or strategic relationships can cause our financial results to differ from our own or the investment community’s expectations in any given period, or over the long-term;

 

 

●

acquisitions, investments, joint ventures or strategic relationships can create demands on our management, operational resources and financial and internal control systems that we are unable to effectively address;

 

 

●

we can experience difficulty in integrating cultures, personnel, operations and financial and other controls and systems and retaining key employees and customers;

 

 

●

we may be unable to achieve cost savings or other synergies anticipated in connection with an acquisition, investment, joint venture or strategic relationship;

 

 

●

we have assumed and may assume unknown liabilities, known contingent liabilities that become realized, known liabilities that prove greater than anticipated, internal control deficiencies or exposure to regulatory sanctions resulting from the acquired company’s or investee’s activities and the realization of any of these liabilities or deficiencies can increase our expenses, adversely affect our financial position or cause us to fail to meet our public financial reporting obligations;

 

 

●

in connection with acquisitions and joint ventures, we often enter into post-closing financial arrangements such as purchase price adjustments, earn-out obligations and indemnification obligations, which can have unpredictable financial results; and

 

 

●

investing in or making loans to early-stage companies often entails a high degree of risk, and we do not always achieve the strategic, technological, financial or commercial benefits we anticipate; we may lose our investment or fail to recoup our loan; or our investment may be illiquid for a greater-than-expected period of time.

 

We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets, or other investments become impaired, which could negatively impact our financial statements or stock price.

 

We are required under generally accepted accounting principles to test goodwill for impairment at least annually and to review our goodwill, amortizable intangible assets, and other assets acquired through merger and acquisition activity, for impairment when events or changes in circumstance indicate the carrying value may not be recoverable. Factors that could lead to impairment of goodwill, amortizable intangible assets, and other assets acquired via acquisitions include significant adverse changes in the business climate and actual or projected operating results (affecting our company as a whole or affecting any particular segment) and declines in the financial condition of our business. We may be required in the future to record additional charges to earnings if our goodwill, amortizable intangible assets or other investments become impaired. Any such charge would adversely impact our financial results.

 

In addition, the Company's expansion strategies include collaborations and investments in joint ventures and companies developing new products related to the Company's business. These strategies carry risks that objectives will not be achieved and future earnings will be adversely affected. For example, the Company has an approximate 2% equity investment in publicly traded ChemoCentryx, Inc. (Nasdaq: CCXI) that is valued at $20.0 million as of June 30, 2021. The ownership of CCXI shares is very concentrated, the share price is highly volatile and there is limited trading of the shares.

 

 

16
Table of Contents

 

Strategic and Operational Risks

 

Our success will be dependent on recruiting and retaining highly qualified personnel and creating and maintaining a culture that includes the employees joining through acquisition.

 

Recruiting and retaining qualified scientific, production, sales and marketing, and management personnel are critical to our success. Our anticipated growth and its expected expansion into areas and activities requiring additional expertise will require the addition of new personnel and the development of additional expertise by existing personnel. In general, we have been experiencing turnover at higher rates than usual and have had some difficulties filling certain positions.  In particular, we operate in several geographic locations where competition for talent is strong, making employee retention even more challenging. For example, some of our fastest growing businesses are located in California and Massachusetts, both of which generally have low unemployment and a competitive environment for finding and retaining talent. Our growth by acquisition also creates challenges in retaining employees. As we integrate past and future acquisitions and evolve our corporate culture to incorporate the new workforces, some employees may not find such integration or cultural changes appealing. Finally, as the geographies in which we operate recover from the recent pandemic and we return employees who had been working from home back to our sites, we may not be able to retain people who prefer continuing to work from home. The failure to attract and retain such personnel could adversely affect our business.

 

Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customers’ needs.  Our growth can also be negatively impacted if our customers do not grow as anticipated. 

 

We generally sell our products and services in industries that are characterized by rapid technological change, frequent new product introductions and new market entrants and competitors. If we do not develop innovative new and enhanced products and services on a timely basis, our offerings will become obsolete over time and our business and financial statements will suffer. Our success will depend on several factors, including our ability to:

 

 

●

correctly identify and or predict customer needs and preferences;

 

 

●

allocate our research funding to products with higher growth prospects;

 

 

●

anticipate and respond to our competitors’ development of new products and technological innovations;

 

 

●

differentiate our offerings from our competitors’ offerings and avoid our products becoming commodities;

 

 

●

innovate and develop new technologies and applications, and acquire or obtain rights to third-party technologies that may have valuable applications in the markets we serve;

 

 

●

obtain adequate intellectual property rights with respect to key technologies;

 

 

●

successfully commercialize new technologies in a timely manner, price them competitively and cost-effectively manufacture and deliver sufficient volumes of new products of appropriate quality on time;

 

 

●

obtain necessary regulatory approvals of appropriate scope (including with respect to certain diagnostic medical device products by demonstrating satisfactory clinical results where applicable, as well as achieving third-party reimbursement); and

 

 

●

stimulate customer demand for and convince customers to adopt new technologies.

 

If we fail to accurately predict future customer needs and preferences or fail to produce viable technologies, we may invest heavily in research and development of products that do not lead to significant revenue, which would adversely affect our business and financial statements. Even when we successfully innovate and develop new and enhanced products, we often incur substantial costs in doing so, and our profitability may suffer.

 

We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive.

 

We face intense competition across most of our product lines. Competitors include companies ranging from start-up companies, which may be able to more quickly respond to customers' needs, to large multinational companies, which may have greater financial, marketing, operational, and research and development resources than us. In addition, consolidation trends in the pharmaceutical, biotechnology and diagnostics industries have served to create fewer customer accounts and to concentrate purchasing decisions for some customers, resulting in increased pricing pressure on us. Moreover, customers may believe that consolidated businesses are better able to compete as sole source vendors, and therefore prefer to purchase from such businesses. The entry into the market by manufacturers in China, India and other low-cost manufacturing locations is also creating increased pricing and competitive pressures, particularly in developing markets.  In order to compete effectively, we must retain longstanding relationships with major customers and continue to grow our business by establishing relationships with new customers, continually developing new products and services to maintain and expand our brand recognition and leadership position in various product and service categories and penetrating new markets, including high-growth markets. Our ability to compete can also be impacted by changing customer preferences and requirements (for example increased demand for more environmentally-friendly products and supplier practices).  Our failure to compete effectively and/or pricing pressures resulting from competition may adversely impact our business and financial statements, and our expansion into new markets may result in greater-than-expected risks, liabilities and expenses.

 

17
 

 

A significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.

 

The integrity and protection of our own data, and that of our customers and employees, is critical to our business. We rely on information technology systems, some of which are provided and/or managed by third parties, to process, transmit and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers, other business partners and patients), and to manage or support a variety of critical business processes and activities (such as receiving and fulfilling orders, billing, collecting and making payments, shipping products, providing services and support to customers and fulfilling contractual obligations). These systems, products and services (including those we acquire through business acquisitions) can be damaged, disrupted or shut down due to attacks by computer hackers, computer viruses, ransomware, human error or malfeasance, power outages, hardware failures, telecommunication or utility failures, catastrophes or other unforeseen events, and in any such circumstances our system redundancy and other disaster recovery planning may be ineffective or inadequate. Attacks can also target hardware, software and information installed, stored or transmitted in our products after such products have been purchased and incorporated into third-party products, facilities or infrastructure. Security breaches of systems provided or enabled by us, regardless of whether the breach is attributable to a vulnerability in our products or services, or security breaches of third party systems we rely on to process, store or transmit electronic information, can result in the misappropriation, destruction or unauthorized disclosure of confidential information or personal data belonging to us or to our employees, partners, customers, patients or suppliers. These attacks, breaches, misappropriations and other disruptions and damage can interrupt our operations or the operations of our customers and partners, delay production and shipments, result in theft of our and our customers’ intellectual property and trade secrets, result in disclosure of personally identifiable information, damage customer, patient, business partner and employee relationships and our reputation and result in defective products or services, legal claims and proceedings, liability and penalties under privacy laws and increased costs for security and remediation, in each case resulting in an adverse effect on our business and financial statements.

 

In addition, our information technology systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving legal and regulatory standards, evolving customer expectations, changes in the techniques used to obtain unauthorized access to data and information systems, and the information technology needs associated with our changing products and services. There can be no assurance that we will be able to successfully maintain, enhance and upgrade our systems as necessary to effectively address these requirements.

 

If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and security requirements and prevent data breaches, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. For example, in the United States, certain of our businesses are subject to HIPAA.  Entities that are found to be in violation of HIPAA as the result of a breach of unsecured patient health information, a complaint about privacy practices or an audit by the HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Individual states regulate data breach and security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. Most notably, in the last several years, some states, including California and Virginia, have passed broad privacy legislation that could result in more material impacts as implementing regulations are issued. European laws require us to have an approved legal mechanism to transfer personal data out of Europe.  Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to €20 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. Several other countries such as China and Russia have passed, and other countries are considering passing, laws that require personal data relating to their citizens to be maintained on local servers and impose additional data transfer restrictions., Government enforcement actions can be costly and interrupt the regular operation of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely affect our business, reputation and financial statements.

 

If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.

 

Our facilities, supply chains, distribution systems and information technology systems are subject to catastrophic loss due to fire, flood, earthquake, hurricane, power shortage or outage, public health crisis (including epidemics and pandemics) and the reaction thereto, war, terrorism, riot or other natural or man-made disasters, such as the COVID-19 pandemic. If any of these facilities, supply chains or systems were to experience a catastrophic loss, it could disrupt our operations, delay production and shipments, result in defective products or services, diminish demand, damage customer relationships and our reputation and result in legal exposure and significant repair or replacement expenses. The third-party insurance coverage that we maintain varies from time to time in both type and amount depending on cost, availability and our decisions regarding risk retention, and may be unavailable or insufficient to protect us against such losses.

 

18
 

 

The manufacture of many of our products is a complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial statements could suffer.

 

The manufacture of many of our products is a complex process, due in part to strict regulatory requirements for some of our products. Problems can arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with reliable sourcing of raw materials or components, natural disasters and environmental factors, and if not discovered before the product is released to market can result in recalls and product liability exposure. Because of the quality requirements of some of our customers as well as stringent regulations of the FDA and similar agencies regarding the manufacture of certain of our products, alternative manufacturing or sourcing is not always available on a timely basis to replace such production capacity. Any of these manufacturing problems could result in significant adverse impacts to our business and financial statements.

 

If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our business and financial statements may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.

 

We purchase materials, components and equipment from third parties for use in many of our manufacturing operations. Our profitability could be adversely impacted if we are unable to adjust our purchases to reflect changes in customer demand and market fluctuations, including those caused by seasonality or cyclicality. During a market upturn, suppliers from time to time extend lead times, limit supplies or increase prices. If we cannot purchase sufficient products at competitive prices and quality and on a timely enough basis to meet increasing demand, we may not be able to satisfy market demand, product shipments may be delayed, our costs may increase or we may breach our contractual commitments and incur liabilities. Conversely, in order to secure supplies for the production of products, we sometimes enter into noncancelable purchase commitments with vendors, which can impact our ability to adjust our inventory to reflect declining market demands. If demand for our products is less than we expect, we may experience additional excess and obsolete inventories and be forced to incur additional charges and our business and financial statements may suffer.

 

In addition, some of our businesses purchase certain requirements from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties or if our relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses can also be disrupted by supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability of key raw materials or commodities and external events such as natural disasters, pandemic health issues, war, terrorist actions, governmental actions (such as trade protectionism) and legislative or regulatory changes. Any of these factors can result in production interruptions, delays, extended lead times and inefficiencies. Because we cannot always immediately adapt our production capacity and related cost structures to changing market conditions, at times our manufacturing capacity exceeds or falls short of our production requirements. Any or all of these problems can result in the loss of customers, provide an opportunity for competing products to gain market acceptance and otherwise adversely affect our business and financial statements.

 

 

The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations. Our business could be adversely affected by disruptions at our sites. 

 

The Company's internal quality control, packaging and distribution operations support the majority of the Company's sales. Since certain Company products must comply with FDA regulations and because in all instances, the Company creates value for its customers through the development of high-quality products, any significant decline in quality or disruption of operations for any reason could adversely affect sales and customer relationships, and therefore adversely affect the business. While we have taken certain steps to manage these operational risks, the Company's future sales growth and earnings may be adversely affected by perceived disruption risks or actual disruptions.

 

We rely upon our manufacturing operations to produce many of the products we sell and our warehouse facilities to store products, pending sale. Any significant disruption of those operations for any reason, such as strikes or other labor unrest, power interruptions, fire, hurricanes or other events beyond our control could adversely affect our sales and customer relationships and therefore adversely affect our business. We have significant operations in California, near major earthquake faults, which make us susceptible to earthquake risk. Although most of our raw materials are available from a number of potential suppliers, our operations also depend upon our ability to obtain raw materials at reasonable prices. If we are unable to obtain the materials we need at a reasonable price, we may not be able to produce certain of our products or we may not be able to produce certain of these products at a marketable price, which could have an adverse effect on our results of operations.

 

Defects and unanticipated use or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial statements.

 

Certain of our products and services are sold for use in diagnostics.  For those products and services in particular, manufacturing or design defects in, unanticipated use of, safety or quality issues (or the perception of such issues) with respect to, “off label” use of, or inadequate disclosure of risks relating to the use of products and services that we make or sell (including items that we source from third-parties) can lead to personal injury, death, and/or property damage and adversely affect our business and financial statements. These events can lead to recalls or safety alerts, result in the removal of a product or service from the market and result in product liability or similar claims being brought against us. Recalls, removals and product liability and similar claims (regardless of their validity or ultimate outcome) result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products and services. Our business can also be affected by studies of the utilization, safety and efficacy of medical device products and components that are conducted by industry participants, government agencies and others. Any of the above can result in the discontinuation of marketing of such products in one or more countries and give rise to claims for damages from persons who believe they have been injured as a result of product issues, including claims by individuals or groups seeking to represent a class.

 

Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.

 

Most of our reagent products need to be stored and shipped at certain cold temperatures.  Consequently, we ship a significant portion of our products to our customers by express mail or air delivery through package delivery companies, such as FedEx in the U.S. and DHL in Europe. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely affected.

 

19
 

 

Intellectual Property Risks

 

We are dependent on maintaining our intellectual property rights. If we are unable to adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.

 

Many of the markets we serve are technology-driven, and as a result intellectual property rights play a significant role in product development and differentiation. We own numerous patents, trademarks, copyrights, trade secrets and other intellectual property and licenses to intellectual property owned by others, which in aggregate are important to our business. The intellectual property rights that we obtain, however, are not always sufficiently broad and do not always provide us a significant competitive advantage, and patents may not be issued for pending or future patent applications owned by or licensed to us. In addition, the steps that we and our licensors have taken to maintain and protect our intellectual property do not always prevent it from being challenged, invalidated, circumvented, designed-around or becoming subject to compulsory licensing. In some circumstances, enforcement is not available to us because an infringer has a dominant intellectual property position or for other business reasons. We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements adequately protect our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or other proprietary rights.

 

These risks are particularly pronounced in countries in which we do business that do not have levels of protection of corporate proprietary information, intellectual property, technology and other assets comparable to the United States. We operate globally, with manufacturing operations in China and the UK, and approximately 46% of our revenue from outside the United States.   The laws, regulations and enforcement mechanisms in other countries may in some cases be less protective of our intellectual property rights. Our failure to obtain or maintain intellectual property rights that convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized use of such property and the cost of enforcing our intellectual property rights can adversely impact our business and financial statements.

 

We may be involved in disputes to determine the scope, coverage and validity of others' proprietary rights, or to defend against third-party claims of intellectual property infringement, any of which could be time-intensive and costly and may adversely impact our business.

 

Our success depends in part on its ability to operate without infringing the proprietary rights of others, and to obtain licenses where necessary or appropriate. We have obtained and continue to negotiate licenses to produce a number of products claimed to be owned by others. Since we have not conducted a patent infringement study for each of our products, it is possible that some of our products may unintentionally infringe patents of third parties.

 

We have been and may in the future be sued by third parties alleging that we are infringing their intellectual property rights. These lawsuits are expensive, take significant time, and divert management's focus from other business concerns. If we are found to be infringing the intellectual property of others, we could be required to cease certain activities, alter our products or processes or pay licensing fees. This could cause unexpected costs and delays which may have a material adverse effect on us. If we are unable to obtain a required license on acceptable terms, or unable to design around any third party patent, we may be unable to sell some of our products and services, which could result in reduced revenue. In addition, if we do not prevail, a court may find damages or award other remedies in favor of the opposing party in any of these suits, which may adversely affect our earnings.

 

20
 

 

Financial and Tax Risks

 

We have entered into and drawn on a revolving credit facility, and we may incur additional debt in the future.  The burden of this additional debt could adversely affect us, make us more vulnerable to adverse economic or industry conditions, and prevent us from funding our expansion strategy.

 

We currently have a Credit Agreement that provides for a revolving credit facility of $600 million, which can be increased by an additional $200 million subject to certain conditions, and a term loan of $250 million. Borrowings under the Credit Agreement bear interest at a variable rate. As of August 20, 2021, the Company had drawn $335 million under the Credit Agreement.

 

The terms of the Credit Agreement and the burden of the indebtedness incurred thereunder could have negative consequences for us, such as:

 

 

●

limiting our ability to obtain additional financing to fund our working capital, capital expenditures, debt service requirements, expansion strategy, or other needs;

 

 

●

increasing our vulnerability to, and reducing our flexibility in planning for, adverse changes in economic, industry and competitive conditions; and

 

 

●

increasing our vulnerability to increases in interest rates.

 

The Credit Agreement also contains negative covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things, sell, lease or transfer any properties or assets, with certain exceptions; and enter into certain merger, consolidation or other reorganization transactions, with certain exceptions.

 

A breach of any of these covenants could result in an event of default under our credit facility. Upon the occurrence of an event of default, the lender could elect to declare all amounts outstanding under such facility to be immediately due and payable and terminate all commitments to extend further credit. In addition, the Company would be subject to additional restrictions if an event of default exists under the Credit Agreement, such as a prohibition on the payment of cash dividends.

 

Our business and financial statements can be adversely affected by foreign currency exchange rates, changes in our tax rates and tax liabilities and assessments (including as a result of changes in tax laws).

 

International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally invoice third-party customers in currencies other than the one in which they primarily do business (the "functional currency"). Movements in the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow, exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In fiscal 2021, currency translation had an unfavorable effect of $5.2 million on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.

 

As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. In particular, we are affected by the impact of changes to tax laws or related authoritative interpretations in the United States, including tax reform under the Tax Cuts and Jobs Act which became effective in late 2017, which included broad and complex changes to the United States tax code.  Interpretations, assumptions and guidance regarding the Tax Act that have been issued subsequently have had a material impact on our effective tax rate, and we anticipate that there may be additional changes to the U.S. tax code under a new Administration.

 

In preparing our financial statements, we record the amount of tax that is payable in each of the countries, states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of operations and cash flows.

Dividends on our common stock could be reduced or eliminated in the future.

For many years, our Board has declared quarterly dividends ranging from of $0.25 to $0.32 cents per share. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

 

21
 

 

Legal, Regulatory, Compliance and Reputational Risks 

 

Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results.   

 

As referenced in more detail above, we and our customers must comply with a wide array of federal, state, local and international regulations, in such areas as medical device, healthcare, import and export, anticorruption, and privacy. We develop, configure and market our products to meet customer needs created by those regulations. Any significant change in regulations could reduce demand for our products or increase our expenses. For example, many of our instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs and diagnostic products. Changes in the U.S. FDA’s regulation of drug or medical device products could have an adverse effect on the demand for these products.

 

We have agreements relating to the sale of our products to government entities in the U.S. and elsewhere and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government (less than 2% of our fiscal 2021 sales were made to the U.S. federal government). The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.

 

We are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the U.S. FDA, the U.S. Drug Enforcement Agency (the DEA), the U.S. Department of Health and Human Services (the DHHS), and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices. Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the FDA, the DHHS, foreign agencies and/or comparable state agencies as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale. The manufacture, distribution and marketing of many of our products and services, including medical devices and pharma services, are subject to extensive ongoing regulation by the FDA, the DEA, and other equivalent local, state, federal and non-U.S. regulatory authorities. In addition, we are subject to inspections by these regulatory authorities. For example, the EU has adopted the In Vitro Diagnostic Regulation (the “EU IVDR”), which imposes stricter requirements for the marketing and sale of in vitro diagnostic medical devices, including in the area of clinical evaluation requirements, quality systems and post-market surveillance.  Manufacturers of currently approved in vitro diagnostics medical devices have until May 2022 to meet the EU IVDR. Complying with EU IVDR, the regulation applicable to the Company, requires material modifications to our quality management systems, additional resources in certain functions, updates to technical files and additional clinical data in some cases, among other changes. Failure by us or by our customers to comply with the requirements of the EU IVDR, or other requirements imposed by these or similar regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are the sole manufacturer of a number of products for many of our customers and a negative regulatory event could impact our customers' ability to provide products to their customers.

 

We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the importation and exportation of products, the handling, transportation and manufacture of substances that could be classified as hazardous, and our business practices in the U.S. and abroad such as anti-competition laws. Any noncompliance by us with applicable laws and regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of operations. 

 

Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto can have an adverse effect on our business and financial statements.

 

Significant developments or changes in U.S. laws and policies (including as a result of the new U.S. administration), such as laws and policies governing foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate, or governing the health care system and drug prices, can adversely affect our business and financial statements. For example, the previous U.S. administration increased tariffs on certain goods imported into the United States and trade tensions between the United States and China escalated, with each country imposing significant, additional tariffs on a wide range of goods imported from the other country. The U.S. and China could impose other types of restrictions such as limitations on government procurement or technology export restrictions, which could affect our access to markets. These factors have adversely affected, and in the future could further adversely affect, our business and financial statements.

 

Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business partners.

 

We cannot provide assurance that our internal controls and compliance systems, including our Code of Ethics and Business Conduct, protect us from acts committed by employees, agents or business partners of ours (or of businesses we acquire or partner with) that violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud, kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, economic and trade sanctions, money laundering and data privacy. In particular, the U.S. Foreign Corrupt Practices Act, the UK Bribery Act and similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and subject us to civil or criminal investigations in the United States and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal, monetary and non-monetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable for violations committed by companies in which we invest or that we acquire. We also rely on our suppliers to adhere to our supplier code of conduct, and material violations of such code of conduct could occur that could have a material effect on our business and financial statements.

 

22
 

 

Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial statements.

 

Certain of our products are medical devices, diagnostics tests and other products that are subject to regulation by the U.S. FDA or state CLIA regulations, by other federal and state governmental agencies, by comparable agencies of other countries and regions and by regulations governing hazardous materials and drugs-of abuse (or the manufacture and sale of products containing any such materials). The global regulatory environment has become increasingly stringent and unpredictable. Several countries that did not have regulatory requirements for medical devices have established such requirements in recent years, and other countries have expanded, or plan to expand, their existing regulations, including implementation of IVDR regulations in Europe. Failure to meet these requirements adversely impacts our business and financial statements in the applicable geographies.

 

Government authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law. Failure to obtain required regulatory clearances before marketing our products (or before implementing modifications to or promoting additional indications or uses of our products), other violations of laws or regulations, failure to remediate inspectional observations to the satisfaction of these regulatory authorities, real or perceived efficacy or safety concerns or trends of adverse events with respect to our products (even after obtaining clearance for distribution) and unfavorable or inconsistent clinical data from existing or future clinical trials can lead to FDA Form 483 Inspectional Observations, warning letters, notices to customers, declining sales, loss of customers, loss of market share, remediation and increased compliance costs, recalls, seizures of adulterated or misbranded products, fines, expenses, injunctions, civil penalties, criminal penalties, consent decrees, administrative detentions, refusals to permit importations, partial or total shutdown of production facilities or the implementation of operating restrictions, narrowing of permitted uses for a product, refusal of the government to grant 510(k) clearance, suspension or withdrawal of approvals, pre-market notification rescissions and other adverse effects.  Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions brought against us, our business may be impaired. Ensuring that our internal operations and business arrangements with third parties comply with applicable laws and regulations also involves substantial costs.

 

More specifically, as a healthcare provider, the Company’s Exosome Diagnostics’ ExoDx Prostate business is subject to extensive regulation at the federal, state, and local levels in the U.S. and other countries where it operates. The Company’s failure to meet governmental requirements under these regulations, including those relating to billing practices and financial relationships with physicians, hospitals, and health systems, could lead to civil and criminal penalties, exclusion from participation in Medicare and Medicaid, and possibly prohibitions or restrictions on the use of its laboratories. While the Company believes that it is in material compliance with all statutory and regulatory requirements, there is a risk that government authorities might take a contrary position. Such occurrences, regardless of their outcome, could damage the Company’s reputation and adversely affect important business relationships it has with third parties. 

 

Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Company’s reputation and have a material adverse effect upon the Company’s business, a risk that has been elevated with the acquisition of Exosome Diagnostics, whose laboratory testing service is a healthcare provider that obtains and uses protected health information.

 

If the Company does not comply with existing or new laws and regulations related to protecting the privacy and security of personal or health information, it could be subject to monetary fines, civil penalties or criminal sanctions. In the U.S., the Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy and security regulations, including the expanded requirements under U.S. Health Information Technology for Economic and Clinical Health Act (HITECH), establish comprehensive standards with respect to the use and disclosure of protected health information (PHI) by covered entities, in addition to setting standards to protect the confidentiality, integrity and security of PHI. HIPAA restricts the Company’s ability to use or disclose PHI, without patient authorization, for purposes other than payment, treatment or healthcare operations (as defined by HIPAA), except for disclosures for various public policy purposes and other permitted purposes outlined in the privacy regulations. If the laboratory operations for the Company’s business use or disclose PHI improperly under these privacy regulations, they may incur significant fines and other penalties for wrongful use or disclosure of PHI in violation of the privacy and security regulations, including potential civil and criminal fines and penalties.

 

23
 

 

 

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

There are no unresolved staff comments as of the date of this report.

 

ITEM 2. PROPERTIES

 

The Company owns the facilities that its headquarters and R&D Systems subsidiary occupy in Minneapolis, Minnesota. The Minneapolis facilities are utilized by both the Company's Protein Sciences and Diagnostics and Genomics segments.

 

The Minneapolis complex includes approximately 800,000 square feet of space in several adjoining buildings. Bio-Techne uses approximately 625,000 square feet of the complex for administrative, research, manufacturing, shipping and warehousing activities. The Company is currently leasing the remaining space in the complex as retail and office space. The Company also owns a 54,000 square foot facility in Saint Paul, Minnesota that will be utilized for additional manufacturing capabilities and activities.

 

The Company also owns a 34,000 square foot manufacturing facility in Flowery Branch, Georgia. This facility is utilized by the Company’s Protein Sciences segment.

 

The Company owns a 17,000 square foot facility that its Bio-Techne Europe subsidiary occupies in Abingdon, England. This facility is utilized by the Company's Protein Sciences and Diagnostics and Genomics segments.

 

The Company owns a 9,000 square foot facility that its Canada subsidiaries occupy in Toronto, Canada. This facility is utilized by the Company's Protein Sciences and Diagnostics and Genomics segments.

 

The Company owns a 52,700 square foot manufacturing facility in Wallingford, Connecticut. This facility is utilized by the Company's Protein Sciences segment.

 

The Company leases the following material facilities, all of which are primarily utilized by the Company's Protein Sciences segment with the exception of the locations used by the Company's ProteinSimple and CyVek subsidiaries, which support both the Protein Sciences segment and the Diagnostics & Genomics segment). Certain locations are not named because they were not significant individually or in the aggregate as of the date of this report.

 

Subsidiary

  

Location

  

Type

  

Square Feet

  
               

Bio-Techne Europe

  

Langley, United Kingdom

  

Warehouse

  

14,300

  

Bio-Techne China

  

Shanghai and Beijing, China

  

Office/warehouse

  

17,000

  

Boston Biochem

  

Cambridge, Massachusetts

  

Office/lab

  

7,400

  

Tocris

  

Bristol, United Kingdom

  

Office/manufacturing/lab/warehouse

  

30,000

  

PrimeGene

  

Shanghai, China

  

Office/manufacturing/lab

  

20,600

  

Bionostics

  

Devens, Massachusetts

  

Office/manufacturing

  

70,000

  

Novus Biologicals

  

Centennial, Colorado

  

Office/warehouse

  

22,500

  

ProteinSimple

  

San Jose, California

  

Office/manufacturing/warehouse

  

167,000

  
ProteinSimple Ltd.   Ottawa, Canada   Office/manufacturing/warehouse   10,800  

CyVek

  

Wallingford, Connecticut

  

Office/manufacturing/warehouse

  

17,500

  

Cliniqa

  

San Marcos, California

  

Office/manufacturing/warehouse

  

62,200

  

Advanced Cell Diagnostics

  

Newark, California

  

Office/manufacturing/warehouse

  

55,900

  

Bio-Techne France

  

Rennes, France

  

Office/warehouse

  

11,000

  

Exosome Diagnostics

  

Waltham, Massachusetts

  

Office/manufacturing/warehouse

  

28,000

  
R&D Systems   Minneapolis, Minnesota   Office/manufacturing/warehouse   10,700  
Asuragen   Austin, Texas   Office/manufacturing/warehouse   47,400  

 

The Company entered into a definitive agreement to lease a 25,000 square foot facility in Dublin, Ireland. Construction is currently underway and once complete, the commencement of the lease will occur. The Company believes the owned and leased properties, inclusive of the leased property in Ireland, are adequate to meet its occupancy needs in the foreseeable future.

 

ITEM 3. LEGAL PROCEEDINGS

 

As of August 20, 2021, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

24
Table of Contents
 

 

PART II

 

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED SHAREHOLDER

MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Holders of Common Stock and Dividends Paid

 

As of August 20, 2021 there were over 55,000 beneficial shareholders of the Company's common stock and over 90 shareholders of record. The Company paid annual cash dividends totaling $49.6 million, $48.9 million, and $48.4 million in fiscal 2021, 2020, and 2019, respectively. The Board of Directors periodically considers the payment of cash dividends, and there is no guarantee that the Company will pay comparable cash dividends, or any cash dividends, in the future. 

 

In connection with the acquisition of Exosome Diagnostics, Inc. on August 1, 2018, the Company entered into a new credit facility that provides for a revolving credit facility of $600 million, which can be increased by an additional $200 million subject to certain conditions, and a term loan of $250 million.  The credit facility is governed by a Credit Agreement dated August 1, 2018 and matures on August 1, 2023.  The Credit Agreement that governs the revolving line of credit contains customary events of default and would prohibit payment of dividends to Company shareholders in the event of a default thereunder.

 

Issuer Purchases of Equity Securities

 

During the years ended June 30, 2021 and June 30, 2020, the Company repurchased 120,000 shares of its common stock at an average share price of $359.82 and 279,381 shares at an average share price of $179.37, respectively. During fiscal 2019, the Board implemented a new repurchase plan, which grants management the discretion to mitigate the dilutive effect of stock option exercises by authorizing repurchase of shares up to the amount of stock returned to the corporation through stock option exercises, beginning with those option exercises occurring in fiscal year 2018. As of June 30, 2021, we have authorization of approximately $63 million that may yet be used to purchase additional shares under our current stock repurchase program. 

 

25
Table of Contents

 

Stock Performance Graph

 

The following chart compares the cumulative total shareholder return on the Company's common stock with the S&P Midcap 400 Index and the S&P 400 MidCap Life Sciences Tools and Services Index.  The comparison assumes $100 was invested on the last trading day before July 1, 2016 in the Company's common stock and in each of the foregoing indices and assumes reinvestment of dividends.

 

 

 
grph01.jpg

 
     
 

 

  

 

26
Table of Contents
 

 

ITEM 6. SELECTED FINANCIAL DATA

RESERVED

 

 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

 

 

The following management discussion and analysis (“MD&A”) provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the effect of acquisitions and changes in foreign currency at the corporate and segment level. We also provide quantitative information about discrete tax items and other significant factors we believe are useful for understanding our results. The MD&A should be read in conjunction with the consolidated financial information and related notes included in this Form 10-K. This discussion contains various “Non-GAAP Financial Measures” and also contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” located at the end of this MD&A and “Forward-Looking Information and Cautionary Statements” and “Risk Factors” within Items 1 and 1A of this Form 10-K.

 

OVERVIEW

 

Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

During our fiscal year 2021, we operated with two operating segments – our Protein Sciences segment and our Diagnostics and Genomics segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Genomics and Diagnostics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for spatial genomics research and clinical use.    

 

OVERALL RESULTS

 

Operational Update

 

For fiscal 2021, consolidated net sales increased 26% as compared to fiscal 2020. Organic growth was 22%, with currency translation and acquisitions having a 3% and 1% impact on revenue respectively. Organic revenue growth was broad based and driven by accelerated momentum of the Company's long-term growth strategy as well as customer site closures in the latter half of fiscal 2020 due to the COVID-19 pandemic. 

 

For fiscal 2021, consolidated earnings, including non-controlling interest, decreased 39% compared to fiscal 2020. The decrease in earnings was primarily due to a non-operating loss of approximately $67.9 million on our ChemoCentryx investment, compared to a gain on investment of $137 million in the last fiscal year. After adjusting for acquisition related costs, intangibles amortization, stock-based compensation, restructuring costs, the loss on investment, certain income tax items in both years, and non-controlling interest, adjusted net earnings increased 52% in fiscal 2021 as compared to fiscal 2020. Adjusted earnings growth was driven by volume leverage, operational productivity, and product mix.

 

For fiscal 2020, consolidated net sales increased 4% as compared to fiscal 2019. Organic growth was 4%, with currency translation and acquisitions having an immaterial impact on revenue. The Company experienced broad-based organic revenue growth in most major geographic regions and end-markets prior to the onset of the COVID-19 pandemic. This broad-based organic growth was partially offset by the negative impacts associated with the COVID-19 pandemic experienced by the Company in the latter half of fiscal year 2020.

 

For fiscal 2020, consolidated earnings, including non-controlling interest, increased 139% compared to fiscal 2019. The increase in earnings was primarily due to a non-operating gain of approximately $137 million on our ChemoCentryx investment and a gain of approximately $7 million on the settlement of the escrow balance associated with the Exosome acquisition. After adjusting for acquisition related costs, stock-based compensation, and certain income tax items in both years, adjusted net earnings increased 2% in fiscal 2020 as compared to fiscal 2019. Adjusted earnings growth was driven by volume leverage, which was partially offset by business impacts associated with the COVID-19 pandemic. 

 

27
 

 

COVID-19 Business Update

 

The global spread of COVID-19 in the past 18 months has led to unprecedented restrictions on, and disruptions in, business and personal activities, including as a result of preventive and precautionary measures that we, other businesses, our communities and governments have taken and are taking to mitigate the spread of the virus and to manage its impact. While a number of vaccines developed in response to the pandemic appear to be effective in mitigating spread of the disease, we continue to actively monitor the pandemic on a global scale.  We have taken and intend to continue taking steps to identify and mitigate the adverse impacts on, and risks to, our business (including but not limited to our employees, customers, business partners, manufacturing capabilities and capacity, and supply and distribution channels) posed by the spread of COVID-19 and the governmental and community responses thereto.

 

The Company has responded to the pandemic by leveraging our deep product portfolio and scientific expertise to develop robust COVID-19 product and service offerings providing critical support for both clinical care and therapeutic development. While our sales related to COVID-19 specific products have been modest, fiscal 2021 growth benefited from the reopening of customer sites initially closed in the latter half of fiscal 2021 and our ongoing efforts to utilize our portfolio of products and services to enable solutions for this evolving pandemic.

 

We are unable to forecast the impact of COVID-19 on future revenue given the uncertainty that some customer sites may close again due to increases in COVID-19 cases occurring in their region and over the duration of the COVID-19 pandemic, especially if current vaccines prove to be ineffective against new strains of the Coronavirus that may develop over time. We anticipate a positive long-term outlook for sales growth resulting from expected future funding increases within life-science research in response to the current pandemic. Similar to current periods, we anticipate the impact on EPS to be similar to that of sales growth.

 

The Company remains in a strong financial position with sufficient available cash as well as access to additional funding, if necessary, through our long-term debt agreement. We did not experience any material changes to our June 30, 2021 nor our June 30, 2020 Balance Sheet, resulting from COVID-19 for items such as additional reserves or asset impairments resulting from the pandemic.

 

The Company has remained fully operational as we abided by local COVID-19 safety regulations across the world this past year. As the pandemic has eased, in most locations we will be returning all employees to on site work, although in certain instances we will continue to operate with appropriate safety measures, including staggered shifts, social distancing and hygiene best practices recommended by public health officials.  In addition, the Company has taken and will continue to take additional steps to monitor and strengthen our supply chain to maintain an uninterrupted supply of our critical products and services.

 

28
Table of Contents

 

RESULTS OF OPERATIONS

 

Net Sales

 

Consolidated organic net sales exclude the impact of companies acquired during the first 12 months post-acquisition and the effect of the change from the prior year in exchange rates used to convert sales in foreign currencies (primarily the euro, British pound sterling, and Chinese yuan) into U.S. dollars.

 

Consolidated net sales growth was as follows:

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Organic sales growth

     22

%

     4

%

     10

%

Acquisitions sales growth

     1

%

     0

%

     2

%

Impact of foreign currency fluctuations

     3

%

     0

%

     (1

)%

Consolidated net sales growth

     26

%

     4

%

     11

%

 

Consolidated net sales by segment were as follows (in thousands): 

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Protein Sciences

   $ 704,564     $ 555,352     $ 543,159  

Diagnostics and Genomics

     227,744       184,549       171,674  

Intersegment

     (1,276

)

     (1,210

)

     (827

)

Consolidated net sales

   $ 931,032     $ 738,691     $ 714,006  

 

In fiscal 2021, Protein Sciences segment net sales increased 27% compared to fiscal 2020. Organic growth for the segment was 24% for the fiscal year, with foreign currency translation having a favorable impact of 3%, and acquisitions contributing an immaterial amount. 

 

Overall segment growth was driven by continued market acceptance of our portfolio of productivity enhancing solutions across end-markets and geographies combined with the reopening of customer sites that were closed in the latter half of fiscal 2020 due to COVID-19. 

 

In fiscal 2021, Diagnostics and Genomics segment net sales increased 23% compared to fiscal 2020. Organic growth was 18% with acquisitions and foreign currency having a favorable impact of 4% and 1% impact on revenue, respectively.

 

Overall segment revenue growth was broad based across product lines and geographies.  RNAscope products had an exceptional year in both the Academia and Bio-Pharma end markets, while the Exosome product line also provided year over year growth despite navigating limitations and/or customer avoidance of non-essential medical procedures throughout fiscal 2021 associated with the COVID-19 pandemic.   

 

In fiscal 2020, Protein Sciences segment net sales increased 2% compared to fiscal 2019. Organic growth for the segment was 3% for the fiscal year, with foreign currency translation having an unfavorable impact of 1%, and acquisitions contributing an immaterial amount. 

 

Overall segment growth was driven by strong Bio-Pharma sales in North America and strong overall performance in China, which was partially offset by the disruption in research markets due to numerous customer site closures relating to the COVID-19 pandemic that occurred in the second half of fiscal 2020.

 

In fiscal 2020, Diagnostics and Genomics segment net sales increased 8% compared to fiscal 2019. Organic growth was 8% with acquisitions and foreign currency having an immaterial impact on revenue.

 

Overall segment revenue growth was driven by strong performance in our ExoDx Prostate Test, RNAscope, hematology, and assay development products lines prior to the onset of the COVID-19 pandemic. The closure of academic site labs and limitation of non-essential medical procedures resulting from the COVID-19 pandemic significantly impacted sales of our RNAscope product line and our ExoDx Prostate Test, respectively, in the latter portion of the fiscal year. These negative sales impacts were partially offset through growth in supplying specialty diagnostic antibodies and other raw materials to COVID-19 testing manufacturers.

 

29
Table of Contents

 

Gross Margins

 

Consolidated gross margins were 68.0%, 65.4%, and 66.3% in fiscal 2021, 2020, and 2019. Consolidated gross margins were positively impacted as a result of broad based revenue growth and cost management. Excluding the impact of acquired inventory sold, amortization of intangibles, and stock compensation expense, adjusted gross margins were 72.2%, 70.3%, and 71.5% in fiscal 2021, 2020, and 2019 respectively. Fiscal 2021 adjusted gross margin was positively impacted by volume leverage and product mix when compared to fiscal 2020 and fiscal 2019.

 

A reconciliation of the reported consolidated gross margin percentages, adjusted for acquired inventory sold and intangible amortization included in cost of sales, is as follows:

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Consolidated gross margin percentage

     68.0

%

     65.4

%

     66.3

%

Identified adjustments:

                        

Costs recognized upon sale of acquired inventory

     0.2

%

     -

%

     0.5

%

Amortization of intangibles

     3.8

%

     4.7

%

     4.7

%

Stock compensation expense - COGS

     0.2

%

     0.2

%

     -

%

Non-GAAP adjusted gross margin percentage

     72.2

%

     70.3

%

     71.5

%

 

Fluctuations in adjusted gross margins, as a percentage of net sales, have primarily resulted from changes in foreign currency exchange rates and changes in product mix. We expect that, in the future, gross margins will continue to be impacted by the mix of our portfolio growing at different rates as well as future acquisitions.

 

Management uses adjusted operating results to monitor and evaluate performance of the Company’s two segments. Segment gross margins, as a percentage of net sales, were as follows: 

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Protein Sciences

     76.0

%

     75.0

%

     76.8

%

Diagnostics and Genomics

     60.5

%

     55.6

%

     54.4

%

 

The changes in the Protein Sciences segment’s gross margin percentage for fiscal 2021 as compared to fiscal 2020 and 2019 was primarily attributable to mix of product sales within the segment. 

 

The increase in Diagnostics and Genomics in gross margin for fiscal 2021 as compared to fiscal 2020 was primarily due to volume leverage. The increase in Diagnostics and Genomics in gross margin for fiscal 2020 as compared to fiscal 2019 was primarily due to volume leverage, operational productivity, and revenue growth against a similar cost base in recent acquisitions.

 

30
Table of Contents

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses increased $64.4 million (25%) in fiscal 2021 when compared to fiscal 2020. Selling, general, and administrative expenses increased primarily due to investments made by the Company to support volume growth within each of the segments as well as additional expenses related to the acquisition of Asuragen, Inc.

 

Selling, general and administrative expenses decreased $3.8 million (1%) in fiscal 2020 when compared to fiscal 2019. Selling, general, and administrative expenses decreased primarily due to a reduction in corporate expenses and a gain resulting from a settlement of amounts held in escrow from the ExosomeDx acquisition between the Company and the former shareholders. These reductions to our selling, general, and administrative expenses were partially offset by an increase in expense within the segments. 

 

Consolidated selling, general and administrative expenses were composed of the following (in thousands):

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Protein Sciences

   $ 159,489     $ 138,792     $ 135,513  

Diagnostics and Genomics

     75,160       65,407       61,646  

Total segment expenses

     234,649       204,199       197,159  

Amortization of intangibles

     27,788       26,358       25,210  

Acquisition related expenses

     7,097       415       2,282  

Gain on escrow litigation

     -

 

     (7,159 )     -  

Restructuring costs

     142       87       -  

Stock-based compensation

     50,200       32,667       33,057  

Corporate selling, general and administrative expenses

     5,075       4,016       6,651  

Total selling, general and administrative expenses

   $ 324,951     $ 260,583     $ 264,359  

 

Research and Development Expenses

 

Research and development expenses increased $5.4 million (8%) and $2.8 million (4%) in fiscal 2021 and 2020, respectively, as compared to prior year periods. The increase in research and development expenses in fiscal 2021 as compared to fiscal 2020 was primarily attributable to continued investment in future growth platforms of the Company and recent acquisitions. The increase in research and development expenses in fiscal 2020 as compared to fiscal 2019 was primarily attributable to continued investment in future growth platforms of the Company, recent acquisitions, and the development of new COVID-19 products.

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Protein Sciences

   $ 46,361     $ 43,022     $ 40,735  

Diagnostics and Genomics

     24,242       22,170       21,678  

Total segment expenses

     70,603       65,192       62,413  

Unallocated corporate expenses

     -       -       -  

Total research and development expenses

   $ 70,603     $ 65,192     $ 62,413  

 

31
Table of Contents

 

Net Interest Income / (Expense)

 

Net interest income/(expense) for fiscal 2021, 2020, and 2019 was $(13.5) million, $(18.6) million, and $(21.1) million, respectively. Net interest expense in fiscal 2021 decreased when compared to fiscal 2020 due to a reduction in our average long-term debt, which coincided with a reduction in the notional amount on our variable interest derivative. Net interest expense in fiscal 2020 decreased when compared to fiscal 2019 due to a reduction in our average long-term debt.

 

Other Non-Operating Expense, Net

 

Other non-operating expense, net, consists of foreign currency transaction gains and losses, rental income, building expenses related to rental property and the Company's gains and losses on investments as follows (in thousands):

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Foreign currency gains (losses)

   $ (6,650 )   $ 1,703

 

   $ (455

)

Rental income

     1,036       1,140       1,141  

Real estate taxes, depreciation and utilities

     (1,845

)

     (1,915

)

     (1,897

)

Gain (loss) on investment

     (68,047 )     137,508

 

     (12,370 )

Miscellaneous (expense) income

     (136

)

     (786 )     13

 

Other non-operating income (expense), net

   $ (75,642 )   $ 137,650

 

   $ (13,568

)

 

During fiscal 2021, the Company recognized losses of $67.9 million related to changes in fair value associated with changes in the stock price of our ChemoCentryx, Inc. (CCXI) investment.

 

During fiscal 2020, the Company recognized gains of $137.5 million related to changes in fair value associated with changes in the stock price of our ChemoCentryx, Inc. (CCXI) investment.

 

During fiscal 2019, the Company recognized losses of $16.1 million related to changes in fair value associated with changes in the stock price of our ChemoCentryx, Inc. (CCXI) investment, which were partially offset by a $3.7 million gain realized upon acquisition from our historical investment in B-MoGen.

 

 

Income Taxes

 

Income taxes for fiscal 2021, 2020, and 2019 were at effective rates of 5.8%, 17.1%, and 14.2%, respectively, of consolidated earnings before income taxes. The change in the effective tax rate was driven by discrete tax items. The Company's discrete tax benefits in fiscal 2021 primarily related to share-based compensation excess tax benefits of $28.1 million. The Company's discrete tax benefits in fiscal 2020 primarily related to share-based compensation excess tax benefits of $17.7 million. The Company's discrete tax benefits in fiscal 2019 primarily related to share-based compensation excess tax benefits of $7.2 million, $3.2 million related to deductible acquisition payments made to employees and third parties, and $2.0 million for tax refunds relating to certain state apportionments.

 

32
Table of Contents

 

Net Earnings

 

Non-GAAP adjusted consolidated net earnings and earnings per share are as follows (in thousands):

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Earnings before taxes - GAAP

   $ 148,175     $ 276,477     $ 112,015  

Identified adjustments attributable to Bio-Techne:

                        

Costs recognized upon sale of acquired inventory

     1,565       -       3,739  

Amortization of intangibles

     64,239       60,865       58,550  

Acquisition related expenses

     7,489       793       2,656  

Gain on escrow settlement

     -

 

     (7,170 )     -  

Restructuring costs

     142       87       -  

Stock-based compensation, inclusive of employer taxes

     51,846       34,262       33,057  

Realized (gain) loss on investments and other

     68,391       (136,716 )     12,370

 

Impact of non-controlling interest (pre-tax)

     680       -       -

 

Earnings before taxes - Adjusted

   $ 342,527     $ 228,598     $

222,387

  
                         
Non-GAAP tax rate     20.2 %     21.6 %     21.1 %
Non-GAAP tax expense     69,334       49,280       46,931  

 

                        
Non-GAAP adjusted net earnings attributable to Bio-Techne   $ 273,193       179,318       175,456  
                         
Earnings per share - diluted - Adjusted     6.75       4.55       4.51  

 

Depending on the nature of discrete tax items, our reported tax rate may not be consistent on a period to period basis. The Company independently calculates a non-GAAP adjusted tax rate considering the impact of discrete items and jurisdictional mix of the identified non-GAAP adjustments. The following table summarizes the reported GAAP tax rate and the effective Non-GAAP adjusted tax rate for the periods ended June 30, 2021, 2020, and 2019.

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

GAAP effective tax rate

     5.8 %     17.1

%

     14.2

%

Discrete items

     19.0       7.0       11.2  

Long-term GAAP tax rate

     24.8 %     24.1 %     25.4  
                         

Rate impact items

                        
Stock based compensation     (5.7 )%     (2.4 )%     (4.8 )%
Acquisition costs     (0.2 )     0.4       0.5  
Change in fair value of investments     0.5       (0.4 )     -  
Other     0.8       (0.1 )     -  
Total rate impact items     (4.6 )%     (2.5 )%     (4.3 )%
                         
Non-GAAP tax rate     20.2 %     21.6 %     21.1 %

 

Refer to Note 11 for additional discussion relating to the change in discrete tax items between fiscal 2021 and fiscal 2020.

 

33
Table of Contents
 

 

LIQUIDITY AND CAPITAL RESOURCES

 

Cash, cash equivalents and available-for-sale investments at June 30, 2021 were $231.6 million compared to $270.9 million at June 30, 2020. Included in available-for-sale investments at June 30, 2021 and June 30, 2020 was the fair value of the Company's investment in CCXI of $20.0 million and $87.8 million, respectively.

 

At June 30, 2021, approximately 12% of the Company's cash and equivalent account balances of $199.1 million were located in the U.S., with the remainder located in primarily in Canada, China, the U.K. and other European countries.

 

At June 30, 2021, approximately 61% of the Company's available-for-sale investment account balances of $32.5 million were located in the U.S., with the remaining 39% in China.

 

The Company has either paid U.S. taxes on its undistributed foreign earnings or intends to indefinitely reinvest the undistributed earnings in the foreign operations or expects the earnings will be remitted in a tax neutral transaction. Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available funds, including funds available through our line-of-credit and cash generated from operations.

 

Future acquisition strategies may or may not require additional borrowings under the line-of-credit facility or other outside sources of funding.

 

Cash Flows From Operating Activities

 

The Company generated cash from operations of $352.2 million, $205.2 million, and $181.6 million in fiscal 2021, 2020, and 2019 respectively. The increase in cash generated from operating activities in fiscal 2021 as compared to fiscal 2020 was mainly a result of an increase in year over year operating income of $79.9 million and a $29.3 million benefit to operating cash from year-over-year changes in operating assets and liabilities as well as a non-cash stock-based compensation expense of $16.6 million. The increase in cash generated from operating activities in fiscal 2020 as compared to fiscal 2019 was mainly a result of higher GAAP earnings and lower accounts receivable balances in fiscal 2020, which were partially offset by the gain on investments included within earnings.

 

Cash Flows From Investing Activities

 

We continue to make investments in our business, including capital expenditures. The Company acquired Eminence Biotechnology and Asuragen, Inc. during fiscal year 2021 for a total of approximately $225.4 million, net of cash acquired. The Company did not make any acquisitions in fiscal 2020. Net cash paid for acquisitions of Quad, Exosome, and B-MoGen was $289.5 million in fiscal 2019.

 

The Company's net proceeds (outflow) from the purchase, sale and maturity of available-for-sale investments in fiscal 2021, 2020, and 2019 were $26.7 million, $76.9, and ($21.9 million) million, respectively. The decrease in fiscal 2021 compared to fiscal 2020 was driven by the sale of a portion of the CCXI investment in fiscal year 2020, which did not reoccur in fiscal year 2021. The increase in fiscal 2020 compared to fiscal 2019 was driven by the sale of a portion of the Company’s investment in CCXI in fiscal 2020.The Company's investment policy is to place excess cash in certificates of deposit with the objective of obtaining the highest possible return while minimizing risk and keeping the funds accessible.

 

Capital additions in fiscal year 2021, 2020, and 2019 were $44.3 million, $51.7 million, and $25.4 million. Fiscal 2021 capital expenditures related to investments in new buildings, in particular, the Company's GMP manufacturing facility. Capital additions planned for fiscal 2022 are approximately $68.4 million and are expected to be financed through currently available cash and cash generated from operations. Increase in expected additions in fiscal 2022 is related to increasing capacity to meet expected sales growth across the Company and reduced expenditures in the comparable period, fiscal year 2021, due to the COVID-19 pandemic. 

 

34
 

 

Cash Flows From Financing Activities

 

In fiscal 2021, 2020, and 2019, the Company paid cash dividends of $49.6 million, $48.9 million, $48.4 million, respectively. The Board of Directors periodically considers the payment of cash dividends.

 

The Company received $65.1 million, $71.0 million, $38.0 million, for the exercise of options for 627,000, 743,000, 382,000 shares of common stock in fiscal 2021, 2020 and 2019, respectively. 

 

During fiscal 2021, 2020, and 2019, the Company repurchased $43.2 million, $50.1 million, and $15.4 million, respectively, in share repurchases included as a cash outflow within Financing Activities.

 

During fiscal 2021, 2020, and 2019, the Company drew $256.0 million, $40.0 million, and $580.0 million, respectively, under its revolving line-of-credit facility. Repayments of $271.5 million, $188.5 million, and $413.5 million were made on its line-of-credit in fiscal 2021, 2020, and 2019, respectively. 

 

During fiscal 2021, there were no payments related to contingent consideration classified as financing activities. The Company made $0.3 million in contingent consideration payments, which were classified within operating activities. During fiscal 2020, the Company made $4.4 million ($4 million for Quad and $0.4 million for B-MoGen) in cash payments towards the Quad, Exosome, and B-MoGen contingent consideration liabilities. Of the $4.4 million in total payments, $3.4 million is classified as financing on the statement of cash flows. The remaining $1 million is recorded as operating on the statement of cash flows as it represents the consideration liability that exceeds the amount of the contingent consideration liability recognized at the acquisition date. During fiscal 2019, the Company made no cash payments towards the Quad, Exosome, and B-MoGen contingent consideration liabilities.

 

During fiscal 2021 and 2020, the Company paid $19.3 million and $3.8 million, respectively, for net share settlements. During fiscal 2019, other financial activities includes payments for net share settlements as well as the final payment of $1.4 million related to Eurocell. This is included as a cash outflow within the other financing activities line of the consolidated statements of cash flows. 

 

35
Table of Contents

 

 

CRITICAL ACCOUNTING POLICIES

 

Management's discussion and analysis of the Company's financial condition and results of operations are based upon the Company's Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

The Company has identified the policies outlined below as critical to its business operations and an understanding of results of operations. The listing is not intended to be a comprehensive list of all accounting policies; investors should also refer to Note 1 to the Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.

 

Business Combinations

 

We allocate the purchase price of acquired businesses to the estimated fair values of the assets acquired and liabilities assumed as of the date of the acquisition. The calculations used to determine the fair value of the long-lived assets acquired, primarily intangible assets, can be complex and require significant judgment. We weigh many factors when completing these estimates including, but not limited to, the nature of the acquired company’s business; its competitive position, strengths, and challenges; its historical financial position and performance; estimated customer retention rates; discount rates; and future plans for the combined entity. We may also engage independent valuation specialists, when necessary, to assist in the fair value calculations for significant acquired long-lived assets.

 

The fair value of acquired technology is generally the primary asset identified and therefore estimated using the multi-period excess earnings method. The multi-period excess earnings method model estimates revenues and cash flows derived from the primary asset and then deducts portions of the cash flow that can be attributed to supporting assets, such as Trade Names and in-process research and development, that contributed to the generation of the cash flows. The resulting cash flow, which is attributable solely to the primary asset acquired, is then discounted at a rate of return commensurate with the risk of the asset to calculate a present value. The Trade Name is generally calculated using the relief from royalty method, which calculates the cost savings associated with owning rather than licensing the technology. Assumed royalty rates are applied to the projected revenues for the remaining useful life of the technology to estimate the royalty savings. In-process research and development assets are valued using the multi-period excess earnings method when the cash flows from the in-process research and development assets are separately identifiable from the primary asset. In circumstances that Customer Relationship assets are identified that are not the primary asset, they are valued using the distributor model income approach, which isolates revenues and cash flow associated with the sales and distribution function of the entity and attributable to customer-related assets, which are then discounted at a rate of return commensurate with the risk of the asset to calculate a present value.  

 

We estimate the fair value of liabilities for contingent consideration by discounting to present value the probability weighted contingent payments expected to be made. For potential payments related to financial performance based milestones, projected revenue and/or EBITDA amounts, volatility and discount rates assumptions are included in the estimated amounts. For potential payments related to product development milestones, the fair value is based on the probability of achievement of such milestones. The excess of the purchase price over the estimated fair value of the net assets acquired is recorded as goodwill. Goodwill is not amortized, but is subject to impairment testing on at least an annual basis.

 

We are also required to estimate the useful lives of the acquired intangible assets, which determines the amount of acquisition-related amortization expense we will record in future periods. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization.

 

While we use our best estimates and assumptions, our fair value estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Any adjustments required after the measurement period are recorded in the consolidated statements of earnings.

 

The judgments required in determining the estimated fair values and expected useful lives assigned to each class of assets and liabilities acquired can significantly affect net income. For example, different classes of assets will have useful lives that differ. Consequently, to the extent a longer-lived asset is ascribed greater value than a shorter-lived asset, net income in a given period may be higher. Additionally, assigning a lower value to amortizable intangibles would result in a higher amount assigned to goodwill. As goodwill is not amortized, this would benefit net income in a given period, although goodwill is subject to annual impairment analysis.

 

36
 

Impairment of Goodwill

 

Goodwill

 

Goodwill was $843.1 million as of June 30, 2021, which represented 37.3% of total assets. Goodwill is tested for impairment on an annual basis in the fourth quarter of each year, or more frequently if events occur or circumstances change that could indicate a possible impairment.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.

 

There has been no impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC 350 guidance for goodwill and other intangibles on July 1, 2002.

 

2021 Goodwill Impairment Analyses

 

In completing our 2021 annual goodwill impairment analyses, we elected to perform a quantitative assessment for each of our five reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017-04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

Because our 2021 quantitative analyses included all of our reporting units, the summation of our reporting units' fair values, as indicated by our discounted cash flow calculations, were compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit's results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

The quantitative assessment completed as of April 1, 2021 indicated that all of the reporting units had a substantial amount of headroom. Accordingly, the Company determined there was no indication of impairment of goodwill in our annual goodwill impairment analysis. Further, no triggering events were identified in the year ended June 30, 2021 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

2020 Goodwill Impairment Analyses

 

In completing our 2020 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017-04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

Because our 2020 quantitative analyses included all of our reporting units, the summation of our reporting units' fair values, as indicated by our discounted cash flow calculations, were compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit's results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

The quantitative assessment completed as of April 1, 2020 indicated that all of the reporting units had a substantial amount of headroom. Accordingly, the Company determined there was no indication of impairment of goodwill in our annual goodwill impairment analysis. Further, no triggering events were identified in the year ended June 30, 2020 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative impairment assessments performed utilized a consistent process with our fiscal 2021 quantitative goodwill impairment assessment described above. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment. This impairment assessment performed was sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit's results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test as of April 1, 2019, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. 

 

 

37
 

 

NEW ACCOUNTING PRONOUNCEMENTS

 

Information regarding the accounting policies adopted during fiscal 2021 and those not yet adopted can be found under caption “Note 1: Description of Business and Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements appear in Item 8 of this report. 

 

SUBSEQUENT EVENTS

 

None

 

NON-GAAP FINANCIAL MEASURES

 

This Annual Report on Form 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

 

●

Organic growth

●

Adjusted gross margin
● Adjusted operating margin

●

Adjusted net earnings

●

Adjusted effective tax rate

 

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

 

Our non-GAAP financial measure of organic growth represents revenue growth excluding revenue from acquisitions within the preceeding 12 months as well as the impact of foreign currency. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period.

 

Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including non-recurring costs and gains. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on legal settlements and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Additionally, these amounts can vary significantly from period to period based on current activity.

 

The Company’s non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes stock-based compensation expense, which is inclusive of the employer portion of payroll taxes on those stock awards, restructuring, impairments of equity method investments, gain and losses from investments, and certain adjustments to income tax expense. Impairments of equity investments are excluded as they are not part of our day-to-day operating decisions. Additionally, gains and losses from other investments that are either isolated or cannot be expected to occur again with any predictability are excluded.   Costs related to restructuring activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

 

The Company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.

 

Readers are encouraged to review the reconciliations of the adjusted financial measures used in management's discussion and analysis of the financial condition of the Company to their most directly comparable GAAP financial measures provided within the Company's consolidated financial statements.

 

38
Table of Contents
 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES

ABOUT MARKET RISK

 

The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency exchange rates. Approximately 31% of the Company's consolidated net sales in fiscal 2021 were made in foreign currencies, including  13% in euro, 5% in British pound sterling, 7% in Chinese yuan and the remaining 6% in other currencies. The Company is exposed to market risk primarily from foreign exchange rate fluctuations of the euro, British pound sterling, Chinese yuan and Canadian dollar as compared to the U.S. dollar as the financial position and operating results of the Company's foreign operations are translated into U.S. dollars for consolidation.

 

Month-end exchange rates between the euro, British pound sterling, Chinese yuan, Canadian dollar and the U.S. dollar, which have not been weighted for actual sales volume in the applicable months in the periods, were as follows:

 

   

Year Ended June 30,

          
   

2021

     2020     2019  

Euro:

                        

High

   $ 1.23     $ 1.12     $ 1.17  

Low

     1.16       1.09       1.12  

Average

     1.20       1.11       1.14  

British pound sterling:

                        

High

   $ 1.42     $ 1.32     $ 1.32  

Low

     1.29       1.22       1.27  

Average

     1.35       1.26       1.29  

Chinese yuan:

                        

High

   $ 0.16     $ 0.15     $ 0.15  

Low

     0.14       0.14       0.14  

Average

     0.15       0.14       0.15  

Canadian dollar:

                        

High

   $ 0.83     $ 0.77     $ 0.77  

Low

     0.75       0.71       0.74  

Average

     0.78       0.74       0.76  

 

The Company's exposure to foreign exchange rate fluctuations also arises from trade receivables and intercompany payables denominated in one currency in the financial statements, but receivable or payable in another currency.

 

The Company does not enter into foreign currency forward contracts to reduce its exposure to foreign currency rate changes on forecasted intercompany sales transactions or on intercompany foreign currency denominated balance sheet positions. Foreign currency transaction gains and losses are included in "Other non-operating expense, net" in the Consolidated Statement of Earnings and Comprehensive Income. The effect of translating net assets of foreign subsidiaries into U.S. dollars are recorded on the Consolidated Balance Sheet as part of "Accumulated other comprehensive income (loss)."

 

The effects of a hypothetical simultaneous 10% appreciation in the U.S. dollar from June 30, 2021 levels against the euro, British pound sterling, Chinese yuan and Canadian dollar are as follows (in thousands):

 

Decrease in translation of 2021 earnings into U.S. dollars

   $ 4,456  

Decrease in translation of net assets of foreign subsidiaries

     56,008  

Additional transaction losses

     1,755  

 

39
Table of Contents

 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

 

CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME

Bio-Techne Corporation and Subsidiaries
(in thousands, except per share data)

 

  

Year Ended June 30,

 
  

2021

  

2020

  2019 
             

Net sales

 $931,032  $738,691  $714,006 

Cost of sales

  298,182   255,497   240,515 

Gross margin

  632,850   483,194   473,491 
             

Operating expenses:

            

Selling, general and administrative

  324,951   260,583   264,359 

Research and development

  70,603   65,192   62,413 

Total operating expenses

  395,554   325,775   326,772 

Operating income

  237,296   157,419   146,719 
             

Other income (expense):

            

Interest expense

  (13,952

)

  (19,197

)

  (21,705

)

Interest income

  473   605   569 

Other non-operating income (expense), net

  (75,642)  137,650

 

  (13,568

)

Total other income (expense), net

  (89,121)  119,058

 

  (34,704

)

Earnings before income taxes

  148,175   276,477   112,015 

Income taxes (benefit)

  8,590   47,181   15,943

 

Net earnings, including noncontrolling interest  139,585   229,296   96,072 
Net earnings (loss) attributable to noncontrolling interest  (825)  -   - 
Net earnings attributable to Bio-Techne  140,410   229,296   96,072 

Other comprehensive income (loss):

            

Foreign currency translation adjustments

  32,951

 

  (9,963

)

  (4,487

)

Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8.

  7,060

 

  (3,715

)

  (9,537)

Other comprehensive income (loss)

  40,011

 

  (13,678

)

  (14,024)
Other comprehensive income (loss) attributable to noncontrolling interest  103   -   - 
   39,908   (13,678)  (14,024)
Comprehensive income attributable to Bio-Techne $180,318   215,618  $82,048 
             

Earnings per share:

            

Basic

 $3.62  $6.00  $2.54 

Diluted

 $3.47  $5.82  $2.47 
             

Weighted average common shares outstanding:

            

Basic

  38,747   38,201   37,781 

Diluted

  40,483   39,401   38,892 

 

See Notes to Consolidated Financial Statements.

 

40
Table of Contents
 

 

CONSOLIDATED BALANCE SHEETS

Bio-Techne Corporation and Subsidiaries
(in thousands, except share and per share data)

 

  

June 30,

 
  

2021

  2020 

ASSETS

        

Current assets:

        

Cash and cash equivalents

 $199,091  $146,625 

Short-term available-for-sale investments

  32,463   124,268 

Accounts receivable, less allowance for doubtful accounts of $1,229 and $775, respectively

  145,385   122,534 

Inventories

  116,748   103,152 

Other current assets

  16,919   24,341 

Total current assets

  510,606   520,920 
         

Property and equipment, net

  207,907   176,829 

Right of use asset

  73,834   71,465 

Goodwill

  843,067   728,308 

Intangible assets, net

  615,968   516,545 

Other assets

  11,575   13,522 

Total assets

 $2,262,957  $2,027,589 

LIABILITIES AND SHAREHOLDERS' EQUITY

        

Current liabilities:

        

Trade accounts payable

 $29,384  $23,090 

Salaries, wages and related accruals

  51,294   31,087 

Accrued expenses

  15,282   9,093 

Contract liabilities

  18,995   13,049 

Income taxes payable

  5,336   2,376 

Operating lease liabilities - current

  11,602   9,535 

Contingent consideration payable

  4,000   5,938 

Current portion of long-term debt obligations

  12,500   12,500 
Other current liabilities  3,891   - 

Total current liabilities

  152,284   106,668 
         

Deferred income taxes

  93,125   101,090 

Long-term debt obligations

  328,827   344,243 

Long-term contingent consideration payable

  25,400   199 

Operating lease liabilities

  67,625   67,248 

Other long-term liabilities

  24,462   26,949 
Bio-Techne's shareholders' equity:        
         

Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding

  -   - 

Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,955,484 and 38,453,046 shares, respectively

  390   385 

Additional paid-in capital

  534,411   420,536 

Retained earnings

  1,085,461   1,057,470 

Accumulated other comprehensive loss

  (57,291

)

  (97,199

)

Total Bio-Techne shareholders' equity  1,562,971   1,381,192 
Noncontrolling interest  8,263   - 

Total shareholders' equity

  1,571,234   1,381,192 

Total liabilities and shareholders’ equity

 $2,262,957  $2,027,589 

 

See Notes to Consolidated Financial Statements.

 

41
Table of Contents
 

 

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Bio-Techne Corporation and Subsidiaries
(in thousands) 

 

  

Common Stock

  

Additional
Paid-in

  

Retained

  

Accumulated
Other
Comprehensive

   

Noncontrolling

Interest

     
  

Shares

  

Amount

  

Capital

  

Earnings

  

Income(Loss)

      

Total

 
                             

Balances at June 30, 2018

  37,608  $376  $246,568  $876,931  $(44,814

)

 $-  $1,079,061 

Cumulative effect adjustments due to adoption of new accounting standards and other

            25,276   (24,682

)

     594 

Net earnings

            96,072         96,072 

Other comprehensive income (loss)

               (14,024

)

     (14,024

)

Share repurchases

  (95

)

  (1

)

     (15,404

)

        (15,405

)

Common stock issued for exercise of options

  382   4   36,272            36,276 

Common stock issued for restricted stock awards

  29   -      (2,575

)

        (2,575

)

Cash dividends

            (48,366

)

        (48,364

)

Stock-based compensation expense

         31,775            31,775 

Common stock issued to employee stock purchase plan

  10   -   1,676            1,676 

Employee stock purchase plan expense

         505            505 
Balances at June 30, 2019  37,934  $379  $316,797  $931,934  $(83,521) $-  $1,165,589 

Cumulative effect adjustments due to adoption of new accounting standards and other

            (879

)

        (879

)

Net earnings

            229,296         229,296 

Other comprehensive income (loss)

               (13,678

)

     (13,678

)

Share repurchases

  (279

)

  (3

)

     (50,109

)

        (50,112

)

Surrender and retirement of stock to exercise option

  (2

)

  -   (400

)

           (400

)

Common stock issued for exercise of options

  730   7   69,461   (1,642

)

        67,826 

Common stock issued for restricted stock awards

  56   1   (1

)

  (2,229

)

        (2,228

)

Cash dividends

            (48,902

)

        (48,902

)

Stock-based compensation expense

         31,932            31,932 

Common stock issued to employee stock purchase plan

  14   -   2,312            2,312 

Employee stock purchase plan expense

         435            435 
Balances at June 30, 2020  38,453  $385  $420,536  $1,057,470  $(97,199) $-  $1,381,192 
Cumulative effect adjustments due to adoption of new accounting standards and other            (276)        (276)
Non-controlling interest in Eminence                  8,985   8,985 
Net earnings            140,410    

 

 

(825

)  139,585 
Other comprehensive income (loss)               39,908   103   40,011 
Share repurchases  (120)  (1)     (43,177)        (43,178)
Common stock issued for exercise of options  573   6   62,102   (12,287)        49,821 
Common stock issued for restricted stock awards  38   0   (0)  (7,057)        (7,057)
Cash dividends            (49,622)        (49,622)
Stock-based compensation expense         48,065            48,065 
Common stock issued to employee stock purchase plan  11   0   2,791            2,791 
Employee stock purchase plan expense         917            917 
Balances at June 30, 2021  38,955  $390  $534,411  $1,085,461  $(57,291) $8,263  $1,571,234 

 

See Notes to Consolidated Financial Statements.

 

42
Table of Contents
 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

Bio-Techne Corporation and Subsidiaries
(in thousands)

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Cash flows from operating activities:

            

Net earnings, including non-controlling interest

 $139,585  $229,296  $96,072 

Adjustments to reconcile net earnings to net cash provided by operating activities:

            

Depreciation and amortization

  87,747   82,737   78,171 

Costs recognized on sale of acquired inventory

  1,565   -   3,739 

Deferred income taxes

  (27,431)  13,130

 

  (13,582

)

Stock-based compensation expense

  48,982   32,367   32,280 

Fair value adjustment to contingent consideration payable

  5,300

 

  (905

)

  (2,000)

Contingent consideration payments

  (337

)

  (958)  -

 

(Gain) Loss on investment, net

  -   -

 

  (3,702

)

Fair value adjustment on available for sale investments

  67,879   (137,527)  16,067 

Leases, net

  75   225   - 

Gain on escrow settlement

  -

 

  (7,170)  - 

Other operating activity

  (464

)

  (732)  2,325 

Change in operating assets and liabilities, net of acquisitions:

            

Trade accounts and other receivables

  (15,549)  6,556

 

  (15,000

)

Inventories

  (7,140

)

  (14,861

)

  (13,647

)

Prepaid expenses

  (1,101

)

  (2,605

)

  (698)

Trade accounts payable and accrued expenses

  19,091   10,343   6,101 

Salaries, wages and related accruals

  20,536   2,552   5,013

 

Income taxes payable

  13,426

 

  (7,231

)

  (9,520

)

Net cash provided by operating activities

  352,164   205,217   181,619 
             

Cash flows from investing activities:

            

Proceeds from sale and maturities of available-for-sale investments

  66,377   147,120   21,579 

Purchase of available-for-sale investments

  (39,684

)

  (70,187

)

  (43,475

)

Additions to property and equipment

  (44,301

)

  (51,744

)

  (25,411

)

Acquisitions, net of cash acquired

  (225,352)  -

 

  (289,492

)

Investment in unconsolidated entity, net

  (556)  1,906   - 

Other investing activities

  -   -   - 

Net cash provided by (used in) investing activities

  (243,516)  27,095

 

  (336,799

)

             

Cash flows from financing activities:

            

Cash dividends

  (49,622

)

  (48,902

)

  (48,364

)

Proceeds from stock option exercises

  65,092   70,983   37,950 

Re-purchases of common stock

  (43,178

)

  (50,112

)

  (15,405)

Borrowings under line-of-credit agreement

  256,000   40,000   580,000 

Payments on line-of-credit

  (271,500

)

  (188,500

)

  (413,500

)

Contingent consideration payments

  -

 

  (3,400)  -

 

Other financing activities

  (19,343

)

  (3,872

)

  (6,297

)

Net cash provided by (used in) financing activities

  (62,551

)

  (183,802)  134,384

 

             

Effect of exchange rate changes on cash and cash equivalents

  6,369

 

  (2,771

)

  (308

)

Net change in cash and cash equivalents

  52,466   45,739

 

  (21,104)

Cash and cash equivalents at beginning of year

  146,625   100,886   121,990 

Cash and cash equivalents at end of year

 $199,091  $146,625  $100,886 

 

See Notes to Consolidated Financial Statements.

 

43
Table of Contents

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Bio-Techne Corporation and Subsidiaries

 

Years ended June 30, 2021, 2020 and 2019

 

 

 

Note 1. Description of Business and Summary of Significant Accounting Policies:

 

Description of business: Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.

 

Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. The Company consolidated our partial acquisition of Eminence in our consolidated financial statements on a one month lag. Refer to Note 4 for additional discussion regarding Eminence.

 

Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.

 

Revenue recognition: The Company adopted ASC 606 - Revenue from Contracts with Customers on July 1, 2018 using the modified retrospective transition approach. ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note 2 for additional information regarding our revenue recognition policy under ASC 606.

 

Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.

 

Advertising costs: Advertising expenses were $4.7 million, $4.2 million, and $4.1 million for fiscal 2021, 2020, and 2019 respectively. The Company expenses advertising expenses as incurred.

 

Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note 11 for additional information regarding income taxes.

 

Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.

 

Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.

 

Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to six months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on available-for-sale securities are included within other income (expense) in accordance with ASU 2018-02, which the Company adopted on  July 1, 2018. 

 

44
 
 

Trade accounts receivable and allowances: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. The Company adopted ASU 2016-13 on July 1, 2020, which reflects the expected credit losses on financial instruments within its scope, including trade receivables. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables. Refer to the Recently Adopted Accounting Pronouncements section of Note 1 for further details.

 

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration.

 

For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 - Inventory.

 

Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.

 

Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income.

 

Intangible assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.

 

In conjunction with the Asuragen acquisition that occurred in fiscal year 2021, the Company reassessed the useful life of a tradename from a previous acquisition due to the planned integration and cobranding strategy developed with the most recent transaction.  As a result, the Company accelerated the amortization of the trade name to be consistent with the life used for the Asuragen trade name.  The accelerated amortization resulted in a $1.4 million impact in fiscal 2021, a $5.7 million impact in fiscal years 2022 through 2025, and a $4.3 impact in fiscal year 2026.

 

In fiscal year 2020, the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal 2020 and $0.6 million in fiscal 2021.

 

Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.

 

The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. No other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2019, 2020, and 2021.

 

45
 
 

Impairment of goodwill: We evaluate the carrying value of goodwill during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2021, 2020, and 2019 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment. Further, the Company elected April 1 as the annual goodwill impairment assessment date for the Asuragen acquisition, acquired on April 6, 2021.

 

2021 Goodwill Impairment Analyses

 

In completing our 2021 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017-04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2021. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2021, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2020 Goodwill Impairment Analyses

 

The Company elected to perform a quantitative assessment for all of our reporting units in our 2020 goodwill impairment analysis. The quantitative assessment completed utilized a consistent process and methodology to the 2021 goodwill impairment assessment. The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2020. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2020, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.

 

Because our quantitative analysis performed as of January 1, 2019 included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was not impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.

 

The quantitative assessments completed as of January 1, 2019 indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test on April 1, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

 

Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, no triggering events or items beyond the realignment discussed above were identified in the year ended June 30, 2019 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

 

46
 
 

Other Significant Accounting Policies

 

The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:

 

Policy

 

Note

 

Fair value measurements

  5 

Earnings per share

  9 

Share-based compensation

  10 

Operating segments

  12 

 

 

Recently Adopted Accounting Pronouncements

 

In  February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic 842) through ASU No. 2018-10 and ASU 2019-01. Additionally, the FASB issued ASU 2018-11, allowing an entity to elect a transition method where they do not recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU 2018-11 when adopting Leases (Topic 842). The Company adopted the standard effective  July 1, 2019 and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC 840 - Leases into operating lease liabilities upon adoption of Topic 842. In adopting ASC 842, the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note 7 for additional information on leases.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendment in this update replaced the previous incurred loss impairment methodology with a methodology that reflects expected credit losses on financial instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted this standard on July 1, 2020 using a modified retrospective transition approach with a cumulative impact of $0.3 million to retained earnings. The adoption of this ASU did not have a material impact on the Company's financial statements as the Company's primary financial instruments impacted by the ASU were trade accounts receivable, where we have high historical and expected future collections due to the length of receivables and the credit quality of our customers.

 

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is not affected by the new standard. The Company adopted this standard on a prospective basis on July 1, 2020. Accordingly, as of July 1, 2020, the Company will record eligible costs to be capitalized within prepaid assets or other non-current assets depending on the nature of the duration of the asset.

 

In  March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting and in January 2021 issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope. These ASUs provide expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in 2021, to a new reference rate. The provisions of the ASUs impact contract modifications and other changes that occur while LIBOR is phased out. The Company adopted the optional relief guidance provided within these ASUs in the fourth quarter of fiscal 2021 and continues to monitor its debt and derivative instruments that utilize LIBOR as the reference rate. The adoption of the standard did not impact our financial results for fiscal 2021.

 

47
Table of Contents
 
 

Note 2. Revenue Recognition:

 

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at a point in time. Prior to fiscal year 2021, the Company has not recognized revenue upon completion of the performance obligation for laboratory services, but rather upon cash receipt, which was subsequent to the performance obligation being satisfied. The Company accounted for these services based on cash receipts as we did not have significant historical experience collecting payments from Medicare or other insurance providers and considered the variable consideration for such services to be constrained as it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. Given Medicare coverage for our laboratory services became effective on December 1, 2019, the Company considered that it had sufficient data to estimate variable consideration as of July 1, 2020 for laboratory services that are reimbursed by Medicare. The amount of cash received in fiscal year 2021 for laboratory services reimbursed by Medicare that were performed prior to July 1, 2020 was approximately $0.5 million. The Company continues to record revenue based on cash receipts for laboratory services not reimbursed by Medicare, as the variable consideration remains constrained. We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date.

 

The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance.  The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of June 30, 2021 and June 30, 2020.

 

Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.

 

Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.

 

Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over the contract period. Contract assets as of June 30, 2021 are not material.

 

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2021 and June 30, 2020 were approximately $20.0 million and $14.2 million, respectively. Contract liabilities as of June 30, 2020 subsequently recognized as revenue during the year ended June 30, 2021 were approximately $10.6 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the balance sheet. 

 

Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.

 

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.

 

48
Table of Contents
 

The following tables present our disaggregated revenue for the periods presented.

 

Revenue by type is as follows:

 

  

Year ended June 30,

     
  

2021

  2020  2019 

Consumables

 $751,985  $602,642  $588,979 

Instruments

  93,782   71,462   67,538 

Services

  66,416   47,459   38,050 

Total product and services revenue, net

  912,183  $721,563   694,567 

Royalty revenues

  18,849   17,128   19,439 

Total revenues, net

 $931,032  $738,691  $714,006 

 

Revenue by geography is as follows:

 

  

Year Ended June 30,

 
  2021  2020  2019 

Net sales:

            

United States

 $502,080  $404,407  $391,191 

EMEA, excluding U.K.

  204,264   155,289   155,821 

U.K.

  40,945   30,411   34,975 

APAC, excluding Greater China

  69,013   60,362   52,913 

Greater China

  87,556   68,792   57,799 

Rest of world

  27,174   19,430   21,307 

Total external sales

 $931,032  $738,691  $714,006 

 

49
Table of Contents
 
 

Note 3. Supplemental Balance Sheet and Cash Flow Information:

 

Available-For-Sale Investments:

 

The fair value of the Company's available-for-sale equity investments as of June 30, 2021 and June 30, 2020 were $20.0 million and $87.8 million, respectively. The decrease was due to year-over-year decrease in the stock price of CCXI, which was $13.39 per share at June 30, 2021 compared to $57.54 per share at June 30, 2020. The amortized cost basis of the Company's investment in CCXI was $6.6 million and $6.6 million as of June 30, 2021 and 2020, respectively. The Company's available-for-sale debt securities as of June 30, 2021 and June 30, 2020 were $12.5 million and $36.4 million, respectively. The decrease is due to the timing of debt maturities and cash balances at the balance sheet date. 

 

Inventories:

 

Inventories consist of (in thousands):

 

  

June 30,

 
  

2021

  2020 
         

Raw materials

 $55,096  $51,530 

Finished goods(1)

  67,108   56,268 

Inventories, net

 $122,204  $107,798 

 

(1) Finished goods inventory of $5,456 and $4,646 is included within other long-term assets in the June 30, 2021 and June 30, 2020 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

  

June 30,

 
  

2021

  2020 

Cost:

        

Land

 $8,612  $8,516 

Buildings and improvements

  190,661   184,430 

Machinery, equipment and other

  198,483   153,704 

Property and equipment

  397,756   346,650 

Accumulated depreciation and amortization

  (189,849

)

  (169,821

)

Property and equipment, net

 $207,907  $176,829 

 

50
Table of Contents
 

Intangibles assets were comprised of the following (in thousands):

 

        

June 30,

 
  

Useful Life

(years)

  

2021

  2020 
               

Developed technology

  9-15  $552,160  $434,653 

Trade names

  2-20   147,640   146,713 

Customer relationships

  7-16   232,493   211,750 

Patents

   10    2,926   2,475 
Other intangibles(1)  5-15   6,316   - 

Definite-lived intangible assets

        941,535   795,591 

Accumulated amortization

        (348,267

)

  (279,046

)

Definite-lived intangibles assets, net

        593,268   516,545 
In process research and development        22,700   - 
Total intangible assets, net       $615,968  $516,545 

 

(1) Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired.

 

Changes to the carrying amount of net intangible assets consist of (in thousands):

 

   

June 30,

 
   2021  2020 
          

Beginning balance

  $516,545  $579,429 

Acquisitions (Note 4)

   153,311   - 

Other additions

   5,912   311 

Amortization expense

   (64,940

)

  (61,095

)

Currency translation

   5,140

 

  (2,100

)

Ending balance

  $615,968  $516,545 

 

Amortization expense related to developed technologies included in cost of sales was $36.5 million, $34.5 million, and $33.3 million in fiscal 2021, 2020, and 2019, respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $28.4 million, $26.6 million, and $25.4 million, in fiscal 2021, 2020, and 2019 respectively.

 

The estimated future amortization expense for intangible assets as of June 30, 2021, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows (in thousands):

 

2022

 $74,482 

2023

  72,649 

2024

  69,780 

2025

  66,523 

2026

  62,739 

Thereafter

  247,095 

Total

 $593,268 

 

51
Table of Contents
 

Changes in goodwill by segment and in total consist of (in thousands):

 

  

Protein

Sciences

  

Diagnostics &

Genomics

  

Total

 

June 30, 2019

 $377,407  $355,260  $732,667 

Acquisitions (Note 4)

  (326

)

  -   (326

)

Currency Translation

  (4,000

)

  (31

)

  (4,031

)

June 30, 2020

 $373,081  $355,229  $728,310 
Acquisitions (Note 4)  7,848   94,970   102,818 
Currency translation  11,788   151   11,939 
June 30, 2021 $392,717  $450,350  $843,067 

 

Supplemental Cash Flow Information:

 

Supplemental cash flow information was as follows (in thousands):

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Income taxes paid

 $20,952  $41,992  $36,814 

Interest paid

  13,576   18,615   21,497 

Non-cash activities:

            

Acquisition-related liabilities(1)

  23,600

 

  (2,105)  12,600 
Other intangibles(2)  4,000   -   - 

 

 

(1) Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.

(2) $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021. 

 

52
Table of Contents
 
 

Note 4. Acquisitions:

 

We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.

 

2021 Acquisitions

 

Eminence Biotechnology

 

On October 20, 2020, the Company acquired 47.6% of the outstanding equity shares of Changzhou Eminence Biotechnology Co., Ltd. (Eminence) for approximately $9.8 million, net of cash acquired. The fair value of the noncontrolling interest of $9.0 million included in the consolidated balance sheet was a non-cash activity within the statement of cash flows. Eminence is considered a variable interest entity as it is an early stage biotechnology company that required additional funding through a subsequent equity investment, which was used to fund Eminence’s expansion and GMP manufacturing capabilities within China. On April 2, 2021, the Company invested approximately $6 million of additional funding into Eminence, increasing our percentage of outstanding equity shares to 57.4%. The Company was considered the primary beneficiary at the time of initial acquisition given the Company was the largest shareholder coupled with its ability to exercise significant influence over the entity. As of June 30, 2021, the Company’s investment at risk is limited to its $15.8 million in investments.

 

As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC 805, Business Combinations. In applying ASC 805 to the transaction, the Company has elected to include Eminence in our consolidated financial statements on a one month lag.

 

The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The fair value of the noncontrolling interest in Eminence was calculated utilizing cash flow projections discounted to the acquisition date and control premiums calculated using market data. Acquired goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences reportable segment in the second quarter of fiscal year 2021.

 

The allocation of purchase consideration related to Eminence was completed in the fourth quarter of fiscal year 2021. The fair values of the assets acquired and liabilities assumed at acquisition date and the updated final amounts as of June 30, 2021 are as follows (in thousands):

 

  

Preliminary
Allocation at
Acquisition
Date

  

Adjustments to Fair Value

  

Final Allocation at June 30, 2021

Current assets, net of cash

 $3,145  $-  $3,145

Equipment and other long-term assets

  1,639   -   1,639
Intangible assets:           

Developed technology

  6,778   -   6,778

Customer relationships

  2,133   -   2,133

Goodwill

  8,811   (963)  7,848

Total assets acquired

  22,506   (963)  21,543

Liabilities

  1,436   -   1,436

Deferred income taxes, net

  2,320   (963)  1,357

Net assets acquired

 $18,750  $-  $18,750
            

Cash paid, net of cash acquired

  9,765   -   9,765
Fair value of noncontrolling interest in Eminence  8,985   -   8,985

Net assets acquired

 $18,750  $-  $18,750

 

As summarized in the table, there were adjustments totaling $1.0 million to goodwill during the measurement period. These adjustments relate to refinements within our deferred tax amounts based on factors existing on the acquisition date.


Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 13 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 10 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.

 

53
 
 
Asuragen, Inc.
 

On April 6, 2021, the Company acquired all of the ownership interests of Asuragen, Inc. for approximately $216 million, net of cash acquired, plus contingent consideration of up to $105.0 million, subject to certain revenue thresholds. The Asuragen acquisition adds a leading portfolio of best in-class molecular diagnostic and research products, including genetic screening, oncology testing kits, molecular controls, a GMP compliant manufacturing facility, and a CLIA-certified laboratory. The transaction was accounted for in accordance with ASC 805, Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the fourth quarter of fiscal year 2021. 

 

The allocation of purchase consideration related to Asuragen Inc is considered preliminary with provisional amounts primarily rel ated to goodwill and income tax assessment of acquired net operating losses. The Company expects to finalize the allocation of purchase price within the one-year measurement-period following the acquisition. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations in fiscal year 2021 were approximately $7.1 million and $ 3.4 million, respectively. The preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date and at June  30, 2021 are as follows (in thousands):

 

    

Preliminary allocation at acquisition date and at June 30, 2021

Current assets, net of cash

   $10,422

Equipment and other long-term assets

    3,762
Intangible assets:     

Developed technology

    107,000
In-process research and development    22,700

Customer relationships

    11,700
Tradenames    2,000
Non-competition agreement    1,000

Goodwill

    94,970

Total assets acquired

    253,554
      

Liabilities

    4,003

Deferred income taxes, net

    15,664

Net assets acquired

   $233,887
      

Cash paid, net of cash acquired

    215,587
Contingent consideration payable    18,300

Net assets acquired

   $

233,887

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology, in-process research and development, and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 16 years.  The amount recorded for tradenames and the non-competition agreement is being amortized with the expense reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for tradenames and the non-competition agreement is estimated to be 5 years and 3 years, respectively. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.

 

 

54
 

2019 Acquisitions

 

Quad Technologies

 

On July 2, 2018, the Company acquired QT Holdings Corporation (Quad) for approximately $20.5 million, net of cash acquired, plus contingent consideration of up to $51.0 million, subject to certain product development milestones and revenue thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019.

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible assets acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for our calculation of acquired net operating losses (NOLs).

 

Exosome Diagnostics

 

On August 1, 2018, the Company acquired Exosome Diagnostics, Inc. (ExosomeDx) for approximately $251.6 million, net of cash acquired, plus contingent consideration of up to $325.0 million, subject to certain EBITA thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2019 are 15 years for developed technology and trade names, and 14 years for customer relationships. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.

 

Note: As part of the ExosomeDx acquisition, a certain amount of the cash payment was held in escrow. As part of the finalization of the outstanding amounts held in escrow, the Company recognized a gain of $7.2 million during fiscal year 2020 related to returned proceeds and a relief of any future contingent payments as described in Note 5. The gain was recorded within selling, general, and administrative costs in the Consolidated Statement of Comprehensive Income. 

 

B-MoGen Biotechnologies

 

On June 4, 2019, the Company acquired the remaining interest in B-MoGen Biotechnologies Inc. (B-MoGen) for approximately $17.5 million, net of cash acquired, plus contingent consideration of up to $38.0 million, subject to certain product development milestones and revenue thresholds. The Company previously held an investment of $1.4 million in B-MoGen and recognized a gain of approximately $3.7 million on the transaction within other non-operating income fiscal year 2019 in the consolidated statements of earnings and comprehensive income, which represented the adjustment of our historical investment to its fair value. 

 

The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the fourth quarter of fiscal year 2019. Purchase accounting remained opened as disclosed in our prior year 10-K/A for working capital adjustments and our income tax assessment of acquired net operating losses (NOLs) with the completion of the stub period tax returns. Our purchase accounting was finalized in fiscal 2020 with an immaterial adjustment of $0.3 million to deferred tax amounts and goodwill. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible asset acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.

 

55
 
 
  

B-MoGen

Biotechnologies

  

Exosome

Diagnostics

  

Quad

Technologies

Current assets, net of cash

 $504  $2,611  $36

Equipment and other long-term assets

  269   2,212   228
Intangible assets:           

Developed technology

  14,000   105,000   12,256

Trade name

  -   58,000   -

Customer relationships

  400   2,300   -

Goodwill

  16,131   105,362   14,481

Total assets acquired

  31,304   275,485   27,001
            

Liabilities

  211   3,716   296

Deferred income taxes, net

  3,051   16,346   943

Net assets acquired

 $28,042  $255,423  $25,762
            

Cash paid, net of cash acquired

  17,448   251,623   20,462

Additional consideration(1)

  10,594   3,800   5,300

Net assets acquired

 $28,042  $255,423  $25,762

 

(1)Additional consideration for the B-MoGen acquisition includes a previously held investment of $1.4 million and a gain of approximately $3.7 million recorded on the transaction. The remaining additional consideration for B-MoGen, ExosomeDx, and Quad relate to the opening balance sheet value of contingent consideration.  

 

Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes, and the future tax benefit of net operating loss and tax credit carryforwards which will be deductible by the Company in future periods. 

 

56
Table of Contents
 
 

Note 5. Fair Value Measurements:

 

The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.

 

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

 

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

 

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

 

  

Total

carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30,

2021

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $19,963  $18,581  $1,382  $- 

Certificates of deposit (2)

  12,500   12,500   -   - 
Derivative instruments - cash flow hedges  275   -   275   - 

Total Assets

 $32,738  $31,081  $1,657  $- 
                 

Liabilities

                

Contingent consideration

 $29,400  $-  $-  $29,400 

Derivative instruments - cash flow hedges

  8,376   -   8,376   - 

Total Liabilities

 $37,776  $-  $8,376  $29,400 

 

 

  

Total

carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30,

2020

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $87,842  $79,846  $7,996  $- 

Certificates of deposit (2)

  36,426   36,426   -   - 

Total Assets

 $124,268  $116,272  $7,996  $- 
                 

Liabilities

                

Contingent consideration

  6,137  $-   -   6,137 

Derivative instruments - cash flow hedges

  17,331   -   17,331   - 

Total Liabilities

 $23,468  $-  $17,331  $6,137 

 

 

(1) Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2021 and June 30, 2020 was $6.6 million and $6.6 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.4 million as of June 30, 2021. The fair value of the warrant as of  June 30, 2020 was $8.0 million 

 

(2) Included in available-for-sale investments on the balance sheet.  The certificate of deposits have contractual maturity dates within one year.

 

57
Table of Contents
 

Fair value measurements of available for sale securities

 

Available for sale securities excluding warrants are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level 2 asset. 

 

Fair value measurements of derivative instruments

 

In October 2018, the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note 6 to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount. The notional amount decreased by $100 million in   October 2020 and will further decrease by $80 million in   October 2021 and $200 million in   October 2022. In   June 2020, the Company de-designated $80 million of the notional amount set to expire in  October 2020. The net loss associated with the  June 2020 de-designated portion of the derivative instrument was not reclassified into earnings based on the amount of probable variable interest payments to occur within a two month time period of the forecasted hedged transaction. In  December 2020, the Company de-designated an additional $80 million of notional amount set to expire in  October 2021. During fiscal year 2021, the Company recorded a loss in other non-operating income related to variable interest debt payments in certain months on a portion of the de-designated derivative that is not expected to occur. The remaining variable interest payments for the portion of the de-designated derivative were considered probable of occurring and therefore remain in accumulated other comprehensive income as of  June 30, 2021. The fair value of the portion of the de-designated derivative was $0.8 million as of  June 30, 2021, which is recorded within short-term liabilities on the Consolidated Balance Sheet. The fair value of the designated derivative instrument is $7.6 million as of June 30, 2021 and is recorded within other long-term liabilities on the Consolidated Balance Sheet. 

 

In May 2021, the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt. The forward starting swap reduces the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swap, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on $200 million of notional principal amount. The effective date of the swap is November 2022 with the full swap maturing in November 2025. The fair value of the derivative instrument was $0.3 million as of June 30, 2021 which is recorded within other long-term assets on the Consolidated Balance Sheet.

 

Changes in the fair value of the designated hedged instrument are reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $8.6 million to interest expense, $0.5 million to non-operating income for the portion of de-designated variable payments considered probable to not occur, and related tax benefits of $2.1 million during the fiscal year ended  June 30, 2021 relating to the cash flow hedge entered into in October 2018. No amounts were reclassified relating to the cash flow hedge entered into in May 2021 as they will be recorded within the effective period of the cash flow hedge.

 

The Company reclassified $3.5 million, net of taxes, to interest expense during the fiscal year ended  June 30, 2020. The change in the fair value of the de-designated notional hedged amount was not material as of June 30, 2020. The instruments were valued using observable market inputs in active markets and therefore are classified as Level 2 liabilities.

 

The Company did not reclassify any amounts out of other comprehensive income into interest expense during the fiscal year ended June 30, 2019.

 

58
 

Fair value measurements of contingent consideration

 

The Company has $29.4 million, which is the fair value, of contingent consideration related to the Asuragen, Quad, and B-MoGen acquisitions. The Company is required to make contingent consideration payments of up to $105.0 million, $51.0  million, and $38.0 million, respectively, as part of these acquisition agreements. The contingent agreement with Asuragen was based on achieving certain revenue thresholds, the contingent agreement with Quad is based on meeting certain product development milestones and revenue thresholds, and the contingent agreement with B-MoGen is based on meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the Asuragen acquisition was $18.3 million as discussed in Note 4. The preliminary fair value of the revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors.   

 

During the fourth quarter of fiscal 2020, the Company's obligation for potential contingent consideration payments related to the ExosomeDx acquisition were relieved as part of the Company's escrow settlement with the former shareholders of ExosomeDx. As the result of this settlement, the Company reversed an accrual for the fair value of the contingent liability at the date of settlement.

 

The ultimate settlement of contingent consideration liabilities for the Asuragen, Quad, and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.

 

The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

 

  

June 30,

 
  

2021

  2020 
         

Fair value at the beginning of period

 $6,137  $12,600 

Purchase price contingent consideration (Note 4)

  18,300   - 

Payments

  (337

)

  (4,358)

Gain on escrow settlement

  -

 

  (1,200)

Change in fair value of contingent consideration

  5,300

 

  (905

)

Contingent consideration payable

 $29,400  $6,137 

 

Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.

 

Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.

 

Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility  and long-term debt approximates fair value because our interest rate is variable and reflects current market rates. 

 

59
Table of Contents
 
 

Note 6. Debt and Other Financing Arrangements: 

 

On August 1, 2018, the Company entered into a new uncollateralized revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined for the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 12.5 basis points. The Company has recorded $12.5 million of our outstanding borrowings under the Credit Agreement as a current liability in our Consolidated Balance sheet, which represents our required quarterly debt payments to be made in fiscal year 2022.

 

The Credit Agreement matures on August 1, 2023 and contains customary restrictive and financial covenants and customary events of default. At the closing on August 1, 2018 the company borrowed $250.0 million under the term loan and $330.0 million under the revolving credit facility. As of June 30, 2021 and 2020, the outstanding balance under the Credit Agreement was $341 million and $357 million respectively. 

 

 
 

Note 7. Leases: 

 

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016-02 and related standards (collectively ASC 842, Leases), which replaced previous lease accounting guidance, on July 1, 2019. 

 

The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During fiscal year 2021, the Company recognized $3.6 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income.  During fiscal year 2021, the Company also recognized $32.5 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income. 

 

The following table summarizes the balance sheet classification of the Company’s operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):

 

  Balance Sheet Classification 

As of:

June 30,

2021

 

Operating leases:

      

Operating lease right of use assets(1)

 Right of Use Asset $73,834 
       

Current operating lease liabilities(1)

 Operating lease liabilities current $11,602 

Noncurrent operating lease liabilities(1)

 Operating lease liabilities  67,625 

Total operating lease liabilities

   $79,227 
       

Weighted average remaining lease term (in years):

    7.97 
       

Weighted average discount rate:

    3.93

%

(1) The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.

 

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended  June 30, 2021 (in thousands):

 

  

For the year

ended June

30, 2021

 

Cash amounts paid on operating lease liabilities(1)

 $13,492 
     

Right of use assets obtained in exchange for lease liabilities

  12,144 

 

(1) Total cash paid for the Company's operating leases during the year ended June 30, 2021 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.  

 

60
Table of Contents
 

The following table summarizes payments by date for the Company’s operating leases, which is then reconciled to our total lease obligation (in thousands):

 

  

June 30, 2021

Operating

Leases

 

2022

 $14,349 

2023

  13,371 

2024

  11,840 

2025

  10,780 

2026

  10,120 

Thereafter

  32,331 

Total

 $92,791 

Less: Amounts representing interest

  13,564 

Total lease obligations

  79,227 

 

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options.

 

 

 

61
Table of Contents

 
 

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss): 

 

Supplemental Equity

 

The Company has declared cash dividends per share of $1.28 in each of the full fiscal years ended  June 30, 2021, June 30, 2020, and June 30, 2019. During the years ended June 30, 2021 and June 30, 2020, the Company repurchased 120,000 shares at an average share price of $359.81 and 279,381 shares at an average share price of $179.37, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year 2021, 2020 and 2019, the amounts within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise options due to net settlement stock options exercises were not material.

 

 

Accumulated Other Comprehensive Income (loss) 

 

Changes in accumulated other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows (in thousands):

 

  

Unrealized

Gains

(Losses)

on

Available-

for-Sale

Investments

  

Foreign

Currency

Translation

Adjustments

  

Unrealized

Gains

(Losses) on

Derivatives

Instruments

  

Total

 

Balance June 30, 2018 

 $24,682  $(69,496

)

 $-  $(44,814

)

Cumulative effect adjustment for adoption for ASU 2018-02

  2,371   -   -   2,371 

Cumulative effect adjustment for adoption for ASU 2016-01

  (27,053

)

  -   -   (27,053

)

Other comprehensive income (loss) before reclassifications

  -   (4,487

)

  (9,537

)

  (14,024

)

Balance June 30, 2019

 $-  $(73,983

)

 $(9,537

)

 $(83,521

)

Other comprehensive income (loss) before reclassifications

  -   (9,963

)

  (7,179

)

  (17,142

)

Reclassification from loss on derivatives to interest expense, net of taxes

  -   -   3,464   3,464 

Balance June 30, 2020

 $-  $(83,946

)

 $(13,253

)

 $(97,199

)

Other comprehensive income (loss) before reclassifications(2)  -   32,848   100   32,948 
Reclassification from loss on derivatives to interest expense, net of taxes(1)  -   -   6,960   6,960 
Balance June 30, 2021 $-  $(51,098) $(6,193) $(57,291)

 

(1) Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company had deferred tax benefits of $1,908 and $4,058 included in the accumulated other comprehensive income loss as of June 30, 2021 and June 30, 2020, respectively.

(2) Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence. 

 

62
Table of Contents
 
 

Note 9. Earnings Per Share:

 

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

 

  

Year Ended June 30,

 
  

2021

  

2020

  

2019

 

Earnings per share – basic:

            
Net earnings, including noncontrolling interest  139,585   229,296   96,072 
Less net earnings attributable to noncontrolling interest  (825)  -   - 

Net income

 $140,410  $229,296  $96,072 

Income allocated to participating securities

  (86

)

  (224

)

  (105

)

Income available to common shareholders

 $140,324  $229,072  $95,967 

Weighted-average shares outstanding – basic

  38,747   38,201   37,781 

Earnings per share – basic

 $3.62  $6.00  $2.54 
             

Earnings per share – diluted:

            

Net income

 $140,410  $229,296  $96,072 

Income allocated to participating securities

  (86

)

  (224

)

  (105

)

Income available to common shareholders

 $140,324  $229,072  $95,967 

Weighted-average shares outstanding – basic

  38,747   38,201   37,781 

Dilutive effect of stock options and restricted stock units

  1,736   1,200   1,111 

Weighted-average common shares outstanding – diluted

  40,483   39,401   38,892 

Earnings per share – diluted

 $3.47  $5.82  $2.47 

 

Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.

 

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.6 million, 0.9 million, and 1.3 million for the fiscal years ended June 30, 2021, 2020 and 2019, respectively.

 

63
Table of Contents
 
 

Note 10. Share-based Compensation and Other Benefit Plans:

 

The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. 

 

Equity incentive plan: The Company's Second Amended and Restated 2010 Equity Incentive Plan (the Second A&R 2010 Plan) provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There were 7.5 million shares of common stock authorized for grant under the Second A&R 2010 Plan. In October 2020, the shareholders approved an amended and restated incentive plan - the 2020 Equity Incentive Plan. The maximum aggregate number of shares of common stock reserved and available for awards under the Amended Plan is 2,484,202 shares, which includes an additional 1,300,000 shares authorized by the 2020 Equity Incentive Plan. Shares issued after the shareholder meeting are issued under the 2020 Equity Incentive Plan. At June 30, 2021, there were 1.1 million shares of common stock available for grant under the 2020 Equity Incentive Plan. The maximum term of incentive options granted under the 2020 Equity Incentive Plan is ten years. The 2020 Equity Incentive Plan replaced the Company's second A&R 2010 Plan, which had previously amended and restated the Company's Amended and Restate 2010 Equity Incentive Plan (the A&R 2010 Plan). The A&R 2010 Plan had previously replaced the Company's 1998 Nonqualified Stock Option Plan (the 1998 Plan). The Second A&R 2010 Plan and the 1998 Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of  June 30, 2021 under the 2020 Equity Incentive Plan were 3.7 million.

 

The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

 

  

Year Ended June 30,

 
  

2021

  2020  2019 
                   

Dividend yield

   0.24%     0.67%     0.74%  

Expected volatility

  25%-30%   22%-24%   20%-23% 

Risk-free interest rates

  0.2%-0.7%   1.3%-1.9%   2.5%-3.0% 

Expected lives (years)

   4.4     4.0     4.1  

 

The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted.

 

Stock option activity under the Plans for the three years ended June 30, 2021, consists of the following (shares in thousands): 

 

  

Number of

Shares (in

thousands)

  

Weighted
Average
Exercise
Price

  

Aggregate
Intrinsic
Value

(millions)

  

Weighted

Average

Contractual

Life (years)

 
                 

Outstanding at June 30, 2018

  3,452  $105.17         

Granted

  917   173.89         

Forfeited

  (330

)

  129.93         

Exercised

  (383

)

  95.29         

Outstanding at June 30, 2019

  3,656  $121.16         

Granted

  752   190.80         

Forfeited

  (56

)

  95.97         

Exercised

  (743

)

  157.45         

Outstanding at June 30, 2020

  3,609  $140.28         
Granted  763   277.75         
Forfeited  (28)  214.33         
Exercised  (627)  112.53         
Outstanding at June 30, 2021  3,717  $172.63  $1,031.9   4.1 
                 

Exercisable at June 30, 2019:

  1,467   98.70         

Exercisable at June 30, 2020:

  1,564   112.60         
Exercisable at June 30, 2021:  1,764   126.44  $571.3   3.0 

 

The weighted average fair value of options granted during fiscal 2021, 2020, and 2019 was $59.75, $37.01, and $34.66 respectively. The total intrinsic value of options exercised during fiscal 2021, 2020, and 2019 were $145.6 million, $99.3 million, and $159.0 million, respectively. The total fair value of options vested during fiscal 2021, 2020, and 2019 were $70.5 million, $71.1 million, and $31.7 million, respectively.

 

64
Table of Contents
 

Restricted common stock activity under the Plans for the three years ended June 30, 2021, consists of the following (units in thousands):

 

  

Number of

Shares (in

thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Unvested at June 30, 2018

  35  $117.39     

Granted

  15   177.93     

Vested

  (20

)

  116.76     

Forfeited

  -   -     

Unvested at June 30, 2019

  30  $147.94     

Granted

  15   193.48     

Vested

  (18

)

  142.12     

Forfeited

  -   -     

Unvested at June 30, 2020

  28  $177.20     
Granted  12   264.73     
Vested  (17)  171.64     
Forfeited  -   -     
Unvested at June 30, 2021  23  $226.07   6.07 

 

The total fair value of restricted shares that vested was $2.8 million for fiscal 2021, $2.5 million for fiscal 2020, and $2.3 million for fiscal 2019.

 

Restricted stock unit activity under the Plans for the three years ended June 30, 2021, consists of the following (units in thousands):

 

  

Number of

Units

(in thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Outstanding at June 30, 2018

  148  $117.95     

Granted

  56   170.96     

Vested

  (28

)

  110.86     

Forfeited

  (36

)

  143.72     

Outstanding at June 30, 2019

  139  $134.17     

Granted

  31   192.08     

Vested

  (51

)

  111.07     

Forfeited

  (3

)

  155.60     

Outstanding at June 30, 2020

  116  $159.25     
Granted  31   300.78     
Vested  (51)  130.18     
Forfeited  -   -     
Outstanding at June 30, 2021  96  $220.53   5.36 

 

The total fair value of restricted stock units that vested was $6.7 million for fiscal 2021, $5.7 million for fiscal 2020, and $3.1 million for fiscal 2019. The restricted stock units vest over a three-year period.

 

Stock-based compensation cost, inclusive of payroll taxes, of $46.4 million, $32.4 million, and $32.3 million was included in selling, general and administrative expense in fiscal 2021, 2020 and 2019, respectively. Additionally, stock-based compensation costs, inclusive of payroll taxes, of $1.6 million was included in cost of goods sold in 2021. As of June 30, 2021, there was $37.1 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2022 through 2024 using a 4.6% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years.

 

Employee stock purchase plan: In fiscal year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.9 million, $0.4 million, and $0.5 million for the ESPP in fiscal 2021, 2020, and 2019, respectively.

 

Profit sharing and savings plans: The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $3.4 million, $3.2 million, and $2.8 million for the years ended June 30, 2021, 2020, and 2019, respectively. The Company operates defined contribution pension plans for its U.K. employees. The Company has recorded an expense for contributions to the plans of $1.6 million for year ended June 30, 2021 and $1.4 million for each of the years ended June 30,  2020 and 2019.

 

Performance incentive programs: In fiscal 2021, under certain employment agreements, a Management Incentive Plan, and a business incentive plan, available to executive officers, certain management personnel, and certain other professional employees, the Company recorded cash bonuses of $21.1 million, granted options for 762,761 shares of common stock, issued 11,803 restricted common shares and 30,823 restricted stock units. In fiscal 2020 and fiscal 2019, the Company recorded cash bonuses of $10.5 million and $9.3 million, granted options for 751,499 and 618,898 shares of common stock, and issued 15,398 and 11,279 restricted common stock shares and 30,858 and 25,903 restricted stock, respectively.

 

65
Table of Contents
 
 

Note 11. Income Taxes:

 

Income before income taxes was comprised of the following (in thousands):

 

   

Year Ended June 30,

  
   

2021

     2020     2019  

Domestic

   $ 95,662     $ 245,365     $ 64,081  

Foreign

     52,513       31,112       47,934  

Income before income taxes

   $ 148,175     $ 276,477     $ 112,015  

 

The provision for income taxes consisted of the following (in thousands):

 

   

Year Ended June 30,

  
    2021     2020     2019  

Taxes on income consist of:

                        

Currently tax provision:

                        

Federal

   $ 15,179     $ 18,976     $ 16,090  

State

     6,681       6,018       544  

Foreign

     14,743       8,580       13,329  

Total current tax provision

     36,603       33,574       29,963  

Deferred tax provision:

                        

Federal

     (20,812 )     14,074

 

     (6,903

)

State

     (4,962 )     2,055

 

     (3,977

)

Foreign

     (2,239 )     (2,522

)

     (3,142

)

Total deferred tax provision

     (28,013 )     13,607

 

     (14,021

)

Total income tax provision

   $
8,590
    $ 47,181     $ 15,943

 

 

The Company’s effective income tax rate for fiscal 2021 was 5.8% vs 17.1% in the prior year. The change in the effective tax rate for fiscal 2021 and 2020 was driven by changes in net discrete tax benefits of $28.1 million and $19.4 million for fiscal year 2021 and 2020, respectively.

 

The Company's effective income tax rate for fiscal 2020 was 17.1% for fiscal 2020 vs 14.2% in the prior year. The change in the effective tax rate for fiscal 2020 and 2019 were driven by the changes in the net discrete tax benefits $19.4 million and $12.7 million, respectively. 

 

The Company's discrete tax benefits in fiscal 2021 primarily related to share-based compensation excess tax benefits of $28.1 million.

 

The Company's discrete tax benefits in fiscal 2020 primarily related to share-based compensation excess tax benefits of $17.7 million.

 

The Company's discrete tax benefits in fiscal 2019 primarily related to share-based compensation excess tax benefits of $7.2 million, $3.2 million related to fiscal 2019 acquisitions, and $2.0 million for tax refunds relating to certain state apportionments. 

 

The Company continues to monitor newly enacted regulations, clarifications, and changes in guidance the Tax Cuts and Jobs Act “Tax Act”, which was enacted on  December 22, 2017. The Company recognizes changes in legislation in the period enacted, which may have a material impact on our effective tax rate in future periods.

 

66
Table of Contents
 

The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided:

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Income tax expense at federal statutory rate

     21.0

%

     21.0

%

     21.0

%

State income taxes, net of federal benefit

     0.6

 

     2.3

 

     (1.5

)

Research and development tax credit

     (1.8

)

     (0.7

)

     (1.6

)

Contingent consideration adjustment

     0.8

 

     (0.2

)

     (0.4

)

Foreign tax rate differences

     0.8

 

     (0.2

)

     0.2

 

Option exercises

     (16.9

)

     (5.7

)

     (5.8

)

U.S. taxation of foreign earnings

     (0.1 )     0.9

 

     3.7

 

Foreign derived intangible income

     (5.1 )     (0.9

)

     (2.0 )

Executive compensation limitations

     6.5       1.6

 

     0.4  

Other, net

     0.0       (1.0

)

     0.2

 

Effective tax rate

     5.8

%

     17.1

%

     14.2

%

 

Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):

 

   

June 30

  
   

2021

     2020  
                 

Inventory

   $ 6,730     $ 7,769  

Net operating loss carryovers

     31,345       25,707  

Tax credit carryovers

     14,486       9,568  

Excess tax basis in equity investments

     2,429       2,423  

Deferred compensation

     11,108       10,755  

Derivative - cash flow hedge

     1,908       4,058  

Lease liability

     17,016       16,256  

Other

     8,526       4,340  

Valuation allowance

     (6,665

)

     (7,523

)

Deferred tax assets

     86,883       73,353  
                 

Net unrealized gain on available-for-sale investments

     (3,159

)

     (19,102

)

Intangible asset amortization

     (150,765

)

     (128,279

)

Depreciation

     (9,099

)

     (10,764

)

Right of use asset

     (15,868

)

     (15,118 )

Other

     (1,117

)

     (1,180

)

Deferred tax liabilities

     (180,008

)

     (174,443

)

Net deferred tax liabilities

   $ (93,125 )   $ (101,090

)

 

67
Table of Contents
 

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of June 30, 2021 was $6.7 million compared to $7.5 million in the prior year. 

 

As of June 30, 2021, the $6.7 million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Quad, ExosomeDx, ACD, Novus, ProteinSimple and CyVek as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than not that these tax carryovers will not be realized.

 

As of June 30, 2021, the Company has federal operating loss carryforwards of approximately $92.1 million and state operating loss carryforwards of $129.6 million from its acquisitions of Asuragen (refer to note 4), Quad, ExosomeDx, ACD, ProteinSimple and CyVek, which are not limited under IRC Section 382. As of June 30, 2021, the Company has foreign net operating loss carryforwards of $13.9 million. The net operating loss carryforwards expire between fiscal 2022 and 2036. The Company has a deferred tax asset of $26.6 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2021, the Company has federal and state tax credit carryforwards of $10.1 million and $4.4 million, respectively. The federal tax credit carryforwards expire between 2028 and 2038. The majority of the state credit carryforwards have no expiry date. The Company has a deferred tax asset of $12.6 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

The Company has not recognized a deferred tax liability for unremitted foreign earnings of approximately $223 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely. The transition tax included as part of the Tax Act resulted in the previously untaxed foreign earnings being included in the federal and state fiscal 2018 taxable income. The one-time transition tax was based on certain foreign earnings for which earnings have been previously indefinitely reinvested as well as the amount of earnings held in cash and other specified assets.   No additional income taxes have been provided for cumulative unremitted foreign earnings as at this time our intention with respect to unremitted foreign earnings is to continue to indefinitely reinvest outside the U.S. those earnings needed for working capital or additional foreign investment. If there are policy changes, we would record applicable taxes at that time.

We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.  In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes. Therefore, it is not practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.

The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):

 

   

Year Ended June 30,

  
   

2021

     2020     2019  

Beginning balance

   $ 4,297     $ 5,032     $ 1,947  

Additions due to acquisitions

     -       -       900  

Additions for tax positions of prior year

     4,038       306       2,185  

Decrease in unrecognized tax benefits for prior year positions

     (778

)

     (1,041 )     -  
Settlements     (286 )     -       -  

Ending balances

   $ 7,271     $ 4,297     $ 5,032  

 

Included in the balance of unrecognized tax benefits at June 30, 2021 are potential benefits of $5.2 million that, if recognized, would affect the effective tax rate on income from continuing operations. The amount of interest and penalties recognized on the balance sheet as of June 30, 2021 is not material. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. It is reasonably possible that the unrecognized tax benefits may decrease by $2.6 million as a result of ongoing discussions with the German tax authorities regarding a historical local matter. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for 2017 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.

 

68
Table of Contents
 
 

Note 12. Segment Information:

 

The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.

 

The Company's Protein Sciences segment is comprised of the reagent solutions and analytical solutions. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2021, 2020, and 2019.

 

The Company's Diagnostics and Genomics segment is comprised of diagnostics reagents, genomics, and our Exosome and Asuragen acquisitions. Diagnostics reagents develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. Genomics, Exosome, and Asuragen consists of Genomics and Exosome products and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment’s net sales for the fiscal years ended June 30, 2021, 2020, and 2019. 

 

There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.

 

Following is financial information relating to the operating segments (in thousands):

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Net sales:

            

Protein Sciences

 $704,564  $555,352  $543,159 

Diagnostics and Genomics

  227,744   184,549   171,674 

Intersegment

  (1,276

)

  (1,210

)

  (827

)

Consolidated net sales

 $931,032  $738,691  $714,006 
             

Operating Income:

            

Protein Sciences

 $328,837  $234,929  $240,919 

Diagnostics and Genomics

  38,425   14,965   10,079 

Segment operating income

  367,262   249,894   250,998 

Costs recognized upon sale of acquired inventory

  (1,565)  -

 

  (3,739

)

Amortization of acquired intangible assets

  (64,239

)

  (60,865

)

  (58,550

)

Gain on escrow settlement

  -   7,169   - 

Acquisition related expenses

  (7,114

)

  (416

)

  (2,282

)

Restructuring costs

  (142

)

  (87)  -

 

Stock-based compensation, inclusive of employer taxes

  (51,846

)

  (34,262

)

  (33,057

)

Corporate general, selling and administrative expenses

  (5,060

)

  (4,015

)

  (6,651

)

Consolidated operating income

 $237,296  $157,419  $146,719 

 

69
Table of Contents
 

The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment’s operating results, it is not discretely identifiable.

 

The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) :

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Consumables revenue - Protein Sciences

 $557,037  $431,052  $430,655 

Consumables revenue - Diagnostics and Genomics

  194,948   171,590   158,324 

Total consumable revenue

 $751,985  $602,642  $588,979 

 

The following is financial information relating to geographic areas (in thousands):

 

  

Year ended June 30,

 

Long-lived assets:

 

2021

  2020 

United States and Canada

 $190,501  $162,039 

Europe

  13,949   13,120 

Asia

  3,457   1,670 

Total long-lived assets

 $207,907  $176,829 

Intangible assets:

        

United States and Canada

 $594,512  $499,875 

Europe

  9,369   12,349 

Asia

  12,087   4,321 

Total intangible assets

 $615,968  $516,545 

 

Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

 

 

 

Note 13. Subsequent Events:

 

None

 

70
Table of Contents
 
 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors

Bio-Techne Corporation:

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Bio-Techne Corporation and subsidiaries (the Company) as of June 30, 2021 and 2020, the related consolidated statements of earnings and comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended June 30, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended June 30, 2021, in conformity with U.S. generally accepted accounting principles.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of June 30, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated August 25, 2021 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

 

Change in Accounting Principle

 

As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases as of July 1, 2019, due to the adoption of Accounting Standards Update 2016-02, Leases (Topic 842) and related amendments.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Goodwill impairment analysis for the Exosome reporting unit

 

As discussed in Note 1 to the consolidated financial statements, the goodwill balance as of June 30, 2021 was $843.1 million, of which $105.4 million related to the Exosome reporting unit. The Company performs goodwill impairment testing on an annual basis and whenever events or changes in circumstances indicate that the carrying value of a reporting unit likely exceeds its fair value. This involves estimating the fair value of the reporting units using a discounted cash flow model.

 

We identified the evaluation of the goodwill impairment analysis for the Exosome reporting unit as a critical audit matter. There was a high degree of subjectivity in applying and evaluating certain key assumptions used in the discounted cash flow model to estimate the fair value of the Exosome reporting unit. Specifically, the revenue growth rates and the discount rate were challenging to test as they represented subjective determinations of future market and economic conditions. Changes to those assumptions could have had a significant effect on the Company’s assessment of the fair value of the Exosome reporting unit.

 

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the goodwill impairment process. This included controls related to the Company’s determination of the estimated fair value of the Exosome reporting unit, including controls related to the development of the assumptions for the revenue growth rates and discount rate. We performed sensitivity analyses over the revenue growth rate and discount rate assumptions to assess their impact on the Company’s determination that the fair value of the Exosome reporting unit exceeded its carrying value. We evaluated the reasonableness of the Company’s forecasted revenue growth rates for the Exosome reporting unit by comparing the growth rate assumptions to industry related third-party data. We also compared the Company’s historical revenue forecasts to actual results to assess the Company’s ability to accurately forecast. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in evaluating the discount rate used in the valuation, by comparing it against a discount rate range that was independently developed using publicly available market data for comparable entities.

 

71
 

 

Fair value measurement of the developed technology and in-process research and development intangible assets acquired in the Asuragen acquisition

 

As discussed in Note 4 to the consolidated financial statements, the Company acquired Asuragen, Inc. (Asuragen) in April 2021, for total consideration of $233.9 million, net of cash acquired. As a result of the acquisition, the Company recognized intangible assets of $144.4 million, including developed technology of $107.0 million and in-process research and development (IPR&D) of $22.7 million. 

 

We identified the assessment of the fair value measurement of the acquired developed technology and IPR&D as a critical audit matter. There was a high degree of subjectivity in applying and evaluating certain key assumptions used to estimate the fair value of the acquired developed technology and IPR&D. Specifically, the revenue growth rates and the discount rates were challenging to test as they represented subjective determinations of future market and economic conditions. Changes to those assumptions could have had a significant effect on the determination of the fair value measurements.

 

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s acquisition-date valuation process, including controls related to the development of the assumptions for the revenue growth rates and discount rates. We performed sensitivity analyses over the revenue growth rates to assess the impact of changes in those assumptions on the Company’s determination of the fair value of the developed technology and IPR&D. We evaluated the reasonableness of the Company’s forecasted revenue growth rates used to determine forecasted revenues by comparing them to historical results and industry related third-party data. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:

 

 

●

evaluating the discount rates used by the Company by comparing them against discount rate ranges that were independently developed using publicly available market data for comparable entities

 

 

●

testing the estimate of the fair value of the intangible assets acquired using the Company’s cash flow forecasts and discount rates, and comparing the results to the Company’s fair value estimates.

 

Initial fair value measurement of the contingent consideration liability related to the Asuragen acquisition

 

As discussed in Note 4 to the consolidated financial statements, the initial fair value of the contingent consideration liability for the Asuragen acquisition was $18.3 million. The contingent consideration liability is recorded at fair value and remeasured each reporting period, with a maximum payout of $105.0 million upon achievement of certain revenue targets through calendar year 2023.

 

We identified the assessment of the initial fair value measurement of the contingent consideration liability as a critical audit matter. There was a high degree of subjectivity in applying and evaluating certain key assumptions used to estimate the initial fair value of the contingent consideration liability. Specifically, the revenue growth rates, volatility, and discount rate were challenging to test as they represented subjective determinations of future market and economic conditions. Changes to those assumptions could have had a significant effect on the determination of the initial fair value of the contingent consideration liability.

 

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s acquisition-date valuation process, including controls related to the development of the assumptions for the revenue growth rates, volatility, and discount rate. We performed sensitivity analyses over the future revenue growth rates to assess the impact of changes in those assumptions on the Company’s determination of the initial fair value of the contingent consideration liability. We evaluated the reasonableness of the Company’s forecasted revenue growth rates used to determine forecasted revenues by comparing them to historical results and industry related third-party data. In addition, we involved valuation professionals with specialized skills and knowledge, who assisted in:

 

 

●

evaluating the Company’s volatility and discount rate, by comparing the Company’s inputs to the volatility and the discount rate to publicly available market data for comparable entities, and assessing the resulting volatility and discount rate

 

 

●

testing the estimate of the initial fair value of the contingent consideration liability using the Company’s forecasted revenues, volatility, and the discount rate, and comparing the results to the Company’s initial fair value estimate.

 

/s/ KPMG LLP

We have served as the Company’s auditor since 2002.

 

Minneapolis, Minnesota
August 25, 2021

 

72
Table of Contents

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors
Bio-Techne Corporation:

 

Opinion on Internal Control Over Financial Reporting

 

We have audited Bio-Techne Corporation and subsidiaries’ (the Company) internal control over financial reporting as of June 30, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of June 30, 2021 and 2020, the related consolidated statements of earnings and comprehensive income, shareholders’ equity, and cash flows for each of the years in the three-year period ended June 30, 2021,and the related notes (collectively, the consolidated financial statements), and our report dated August 25, 2021 expressed an unqualified opinion on those consolidated financial statements.

 

The Company acquired Asuragen, Inc. and a controlling interest in Eminence Biotechnology during 2021, and management excluded from its assessment of the effectiveness of the Company’s internal control over financial reporting as of June 30, 2021, Eminence Biotechnology and Asuragen, Inc.’s internal control over financial reporting associated with 12.0% of total assets and 0.8% of total revenues included in the consolidated financial statements of the Company as of and for the year ended June 30, 2021. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Eminence Biotechnology and Asuragen, Inc.

 

Basis for Opinion

 

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and Limitations of Internal Control Over Financial Reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

 

/s/ KPMG LLP

 

Minneapolis, Minnesota
August 25, 2021

 

73
Table of Contents

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

 

ITEM 9A. CONTROLS AND PROCEDURES

 

 

(a)

Evaluation of Disclosure Controls and Procedures

 

As required by Rule 13a-15(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e). The evaluation was based upon reports and certifications provided by a number of executives.  Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2021, our disclosure controls and procedures were effective.

 

(b)

Management's Annual Report on Internal Control Over Financial Reporting

 

The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting also includes those policies and procedures that:

 

(i)

Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

 

(ii)

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

 

(iii)

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

 

We acquired a controlling interest in Eminence Biotechnology (Eminence) on October 20, 2020 and acquired Asuragen, Inc. (Asuragen) on April 6, 2021. Eminence and Asuragen represented approximately 12.0% of our total assets and 0.8% of our total revenues as of and for the year ended June 30, 2021. We excluded internal control over financial reporting associated with Eminence and Asuragen from our assessment of the effectiveness of our internal control over financial reporting as of June 30, 2021.

 

Under the supervision of the Audit Committee of the Board of Directors and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment and those criteria, our Chief Executive Officer and Chief Financial Officer concluded that our internal control over financial reporting was effective as of June 30, 2021.

 

The attestation report on our internal control over financial reporting issued by KPMG LLP appears in Item 8 of this report.

 

74
Table of Contents

 

(c)

Changes in Internal Control Over Financial Reporting

 

As previously announced, we acquired Eminence Biotechnology on October 20, 2020 and Asuragen, Inc on April 6, 2021. We have not fully evaluated any changes in internal control over financial reporting associated with these acquisitions and therefore any material changes that may result from these acquisitions have not been disclosed in this report. We intend to disclose all material changes resulting from the acquisitions within or prior to the time of our first annual assessment of internal control over financial reporting that is required to include these entities. 

 

There were no other changes in the Company's internal control over financial reporting during fiscal year 2021 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

 

 

 

ITEM 9B. OTHER INFORMATION

 

None.

 

75
Table of Contents
 

 

PART III

 

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Other than "Executive Officers of the Registrant" which is set forth at the end of Item 1 in Part I of this report, the information required by Item 10 is incorporated herein by reference to the sections entitled "Election of Directors," "Principle Shareholders" and "Additional Corporate Governance Matters" in the Company's Proxy Statement for its 2021 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

 

ITEM 11. EXECUTIVE COMPENSATION

 

The information required by Item 11 is incorporated herein by reference to the sections entitled "Election of Directors" and "Executive Compensation" in the Company's Proxy Statement for its 2021 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

 

The information required by Item 12 is incorporated by reference to the sections entitled "Principal Shareholders" and "Management Shareholdings" in the Company's Proxy Statement for its 2021 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by Item 13 is incorporated by reference to the sections entitled "Election of Directors" and "Additional Corporate Governance Matters" in the Company's Proxy Statement for its 2021 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The information required by Item 14 is incorporated herein by reference to the section entitled "Audit Matters" in the Company's Proxy Statement for its 2021 Annual Meeting of Shareholders which will be filed with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year for which this report is filed.

 

76
Table of Contents
 

 

PART IV

 

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

A. (1) List of Financial Statements.

 

The following Consolidated Financial Statements are filed as part of this Annual Report on Form 10-K:

 

Consolidated Statements of Earnings and Comprehensive Income for the Years Ended June 30, 2021, 2020, and 2019

 

Consolidated Balance Sheets as of June 30, 2021 and 2020

 

Consolidated Statements of Shareholders' Equity for the Years Ended June 30, 2021, 2020, and 2019

 

Consolidated Statements of Cash Flows for the Years Ended June 30, 2021, 2020, and 2019

 

Notes to Consolidated Financial Statements for the Years Ended June 30, 2021, 2020, and 2019

 

Reports of Independent Registered Public Accounting Firm          

 

 

A. (2) Financial Statement Schedules.

 

All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the Consolidated Financial Statements or Notes thereto.

 

A. (3) Exhibits.

 

EXHIBIT INDEX

for Form 10-K for the 2021 Fiscal Year

 

 

Exhibit

Number  

Description

3.1

Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's Form 10-Q dated February 9, 2015*
   

3.2

Third Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated February 1, 2018*
   

4.1

Description of Capital Stock -- attached as Exhibit 4.1 hereto
   

10.1**

Management Incentive Plan--incorporated by reference to Exhibit 10.13 of the Company's Form 10-K for the year ended June 30, 2013*
   

10.2**

Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated October 26, 2017*
   

10.3**

Form of Time Vesting Restricted Stock Award Agreement.
   

10.4**

Form of Performance Vesting Restricted Stock Award Agreement.
   

10.5**

Form of Time Vesting Restricted Stock Unit Award Agreement.
   

10.6**

Form of Performance Vesting Restricted Stock Unit Award Agreement.
   

10.7**

Form of the Time Vesting Performance Unit Award Agreement.

   

10.8**

Form of Performance Vesting Performance Unit Award Agreement. 

 

10.9**

Form of Time Vesting Incentive Stock Option Agreement. .
   

10.10**

Form of Performance Vesting Incentive Stock Option Agreement. 
   

10.11**

Form of Employee Non-Qualified Stock Option Agreement.
   

10.12**

Form of Director Non-Qualified Stock Option Agreement for Second Amended and Restated 2010 Equity Incentive Plan--incorporated by reference to Exhibit 10.2 of the Company's Form 8-K dated October 26, 2017*
   

10.13**

Employment Agreement by and between the Company and Charles Kummeth--incorporated by reference to Exhibit 10.11 of the Company's Form 10-K dated September 7, 2017*

 

77
Table of Contents

 

Exhibit

Number 

Description

10.14**

Form of Employment Agreement by and between the Company and Executive Officers of the Company other than the CEO--incorporated by reference to Exhibit 10.12 of the Company's Form 10-K dated September 7, 2017*
   

10.15**

Form of Amendment No. 1 to Executive Employment Agreement – incorporated by reference to Exhibit 10.15 of the Company’s Form 10-Q dated May 11, 2020. 
   

10.16

Credit Agreement by and among the Company, the Guarantors party thereto, the Lenders party thereto, and BMO Harris Bank N.A., as Administrative Agent, dated August 1, 2018--incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated August 2, 2018*
   

10.17**

Form of Indemnification Agreement entered into with each director and executive officer of the Company--incorporated by reference to Exhibit 10.1 of the Company's Form 10-Q dated February 8, 2018*
   

10.20

Development, Supply and Commercialization Agreement by and between the Company and Kantaro Biosciences, LLC dated May 18, 2020 (portions of which have been redacted as noted, subject to confidential treatment) – incorporated by reference to Exhibit 10.1 of the Company's Form 8-K dated May 19, 2020*

 

21

Subsidiaries of the Company
   

23

Consent of KPMG LLP, Independent Registered Public Accounting Firm
   

31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   

31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   

32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   

32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   

101

The following financial statements from the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2021, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Consolidated Statements of Earnings and Comprehensive Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Shareholders' Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.
   

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

-------------

*     Incorporated by reference; SEC File No. 000-17272

**   Management contract or compensatory plan or arrangement

 

 

 

 

Exhibits for Form 10-K have not been included in this report. Exhibits have been filed with the Securities and Exchange Commission. Upon request to the Investor Relations Department, Bio-Techne Corporation will furnish, without charge, any such exhibits as well as copies of periodic reports filed with the Securities and Exchange Commission.

 

 

ITEM 16. FORM 10-K SUMMARY

None.

 

78
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BIO-TECHNE CORPORATION

  
       
       

Date: August 25, 2021

  

/s/ Charles Kummeth

  
   

 By: Charles Kummeth

  
   

 Its: President and CEO

  

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Date    

Signature and Title
   
August 25, 2021

/s/ Robert V. Baumgartner
 

Robert V. Baumgartner
 

Chairman of the Board and Director
   
August 25, 2021

/s/ Julie Bushman
 

Julie Bushman, Director
   
August 25, 2021

/s/ Rupert Vessey
 

Dr. Rupert Vessey, Director
   
August 25, 2021

/s/ Joseph Keegan, Ph.D.
 

Dr. Joseph Keegan, Director
   
August 25, 2021

/s/ John L. Higgins
 

John L. Higgins, Director
   
August 25, 2021

/s/ Roeland Nusse, Ph.D.
 

Dr. Roeland Nusse, Director
   
August 25, 2021

/s/ Alpna Seth, Ph.D.
 

Dr. Alpna Seth, Director
   
August 25, 2021

/s/ Randolph C. Steer, Ph.D., M.D.
 

Dr. Randolph C. Steer, Director
   
August 25, 2021

/s/ Charles Kummeth
 

Charles Kummeth, Director and Chief Executive Officer (principal executive officer)
   

August 25, 2021 

/s/ James Hippel
 

James Hippel, Chief Financial Officer
 

(principal financial officer and principal accounting officer)

 

79
EX-4.1 2 ex_248803.htm EXHIBIT 4.1 ex_248803.htm

Exhibit 4.1

 

DESCRIPTION OF COMMON STOCK

 

The following summary of the common stock, par value $0.01 per share (the “Common Stock”), of Bio-Techne Corporation (the “Company,” “we,” or “our”) is based on and qualified by our Amended and Restated Articles of Incorporation (the “Articles”) and our Third Amended and Restated Bylaws (the “Bylaws”). For a complete description of the terms and provisions of our Common Stock, refer to the full text of the Articles of Incorporation and Bylaws, both of which are exhibits to our Annual Report on Form 10-K to which this description is also an exhibit, and the Minnesota Business Corporation Act (“MBCA”), which is available at https://www.revisor.mn.gov/statutes/cite/302A.

 

Authorized Shares

 

The Company is authorized to issue up to 105,000,000 shares, which consists of 5,000,000 undesignated shares and 100,000,000 shares of Common Stock. As of June 30, 2021, the Company had 38,955,484 shares of Common Stock issued and outstanding.

 

The Common Stock is the only outstanding class of stock of the Company. The Board of Directors of the Company (the “Board”) is authorized to establish one or more classes or series of shares from the undesignated shares and to fix the relative rights and preferences of each such class or series, but the Board has not designated any class or series of shares from the undesignated shares.

 

Dividend Rights

 

Subject to the rights of holders of any preferred stock outstanding, holders of Common Stock are entitled to receive dividends when, as, and if declared by the Board out of net earnings or net assets of the Company that are legally available for the declaration of dividends.

 

Voting Rights

 

All voting rights are vested in the holders of shares of Common Stock. Each holder of Common Stock is entitled to one vote per share, and voting rights are noncumulative. Subject to the rights of the holders of any preferred stock outstanding and except as specifically required otherwise under the MBCA all matters submitted to Company shareholders are decided by a majority vote of the shares entitled to vote and represented at the meeting at which there is a quorum, except for election of directors, which is decided by a majority of votes cast in uncontested elections and by a plurality vote in contested elections.

 

Liquidation and Dissolution Rights

 

Pursuant to applicable law, in the event of the Company’s dissolution, the holders of Common Stock will be entitled to share pro rata in any of the Company’s assets available for distribution after making adequate provision for the discharge of debts, obligations, and liabilities of the Company and after the holders of any series of outstanding preferred stock have received any liquidation preferences.

 

Other Shareholder and Board Rights

 

Holders of shares of Common Stock are not entitled to preemptive rights. The Board may issue rights to subscribe for, purchase, exchange securities for, or convert securities into, shares of the Company or any class or series, and to fix the terms, provisions and conditions of such rights, including the exchange or conversion basis or the price at which such shares may be purchased or subscribed for. The Board may effectuate share dividends or splits by issuance of shares of one class or series to holders of that class or series or to holders of another class or series.

 

 
 

 

Nominations Procedures

 

Shareholders can nominate candidates for election to the Board. However, a shareholder must follow the advance notice procedures provided in Section 2.10 of the Bylaws. In general, for an annual meeting, a shareholder must submit a written notice of such nomination to the Company’s corporate secretary at least 60 days but not more than 90 days prior to the anniversary of the prior year’s annual meeting. The written notice must contain the consent of the nominee(s) to serve as director and provide certain information about the proposed nominee(s) and the shareholder proposing the nomination, as required by Section 2.10 of the Bylaws.

 

Proposal Procedures

 

Shareholders may propose that business (other than nominations to the Board) be considered at a meeting of shareholders only if a shareholder follows the advance notice procedures provided in Section 2.10 of the Bylaws. In general, for an annual meeting, a shareholder must submit a written notice of the proposed business to the Company’s corporate secretary at least 60 days but not more than 90 days prior to the anniversary of the prior year’s annual meeting. The written notice must provide certain information about the proposed business and the shareholder proposing the business, as required by Section 2.10 of the Bylaws..

 

Limitations on Change of Control

 

Certain provisions of the Articles, the Bylaws, and the MBCA may discourage, delay, or prevent a merger, acquisition, or other change of control, including through a change to the members of the Company’s management. These provisions include:

 

 

●

Advance notice requirements for shareholder proposals and nominations (Section 2.10 of the Bylaws);

 

 

●

The ability of the Board to amend the Bylaws (Section 9.1 of the Bylaws);

 

 

●

The ability of the Board to issue purchase rights and additional Common Stock and to designate the terms of and issue new series of preferred stock without shareholder approval (Article 3 of the Articles);

 

 

●

Limitations, pursuant to Section 302A.671 of the MBCA, with respect to the voting of shares acquired in a “control share acquisition”;

 

 

●

The prohibition, pursuant to Section 302A.673 of the MBCA, of business combination transactions involving an “interested shareholder” and the Company for a period of four years after such individual or entity becomes an interest shareholder, unless a proscribed approval is obtained; and

 

 

●

The limitation, pursuant to Section 302A.675 of the MBCA, on purchasing additional shares of Common Stock by a party who has made a takeover offer for the Company unless holders of Common Stock are able to sell shares on substantially equivalent terms to the prior takeover offer, unless a proscribed approval is obtained.

 

 
 

 

Amendment of Articles of Incorporation and Bylaws

 

The holders of a majority of the outstanding shares of Common Stock have the power to amend the Articles of Incorporation. The Board may amend, adopt, or repeal the Bylaws, subject to the limitations see forth in our Bylaws and the MBCA. The holders of a majority of the outstanding shares of Common Stock also have the power to alter or amend, make or adopt, or repeal the Bylaws. 

 

Transfer Agent and Registrar

 

American Stock Transfer & Trust Company is the transfer agent and registrar for the Company’s Common Stock.

 

Listing of Common Stock

 

The Company’s Common Stock is listed on NASDAQ under the symbol “TECH.”

 

 
 EX-10.3 3 ex_248804.htm EXHIBIT 10.3 ex_248804.htm

Exhibit 10.3

 

RESTRICTED STOCK AWARD AGREEMENT
(TIME VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock award to Participant for shares of Company Common Stock pursuant to the Bio-Techne Second Corporation Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock award to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Restricted Stock Award. The Company hereby grants to the Participant on the date set forth above a restricted stock award (the “Award”) for [●] ([●]) shares of Company Common Stock (the “Shares”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. The Company shall cause to be issued such Shares in the Participant’s name, and shall hold such Shares until such time as the risks of forfeiture set forth in this Agreement have lapsed. The Company may also place transfer restrictions on such Shares describing the risks of forfeiture and other transfer restrictions set forth in this Agreement providing for the cancellation of such Shares if they are forfeited as provided in Section 2 below. Subject to the foregoing restrictions on transfer and the terms and conditions of the Plan, the Participant shall have all the rights of a stockholder with respect to the Shares during the period in which the Shares are subject to risk of forfeiture, including without limitation, the right to vote such shares and receive all dividends attributable to such shares.

 

2.     Lapse of Risks of Forfeiture for Restricted Stock; Termination of Relationship.

 

(a)     General. The Shares subject to this Award shall remain subject to forfeiture until the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or has terminated employment through Retirement as of the applicable Vesting Date as set forth in Section 2(b) of this Agreement.

 

 
 

 

 

Date

Shares Vesting

  
     

[●]

[●]

  

[●]

[●]

  

[●]

[●]

  

[●]

[●]

  

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.               

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to the removal of transfer restrictions on the Shares until the Administrator determines the number of Shares, if any, which have vested and for which risks of forfeiture have lapsed.

 

(b)     Termination of Relationship. Except as otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason other than the Participant’s Retirement, the Participant shall forfeit all Shares subject to this Award which, as of the termination date, have not yet vested and for which the risks of forfeiture have not lapsed. If the Participant’s employment with the Company or any Affiliate terminates because of Retirement, if this Award was granted at least six months prior to the date of Participant’s Retirement, then this Award shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Award was not granted at least six months prior to the date of Participant’s Retirement, then to the extent this Award was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Award shall be forfeited.

 

Solely for purposes of this Section 2(b), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

- 2 -
 

 

3.     [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those Shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

4.     General Provisions.

 

(a)      Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(c)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the issuance of any shares of Company Common Stock subject to this Award. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon the grant of this Award. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, which are applicable to the supplemental income attributable to this Award. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3, or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

- 3 -
 

 

(d)     Nontransferability. For so long as the shares of Company Common Stock underlying this Award remain subject to risks of forfeiture, such shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(e)      Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of the Company Common Stock underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of the Company Common Stock underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(g)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock issued to Participant pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(e) and Section 4(f) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(e) and Section 4(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(i)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

- 4 -
 

 

(j)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(l), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(l).

 

- 5 -
 

 

(m)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota. 

 

 

 

[Signature page follows.]

 

- 6 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

 

BIO-TECHNE CORPORATION
       
       
 

By  

  
   

Its

  

 

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 
 EX-10.4 4 ex_248805.htm EXHIBIT 10.4 ex_248805.htm

Exhibit 10.4

 

RESTRICTED STOCK AWARD AGREEMENT
(PERFORMANCE VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock award to Participant for shares of Company Common Stock pursuant to the Bio-Techne Second Corporation Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock award to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Restricted Stock Award. The Company hereby grants to the Participant on the date set forth above a restricted stock award (the “Award”) for [●] ([●]) shares of Company Common Stock (the “Shares”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. The Company shall cause to be issued such Shares in the Participant’s name, and shall hold such Shares until such time as the risks of forfeiture set forth in this Agreement have lapsed. The Company may also place transfer restrictions on such Shares describing the risks of forfeiture and other transfer restrictions set forth in this Agreement providing for the cancellation of such Shares if they are forfeited as provided in Section 2 below. Subject to the foregoing restrictions on transfer and the terms and conditions of the Plan, the Participant shall have all the rights of a stockholder with respect to the Shares during the period in which the Shares are subject to risk of forfeiture, including without limitation, the right to vote such shares and receive all dividends attributable to such shares.

 

2.     Lapse of Risks of Forfeiture for Restricted Stock; Termination of Relationship.

 

(a)     General. The risks of forfeiture for the Shares subject to this Award shall lapse, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the Vesting Date[s] as set forth in Section 2(b) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Award shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event the risks of forfeiture do not lapse with respect to all or any portion of the Award on the Vesting Date[s] pursuant to the performance objectives set forth on Exhibit A, the unvested portion of the Award shall terminate on such date and all Shares subject to such portion Award shall be forfeited.

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan. 

 

Further, in the event of Participant’s Retirement, a pro rata portion of the Shares subject to this Award shall become vested on the Vesting Date immediately following the date of Participant’s Retirement, with such portion determined by multiplying the Shares subject to this Award by a fraction, the numerator of which is the number of whole months that Participant was employed during the performance period and the denominator of which is the total number of months in the performance period. For purposes of this Agreement, “Retirement” means termination of employment for any reason other than for cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to the removal of transfer restrictions on the Shares until the Administrator determines the number of Shares, if any, which have vested and for which risks of forfeiture have lapsed.]

 

(b)     Termination of Relationship. Unless otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason other than the Participant’s Retirement, the Participant shall forfeit all Shares subject to this Award which, as of the termination date, have not yet vested and for which the risks of forfeiture have not lapsed.

 

- 2 -
 

 

3.     [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those Shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

4.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(c)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the issuance of any shares of Company Common Stock subject to this Award. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon the grant of this Award. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, which are applicable to the supplemental income attributable to this Award. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3, or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

- 3 -
 

 

(d)     Nontransferability. For so long as the shares of Company Common Stock underlying this Award remain subject to risks of forfeiture, such shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(e)      Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of the Company Common Stock underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of the Company Common Stock underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(g)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock issued to Participant pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(e) and Section 4(f) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(e) and Section 4(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(i)      Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

- 4 -
 

 

(j)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(l), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(l).

 

- 5 -

 

 

(m)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota. 

 

 

 

[Signature page follows.]

 

- 6 -

 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

 

BIO-TECHNE CORPORATION
       
       
 

By  

  
   

Its

  

 

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 
 EX-10.5 5 ex_248806.htm EXHIBIT 10.5 ex_248806.htm

Exhibit 10.5

 

GLOBAL RESTRICTED STOCK UNIT AGREEMENT

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock unit award to Participant for shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock unit award to Participant.

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows;

 

1.     Grant of Restricted Stock Unit Award. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”) a restricted stock unit award for [●] ([●]) restricted stock units (the “Award”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. Each restricted stock unit shall entitle the Participant to receive one share of Company Common Stock (a “Share,” or the “Shares”). For purposes of this Agreement, to the extent Participant is not employed by the Company, the “Employer” means the Subsidiary that employs Participant.

 

2.     Vesting of Restricted Stock Units; Termination of Relationship.

 

(a)     General. The Award shall vest on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or a Subsidiary on the applicable Vesting Date as set forth in Section 2(b) of this Agreement:

 

 

Date

  

Shares Vesting

  
         
 

[●]

  

[●]

  
 

[●]

  

[●]

  
 

[●]

  

[●]

  
 

[●]

  

[●]

  

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by Participant and the Company or the Employer, or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

 
 

 

Subject to such other terms and conditions set forth in this Agreement, Participant shall not be entitled to the issuance of Shares for any portion of the restricted stock units subject to this Award until the Administrator determines the number of restricted stock units, if any, which have vested.

 

(b)     Termination of Relationship. Except as otherwise provided in this Agreement (including in Section 2(c)) or agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason, including the Participant’s voluntary resignation, the unvested portion of the Award shall terminate and the Participant shall forfeit all Shares subject to this Award which, as of the Termination Date, have not yet vested.

 

(c)     Retirement. If Participant’s employment with the Company or any Subsidiary terminates because of Retirement, this Award was granted at least six months prior to the date of Participant’s Retirement, and this Award is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Award shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company on the applicable Vesting Dates. If, however, this Award was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then this award will terminate upon Participant’s Retirement with no further vesting under Section 2(a).

 

Solely for purposes of this Section 2(c), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. For purposes of this Agreement, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and the Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

(d)     EU Age Discrimination Rules. If Participant is a local national of and employed in a country that is a member of the European Union, the grant of this Award and the terms and conditions governing this Award are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

 

2
 

 

(e)     Termination Date. For purposes of this Agreement, if Participant is employed in the United States, "Termination Date" means the effective date of termination of Participant's employment. If Participant is employed outside of the United States, “Termination Date” means the earliest of (i) the date on which notice of termination is provided to Participant, (ii) the last day of Participant's active service with the Employer or (iii) the last day on which Participant is an employee of the Employer, as determined in each case, without including any required advanced notice period and irrespective of the status of the termination under local labor or employment laws

 

3.     Issuance of Shares.

 

(a)     General. As soon as practicable after each Vesting Date, Participant shall be recorded on the stock transfer books of the Company as the owner of the vested number of Shares set forth in Section 2(a) of this Agreement, less any Shares withheld for payment of taxes as provided in Section 5 below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such Shares, Participant shall not be entitled to vote the Shares represented by such restricted stock units, shall not be entitled to receive dividends or distributions attributable to such Shares, and shall not have any other rights as a shareholder with respect to such Shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such Shares are issued, except as provided in Section 15 of the Plan.

 

(b)     Repatriation and Compliance Obligations. As a condition of the grant of this Award, Participant agrees to repatriate all payments attributable to this Award in accordance with local foreign exchange rules and regulations in Participant's country of residence (and country of employment, if different). In addition, Participant agrees to take any and all actions, and consents to any and all actions taken by the Employer, the Company and its Subsidiaries as may be required to allow the Employer, the Company and its Subsidiaries to comply with local laws, rules and regulations in Participant's country of residence (and country of employment, if different). Finally, Participant agrees to take any and all actions that may be required to comply with Participant's personal legal and tax obligations under local laws, rules and regulations in Participant's country of residence (and country of employment, if different).

 

4.    [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

3
 

 

5.    Tax Obligations. Regardless of any action the Company or the Employer takes with respect to any or all federal, state, local or foreign income tax, social insurance, payroll tax, payment on account or other tax related-items (“Tax Related-Items”), Participant acknowledges that the ultimate liability for all Tax Related-Items associated with this Award is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company, and the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Tax Related-Items in connection with any aspect of this Award, including, but not limited to, the grant of the Award, the vesting of the Award, the subsequent sale of Shares acquired pursuant to the Award and the receipt of any dividends; and (ii) do not commit to structure the terms of the grant or any aspect of this Award to reduce or eliminate Participant’s liability for Tax Related-Items. Further, if Participant is subject to tax in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related-Items in more than one jurisdiction.

 

Prior to the delivery of Shares upon the vesting of this Award, if Participant's country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company or the Employer: (i) shall withhold a sufficient number of whole Shares otherwise issuable upon the vesting of the Award that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld (in which case, the cash equivalent of such withheld Shares shall be used to settle the withholding obligation); (ii) shall withhold an amount from Participant's regular salary and/or wages, or from any other amounts payable to Participant; or (iii) require Participant to make a payment to the Company or the Employer equal to the amount of Tax-Related Items required to be withheld. Depending on the applicable method, the Company or the Employer, as applicable, may withhold or account for Tax-Related Items by considering applicable statutory withholding rates, but such withholding shall not exceed an amount of withholding based on the maximum statutory rates in Participant's applicable tax jurisdictions.

 

In the event the withholding requirements are not satisfied through the withholding of Shares or through Participant's regular salary and/or wages or other amounts payable to Participant, no Shares will be issued to Participant unless and until satisfactory arrangements (as determined by the Committee) have been made by Participant with respect to the payment of any Tax-Related Items which the Company determines, in its sole discretion, must be withheld or collected with respect to this Award. If Participant is subject to taxation in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer may be required to withhold or account for Tax-Related Items in more than one jurisdiction. By accepting the this Award, Participant expressly consents to the withholding of Shares and/or the withholding of amounts from Participant's regular salary and/or wages, or other amounts payable to Participant, as provided for hereunder. All other Tax-Related Items related to this Award and any Shares acquired pursuant to the vesting of this Award are Participant's sole responsibility.

 

4
 

 

6.     Clawback/Recoupment Policy. Notwithstanding any other provision of this Agreement to the contrary, Participant acknowledges and agrees that all Shares acquired pursuant to the Plan shall be and remain subject to any incentive compensation clawback or recoupment policy of the Company currently in effect or as may be adopted by the Company and, in each case, as may be amended from time to time. No such policy adoption or amendment shall require Participant's prior consent. For purposes of the foregoing, Participant expressly and explicitly authorizes the Company to issue instructions, on Participant's behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold Participant's Shares, and other amounts acquired under the Plan to re-convey, transfer or otherwise return such Shares and/or other amounts to the Company.

 

7.     Nature of Grant. In accepting the grant of this Award, Participant acknowledges, understands and agrees that:

 

(a)     the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

 

(b)     the grant of this Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of an Award, or benefits in lieu of an Award, even if Awards have been granted in the past;

 

(c)     all decisions with respect to future grants of Awards or other grants, if any, will be at the sole discretion of the Company;

 

(d)     Participant is voluntarily participating in the Plan;

 

(e)     this Award and the Shares subject to this Award, and the income from and value of same, are not intended to replace any pension rights or compensation;

 

(f)     this Award and the Shares subject to this Award, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;

 

(g)     unless otherwise agreed with the Company in writing, this Award and the Shares subject to this Award, and the income from and value of same, are not granted as consideration for, or in connection with, the service Participant may provide as a director of a Subsidiary;

 

(h)     the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;

 

5
 

 

(i)     no claim or entitlement to compensation or damages shall arise from forfeiture of this Award resulting from the termination of Participant's employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant's employment agreement, if any); and

 

(j)     neither the Company nor the Employer shall be liable for any foreign exchange rate fluctuation between Participant's local currency and the United States Dollar that may affect the value of this Award or of any amounts due to Participant pursuant to the settlement of this Award or the subsequent sale of any Shares acquired upon settlement.

 

8.    Data Privacy. The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Awards under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of Awards under the Plan and its ongoing administration of such Awards, the Company is providing the following information about its data collection, processing and transfer practices. In accepting the grant of this Award, Participant expressly and explicitly consents to the personal data activities as described herein.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for the collection, processing and use of Participant's Personal Data is Participant's consent.

 

(b)     Stock Plan Administration Service Providers. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. You should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is Participant's consent.

 

6
 

 

(d)    Voluntariness and Consequences of Consent, Denial or Withdrawal. Participant's participation in the Plan and Participant's grant of consent hereunder is purely voluntary. Participant may deny or withdraw his or her consent at any time. If Participant does not consent, or if Participant later withdraws his or her consent, Participant may be unable to participate in the Plan. This would not affect Participant's existing employment or salary; instead, Participant merely may forfeit the opportunities associated with participation in the Plan.

 

(e)     Personal Data Retention. Participant understands that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage this Award and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(f)     Personal Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (vi) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understands that Participant can contact his or her Employer's human resources representative.

 

9.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Employer, the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant, the Employer and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The issuance of Shares upon vesting of this Award shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Shares upon vesting will not violate any state or federal securities or other laws. Notwithstanding any other provision of the Plan or this Agreement, unless there is an exemption from any registration, qualification or other legal requirement applicable to the Shares the Company shall not be required to deliver any Shares issuable upon settlement of this Award prior to the completion of any registration or qualification of the Shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. Participant understands that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares. Further, Participant agrees that the Company shall have unilateral authority to amend the Agreement without his or her consent to the extent necessary to comply with securities or other laws applicable to issuance of Shares.

 

7
 

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Nontransferability. The Award For so long as the Shares underlying this Award remain unvested, such Shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(e)      Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Award and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Shares in compliance with the U.S. Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Award or the Shares underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Award or any of the Shares underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(g)     Stock Legend. The Administrator may require that the certificates or book entries for any Shares issued to Participant (or Participant's permitted successors or assigns) pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 5 and Sections 9(e) through 9(f) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 5 or Sections 9(e) through 9(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or assigns of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

8
 

 

(i)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, United States of America, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota, United States of America.

 

(j)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 5(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless Participant and the Company otherwise agree in writing, any determination required under this Section 9(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 9(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 9(l).

 

9
 

 

(m)     Governing Law.  The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota, United States of America.

 

(n)      Language. Participant acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is proficient in the English language, so as to enable Participant to understand the provisions of this Agreement and the Plan. If Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

 

(o)     Electronic Delivery and Participation. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

 

(p)     Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

 

(q)      Addendum. Notwithstanding any provisions of this Agreement to the contrary, this Award shall be subject to any special terms and conditions for Participant's country of residence (and country of employment, if different), as are forth in the applicable Addendum to this Agreement. Further, if Participant transfers residence and/or employment to another country reflected in an Addendum to this Agreement, the special terms and conditions for such country will apply to Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Award and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate Participant's transfer). Any applicable Addendum shall constitute part of this Agreement.

 

(r)      Imposition of Other Requirements. The Company reserves the right to impose other requirements on this Award, any payment made pursuant to this Award, and Participant's participation in the Plan, to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Award and the Plan. Such requirements may include (but are not limited to) requiring Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

 

10
 

 

(s)     Waiver. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach, whether or like or different nature.

 

(t)     Private Offering. The grant of this Award is not intended to be a public offering of securities in Participant’s country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filing with the local securities authorities with respect to the grant of this Award (unless otherwise required under local law). No employee of the Company is permitted to advise Participant on whether Participant should acquire Shares under the Plan or provide Participant with any legal, tax or financial advice with respect to the grant of this Award. Investment in Shares involves a degree of risk. Before deciding to acquire Shares pursuant to this Award, Participant should carefully consider all risk factors and tax considerations relevant to the acquisition of Shares under the Plan or the disposition of them. Further, Participant should carefully review all of the materials related to this Award and the Plan, and Participant should consult with Participant’s personal legal, tax and financial advisors for professional advice in relation to Participant’s personal circumstances.

 

(u)     Exchange Control, Foreign Asset/Account and/or Tax Reporting. Participant acknowledges that there may be certain exchange control, foreign asset/account and/or tax reporting requirements which may affect Participant’s ability to acquire or hold Shares or cash received from participating in the Plan (including the proceeds from the sale of Shares and the receipt of any dividends paid on Shares) in a brokerage or bank account outside Participant’s country. Participant may be required to report such accounts, assets or related transactions to the tax or other authorities in Participant’s country. Participant also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to Participant’s country within a certain time after receipt. Participant acknowledges that it is Participant’s responsibility to comply with such regulations and that Participant should speak to his or her personal advisor on this matter.

 

(v)     Insider Trading/Market Abuse. Participant may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions, including the United States, Participant’s country and the designated broker’s country, which may affect Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., this Award) or rights linked to the value of Shares under the Plan during such times that Participant is considered to have “inside information” regarding the Company (as defined by the laws or regulations in Participant’s country).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Participant acknowledges that it is Participant’s responsibility to comply with any applicable restrictions and that Participant should speak to his or her personal advisor on this matter.

 

(w)     Consent and Agreement With Respect to Plan. Participant (a) acknowledges that a copy of the Plan and the U.S. prospectus for the Plan has been available to Participant; (b) represents that he or she has read and is familiar with the terms and provisions thereof, has had an opportunity to obtain the advice of counsel of his or her choice prior to executing this Agreement and fully understands all provisions of this Agreement and the Plan; (c) accepts this Award subject to all of the terms and provisions thereof; and (d) agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Agreement.

 

 

[Signature page follows.]

 

11
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

BIO-TECHNE CORPORATION
       
       
       
 

By 

    
   

Its

  

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 

[Signature Page to Global Restricted Stock Unit Agreement]

 

 
 

 

BIO-TECHNE CORPORATION

 

ADDENDUM TO
GLOBAL RESTRICTED STOCK UNIT AGREEMENT

 

BIO-TECHNE CORPORATION
SECOND AMENDED AND RESTATED
2010 EQUITY INCENTIVE PLAN

 

In addition to the terms of the Plan and the Agreement, the Award is subject to the following additional terms and conditions as set forth in this addendum (the “Addendum”). All defined terms as contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 9(q) of the Agreement, to the extent Participant transfers residence and/or employment to another country, the additional terms and conditions as set forth in the Addendum for such country (if any) shall also apply to the Award to the extent the Company determines, in its sole discretion, that the application of such addendum is necessary or advisable in order to comply with local laws, rules and regulations, or to facilitate the operation and administration of the Award and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate Participant’s transfer).

 

European Union (“EU”) / European Economic Area (“EEA”) / Switzerland / United Kingdom

 

1.    Data Privacy. If Participant resides and/or works in the EU/EEA, Switzerland or the United Kingdom, Section 8 of the Agreement shall be replaced with the following:

 

The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Awards under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of the Award under the Plan and its ongoing administration of such award, the Company is providing the following information about its data collection, processing and transfer practices, which Participant should carefully review.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Awards or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for such disclosure of Participant's Personal Data is to satisfy its contractual obligations under the terms of the Agreement and this Addendum, and to comply with applicable laws, rules and regulations.

 

1
 

 

(b)     Stock Plan Administrator. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of Awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. Participant should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is to satisfy its contractual obligations under the terms and conditions of this Agreement.

 

(d)     Data Retention. Participant understand that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage the Award and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(e)     Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (v) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understand that Participant can contact his or her Employer's human resources representative.

 

Austria

 

No country-specific provisions.

 

Belgium

 

No country-specific provisions.

 

Canada

 

1.    Settlement in Shares. Notwithstanding anything to the contrary in the Agreement or the Plan, the Award shall be settled only in Shares (and may not be settled in cash).

 

2.   Consent to Receive Information in English. To the extent Participant is resident in Quebec, the parties acknowledge that it is their express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be written in English.

 

2
 

 

Les parties reconnaissent avoir exigé la rédaction en anglais du présent Contrat, ainsi que de tous documents exécutés, avis donnés ou procédures judiciaires intentées, en vertu du, ou liés directement ou indirectement, au présent Contrat.

 

3.    Data Privacy. The following provision supplements Section 8 of the Agreement:

 

Participant hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of Participant’s awards under the Plan. Participant further authorizes the Company, its Subsidiaries, and the stock plan administrator to disclose and discuss Participant’s participation in the Plan with their respective advisors. Participant further authorizes the Company and its Subsidiaries to record such information and to keep such information in his or her employee file.

 

China

 

1.    Award Conditioned on Satisfaction of Regulatory Obligations. If Participant is a national of the People’s Republic of China (“PRC”), the grant of the Award is conditioned upon the Company securing all necessary approvals from the PRC State Administration of Foreign Exchange to permit the operation of the Plan and the participation of PRC nationals employed by the Employer, as determined by the Company in its sole discretion.

 

2.    Immediate Sale of Shares. If Participant is a PRC national, he/she may be required to immediately sell all Shares acquired upon vesting of the Award (in which case, this Addendum shall give the Company the authority to issue sales instructions on Participant's behalf). Participant agrees to sign any additional agreements, forms and/or consents that reasonably may be requested by the Company (or the Stock Plan Administrator) to effectuate the sale of the Shares (including, without limitation, as to the transfer of the sale proceeds and other exchange control matters noted below) and shall otherwise cooperate with the Company with respect to such matters. Participant acknowledges that neither the Company nor the Stock Plan Administrator is under any obligation to arrange for such sale of Shares at any particular price (it being understood that the sale will occur in the market) and that broker’s fees and similar expenses may be incurred in any such sale. In any event, when the Shares are sold, the sale proceeds, less any tax withholding, any broker’s fees or commissions, and any similar expenses of the sale will be remitted to Participant in accordance with applicable exchange control laws and regulations.

 

3
 

 

3.    Exchange Control Restrictions. Participant understands and agrees that, if Participant is subject to exchange control laws in China, Participant will be required to repatriate immediately to China the proceeds from the sale of any Shares acquired under the Plan. Participant further understands that such repatriation of sale proceeds must be effected through a special bank account established by the Company with a financial institution in China and Participant hereby consents and agrees that proceeds from the sale of Shares acquired under the Plan may be transferred to such account by the Company on Participant's behalf prior to being delivered to Participant and that no interest shall be paid with respect to funds held in such account. Sale proceeds may be paid to Participant in U.S. dollars or local currency at the Company’s discretion. If the sale proceeds are paid to Participant in U.S. dollars, Participant understands that Participant must establish and maintain a U.S. dollar bank account in China so that the proceeds may be deposited into such account. If the sale proceeds are paid to Participant in local currency, Participant acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the sale proceeds to local currency due to exchange control restrictions. Participant agrees to bear any currency fluctuation risk between the time the shares of Common Stock are sold and the net proceeds are converted into local currency and distributed to Participant. Participant further agrees to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

 

4.    Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses Participant may incur or suffer resulting from the enforcement of the terms of this section or otherwise from the Company’s operation and enforcement of the terms of the Plan, the Agreement and this Addendum, and the Award in accordance with Chinese law including, without limitation, any applicable rules, regulations, requirements and approvals issued by the State Administration of Foreign Exchange.

 

Czech Republic

 

No country-specific provisions.

 

Denmark

 

1.     Danish Stock Option Act. Notwithstanding anything in the Agreement or the Plan to the contrary, the treatment of the Award upon Participant’s termination of employment with the Company or any Subsidiary, as applicable, shall be governed by the Danish Stock Option Act, as in effect at the time of Participant’s termination (as determined by the Committee in its discretion in consultation with legal counsel). By accepting the Award, Participant acknowledges that he or she has received a Danish translation of an Employer Statement, which is being provided to comply with the Danish Stock Option Act.

 

Finland

 

No country-specific provisions.

 

4
 

 

France

 

1.     Award Not Tax-Qualified. The Award is not intended to qualify for special tax and social security treatment pursuant to Sections L. 225-197-1 to L. 225-197-6 of the French Commercial Code, as amended.

 

2.     Consent to Receive Information in English. By accepting the Award, Participant confirms having read and understood the Plan, the Agreement and this Addendum, including all terms and conditions included therein, which were provided in the English language. Participant accepts the terms of those documents accordingly.

 

Consentement afin de Recevoir des Informations en Anglais

 

En acceptant les Attributions, le Participant confirme avoir lu et compris le Plan, le Contrat et la présente Annexe, en ce compris tous les termes et conditions y relatifs, qui ont été fournis en langue anglaise. Le Participant accepte les dispositions de ces documents en connaissance de cause.

 

Germany

 

No country-specific provisions.

 

Hong Kong

 

1.     Restriction on Sale of Shares. Shares received pursuant to the Award is accepted as a personal investment. To facilitate compliance with securities laws in Hong Kong, Participant agrees not to sell the Shares issued in settlement of the Award within six (6) months of the Date of Grant.

 

2.     Award Is Not Wages. The Award and the Shares underlying the Award do not form part of Participant's wages for purposes of calculating any statutory or contractual payments under applicable law in Hong Kong.

 

3.    Securities Law Notice. WARNING: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Participant is advised to exercise caution in relation to the offer. If Participant is in any doubt about any of the contents of this document, Participant should obtain independent professional advice. Neither the grant of the Award nor the issuance of Shares upon vesting of the Award constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Subsidiaries. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Award (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Subsidiaries and may not be distributed to any other person.

 

4.     Nature of Plan. The Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance.

 

Hungary

 

No country-specific provisions.

 

5
 

 

India

 

1.    Repatriation Requirements. Participant expressly agrees to repatriate all amounts acquired under the Plan in accordance with local foreign exchange rules and regulations. Neither the Company nor any of its Subsidiaries shall be liable for any fines or penalties resulting from Participant’s failure to comply with applicable laws, rules and regulations.

 

Italy

 

1.    Plan Document Acknowledgement. In accepting the Award, Participant acknowledges that he or she has received a copy of the Plan and the Agreement and has reviewed the Plan and the Agreement (including this Addendum), in their entirety and fully understands and accepts all provisions of the Plan and the Agreement (including this Addendum). Participant further acknowledges that he or she has read and specifically and expressly approves the following provisions of the Agreement: Section 5: Tax Obligations; Section 7: Nature of Grant; Section 9(m): Governing Law; Section 9(q): Addendum; Section 9(r): Imposition of Other Requirements; and the Data Privacy provisions for the European Union reflected above.

 

Japan

 

No country-specific provisions.

 

Korea

 

No country-specific provisions.

 

Luxembourg

 

No country-specific provisions.

 

Netherlands

 

1.     Waiver of Termination Rights. As a condition to the grant of the Award, Participant hereby waives any and all rights to compensation or damages as a result of the termination of Participant's employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) Participant ceasing to have rights under or ceasing to be entitled to any Award under the Plan as a result of such termination.

 

Poland

 

No country-specific provisions.

 

6
 

 

Singapore

 

1.     Securities Law Notice. The grant of the Award is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”) and is not made to Participant with a view to the underlying Shares being subsequently offered for sale to any other party. The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore. Participant should note that the Award are subject to section 257 of the SFA and Participant should not make (i) any subsequent sale of the Shares in Singapore or (ii) any offer of such subsequent sale of the Shares subject to the Award in Singapore, unless such sale or offer is made after six (6) months from the Date of Grant or pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA. The Shares are currently traded on the NASDAQ Stock Market LLC, which is located outside of Singapore, under the ticker symbol “TECH” and Shares acquired under the Plan may be sold through this exchange.

 

Spain

 

1.     Nature of Award. The following provision supplements Section 7 of the Agreement:

 

In accepting the grant of the Award, Participant acknowledges that he or she consents to participation in the Plan and has received a copy of the Plan.

 

Participant understands that the Company, in its sole discretion, has unilaterally and gratuitously decided to grant Awards under the Plan to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any Award will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, Participant understands that the Award is granted on the assumption and condition that the Award and any Shares acquired upon vesting of the Award shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever.

 

Further, Participant understands and agrees that, unless otherwise expressly provided for by the Company or set forth in the Agreement, the Award will be cancelled without entitlement to any Shares if Participant terminates employment by reason of, including, but not limited to: resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without cause (i.e., subject to a “despido improcedente”), material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, or under Article 10.3 of Royal Decree 1382/1985. The Committee, in its sole discretion, shall determine the date when Participant’s employment has terminated for purposes of the Award.

 

Participant understands that the grant of this Award would not be granted but for the assumptions and conditions referred to above; thus, Participant acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of, or right to, the Award shall be null and void.

 

7
 

 

Sweden

 

1.     Tax Obligations. The following provision supplements Section 5 of the Agreement:

 

Without limiting the Company's and the Employer's authority to satisfy their withholding obligations for Tax-Related Items as set forth in Section 4 of the Agreement, in accepting the grant of the Award, Participant authorizes the Company and/or the Employer to withhold Shares or to sell Shares otherwise deliverable to Participant upon exercise to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

 

Switzerland

 

1.     Securities Law Notice. Neither the Agreement, the Addendum nor any other materials relating to the Award (i) constitutes a prospectus according to article 35 et seq. of the Swiss Federal Act on Financial Services ("FinSA"), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

 

Taiwan

 

No country-specific provisions.

 

United Kingdom

 

1.     Tax Obligations. The following provision supplements Section 5 of the Agreement:

 

Without limitation to Section 5 of the Agreement, Participant hereby agrees that Participant is liable for all Tax Related-Items and hereby covenants to pay all such Tax Related-Items, as and when requested by the Company, or if different, the Employer, or by Her Majesty’s Revenue & Customs (“HMRC”) (or any other tax authority or any other relevant authority). Participant also hereby agrees to indemnify and keep indemnified the Company and, if different, the Employer, against any Tax Related-Items that they are required to pay or withhold, or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on Participant’s behalf.

 

Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), Participant may not be able to indemnify the Company or the Employer for the amount of any income tax not collected from or paid by Participant, as it may be considered a loan. In this case, the amount of any uncollected amounts may constitute a benefit to Participant on which additional income tax and National Insurance Contributions may be payable. Participant will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying the Company or the Employer for the value of any National Insurance Contributions due on this additional benefit, which the Company or the Employer may recover by any of the means referred to in Section 5 of the Agreement.

 

2.     Exclusion of Claim. Participant acknowledges and agrees that Participant will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from Participant ceasing to have rights under or to be entitled to the Award, whether or not as a result of termination of employment (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Award. Upon the grant of the Award, Participant shall be deemed to have waived irrevocably such entitlement.

 

8

 
 EX-10.6 6 ex_248807.htm EXHIBIT 10.6 ex_248807.htm

Exhibit 10.6

 

RESTRICTED STOCK UNIT AGREEMENT
(PERFORMANCE VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a restricted stock unit award to Participant for shares of Company Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a restricted stock unit award to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.    Grant of Restricted Stock Unit Award. The Company hereby grants to Participant on the date set forth above a restricted stock unit award for [●] ([●]) restricted stock units (the “Award”) on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. Each restricted stock unit shall entitle the Participant to receive one share of Company Common Stock.

 

2.     Vesting of Restricted Stock Units; Termination of Relationship.

 

(a)     Vesting. Vesting of the Award shall occur, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the Vesting Date[s] as set forth in Section 2(b) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Award shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event all or any portion of the Award does not vest on the Vesting Date[s] pursuant to the performance objectives set forth on Exhibit A, the unvested portion of the Award shall terminate on such date and all restricted stock units subject to such portion Award shall be forfeited.

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan. Further, in the event of Participant’s Retirement a pro rata portion of this Award shall become vested on the Vesting Date immediately following the date of Participant’s Retirement, with such portion determined by multiplying the Award by a fraction, the numerator of which is the number of whole months that Participant was employed during the performance period and the denominator of which is the total number of months in the performance period.

 

For purposes of this Agreement, “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to the issuance of shares of stock for any portion of the restricted stock units subject to this Award until the Administrator determines the number of restricted stock units, if any, which have vested.

 

(b)     Termination of Relationship. Unless otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to any Vesting Date, for any reason, including the Participant’s voluntary resignation, the Participant shall forfeit all shares subject to this Award which, as of the termination date, have not yet vested.

 

3.    Issuance of Shares. As soon as practicable after each Vesting Date, Participant shall be recorded on the stock transfer books of the Company as the owner of shares representing the respective number of shares of Company Common Stock set forth in Section 2(a) of this Agreement, less any shares withheld for payment of taxes as provided in Section 5(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such shares, Participant shall not be entitled to vote the shares of Company Common Stock represented by such restricted stock units, shall not be entitled to receive dividends or distributions attributable to such shares of Company Common Stock, and shall not have any other rights as a shareholder with respect to such shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section 15 of the Plan.

 

2
 

 

4.    [TO BE USED IN AGREEMENTS WITH EXECUTIVE OFFICERS: Holding Requirement. Notwithstanding anything in the Plan or this Agreement to the contrary, Participant shall be required to hold 50% of the Net Shares received through this Award until Participant satisfies the stock ownership guidelines established by the Company. Once Participant satisfies such stock ownership guidelines, Participant shall be required to hold 50% of the Net Shares until the earlier of one year after the Vesting Date relating to such Net Shares or the Participant’s termination of service. “Net Shares” are those shares received pursuant to this Award upon a Vesting Date, net of any shares withheld for withholding taxes.

 

**OR**

 

Intentionally omitted.]

 

5.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The issuance of shares upon vesting of this Award shall be effective only at such time as counsel to the Company shall have determined that such issuance will not violate any state or federal securities or other laws. Participant may be required by the Company, as a condition of the issuance of shares, to agree in writing that such shares will be held until such time that the shares are registered or otherwise freely tradeable under applicable state and federal securities laws, for Participant’s own account without a view to any further distribution thereof, and that the certificate(s) for such shares will bear an appropriate legend to that effect and that such shares will not be transferred or disposed of except in compliance with applicable state and federal securities laws.

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

3
 

 

(d)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the issuance of any shares of Company Common Stock subject to this Award. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon vesting of this Award. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, applicable to the supplemental income attributable to this Option. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3, or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

(e)     Nontransferability. For so long as the shares of Company Common Stock underlying this Award remain unvested, such shares shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(f)      Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(g)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of the Company Common Stock underlying this Award, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering, Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of the Company Common Stock underlying this Award without the prior written consent of the underwriter(s) or its representative(s).

 

(h)     Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock issued to Participant pursuant to this Award bear an appropriate legend and stop transfer order to reflect the restrictions of Section 5(b) and Sections 5(f) through 5(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 5(b) or Sections 5(f) through 5(g).

 

(i)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

4
 

 

(j)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(k)    Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(l)      Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(m)    Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 5(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 5(m) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 5(m), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 5(m).

 

(n)     Governing Law.  The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

[Signature page follows.]

 

5
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

 

BIO-TECHNE CORPORATION
       
       
       
 

By 

    
   

Its

  

 

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 

 

[Signature Page to Restricted Stock Unit Agreement]

 

 
 EX-10.7 7 ex_248808.htm EXHIBIT 10.7 ex_248808.htm

Exhibit 10.7

 

PERFORMANCE UNIT AGREEMENT
(TIME VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a performance unit award to Participant pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a performance unit to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Performance Unit Award; Term. The Company hereby grants to Participant on the date set forth above a performance unit (the “Award”) for [●] dollars ($[●]), on the terms and conditions set forth herein.

 

2.     Vesting of Performance Unit.

 

(a)     General. The Award shall vest on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or has terminated employment by Retirement as of the applicable Vesting Date as set forth in Section 2(b) of this Agreement:

 

 

Date

  

Performance Unit Vesting

  
         
 

[●]

  

[●]

  
 

[●]

  

[●]

  
 

[●]

  

[●]

  
 

[●]

  

[●]

  

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.   

 

 
 

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to payment for any portion of the performance units subject to this Award until the Administrator determines the portion of the Award, if any, that has vested.]

 

(b)     Termination of Relationship. Except as otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to the Vesting Date, for any reason other than Retirement, this Award shall terminate and the unvested portion of this Award shall be forfeited by Participant. If the Participant’s employment with the Company or any Affiliate terminates because of Retirement, if this Award was granted at least six months prior to the date of Participant’s Retirement, then this Award shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Award was not granted at least six months prior to the date of Participant’s Retirement, then to the extent this Award was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Award shall be forfeited.

 

Solely for purposes of this Section 2(b), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Further, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

3.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship by the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the payment of the Award to the Participant by the Company.

 

- 2 -
 

 

(c)     Nontransferability. The Award shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(d)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(e)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(f)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(g)    Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(h)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

- 3 -
 

 

(i)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 3(i), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 3(i) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 3(i), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 3(i). 

 

(j)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

 

[Signature page follows.]

 

- 4 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

 

BIO-TECHNE CORPORATION
       
       
       
 

By 

    
   

Its

  

 

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 
 EX-10.8 8 ex_248809.htm EXHIBIT 10.8 ex_248809.htm

Exhibit 10.8

 

PERFORMANCE UNIT AGREEMENT

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee, officer, director of or consultant or advisor to the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a performance unit award to Participant pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a performance unit to Participant;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Performance Unit Award; Term. The Company hereby grants to Participant on the date set forth above a performance unit (the “Award”) for [●] dollars ($[●]), on the terms and conditions set forth herein.

 

2.     Vesting of Performance Unit.

 

(a)     General. Vesting of the Award shall occur, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the Vesting Date[s] as set forth in Section 2(b) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Award shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event all or any portion of the Award does not vest on the Vesting Date[s] pursuant to the performance objectives set forth on Exhibit A, the unvested portion of the Award shall terminate and be forfeited on such date.

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Award may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

 
 

 

Further, in the event of Participant’s Retirement prior to the Vesting Date, if this Award was granted at least six months prior to the date of Participant’s Retirement, then a pro rata portion of the Award shall become vested on the Vesting Date immediately following the date of Participant’s Retirement, with such portion determined by multiplying the Award by a fraction, the numerator of which is the number of whole months that Participant was employed during the performance period and the denominator of which is the total number of months in the performance period. For purposes of this Agreement, “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. For purposes of this Agreement, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, (i) a material breach or Participant's willful and substantial non-performance of Participant's assigned duties and responsibilities (other than as a result of incapacity due to physical or mental illness), (ii) a conviction of or no contest plea with respect to bribery, extortion, embezzlement, fraud, grand larceny, or any felony or similar conviction under local law involving abuse or misuse of Participant's position to seek or obtain an illegal or personal gain at the expense of the Company, the Employer or any Subsidiary, or similar crimes, or conspiracy to commit any such crimes or attempt to commit any such crimes, or (iii) Participant's violation of any policy of the Company, the Employer or any Subsidiary to which Participant may be subject or Participant's willful engagement in any misconduct in the performance of Participant's duties that materially injures the Company, the Employer or any Subsidiary.

 

Subject to such other terms and conditions set forth in this Agreement, the Participant shall not be entitled to payment for any portion of the performance units subject to this Award until the Administrator determines the portion of the Award, if any, that has vested.]

 

(b)     Termination of Relationship. Unless otherwise provided in this Agreement or agreed to in writing by Participant and Company, if Participant ceases to be an employee of the Company or any Subsidiary at any time prior to the Vesting Date, for any reason other than Retirement, this Award shall terminate and the unvested portion of this Award shall be forfeited by Participant.

 

3.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to continuance of employment or any other relationship by the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Award are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the payment of the Award to the Participant by the Company.

 

- 2 -
 

 

(c)     Nontransferability. The Award shall not be transferred, assigned or pledged in any manner by the Participant, in whole or in part.

 

(d)     Second Amended and Restated 2010 Equity Incentive Plan. The Award evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. The Plan governs this Agreement and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(e)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or successors of Participant permitted by this Agreement. This Award is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(f)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(g)     Delay in Payment for Specified Employee. In the event this Award is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(h)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

- 3 -
 

 

(i)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 3(i), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 3(i) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 3(i), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 3(i). 

 

(j)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

 

[Signature page follows.]

 

- 4 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written. 

 

 

BIO-TECHNE CORPORATION
     
     
     
 

 By

  
   

Its

  

 

 

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 
 EX-10.9 9 ex_248810.htm EXHIBIT 10.9 ex_248810.htm

Exhibit 10.9

 

INCENTIVE STOCK OPTION AGREEMENT
(TIME VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant an incentive stock option to Participant to purchase shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of an incentive stock option to Participant and has determined that, as of the effective date of this Agreement, the fair market value of the Company's Common Stock is $[●] per share;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Option. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”), the right and option (the “Option”) to purchase all or portions of an aggregate of [●] ([●]) shares of Common Stock at a per share price of $[●] on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. This Option is intended to be an incentive stock option within the meaning of Section 422, or any successor provision, of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder, to the extent permitted under Code Section 422(d). If the number of shares vesting for Participant in any single year exceeds the limit established by Section 422 of the Internal Revenue Code for incentive stock option treatment, the Option shall be deemed an incentive stock option to the extent of the number of shares within the limit and a nonqualified stock option the extent of the number of shares that exceed the limit.

 

2.     Duration and Exercisability.

 

(a)     General. The term during which this Option may be exercised shall terminate on [●], except as otherwise provided in Sections 2(b) through 2(e) below. This Option shall become exercisable on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company on the applicable Vesting Date as set forth in Sections 2(b) through 2(e) of this Agreement:

 

Date 

Shares Vesting 

  
     

[●]

[●]

  

[●]

[●]

  

[●]

[●]

  

[●]

[●]

  

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Option may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

Once the Option becomes exercisable with respect to any of the shares specified in Section 1, Participant may continue to exercise this Option with respect to such vested shares under the terms and conditions of this Agreement until the termination of the Option as provided herein. If Participant does not purchase upon an exercise of this Option the full number of shares which Participant is then entitled to purchase, Participant may purchase upon any subsequent exercise prior to this Option's termination such previously unpurchased shares in addition to those Participant is otherwise entitled to purchase.

 

(b)     Termination of Employment (other than Disability, Death, or Retirement). Unless otherwise agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary during the term of this Option for any reason other than disability, death, or Retirement (as defined in Section 2(e) of this Agreement) this Option shall completely terminate on the earlier of: (i) the close of business on the three-month anniversary date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(b), all rights of Participant under this Option shall be forfeited.

 

(c)     Disability. If Participant's employment terminates because of disability (as defined in Code Section 22(e), or any successor provision), this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(c), all rights of Participant under this Option shall be forfeited.

 

- 2 -
 

 

(d)     Death. In the event of Participant's death, this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of Participant's death; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following Participant's death, this Option may be exercised by the person or persons to whom Participant's rights under this Option shall have passed by Participant's will or by the laws of descent and distribution only to the extent the Option was exercisable on the Vesting Date immediately preceding the date of Participant's death, but had not previously been exercised. To the extent this Option was not exercisable on the date of Participant’s death, all rights of Participant under this Option shall be forfeited. If such person or persons fail to exercise this Option within the time specified in this Section 2(d), all rights under this Option shall be forfeited.

 

(e)     Retirement. If Participant’s employment with the Company or any Affiliate terminates because of Retirement, this Option shall terminate on the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment because of Retirement, if this Option was granted at least six months prior to the date of Participant’s Retirement and is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Option shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Option was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then to the extent this Option was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(e), all rights of Participant under this Option shall be forfeited.

 

Solely for purposes of this Section 2(e), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Notwithstanding anything in this Option Agreement to the contrary, if, pursuant to this Section 2(e), this Option is exercised after the expiration of the exercise periods that apply for purposes of Code Section 422, or any successor provision, this Option shall be thereafter treated as a nonqualified stock option. For purposes of this Option, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

3.     Manner of Exercise.

 

(a)     General. The Option may be exercised only by Participant (or other proper party in the event of death or incapacity), subject to the conditions of the Plan and subject to such other administrative rules as the Administrator may deem advisable, by delivering within the option period written notice of exercise to the Company at its principal office. The notice shall state the number of shares as to which the Option is being exercised and shall be accompanied by payment in full of the option price for all shares designated in the notice. The exercise of the Option shall be deemed effective upon receipt of such notice by the Company and upon payment that complies with the terms of the Plan and this Agreement. The Option may be exercised with respect to any number or all of the shares as to which it can then be exercised and, if partially exercised, may be so exercised as to the unexercised shares any number of times during the option period as provided herein.

 

- 3 -
 

 

(b)     Form of Payment. Subject to approval by the Administrator, payment of the option price by Participant may be (i) in cash, or with a personal check or certified check, (ii) by the transfer from Participant to the Company of previously acquired shares of Common Stock, (iii) through the withholding of shares of Stock from the number of shares otherwise issuable upon the exercise of the Option (e.g., a net share settlement), (iv) through broker-assisted cashless exercise if such exercise complies with applicable securities laws and any insider trading policy of the Company, (v) such other form of payment as may be authorized by the Administrator, or (vi) by a combination thereof. In the event Participant elects to pay the exercise price in whole or in part with previously acquired shares of Common Stock or through a net share settlement, the Fair Market Value of the shares of Stock delivered or withheld shall equal the total exercise price for the shares being purchased in such manner. For purposes of this Agreement, “previously acquired shares of Common Stock” shall include shares of Common Stock that are already owned by Participant at the time of exercise.

 

(c)     Issuance of Shares. As soon as practicable after the effective exercise of all or any part of the Option, Participant shall be recorded on the stock transfer books of the Company as the owner of the shares purchased, less any shares withheld for payment of taxes as provided in Section 4(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such shares, Participant shall not be entitled to vote the shares of Company Common Stock represented by the Option, shall not be entitled to receive dividends or distributions attributable to such shares of Company Common Stock, and shall not have any other rights as a shareholder with respect to such shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section 15 of the Plan.

 

4.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The exercise of all or any parts of this Option shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Common Stock pursuant to such exercise will not violate any state or federal securities or other laws. Participant may be required by the Company, as a condition of the effectiveness of any exercise of this Option, to agree in writing that all Common Stock to be acquired pursuant to such exercise will be held until such time that the shares are registered or otherwise freely tradeable under applicable state and federal securities laws, for Participant’s own account without a view to any further distribution thereof, and that the certificate(s) for such shares will bear an appropriate legend to that effect and that such shares will not be transferred or disposed of except in compliance with applicable state and federal securities laws.

 

- 4 -
 

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Option are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the date the Company’s withholding obligation arises. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon exercise of the Option. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, applicable to the supplemental income attributable to this Option. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3 or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

(e)     Nontransferability. During the lifetime of Participant, the accrued Option shall be exercisable only by Participant or by the Participant's guardian or other legal representative. The Option shall not be assignable or transferable by Participant, in whole or in part, other than by will or by the laws of descent and distribution.

 

(f)     Second Amended and Restated 2010 Equity Incentive Plan. The Option evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Option and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

- 5 -
 

 

(g)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Option or the Company Common Stock underlying this Option, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Option or any of the underlying shares of Company Common Stock without the prior written consent of the underwriter(s) or its representative(s).

 

(h)    Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock purchased by Participant (or, in the case of death, Participant's successors) bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(b) and Sections 4(f) through 4(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(b) or Sections 4(f) through 4(g).

 

(i)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor(s) of Participant permitted by Section 2 or Section 4(e) above. This Option is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(j)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

(k)     Delay in Payment for Specified Employee. In the event this Option is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

- 6 -
 

 

(l)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(m)   Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(m) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(m), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(m).

 

(n)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

[Signature page follows.]

 

- 7 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

BIO-TECHNE CORPORATION
     
     
     
 

 By

  
   

Its

  

 

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 

 

 

[Signature Page to Incentive Stock Option Agreement]

 

 
 EX-10.10 10 ex_248811.htm EXHIBIT 10.10 ex_248811.htm

Exhibit 10.10

 

INCENTIVE STOCK OPTION AGREEMENT
(PERFORMANCE VESTING)

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S S E T H:

 

WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant an incentive stock option to Participant to purchase shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of an incentive stock option to Participant and has determined that, as of the effective date of this Agreement, the fair market value of the Company's Common Stock is $[●] per share;

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows:

 

1.     Grant of Option. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”), the right and option (the “Option”) to purchase all or portions of an aggregate of [●] ([●]) shares of Common Stock at a per share price of $[●] on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. This Option is intended to be an incentive stock option within the meaning of Section 422, or any successor provision, of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder, to the extent permitted under Code Section 422(d). If the number of shares vesting for Participant in any single year exceeds the limit established by Section 422 of the Internal Revenue Code for incentive stock option treatment, the Option shall be deemed an incentive stock option to the extent of the number of shares within the limit and a nonqualified stock option the extent of the number of shares that exceed the limit.

 

2.     Duration and Exercisability.

 

(a)     General. The term during which this Option may be exercised shall terminate on [●], except as otherwise provided in Sections 2(b) through 2(e) below. This Option shall vest and become exercisable, if at all, on the Vesting Date[s] (as hereinafter defined), subject to the Company’s achievement of the performance objectives during the performance period[s], as both are set forth in Exhibit A to this Agreement, provided that Participant remains employed by the Company on the applicable Vesting Date as set forth in Sections 2(b) through 2(e) of this Agreement. Performance for the period[s] shall be evaluated and determined by and in the sole discretion of the Administrator, and performance between the threshold and maximum levels specified on Exhibit A shall result in vesting in accordance with the scale determined by the Administrator and set forth on Exhibit A. The “Vesting Date[s]” for the Option shall be the later of [●] or the date on which the Administrator evaluates and certifies achievement of the performance criteria for the performance period[s], as set forth on Exhibit A. In the event that any portion of this Option does not vest and become exercisable, Participant’s right and option to purchase the number of shares relating to such unvested portion shall immediately terminate and be forfeited.

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by the Participant and the Company or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Option may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

Once the Option becomes exercisable with respect to any of the shares specified in Section 1, Participant may continue to exercise this Option with respect to such vested shares under the terms and conditions of this Agreement until the termination of the Option as provided herein. If Participant does not purchase upon an exercise of this Option the full number of shares which Participant is then entitled to purchase, Participant may purchase upon any subsequent exercise prior to this Option's termination such previously unpurchased shares in addition to those Participant is otherwise entitled to purchase.]

 

(b)     Termination of Employment (other than Disability, Death or Retirement). Unless otherwise agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary during the term of this Option for any reason other than disability, death or Retirement (as defined in Section 2(e) of this Agreement), this Option shall completely terminate on the earlier of: (i) the close of business on the three-month anniversary date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(b), all rights of Participant under this Option shall be forfeited.

 

(c)     Disability. If Participant's employment terminates because of disability (as defined in Code Section 22(e), or any successor provision), this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of such termination of employment; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(c), all rights of Participant under this Option shall be forfeited.

 

- 2 -
 

 

(d)     Death. In the event of Participant's death, this Option shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of Participant's death; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following Participant's death, this Option may be exercised by the person or persons to whom Participant's rights under this Option shall have passed by Participant's will or by the laws of descent and distribution only to the extent the Option was exercisable on the Vesting Date immediately preceding the date of Participant's death, but had not previously been exercised. To the extent this Option was not exercisable on the date of Participant’s death, all rights of Participant under this Option shall be forfeited. If such person or persons fail to exercise this Option within the time specified in this Section 2(d), all rights under this Option shall be forfeited.

 

(e)     Retirement. If Participant’s employment with the Company or any Affiliate terminates because of Retirement, this Option shall terminate on the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment because of Retirement, if this Option was granted at least six months prior to the date of Participant’s Retirement and is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Option shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company. If, however, this Option was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then to the extent this Option was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(e), all rights of Participant under this Option shall be forfeited.

 

Solely for purposes of this Section 2(e), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Affiliate; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. Notwithstanding anything in this Option Agreement to the contrary, if, pursuant to this Section 2(e), this Option is exercised after the expiration of the exercise periods that apply for purposes of Code Section 422, or any successor provision, this Option shall be thereafter treated as a nonqualified stock option. For purposes of this Option, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

- 3 -
 

 

3.     Manner of Exercise.

 

(a)     General. The Option may be exercised only by Participant (or other proper party in the event of death or incapacity), subject to the conditions of the Plan and subject to such other administrative rules as the Administrator may deem advisable, by delivering within the option period written notice of exercise to the Company at its principal office. The notice shall state the number of shares as to which the Option is being exercised and shall be accompanied by payment in full of the option price for all shares designated in the notice. The exercise of the Option shall be deemed effective upon receipt of such notice by the Company and upon payment that complies with the terms of the Plan and this Agreement. The Option may be exercised with respect to any number or all of the shares as to which it can then be exercised and, if partially exercised, may be so exercised as to the unexercised shares any number of times during the option period as provided herein.

 

(b)     Form of Payment. Subject to approval by the Administrator, payment of the option price by Participant may be (i) in cash, or with a personal check or certified check, (ii) by the transfer from Participant to the Company of previously acquired shares of Common Stock, (iii) through the withholding of shares of Stock from the number of shares otherwise issuable upon the exercise of the Option (e.g., a net share settlement), (iv) through broker-assisted cashless exercise if such exercise complies with applicable securities laws and any insider trading policy of the Company, (v) such other form of payment as may be authorized by the Administrator, or (vi) by a combination thereof. In the event Participant elects to pay the exercise price in whole or in part with previously acquired shares of Common Stock or through a net share settlement, the Fair Market Value of the shares of Stock delivered or withheld shall equal the total exercise price for the shares being purchased in such manner. For purposes of this Agreement, “previously acquired shares of Common Stock” shall include shares of Common Stock that are already owned by Participant at the time of exercise.

 

(c)     Issuance of Shares. As soon as practicable after the effective exercise of all or any part of the Option, Participant shall be recorded on the stock transfer books of the Company as the owner of the shares purchased, less any shares withheld for payment of taxes as provided in Section 4(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such shares, Participant shall not be entitled to vote the shares of Company Common Stock represented by the Option, shall not be entitled to receive dividends or distributions attributable to such shares of Company Common Stock, and shall not have any other rights as a shareholder with respect to such shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such shares are issued, except as provided in Section 15 of the Plan.

 

4.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant and the Company or any Subsidiary.

 

- 4 -
 

 

(b)     Securities Law Compliance. The exercise of all or any parts of this Option shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Common Stock pursuant to such exercise will not violate any state or federal securities or other laws. Participant may be required by the Company, as a condition of the effectiveness of any exercise of this Option, to agree in writing that all Common Stock to be acquired pursuant to such exercise will be held until such time that the shares are registered or otherwise freely tradeable under applicable state and federal securities laws, for Participant’s own account without a view to any further distribution thereof, and that the certificate(s) for such shares will bear an appropriate legend to that effect and that such shares will not be transferred or disposed of except in compliance with applicable state and federal securities laws.

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Withholding Taxes. In order to permit the Company to comply with all applicable federal and state income tax laws or regulations, the Company may take such action as it deems appropriate to ensure that, if necessary, all withholding and employment-related taxes attributable to this Option are withheld from any amounts payable by the Company to the Participant. If the Company is unable to withhold such federal and state taxes, for whatever reason, the Participant hereby agrees to pay to the Company an amount equal to such withholding and employment-related taxes prior to the date the Company’s withholding obligation arises. Subject to such rules as the Administrator may adopt, the Administrator may, in its sole discretion, permit Participant to satisfy such withholding tax obligations, in whole or in part, (i) by delivering shares of Company Common Stock, or (ii) by electing to have the Company withhold shares of Company Common Stock otherwise issuable to Participant upon exercise of the Option. In either case, such shares shall have a Fair Market Value, as of the date the amount of tax to be withheld is determined under applicable tax law, equal to such tax withholding, including payroll taxes, applicable to the supplemental income attributable to this Option. The Participant’s election to deliver shares or to have shares withheld for this purpose shall be made on or before the date that the amount of such tax withholding is determined under applicable tax law. Such election shall be approved by the Administrator and otherwise comply with such rules as the Administrator may adopt to assure compliance with Rule 16b-3 or any successor provision, as then in effect, of the General Rules and Regulations under the Securities Exchange Act of 1934, if applicable.

 

(e)     Nontransferability. During the lifetime of Participant, the accrued Option shall be exercisable only by Participant or by the Participant's guardian or other legal representative. The Option shall not be assignable or transferable by Participant, in whole or in part, other than by will or by the laws of descent and distribution.

 

(f)     Second Amended and Restated 2010 Equity Incentive Plan. The Option evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Option and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

- 5 -
 

 

(g)     Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Common Stock in compliance with the Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Option or the Company Common Stock underlying this Option, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Option or any of the underlying shares of Company Common Stock without the prior written consent of the underwriter(s) or its representative(s).

 

(h)    Stock Legend. The Administrator may require that the certificates or book entries for any shares of Company Common Stock purchased by Participant (or, in the case of death, Participant's successors) bear an appropriate legend and stop transfer order to reflect the restrictions of Section 4(b) and Sections 4(f) through 4(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 4(b) or Sections 4(f) through 4(g).

 

(i)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor(s) of Participant permitted by Section 2 or Section 4(e) above. This Option is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

(j)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota.

 

- 6 -
 

 

(k)     Delay in Payment for Specified Employee. In the event this Option is subject to Code Section 409A and the Administrator determines that the Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to the Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(l)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(m)   Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 4(m), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless the Participant and the Company otherwise agree in writing, any determination required under this Section 4(m) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon the Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 4(m), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  The Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 4(m).

 

(n)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota.

 

[Signature page follows.]

 

- 7 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

 

BIO-TECHNE CORPORATION
     
     
     
 

 By

  
   

Its

  

 

 

 

PARTICIPANT

 

 

 

 
     

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 

 

 

[Signature Page to Incentive Stock Option Agreement]

 

 
 EX-10.11 11 ex_248812.htm EXHIBIT 10.11 ex_248812.htm

Exhibit 10.11

 

GLOBAL EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT

 

BIO-TECHNE CORPORATION

SECOND AMENDED AND RESTATED

2010 EQUITY INCENTIVE PLAN

 

THIS AGREEMENT is made effective as of [●], by and between Bio-Techne Corporation, a Minnesota corporation (the “Company”), and [●] (“Participant”).

 

W I T N E S E T H:

 

WHEREAS, Participant on the date hereof is a key employee or officer of the Company or one of its Subsidiaries; and

 

WHEREAS, the Company wishes to grant a nonqualified stock option to Participant to purchase shares of the Company's Common Stock pursuant to the Bio-Techne Corporation Second Amended and Restated 2010 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, the Administrator of the Plan has authorized the grant of a nonqualified stock option to Participant and has determined that, as of the effective date of this Agreement, the fair market value of the Company's Common Stock is $[●] per share.

 

NOW, THEREFORE, in consideration of the premises and of the mutual covenants herein contained, the parties hereto agree as follows;

 

1.     Grant of Option. The Company hereby grants to Participant on the date set forth above (the “Date of Grant”), the right and option (the “Option”) to purchase all or portions of an aggregate of [●] ([●]) shares of Common Stock (the “Shares”) at a per Share price of $[●] on the terms and conditions set forth herein and subject to adjustment pursuant to Section 15 of the Plan. This Option is a nonqualified stock option and will not be treated as an incentive stock option, as defined under Section 422, or any successor provision, of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations thereunder. For purposes of this Agreement, to the extent Participant is not employed by the Company, the “Employer” means the Subsidiary that employs Participant.

 

2.     Duration and Exercisability.

 

(a)     General. The term during which this Option may be exercised shall terminate on [●], except as otherwise provided in Sections 2(b) through 2(e) below. This Option shall become exercisable on the following dates (the “Vesting Dates”), provided that Participant remains employed by the Company or a Subsidiary on the applicable Vesting Date as set forth in Sections 2(b) through 2(e) of this Agreement:

 

Date 

Shares Vesting

  
     

[●]

[●]

  

[●]

[●]

  

[●]

[●]

  

[●]

[●]

  

 

 
 

 

If and to the extent provided in an employment, change of control, severance or similar agreement executed by Participant and the Company or the Employer, or by a determination by the Administrator, in each case pursuant and subject to Section 15 of the Plan, this Option may become fully-vested and exercisable in connection with a Change of Control as defined in Section 1(f) of the Plan.

 

Once the Option becomes vested and exercisable with respect to any of the Shares specified in Section 1, Participant may continue to exercise the vested portion of this Option under the terms and conditions of this Agreement until the termination of the Option as provided herein. If Participant does not purchase upon an exercise of this Option the full number of Shares which Participant is then entitled to purchase, Participant may purchase upon any subsequent exercise prior to this Option's termination such previously unpurchased Shares in addition to those Participant is otherwise entitled to purchase.

 

(b)     Termination of Employment (other than Disability, Death, or Retirement). Unless otherwise agreed to in writing by Participant and the Company, if Participant ceases to be an employee of the Company or any Subsidiary during the term of this Option for any reason other than disability, death, or Retirement (as defined in Section 2(e) of this Agreement), this Option, whether vested or unvested, shall completely terminate on the earlier of: (i) the close of business on the three-month anniversary date of the Termination Date; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the Termination Date, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such Termination Date, but had not previously been exercised. To the extent this Option was not exercisable upon such Termination Date, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(b), all rights of Participant under this Option shall be forfeited.

 

(c)     Disability. If Participant's employment terminates due to disability (as defined in Code Section 22(e), or any successor provision, if Participant is employed in the United States), this Option, whether vested or unvested, shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of such termination of employment due to disability; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment due to disability, this Option shall be exercisable only to the extent the Option was exercisable on the Vesting Date immediately preceding such termination of employment due to disability, but had not previously been exercised. To the extent this Option was not exercisable upon such termination of employment due to disability, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(c), all rights of Participant under this Option shall be forfeited. For purposes of this Agreement, if Participant is employed outside of the United States, “disability” shall have the same meaning as defined under any long term disability plan maintained by the Employer or, in the absence of such arrangement, as determined by the Committee in its sole discretion.

 

- 2 -
 

 

(d)     Death. In the event of Participant's death, this Option, whether vested or unvested, shall terminate on the earlier of: (i) the close of business on the one year anniversary of the date of Participant's death; and (ii) the expiration date of this Option stated in Section 2(a) above. In such period following Participant's death, this Option may be exercised by the person or persons to whom Participant's rights under this Option shall have passed by Participant's will or by the laws of descent and distribution only to the extent the Option was exercisable on the Vesting Date immediately preceding the date of Participant's death, but had not previously been exercised. To the extent this Option was not exercisable on the date of Participant’s death, all rights of Participant under this Option shall be forfeited. If such person or persons fail to exercise this Option within the time specified in this Section 2(d), all rights under this Option shall be forfeited.

 

(e)     Retirement. If Participant’s employment with the Company or any Subsidiary terminates because of Retirement, this Option, whether vested or unvested, shall terminate on the expiration date of this Option stated in Section 2(a) above. In such period following the termination of Participant's employment because of Retirement, if this Option was granted at least six months prior to the date of Participant’s Retirement and is scheduled to vest pro rata during a period of at least three years and six months following the Date of Grant, then this Option shall continue to vest pursuant to Section 2(a) as if Participant continued to be employed by the Company or a Subsidiary. If, however, this Option was not granted at least six months prior to the date of Participant’s Retirement or is scheduled to vest in less than three years and six months following the Date of Grant, then to the extent this Option was not exercisable on the date of Participant’s Retirement, all rights of Participant under this Option shall be forfeited. If Participant does not exercise the Option within the time specified in this Section 2(e), all rights of Participant under this Option shall be forfeited. Solely for purposes of this Section 2(e), “Retirement” means termination of employment for any reason other than cause on or after attaining age 55 and completing at least five (5) years of continuous service with the Company or any Subsidiary; provided, however, that Participant shall be credited with continuous service only for periods during which Participant is regularly scheduled to work 20 or more hours per week. For purposes of this Option, “cause” shall have the same meaning as reflected in any written employment agreement addressing Participant's employment or, in the absence of any written employment agreement, the following: (i) habitual neglect of, or the willful or material failure to perform the duties of employment hereunder, as determined in good faith by the Company; (ii) embezzlement or any act of fraud; (iii) commission of acts that can be charged as a felony during employment; (iv) dishonesty in dealing between Participant and Company or between Participant and other employees of the Company; (v) use or misuse of any controlled substance, illegal or narcotic drug without a prescription; or use of alcohol in a manner, regardless of time or place, which either adversely affects Participant’s job performance or otherwise could reflect negatively on the public image of the Company; (vi) habitual absenteeism; or (vii) willfully acting in a manner materially adverse to the best interests of the Company.

 

(f)     EU Age Discrimination Rules. If Participant is a local national of and employed in a country that is a member of the European Union, the grant of this Option and the terms and conditions governing this Option are intended to comply with the age discrimination provisions of the EU Equal Treatment Framework Directive, as implemented into local law (the “Age Discrimination Rules”). To the extent that a court or tribunal of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, in whole or in part, under the Age Discrimination Rules, the Company, in its sole discretion, shall have the power and authority to revise or strike such provision to the minimum extent necessary to make it valid and enforceable to the full extent permitted under local law.

 

- 3 -
 

 

(g)     Termination Date. For purposes of this Agreement, if Participant is employed in, the United States, "Termination Date" means the effective date of termination of Participant's employment. If Participant is employed outside of the United States, "Termination Date" means the earliest of (i) the date on which notice of termination is provided to Participant, (ii) the last day of Participant's active service with the Employer or (iii) the last day on which Participant is an employee of the Employer, as determined in each case without including any required advanced notice period and irrespective of the status of the termination under local labor or employment laws.

 

3.     Manner of Exercise.

 

(a)     General. The Option may be exercised only by Participant (or other proper party in the event of death or incapacity), subject to the conditions of the Plan and subject to such other administrative rules as the Administrator may deem advisable, by delivering within the option period written notice of exercise to the Company at its principal office. The notice shall state the number of Shares as to which this Option is being exercised and shall be accompanied by payment in full of the option price for all Shares designated in the notice. The exercise of the Option shall be deemed effective upon receipt of such notice by the Company and upon payment that complies with the terms of the Plan and this Agreement. The Option may be exercised with respect to any number or all of the Shares as to which it can then be exercised and, if partially exercised, may be so exercised as to the unexercised shares any number of times during the option period as provided herein.

 

(b)     Form of Payment. Subject to approval by the Administrator, payment of this Option price by Participant may be (i) in cash, or with a personal check or certified check, (ii) by the transfer from Participant to the Company of previously acquired Shares, (iii) through the withholding of Shares from the number of Shares otherwise issuable upon the exercise of this Option (e.g., a net share settlement), (iv) through broker-assisted cashless exercise if such exercise complies with applicable securities laws and any insider trading policy of the Company, (v) such other form of payment as may be authorized by the Administrator, or (vi) by a combination thereof. In the event Participant elects to pay the exercise price in whole or in part with previously acquired Shares or through a net share settlement, the Fair Market Value of the Shares delivered or withheld shall equal the total exercise price for the Shares being purchased in such manner. For purposes of this Agreement, "previously acquired Shares" shall include Shares that are already owned by Participant at the time of exercise.

 

(c)     Issuance of Shares. As soon as practicable after the effective exercise of all or any part of the Option, Participant shall be recorded on the stock transfer books of the Company as the owner of the Shares purchased, less any Shares withheld for payment of taxes as provided in Section 4(d) below, and the Company shall deliver to Participant one or more duly issued stock certificates or cause book entries to be made evidencing such ownership. All requisite original issue or transfer documentary stamp taxes shall be paid by the Company. Until the issuance of such Shares, Participant shall not be entitled to vote the Shares represented by the Option, shall not be entitled to receive dividends or distributions attributable to such Shares, and shall not have any other rights as a shareholder with respect to such Shares. No adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property), distributions or other rights for which the record date is prior to the date such Shares are issued, except as provided in Section 15 of the Plan.

 

- 4 -
 

 

(d)     Repatriation and Compliance Obligations. As a condition of the grant of this Option, Participant agrees to repatriate all payments attributable to this Option in accordance with local foreign exchange rules and regulations in Participant's country of residence (and country of employment, if different). In addition, Participant agrees to take any and all actions, and consents to any and all actions taken by the Employer, the Company and its Subsidiaries as may be required to allow the Employer, the Company and its Subsidiaries to comply with local laws, rules and regulations in Participant's country of residence (and country of employment, if different). Finally, Participant agrees to take any and all actions that may be required to comply with Participant's personal legal and tax obligations under local laws, rules and regulations in Participant's country of residence (and country of employment, if different).

 

4.     Tax Obligations. Regardless of any action the Company or the Employer takes with respect to any or all federal, state, local or foreign income tax, social insurance, payroll tax, payment on account or other tax related-items (“Tax Related-Items”), Participant acknowledges that the ultimate liability for all Tax Related-Items associated with this Option is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company, and the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Tax Related-Items in connection with any aspect of this Option, including, but not limited to, the grant, vesting or exercise of this Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends; and (ii) do not commit to structure the terms of the grant or any aspect of this Option to reduce or eliminate Participant’s liability for Tax Related-Items. Further, if Participant is subject to tax in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Related-Items in more than one jurisdiction.

 

Prior to the delivery of Shares upon the exercise of this Option, if Participant's country of residence (and/or the country of employment, if different) requires withholding of Tax-Related Items, the Company or the Employer: (i) shall withhold a sufficient number of whole Shares otherwise issuable upon the exercise of this Option that have an aggregate Fair Market Value sufficient to pay the Tax-Related Items required to be withheld (in which case, the cash equivalent of such withheld Shares shall be used to settle the withholding obligation); (ii) shall withhold an amount from Participant's regular salary and/or wages, or from any other amounts payable to Participant; or (iii) require Participant to make a payment to the Company or the Employer equal to the amount of Tax-Related Items required to be withheld. Depending on the applicable method, the Company or the Employer, as applicable, may withhold or account for Tax-Related Items by considering applicable statutory withholding rates, but such withholding shall not exceed an amount of withholding based on the maximum statutory rates in Participant's applicable tax jurisdictions.

 

In the event the withholding requirements are not satisfied through the withholding of Shares or through Participant's regular salary and/or wages or other amounts payable to Participant, no Shares will be issued to Participant unless and until satisfactory arrangements (as determined by the Committee) have been made by Participant with respect to the payment of any Tax-Related Items which the Company determines, in its sole discretion, must be withheld or collected with respect to this Option. If Participant is subject to taxation in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer may be required to withhold or account for Tax-Related Items in more than one jurisdiction. By accepting the grant of this Option, Participant expressly consents to the withholding of Shares and/or the withholding of amounts from Participant's regular salary and/or wages, or other amounts payable to Participant, as provided for hereunder. All other Tax-Related Items related to this Option and any Shares acquired pursuant to the exercise of this Option are Participant's sole responsibility.

 

- 5 -
 

 

5.     Nature of Grant. In accepting the grant of this Option, Participant acknowledges, understands and agrees that:

 

(a)     the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

 

(b)     the grant of this Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past;

 

(c)     all decisions with respect to future options or other grants, if any, will be at the sole discretion of the Company;

 

(d)     Participant is voluntarily participating in the Plan;

 

(e)     this Option and the Shares subject to this Option, and the income from and value of same, are not intended to replace any pension rights or compensation;

 

(f)     this Option and the Shares subject to this Option, and the income from and value of same, are not part of normal or expected compensation for purposes of, including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;

 

(g)     unless otherwise agreed with the Company in writing, this Option and the Shares subject to this Option, and the income from and value of same, are not granted as consideration for, or in connection with, the service Participant may provide as a director of a Subsidiary;

 

(h)     the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;

 

(i)     if the underlying Shares do not increase in value, this Option will have no value;

 

(j)     if Participant exercises this Option and acquires Shares, the value of such Shares may increase or decrease in value, even below the exercise price;

 

- 6 -
 

 

(k)     no claim or entitlement to compensation or damages shall arise from forfeiture of this Option resulting from the termination of Participant's employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant's employment agreement, if any); and

 

(l)      neither the Company nor the Employer shall be liable for any foreign exchange rate fluctuation between Participant's local currency and the United States Dollar that may affect the value of this Option or of any amounts due to Participant pursuant to the exercise of this Option or the subsequent sale of any Shares acquired upon exercise.

 

6.     Data Privacy. The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Options to acquire Shares under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of the Option under the Plan and its ongoing administration of such awards, the Company is providing the following information about its data collection, processing and transfer practices. In accepting the grant of the Option, Participant expressly and explicitly consents to the personal data activities as described herein.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for the collection, processing and use of Participant's Personal Data is Participant's consent.

 

(b)     Stock Plan Administration Service Providers. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. You should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is Participant's consent.

 

- 7 -
 

 

(d)     Voluntariness and Consequences of Consent, Denial or Withdrawal. Participant's participation in the Plan and Participant's grant of consent hereunder is purely voluntary. Participant may deny or withdraw his or her consent at any time. If Participant does not consent, or if Participant later withdraws his or her consent, Participant may be unable to participate in the Plan. This would not affect Participant's existing employment or salary; instead, Participant merely may forfeit the opportunities associated with participation in the Plan.

 

(e)     Personal Data Retention. Participant understands that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage the Option and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(f)     Personal Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (vi) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understands that Participant can contact his or her Employer's human resources representative.

 

7.     General Provisions.

 

(a)     Employment or Other Relationship. This Agreement shall not confer on Participant any right with respect to the continuance of employment or any other relationship with the Employer, the Company or any of its Subsidiaries, nor will it interfere in any way with the right of the Company to terminate such employment or relationship. Nothing in this Agreement shall be construed as creating an employment contract for any specified term between Participant, the Employer and the Company or any Subsidiary.

 

(b)     Securities Law Compliance. The exercise of all or any parts of this Option shall be effective only at such time as counsel to the Company shall have determined that the issuance and delivery of Shares pursuant to such exercise will not violate any state or federal securities or other laws. Notwithstanding any other provision of the Plan or this Agreement, unless there is an exemption from any registration, qualification or other legal requirement applicable to the Shares the Company shall not be required to deliver any Shares issuable upon exercise of this Option prior to the completion of any registration or qualification of the Shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. Participant understands that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares. Further, Participant agrees that the Company shall have unilateral authority to amend the Agreement without his or her consent to the extent necessary to comply with securities or other laws applicable to issuance of Shares.

 

- 8 -
 

 

(c)     Shares Reserved. The Company shall at all times during the term of this Agreement reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of this Agreement.

 

(d)     Transferability. Participant may transfer any or all of this Option to any member of Participant's "immediate family" as such term is defined in Rule 16a-1(e) promulgated under the U.S. Securities Exchange Act of 1934, or any successor provision, or to one or more trusts whose beneficiaries are members of such Participant's "immediate family" or partnerships in which such family members are the only partners; provided, however, that Participant cannot receive any consideration for the transfer and such transferred Option shall continue to be subject to the same terms and conditions as were applicable to such Option immediately prior to its transfer. Further, the transferee shall be subject to all restrictions that generally apply to shareholders of the Company, including but not limited to restrictions on the pledge, encumbrance, sale, assignment, transfer, gift, or disposition of any stock acquired through the exercise of the Option.

 

(e)     Second Amended and Restated 2010 Equity Incentive Plan. The Option evidenced by this Agreement is granted pursuant to the Plan, a copy of which Plan has been made available to Participant and is hereby incorporated into this Agreement. This Agreement is subject to and in all respects limited and conditioned as provided in the Plan. All defined terms of the Plan shall have the same meaning when used in this Agreement. The Plan governs this Option and, in the event of any questions as to the construction of this Agreement or in the event of a conflict between the Plan and this Agreement, the Plan shall govern, except as the Plan otherwise provides.

 

(f)      Lockup Period Limitation. Participant agrees that in the event the Company advises Participant that it plans an underwritten public offering of its Shares in compliance with the U.S. Securities Act of 1933, as amended, and that the underwriter(s) seek to impose restrictions under which Participant may not sell or contract to sell or grant any option to buy or otherwise dispose of part or all of this Option or the Shares underlying this Option, Participant hereby agrees that for a period not to exceed 180 days from the effective date of the prospectus relating to such offering Participant will not sell or contract to sell or grant an option to buy or otherwise dispose of this Option or any of the underlying Shares without the prior written consent of the underwriter(s) or its representative(s).

 

(g)    Stock Legend. The Administrator may require that the certificates or book entries for any Shares purchased by Participant (or Participant’s permitted successors or assigns) bear an appropriate legend and stop transfer order to reflect the restrictions of Section 6(b) and Section 6(g) of this Agreement; provided, however, that failure to so endorse any of such certificates or book entries shall not render invalid or inapplicable Section 6(b) or Section 6(f).

 

(h)     Scope of Agreement. This Agreement shall bind and inure to the benefit of the Company and its successors and assigns and Participant and any successor or assigns of Participant permitted by Section 2 or Section 6(e) above. This Option is expressly subject to all terms and conditions contained in the Plan and in this Agreement, and Participant’s failure to execute this Agreement shall not relieve Participant from complying with such terms and conditions.

 

- 9 -
 

 

(i)     Arbitration. Any dispute arising out of or relating to this Agreement or the alleged breach of it, or the making of this Agreement, including claims of fraud in the inducement, shall be discussed between the disputing parties in a good faith effort to arrive at a mutual settlement of any such controversy. If, notwithstanding, such dispute cannot be resolved, such dispute shall be settled by binding arbitration. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall be a retired state or federal judge or an attorney who has practiced securities or business litigation for at least ten (10) years. If the parties cannot agree on an arbitrator within twenty (20) days, any party may request that the chief judge of the District Court of Hennepin County, Minnesota, United States of America, select an arbitrator. Arbitration will be conducted pursuant to the provisions of this Agreement, and the commercial arbitration rules of the American Arbitration Association, unless such rules are inconsistent with the provisions of this Agreement. Limited civil discovery shall be permitted for the production of documents and taking of depositions. Unresolved discovery disputes may be brought to the attention of the arbitrator who may dispose of such dispute. The arbitrator shall have the authority to award any remedy or relief that a court of this state could order or grant; provided, however, that punitive or exemplary damages shall not be awarded. The arbitrator may award to the prevailing party, if any, as determined by the arbitrator, all of its costs and fees, including the arbitrator’s fees, administrative fees, travel expenses, out-of-pocket expenses and reasonable attorneys’ fees. Unless otherwise agreed by the parties, the place of any arbitration proceedings shall be Hennepin County, Minnesota, United States of America.

 

(j)     Delay in Payment for Specified Employee. In the event this Option is subject to Code Section 409A and the Administrator determines that Participant is a “specified employee” within the meaning of Code Section 409A, then any payment due to Participant’s separation from service shall not be paid earlier than the first day of the seventh month immediately following such separation from service.

 

(k)     Right to Amend. The Company hereby reserves the right to amend this Agreement without Participant’s consent to the extent necessary or desirable to comply with the requirements of Code Section 409A and the regulations, notices and other guidance of general application issued thereunder.

 

(l)     Section 280G.   Notwithstanding anything to the contrary contained in this Agreement, to the extent that any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between Participant and the Company (collectively, the “Payments”) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this Section 6(l), would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in Participant’s receipt on an after-tax basis, of the greatest amount of economic benefits under this Agreement, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.  Unless Participant and the Company otherwise agree in writing, any determination required under this Section 6(l) shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose reasonable determination shall be conclusive and binding upon Participant and the Company for all purposes.  For purposes of making the calculations required by this Section 6(l), the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Sections 280G and 4999 of the Code.  Participant and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 6(l).

 

- 10 -
 

 

(m)     Governing Law. The validity, construction and effect of the Plan and the Agreement, and any rules and regulations relating to the Plan and the Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Minnesota, United States of America.

 

(n)      Language. Participant acknowledges that he or she is proficient in the English language, or has consulted with an advisor who is proficient in the English language, so as to enable Participant to understand the provisions of this Agreement and the Plan. If Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

 

(o)     Electronic Delivery and Participation. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

 

(p)     Severability. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

 

(q)      Addendum. Notwithstanding any provisions of this Agreement to the contrary, this Option shall be subject to any special terms and conditions for Participant's country of residence (and country of employment, if different), as are forth in the applicable Addendum to this Agreement. Further, if Participant transfers residence and/or employment to another country reflected in an Addendum to this Agreement, the special terms and conditions for such country will apply to Participant to the extent the Company determines, in its sole discretion, that the application of such terms and conditions is necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Option and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate Participant's transfer). Any applicable Addendum shall constitute part of this Agreement.

 

(r)      Imposition of Other Requirements. The Company reserves the right to impose other requirements on this Option, any payment made pursuant to this Option, and Participant's participation in the Plan, to the extent the Company determines, in its sole discretion, that such other requirements are necessary or advisable in order to comply with local law, rules and regulations or to facilitate the operation and administration of this Option and the Plan. Such requirements may include (but are not limited to) requiring Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing.

 

- 11 -
 

 

(s)      Waiver. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach, whether or like or different nature.

 

(t)      Private Offering. The grant of this Options is not intended to be a public offering of securities in Participant’s country of residence (and country of employment, if different). The Company has not submitted any registration statement, prospectus or other filing with the local securities authorities with respect to the grant of this Options (unless otherwise required under local law). No employee of the Company is permitted to advise Participant on whether Participant should purchase Shares under the Plan or provide Participant with any legal, tax or financial advice with respect to the grant of this Options. Investment in Shares involves a degree of risk. Before deciding to purchase Shares pursuant to this Options, Participant should carefully consider all risk factors and tax considerations relevant to the acquisition of Shares under the Plan or the disposition of them. Further, Participant should carefully review all of the materials related to this Options and the Plan, and Participant should consult with Participant’s personal legal, tax and financial advisors for professional advice in relation to Participant’s personal circumstances.

 

(u)     Exchange Control, Foreign Asset/Account and/or Tax Reporting. Participant acknowledges that there may be certain exchange control, foreign asset/account and/or tax reporting requirements which may affect Participant’s ability to acquire or hold Shares or cash received from participating in the Plan (including the proceeds from the sale of Shares and the receipt of any dividends paid on Shares) in a brokerage or bank account outside Participant’s country. Participant may be required to report such accounts, assets or related transactions to the tax or other authorities in Participant’s country. Participant also may be required to repatriate sale proceeds or other funds received as a result of participating in the Plan to Participant’s country within a certain time after receipt. Participant acknowledges that it is Participant’s responsibility to comply with such regulations and that Participant should speak to his or her personal advisor on this matter.

 

(v)     Insider Trading/Market Abuse. Participant may be subject to insider trading restrictions and/or market abuse laws based on the exchange on which the Shares are listed and in applicable jurisdictions, including the United States, Participant’s country and the designated broker’s country, which may affect Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., this Option) or rights linked to the value of Shares under the Plan during such times that Participant is considered to have “inside information” regarding the Company (as defined by the laws or regulations in Participant’s country).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Participant acknowledges that it is Participant’s responsibility to comply with any applicable restrictions and that Participant should speak to his or her personal advisor on this matter.

 

- 12 -
 

 

(w)     Consent and Agreement With Respect to Plan. Participant (a) acknowledges that a copy of the Plan and the U.S. prospectus for the Plan has been available to Participant; (b) represents that he or she has read and is familiar with the terms and provisions thereof, has had an opportunity to obtain the advice of counsel of his or her choice prior to executing this Agreement and fully understands all provisions of this Agreement and the Plan; (c) accepts this Option subject to all of the terms and provisions thereof; and (d) agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Agreement.

 

[Signature page follows.]

 

- 13 -
 

 

ACCORDINGLY, the parties hereto have caused this Agreement to be executed on the day and year first above written.

 

 

BIO-TECHNE CORPORATION
     
     
     
 

 By

  
   

Its

  

 

 

PARTICIPANT

 
     

 

 

 

 

 

 

By:

 

 

 

Printed Name: [●]

 

 

 

 

 

[Signature Page to Employee Nonqualified Stock Option Agreement]

 

 
 

 

BIO-TECHNE CORPORATION

 

ADDENDUM TO
GLOBAL EMPLOYEE NONQUALIFIED STOCK OPTION AGREEMENT

 

BIO-TECHNE CORPORATION
SECOND AMENDED AND RESTATED
2010 EQUITY INCENTIVE PLAN

 

In addition to the terms of the Plan and the Agreement, the Option is subject to the following additional terms and conditions as set forth in this addendum (the “Addendum”). All defined terms as contained in this Addendum shall have the same meaning as set forth in the Plan and the Agreement. Pursuant to Section 7(q) of the Agreement, to the extent Participant transfers residence and/or employment to another country, the additional terms and conditions as set forth in the Addendum for such country (if any) shall also apply to the Option to the extent the Company determines, in its sole discretion, that the application of such addendum is necessary or advisable in order to comply with local laws, rules and regulations, or to facilitate the operation and administration of the Option and the Plan (or the Company may establish alternative terms and conditions as may be necessary or advisable to accommodate the Participant’s transfer).

 

European Union (“EU”) / European Economic Area (“EEA”) / Switzerland / United Kingdom

 

1.     Data Privacy. If Participant resides and/or works in the EU/EEA, Switzerland or the United Kingdom, Section 6 of the Agreement shall be replaced with the following:

 

Data Privacy. The Company is located at 614 McKinley Place N.E., Minneapolis, Minnesota, U.S.A. and grants Options to acquire Shares under the Plan to employees of the Company and its Subsidiaries, at its sole discretion. In conjunction with the Company's grant of the Option under the Plan and its ongoing administration of such award, the Company is providing the following information about its data collection, processing and transfer practices, which Participant should carefully review.

 

(a)     Data Collection, Processing and Usage. The Company and the Employer will collect, process and use certain personal information about Participant, specifically, Participant's name, home address, email address and telephone number, date of birth, social security or insurance number, passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant's favor (“Personal Data”), for the exclusive purpose of implementing, administering and managing the Plan. Participant's Personal Data also may be disclosed to certain securities or other regulatory authorities where the Company’s securities are listed or traded or regulatory filings are made. The Company's legal basis for such disclosure of Participant's Personal Data is to satisfy its contractual obligations under the terms of the Agreement and this Addendum, and to comply with applicable laws, rules and regulations.

 

- 2 -
 

 

(b)     Stock Plan Administrator. The Company and the Employer transfer Participant's Personal Data to Morgan Stanley a broker firm/third party service provider based in the United States of America and engaged by the Company to assist with the implementation, administration and management of awards granted under the Plan (the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share Participant's Personal Data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for Participant to receive and trade Shares acquired under the Plan. Participant will be asked to agree to separate terms and data processing practices with the Stock Plan Administrator, which is a condition of Participant's ability to participate in the Plan.

 

(c)     International Personal Data Transfers. The Company and the Stock Plan Administrator are based in the United States of America. Participant should note that Participant's country of residence may have enacted data privacy laws that are different from the United States of America. The Company's legal basis for the transfer of Participant's Personal Data to the United States of America is to satisfy its contractual obligations under the terms and conditions of this Agreement.

 

(d)     Data Retention. Participant understand that Participant's Personal Data will be held only as long as is necessary to implement, administer and manage the Option and Participant's participation in the Plan. When the Company no longer needs Participant's Personal Data, the Company will remove it from its systems. If the Company retains Participant's Personal Data longer, it would be to satisfy the Company's legal or regulatory obligations and the Company's legal basis would be for compliance with applicable laws, rules and regulations.

 

(e)     Data Subject Rights. Participant understands that Participant may have the right under applicable law to (i) access or copy Participant's Personal Data that the Company possesses, (ii) rectify incorrect Personal Data concerning Participant, (iii) delete Participant's Personal Data, (iv) restrict processing of Participant's Personal Data, or (vi) lodge complaints with the competent supervisory authorities in Participant's country of residence. To receive clarification regarding these rights or to exercise these rights, Participant understand that Participant can contact his or her Employer's human resources representative.

 

Austria

 

No country-specific provisions.

 

- 3 -
 

 

Belgium

 

1.     Acceptance of Option. In order for the Option to be subject to taxation at the time of grant, Participant must affirmatively accept the Option in writing within 60 days of the Date of Grant specified above by signing below and returning this original executed Addendum to:

 

VP of Human Resources, Minneapolis Minnesota

 

Participant hereby accepts the Option granted by the Company on the Date of Grant. Participant acknowledges that Participant has been advised to discuss the acceptance of the Option and the applicable tax treatment with a financial and/or tax advisor, and that Participant’s decision to accept the Option is made in full knowledge.

 

Participant Signature: 

 

  
     

Participant Printed Name: 

 

  
     

Date of Acceptance: 

 

  

 

If Participant fails to affirmatively accept the Option in writing within 60 days of the Date of Grant, the Option will not be subject to taxation at the time of grant but instead will be subject to taxation on the date Participant exercises the Option (or such other treatment as may apply under Belgian tax law at the time of exercise).

 

2.     Undertaking for Qualifying Option. If Participant is accepting the Option in writing within 60 days of the Date of Grant and wishes to have the Option subject to a lower valuation for Belgium tax purposes pursuant to article 43, §6 of the Belgian law of 26 March 1999, Participant may agree and undertake to (a) not exercise the Option before December 31 of the third (3rd) calendar year following the calendar year in which the Date of Grant falls, and (b) not transfer the Option under any circumstances (except upon rights Participant’s heir might have in the Option upon Participant’s death). If Participant wishes to make this undertaking, Participant must sign below and return this executed Addendum to the address listed above.

 

Participant Signature:

 

  
     

Participant Printed Name:

 

  

 

3.     Payment of Option Price Limited to Cash Payment. Notwithstanding anything to the contrary in the Agreement or the Plan, Participant shall be permitted to pay the Option price only by means of a cash payment.

 

- 4 -
 

 

Canada

 

1.     No Exercise by Using Previously Owned Shares. Notwithstanding anything in the Agreement or the Plan to the contrary, if Participant is a resident in Canada, Participant shall be unable to use previously-owned Shares to pay the exercise price of the Option.

 

2.     Consent to Receive Information in English. To the extent Participant is resident in Quebec, the parties acknowledge that it is their express wish that this Agreement, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be written in English.

 

Les parties reconnaissent avoir exigé la rédaction en anglais du présent Contrat, ainsi que de tous documents exécutés, avis donnés ou procédures judiciaires intentées, en vertu du, ou liés directement ou indirectement, au présent Contrat.

 

3.     Data Privacy. The following provision supplements Section 6 of the Agreement:

 

Participant hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of Participant’s awards under the Plan. Participant further authorizes the Company, its Subsidiaries, and the stock plan administrator to disclose and discuss Participant’s participation in the Plan with their respective advisors. Participant further authorizes the Company and its Subsidiaries to record such information and to keep such information in his or her employee file.

 

China

 

1.     Option Conditioned on Satisfaction of Regulatory Obligations. If Participant is a national of the People’s Republic of China (“PRC”), the grant of the Option is conditioned upon the Company securing all necessary approvals from the PRC State Administration of Foreign Exchange to permit the operation of the Plan and the participation of PRC nationals employed by the Employer, as determined by the Company in its sole discretion.

 

2.     Mandatory Full Cashless Exercise. Notwithstanding anything in the Agreement or the Plan to the contrary, the Option may be exercised only by using the Broker-Assisted Cashless Exercise method as provided in Section 3(b)(iv) of the Agreement.

 

- 5 -
 

 

3.     Exchange Control Restrictions. Participant understands and agrees that, if Participant is subject to exchange control laws in China, Participant will be required to repatriate immediately to China the proceeds from the sale of any Shares acquired under the Plan. Participant further understands that such repatriation of sale proceeds must be effected through a special bank account established by the Company with a financial institution in China and Participant hereby consents and agrees that proceeds from the sale of Shares acquired under the Plan may be transferred to such account by the Company on Participant's behalf prior to being delivered to Participant and that no interest shall be paid with respect to funds held in such account. Sale proceeds may be paid to Participant in U.S. dollars or local currency at the Company’s discretion. If the sale proceeds are paid to Participant in U.S. dollars, Participant understands that Participant must establish and maintain a U.S. dollar bank account in China so that the proceeds may be deposited into such account. If the sale proceeds are paid to Participant in local currency, Participant acknowledges that the Company is under no obligation to secure any particular exchange conversion rate and that the Company may face delays in converting the sale proceeds to local currency due to exchange control restrictions. Participant agrees to bear any currency fluctuation risk between the time the shares of Common Stock are sold and the net proceeds are converted into local currency and distributed to Participant. Participant further agrees to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.

 

4.     Administration. The Company shall not be liable for any costs, fees, lost interest or dividends or other losses Participant may incur or suffer resulting from the enforcement of the terms of this section or otherwise from the Company’s operation and enforcement of the terms of the Plan, the Agreement and this Addendum, and the Option in accordance with Chinese law including, without limitation, any applicable rules, regulations, requirements and approvals issued by the State Administration of Foreign Exchange.

 

Czech Republic

 

No country-specific provisions.

 

Denmark

 

1.     Danish Stock Option Act. Notwithstanding anything in the Agreement or the Plan to the contrary, the treatment of the Option upon Participant’s termination of employment with the Company or any Subsidiary, as applicable, shall be governed by the Danish Stock Option Act, as in effect at the time of Participant’s termination (as determined by the Committee in its discretion in consultation with legal counsel). By accepting the Option, Participant acknowledges that he or she has received a Danish translation of an Employer Statement, which is being provided to comply with the Danish Stock Option Act.

 

Finland

 

No country-specific provisions.

 

France

 

1.     Option Not Tax-Qualified. The Option is not intended to qualify for specific tax or social security treatment in France.

 

2.     Consent to Receive Information in English. By accepting the Option, Participant confirms having read and understood the Plan, the Agreement and this Addendum, including all terms and conditions included therein, which were provided in the English language. Participant accepts the terms of those documents accordingly.

 

Consentement afin de Recevoir des Informations en Anglais

 

En acceptant les Options d’Achat d’Actions, le Participant confirme avoir lu et compris le Plan, le Contrat et la présente Annexe, en ce compris tous les termes et conditions y relatifs, qui ont été fournis en langue anglaise. Le Participant accepte les dispositions de ces documents en connaissance de cause.

 

- 6 -
 

 

Germany

 

No country-specific provisions.

 

Hong Kong

 

1.     Sale Restriction. Shares received at exercise are accepted as a personal investment. If, for any reason, the Option vests and becomes exercisable and the Option is exercised and Shares are issued to Participant (or Participant’s heirs) within six (6) months of the Date of Grant, Participant (or Participant’s heirs) agrees that he or she will not dispose of any such Shares prior to the six (6)-month anniversary of the Date of Grant.

 

2.     Securities Law Notice. WARNING: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Participant is advised to exercise caution in relation to the offer. If Participant is in any doubt about any of the contents of this document, Participant should obtain independent professional advice. Neither the offer of Options nor the issuance of Shares upon exercise of the Options constitutes a public offering of securities under Hong Kong law and is available only to employees of the Company and its Subsidiaries. The Agreement, including this Addendum, the Plan and other incidental communication materials distributed in connection with the Options (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each eligible employee of the Company or its Subsidiaries and may not be distributed to any other person.

 

3.     Nature of Plan. The Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational Retirement Schemes Ordinance.

 

Hungary

 

No country-specific provisions.

 

India

 

1.     Mandatory Full Cashless Exercise. Notwithstanding anything in the Agreement or the Plan to the contrary, the Option may be exercised only by using the Broker-Assisted Cashless Exercise method as provided in Section 3(b)(iv) of the Agreement.

 

- 7 -
 

 

Italy

 

1.     Mandatory Full Cashless Exercise. Notwithstanding anything in the Agreement or the Plan to the contrary, the Option may be exercised only by using the Broker-Assisted Cashless Exercise method as provided in Section 3(b)(iv) of the Agreement.

 

2.     Plan Document Acknowledgement. In accepting the Option, Participant acknowledges that he or she has received a copy of the Plan and the Agreement and has reviewed the Plan and the Agreement (including this Addendum), in their entirety and fully understands and accepts all provisions of the Plan and the Agreement (including this Addendum). Participant further acknowledges that he or she has read and specifically and expressly approves the following provisions of the Agreement: Section 4: Tax Obligations; Section 6: Nature of Grant; Section 8(m): Governing Law; Section 8(q): Addendum; Section 8(r): Imposition of Other Requirements; and the Data Privacy provisions for the European Union reflected above..

 

Japan

 

No country-specific provisions.

 

Korea

 

No country-specific provisions.

 

Luxembourg

 

No country-specific provisions.

 

Netherlands

 

1.     Waiver of Termination Rights. As a condition to the grant of the Option, Participant hereby waive any and all rights to compensation or damages as a result of the termination of Participant's employment with the Company and the Employer for any reason whatsoever, insofar as those rights result or may result from (a) the loss or diminution in value of such rights or entitlements under the Plan, or (b) Participant ceasing to have rights under or ceasing to be entitled to any Option under the Plan as a result of such termination.

 

Poland

 

No country-specific provisions.

 

Singapore

 

1.     Securities Law Notice. The grant of the Option is being made pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”) and is not made to Participant with a view to the underlying Shares being subsequently offered for sale to any other party. The Plan has not been, and will not be, lodged or registered as a prospectus with the Monetary Authority of Singapore. Participant should note that the Options are subject to section 257 of the SFA and Participant should not make (i) any subsequent sale of the Shares in Singapore or (ii) any offer of such subsequent sale of the Shares subject to the Option in Singapore, unless such sale or offer is made after six (6) months from the Date of Grant or pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA. The Shares are currently traded on the NASDAQ Stock Market LLC, which is located outside of Singapore, under the ticker symbol “TECH” and Shares acquired under the Plan may be sold through this exchange.

 

- 8 -
 

 

Spain

 

1.     Nature of Option. The following provision supplements Section 6 of the Agreement:

 

In accepting the grant of the Option, Participant acknowledges that he or she consents to participation in the Plan and has received a copy of the Plan.

 

Participant understands that the Company, in its sole discretion, has unilaterally and gratuitously decided to grant Options under the Plan to individuals who may be employees of the Company or its Subsidiaries throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any Options will not economically or otherwise bind the Company or any of its Subsidiaries on an ongoing basis. Consequently, Participant understands that the Option is granted on the assumption and condition that the Option and the Shares issued upon exercise of the Option shall not become a part of any employment contract (either with the Company or any of its Subsidiaries) and shall not be considered a mandatory benefit, or salary for any purposes (including severance compensation) or any other right whatsoever.

 

Further, Participant understands and agrees that, unless otherwise expressly provided for by the Company or set forth in the Agreement, the Option will be cancelled without entitlement to any Shares if Participant’s employment is terminated for any reason, including, but not limited to: resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to a “despido improcedente”), material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, or under Article 10.3 of Royal Decree 1382/1985. The Committee, in its sole discretion, shall determine the date when Participant’s employment has terminated for purposes of the Option.

 

Participant understands that this Option grant would not be made to Participant but for the assumptions and conditions referred to above; thus, Participant acknowledges and freely accepts that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any grant of, or right to, the Option shall be null and void.

 

Sweden

 

1. Tax Obligations. The following provision supplements Section 4 of the Agreement:

 

Without limiting the Company's and the Employer's authority to satisfy their withholding obligations for Tax-Related Items as set forth in Section 4 of the Agreement, in accepting the grant of Option, Participant authorizes the Company and/or the Employer to withhold Shares or to sell Shares otherwise deliverable to Participant upon exercise to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.

 

- 9 -
 

 

Switzerland

 

1.     Securities Law Notice. Neither the Agreement, the Addendum nor any other materials relating to the Option (i) constitutes a prospectus according to article 35 et seq. of the Swiss Federal Act on Financial Services ("FinSA"), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (FINMA).

 

Taiwan

 

No country-specific provisions.

 

United Kingdom

 

1.     Tax Obligations. The following provision supplements Section 4 of the Agreement:

 

Without limitation to Section 4 of the Agreement, Participant hereby agrees that Participant is liable for all Tax Related-Items and hereby covenants to pay all such Tax Related-Items, as and when requested by the Company, or if different, the Employer, or by Her Majesty’s Revenue & Customs (“HMRC”) (or any other tax authority or any other relevant authority). Participant also hereby agrees to indemnify and keep indemnified the Company and, if different, the Employer, against any Tax Related-Items that they are required to pay or withhold, or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on Participant’s behalf.

 

Notwithstanding the foregoing, if Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), Participant may not be able to indemnify the Company or the Employer for the amount of any income tax not collected from or paid by Participant, as it may be considered a loan. In this case, the amount of any uncollected amounts may constitute a benefit to Participant on which additional income tax and National Insurance Contributions may be payable. Participant will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying the Company or the Employer for the value of any National Insurance Contributions due on this additional benefit, which the Company or the Employer may recover by any of the means referred to in Section 6(d) of the Agreement.

 

2.     Exclusion of Claim. Participant acknowledges and agrees that Participant will have no entitlement to compensation or damages insofar as such entitlement arises or may arise from the Participant ceasing to have rights under or to be entitled to the Option, whether or not as a result of termination of employment (whether such termination is in breach of contract or otherwise), or from the loss or diminution in value of the Option. Upon the grant of the Option, Participant shall be deemed to have waived irrevocably such entitlement.

 

 

 

*********************

 

- 10 -

 
 EX-21 12 ex_248813.htm EXHIBIT 21 ex_248813.htm

Exhibit 21

 

Bio-Techne Corporation, a Minnesota corporation, had the material subsidiaries below as of the date of filing its Annual Report on Form 10-K for fiscal year ended June 30, 2021. Certain subsidiaries are not named because they were not significant individually or in the aggregate as of such date. Bio-Techne Corporation is not a subsidiary of any other entity. 

 

Name

State/Country of Incorporation

Research and Diagnostic Systems Inc. (R&D Systems)

Minnesota

Bionostics, Inc

Massachusetts

Bio-Techne China Co. Ltd

China

Shanghai PrimeGene Bio-Tech Co., Ltd.

China

ProteinSimple

Delaware

ProteinSimple Ltd.

Canada

Novus Biologicals, LLC

Delaware

Bio-Techne Ltd.

United Kingdom

Tocris Cookson Limited

United Kingdom

Cliniqa Corporation

California

Advanced Cell Diagnostics, Inc.

California

QT Holdings Corporation

Delaware

Exosome Diagnostics, Inc. 

Delaware
Asuragen, Inc. Delaware

B-MoGen Biotechnologies Inc.

Minnesota

 

 
 EX-23 13 ex_248814.htm EXHIBIT 23 ex_248814.htm

Exhibit 23

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the registration statements (Nos. 333-37263, 333-88885, 333-49962, 333-170576, 333-199847, 333-207710, 333-221143, and 333-249974) on Form S-8 of our reports dated August 25, 2021, with respect to the consolidated financial statements of Bio-Techne Corporation and the effectiveness of internal control over financial reporting.

 

/s/ KPMG LLP

 

Minneapolis, Minnesota

August 25, 2021

 

 
 EX-31.1 14 ex_248815.htm EXHIBIT 31.1 ex_248815.htm

Exhibit 31.1

 

CERTIFICATION

 

I, Charles Kummeth, certify that:

 

 

1.

I have reviewed this annual report on Form 10-K of Bio-Techne Corporation;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: August 25, 2021

 

 

/s/ Charles Kummeth

  

Charles Kummeth

Chief Executive Officer

  

 

 
 EX-31.2 15 ex_248816.htm EXHIBIT 31.2 ex_248816.htm

Exhibit 31.2

 

 

CERTIFICATION

 

I, James T. Hippel, certify that:

 

 

1.

I have reviewed this annual report on Form 10-K of Bio-Techne Corporation;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

 

4.

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: August 25, 2021

 

 

/s/ James Hippel

  

James Hippel

Chief Financial Officer

  

 

 
 EX-32.1 16 ex_248817.htm EXHIBIT 32.1 ex_248817.htm

Exhibit 32.1

 

 

BIO-TECHNE CORPORATION

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Bio-Techne Corporation (the “Company”) on Form 10-K for the year ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles Kummeth, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

 

/s/ Charles Kummeth

  
 

Charles Kummeth

Chief Executive Officer

August 25, 2021

  

 

 
 EX-32.2 17 ex_248818.htm EXHIBIT 32.2 ex_248818.htm

Exhibit 32.2

 

 

BIO-TECHNE CORPORATION

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Bio-Techne Corporation (the “Company”) on Form 10-K for the year ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James T. Hippel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

 

/s/ James Hippel

  
 

James Hippel

Chief Financial Officer

August 25, 2021

  

 

 
 EX-101.SCH 18 tech-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Statements of Earnings and Comprehensive Income link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Acquisitions link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Debt and Other Financing Arrangements link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Leases link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Earnings Per Share link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Segment Information link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 2 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 4 - Acquisitions (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 5 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Earnings Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 11 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 12 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 2 - Revenue Recognition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 4 - Acquisitions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 5 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 6 - Debt and Other Financing Arrangements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 7 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 7 - Leases - Balance Sheet Classification (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 7 - Leases - Cash Paid (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 9 - Earnings Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 11 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 12 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 19 tech-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 20 tech-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 21 tech-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Intangible assets Dividend yield us-gaap_DerivativeNotionalAmount Derivative, Notional Amount Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Revenue Recognition Hedging Relationship [Domain] Note 3 - Supplemental Balance Sheet and Cash Flow Information us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets Current assets, net of cash Risk-free interest rates Note 4 - Acquisitions Cash Flow Hedging [Member] Note 5 - Fair Value Measurements Note 7 - Leases us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets In-process research and development Not Designated as Hedging Instrument [Member] Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Note 9 - Earnings Per Share Note 10 - Share-based Compensation and Other Benefit Plans Hedging Relationship [Axis] Income Tax Disclosure [Text Block] Note 11 - Income Taxes Note 12 - Segment Information Hedging Designation [Axis] Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) Hedging Designation [Domain] Contingent consideration payable Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) Expected volatility Designated as Hedging Instrument [Member] us-gaap_LiabilitiesCurrent Total current liabilities Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) Other current liabilities Expected lives (years) (Year) Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred, Total Net assets acquired us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms Balance, weighted average contractual life (Year) Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1 Net assets acquired Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) us-gaap_FinitelivedIntangibleAssetsAcquired1 Finite-lived Intangible Assets Acquired Note 7 - Leases - Balance Sheet Classification (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 7 - Leases - Cash Paid (Details) Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Contingent consideration payable Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) Share-based Payment Arrangement, Option, Activity [Table Text Block] Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Granted, weighted average exercise price (in dollars per share) Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) Foreign currency translation adjustments us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired us-gaap_DerivativeLiabilitiesCurrent Derivative Liability, Current us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Vested, weighted average exercise price (in dollars per share) Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Forfeited, weighted average exercise price (in dollars per share) Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, weighted average exercise price (in dollars per share) Balance, weighted average exercise price (in dollars per share) Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, shares (in shares) Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) Notes To Financial Statements us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance, shares (in shares) Balance, shares (in shares) Notes To Financial Statements [Abstract] us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent Other comprehensive income (loss) before reclassifications us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent Reclassification from loss on derivatives to interest expense, net of taxes us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Granted, shares (in shares) Proceeds from sale and maturities of available-for-sale investments us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, shares (in shares) Current portion of long-term debt obligations Other comprehensive income (loss) us-gaap_OtherComprehensiveIncomeLossNetOfTax Other comprehensive income (loss) tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxesNet Deferred income taxes, net, adjustments This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to deferred income taxes, after deferred tax assets, assumed in connection with a business combination for which the initial accounting was incomplete. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Exercisable, weighted average exercise price (in dollars per share) Equity Securities [Member] Exercisable, weighted average contractual life (Year) us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Exercisable, aggregate intrinsic value us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Exercisable, shares (in shares) us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total shareholders' equity Balances Balances us-gaap_LinesOfCreditCurrent Line of Credit, Current Outstanding, weighted average contractual life (Year) Outstanding, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Forfeited, weighted average exercise price (in dollars per share) Contract liabilities Schedule of Goodwill [Table Text Block] Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued expenses Salaries, wages and related accruals Income taxes payable Lessee, Operating Leases [Text Block] Trade accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Outstanding, shares (in shares) Outstanding, shares (in shares) Retirement Plan Type [Axis] Retirement Plan Type [Domain] Credit Facility [Axis] Credit Facility [Domain] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Other Intangible Assets [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property and equipment Dilutive effect of stock options and restricted stock units (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Noncompete Agreements [Member] Income taxes paid Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Weighted average common shares outstanding: Developed Technology Rights [Member] Patented Technology [Member] us-gaap_Assets Total assets Patents [Member] Plan Name [Axis] Plan Name [Domain] Changzhou Eminence Biotechnology [Member] Acquisition of Changzhou Eminence Biotechnology Co, Ltd. In Process Research and Development [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Income available to common shareholders Customer Relationships [Member] us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Income available to common shareholders us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Income allocated to participating securities Income allocated to participating securities Finite-Lived Intangible Assets by Major Class [Axis] Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Costs recognized on sale of acquired inventory Costs recognized upon sale of acquired inventory The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting. Award Type [Domain] Business Description and Accounting Policies [Text Block] Award Type [Axis] Net income us-gaap_NetIncomeLoss Net earnings attributable to Bio-Techne Other comprehensive income (loss) attributable to noncontrolling interest us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Total Total intangible assets Intangible assets, net Beginning balance Ending balance Restricted Stock Units (RSUs) [Member] us-gaap_FiniteLivedIntangibleAssetsGross Definite-lived intangibles assets Restricted Stock [Member] Net earnings (loss) attributable to noncontrolling interest us-gaap_GoodwillForeignCurrencyTranslationGainLoss Currency Translation us-gaap_GoodwillPurchaseAccountingAdjustments Goodwill, Purchase Accounting Adjustments us-gaap_GoodwillAcquiredDuringPeriod Acquisitions (Note 4) In process research and development Business Combination Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Goodwill Goodwill Balance Balance Non-controlling interest in Eminence Property and equipment, cost Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] us-gaap_DerivativeFairValueOfDerivativeLiability Derivative instruments - cash flow hedges Net earnings Net earnings, including non-controlling interest Net earnings, including noncontrolling interest us-gaap_Investments Investments, Total Derivative Instrument [Axis] Other operating activity Derivative Contract [Domain] Cash flows from investing activities: us-gaap_AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale, Total Earnings per share: Earnings Per Share [Text Block] Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding Represents the value of undesignated capital stock as of the balance sheet date. Surrender and retirement of stock to exercise option Represents the value of stocks surrendered and retired to exercise options. Income taxes payable us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Trade accounts payable and accrued expenses tech_LineOfCreditFacilityAdditionalBorrowingCapacity Line of Credit Facility, Additional Borrowing Capacity The element representing the additional borrowing capacity under a line of credit. Surrender and retirement of stock to exercise option (in shares) Represents the shares of stock surrendered and retired to exercise options during the period. Intersegment Eliminations [Member] Salaries, wages and related accruals us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Income taxes (benefit) Income Tax Expense (Benefit), Total Total income tax provision Contingent Consideration, Policy [Policy Text Block] Disclosure of accounting policy for contingent consideration. CCXI [Member] Related to the CCXI investment. CHINA B-MoGen [Member] Represents information pertaining to B-MoGen Biotechnologies. Building, Building Improvements and Leasehold Improvements [Member] Information pertaining to building, building improvements and leasehold improvements. us-gaap_OperatingExpenses Total operating expenses tech_BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value Represents the amount of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages, before remeasurement to fair value. us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost tech_StockRepurchasedDuringPeriodAverageSharePrice Stock Repurchased During Period, Average Share Price (in dollars per share) Total cost of shares repurchased divided by the total number of shares repurchased. GB Profit Sharing and Savings Plan [Member] Represents the GB Profit Sharing and Savings Plan US Profit Sharing and Savings Plan [Member] Represents the US Profit Sharing and Savings Plan. tech_EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent Foreign derived intangible income Percentage of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Global Intangible Low-Taxed Income (GILTI) and Foreign-Derived Intangible Income (FDII). Cash and cash equivalents Royalty [Member] UNITED KINGDOM ChemoCentryx, Inc (CCXI) [Member] Represents ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer primarily focused on orphan and rare diseases. us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Stock-based compensation, inclusive of employer taxes us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value of contingent consideration Amendment Flag ICFR Auditor Attestation Flag tech_IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments Income Tax Expense (Benefit) Discrete Tax Items State Apportionments Represents income tax expense (benefit) for discrete tax items relating to certain state appointments. us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income attributable to Bio-Techne City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Balances (in shares) Balances (in shares) Fair value adjustment on available for sale investments The amount of fair value adjustment made on available for sale securities during the period. Current Fiscal Year End Date us-gaap_VariableLeaseCost Variable Lease, Cost Weighted average discount rate: Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] United States and Canada [Member] Geographical location of the United States and Canada. Document Period End Date Right of use assets obtained in exchange for lease liabilities Rest of World [Member] Rest of the geographical locations in the world. us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses Weighted average remaining lease term (in years): (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company us-gaap_DividendsCommonStockCash Cash dividends Document Information [Line Items] Document Information [Table] Service [Member] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair value at the beginning of period Contingent consideration payable Entity Public Float us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Payments Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_RestructuringCharges Restructuring costs Entity Voluntary Filers us-gaap_BusinessCombinationAcquisitionRelatedCosts Acquisition related expenses Entity Well-known Seasoned Issuer Purchase price contingent consideration (Note 4) Acquisition of Asuragen, Inc. [Member] Represents information regarding the acquisition of Asuragen, Inc. Equity Incentive Plan 2010 [Member] Information pertaining to the 2010 Equity Incentive Plan. Employee Stock Purchase Plan 2014 [Member] Information pertaining to the 2014 Employee Stock Purchase Plan. Performance Incentive Programs [Member] Information pertaining to the Performance Incentive Programs. Stock-based compensation expense us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Trade accounts and other receivables Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Liability Class [Axis] Employee stock purchase plan expense Fair Value by Liability Class [Domain] Entity [Domain] Legal Entity [Axis] Customer Concentration Risk [Member] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets, Total Amortization expense Gain on escrow settlement Gain (Loss) on Escrow Settlement Gain on escrow settlement The amount of gain (loss) during the period on escrow settlement. tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill Total assets acquired Amount of assets acquired, including goodwill, at the acquisition date. Entity Address, City or Town Leases, net The amount of noncash portion of lease expense during the period. Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares (in shares) Share repurchases (in shares) Entity Common Stock, Shares Outstanding Revenue, Segment Benchmark [Member] us-gaap_StockRepurchasedDuringPeriodValue Share repurchases us-gaap_AdvertisingExpense Advertising Expense tech_DerivativeNotionalAmountDedesignated Derivative Notional Amount, Dedesignated The amount of dedesignated derivative notional amount. tech_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement Gain on escrow settlement Amount of gain on escrow settlement of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Undesignated capital stock, shares authorized (in shares) Represents the shares authorized for undesignated capital stock. Undesignated capital stock, no par (in dollars per share) Represents the no par value for undesignated capital stock. Undesignated capital stock, shares outstanding (in shares) Represents the shares outstanding for undesignated capital stock. tech_DerivativeNotionalAmountDecreaseInPeriod Derivative Notional Amount, Decrease in Period The amount of decrease during the period in the notional amount of the derivative. Undesignated capital stock, shares issued (in shares) Represents the shares issued for undesignated capital stock. Investments [Domain] tech_VariableInterestEntityPrimaryBeneficiaryMaximumLossExposurePortionStemmingFromInitialInvestment Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment Portion of the amount of maximum exposure to loss from involvement with consolidated variable interest entity (VIE) stemming from the reporting entity's initial investment in the VIE. us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Investment Type [Axis] Common stock issued to employee stock purchase plan (in shares) Local Phone Number Common stock issued for exercise of options (in shares) Exercised, shares (in shares) us-gaap_TableTextBlock Notes Tables Common stock issued to employee stock purchase plan Common stock issued for restricted stock awards (in shares) us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Operating Loss Carryforwards [Member] Information for deferred tax assets related to operating loss carryforwards. Common stock issued for exercise of options Tax Credit Carryforwards [Member] Information for deferred assets related to tax credit carryforwards. Common stock issued for restricted stock awards us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage us-gaap_GainOnSaleOfInvestments (Gain) Loss on investment, net Selling, general and administrative Corporate general, selling and administrative expenses Granted, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares) Raw materials us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders’ equity UNITED STATES Retained earnings Retained Earnings (Accumulated Deficit), Ending Balance Accumulated other comprehensive loss Research and development Debt Disclosure [Text Block] us-gaap_InterestExpense Interest Expense, Total Interest expense Change in operating assets and liabilities, net of acquisitions: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Operating lease liabilities Noncurrent operating lease liabilities Schedule of Inventory, Current [Table Text Block] Total lease obligations us-gaap_OperatingLeaseLiability Operating Lease, Liability, Total Total operating lease liabilities Deferred income taxes us-gaap_DeferredIncomeTaxesAndTaxCredits us-gaap_IntangibleAssetsNetIncludingGoodwill Total intangible assets, net Operating lease liabilities - current Current operating lease liabilities Thereafter us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive Subsequent Events [Text Block] Right of use asset Operating Lease, Right-of-Use Asset 2023 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo 2024 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total 2025 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour Less: Amounts representing interest us-gaap_DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit), Total Total deferred tax provision 2026 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2026 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2022 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths Thereafter us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Finite-Lived Intangible Asset, Expected Amortization, Year Four 2022 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Finite-Lived Intangible Asset, Expected Amortization, Year Five us-gaap_OfficersCompensation Salary and Wage, Officer, Excluding Cost of Good and Service Sold 2023 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Contingent Consideration [Member] Liabilities that are contingent on agreed-upon conditions that arise from business combinations. Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities Excess Tax Benefit from Share-based Compensation, Operating Activities us-gaap_HedgingAssetsNoncurrent Hedging Assets, Noncurrent, Total Foreign Currency Transactions and Translations Policy [Policy Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock-based compensation expense us-gaap_ShareBasedCompensation Other assets us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss Currency translation Operating expenses: Comprehensive Income, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Total Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Research and Development Expense, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1 Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract (Year) tech_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements Acquisitions (Note 4) Amount of increase (decrease) from new acquisitions and adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Depreciation and amortization us-gaap_LiabilitiesFairValueDisclosure Total Liabilities tech_DeferredTaxAssetsLeaseLiabilities Lease liability Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from lease liabilities. us-gaap_AssetsCurrent Total current assets Investments, Fair Value Disclosure us-gaap_InvestmentsFairValueDisclosure Investments, Fair Value Disclosure, Total Contingent consideration payments Advertising Cost [Policy Text Block] Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,955,484 and 38,453,046 shares, respectively Fair value adjustment to contingent consideration payable Adjustments to reconcile net earnings to net cash provided by operating activities: Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Common stock, shares issued (in shares) Other intangibles us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 Noncash or Part Noncash Acquisition, Intangible Assets Acquired Certificates of Deposit [Member] Common stock, par value (in dollars per share) Asia [Member] Deferred Tax Asset [Domain] us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible Decrease in Unrecognized Tax Benefits is Reasonably Possible us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance, Total Valuation allowance Statistical Measurement [Domain] Cash amounts paid on operating lease liabilities Maximum [Member] tech_ProceedsFromLaboratoryServicesReimbursedByMedicare Proceeds from Laboratory Services Reimbursed by Medicare Represents the cash received from laboratory services reimbursed by Medicare. Minimum [Member] Valuation Allowance by Deferred Tax Asset [Axis] Product and Service [Axis] Other current assets us-gaap_DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance, Total Deferred tax assets Product and Service [Domain] Statistical Measurement [Axis] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Interest paid Other us-gaap_NoncurrentAssets Total long-lived assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Geographical [Axis] Property, Plant and Equipment [Table Text Block] Geographical [Domain] us-gaap_DeferredIncomeTaxLiabilities Deferred tax liabilities Europe [Member] Inventories Excess tax basis in equity investments Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Derivative - cash flow hedge us-gaap_DeferredTaxAssetsInventory Inventory Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Cumulative Effect, Period of Adoption [Domain] Lessee, Operating Lease, Asset and Liabilities [Table Text Block] The tabular disclosure for asset and liabilities of operating leases of the lessee. Cumulative Effect, Period of Adoption [Axis] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Cumulative Effect, Period of Adoption, Adjustment [Member] Noncontrolling interest Lessee, Operating Lease, Cash Flow Information [Table Text Block] The tabular disclosure of cash flow information of operating leases of the lessee. Cash flows from operating activities: Schedule of Segment Reporting Information, by Segment [Table Text Block] Revenue [Policy Text Block] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Accounts receivable, less allowance for doubtful accounts of $1,229 and $775, respectively us-gaap_NumberOfReportableSegments Number of Reportable Segments Deferred compensation Term Loan [Member] Represents information about term loan. AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Building and Building Improvements [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] AOCI Attributable to Parent [Member] Additional paid-in capital Land [Member] Acquisition-related liabilities Non-cash change in the liability related to acquisition. Property, Plant and Equipment, Policy [Policy Text Block] Other non-operating income (expense), net Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Nonoperating Income (Expense), Total Total other income (expense), net Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Tax credit carryovers Net operating loss carryovers Exosome Diagnostics, Inc [Member] Represents information about Exosome Diagnostics, Inc. QT Holdings Corporation [Member] Represents information about QT Holdings Corporation. Current assets: Interest income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Inventory, Policy [Policy Text Block] tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate Represents the forfeiture rate used under share-based compensation arrangement by share-based payment award. Effect of exchange rate changes on cash and cash equivalents us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities Accounting Standards Update 2016-01 [Member] Forward Starting Swap [Member] Represents forward starting swap. Executive Officer [Member] Operating income Operating income us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities tech_InvestmentInUnconsolidatedEntity Investment in unconsolidated entity, net Represents the amount of investment in unconsolidated entity. Other income (expense): Other us-gaap_DeferredTaxLiabilitiesOther us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities us-gaap_DeferredTaxLiabilities Net deferred tax liabilities us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets Intangible asset amortization us-gaap_GrossProfit Gross margin New Forward Starting Swap [Member] Represents the new forward starting swap. Cost of sales Deferred income taxes Deferred Income Tax Liabilities, Net, Total tech_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfProperty Lessee, Operating Lease, Lease Not yet Commenced, Area of Property (Square Foot) Area of property under an operating lease not yet commenced. tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment Contingent consideration adjustment Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to contingent consideration adjustments. Consolidation Items [Domain] Bio-Techne's shareholders' equity: us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total Right of use asset us-gaap_DeferredTaxLiabilitiesLeasingArrangements tech_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentalImpact Lessee, Operating Lease, Lease Not yet Commenced, Annunal Rental Impact The annual rental impact of an operating lease not yet commenced. Consolidation Items [Axis] Accounting Standards Update 2016-02 [Member] Other financing activities The 2020 Equity Incentive Plan [Member] Represents the 2020 Equity Incentive Plan. us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome Net unrealized gain on available-for-sale investments Marketable Securities, Policy [Policy Text Block] Consolidated Entities [Axis] Consolidated Entities [Domain] us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Contingent consideration payments Accounting Standards Update [Domain] us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Depreciation Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] Accounting Standards Update [Axis] tech_InventoryNetCurrentAndNonCurrent Inventories, net Amount of inventory, net of reserves, including both current and non-current portions. Finished goods Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. Includes both current and non-current amounts. tech_IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions Represents income tax expense (benefit) for discrete tax items relating to acquisitions. tech_InventoryFinishedGoodsNetOfReservesNonCurrent Inventory, Finished Goods, Net of Reserves, Non-current Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. us-gaap_PaymentsOfDividendsCommonStock Cash dividends us-gaap_UndistributedEarningsOfForeignSubsidiaries Undistributed Earnings of Foreign Subsidiaries Noncontrolling Interest [Member] us-gaap_PaymentsForRepurchaseOfCommonStock Re-purchases of common stock Scenario [Domain] Forecast [Member] Retained Earnings [Member] Proceeds from stock option exercises Revenues, net Net sales Title of Individual [Domain] State Title of Individual [Axis] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit State Scenario [Axis] us-gaap_CurrentForeignTaxExpenseBenefit Foreign us-gaap_DeferredRentCredit Deferred Rent Credit us-gaap_DeferredForeignIncomeTaxExpenseBenefit Foreign Additional Paid-in Capital [Member] Accounting Standards Update 2016-13 [Member] Federal Common Stock [Member] us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Equity Components [Axis] Accounting Standards Update 2018-02 [Member] Equity Component [Domain] us-gaap_LongTermDebt Long-term Debt, Total us-gaap_CurrentIncomeTaxExpenseBenefit Total current tax provision Other Noncurrent Assets [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Foreign us-gaap_ReclassificationFromAociCurrentPeriodTax Reclassification from AOCI, Current Period, Tax, Total us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Earnings before income taxes Domestic Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Comprehensive Income (Loss) Note [Text Block] Other comprehensive income (loss): Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] tech_IncomeTaxExpenseBenefitDiscreteTaxItems Income Tax Expense (Benefit), Discrete Tax Items Represents the income tax expense (benefit) related to discrete tax items. State and Local Jurisdiction [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] Foreign Tax Authority [Member] Equipment [Member] Revenue from Contract with Customer [Text Block] Document Annual Report Accounts Receivable [Policy Text Block] Machinery and Equipment [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Balance Ending balances us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounting Policies [Abstract] Document Transition Report Selling, General and Administrative Expenses [Member] Entity Interactive Data Current us-gaap_CommonStockDividendsPerShareDeclared Common Stock, Dividends, Per Share, Declared (in dollars per share) us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities Settlements Additions due to acquisitions Additions for tax positions of prior year Security Exchange Name us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Decrease in unrecognized tax benefits for prior year positions tech_FixedLeaseCost Fixed Lease, Cost Represents the amount of fixed lease cost. Title of 12(b) Security Long-term debt obligations us-gaap_ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt, Total Cost of Sales [Member] Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] Represents information pertaining to trade names, customer relationships, non-compete agreements and patents. Borrowings under line-of-credit agreement Proceeds from Long-term Lines of Credit tech_FinitelivedIntangibleAssetsOtherAdditions Other additions Amount of other additions lacking physical substance with a definite life. Income Statement Location [Axis] Income Statement Location [Domain] tech_AmortizationOfAcquiredIntangibleAssets Amortization of acquired intangible assets Represents the amount of amortization of acquired intangible assets. tech_EffectiveIncomeTaxRateReconciliationOptionExercises Option exercises Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to option exercises. Segments [Axis] Segments [Domain] us-gaap_PaymentsToAcquireAvailableForSaleSecurities Purchase of available-for-sale investments us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount us-gaap_SharePrice Share Price (in dollars per share) us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) us-gaap_RepaymentsOfLinesOfCredit Payments on line-of-credit Diluted (in shares) tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets Total assets acquired, adjustments This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to assets acquired in connection with a business combination for which the initial accounting was incomplete. us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Asset Class [Axis] tech_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] Diluted (in dollars per share) Basic (in shares) us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Other, net EMEA, excluding U.K. [Member] Regions of Europe, Middle East and Africa, excluding the United Kingdom. us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent, Total Effective tax rate APAC, excluding Greater China [Member] Represents the APAC, excluding Greater China. Instruments [Member] Represents the information pertaining to instruments which typically consist of longer-lived assets. us-gaap_AvailableForSaleSecurities Available-for-sale Securities, Total Business Acquisition [Axis] Consumables [Member] Represents the information pertaining to consumables products. Basic (in dollars per share) us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate U.S. taxation of foreign earnings Business Acquisition, Acquiree [Domain] Product and Services [Member] Represents the product and services provided by the company. Statement of Cash Flows [Abstract] Diagnostics and Genomics [Member] Consist of the ACD operating segment and the Diagnostics operating segment. Protein Sciences [Member] Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment. Short-term available-for-sale investments us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total us-gaap_DerivativeLiabilityFairValueGrossAsset Derivative instruments - cash flow hedges us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability, Total Credit Agreement [Member] Represents the information pertaining to credit agreement. Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_AvailableForSaleEquitySecuritiesAmortizedCostBasis Available-for-sale Equity Securities, Amortized Cost Basis, Total us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Executive compensation limitations Schedule of Intangible Assets and Goodwill [Table Text Block] us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Long-term contingent consideration payable us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes State income taxes, net of federal benefit us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal Liabilities Amount of liabilities excluding deferred income taxes assumed at the acquisition date. us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Foreign tax rate differences tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets Equipment and other long-term assets Amount of equipment and other long-term assets acquired at the acquisition date. us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Research and development tax credit us-gaap_PaymentsForProceedsFromOtherInvestingActivities Other investing activities Cash flows from financing activities: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Other long-term liabilities us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Income tax expense at federal statutory rate Corporate, Non-Segment [Member] us-gaap_HedgingLiabilitiesNoncurrent Hedging Liabilities, Noncurrent us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Net assets acquired us-gaap_StockholdersEquity Total Bio-Techne shareholders' equity Balance Balance us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Payments to Acquire Businesses, Net of Cash Acquired, Total Acquisitions, net of cash acquired Class of Stock [Axis] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Deferred income taxes, net Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_PaymentsToAcquireBusinessesGross Payments to Acquire Businesses, Gross Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8. Operating Segments [Member] EX-101.PRE 22 tech-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 23 grph01.jpg begin 644 grph01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 L17AI9@ 34T *@ @ 0$Q ( M * &@ !''EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! M 0$! 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D: M)BH*# MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3 MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN!^(?B?7+77 M?#_A'PA-;VFKZ\\I-]<1^8MG#$NYW"'AGYX!X^4@]>%=2U1O&FK MVOB#P_;6)NUU);5+:X5U!+1B)." %)R?[PP>H !Z!17C6AW'Q7\:^%QXRTSQ M-8:0ET6GL?#_ /9R31O$IPJO.?G!?:8\:_&GQ3=>&?!>M^#IUL& MU*VO)[^U,*2*QMMI<9920,*Y&"#@B@#Z,HKP?XC_ !6\0VOCSPU:^$+\6^D7 M LFO2(8I/,-RS,BY921^[0GC'6H9_&/B34/%?B^";XL:;X4ATG4)8+2RO+&U M_45X"TTB6/3_%?B6[>!9C K+Y,);S) M@C CD!#TQ\QQCBM)OB-K5Y^S5=^*+>Y^S>(;&'[/)]"AT+4K3XJ:5XOGO+RW@ET""PMEE<2\$ Q$N"#QT SC M/]T]]I?BS7)OBE\0=*+M>VFBVEK+I]DL:@[W@WLH8#<=S>I.,\4 >C45X/\ M#+X@>,/$WB#2+H>)]/UZWO6F35M#-M#:3:4!@J\>2'F49 S\PQDNMX4\20^%=$T6^?3HW_LZ.[ENY4QO9A(<*!D$8QPW(H ];HKP/Q!\4 MO&=M\,M4@\Z"S\7Z)K,6F7,]K$CQW ;.V15D! W8]!TSA<[1N#XIW^NK\/KK M2)OL/]JZF]EK%F8E)21%&^([@2N"$1?:9:1WFI M7=U%964,N?+::0G&[!!P ">HSP,C.:XO6]0^(WPOTZT\2^)_%=KXGTE)(XM3 MLO[-CMV@5V5?,B=,%R"<<@ @].> #V.BO#-6\7>(+WXL>*=&_P"%H:?X.T[3 M#;?9$O+.UD$WF1!FVM(5)P>>I^\.E>N^%ENE\+V/V[78O$,S(7.J0PI$ER"2 M58*A*@;2!P><9[T :U%>!^%/B/J'BGXCSVLOQ-ATR,:U)%:Z$^CQN+FV20;4 M%R0,%QE1R6STR2!7I7Q/N?$^F>$SK7@VYVW.ERBZN;)HD=;VW7F2/)!*G'.5 M(. 1U(P =E17E?A_Q]J7Q%\<+/X0O7M?"VDV*RW[F!"UW<2IN6'+*2NS^(J> MN1W!KB?!GB_Q-XF\*VNJZM\,=+NOLNN0QPQ32^2A*3"X2*3Y&!49^8XQP&% 'L5%>!2>-O$N@ZGX=N+3X MI:5XV-_J,-K<:+;6-LLACD!W-F%BP*]CP,XSG[I]7^(OBX>!? .I^(!"L\MJ MBB&)CP\C,%7..V6!/L#0!TU%>86>E?%_3=0TJ_N?$>F:U%<3J-1TI[*.WCM( MVY8QS+\[[?NC(]"0>:T_!'B35M7^(_CO2]1NO.L])N;:.RB\M%\I7C8L,@ M MD@=2: .\HKY[U;XD>-S\,[V^TO5PNK?\)E)I%O*;:$XAVG;'@ICKCYL9]Z;X MU^,7B9?A1X2U+PS?"WU>^MY;C49E@C;:L&(Y,JZD+F1NP[>E 'T-17F?@_Q; MK>J_%.72+^]\VP7PY:WPA\I%_?/MW/D 'G)XSCVKF?%'Q$\4Z=H7Q1N+/5/+ MET&^LX=-;[/$?(2210XP5^;()^]GVH ]RHJ&SD:6PMY)#EWB5F..I(KQ36/B M;XFM/BA<7]M=K_PA.FZU!HEW#Y"3_&J\\; M>%O#]]XK\.>,?L-E:K"@TO\ LN&3:^3_%G&.U5KN]\=>&/&'@S2-4\ M;'5X]>N;A9G72H+*_#GC'[#96JPH-+_LN&3: M^3_%G&.U 'K%%>-:AJGQ"TG6M'\%6OBV#5-9UTM=-J]QI44(TZU0?-MC4E9' M)!QNXXQQG+_!GQ%TCPSXUUJ#Q%8^($E^Q:BEFMK+!-&H8HR)\NT@C M!Y.3Z"@#U"BO$O%#?$G2?B3X>\.VWQ'Q#XA>Z:-_[#MO]$6)=X7!R7X.,Y'3 M/-4_&WCGQUXO+*/EVX/ECRCGY2,#/U ![S M17GWC#Q;J%GXN\ 0Z)>A-.URZD%P!&C">+RU9>2"1USD$5Z#0 45XCXC\6>( M)_C!XAT)?B78^#=-T^&V>W6\L[602EXU+ &4J>#SU/7M67<_$_Q=;_!SQ9J$ M.MP7][HFKK96>O6]I&$O(S(H)"8*$X/51C!&"?O$ ^@J*\J\)W6JW'BFRCD^ M-^C^(T+,6TNVL;-9+D!22 8W+#&,\#H*RO&3?$?1?'^@:19_$7;;^([NX2(? MV';G[$B ,%YR9.&QDD=,T >U45YGX"UCQ,/B?XF\+^)->_MJ/2;2T>.;['%; M[GD7E$-XS\1Z!XH\.)9_%#2O'D>I:E'9W&EVEC;(Z1OG=+F%F(V]>< M#IU&:O\ A/XJ:O\ \+MUWPSXFF,FD37\MGI4YA51#,AR(2R@9W*>K9.0 .IH M ]HHKQ[PEXG^(7BCX<6]]I$T%[J3:G<0S2SPQ1A8D?Y1N! 3(!7(BD)R/N_> M'JNDR7LNDVTFJ1^7>-&#,GEA-K>FT/(!CV=A[T 7**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** . ^(GA;7+KQ!X?\8>$(X;O5 M]!>4&PN)?+6[AD7:Z!SPKXZ$\>*M2U-?&FD6GA[P_<6+6BZ:E MTES<.[##2"5. ,$C!]!QW/H%% 'C.B6WQ8\%>%O^$-TOPWI^KI;[H+#Q -02 M%(HF/RM) WSDIDYQZ #=C+0Q_!Z^TR]^'VE0PB^TO2K;48M6N@ZJ UQ&0<*Q M#$%F(& > ,U[910!\V:1\'O&=IX.LEO]/$^KKXHLIY1]IB^6QMH6C1L[L8&X M@+][&.*]#\)?#.U;Q5XQO_&7AC3;M;_5FGL);R"&X+0D=1G<5&>QQ]*]0HH M\FU_X;ZMXR^+;7]]=:IX?T/1].2WTJYTF\CAEDD;[Y7&XHN"5((&<#''7G;K MX7>*M&\/_$#POHT%WJ^F:PD%WIUW>7D)EEN-RF8.25.X]=Q !V=Z* /' M-9^&6H>&]2\->+OASHUK%K%A'';ZGID)B@2\A*XDP20@<<\YYX/. #M:5X6\ M1Q?$SX@:Q"ATR/6K.T33+UFBDVRI;[22F6^Z_8C!QQD5N:3\0;&\L]7"W("C.&,4F%&3A1W.!)'\2?"TMVMLNH3+*TT<)#V,Z!3 M(0(V8E %1RP"N2%;^$G!H \OM_!'C?Q#XP\,W6O>$=-T74-'U!;K4/$]I=0[ M]35",CRHP#\X ^\..>%!*G>L]'\<_#;Q'KH\*>'(/%6AZU?2:C''_:*6DUI* M^-ZL9!AE.,#&3A>2._>GQMX?&L7&F&^87-OYF\FWE\LM&H>1%EV['=5.2BL6 M&#D<'%>S^(?AB_LKN[M]1<06ELMW(TMI-%OA8D*\89 902I V;LG ZD @'F- M_P#"[Q9/X#NI[V*"^\3ZUKUOJE_#;2*D=O&AX12Y .T$]SUP-V,FUXA^%6L6 M_P =-&\2>&X/,T.XOUO]2A$B(MO.!AI I()W@Y.T$DYSVKU;0_$FE^(ENO[) MFDD:SE$-PDMO)"\3E0VTK(JD'##MQTZUS>C^/=2OGT6?4-#M;;3]:NI+2UD@ MU%IIE=5D8%XS"H"XB;)#-CCCJ0 6?B;X,N?&_A$6.F7<=GJ5I=17ME-+GRUF MC)QNP"<$$CH<<'!QBN*US3?B/\3].L_#/B?PO:^&M*:6.75+Y=1CN#.>Z3XB:!%IVGW&HWB1->Q&8?9XIIHXH]^S>[^6/+3<<;Y @ MZ^AK9URZU.RTUI]&LK2]F0Y>.[NVMU" $DAECD).0.,#J>>.0#@-'^&\5W\6 MO&>L>*O#>GWNFWWV3^S9;R&&<'9%MDVJ$++Q%XELK?3+;4HX)+*&SGEO9IO-76 ML*L7P?NH'X#'H":N3^//#EOI=IJ#W[R6]Y&\L7DVLLKA$XD9D52R*AX8L %/ M#8/% 'E:>!/'FIQZ1X2U;1=*M=,TG61J/_"0VA@A$T:L6 2WB52CG=@G ''/ MJ?=JY'2?B+I.HZ]=Z1<;[:XCU%K"W<)))%<$1"0'S0FQ&8%L(6R=O&6")HXR!(RR2*JL$) ;!.T]<8H Y[X.^$M4\)?#V[ MTO6+!;*ZDOKB58E=&RC8"G*$CH /;%>=>#/"'B;PSX5M=*U;X&Z1KUW"7+W] MSJ-CYDNYRPSN5CP"!U/2O=-!\3Z5XD28Z3-*S0;#)'<6TMO(H895MDBJVUAG M#8P<'!X-9$OB_4YI;^YT;0!?Z3IL[V]Q,+HBXE>,XE\B!8V\S:01@NI9E8 = M"0#B[SX>:_X[^)T^N^(9=7\*V5CIL%OIS:3J,2REV&Z8;EW8 8LO0;@%/08K M U'X6^+=,\#^/_!VCVMUJNGZC<6MYI-U;&TX73M/8Y[7XB^$!X\^'^HZ!YWV:6Y16AD;HDBL&7= MCMD8/7@G%2W7C_PS:0V,TNIAH;Z 7,,L,$DJ+"2%$DC(I$298#<^T=>>#AT_ MCOP_;W5_;R7!P: .1LM4^+VHWVE: M=<>'--T2*VF4ZCJTE\ES'=QKPPCB7YUW=1DYZ9*U7N-*\;>"/B5XBUOPOX:A M\3Z=XB\F5XQJ$=I):R1KMP2_W@W3'/2W'Q*TK[=I4%A%Y3D8(8 @?-R*N0>/M!*ZJD]];V\_[F*:2&/S_P#5;Y=@ M"!SD+YFPMZ9XH \Q_P"%7^*8/AIH]G+;07.L3>*H]_!OQ.)/B#Y%EY\5S";?0(C<1 /'+=">0 %ODVXQEL9SQFO:]/ M\<^'M5U@:78WLDET99H%W6LR(TD1(D02,H0LNTG:#G'/3FI?&'B1/"7A6\UJ M2UENQ; $0Q*Q+$D#JJL0.>N,4 >=S^&_&?A+QAIWBGPUH,.O^?H<&F7VG-?) M;20O& =X=LJ1QCC/?ZUD:E\.?&&K?"[QW+>:; GB'Q3?P7,6EPW*-Y$<"4K,3"DJ[FV!8F.Y@$ M8Y.P_2M73?%^B:OJKZ=I]X9;A0[+F"1$F"-M[)++O0 ACD("V[J,@CC'J.K>,K^#Q)?:-H>D6^H7&G6:WD\, MU_Y$TR-GB",1MYA&W&6*+N91GKB+5_B"NFZWI%@FFLQU&*"4QW$I@N-LLHC MCA*'S&3.Z125V+SSTH YSQIX=\6>+/V=4T6;3&;Q+)!;)/;-<199XY4W-OW; M.0I;KWQUXK5\8>&=7U3Q]X U*PM/-M-'GN'OI/-1?)#1JJ\$@MD@_=!K3U'Q M5K::_JVGZ-HNG7,6E01333WFJ/;%MZLV H@<U;XR":PMPWA+6+BTOM8/FH M!YD <;-A.XAN,D \OUX-7?B)X5UZZ^,-IXCLO =IXQTN/119M;W=U;Q(LOG. MV<2YY (YV_Q=>M=GJ_Q!MM/\6Z'HMI;)=QZK;R7+W7G%!;H(9)8CM"DL'\F0 M=L;>_2HM3^)VDZ=HEM=)_I=Y/;VL_D6ZRF)%G90FZ8QX3.25#A6;'0$T /\ MAXM_#:7T-]\/K+P3&'5XX;.Z@E6Y)!#,1$H (PHYZY]JK_&;PYJOBSX5:IH^ M@6OVN_G>$QP^8J;MLJ,>6( X!/6MZ3QGH$6JSZ?-?^7+ '\R1X9%@!1-[KYQ M7RRRKEBH;< "2.#5,?$?PO\ 9)KB6^GMTA:%76YL+B&0><2(B$= Q5B" P&. M#S0!@^.O"GB(^(O#_C+P;%;W>JZ-$\$^FW,OEK=P.,,JOT5QS@GCG/;!J:7H M?B_QG\1M)\3>-=&@\.V&@)+]BTU+Q+J2::10K2,Z<;0,8'!ROH37H6CZW8:] M8F[TR5Y(UD:)UEA>*2-U."KQN R'V8 X(/0BN7F^)MDE_P")88;&6>#0H(G6 M9''^F2O))%Y: C Q)&4W$_>W=,9(!!XN\-ZOJ7Q<\#:W86?G:?I/VW[9*)47 MR_,B"I\I()R1C@''?%<=H7P7U/Q'!K^K>--9\0:%J.NWDSSZ?IVH1B%H#Q&D M@4,), D=<8.,#G/>/X[O(!+I]SI$*:^NH16$=FEZ6@D:2,RJ_G>6&";%W"O!_:$$0F@P!$P\ MGC\4^"O^$=A2,-%-_:L5WYK9^[M0 CCG)I8_B)X>%S!:75U)#>.+<2QBVE=+ M=IPIB5Y0FQ=Q8 %B 3D#D$!+_P"(&EVWB2PT6S#W=Q<:B;&>3RY$B@(A>5B) M"FQV78%*JV5+&KR*>6"_D,<"I(SM:3*K1N^Q94)0!XL]9%R@')('-;=EJ-KJ#7( MLY#)]EG:WE;80 Z@%@"1AL9P2,@$$=00 #S'PO;ZO:^)[&4_ [1_#Z^9M?4[ M;4+(R6RD$,P"(&/!(P#R#6WXW\-ZMJ_Q'\":IIUKYUGI-S44 >6:UH_C'PK\5]1\5^$O#\'B6SUNSBAN;7[:* /)];^'=YX2^(NE>,?AEHUOL=?L6KZ1;>5;I+ >?,0,54," 2 1DJO M^UFDWPJU+6K'Q];ZE!]AN+_6CJ6B7@D1F611E)!M)*Y/RG.#AC7LM% 'GWP4 M\-ZWX5^',>G>)[7[+J!NYII(_,1^&;(.4)'->@T44 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;XB MMM2O/#6H6NAS10:A/;O%;S3$A8F88WG )XSGIU%:5>>_$7QYJ/A-[I],ELW% MC8"\EMFTZZNI)/F889XL);J0AP[ELG=P O(!4USX4O#I#V7@^X:);C1KC2)T MU+4;B5/+:,"(H&W[-CJ.%VC:[=< 5>U+P)J=Y-KCQ3V@&H+I0BW.WR_99=\F M[Y>X^[C.3UQ3(_&GB ^))=ZZ;_9,7B'^Q3"(9//8-$&$OF;]HPS*"NPY /(J MOX>\1Z]K_BKPKJ5Y<01:9JUC?7$%E;JZ%%!BV"7+D2,%/W@JX)88YS0 Z7P! MK4LBZ9YU@-'M-1O=3MKCS7-Q+)/',!$Z;-JJK7$GSAF)"K\H).*NL>![^T\- M6DD\T;-IFA65H%MX9IR]S;SQ2K\D<;.8RT8!(4L 2=O%3^,%U,Z[J]X)-6O+ M"VM0(I=!U01R:3*B!R9K8R1K,6#AP#O) "[ #ELWQ-XGNU\0:3?QZM,NAV<5 MI]NUF.22WMK65F64^9"#^\$T15 '!6,R*(9_!?@"TN==O;.75?*AM#<3R"&"6Z8!2[,?8YKUI;J,H1#3'B'6=5\,ZA?W6KWD M5SX?\,+J5K)#.T0N+@27 \R55(64$6R#:P*_,W'- '7WG@/4)? /A+38YHWU M+P[';ADCOI[2.X*VY@<">(>8G#E@P4YQ@C#&H]-\&:]X=DM-0T*+26OS:W,% MQ;W%Y:XDDE(.0V[;O)R"GW:;\3[[5TT[PQ+HMS M7SOW;*0([73GAC607$OW"[%]V"I+;?+VG(YW=JUM7UU?$>IZ#I5C-JF MGV.H74RW3M;7%A/((H3((U9U1U!."63!PA /6@"QX*\+WVCW][J.KP6\5U<0 M109CU6\U!V5"S.26;/$::%XITC^U-.\/2Z;'8ZA=S74=_/*_ MVBQ:9R\F(?+9)2&9F7+J.0""!S#J5]+X/LI;'3/$$=P\M\B0PZA'<:EF)I-O.VG7UW-)=VDP#-;71@ $ M9=60/@$AB2F3G=C% &O+X*UDZT\"3V;:--K<6M/-3OW M#"DC;P#63%X;\2>';CP):Z?9VNH7.FI?K<,TLD=N X!&91&Q0\\90Y(([Y&Y MXD\037_PYT36]/>>Q.HWFE2[4D*LJ37,.Y"1C(*L5([@FH_B1J^HZ<8(=(G6 MVGDTS49EG8R'88XE8$(KJI/)P6!VG!'<$ QW^&FNV6BW6G:7=Z=/_;.C?V5J M4]RTD?V"]>M-(UVWTF\A5]0UN.^15O);8 MRVRQ0(T331KOB8^4W* \8'I?8KJ[A "DQ2!E M/R%U8KO0'@%AG! .?T_X>Z]816I\RQDDCU*\N'62]GD*Q7$&S_6.K.[HQ/WO MO 9RN=H2'X=:];:0='AN-.:TU"TTZ*_G>63S+=[9$1_*3;B0,L:XR4VG)(;. M*FT3Q#J>VUT'2+R47MQJ%W'NUV SR:='"JOY+[)?W[?O$VOYG*L"2Q',%_XY MUG2-6N[":WABU*>]M;0R0PW5_%"QM#-(RP(=[CY& "!/O!FZ&@#4TKP1J=A< MZ-+)-:,+#7=1U*0*[?-'<+'G+GL,'!/&=;7K"_P#%_P -9K5((['4 M-1LD;R)W;;#(0&V,VW=P>,[<^W:N5'COQ=>_9K6TM+'3KP:5>WT[:CI]PHD- MO,L:E(F='1) P8!N5![XYVM(\4Z[XEO]^BQ:?!:VL-G+RCDNO$T&LE$E=@D:10JR9*#+9C;' !&. MG01>#_A]>>'M:LWN_)FMM-29+:Y;5+R>20.<+B!V\J#"\-MWY/3;5#2OB/XE MU>*2YTW0WOH[FSN9[2!=,NH! Z.Z;<'@9!S77>$=9NM;L[Y=0N MK>XDMYO+W0V%Q82*"BMAX)B70\\'<01@C% &7XQ\*ZGX@FNH7TS0-;M)HBMH MVK9233'9-K-'MB1@01NQC;CZW\.O$5W.#I^I6KWRPVZ6OB*XE<7M@ M8XPD@1 K"19,,Q!=>96)SA35S1]*M=.\=>(WDOM35-&75-.BMDD00%I8HQ%,Q9MX!N8B7 M4+]U_EZ4 ;%A\/+.^UR\U3QCHVC:G)/:6D,:SQ_:S$T:,),/*F2"2,'J<9.# M6YXJT2?7;/3X;9HE-MJ=K=R>:2 4BE5V P#R0#CM[BN.U/Q+K\?B'3=)NY(9 MKZRUV.-VL-]M%>Q26%Q(J,C.VWYUY!9A\JM[#H/!/B+5-9DNK?7)+474,,,K M6ZZ?<64T)?>"K1S%MZ I@2HVUB&&!MR0#G=.^&6K64UF\M[9R_8[V<0$%QLL MA9RV]M$!M^\IDR>W+8)Z4Q?AWXCL]$.E6,NER17MKIJ7DL\T@:"2U1%;RU"$ M.KB-<$E"IR<-G L7OQ#U.U\8)9126-U9S7ES:*D6G70$1BAD?)NVQ%(VZ(AH MU&5R1D[2:J6WQ(\1V_A^*_U2#2[B74-"M]3LDMH9(UADED2,)(2[%U!E0Y&W M@,/0T ;B>'/%>GVNKZ7HEUI=M:W<]]=V^HR-(]Q'+<%W51%M"KLDD^_N;*KC M9D\'#$@ *,\?Q'N? M!\^L-XJ\46NNWT5W);S6PC-NKQQ*#"#\L;.^S)ZC<M2ZK M-';WVM7CW4JV,I9;;,21*$=E&XA8U;<5')/&!7*CX3WUN^KP6WB">:TN-*M; M.R%TD)*2P2O(I<1Q)E02N"#D[GW9^4BI%\4M>FT74-7ATSS+4:7>WMONTF[B M2T>%"T2R3OB.8.!SLVX/ SG-:MQXR\1Z:ILKT:9/J=_:6LVE-%;R)&TDLWE. MCJ9"6$>^)B05R">E $TW@[7+N[DU^<:?'K0U2"^ALTN7:W"10M!Y;3>6&R5D MD;=Y?!*C!QDZ5EX6O8?A_J^DS2P'4M6%[-*58^3'-<%VV@XR44N%SC) S@9Q M6'I7BG7M3U";1="^PV][]KU69I[]9KB,QP7?DH@'F!@6+ D@[4"X5,$!7_\ M"?ZW)XQ-C!IC26D&I1:?<6\.F74S#,XI)/ >MOJ$-B);#^Q8=:N=5%P9G M^TL)XY@T>S9M!5YVPV_D < YSI^$_$NLZGKMS8Z\+:VE6)Y19?89[>6#;)MP M)')CN4P1F2,@ [>/G&,.X\3:[8>)=4LM,N('DO?%<6FQF_5YH[:)M.64E$#K M_$N=N0#ENA.0 +H'P^US1X64BP^T1:<-+AO)=3O+MFB=T\R0139CB^6-6$0# M M@;U4<]5H5A=^%[>RT*WM4GTY)GBMYU=M\4.PN#(-F"=WR9W9;(8DDD5RL' MC;Q'K=I'IUC_ &=:ZBEMJ,MY/.)M^&A$:[B5(5OGW9P0,## CJ: "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ KG]<\#>'O$=U/<:Q923O:WJ* ,+5O!FAZW=RW-_;S[YXQ%< M+!>30)#-"GTJ+3C:21P07$MU"T%U+%)%+*SM(RRJP==QD?(!QAB.G%)= M^"/#UZEBDVG!8[")8((H97B0Q*01&ZHP$B J/D<,O7CDUO44 5+S2K/4+JQN M;R'S)=/F,]LVXCRW*,A. >?E=A@Y'/KBL1/AWX5BTB+2XM)2.RAMKFTCA2:1 M0L5PP:9>&S\Q4<]1CC%=-10!@7'@?P_>PCM3:W \NY-VMRM_.MSYQ4H7-P'\TG8=O+?=P.@ K*D^%.@/K%O M/&DL&G06EQ;BPMYYH@3-,)7.]9 =A.X&/[IW=.,5V]% &;JOA_3-:T4:5?VY M^Q*T;)'!*\!C,;!D*M&59=I52,$=*HKX(T/R]D\=[=_NYH@UYJ5S<,$E4)(H M:21B 0!T/'48)KH** ,"Y\$>'[N[AN)[%BT21)L6XE6.58CF,2QA@LNT\C>& MQ5[6-!T_78X5U&*0M Y>&:WN)()8B1@E9(V5UR"0<'D'!K1HH P#X(T'^S8; M)+6:)(9GG2>&\FCN/,?.]S.KB0LV3N)8D]\TS_A O#2V+VD.F"WB9H7'V:>2 M%HFB79&T;(P:,A1C*D$@D'.3GHJ* ,.U\&:!9&,VUAL:.TFLPWG.2T4KAY Q M+99F90QDFM7:P;%K'#&D8N91'(L/,7F1AMLI0@%2X8@CBN M@HH YQ? /AH27#'3BZW$XE:.)93F3RHRVV+<>24"DFM/1]"L-"AE33T MFS._F2RW%S)<2R-@ ;I)&9C@ G@=*T** *D&F6=MJ=WJ$$.VZO%C6>3<3O M" A>"<#&X]*Q[3X?^&+*WO;>'2U:&]MS:RQ3322JL))/E1AV(B3))VIM'3C@ M8Z.B@#GX/ WAZ"*-#8-/LNC>&2ZN)9Y))?*:+<[NQ:3]V[+AB1CMP*M:'X8T MKP[YATR*??(B1M)=]HDN5'VN;9')(&$C(F_:FX.V[: &SDY(%3_P#"%^'_ +#'9MIJ/;1: M;_92Q.[L/LO'[OD\_='S'YN.M;M% &5HGAK2_#QN6TN*99+MP]Q+/=2W$DK M8!9Y&9B0..3T '855@\$:!;:E'>Q6DNZ&8W$,#7@/6M2B@#G;OP'X=O(#%+92H#-<3 M%X+N:%V,[EYE+HX8H[')3.W@<<#$G_"$^'AJ\6I)IPCFA9'6*.:1(-Z+M1S M&$;,J@!6*DC:N"-HQO44 8VC^$M&T&[>YTNVECD:,Q+YES+*L,9.2D2NQ$29 M ^5 H^5>.!A7\*:*^H?;FL\W'V]=1W^:_P#Q\+#Y(?&93%=2QMF=B\REE8$H['+(3M.!QP,#^ O#P6 MUAAMUC6YE5)8X?\ 5+*@;;,%[>8&QD^M=%10!FVOA[3+*2VDMK=DDM6E>.3S MG+$RG,FYB*^,]2N=(^/6D7U[J]U<::?*MEMM+O0)-/9GB&)H",.DK2)GJ MY7D?<6@#VJBO )?&WB;5-<\9![C4-*FO-#3^S;*\26Q33R\K1*S/*$59",-O MR,L=JEBHK0FU>>?4H/"\DVJZ4EI/J OY(M>N;@R316B21[+IRK[<2;BF%&5Z M$9R >WT5A>#-0OM5\ :'J.I#-]=:=#--N&S,C1@G([9)K1T^\FNC4PCD+J?D5P02H[..U %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH *R[GPUHMYX@MM=NM+M9=5M(S'!>/ M$#)&I[ _GCTRV,9.=2B@"G<:/IEW+<27>G6D\EU!]FG>6!6,L7/[MB1\R\GY M3QR:IOX1\-R:.FDOX?TIM-CD\U+(V49A5^?F";=H/)YQW-;%% %4!1@#@ M=JSM,_Y"&K_]?B_^B(JT:SM,_P"0AJ__ %^+_P"B(J -&BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HK U+Q9%9:I+I]EI>I:O(M#^->C1ZEJDVE^&KI5BM6BMEF@ MGA+.JJ_"KE3R-^0#UBBO!Y?C3?ZCJGB>72-3L5L180?V/"K1O(C/ M<>2TSCKOYW^6> I3(!)K7E\6^)9=:F\*Q:Y/%-:WU^AU46\!GECAMHYD5E,? ME_>G )"@D(.A)- 'L-9VF?\ (0U?_K\7_P!$157\):U+K_@C1]:NHQ'+?6$5 MS(D8) 9D#$ =>IJ319TN;G598Q(%:\&!)&R-_J(ARK $?E0!JT444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 57OK^UTRQEO=0N([:VA7=)+*VU5 M'N:F:1%D5&=0[YVJ3RV.N!WKS:>UU+QQXEN/LNH+)965PR1WD29M[0JV/W0; MB:Y]7(V1'@ L#D \]\476A7WQ7$I+,S,6>1S]YW8\LQ/)8\FKU !1110 4444 %%%% !7 M-:A\/O#FI^+X/$MW9,VH0@9Q*PCE92I1W0':S+M&"1V'7:N.EHH QM0\):'J MUW?7.HV"W$NH68L;DL[8>$,6"XS@$%B0PP<]^!5*;X>>&;C2H]/EL9S%'-). M)1?3B"*UMHK>VC6*&) D<:#"HH& M.P JEIG_ "$-7_Z_%_\ 1$5:-9VF?\A#5_\ K\7_ -$14 :-%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 51UJ_N--T>>[L[3[9-&!MB,JQ+UQN9VX51 MU)Y( . >E8WBGQ9_9/FV6G^5]L2'SKBYN,K;V$1R!+*W>5@ QN&?E !G:%HE[XQU"75= M1GD:QE78]\ 8WO$[Q6PZPVWJ_#R]\=Z]IGQJTOPXWV#3M' MND587OT=1J#DKO$9:SX^\2^&W\2IJ\&DR26.E MR7UBD"2KB3S"D49WL#<##1;GC"!6.WJ137^(&LRQ66GZ5J.E7>K7$EVTTLVD M7-LEJL$*N8GMY)1('9G7#$@;3G:>X!Z?6=IG_(0U?_K\7_T1%3/#FMIX@\)Z M9KGE_9TOK..Z*,W^K#(&P3[9ZTFBW$-U#;)&P93^XB'!'O0!J MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 444$X&30 5QOB#QN+6:2+2GC%O9S*E]? MR(71&S_Q[Q(O,L[=-J_=SSSA3+-X^TQH;B2.VN+BS9_LUG)$ 6U*8YS' ND/\4AY/(&!U ':; MI5]K]Y#K'BJ#R$B;S+#2"0RVQ[22XX>7\U3MD_-74444 %%%% !1110 4444 M %%%% !1110 5Q^N_#FS\0>,K+7+_5-0:"U*N=-,NZ!I%9&1AD93F-2P4@,5 M7/\ %N["B@#CE^'%I]HN+B;7M>GN7MI+6UN9+T>=8QO()"(I H8G6%**HP$&-H(.--L5I%_P \8%_A08&3U;&3V Z"BB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHK@=0^(]W!\8+;P78Z1'/'Y"R7$LMTL4K;L M'?$C<.J+DMSN.&P/E^8 [ZBO/[SXF7FE2:XFL>'&@.FVZSQ"&]68L7F\J&*8 MJNV%WRC@ OA6))XP62_$Z\5CIL&A02Z_%=W-O/9F_98%6"%96=9O*RV5DC & MP:9IG_(0U?_K\7_T1%0!HT444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8FN:W=6MPFF:)8M> MZK-'O0."L$"YQOE?L,@X498XX&,D &GJ%S+9Z?-<6]I+>RQKE+>$J&D/8 L0 M!]2:X-#J6I>(6V26][XDA!5Y "]EH*..5 X\R8K]"<\[$.#/I4VJ:PEQI>CZ MO=7,'G$ZEX@? !? #0VB_= &,;AE4Y^^^XCL=)TBQT/38['2[=;>WCR0HR2Q M)R68GEF)Y).23R: *V@>'K3P_9R1VS23W%P_FW5Y.VZ:YD[N[?H , # &* MU:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@?%?PZO?%7CS1]7N M]8C_ ++TV1;B*U:U7SH)5>-_W4HP0',2[MV2.0/O?+WU% 'GFI_#&]\02W(&=)E:7#;92K11C 5 0#QDY"3?#"\:0ZE!KT,6O2W5 MU//=FP+0.)XEB95A\W*X6./!WGE3G(.*]$HH H:-H]KH?AZQT:T!:ULK9+:, M2 />M6L[3/^0AJ_\ U^+_ M .B(J -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "D9@JEF( R23TJEK&M6&A6!O-3G$4>X(@ +/(YZ( MBCEF/8 $UAGQ3-9V+WGB:R6QBO6$6G:6H\V\N#@Y5E!P6(Q\HR% )9NNT BN M?%$^K%YM#N(;'0[1M]YKMQM\ME4_,D(/#=P9#\H[;CT4KJ'C=P6\[3O#+#[N M#'<:D/?H8HCZ<.P_NC[S['P[=ZS+#>>+8H4@MV5K+182&@M=OW6D(XDD&./X M5_A!(W'JZ ([>WAM+>.WM8HX88E"1QQJ%5%'0 #@"I*** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH ***X^]^(MG:_$:'PC!IFH7L_EJUUKI=C;27_AS68KV[>7R-._T9IWCCC\QY>)B M@4#C!8-G V\B@#K:SM,_Y"&K_P#7XO\ Z(BJQIVH6VK:7:ZCI\HFM;N%9H9! M_$C#(/Y&J^F?\A#5_P#K\7_T1%0!HT444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%4-'0=&GU&YCDE6+:JQ1 %Y79@ MB(N<#+,RJ,D#)YKFY?'T^D:Q:Z9XHT?[)=7Z,UC#I]S]M>9EY*% BLK8YS@I MP;47TKPQ:C5+^-ML\A;;;6GKYD@!^;_IFN6/? YI?[>DM= M%N+[QG;VVC6LK".*W:?SI6#9&UMHP7/9$W>Q-9UGINI:Y8QV5O:R>%?#B+L2 MU@Q%>3KVY7B!#Z#YSZH>* )]6U>WO-?6W\.:=;:MKMGNB:YD'[G30V"WF2=F M( _=K\QXS@_OKF34]7F&V6^G4!@O79&HXC3_ &1UZDL>:TM/ MTZSTFQCLM-MH[6VB&$BB7 '_ -?U/4U9H **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "O,O%W@37M=^*VB:Y8+IUG:V!$G]IP,\5 MVH#1EX9 .)E95=5R0 )'R.F[TVB@#R:/X>>*=1N/$M]XHMM#U'4]7@,$,TFH M7#0Q6ZR!TM1$L2%8SCYF#DD\E6Y!2'X9:_I\XU328]&MK@7-V8M&2XD2SM8I MX$C(C<19R&C#D"-0=S#CJ?6J* ,OPYHB^'_">F:(LS3+86<=KYOW2^Q N>.F M<4FBP);7.JQ1F0JMX,&21G;_ %$1Y9B2?SK5K.TS_D(:O_U^+_Z(BH T:*** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJCJFMZ7H=M]H MUG4;6QB)P'N)E0$^@R>3[4S2=;M=;BEEL([GR8R LL]N\2R^Z;@-P]QQ0!HU M3U74HM)T][N>&ZG5< 1VMN\TC$\ !5!/7OT'+(=*MI#M2R MTQ_L^_G[OFG,KM_N;/I4]GJFJW-G#9^#]$>VLHE"1W^M&2-0HZ%8C^]D_P"! M[,^IH P_'MUX@U/PJ);P1>&M*.H6".\KI)=@->0KYFZ^'MC MKD!_X3"]O-VC@92&!B2)EVG('S$EO]K!Q5VT\$Z/9ZG:WZMJD]Q9 MNTD'VS6+NY2-BC(6"22LN=KL,X[F@!^E>%;:QOAJ>HW$VK:MM*_;;O&8P>JQ M(/EC7V49/7I74KE5("QLT<;,0(T=P,*SD M_*#UXZ;ER =+17,P_$7PM/\ ;RFJ;4L(99YI)+>5$:.-]CO&Q4"50XVYC+SB%YY+<1"QG,ZR1J6=6A">8NU5+'*@ 8/0B@#I:SM,_ MY"&K_P#7XO\ Z(BJ[;SQ75M%<6TBRPRH'CD0Y5U(R"#W!%4M,_Y"&K_]?B_^ MB(J -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBLC5/%F@:+=?9M4UBSM[G (MVF!E( M/0A!\Q_*@#7HK,T?7K37/--C#?(D6/GNK&:W#YS]WS%7=TZCBL75?$NMV,TH M>PT73+=68+M]0O7W 2^'K M.6Z$>1QM"B7+#U(P?3M63]E^WCY])\;:Z3U>\O18Q'W:/S(ACVV'Z4 >@:AJ M5CI-FUWJEY;V5LF TUQ*(T&>G)XK&A\;:9>W,4.E0:CJ0D<+YUK8RF$9[^:0 M$Q]&-5X7\6R6L5K9Z)HVFVT:JD?VJ^DN&4#H/+6,#C _CJ7^PO$EW_R$O%KP M ]4TJPC@'TS+YI_(@T :>KMKF84T&+3SNSYLU[(_[OIC:BK\_?.67H.N>.<3 M7K71]6#>(O'$%Y=*I']EV," $GOY2^9,2/\ >Q[5H?\ "!:+/SJIOM6)ZC4; M^:9#_P!LBWE_DM;=AIEAI5N(-+LK:RA'2.WB6-?R4 4 L44 M>*:CX5\8^+[CQ%J6OZ'=VVIR0+#I$#7%M]EAMX[B.;R\K*S&:0QC+E0 1C(& M +4OA+Q-%KDOBJ+0IY9;J^OW.E"X@$\236T<,;,QD\L_- "0') <8R017L-% M &-X2T:;0/!&CZ+<2AI[&PBMGDC'!94"DC/N.]2:+$\-SJJ23R3L+P9DD"AF M_<1==H _2M6L[3/^0AJ__7XO_HB*@#1HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBJ-MK>E7NHRZ?9ZE9W%Y"NZ6W MBG5I(QTRR@Y'4=?6@"]17'>(?'4NC7LEK]AM+0JVU)]5U&.!)O>-$WR/]-HS M4>F^*M..Y .QN+F"TMWGN MYHX(4&6DE<*JCW)Z5Y?X@\3^--8UC5SX&:TGT[26AA1;2Z0SW4DD,) !@K]UCN]+T'P[U"]F6?4O[+M7!R'E635KE3_ +,UR=J_A'BLS4?@I&"=_5]9U'Q!Y*>'K+Q/%"N=[PP0V M2RYQC%XO"'AM-,C-J[>?/,[VMK]GC_>3/(%5-S850^T M L>%%;] ' :;X:\2V]ZMY#;V-K&]>N)&> M_P#%L\3/]\:980P!O;,@E;_Q[/O73T4 P='=7/\))8*#ZY(QWH UZ9-/%;PM+<2I%&O+.[!0/ MQ-4%_MBXOXI";:TL&@!DA9"]P)"#QN#;%VG'9\\].M01>%].-G#!JH?6FAF\ M])M3VSLLF,;AD87CLH Y- '/^*=4O]?U[_A%/"=_+9:A9Q&_O+M8W"1;?]1$ M6X!WR8) )RD+-?VL9L8A-=AY ME'V>,@D._/RJ0K')P/E/I6>/&GA8Z2=4'B72#IXF\@W?V^+RA+C=LW[L;L01WK.TS_D(:O_ -?B_P#HB*@# M1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KWM_9Z=;M<:A=06 MD*]9)Y BC\3Q0!8HK,TGQ'I.NO*-'O%O%B +2PJQB.?[LF-K=.@)QQZUS.N^ M.+VPU&2R0Z+IK!RJ?;;PW%Q( ?O+:P@LP(Y^^#ZB@#N:HZIK>EZ';?:-9U&U ML8BK:NVGZ0+ZSM&OU;! M&R:.)54C.]GD8 +],GD<&N.MO'NI:A?Q_9/L-W"C_O+;18)M19QW7[1^[AC/ MUS70P^!- $RSW]J^K7*G(FU29KHJ?51(2J?\! KH5540*BA548 P * .$U? M1-<\87$*';YTJ1[V"+O8#] #Z*QCKTE]:WA\/V,EY<6TGE M7*O:Q.V2&P[)\P&.2H(],U,MCJ,^H17-WJ+10" +)I\"*8VD(.XF0KO(&>,; M>G.>E $VIZQ8Z/'$^H3^5YSB.)%1G>1O154$L?H*@DN=7N;J]M;6R6RCCCQ; MWURRRK(^!R(E8':,GJRG(Z8YJ;2=&T_0[,VNE6JV\3.9'P26D<]69CDLQP,D MDDU>H R$\/K.=/GUB[N+Z\LAD2"1H8W?(.XQ(VPXQQD''K6JD:1+MC147T48 M%.HH **** "BBB@ HHHH **** "BBB@ KQ;QCIUQ;_'S2+W0](N[F[NC$;R. M]L5FL[B)'B'FQ2#_ %3Q#,@ 'A3#=/XBFO[34M5LM7U31+&74+6SD?2 MF6ZD26U41L]M'&I WB5 WEKP1G@Y/ME% &%X,T^^TKP!H>G:D<7UKIT,,VX[ M\2+& M6L[3/^0AJ_\ U^+_ M .B(J -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH ***:\B1KF1U0>K'% #J*BDNK>&U:YFGCC@49:5G 4#U)Z5D3>-_"EO MGS_$^C18Z[]0B'\VH W**HZEK6G:19)=ZE=QP6[D*DC'(8D9 &.O K-MO'&@ MWEU%;VES/-)*X1/+LIV7).!E@F /?.P6EJT MO(QP2. >1P3S6;9>/+"[OKB"XM+K3X[6-I+FXO9((T@4=W'F%EYXR5Q0!U%% M<=J7CT13V?\ 8L>EZA:WYVV=X^KHD5PP.U@I17)PQP3CK5G2?%5S+<:G'K<% MK U@H9XM/:XNF7!YR3"F[MPH/>@#J*J:IJ=IHVESZAJ,OE6UNNYV"ECZ #D MDG ')) %<9JFOZA$MO>7/B633].OI66!H?#DR/"H;'[UI2P4\_>9%!P2!BN M-\?>/M(;X;:SIMEXHU'4;NVN[5_[6%O%*$*W41)0PJJ?+M)&<9/&>E 'J%AX MO@NM1CL=1TW4-&GGC:2W_M"-%6=5Y;:R.P! .=K$-C)QP<:EYJME8Z8=0GFS M:@ B2)&EW9.!@*"3DGM7R]X3R9BN MYY5W)M0*VW!#%&(YPH]RCN/'\RW5M!H^GZ%;VJ8MU@"70GQT6-C+&$^KQ@>U M &PGC#[6RC2?#^N7JL1^\:S^RJ!Z_P"D&,X^@/MFG>*]<;1X(?+UO1=)+$[Y M=58GCML0.FXY]ZQ/^$?UF\BL7UJ37-1-PQ%U VJ1VB6PW =+<+O&.<;CTP:T MM+T)=%N+]M'\(Z3:.@)M[A;@"2Z/^VWEEEX[DM0!CZ?K=_)J$=W;7WB/Q&RY MQ;VNF16=DQ(QG?,JE@.O$C?CTJY/H&MZYJJZGBP>3H^G6MA$>J6T*Q@_7 YJJ9O$9AL2++2Q(S'[:OVR0A%SQY9\KYCC M)Y"X/'/6G%O$'FWP$6FA #]B8RR$DY_Y:#;QQZ$T :M%9)_X2+R[' TP/N/V MT9D(VY'^K]\9Z]Z4CQ!YM]AM-\O!^Q?+)D'/'F<\\>E &K163CQ%Y5C\VE^9 MN/VWY9,%=W'E\]<9Z]Z4CQ!YM]AM-\O!^Q?+)D'/'F<\\>E &K163CQ%Y5C\ MVE^9N/VWY9,%=W'E\]<9Z]Z4_P#"0>;?8.FF/!^Q<29SGCS/P]* -6BLC/B, M1V/R:6S[C]M&Z0#;N_Y9\'G&>O>G[]?$M]^XTTQA3]B/G2 L>WF?+P/IF@#4 MHK(\WQ'Y-B?L>EF1F/VT?:Y $7=QY9\OYCC)YV\\>],=;OO#5JMI M:V^FQ"]2YAO'!:8[OLRR'RL(58>;@;^43/#<@'H]%IQ[T :M%9 UB^6.Q,WA[4 ]TQ698Y(&%KSC+GS!D'KE-W YP>*=_PD$:R M7RS:?J<8L@2S_8W<2@'&8]@)?UP!GVH U:*R?^$GTI5L&FEGM_[0;;;K?7% &C138Y$ MFC62%UD1AE64Y!'L:=0 4444 %%%% !1110 4444 %%%4;#6M.U2\O[6PNDF MGT^8072*#^[Z!:7.MQ3RF-&L@@7@9+;I&5=ON"<]LU;CT/3X]574S;+ M)J"Q"(74GS.%QT!/3/?&,UH4 94EMK-W=7T4UY!:6$D9CMFM$)N4) ^7H$TZ;CDD.W(Y].F.*U** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ***C:XA2X2!Y46:169(RP#,%QN M('4@;AGTR/6@"2BBB@ K.TS_ )"&K_\ 7XO_ *(BK1K.TS_D(:O_ -?B_P#H MB*@#1HHHH ***@NKZTL8]][=0VZ?WII @_,T 3T52N=8T^TTG^TYKI#9;583 M1YD5@> 1MSG.1TK"/Q%T1K@P6\6J32*N]_\ B63QJBCJQ:1%&!U)SQ0!U5%< MOK7CK3M/TJWO]+DM=5AN)C DD%]$(]X&=N[)R?9034%AXIURXU][&_T:UM([ M>,RS^5-6]O>^'Q>P6LC>4ULVC9 MN0PR=Y\V6,*F,?PDY[\X$^F1^(;+6;U;V;5=3AC@/DO.+.*WEDX("",>:#U7 M+<=>#P: .IHKB;_PU?:M&M]/I3-=S2GSK.X\2W:01IV*K&I0D_W=H ]36KIF M@W.B7%]#HMOI5A8RH3"5BD>1I< !I/F&X#G@')&.10!)=>.?"EE)Y=SXDTJ. M7IY7VR,N?^ @Y/Y5>CUFRN-%;5;1Y+JU",ZFWA>1G R#M0#<3QT YK.@T35X M=-@AAU.PLKA9"TLEAI@C21.RA&=L?7)^@J\VEW;ZA=3MK=]Y$\9CCM%2$) 2 M -ZMY>_=P3RQ'/3I0!F#QA+,,V/A;Q!=#U-LD'_HYT/Z5KW]SJ,>G)-I>G1W M%TVW-O<7(A"@]B:5.D MTD*V=O+<2SI';!,RM Q1%\P%7). Y)C49!4GMO#VK7EWX0LUM?%5C8-:PS7$ MPU",7%RMIO)@>3,JE,0["Q8$DGD@YSS-]!JMKX_U6'P[\,++Q%I6C^796FZ_ MM[>.VD>))Y65)%)WMYL>6'9%]ZZ;X8:A'9>"VDUV#3]#>.]NK>&V:[1W@BBE M:,1/)A0=A1D&,C8J2RU*[\;-JUG=,T4,5I91M%,PX/,:LPP3_> M JQJJQZGK%ZD>I^)K=[.'<\%G;/%"^.R2-%AV.>BN?TJW-X_\(0/L?Q1I!D_ MYYI>QLW_ 'R"33/^$_\ #[?\>\M]=^GV32[F?/\ WQ&: *^D^9I<$%W9:=XF MU)KUBDB7MVI:W .-S)+*H7/7Y03@=*@O/#$-_JVI22Z#=R?*TD,L^MS+%<2' MG:$5SY:G/]WC'2K_ /PF:R?\>GAWQ!<>G_$O,.?^_I2C_A(=?G_X]/!E]'Z& M]O;:,?\ CCR']* &Z9IFJ:3I-O!I>DZ79-+*SWD#WTLR@< %7,8+$J.<@ =. M>M9Z?#?2A=7I&@^%4A9"+-O[$5Y(W[,[%L.!Z +GUK2^T>-[C[NFZ#8CL7OI MK@_B!$@_6C^S?&,__'QXCTRV'I::2VX?\"DF8'_OD4 /B\.7::/8Z<-1M[>& MW)\^*STZ*.&==V0GEMO"#MP>,K&&!] MV+=:K_\ "*ZE-_Q_>,=;E'=(A;0K^&R(-_X]2?\ "!Z/)_Q_3:M?>HNM6N70 M_P# /,V_I0!)?:;HUA9V2ZQK5Y"MFQD26XU>6 R$G/[PAU#C(X#9 '&.M9#: M]X >YOI(+Z+5)+Y3'!] !6[9>#/#&FR>98^'M,@DSDR):) MO)]2V,G\ZVP J@*, < #M0!PRW.B26]I!IGP_P!0O8K(EK17TJ*W$!)R2GV@ MQETW3T_N6&G%W'_ Y)"#_P!\4?\ "%KH-\;93^%N(QCVK MI:* ,&T\#>%[*83PZ#8M./\ EO-")9?^^WRWZU=UO0--\1:)+I&KVYFL92A: M))'B.4<.N&0AAAE4\$=*T:* .8_X5[H#7EG=3_VMZKX:T>^NY<>9<7-A%)(^ ,LRDG 'T%;=% %+2M%TK0K5K70 M],L]-MW31[$O8,6M&^S)FW).3L./ER0#QUQ3/^$:TU3?& M$74#7_,[07LT9SG.5VL-AR>JXK6HH RO[#=#8>1J^IQ+9GE?.5_M SG$A=6+ M>F00<=Z/[+U-/MYCU^Y8W)S;^=;PL+3DG"[44L,''S$GCJ36K10!E"UU]&L0 MNJV+I'Q>>98-NGYZH1*!&<>H?GTI-OB)5OB9M,D8M_H0\J1 HS_RT.XY.,= M.?TUJ* ,KS/$"M8#[-ILBGB];[1(A7GK&-ASQDX)'IGO2>;XBVWV+/2P5/\ MH7^ER'S!G_EI^[^7C'3=S^=:U% &5O\ $!:QS#I@4_\ '[^]D)7G_EG\O/'K MBDV>(G2^'G:7"Q(^Q/Y,D@49.?,7,=".?6M:B@#E/%%SXDT?PT=3M;I;N MZM(X=R6SSUSFM)$2-<1JJC).%&.:=10 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !7A7CZU&UO"]PD[Q(TT:LJ2%064-C< >H!VC/K@>E M'AFL6.HZ9<_%2)M1O-2G:UTN2XG4S*JK]U!$7&!T&>_-9]V='\YA>_ M8?\ A O[5U/[#D)]AW_9$\O9CY?]9]IVXXW;MO.*^AZ* /)/'#2)^S';-XO2 M>1UMM,.I(QQ*W^D0>8"?[V,_C7D/A>%--^+WAZZ\(S^&'U&[DE:*)+QVA@9[ M9B4;9&,#][L7DDM'SC+$_6&H:;8ZO8266JV=O?6DN/,M[F)9(WP01E6!!P0# M]17-:-X%\)6VL7]Q;^%M%BFM;Y&MY(]/B5H2(8F!4AG/;!X.>*%SX6^)E]?S2W'BR"*UD)*6ULPC\K/8 M.L(8X[9)]\UZ710!YK:^"O&\'A_^R9O$JW2&9I'N+FYEDF<$8,9; ^3V&/K5 M>V^%#VFL2ZI;Z7X7BNI8_*;%M<%,8 R$\T*#QU S7J5% ' ?\(-JKZ5'IL\' MA:XLXI#*D-UIT\X5\8S\\Q[5HIH7BA+Z2]2?PLEU*NR2<:/+YCKTP6\_)' K MKJ* .92Q\:HNV/5_#T:^BZ/-C_TIIWV+QN?^8]X?'_<$G/\ [=UTE% '-_V? MXU/WO$>B#_\4:>/]S1R/YS&NDHH YO\ L;Q2?O>+(A_N M:6@_FQH_L'Q(?O>,9Q_N:? /Y@UTE% '-_\ ".:ZWW_&VJ+_ -2T\+Z%J]E>723P-J6K3I)&H M@BC*,I@D!^:-FSN/##TK;\'> -+T71 FI>']$COWNKF=OLL"R+&LD\DB(':- M20J,J]!]W@8KLJ* &0P16Z;((DB7^ZB@#]*?110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 5G:9_P A#5_^OQ?_ $1%6C6=IG_(0U?_ *_%_P#1$5 &C1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% 'A>F>,/&]I?>.=.U.]O)/$L5O++I^E)8K+&&(C$;VTBY!5!(A:-@ M3\P8\A\ZLGB[5[FZM?#MCKNLVFHK+>M?SZA;61N8&AMT=(@(T,)1C(K9&YNH MW#MUMI\*/!UFVJ;-*WQZF"LD4DSE(5.TE8AG]T-R*WRX((7! 50+4OPY\,3Z M?]CEL9V7SWN#/]NG^T.[IL"*UMHK> MVC6*&) D<:#"HH& .P JEIG_(0U?_K\7_T1%0!HT444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %9VF?\ (0U?_K\7_P!$15HUG:9_R$-7_P"OQ?\ T1%0!HT444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0!B>,=5U+1/"&H:CH=@=0OX(P8;<(SY)8 MM7YF"@EMHP3MP",YKS?1/B=XA MU7P;H/V&^T.\U6^MKNXEO/)D>,+;0HS1R1!D*3%Y%!P2H + 88 >K:OIHU?2 M9[$W=W9>:!BXLIC%+&00058>XZ$$$9!!!(KB-.^#>DZ?X=L["+5=2BOX!)YN MJ6YC26420K#(NUD9%0I'& ,C8IW9R2 =GH.L)KOA?3=:CB>&._LXKM8C\S( M'0/MXZD9QQ5.QU2&&\U%Y(+\+/2.X]:M1ZKITKVJ17]J[7JL]JJS*3.J@ M%BG/S C)'3(H A_MRT_YY7_ /X+Y_\ XBC^W+3_ )Y7_P#X+Y__ (BGV.N: M3J=Y=VFFZG9WES9/LNH;>X21X&R1M=0QM(\!Y[F58XUR<#+,0!DD"@"G1Q\P]16;=>-/"UC;VT][XET>WANT\RWDFOXD69>FY"6^8> MXH M?VY:?\\K_P#\%\__ ,11_;EI_P \K_\ \%\__P 15Z&:*YMXY[>1)895 M#QR1L&5U(R"".H([T^@#._MRT_YY7_\ X+Y__B*/[5__P""^?\ ^(K1 MHH SO[5_P#^"^?_ .(H_MRT_P">5_\ ^"^?_P"(K1HH SO[5__ M ."^?_XBC^W+3_GE?_\ @OG_ /B*T:* ,[^W+3_GE?\ _@OG_P#B*/[5__P""^?\ ^(K1JC#KFDW&L3:1;ZG9RZE;IOFLDN$::->/ MF9 =P'S+R1_$/6@"O#KT;2SB:UOD19 (F%A.=Z[5.?NQM+:A)E)N$ !+)S\P 95__P""^?\ ^(K1HH SO[5_P#^ M"^?_ .(H_MRT_P">5_\ ^"^?_P"(K1HH SO[5__ ."^?_XBC^W+3_GE M?_\ @OG_ /B*T:* ,[^W+3_GE?\ _@OG_P#B*/[Q>]U>^MK"U0@- M/=3+$BDG RS$ 9/%+%J5C/Y'DWEO)]IA-Q!LE4^;$-N9%Y^91O3D5__P""^?\ ^(H_MRT_YY7_ /X+Y_\ XBM&B@#._MRT M_P">5_\ ^"^?_P"(H_MRT_YY7_\ X+Y__B*T:* ,[^W+3_GE?_\ @OG_ /B* M/[5_P#^"^?_ .(K1HH SO[5__ ."^ M?_XBM&B@#._MRT_YY7__ (+Y_P#XBC^W+3_GE?\ _@OG_P#B*T:* ,[^W+3_ M )Y7_P#X+Y__ (BC^W+3_GE?_P#@OG_^(K1HH SO[5__P""^?\ ^(J* M'7HVEG$UK?(BR 1,+"<[UVJ<_E76KSZ5;:G9S:C;+OGLX[A& MFB7CED!R!\PZCN/6HK?Q-H-WJ$-A::WIT]Y<1">&WBNXVDDC*[@ZJ#DJ5Y!' M&.: '?VY:?\ /*__ /!?/_\ $4?VY:?\\K__ ,%\_P#\14FG:UI>L>?_ &1J M5G?_ &=_+F^RSK+Y3_W6VDX/L:NT 9W]N6G_ #RO_P#P7S__ !%']N6G_/*_ M_P#!?/\ _$5HT4 9W]N6G_/*_P#_ 7S_P#Q%']N6G_/*_\ _!?/_P#$5HT4 M 9W]N6G_ #RO_P#P7S__ !%']N6G_/*__P#!?/\ _$5HT4 9W]N6G_/*_P#_ M 7S_P#Q%']N6G_/*_\ _!?/_P#$5HT4 9W]N6G_ #RO_P#P7S__ !%']N6G M_/*__P#!?/\ _$5HT4 9W]N6G_/*_P#_ 7S_P#Q%']N6G_/*_\ _!?/_P#$ M5HT4 9W]N6G_ #RO_P#P7S__ !%']N6G_/*__P#!?/\ _$5HU4U+5=/T:R:\ MUB_MK"U4@-/=3+$@)X +,0.: *\FM(_EI:6UX\KRHN)+*9%"E@&)9E &%)/) M[5IUGW.O:/96BW5YJMC;V[0_:%FEN45#%E1Y@).-N709Z?,OJ*5 9FW6\L%R(P69V9 RAVPN[*C9707'@ M;^Q?BEX4N]&AO)$CTN[LY+EB[16J1P0QP(/X8P2'8#J69SSV]0HH \F^$6GZ MWI=]#8ZE:W3166BQ6UQ/?::L#6]PLK?N890BF:(C+$Y<9P=PW8KUFBB@ HHH MH **** "BBB@ HHHH **** "BBB@ KA?B787]Q-X:O;.6^AMM/U0S74NG6OV MF>%3!(BR+%L?=AG ^ZQ&[.."1W5% 'E7AGPS?>)/#8M?%6F2Z9'%HD%GY%K" M;3S-TAEE0*F JNJ0*Z+CJZ\=!7TK1]6G^#_@;PK<:;>11WTL4.K(\#J8;= T MCK)Q\@@I:** "BBB@ HHHH **** M"BBB@ HHHH **** "O#;"Q\5Z-J%[;V]C>7EXK:PS&?3!Y=LT\H:"6"Y$89] MY92ZAVX!R%V5[E10!Y?<^"1H_P 6-!O](L[NYC_L:ZM)))"[0PK'%"D,(/W8 MU.';'&69S]*?PBTJ_L=<+76DWMLD6B6]O-)>6TD M9A+(?LD.[ EB4'(?YVY M&9&R /7** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@_B7I]_2K(O&0Z^P]6HH \"O?#>J1_#+PW%#8:K'J MLWABXTF2W_LA[E/WFP^4^&4V\A8#$C H &STKW+2;>:TT6RMKM_,GAMXXY7! MSN8* 3^=6Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO3-/\5Z3+ M=64%E>7-V8]5CD>;2QY=G)/./(D@N @:0/OWN-[8"G(3:*T-5L)M1^($.@Z; MHMYHNDZ*/-@O(]*FSJ=X;#S+N)I"^T,!O ##YQD'=P3S7J5%% !1110 4444 % M%%% !1110 4444 %%%% !7 _$S3]0N-1\-7]I+?PVEC=3FZFTZR%W-#O@=$8 M0E'W#)VGY3@/VZCOJ* /'8;C6=,\&OK6J^"VOM2L--L;.RTBWTXF-+@9E:14 M53M52T62H^4Q$#!'%*Z\$23_ ^\.W0_M34]5M=,FO;Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH[F M!+JUEMY3(J3(48Q2-&X!&#M=2&4^A!!'4&N?_P"$#TC_ )_/$'_A1ZA_\?H MTM:U^P\/PVTFI-F:2&_\ M3ZA$KH8)8_ED#2%&W2*<@ D!ES@D&+0_AW<-K^H:CK_VRS2:UMX((K'Q7J-P MY*-,S,\C&-L?O% 7D##$8W'(!Z)7.^-O%,OA+1+>]MK!+^:XO8+..*2X,*[I M7" E@K$ $^AIO_"!Z1_S^>(/_"CU#_X_5'X@>#KGQ+X-L]&TM;:?[+>6TQBU M.=V2:.)@2CN5=F+ 8)8-G)SF@"I/\1Y],_X2.WU_3;&QN]"M8;J1H[Z6:V9) M20N9%@WJ?E/ C;M^&[_PG7AU=;327U "[>9;?(AD,(F9=PA,VWRQ(1T0L&/' M'-<%J/PLUC4=)\3P6%IH?AV+5M-BLX-+TZ=VM3*LA9IY"(4PV,+PAX')J\?A MOK7G3Z2+FQ_L.ZU]-Y7\:LW?BR+P_I]J_C 06-Y=2.D-KI MS37S2;5+$J%B5R H)8[,+W-9?C/P5JNO_#;6O#T&N3:A>:@JB&;4Q$BQ8=3C M,,2\?*>JDY[TGCWP9?\ B+6M"UC29$:?2OM$;6SZA<6(E29 ,B:#+J59%.,8 M8$@XXH T9OB-X4@N((6UB-_/CAD$T44DD,:S'$1DE52D>X]-Y&:H:3\3M)O? M$VH:'J,! B,WS80MD[>,YK'\,^ ?$7@>]N1X7 M_L,6^I16:W'GO<;;-HALD\N,EFD4KT#2J0W4D<4DOPWUEM0EN$NK(*_C*+7A M^\?/V=8PI3[OW^#QT]Z .IT?X@^&=>U*WL-+U!Y;BY$Q@#VLT:R^4VV0*[H% M8J>H!S@@].:L:/XU\/Z_J3V.DZAY\ZAV7,,B),J/L=HG90LH5A@E"P!KCO#7 MPVUC1KSPC+=75DR:+<:I)="*5\NMT6,83Y1DC(SG&.V:7P!\,;SPIJ6GG4/L MMS#I$,\-I=_;[N:602/P1"["*#Y P4/N(!!7% '1ZAXLU*7Q)?:)X6T:#4[ MG3($EOGN[XVL:-("8XT(CW\B:%= MB.K)&^]2IP5(7&T8;D@8>M?#[Q-J$GB***\TF2/Q5;6T.I7+>;$;5HU\MVAB M^?>"G16=<-U)% '2ZW\2O"OAZ^O[/5M0GBFTY(Y+P1V%Q*L"N/D9F1" #ZYZ M\=:MVOCCP[=VFIW*:B(8]* :]^U0R6[0JPW*Q615)5@#M8 AL<$UYY\0O FJ MP^'?B'>V$)OQK%CIT%E;6RO+<'R#M?*A>^0>,]#G%:VJ?#G6O$\?BFXUNYL; M.]U:VM+:U2SDDEC3[.YD5W+*I^9SRH'RKW;- '1/\2_"D5B]U-J,L*I=16CQ M2V4Z3++*NZ,&$H' 8(=4DTNVNQJFFS-:03R21+;VK,S'>T:EI&+ MM@;0 !DY)IOC/X;>(O$GBVXOTFTV[M?MMG458D+R"R[>1D ML-M:T7Q!\,3WTMI'J>9(DF<.8)!'*(?]:(I"NR4IW"%B,'C@UR.@_#C7M,U3 MP\UU+IQM=%U>_O/,CGD+S17 DV_*8P%8%QD;B..O:H+?X6ZZ-)TK09[K3QIF MA"]:RN$ED,]TTJ2)&)%*XC"B5BQ#/NP, 9- '=>'_''A_P 471MM%O7FF^RI M>*DEM+#OA ]5\/>(M&OKVXM'AL/"T.C2K" M[$M.D@8L 5 *8S@G!]J] H **** "BBB@ HHK*_X1RR\R^?S]3S? B4?VKZTBZ2Z@29X&= 1AT8JPY]QP>A&",@@U@ M^*?"-Q>^$_L?AV\O8=1MT*VB45DGPU8F.Q M3S]4Q8-NB_XFUUECG/[P^9F49'23<,<=.*O6UFEHLWD/,3-*TK&:9Y<,?3<3 MM7T48 [ 4 ZVTFE^';N[L+NUN;S0I9?],DEXCF:!@!&5^^<.Q+P:-J M%_X?M[;2=7U5]*AGBU$RS1RAY$4M$8E&TM&>0YP#FM'7/B1'H7Q4T;P=/II> M+5(!(;\3X$+,75%*;>SR6\3 M/(Y5DA]4?B)\--7\6^)+K5=)O;2TE&CQ6UE+([!X;J.[6=7 MX4@+A<9Y//3O0 GASXSP>(+F\0Z;#8Q0:S;:9!+/=NWVD3EMCJ$A.&(4$*<* M<\NO6MJW^)VDZEXRT;0M$1[Z+4OM@:]VR1)&;?&=FY,2@MN7S: M:^F>&(K^WCEAFD\ZYCFP(V*% $8 #(#'G)!.< ZE?B9X18SXU,"L&]^'WB'P[868T_2M.$EQXSM-2@L],$DD%I$(RN)"(U*J"!E\8YS@9Q0 M![%H>OZ;XCL7N](N&FCBF>"57B>*2*1#AD=' 9&'H0#R#WKB-8^,NG:7XDU_ M2H;![H:+9I(9UFVB>X>981"!MX =P"^3@AACY:WO!OAK4-'@URYUB6".^UK4 M9;V1+*1GCMP55%57906(5 2Q4P,8&3U7@ M;PW/X7\.-:WLD'C*LO3L10!8JGJFK:?HMB;S5KR&SM MPP7S)GV@L3@*/4GL!R:Q_P#A ](_Y_/$'_A1ZA_\?JMX[\+W&OQZ1<62-/)I M=T9_LWVZ:T:52C(2LT9#*XW9!Z'D'KF@#H=+U;3]:L1>:3>0WEN6*^9"^X!@ M<%3Z$=P>15RN#\'_ _&F7U[JVI-?6US=7@N([2+7+R9$"HJCS2TF)F.W)W MC&%Y YZG5- L]8FAENYM0C:'[HM-2N+93SGYEB=0WX@T 9WCKQA#X)\/QZE/ M%'*9KN&TC\Z;R8E:1L;I)-K;$49).T].E9>N_$"\\.>#K'6-6T2&VGN[]+,K M)J -K$'+;9VN$1L1$ '<4!RP! ZUM>,M)O-;\.OI]E9:3J"32H+FSU8/Y,\6 MF3"QU"RL]0OKDZ#:VACLKFX,00S/L#;]A)7D$ M';RI!P,XK5\,>*[G6=AU*XCU:SNTN3>3@QV\2QAXE.W*$%&VE<$D[B5 M->EZ+X8TOP\MY_9,,LTCF/VET[[9CR%4;M_F>7R-K1'&T?ZP< M\<]=HW@N\T[X>:WI$TUN=2UAKVXE*,QACEN"QVAB,E5W 9QDX)P.E>=7'P%U MN33[F&/4-/)?1K.U@B:1_+CNT%LL\GW,X9;50#U.>0* /41X]TBWM]6N-3N8 M88=-U,::?LXFFD>5MFU-GE!BY+CY4WC'.[KB3P5XQB\9VNJW-O:FWBL-3FL$ M+,291&%^<@JI0G=]T\C% MO7T +6C^,M8\0+%J6B^'$NM FNF@CNCJ 2Y=%8HTPA9 NS<#C]YN*C.W)"U< MNOB#X9LM4FL+K4'CFA:1'?[),82\<9D=!*$V,ZJ"2H8L,$8R,5E>&?#OBKPC MIMMX]U&_ MU>5M/U%H+F]N8;IYY9+Q[:2&18K5$\LA0A6'C26\N/LMWIO]MS:Q#+ M+J%V7C:0$A1;!A"'#,P\TEB5X*Y.: .C\;>-U\(W&CVD=O;376KW#P0F\N_L ML";4+?-)L?!)VJHQR6ZBI;WQYI>AV-FWBD2Z5?3VIN9K)8VNGMD7&]G,(8!% M)QO.%^G2H?'_ (:NO%6EVVGKI6C:O8&1FNK34Y)8&^Z0CPS1JQC=23GY#D,1 ME>_,:%\/?%?A"/1[O1K[3=4U*UT#^R)O[2FECCC82&2-T*JQ=5+%-IV$JJ\K MV .IM_B%HIL]2O+N]MA;6>HKI\;6AEG::1@A1501@L[;QA8]XQR&/.([CXH^ M$+:!)9-4D97M9+O$5E/(R11MMD9E5"4V'(8, 5P<@8-?"S6KNSOWEO;.2 M];Q.FN0+#<3VJ3((EC9"Z9>%B"Y!7?CY>3S45O\ ";58+F^N(CIMLU]H>H64 ML:75Q-_I-S(&#&27H/97UF-8EUA;AKV\5ED=2=JV@?RE8.SXD+.=IP5)YH [+1_' M'A[7M6DTW2K\S7*"1@#;R(DJQR>6[1NRA9 '&"4)%97B'QAX@T;QCI.A6N@: M;=#69)DLYY-6DB_U47F,9%%NVW@$#!;\*R/!/PZUCPOXUEU&.6RTW2Y%N/M- MEIUW.\%]*\@*3?9Y01 P4 ':[] !@9STFO\ AJ\U7QWX3UJWD@6VT62[>X1V M(=Q+ 8UV @\GG)''K0!-_PG&@QZU'H]S?*E^TRVS!8Y&@6X9=PA\_:(]Y'1 M"0QXXYQ3I/&_AZ+7QHTFH8O#.+7/DR>4)RNX0F;;Y8D(Z(6W'CCD5R4_PZUF M2\N],2XL1H5YXB779+DRR?:E.X2&$1[=O+J 'W\*3\I-$_PZUF2\N],2XL1H M5YXB779+DRR?:E.X2&$1[=O+J 'W\*3\I- %_2OB]H$^@6VHZXS:9)<-@)KR&X^#.O_V#I\%J^EIJMHMY]GU2WO[FUN+)Y;AI%9'12)%V M.5:-E4C)P_S<>@^-/#FM:[X=TVRT^]BGDM[J)[^&XF>VBU*$*RR1.8U8JK9! M(VE3C!!!H G;XB>&5L=/NQ?S2)J4DL-JD5E.\DDD6=Z>6J%PPVGY2 >*I:M\ M4_#.G^'8]4L[PZ@;G3YM0LX8893YL<8Y+D(?*7<0NYP #GT(KGO#'PQUG1G\ M*FYDTM%T;5;^\FCM6<)Y26.2,B,EL"0@J0O08)H ].L/$,5UX)MO$EQ T,4NG+?O M"AWLBF,2%0>-Q X[9KGO"_Q)76/"LWB76[.STO1([5+I;Z#45N4&?O1.-JNL MJG *A2"3@$GBN@T/2[[2/ VG:2DUNNH6>G16PE*M)$)4C"[L94LNX9QE21Z5 MY:/@IJ5S9^(?+32?#KZK8VR?8=*N9GM9;N*;SO.(*H8E)4(%7=M#,0<]0#T6 M;XB>&+?2?[1N-0DBA^V+8,DEG.LR3MRL;1%/,4D&WXPTTV6D?' ^5% P.V:UK/X>W%M\7[CQ0UU$VDM&]Q!9\[X[V1$ MBDEZ8P8HP.N!W +%M\4O#@T>"]U*^CC:;[0^RSBN+D)%#(8WD;$2LB CE MF4*#G!(&:U+GQUX;M=8CTR75$-Q((3NCC=XD\W/E!Y54HA?!VAF!;C&^Z>>*0%4);&\ADPN<<-WJSJOPOU' M4/&6HZA.]E?66KR64UV);V\MUB>!55L6T;[)0=B,N]QL/]X#D [*/QQX>E\3 M'0([\G4!,UOM^SR>69502-&)=OEEPI!*ALCTJAKGQ"L/#?BZ72M8C^SV,&C- MJLU_N9]@$RQ;/+523]_.0?P[UA0_#K6+7XJ'Q'ILMEI=M+?-/>RV-W.IU"$Q MX6*:U8-'O5BW[Q7'4ML#'@^(OPXU?Q=K.I7>FW%E%'=^'7TI!<.X(E-RDNXX M4_+M0C/7...] '2'XC>%Q97ETVHR*ME<16LT36^X,"I52". M1P#5'1?B=I.HZ+JFJWZM86MEK#Z3#A7EDNG!4)MB";][%O\ 5A21@^AQB:M\ M-M;N?%&IZY97-B9#J6EZA8P2RR*KFVB:.1)"%.S<'." W09%5G^%VNW.@7(N M[FR&HGQ6_B"**VO)X8W1AM,1F11)&VUFPZ@X('J10!UES\4?!MG:QW%WK20Q M26[W"-)!*,JCB-UQMSY@?4'D'V->/:I\( M]?O[/3DLYM(TZ33;B75H0)9[H2Z@TH91*\P9VCVK\S @LS9V# KU^W,QMHC= M*B3E!YBQL64-CD D D9[X'TH DHHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **Q_%#:XNBL?"ZQM?[UPLB @KW&2R@'WY],X#N#DMG:!A!D77C?Q(-'U">/5-DGAVRO; MF5U@B*ZFUO=R0JLF5^4,D)SY>TYDR" * /8J*X[QWXR?P?-:7 MYKF/[)=W M#P)*B+)Y2H0#E"<_-Q@K[Y[58_B1+97ES;^)-)BTX6-Q+;WDT%X9XXV6T6Z0 MAC&F0T>\'(7!4#G=0!W=%>>V/Q.OKO7H].;PK>$1O%!>O;+/,;>=X5D*AA!Y M15?,0%FD0]3MQ@G-C^)^M:K%9"UTJUTRY75;."]MYKQC+%'*&8H\;PK(CX3N MFT@@H[*8]G]C7EQN@@(?9''$C[4;:N\LP7EOI5QX;M4UFXNX($@&J$P!)H)I5 M>:7KVLZO]AT73]7N8M16:]-[-J%E#YT*1 ($D6,F)F#SQ,"F P3_ 'JHVFN^ M([K6%\+2ZS?65V^J21FZGMK9KN.V%KYJ;MJ& EG#8*J?D&#ALX /4:*\^\/^ M*O$'B73+*ZT][-+A=!@N;E9$)@:XG8?.,?,=B12,$#+N\Q06'#+@/XXU^;PO MH%PU]J$;GPVFKW]W865O*=Q S)(LA4>4N&+)'B1LC:1@T >P45Q?C7QM_P ( MK'9WT<4EW"=/N[PQQR+&DHBC1@#E&;G=Q@C'<-VT=#\37NH?VW!J6D"VO]'D M5'M[6Y^T+,&A65=K%4.[#[<$=1U(YH Z.BO+8/B7K6K/I M]-L]/D?6(K2_@ M>\9I(XVAD'T5M8@BN-&47V?M"2 M3)&/./E_N2/-C8@>9P6P21@@'HM%>>2>-]37R^<'O H0B-(55L,WS8V#'('8 M 'I]%>4M\4]3AG@UF\TLPZ1=:,UY8VL4OG/Y&_>C*J'P&XW$8 MK67XEWD6F07.H^&YK1[F[.G6\H[5QMI\3K@7,?VO1P-,6 M\73Y;W[9NF\TV8N=WE",*5P<$AAR>!0!Z)17FVJ^//$-MINAZG<:.FFV]W=+ M*$CNTG%U UE6Q* QN&B3=@$&. M-GN4GD(9A&Q4(ELYR 2Q(&!0!WE%>2:-\2M:CB"WUF]_J$LOD);R7$<,2N^I M7-L@)6(D;1&@+9.0,[CT5S>M^*;G3;G0[>STZ*YDU8OEIKDQ) J1^8S$A&+?* M" .3CH,DYGL6M;E4E59(IKF./:SS6X3=MD!Q&9 M1NVN,!J /3Z*\WMOBI>/''<7GAZ."UFMGO4D2_WLMO%(!UX8_(SX*J'";LB MU'\1M:^UI9CP[:S.M]#IDDO]IE0;B2T6<$#R?N MM)Z@8(5CE0 >BT5YK9?% MR74+BSCM/#-Y.6BA>]6W2>1TR<@4?$'Q4UM/"NJ7% MAH]O8RR:?J$^FW1O?-(-K*L4C.ABP#\^Y1E@V &VY. #UBBN?USQ!J&F2:38 M66F07>K:F7"PO=F*"/9&7*M8\6^.;N9C]CT2+1 M[2YALQ(C,9)FER7_ '>(^6VR5LH-PP_7/*ZVH_$>8QVD$-A)!L+83^']/\C3SJ.F6]S]TH:5:I)(D+2I"OE023.[ MNVU5"1JS$DD#@5SNE:5X8U3Q4-=L['5H[QR[A+NTO+>!9% !D\J550.1)PV, MM\Y&2&(N>.]#N?$.CV-G:QR.%U2TFF\JEW4$V[4O,G9GGMG"![DONRL3X5\H<;6*ALT =E<>%-&N MK6_@FM#LU"[6]N"DTBL9U"!9%8,&1AY28*D8*YZYK*UGPGX.TSP_%=:M9>3I MVAP/(666;'E!A*XD"G,P+(&*OOW$9()-PL!JW@Y-4AAAN([.S2X MBM392F966=@LK)"S@;B; M:^(&GM.VAP6TBMUMO(VI"S!#Z]_;%U8F2[+K M(X,\GDR.J;%=X=WENX4X#,I(P,'@8KP?#_PY;J!'9W!82PRK))?SO(AA),:J M[.65%W-A 0OS'CDUYEI'PZUR6[?^T/#<=K8WUQID]W8A;2* &*64SJ(XF(*; M74#>7=EX8G[HZGXF^$+[7;C239V%SJ&F6EM<1'3['[&&65MGE/BZ4Q@ *Z[E M&]=PV\%A0!T,?PZ\+10W42Z:QCNH_+*/=3,(4#^8%AR_[D!P& CVX*J1]T86 MTM/#.@M<^&H()I&OA]HNK>19[LS"8^47D9MV02N&+' Y)P,FN*3X>:RFKR:D MEH!JRZS \6J/.DDPMQIZPR-YGRL09 V1M4MUVXQ6?I7@'6;?4=*DMO"QTM;1 M=,2\?[5"PN98;D/-.-KDME>=S8=NZY R >EV'@;P]IIMVM;*0R6URMU%+/=S M32"18FB7+NY8JJ.P"DE1N.!FK?\ PC&D?\(Y_8/V/_B6]H?,?*G?O#!\[@P; MY@P.00"","O'I_ MWX9\(VMQ=6%GI]LNEVR:TLMW# EZZ7D3-#)(6"DM'O0, MQV_-MR :Z_X>S3-X'\07_A/3(+=9]2N)=,M7=3"RJB*%#1L4VY1E&QBHQ@$@ M4 ;VC^'?"FVQG"LUAJ'GRS2,S9\U@SR$EF_?9WY)Y S\H E?X?^')- M/>TDM+AQ)>7\W[GR?>^[QTXKCQH/B./51KJZ!<,USJE M[,UB;B 301RVT<*,Q\S81NBR0K,0&& 3D5G:#\.-6LX-+N[K1XTU2RET15G\ MV,R0Q0PQ)JZ;H6FZ1#/%IMHEM%/LWHA.W"1K$H S\ MH"(H &!QGJ23R,MI\/KWR?#TRR1Q:1:2VR9:Y@B:WBVB6$SY"SHN%WH6<94[ MAP:S?AEX,U?P[KTUSJ]O?)<&VDBO;R66S$-_,901*JPQB63(#-OF8.N\C!W, M1)XN\-:]XLU:[M[;2YM,#6%_927TUZDMM/%+&RQ"./<61RY1G;RTX1EW.,$@ M'1"#PG\1K!G:%[R*"*2U>.5)K5XTF12P*-L8!DVD$CI@@UN1:-I\5QJ,ZVRE M]3*F\WDLLV$$8RIR,;5 P!@USWA2WU>/5=3U75-%FL#J+V\*6S30O)$L<.&D M,Y;: M S#9G;AFXY--C^'?A>&"YACTU@EP%&#=3$PA9/,40DOF$!\,!'M (![#'344 M +? &5R/.6$0!N3S^[ 7'3OC/-;=% M ',6OPZ\+6GE>7IA?R65HQ-:=0N&F3R"QBV2F3>A7>P!4C@[>G%=310!S=I\/O#%CY'V;32OD. MCQDW,K$,D[W"G)8Y_>R.W/7..F!6+XJ^%EKK\;0:=<0Z7!.+D73K'.\T@N)- M\P#K.JX+9(5T=0>0O:N^HH I2:/92W6GW,L.^;3MWV9RY&S3,X>1"">>3F>V\&Z':;/)LW+)=1W@:2YE=C-'$(4>&/,MV&FLHMPH"+=2A) LAD02*&VRA78L X;!/%23^!/#=S8 MBSGTW?;K!=6X3SY/]79+N6.>,[2A(F5A)DJ2"=W()SFI-+\.Z3HMP\VE64=JSV\-J1&2%$46[RU"Y MP,>8W0#]!GNKVYET]3-?W%O=7+AV!DD@(:)N#QM*@X'!YR#DYVJ* .83X<^ M%HY+EAIC,+F"6V>-[J9D2*1U=TC0OMC&Y58! NTCY<58L_!&@6+K)!9R-,IE M)FFNI99',JJKEW=BSDJBC+$X"@#%;]% ',_\*[\,"YM)ETYU-F+?RD6[F$>8 M !$S('VNR@ ;F!.!@DCBK6E^#M%T:1Y-.@N(G81J&:]G%#)++*X5(U R6 M8G@ 9)-5]+UC3-BZC::C;;BGG6DZRIN'4;E)&>1Q0!Y>=+:XBF:WD\J98W#&)]H;:V.APRG![$'O1'=V\UQ-!#/%)-;D":-7!:,D9 M&X=1DFV=M.Q6*:XNXXTD(ZA6) )&.U7+G4+. MRT][^\NX+>SC3S'N)90L:K_>+$X ]Z +%%91\5>'QIUKJ!UW3!97DGE6US]L MC\N=\D;4;.&.01@<\&I?[>T?^V_[&_M6Q_M3;N^P_:4\_&,Y\O.[&.>G2@#0 MHJ**ZMYYIH89XY);=@DR(X+1L5# ,.Q((//8@U3B\1:+/K4FCP:Q82:G$"9+ M)+I#,F!DYC!W#@CMWH T:*CMKF"\M8[FTFCG@E4/'+$X974\@@C@CWJ2@ HJ M**[M[B>>&"XBEEMF"3QHX+1,5# ,!T)5@<'L0>]2T %%1075O=>9]EGBF\J0 MQ2>6X;8XZJ<="/2H-,UC3-:MY)]&U&TU"&.0Q/):SK*J. "5)4G! (XZ\B@" MY161%XM\.3ZR=(A\0:7)J0D:,V27L9F#KG*[,[LC!R,<8K7H **9--%;6\D] MQ(D4,2EY))&"JB@9))/0 =Z-X0G ;;UQD$9H E MHJ%;NV>\DM$N(FN8D622$."Z*Q(5BO4 E6P>^#Z5-0 445475=/;5FTI;^V. MHI%Y[68F7SECSC>4SG;D@9QCF@"W16=:>(M$U#5I]+L-8L+K4+;<9[2&Z1Y8 MMI"MN0'*X) .1P338_$NA2V=Y=Q:UI[VUBY2[F6Z0I;L.H=LX4CT.* -.BL_ M2?$&C:_'))H6K6.II$0LC6=RDP0GH"5)Q3#XET(:[_8AUK3QJW3[ ;I//^[N M_P!7G=]WYNG3F@#3HJ*UN[>]@$]G/%<1%F421.&4E2589'<$$'T((I8+F"ZC M,EK-',BN\9:-PP#(Q5ER.X92".Q!':@"2BHI;NWMYX(9[B**6Y8I!&[@-*P4 ML0H/4A5)P.P)[4Z66."%YIY%CBC4L[NV%4#DDD]!0 ^BJ$NNZ3;V\$\^J644 M-Q$9X9'N$"RQC&74DX*_,O(X^8>M7)98X(7FGD6.*-2SN[850.223T% #Z*9 M'-%-;K/%(CPNH=9%8%64C((/ICO4"ZG8/I\-^E[;M9S[#%<"53')O(";6S@[ MBP QU)&.M %JBBB@ HHHH **** "BHK2[M[^SBNK&XBN;:90\4T+ATD4]"&' M!'N*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** .9\>6V]O(SOL7N/$YU4:.LVCP1/.2)#>7 MFN@O0^4(@_G<<-O M^8#&WJO51:6XO& MO!!$+EHQ$TX0;R@)(4MUP"2<>YIMK8VEBLJV-K#;":5II1#&$WR,XET17DCFF59XGMXEN'<*<2<$Y=L[",@JDZ'JFB^']/>33-9R8S%O\S48 MY(L%AY9-NC3[5;X"71GM=,BM#,\),NZ, M[(U?9@_.=H.SH,[0*[6B@#QF_P!-=(9M2CTS4M375=/U6WGBCTBXBQ>W/D%0 M(I$#)&5C*>8PV\$LPW&N@M?)O/$FDZ/>:7>V<>D7,=PTPTBX*WUX(2ID\X1^ M6L8WD%RVYV&.%&9/1J* ./\ !.B#0_$7B^*"SEMK2;4H98&D#'S\VD.]][ M>M>TT4 >*/!?P_VU'I%CXE6SU+6(_L]Y<)J"S1JME& SA"D\BEE* NZ*#@N? MEP5LK7Q==:!]MU23Q()H;+2$N(XY;B.38?\ C]*(I&Z7 Y(! M=^&(K_3O 'B>33M-U"YE>]NY;&WU.*19KA"HV;A(5=LC^\0S8^8AB34?PV^W MZ?K-[IC6M[)I?E*UMJE[8W$$USL5$6-ED \ORTPH)'[S[P)(D->D44 >:Z+X M1UK5?MD6I7D-GI47B:?44M3ISK7=&6,B8R8",0IR(^5R >:9_]?\ :X]_V+=Q_J?M.W[/QCR\?-MKVNB@#RC2]'U+ M6O$%A9:A_P )"?##MJ1B2[N+F)I([DUJ;2HX[B28R17*P6D2*"H"G?!," NPP[)1\P8-EL>GTR6*.>%X9XUD MBD4JZ.N58'@@@]10!RGQ"N;H:!9I86]_*MU=JDD]B;G=;)L=A(R6Q$KKN"C: MK+RPRP .<1/^$B;X0:"NH#6!=I/;IJWD>:+WR%EQ)C:3(3@#)0EBN2I)()]) MHH \4T33_$ENU[-I<>OPV]N;S4;:&X6:-KIEOED6-U;&YI(@R_-R0V3WJS?V MOBN>"::XO/$%FE]917LHABN9Q;N]VS^1LB=)!MC\M&$1#@#/(SGV*B@#Q6SD M\7R6R-J$'B2#3O(T\7:)+<23B$7-T)#&P592Q7R"V%$WED!LMS3;VR\73Z+? MSPR^)U-GI%W/I*B:=97<7+FV$B@YDD\K;\DF6(/S GI[910!Q?C_ .U?:M(\ M[^VO[%S/]L_L/S_M'F^7^YSY'[S9]_I\N[9NXJC\-='U>RU?5;[Q)%>+J5U9 M:?\ :9)I7:.280?O=HSLR'R#MX'0<5Z%10!Y)IK:GI=Y:P>%='U&_6SCNGBT M[7M(\EM,<1RD+#>!51@[E(R TI96W;\!C6&MEK,?A?6]%TO2]0N;&?34CM;R MXTJYAFW1F/R[7RGY58PTA#<[PP4,61B?=Z* .=T;P[J%MXDNM=US4K6]O9K2 M.S46=DUM&L:.[\AI)"S9<\[@ .@Y)/#%-5LO#5AXSTA;>*#7[>?R+MM&CL5G1 M!?-?S-FX"?+L*& @S?N]ID/K5S3%U[2]7U!]-L/$4DZ7VMSW-J_G1VTUL9)G M@$)8>6)'E,95E!?#.3E<5[)10!XKX9AU]O&>E7%_;:S+IMMJ1NHGN;>]80HV MGW*N ;AGEXDPG.W<<$( ZY]"\;_;=2\-Q:9I%D;N35ID@=)M\40@^_*)6",8 MPT:M'RO5P,9XKJ** /"_$.C^(Y;4:3/H-P'TZ#4(X?L227$)BF>WEB1)/+7= MM!>,#:#^Z[]3W?CRSU:]U[3AITFJI;0Z7J,S?8)I8U:X7R# ',9&3G?M4]?F M&",BNYHH \5AO-:M=6TJ/6I_$46J76IV\,:NTXM);7[(&*'/[HOO5BP_UN0? MX,UEIX7UFV\&:+9SV_B)[5-.T6YN;8/=,89H[I1*$1>4*Q$DH@&-JMC/-6AOY-9NK1 MXYI&N+Y;B*..3S_EC$X\07ES);PH\ M5Q;S6T,I=#:*XO_$3W4LFG+?J+.[M MS%*;I!/LEDF?/R>9N,"K%MP>!@5[C10!Y3JNG^,;1M9TG0I-5:+2K:XNM.NI M+B25KEID41Q;W;,C1DW.%9CC$)ZXQ1L(] XML 24 tech20200630b_10k_htm.xml IDEA: XBRL DOCUMENT 0000842023 2020-07-01 2021-06-30 0000842023 2020-12-31 0000842023 2021-08-20 0000842023 2019-07-01 2020-06-30 0000842023 2018-07-01 2019-06-30 0000842023 2021-06-30 0000842023 2020-06-30 0000842023 us-gaap:CommonStockMember 2018-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000842023 us-gaap:RetainedEarningsMember 2018-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2018-06-30 0000842023 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CommonStockMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-06-30 0000842023 us-gaap:CommonStockMember 2018-07-01 2019-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2019-06-30 0000842023 us-gaap:RetainedEarningsMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2019-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2018-07-01 2019-06-30 0000842023 us-gaap:CommonStockMember 2019-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000842023 us-gaap:RetainedEarningsMember 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2019-06-30 0000842023 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CommonStockMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2019-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-06-30 0000842023 us-gaap:CommonStockMember 2019-07-01 2020-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2020-06-30 0000842023 us-gaap:RetainedEarningsMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2019-07-01 2020-06-30 0000842023 us-gaap:CommonStockMember 2020-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000842023 us-gaap:RetainedEarningsMember 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2020-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CommonStockMember 2020-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2020-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-06-30 0000842023 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-06-30 0000842023 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2020-07-01 2021-06-30 0000842023 us-gaap:CommonStockMember 2021-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000842023 us-gaap:RetainedEarningsMember 2021-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000842023 us-gaap:NoncontrollingInterestMember 2021-06-30 0000842023 srt:MinimumMember us-gaap:EquipmentMember 2020-07-01 2021-06-30 0000842023 srt:MaximumMember us-gaap:EquipmentMember 2020-07-01 2021-06-30 0000842023 srt:MinimumMember tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMember 2020-07-01 2021-06-30 0000842023 srt:MaximumMember tech:BuildingBuildingImprovementsAndLeaseholdImprovementsMember 2020-07-01 2021-06-30 0000842023 srt:MinimumMember 2020-07-01 2021-06-30 0000842023 srt:MaximumMember 2020-07-01 2021-06-30 0000842023 us-gaap:TradeNamesMember 2020-07-01 2021-06-30 0000842023 us-gaap:TradeNamesMember 2021-06-30 0000842023 us-gaap:TradeNamesMember 2019-07-01 2020-06-30 0000842023 us-gaap:TradeNamesMember 2020-06-30 0000842023 us-gaap:AccountingStandardsUpdate201602Member 2019-07-01 0000842023 us-gaap:AccountingStandardsUpdate201613Member 2020-07-01 0000842023 tech:ConsumablesMember 2020-07-01 2021-06-30 0000842023 tech:ConsumablesMember 2019-07-01 2020-06-30 0000842023 tech:ConsumablesMember 2018-07-01 2019-06-30 0000842023 tech:InstrumentsMember 2020-07-01 2021-06-30 0000842023 tech:InstrumentsMember 2019-07-01 2020-06-30 0000842023 tech:InstrumentsMember 2018-07-01 2019-06-30 0000842023 us-gaap:ServiceMember 2020-07-01 2021-06-30 0000842023 us-gaap:ServiceMember 2019-07-01 2020-06-30 0000842023 us-gaap:ServiceMember 2018-07-01 2019-06-30 0000842023 tech:ProductAndServicesMember 2020-07-01 2021-06-30 0000842023 tech:ProductAndServicesMember 2019-07-01 2020-06-30 0000842023 tech:ProductAndServicesMember 2018-07-01 2019-06-30 0000842023 us-gaap:RoyaltyMember 2020-07-01 2021-06-30 0000842023 us-gaap:RoyaltyMember 2019-07-01 2020-06-30 0000842023 us-gaap:RoyaltyMember 2018-07-01 2019-06-30 0000842023 country:US 2020-07-01 2021-06-30 0000842023 country:US 2019-07-01 2020-06-30 0000842023 country:US 2018-07-01 2019-06-30 0000842023 tech:EMEAExcludingUKMember 2020-07-01 2021-06-30 0000842023 tech:EMEAExcludingUKMember 2019-07-01 2020-06-30 0000842023 tech:EMEAExcludingUKMember 2018-07-01 2019-06-30 0000842023 country:GB 2020-07-01 2021-06-30 0000842023 country:GB 2019-07-01 2020-06-30 0000842023 country:GB 2018-07-01 2019-06-30 0000842023 tech:APACExcludingGreaterChinaMember 2020-07-01 2021-06-30 0000842023 tech:APACExcludingGreaterChinaMember 2019-07-01 2020-06-30 0000842023 tech:APACExcludingGreaterChinaMember 2018-07-01 2019-06-30 0000842023 country:CN 2020-07-01 2021-06-30 0000842023 country:CN 2019-07-01 2020-06-30 0000842023 country:CN 2018-07-01 2019-06-30 0000842023 tech:RestOfWorldMember 2020-07-01 2021-06-30 0000842023 tech:RestOfWorldMember 2019-07-01 2020-06-30 0000842023 tech:RestOfWorldMember 2018-07-01 2019-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2021-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2020-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2021-06-30 0000842023 tech:ChemoCentryxIncCCXIMember 2020-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMember 2021-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMember 2020-06-30 0000842023 us-gaap:LandMember 2021-06-30 0000842023 us-gaap:LandMember 2020-06-30 0000842023 us-gaap:BuildingAndBuildingImprovementsMember 2021-06-30 0000842023 us-gaap:BuildingAndBuildingImprovementsMember 2020-06-30 0000842023 us-gaap:MachineryAndEquipmentMember 2021-06-30 0000842023 us-gaap:MachineryAndEquipmentMember 2020-06-30 0000842023 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2020-07-01 2021-06-30 0000842023 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2020-07-01 2021-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember 2021-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 srt:MinimumMember us-gaap:TradeNamesMember 2020-07-01 2021-06-30 0000842023 srt:MaximumMember us-gaap:TradeNamesMember 2020-07-01 2021-06-30 0000842023 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-07-01 2021-06-30 0000842023 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-07-01 2021-06-30 0000842023 us-gaap:CustomerRelationshipsMember 2021-06-30 0000842023 us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 us-gaap:PatentsMember 2020-07-01 2021-06-30 0000842023 us-gaap:PatentsMember 2021-06-30 0000842023 us-gaap:PatentsMember 2020-06-30 0000842023 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2020-07-01 2021-06-30 0000842023 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2020-07-01 2021-06-30 0000842023 us-gaap:OtherIntangibleAssetsMember 2021-06-30 0000842023 us-gaap:OtherIntangibleAssetsMember 2020-06-30 0000842023 us-gaap:InProcessResearchAndDevelopmentMember 2021-06-30 0000842023 us-gaap:InProcessResearchAndDevelopmentMember 2020-06-30 0000842023 us-gaap:PatentedTechnologyMember 2020-07-01 2020-09-30 0000842023 us-gaap:DevelopedTechnologyRightsMember us-gaap:CostOfSalesMember 2020-07-01 2021-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember us-gaap:CostOfSalesMember 2019-07-01 2020-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember us-gaap:CostOfSalesMember 2018-07-01 2019-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2021-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-06-30 0000842023 tech:TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-06-30 0000842023 tech:ProteinSciencesMember 2019-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2019-06-30 0000842023 tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 tech:ProteinSciencesMember 2020-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2020-06-30 0000842023 tech:ProteinSciencesMember 2020-07-01 2021-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2020-07-01 2021-06-30 0000842023 tech:ProteinSciencesMember 2021-06-30 0000842023 tech:DiagnosticsAndGenomicsMember 2021-06-30 0000842023 us-gaap:PatentedTechnologyMember 2020-07-01 2021-06-30 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2020-10-20 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2020-10-20 2020-10-20 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2021-04-02 2021-04-02 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2021-04-02 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2021-06-30 0000842023 tech:ChangzhouEminenceBiotechnologyMember us-gaap:DevelopedTechnologyRightsMember 2020-10-20 0000842023 tech:ChangzhouEminenceBiotechnologyMember us-gaap:DevelopedTechnologyRightsMember 2021-06-30 0000842023 tech:ChangzhouEminenceBiotechnologyMember us-gaap:CustomerRelationshipsMember 2020-10-20 0000842023 tech:ChangzhouEminenceBiotechnologyMember us-gaap:CustomerRelationshipsMember 2021-06-30 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2020-10-21 2021-06-30 0000842023 tech:ChangzhouEminenceBiotechnologyMember us-gaap:DevelopedTechnologyRightsMember 2020-10-20 2020-10-20 0000842023 tech:ChangzhouEminenceBiotechnologyMember us-gaap:CustomerRelationshipsMember 2020-10-20 2020-10-20 0000842023 tech:AcquisitionOfAsuragenIncMember 2021-04-06 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:DevelopedTechnologyRightsMember 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:InProcessResearchAndDevelopmentMember 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:CustomerRelationshipsMember 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:TradeNamesMember 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:NoncompeteAgreementsMember 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:DevelopedTechnologyRightsMember 2021-04-06 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:CustomerRelationshipsMember 2021-04-06 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:TradeNamesMember 2021-04-06 2021-04-06 0000842023 tech:AcquisitionOfAsuragenIncMember us-gaap:NoncompeteAgreementsMember 2021-04-06 2021-04-06 0000842023 tech:QTHoldingsCorporationMember 2018-07-02 2018-07-02 0000842023 tech:QTHoldingsCorporationMember 2018-07-02 0000842023 tech:QTHoldingsCorporationMember us-gaap:DevelopedTechnologyRightsMember 2018-07-02 2018-07-02 0000842023 tech:ExosomeDiagnosticsIncMember 2018-08-01 2018-08-01 0000842023 tech:ExosomeDiagnosticsIncMember 2018-08-01 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:DevelopedTechnologyRightsMember 2018-08-01 2018-08-01 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:TradeNamesMember 2018-08-01 2018-08-01 0000842023 tech:BMoGenMember 2018-08-01 2018-08-01 0000842023 tech:BMoGenMember 2019-06-04 2019-06-04 0000842023 tech:BMoGenMember 2019-06-04 0000842023 tech:BMoGenMember 2019-07-01 2020-06-30 0000842023 tech:BMoGenMember us-gaap:DevelopedTechnologyRightsMember 2019-06-04 2019-06-04 0000842023 tech:BMoGenMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember 2020-06-30 0000842023 tech:QTHoldingsCorporationMember 2020-06-30 0000842023 tech:BMoGenMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:QTHoldingsCorporationMember us-gaap:DevelopedTechnologyRightsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:TradeNamesMember 2020-06-30 0000842023 tech:BMoGenMember us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember us-gaap:CustomerRelationshipsMember 2020-06-30 0000842023 tech:ExosomeDiagnosticsIncMember 2019-07-01 2020-06-30 0000842023 tech:QTHoldingsCorporationMember 2019-07-01 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000842023 tech:CCXIMember 2021-06-30 0000842023 tech:CCXIMember 2020-06-30 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2018-10-31 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2020-10-01 2020-10-31 0000842023 srt:ScenarioForecastMember tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2021-10-01 2021-10-31 0000842023 srt:ScenarioForecastMember tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2022-10-01 2022-10-31 0000842023 us-gaap:OtherNoncurrentLiabilitiesMember tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2020-06-30 0000842023 us-gaap:OtherNoncurrentLiabilitiesMember tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2020-12-31 0000842023 us-gaap:OtherCurrentLiabilitiesMember tech:ForwardStartingSwapMember us-gaap:NondesignatedMember 2021-06-30 0000842023 us-gaap:OtherNoncurrentLiabilitiesMember tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2021-06-30 0000842023 tech:NewForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2021-05-31 0000842023 us-gaap:OtherNoncurrentAssetsMember tech:NewForwardStartingSwapMember us-gaap:CashFlowHedgingMember 2021-06-30 0000842023 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-06-30 0000842023 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-06-30 0000842023 tech:AcquisitionOfAsuragenIncMember 2021-06-30 0000842023 tech:QTHoldingsCorporationMember 2021-06-30 0000842023 tech:BMoGenMember 2021-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2020-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2019-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2020-07-01 2021-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2019-07-01 2020-06-30 0000842023 us-gaap:FairValueInputsLevel3Member tech:ContingentConsiderationMember 2021-06-30 0000842023 us-gaap:RevolvingCreditFacilityMember tech:CreditAgreementMember 2018-08-01 0000842023 tech:CreditAgreementMember tech:TermLoanMember 2018-08-01 0000842023 us-gaap:RevolvingCreditFacilityMember tech:CreditAgreementMember 2018-08-01 2018-08-01 0000842023 tech:CreditAgreementMember tech:TermLoanMember 2018-08-01 2018-08-01 0000842023 tech:CreditAgreementMember 2021-06-30 0000842023 tech:CreditAgreementMember 2020-06-30 0000842023 srt:MaximumMember 2021-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-06-30 0000842023 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201601Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2018-07-01 2019-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2019-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2019-07-01 2020-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-07-01 2021-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2021-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2020-07-01 2021-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0000842023 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-06-30 0000842023 tech:ChangzhouEminenceBiotechnologyMember 2020-07-01 2021-06-30 0000842023 tech:EquityIncentivePlan2010Member 2010-06-30 0000842023 tech:The2020EquityIncentivePlanMember 2020-10-31 0000842023 tech:The2020EquityIncentivePlanMember 2020-10-01 2020-10-31 0000842023 tech:The2020EquityIncentivePlanMember 2021-06-30 0000842023 srt:MaximumMember tech:The2020EquityIncentivePlanMember 2009-07-01 2010-06-30 0000842023 srt:MinimumMember 2019-07-01 2020-06-30 0000842023 srt:MaximumMember 2019-07-01 2020-06-30 0000842023 srt:MinimumMember 2018-07-01 2019-06-30 0000842023 srt:MaximumMember 2018-07-01 2019-06-30 0000842023 us-gaap:RestrictedStockMember 2018-06-30 0000842023 us-gaap:RestrictedStockMember 2018-07-01 2019-06-30 0000842023 us-gaap:RestrictedStockMember 2019-06-30 0000842023 us-gaap:RestrictedStockMember 2019-07-01 2020-06-30 0000842023 us-gaap:RestrictedStockMember 2020-06-30 0000842023 us-gaap:RestrictedStockMember 2020-07-01 2021-06-30 0000842023 us-gaap:RestrictedStockMember 2021-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2018-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2019-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2020-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2021-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2018-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2021-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2020-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2019-06-30 0000842023 us-gaap:CostOfSalesMember 2019-07-01 2020-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2014-10-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2020-07-01 2021-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2019-07-01 2020-06-30 0000842023 tech:EmployeeStockPurchasePlan2014Member 2018-07-01 2019-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2020-07-01 2021-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2019-07-01 2020-06-30 0000842023 tech:USProfitSharingAndSavingsPlanMember 2018-07-01 2019-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2020-07-01 2021-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2019-07-01 2020-06-30 0000842023 tech:GBProfitSharingAndSavingsPlanMember 2018-07-01 2019-06-30 0000842023 srt:ExecutiveOfficerMember tech:PerformanceIncentiveProgramsMember 2020-07-01 2021-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember tech:PerformanceIncentiveProgramsMember 2020-07-01 2021-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember tech:PerformanceIncentiveProgramsMember 2020-07-01 2021-06-30 0000842023 srt:ExecutiveOfficerMember tech:PerformanceIncentiveProgramsMember 2019-07-01 2020-06-30 0000842023 srt:ExecutiveOfficerMember tech:PerformanceIncentiveProgramsMember 2018-07-01 2019-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember tech:PerformanceIncentiveProgramsMember 2019-07-01 2020-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockMember tech:PerformanceIncentiveProgramsMember 2018-07-01 2019-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember tech:PerformanceIncentiveProgramsMember 2019-07-01 2020-06-30 0000842023 srt:ExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember tech:PerformanceIncentiveProgramsMember 2018-07-01 2019-06-30 0000842023 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2021-06-30 0000842023 us-gaap:StateAndLocalJurisdictionMember 2021-06-30 0000842023 us-gaap:ForeignCountryMember 2021-06-30 0000842023 tech:OperatingLossCarryforwardsMember 2021-06-30 0000842023 tech:TaxCreditCarryforwardsMember 2021-06-30 0000842023 2017-06-30 0000842023 2017-07-01 2018-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:ProteinSciencesMember 2020-07-01 2021-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:ProteinSciencesMember 2018-07-01 2019-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:DiagnosticsAndGenomicsMember 2020-07-01 2021-06-30 0000842023 us-gaap:SalesRevenueSegmentMember us-gaap:CustomerConcentrationRiskMember tech:DiagnosticsAndGenomicsMember 2018-07-01 2019-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2020-07-01 2021-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2018-07-01 2019-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndGenomicsMember 2020-07-01 2021-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndGenomicsMember 2018-07-01 2019-06-30 0000842023 us-gaap:IntersegmentEliminationMember 2020-07-01 2021-06-30 0000842023 us-gaap:IntersegmentEliminationMember 2019-07-01 2020-06-30 0000842023 us-gaap:IntersegmentEliminationMember 2018-07-01 2019-06-30 0000842023 us-gaap:OperatingSegmentsMember 2020-07-01 2021-06-30 0000842023 us-gaap:OperatingSegmentsMember 2019-07-01 2020-06-30 0000842023 us-gaap:OperatingSegmentsMember 2018-07-01 2019-06-30 0000842023 us-gaap:CorporateNonSegmentMember 2020-07-01 2021-06-30 0000842023 us-gaap:CorporateNonSegmentMember 2019-07-01 2020-06-30 0000842023 us-gaap:CorporateNonSegmentMember 2018-07-01 2019-06-30 0000842023 tech:ConsumablesMember tech:ProteinSciencesMember 2020-07-01 2021-06-30 0000842023 tech:ConsumablesMember tech:ProteinSciencesMember 2019-07-01 2020-06-30 0000842023 tech:ConsumablesMember tech:ProteinSciencesMember 2018-07-01 2019-06-30 0000842023 tech:ConsumablesMember tech:DiagnosticsAndGenomicsMember 2020-07-01 2021-06-30 0000842023 tech:ConsumablesMember tech:DiagnosticsAndGenomicsMember 2019-07-01 2020-06-30 0000842023 tech:ConsumablesMember tech:DiagnosticsAndGenomicsMember 2018-07-01 2019-06-30 0000842023 tech:UnitedStatesAndCanadaMember 2021-06-30 0000842023 tech:UnitedStatesAndCanadaMember 2020-06-30 0000842023 srt:EuropeMember 2021-06-30 0000842023 srt:EuropeMember 2020-06-30 0000842023 srt:AsiaMember 2021-06-30 0000842023 srt:AsiaMember 2020-06-30 iso4217:USD shares thunderdome:item iso4217:USD shares utr:Y pure utr:sqft 0000842023 BIO-TECHNE Corp false --06-30 FY 2021 1229000 775000 0 0 5000000 5000000 0 0 0 0 0.01 0.01 100000000 100000000 38955484 38955484 38453046 38453046 0.574 P15Y P5Y 1.28 1.28 279381 600000 P10Y P3Y 1400000 -2239000 0 0 0 0 10-K true 2021-06-30 false 0-17272 MN 41-1427402 614 McKinley Place N.E. Minneapolis MN 55413 612 379-8854 Common Stock, $0.01 par value TECH NASDAQ Yes No Yes Yes Large Accelerated Filer false false false true 12400000000 39079539 931032000 738691000 714006000 298182000 255497000 240515000 632850000 483194000 473491000 324951000 260583000 264359000 70603000 65192000 62413000 395554000 325775000 326772000 237296000 157419000 146719000 13952000 19197000 21705000 473000 605000 569000 -75642000 137650000 -13568000 -89121000 119058000 -34704000 148175000 276477000 112015000 8590000 47181000 15943000 139585000 229296000 96072000 -825000 0 0 140410000 229296000 96072000 32951000 -9963000 -4487000 7060000 -3715000 -9537000 40011000 -13678000 -14024000 103000 0 0 39908000 -13678000 -14024000 180318000 215618000 82048000 3.62 6.00 2.54 3.47 5.82 2.47 38747000 38201000 37781000 40483000 39401000 38892000 199091000 146625000 32463000 124268000 145385000 122534000 116748000 103152000 16919000 24341000 510606000 520920000 207907000 176829000 73834000 71465000 843067000 728308000 615968000 516545000 11575000 13522000 2262957000 2027589000 29384000 23090000 51294000 31087000 15282000 9093000 18995000 13049000 5336000 2376000 11602000 9535000 4000000 5938000 12500000 12500000 3891000 0 152284000 106668000 93125000 101090000 328827000 344243000 25400000 199000 67625000 67248000 24462000 26949000 0 0 390000 385000 534411000 420536000 1085461000 1057470000 -57291000 -97199000 1562971000 1381192000 8263000 0 1571234000 1381192000 2262957000 2027589000 37608000 376000 246568000 876931000 -44814000 0 1079061000 25276000 -24682000 594000 96072000 96072000 -14024000 -14024000 95000 1000 15404000 15405000 382000 4000 36272000 36276000 29000 0 -2575000 -2575000 48366000 48364000 31775000 31775000 10000 0 1676000 1676000 505000 505000 37934000 379000 316797000 931934000 -83521000 0 1165589000 -879000 -879000 229296000 229296000 -13678000 -13678000 279000 3000 50109000 50112000 -2000 0 -400000 -400000 730000 7000 69461000 -1642000 67826000 56000 1000 -1000 -2229000 -2228000 48902000 48902000 31932000 31932000 14000 0 2312000 2312000 435000 435000 38453000 385000 420536000 1057470000 -97199000 0 1381192000 -276000 -276000 8985000 8985000 140410000 -825000 139585000 39908000 103000 40011000 120000 1000 43177000 43178000 573000 6000 62102000 -12287000 49821000 38000 0 -0 -7057000 -7057000 49622000 49622000 48065000 48065000 11000 0 2791000 2791000 917000 917000 38955000 390000 534411000 1085461000 -57291000 8263000 1571234000 139585000 229296000 96072000 87747000 82737000 78171000 1565000 0 3739000 -27431000 13130000 -13582000 48982000 32367000 32280000 5300000 -905000 -2000000 -337000 -958000 0 -0 -0 3702000 67879000 -137527000 16067000 75000 225000 0 -0 7170000 -0 -464000 -732000 2325000 15549000 -6556000 15000000 7140000 14861000 13647000 1101000 2605000 698000 19091000 10343000 6101000 20536000 2552000 5013000 13426000 -7231000 -9520000 352164000 205217000 181619000 66377000 147120000 21579000 39684000 70187000 43475000 44301000 51744000 25411000 225352000 -0 289492000 556000 -1906000 -0 -0 -0 -0 -243516000 27095000 -336799000 49622000 48902000 48364000 65092000 70983000 37950000 43178000 50112000 15405000 256000000 40000000 580000000 271500000 188500000 413500000 -0 3400000 -0 -19343000 -3872000 -6297000 -62551000 -183802000 134384000 6369000 -2771000 -308000 52466000 45739000 -21104000 146625000 100886000 121990000 199091000 146625000 100886000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">1.</em></b> <b><i>Description of Business and Summary of Significant Accounting Policies:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Description of business:</i> Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Use of estimates:</i> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Principles of consolidation:</i> The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. The Company consolidated our partial acquisition of Eminence in our consolidated financial statements on a <em style="font: inherit;">one</em> month lag. Refer to Note <em style="font: inherit;">4</em> for additional discussion regarding Eminence.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Translation of foreign financial statements:</i> Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Revenue recognition:</i> The Company adopted <i>ASC <em style="font: inherit;">606</em> </i>- <i>Revenue from Contracts with Customers</i> on <em style="font: inherit;"> July 1, 2018 </em>using the modified retrospective transition approach. ASC <em style="font: inherit;">606</em> provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC <em style="font: inherit;">606</em> is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note <em style="font: inherit;">2</em> for additional information regarding our revenue recognition policy under <i>ASC <em style="font: inherit;">606</em></i>.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Research and development:</i> Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Advertising costs:</i> Advertising expenses were $4.7 million, $4.2 million, and $4.1 million for fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> respectively. The Company expenses advertising expenses as incurred.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Income taxes:</i> The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than <em style="font: inherit;">not</em> that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than <em style="font: inherit;">fifty</em> percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note <em style="font: inherit;">11</em> for additional information regarding income taxes.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Comprehensive income: </i>Comprehensive income includes charges and credits to shareholders' equity that are <em style="font: inherit;">not</em> the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Cash and cash equivalents:</i> Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of <em style="font: inherit;">three</em> months or less.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Available-for-sale investments:</i> Available-for-sale investments consist of debt instruments with original maturities of generally <em style="font: inherit;">three</em> months to <em style="font: inherit;">six</em> months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on available-for-sale securities are included within other income (expense) in accordance with ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">02,</em> which the Company adopted on <em style="font: inherit;"> July 1, 2018. </em><em style="font: inherit;"/></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Trade accounts receivable and allowances: </i>Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do <em style="font: inherit;">not</em> bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> on <em style="font: inherit;"> July 1, 2020, </em>which reflects the expected credit losses on financial instruments within its scope, including trade receivables. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&amp;A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does <em style="font: inherit;">not</em> have material long-term customer receivables. Refer to the Recently Adopted Accounting Pronouncements section of Note <em style="font: inherit;">1</em> for further details.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Inventories:</i> Inventories are stated at the lower of cost (<em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory <em style="font: inherit;">not</em> meeting quality control standards and inventory subject to expiration.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been <em style="font: inherit;">no</em> material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with <i>ASC <em style="font: inherit;">330</em> - Inventory</i>.</p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Property and equipment:</i> Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/><i>Contingent Consideration:</i> Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Intangible assets: </i>Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In conjunction with the Asuragen acquisition that occurred in fiscal year <em style="font: inherit;">2021,</em> the Company reassessed the useful life of a tradename from a previous acquisition due to the planned integration and cobranding strategy developed with the most recent transaction.  As a result, the Company accelerated the amortization of the trade name to be consistent with the life used for the Asuragen trade name.  The accelerated amortization resulted in a $1.4 million impact in fiscal <em style="font: inherit;">2021,</em> a $5.7 million impact in fiscal years <em style="font: inherit;">2022</em> through <em style="font: inherit;">2025,</em> and a $4.3 impact in fiscal year <em style="font: inherit;">2026.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In fiscal year <em style="font: inherit;">2020,</em> the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal <em style="font: inherit;">2020</em> and $0.6 million in fiscal <em style="font: inherit;">2021.</em></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;"/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Impairment of long-lived assets and amortizable intangibles: </i>We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant decrease in the market value of an asset, (<em style="font: inherit;">2</em>) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (<em style="font: inherit;">3</em>) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are <em style="font: inherit;">not</em> available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. <em style="font: inherit;">No</em> other triggering events were identified and <em style="font: inherit;">no</em> impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years <em style="font: inherit;">2019,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2021.</em></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><em style="font: inherit;"/></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Impairment of goodwill: </i>We evaluate the carrying value of goodwill during the <em style="font: inherit;">fourth</em> quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant adverse change in legal factors or in business climate, (<em style="font: inherit;">2</em>) unanticipated competition, (<em style="font: inherit;">3</em>) an adverse action or assessment by a regulator, or (<em style="font: inherit;">4</em>) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form <em style="font: inherit;">one</em> reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had <em style="font: inherit;">five</em> reporting units for our <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> goodwill impairment assessment performed on <em style="font: inherit;"> April 1 </em>of each of the respective fiscal years, the date of our annual goodwill impairment assessment. Further, the Company elected <em style="font: inherit;"> April 1 </em>as the annual goodwill impairment assessment date for the Asuragen acquisition, acquired on <em style="font: inherit;"> April 6, 2021.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><em style="font: inherit;">2021</em> <i>Goodwill Impairment Analyses</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff">In completing our <em style="font: inherit;">2021</em> annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU <em style="font: inherit;">2017</em>-<em style="font: inherit;">04,</em> a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of <em style="font: inherit;"> April 1, 2021. </em>This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did <em style="font: inherit;">not</em> identify any triggering events after our annual goodwill impairment through <em style="font: inherit;"> June 30, 2021, </em>the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;"><em style="font: inherit;">2020</em> </span><i><span style="background-color:#ffffff;">Goodwill Impairment Analyses</span></i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">The Company elected to perform a quantitative assessment for all of our reporting units in our <em style="font: inherit;">2020</em> goodwill impairment analysis. The quantitative assessment completed utilized a consistent process and methodology to the <em style="font: inherit;">2021</em> goodwill impairment assessment. The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of <em style="font: inherit;"> April 1, 2020. </em>This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did <em style="font: inherit;">not</em> identify any triggering events after our annual goodwill impairment through <em style="font: inherit;"> June 30, 2020, </em>the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. </span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;"><em style="font: inherit;">2019</em> </span><i><span style="background-color:#ffffff;">Goodwill Impairment Analyses</span></i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">At the beginning of the quarter ended <em style="font: inherit;"> March 31, 2019, </em>the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">Because our quantitative analysis performed as of <em style="font: inherit;"> January 1, 2019 </em>included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was <em style="font: inherit;">not</em> impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">The quantitative assessments completed as of <em style="font: inherit;"> January 1, 2019 </em>indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">In conducting our annual goodwill impairment test on <em style="font: inherit;"> April 1, </em>we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">Based on its annual analysis, the Company determined there was <em style="font: inherit;">no</em> indication of impairment of goodwill. Further, <em style="font: inherit;">no</em> triggering events or items beyond the realignment discussed above were identified in the year ended <em style="font: inherit;"> June 30, 2019 </em>that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.</span></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"/><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><i>Other Significant Accounting Policies </i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Policy</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-right: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Note</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value measurements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-right: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">5</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-right: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">9</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-right: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">10</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating segments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-right: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">12</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i/></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In <em style="font: inherit;"> February 2016</em><i>,</i> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em><i>,</i> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic <i><em style="font: inherit;">842</em></i>) through ASU <i><em style="font: inherit;">No.</em></i> <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">10</em></i> and ASU <i><em style="font: inherit;">2019</em></i>-<i><em style="font: inherit;">01.</em></i> Additionally, the FASB issued ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11,</em></i> allowing an entity to elect a transition method where they do <i><em style="font: inherit;">not</em></i> recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11</em></i> when adopting Leases (Topic <i><em style="font: inherit;">842</em></i>). The Company adopted the standard effective <em style="font: inherit;"> July 1, 2019 </em>and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC <i><em style="font: inherit;">840</em></i> - Leases into operating lease liabilities upon adoption of Topic <i><em style="font: inherit;">842.</em></i> In adopting ASC <i><em style="font: inherit;">842,</em></i> the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC <i><em style="font: inherit;">842,</em></i> the Company also made the accounting policy elections to <i><em style="font: inherit;">not</em></i> capitalize short term leases (defined as a lease with a lease term that is less than <i><em style="font: inherit;">12</em></i> months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note <i><em style="font: inherit;">7</em></i> for additional information on leases.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>), Measurement of Credit Losses on Financial Instruments</i>. The amendment in this update replaced the previous incurred loss impairment methodology with a methodology that reflects expected credit losses on financial instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted this standard on <em style="font: inherit;"> July 1, 2020 </em>using a modified retrospective transition approach with a cumulative impact of $0.3 million to retained earnings. The adoption of this ASU did <em style="font: inherit;">not</em> have a material impact on the Company's financial statements as the Company's primary financial instruments impacted by the ASU were trade accounts receivable, where we have high historical and expected future collections due to the length of receivables and the credit quality of our customers.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</i>. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is <em style="font: inherit;">not</em> affected by the new standard. The Company adopted this standard on a prospective basis on <em style="font: inherit;"> July 1, 2020. </em>Accordingly, as of <em style="font: inherit;"> July 1, 2020, </em>the Company will record eligible costs to be capitalized within prepaid assets or other non-current assets depending on the nature of the duration of the asset.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2020</em><i>,</i> the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04</em><i>,</i> <i>Facilitation of the Effects of Reference Rate Reform on Financial Reporting </i>and in <em style="font: inherit;"> January 2021 </em>issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2021</em>-<em style="font: inherit;">01,</em> <i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Scope.</i> These ASUs provide expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in <em style="font: inherit;">2021</em><i>,</i> to a new reference rate. The provisions of the ASUs impact contract modifications and other changes that occur while LIBOR is phased out. The Company adopted the optional relief guidance provided within these ASUs in the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2021</em> and continues to monitor its debt and derivative instruments that utilize LIBOR as the reference rate. The adoption of the standard did <em style="font: inherit;">not</em> impact our financial results for fiscal <em style="font: inherit;">2021.</em></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"/></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <i>Use of estimates:</i> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates. <i>Principles of consolidation:</i> The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. The Company consolidated our partial acquisition of Eminence in our consolidated financial statements on a <em style="font: inherit;">one</em> month lag. Refer to Note <em style="font: inherit;">4</em> for additional discussion regarding Eminence. <i>Translation of foreign financial statements:</i> Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income. <i>Revenue recognition:</i> The Company adopted <i>ASC <em style="font: inherit;">606</em> </i>- <i>Revenue from Contracts with Customers</i> on <em style="font: inherit;"> July 1, 2018 </em>using the modified retrospective transition approach. ASC <em style="font: inherit;">606</em> provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC <em style="font: inherit;">606</em> is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note <em style="font: inherit;">2</em> for additional information regarding our revenue recognition policy under <i>ASC <em style="font: inherit;">606</em></i>. <i>Research and development:</i> Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications. <i>Advertising costs:</i> Advertising expenses were $4.7 million, $4.2 million, and $4.1 million for fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> respectively. The Company expenses advertising expenses as incurred. 4700000 4200000 4100000 <i>Income taxes:</i> The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than <em style="font: inherit;">not</em> that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than <em style="font: inherit;">fifty</em> percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note <em style="font: inherit;">11</em> for additional information regarding income taxes. <i>Comprehensive income: </i>Comprehensive income includes charges and credits to shareholders' equity that are <em style="font: inherit;">not</em> the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity. <i>Cash and cash equivalents:</i> Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of <em style="font: inherit;">three</em> months or less. <i>Available-for-sale investments:</i> Available-for-sale investments consist of debt instruments with original maturities of generally <em style="font: inherit;">three</em> months to <em style="font: inherit;">six</em> months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on available-for-sale securities are included within other income (expense) in accordance with ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">02,</em> which the Company adopted on <em style="font: inherit;"> July 1, 2018. </em> <i>Trade accounts receivable and allowances: </i>Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do <em style="font: inherit;">not</em> bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> on <em style="font: inherit;"> July 1, 2020, </em>which reflects the expected credit losses on financial instruments within its scope, including trade receivables. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&amp;A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does <em style="font: inherit;">not</em> have material long-term customer receivables. Refer to the Recently Adopted Accounting Pronouncements section of Note <em style="font: inherit;">1</em> for further details. <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Inventories:</i> Inventories are stated at the lower of cost (<em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory <em style="font: inherit;">not</em> meeting quality control standards and inventory subject to expiration.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been <em style="font: inherit;">no</em> material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with <i>ASC <em style="font: inherit;">330</em> - Inventory</i>.</p> <i>Property and equipment:</i> Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years. P3Y P5Y P5Y P40Y <i>Contingent Consideration:</i> Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income. <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Intangible assets: </i>Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In conjunction with the Asuragen acquisition that occurred in fiscal year <em style="font: inherit;">2021,</em> the Company reassessed the useful life of a tradename from a previous acquisition due to the planned integration and cobranding strategy developed with the most recent transaction.  As a result, the Company accelerated the amortization of the trade name to be consistent with the life used for the Asuragen trade name.  The accelerated amortization resulted in a $1.4 million impact in fiscal <em style="font: inherit;">2021,</em> a $5.7 million impact in fiscal years <em style="font: inherit;">2022</em> through <em style="font: inherit;">2025,</em> and a $4.3 impact in fiscal year <em style="font: inherit;">2026.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In fiscal year <em style="font: inherit;">2020,</em> the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal <em style="font: inherit;">2020</em> and $0.6 million in fiscal <em style="font: inherit;">2021.</em></p> P1Y P20Y 1400000 5700000 4300000 1300000 600000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Impairment of long-lived assets and amortizable intangibles: </i>We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant decrease in the market value of an asset, (<em style="font: inherit;">2</em>) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (<em style="font: inherit;">3</em>) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are <em style="font: inherit;">not</em> available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results <em style="font: inherit;"> may </em>differ from assumed and estimated amounts. <em style="font: inherit;">No</em> other triggering events were identified and <em style="font: inherit;">no</em> impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years <em style="font: inherit;">2019,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2021.</em></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><em style="font: inherit;"/></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Impairment of goodwill: </i>We evaluate the carrying value of goodwill during the <em style="font: inherit;">fourth</em> quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are <em style="font: inherit;">not</em> limited to, (<em style="font: inherit;">1</em>) a significant adverse change in legal factors or in business climate, (<em style="font: inherit;">2</em>) unanticipated competition, (<em style="font: inherit;">3</em>) an adverse action or assessment by a regulator, or (<em style="font: inherit;">4</em>) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form <em style="font: inherit;">one</em> reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had <em style="font: inherit;">five</em> reporting units for our <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> goodwill impairment assessment performed on <em style="font: inherit;"> April 1 </em>of each of the respective fiscal years, the date of our annual goodwill impairment assessment. Further, the Company elected <em style="font: inherit;"> April 1 </em>as the annual goodwill impairment assessment date for the Asuragen acquisition, acquired on <em style="font: inherit;"> April 6, 2021.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><em style="font: inherit;">2021</em> <i>Goodwill Impairment Analyses</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff">In completing our <em style="font: inherit;">2021</em> annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU <em style="font: inherit;">2017</em>-<em style="font: inherit;">04,</em> a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of <em style="font: inherit;"> April 1, 2021. </em>This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did <em style="font: inherit;">not</em> identify any triggering events after our annual goodwill impairment through <em style="font: inherit;"> June 30, 2021, </em>the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;"><em style="font: inherit;">2020</em> </span><i><span style="background-color:#ffffff;">Goodwill Impairment Analyses</span></i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">The Company elected to perform a quantitative assessment for all of our reporting units in our <em style="font: inherit;">2020</em> goodwill impairment analysis. The quantitative assessment completed utilized a consistent process and methodology to the <em style="font: inherit;">2021</em> goodwill impairment assessment. The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of <em style="font: inherit;"> April 1, 2020. </em>This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did <em style="font: inherit;">not</em> identify any triggering events after our annual goodwill impairment through <em style="font: inherit;"> June 30, 2020, </em>the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. </span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;"><em style="font: inherit;">2019</em> </span><i><span style="background-color:#ffffff;">Goodwill Impairment Analyses</span></i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">At the beginning of the quarter ended <em style="font: inherit;"> March 31, 2019, </em>the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">Because our quantitative analysis performed as of <em style="font: inherit;"> January 1, 2019 </em>included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was <em style="font: inherit;">not</em> impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">The quantitative assessments completed as of <em style="font: inherit;"> January 1, 2019 </em>indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">In conducting our annual goodwill impairment test on <em style="font: inherit;"> April 1, </em>we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than <em style="font: inherit;">not</em> that the fair value of a reporting unit is less than its carrying amount.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><span style="background-color:#ffffff;">Based on its annual analysis, the Company determined there was <em style="font: inherit;">no</em> indication of impairment of goodwill. Further, <em style="font: inherit;">no</em> triggering events or items beyond the realignment discussed above were identified in the year ended <em style="font: inherit;"> June 30, 2019 </em>that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.</span></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">In <em style="font: inherit;"> February 2016</em><i>,</i> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em><i>,</i> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic <i><em style="font: inherit;">842</em></i>) through ASU <i><em style="font: inherit;">No.</em></i> <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">10</em></i> and ASU <i><em style="font: inherit;">2019</em></i>-<i><em style="font: inherit;">01.</em></i> Additionally, the FASB issued ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11,</em></i> allowing an entity to elect a transition method where they do <i><em style="font: inherit;">not</em></i> recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU <i><em style="font: inherit;">2018</em></i>-<i><em style="font: inherit;">11</em></i> when adopting Leases (Topic <i><em style="font: inherit;">842</em></i>). The Company adopted the standard effective <em style="font: inherit;"> July 1, 2019 </em>and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC <i><em style="font: inherit;">840</em></i> - Leases into operating lease liabilities upon adoption of Topic <i><em style="font: inherit;">842.</em></i> In adopting ASC <i><em style="font: inherit;">842,</em></i> the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC <i><em style="font: inherit;">842,</em></i> the Company also made the accounting policy elections to <i><em style="font: inherit;">not</em></i> capitalize short term leases (defined as a lease with a lease term that is less than <i><em style="font: inherit;">12</em></i> months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note <i><em style="font: inherit;">7</em></i> for additional information on leases.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>), Measurement of Credit Losses on Financial Instruments</i>. The amendment in this update replaced the previous incurred loss impairment methodology with a methodology that reflects expected credit losses on financial instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted this standard on <em style="font: inherit;"> July 1, 2020 </em>using a modified retrospective transition approach with a cumulative impact of $0.3 million to retained earnings. The adoption of this ASU did <em style="font: inherit;">not</em> have a material impact on the Company's financial statements as the Company's primary financial instruments impacted by the ASU were trade accounts receivable, where we have high historical and expected future collections due to the length of receivables and the credit quality of our customers.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</i>. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is <em style="font: inherit;">not</em> affected by the new standard. The Company adopted this standard on a prospective basis on <em style="font: inherit;"> July 1, 2020. </em>Accordingly, as of <em style="font: inherit;"> July 1, 2020, </em>the Company will record eligible costs to be capitalized within prepaid assets or other non-current assets depending on the nature of the duration of the asset.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2020</em><i>,</i> the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2020</em>-<em style="font: inherit;">04</em><i>,</i> <i>Facilitation of the Effects of Reference Rate Reform on Financial Reporting </i>and in <em style="font: inherit;"> January 2021 </em>issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2021</em>-<em style="font: inherit;">01,</em> <i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Scope.</i> These ASUs provide expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in <em style="font: inherit;">2021</em><i>,</i> to a new reference rate. The provisions of the ASUs impact contract modifications and other changes that occur while LIBOR is phased out. The Company adopted the optional relief guidance provided within these ASUs in the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2021</em> and continues to monitor its debt and derivative instruments that utilize LIBOR as the reference rate. The adoption of the standard did <em style="font: inherit;">not</em> impact our financial results for fiscal <em style="font: inherit;">2021.</em></p> 80600000 79500000 800000 -300000 4000000.0 -300000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Note <em style="font: inherit;">2</em></i></b><b>.</b><b><i> Revenue Recognition:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has <em style="font: inherit;">no</em> alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at a point in time. Prior to fiscal year <em style="font: inherit;">2021,</em> the Company has <em style="font: inherit;">not</em> recognized revenue upon completion of the performance obligation for laboratory services, but rather upon cash receipt, which was subsequent to the performance obligation being satisfied. The Company accounted for these services based on cash receipts as we did <em style="font: inherit;">not</em> have significant historical experience collecting payments from Medicare or other insurance providers and considered the variable consideration for such services to be constrained as it would <em style="font: inherit;">not</em> be probable that a significant amount of revenue would <em style="font: inherit;">not</em> need to be reversed in future periods for the services provided. Given Medicare coverage for our laboratory services became effective on <em style="font: inherit;"> December 1, 2019, </em>the Company considered that it had sufficient data to estimate variable consideration as of <em style="font: inherit;"> July 1, 2020 </em>for laboratory services that are reimbursed by Medicare. The amount of cash received in fiscal year <em style="font: inherit;">2021</em> for laboratory services reimbursed by Medicare that were performed prior to <em style="font: inherit;"> July 1, 2020 </em>was approximately $0.5 million. The Company continues to record revenue based on cash receipts for laboratory services <em style="font: inherit;">not</em> reimbursed by Medicare, as the variable consideration remains constrained. We recognize royalty revenues in the period the sales occur using <em style="font: inherit;">third</em> party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company elected the exemption to <em style="font: inherit;">not</em> disclose the unfulfilled performance obligations for contracts with an original length of <em style="font: inherit;">one</em> year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance.  The Company's unfulfilled performance obligations for contracts with an original length greater than <em style="font: inherit;">one</em> year were <em style="font: inherit;">not</em> material as of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Contracts with customers that contain instruments <em style="font: inherit;"> may </em>include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Payment terms for shipments to end-users are generally net <em style="font: inherit;">30</em> days. Payment terms for distributor shipments <em style="font: inherit;"> may </em>range from <em style="font: inherit;">30</em> to <em style="font: inherit;">90</em> days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than <em style="font: inherit;">one</em> year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over the contract period. Contract assets as of <em style="font: inherit;"> June 30, 2021 </em>are <em style="font: inherit;">not</em> material.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020 </em>were approximately $20.0 million and $14.2 million, respectively. Contract liabilities as of <em style="font: inherit;"> June 30, 2020 </em>subsequently recognized as revenue during the year ended <em style="font: inherit;"> June 30, </em><em style="font: inherit;">2021</em> were approximately $10.6 million. Contract liabilities in excess of <em style="font: inherit;">one</em> year are included in Other long-term liabilities on the balance sheet. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Any claims for credit or return of goods must be made within <em style="font: inherit;">10</em> days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have <em style="font: inherit;">not</em> been material.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The following tables present our disaggregated revenue for the periods presented.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Revenue by type is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Year ended June 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><i>2021</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2020</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2019</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Consumables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">751,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">588,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">93,782</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product and services revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">912,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">721,563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">694,567</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total revenues, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">931,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Revenue by geography is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2021</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2020</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2019</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">502,080</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">404,407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">391,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">EMEA, excluding U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">204,264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">APAC, excluding Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">69,013</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Rest of world</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,174</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,307</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total external sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">931,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 500000 20000000.0 14200000 10600000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Year ended June 30,</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><i>2021</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2020</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2019</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Consumables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">751,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">602,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">588,979</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Instruments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">93,782</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">71,462</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">66,416</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,459</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product and services revenue, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">912,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">721,563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">694,567</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,849</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,128</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,439</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total revenues, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">931,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2021</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2020</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2019</i></i></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 14%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">502,080</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">404,407</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">391,191</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">EMEA, excluding U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">204,264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.K.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,411</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,975</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">APAC, excluding Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">69,013</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60,362</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Greater China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,556</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,792</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57,799</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Rest of world</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,174</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,430</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,307</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total external sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">931,032</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 751985000 602642000 588979000 93782000 71462000 67538000 66416000 47459000 38050000 912183000 721563000 694567000 18849000 17128000 19439000 931032000 738691000 714006000 502080000 404407000 391191000 204264000 155289000 155821000 40945000 30411000 34975000 69013000 60362000 52913000 87556000 68792000 57799000 27174000 19430000 21307000 931032000 738691000 714006000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">3.</em></b><b><i> Supplemental Balance Sheet and Cash Flow Information:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Available-For-Sale Investments:</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The fair value of the Company's available-for-sale equity investments as of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020 </em>were $20.0 million and $87.8 million, respectively. The decrease was due to year-over-year decrease in the stock price of CCXI, which was $13.39 per share at <em style="font: inherit;"> June 30, 2021 </em>compared to $57.54 per share at <em style="font: inherit;"> June 30, 2020. </em>The amortized cost basis of the Company's investment in CCXI was $6.6 million and $6.6 million as of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020,</em> respectively. The Company's available-for-sale debt securities as of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020 </em>were $12.5 million and $36.4 million, respectively. The decrease is due to the timing of debt maturities and cash balances at the balance sheet date. </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Inventories:</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Inventories consist of (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">55,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">51,530</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,108</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Inventories, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">122,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,798</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">(<em style="font: inherit;">1</em>) Finished goods inventory of $<span style="background-color:#ffffff;">5,456 </span>and $4,646 is included within other long-term assets in the <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020 </em>Balance Sheets, respectively, as it forecasted to be sold after the <em style="font: inherit;">12</em> months subsequent to the consolidated balance sheet date.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Property and Equipment:</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Property and equipment consist of (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cost:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,516</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Buildings and improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190,661</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184,430</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Machinery, equipment and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">198,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">397,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">346,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(189,849</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(169,821</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">207,907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176,829</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Intangibles assets were comprised of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><i> </i></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><i> </i></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><i> </i></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><i> </i></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><i> </i></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Useful Life</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 49%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 4%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">552,160</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">434,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">147,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">146,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">232,493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">211,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Patents</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">10</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,926</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,475</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%; padding-left: 18pt;">Other intangibles<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;">5</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%; text-align: center;"><em style="font: inherit;">-</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;">15</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">6,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Definite-lived intangible assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">941,535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">795,591</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated amortization</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(348,267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(279,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Definite-lived intangibles assets, net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">593,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%; padding-left: 18pt;">In process research and development</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">22,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%; padding-left: 0pt;">Total intangible assets, net</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">615,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>) </sup>Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the <em style="font: inherit;">first</em> quarter of fiscal <em style="font: inherit;">2021</em> for certain <em style="font: inherit;">third</em> party patented technology acquired.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Changes to the carrying amount of net intangible assets consist of (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2021</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 265px;"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td style="width: 13px;"> </td><td style="width: 17px;"> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">579,429</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">153,311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other additions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(64,940</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(61,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Currency translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,140</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">615,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Amortization expense related to developed technologies included in cost of sales was $36.5 million, $34.5 million, and $33.3 million in fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $28.4 million, $26.6 million, and $25.4 million, in fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The estimated future amortization expense for intangible assets as of <em style="font: inherit;"> June 30, 2021,</em><span style="background-color:#ffffff;"> excluding any possible future amortization associated with acquired IPR&amp;D which has <em style="font: inherit;">not</em> met technological feasibility, is as follows (in thousands):</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74,482</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,649</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">69,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">66,523</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">247,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">593,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Changes in goodwill by segment and in total consist of (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Protein</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Sciences</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Diagnostics &amp;</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Genomics</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">377,407</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">355,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">732,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Currency Translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(4,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">373,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">355,229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">728,310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Acquisitions (Note 4)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,848</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">102,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Currency translation</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">11,788</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">11,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">392,717</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">450,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">843,067</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Supplemental Cash Flow Information:</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Supplemental cash flow information was as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income taxes paid</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,952</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,992</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest paid</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,615</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-cash activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Acquisition-related liabilities<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 27pt;">Other intangibles<sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">1</em>) Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes <em style="font: inherit;">4</em> and <em style="font: inherit;">5.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">2</em>) $4.0 million of the <em style="font: inherit;">third</em> party patented technology acquired in fiscal <em style="font: inherit;">2021</em> was a non-cash activity within the consolidated statement of cash flows as a cash payment was <em style="font: inherit;">not</em> made within the fiscal year ended <em style="font: inherit;"> June 30, 2021. </em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 20000000.0 87800000 13.39 57.54 6600000 6600000 12500000 36400000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">55,096</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">51,530</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,108</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Inventories, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">122,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">107,798</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 55096000 51530000 67108000 56268000 122204000 107798000 5456000 4646000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cost:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,516</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Buildings and improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190,661</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184,430</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Machinery, equipment and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">198,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">397,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">346,650</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(189,849</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(169,821</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">207,907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176,829</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 8612000 8516000 190661000 184430000 198483000 153704000 397756000 346650000 189849000 169821000 207907000 176829000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><i> </i></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><i> </i></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><i> </i></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><i> </i></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><i> </i></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Useful Life</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 49%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 4%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">552,160</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">434,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">147,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">146,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">232,493</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">211,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Patents</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">10</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,926</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,475</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%; padding-left: 18pt;">Other intangibles<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;">5</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%; text-align: center;"><em style="font: inherit;">-</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;">15</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">6,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Definite-lived intangible assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">941,535</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">795,591</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated amortization</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(348,267</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(279,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Definite-lived intangibles assets, net</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">593,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%; padding-left: 18pt;">In process research and development</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">22,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%; padding-left: 0pt;">Total intangible assets, net</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;"> </em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">615,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> P9Y P15Y 552160000 434653000 P2Y P20Y 147640000 146713000 P7Y P16Y 232493000 211750000 P10Y 2926000 2475000 P5Y P15Y 6316000 0 941535000 795591000 348267000 279046000 593268000 516545000 22700000 0 615968000 516545000 5000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2021</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13px;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 265px;"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td style="width: 13px;"> </td><td style="width: 17px;"> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">579,429</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">153,311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other additions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(64,940</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(61,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Currency translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,140</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">615,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 13px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 17px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 516545000 579429000 153311000 0 5912000 311000 64940000 61095000 -5140000 2100000 615968000 516545000 36500000 34500000 33300000 28400000 26600000 25400000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74,482</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,649</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">69,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">66,523</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">247,095</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">593,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 74482000 72649000 69780000 66523000 62739000 247095000 593268000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Protein</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Sciences</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Diagnostics &amp;</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Genomics</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">377,407</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">355,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">732,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions (Note 4)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(326</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Currency Translation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(4,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">373,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">355,229</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">728,310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Acquisitions (Note 4)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,848</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">94,970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">102,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Currency translation</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">11,788</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">11,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">392,717</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">450,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">843,067</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 377407000 355260000 732667000 -326000 0 -326000 -4000000 -31000 -4031000 373081000 355229000 728310000 7848000 94970000 102818000 11788000 151000 11939000 392717000 450350000 843067000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income taxes paid</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,952</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,992</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest paid</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,615</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-cash activities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Acquisition-related liabilities<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 27pt;">Other intangibles<sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 20952000 41992000 36814000 13576000 18615000 21497000 23600000 -2105000 12600000 4000000 0 0 4000000.0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Note <em style="font: inherit;">4</em></i></b><b>.</b><b><i> Acquisitions:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><em style="font: inherit;">2021</em> Acquisitions</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Eminence Biotechnology</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On <em style="font: inherit;"> October 20, 2020, </em>the Company acquired 47.6% of the outstanding equity shares of Changzhou Eminence Biotechnology Co., Ltd. (Eminence) for approximately $9.8 million, net of cash acquired. The fair value of the noncontrolling interest of $9.0 million included in the consolidated balance sheet was a non-cash activity within the statement of cash flows. Eminence is considered a variable interest entity as it is an early stage biotechnology company that required additional funding through a subsequent equity investment, which was used to fund Eminence’s expansion and GMP manufacturing capabilities within China. On <em style="font: inherit;"> April 2, 2021, </em>the Company invested approximately $6 million of additional funding into Eminence, increasing our percentage of outstanding equity shares to <span style="-sec-ix-hidden:c76648678">57.4%.</span> The Company was considered the primary beneficiary at the time of initial acquisition given the Company was the largest shareholder coupled with its ability to exercise significant influence over the entity. As of <em style="font: inherit;"> June 30, 2021, </em>the Company’s investment at risk is limited to its $15.8 million in investments.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC <em style="font: inherit;">805,</em> <i>Business Combinations</i>. In applying ASC <em style="font: inherit;">805</em> to the transaction, the Company has elected to include Eminence in our consolidated financial statements on a <em style="font: inherit;">one</em> month lag.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The fair value of the noncontrolling interest in Eminence was calculated utilizing cash flow projections discounted to the acquisition date and control premiums calculated using market data. Acquired goodwill is <em style="font: inherit;">not</em> deductible for income tax purposes. The business became part of the Protein Sciences reportable segment in the <em style="font: inherit;">second</em> quarter of fiscal year <em style="font: inherit;">2021.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The allocation of purchase consideration related to Eminence was completed in the <em style="font: inherit;">fourth</em> quarter of fiscal year <em style="font: inherit;">2021.</em> The fair values of the assets acquired and liabilities assumed at acquisition date and the updated final amounts as of <em style="font: inherit;"> June </em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021</em> are as follows (in thousands):</p> <p style="margin-left: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Preliminary<br/> Allocation at<br/> Acquisition<br/> Date</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="background-color:#ffffff;">Adjustments to Fair Value</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="background-color:#ffffff;">Final Allocation at June 30, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,145</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,639</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,639</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Intangible assets:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,778</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,133</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,811</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,848</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,506</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,543</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,436</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,320</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,357</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,765</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,765</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Fair value of noncontrolling interest in Eminence</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,985</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">As summarized in the table, there were adjustments totaling $1.0 million to goodwill during the measurement period. These adjustments relate to refinements within our deferred tax amounts based on factors existing on the acquisition date.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><br/> Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 13 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 10 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <i>Asuragen, Inc.</i> </div> <div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">   </div> <div style="font-size:10pt"> <div style="font-family:&quot;Times New Roman&quot;"> <div style="font-variant:normal"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">On <em style="font: inherit;"> April 6, 2021, </em>the Company acquired all of the ownership interests of Asuragen, Inc. for approximately $216 million, net of cash acquired, plus contingent consideration of up to $105.0 million, subject to certain revenue thresholds. The Asuragen acquisition adds a leading portfolio of best in-class molecular diagnostic and research products, including genetic screening, oncology testing kits, molecular controls, a GMP compliant manufacturing facility, and a CLIA-certified laboratory. The transaction was accounted for in accordance with ASC <em style="font: inherit;">805,</em> <i>Business Combinations</i>. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is <em style="font: inherit;">not</em> deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the <em style="font: inherit;">fourth</em> quarter of fiscal year <em style="font: inherit;">2021.</em> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> </div> </div> </div> <div style="font-size:10pt"> <div style="font-family:&quot;Times New Roman&quot;"> <div style="font-variant:normal"> The allocation of purchase consideration related to Asuragen Inc is considered preliminary with provisional amounts primarily rel <span style="background-color:#ffffff;">ated to goodwill and income tax assessment of acquired net operating losses. The Company</span> expects to finalize the allocation of purchase price within the <em style="font: inherit;">one</em>-year measurement-period following the acquisition. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations in fiscal year <em style="font: inherit;">2021</em> were approximately <span style="background-color:#ffffff;">$7.1 </span>million and $ <span style="background-color:#ffffff;">3.4 m</span>illion, respectively. The preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date and at <em style="font: inherit;"> June </em> <em style="font: inherit;">30,</em> <em style="font: inherit;">2021</em> are as follows (in thousands): </div> </div> </div> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Preliminary allocation at acquisition date and at June <span style="background-color:#ffffff;">30, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,422</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,762</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Intangible assets:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">107,000</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">In-process research and development</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,700</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,700</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Tradenames</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,000</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Non-competition agreement</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">94,970</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">253,554</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,003</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,664</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">233,887</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">215,587</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Contingent consideration payable</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,300</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">233,887</p> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology, in-process research and development, and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be<span style="background-color:#ffffff;"> 14 </span>years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be<span style="background-color:#ffffff;"> 16 y</span>ears.  The amount recorded for tradenames and the non-competition agreement is being amortized with the expense reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for tradenames and the non-competition agreement is estimated to be 5 years and 3 years, respectively. <span style="background-color:#ffffff;">The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><em style="font: inherit;">2019</em> Acquisitions</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Quad Technologies</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> July 2, 2018, </em>the Company acquired QT Holdings Corporation (Quad) for approximately $20.5 million, net of cash acquired, plus contingent consideration of up to $51.0 million, subject to certain product development milestones and revenue thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is <em style="font: inherit;">not</em> deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the <em style="font: inherit;">first</em> quarter of fiscal year <em style="font: inherit;">2019.</em> Purchase accounting was finalized during fiscal <em style="font: inherit;">2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible assets acquired in fiscal <em style="font: inherit;">2019</em> is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for our calculation of acquired net operating losses (NOLs).</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Exosome Diagnostics</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> August 1, 2018, </em>the Company acquired Exosome Diagnostics, Inc. (ExosomeDx) for approximately $251.6 million, net of cash acquired, plus contingent consideration of up to $325.0 million, subject to certain EBITA thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is <em style="font: inherit;">not</em> deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the <em style="font: inherit;">first</em> quarter of fiscal year <em style="font: inherit;">2019.</em> Purchase accounting was finalized during fiscal <em style="font: inherit;">2019.</em> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal <em style="font: inherit;">2019</em> are 15 years for developed technology and trade names, and 14 years for customer relationships. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs t<span style="background-color:#ffffff;">o be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="background-color:#ffffff;">Note: As part of the ExosomeDx acquisition, a certain amount of the cash payment was held in escrow. As part of the finalization of the outstanding amounts held in escrow, the Company recognized a gain of $7.2 million during fiscal year <em style="font: inherit;">2020</em> relat</span>ed to returned proceeds and a relief of any future contingent payments as described in Note <em style="font: inherit;">5.</em> The gain was recorded within selling, general, and administrative costs in the Consolidated Statement of Comprehensive Income. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>B-MoGen Biotechnologies</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> June 4, 2019, </em>the Company acquired the remaining interest in B-MoGen Biotechnologies Inc. (B-MoGen) for approximately $17.5 million, net of cash acquired, plus contingent consideration of up to $38.0 million, subject to certain product development milestones and revenue thresholds. The Company previously held an investment of $1.4 million in B-MoGen and recognized a gain of approx<span style="background-color:#ffffff;">imately $3.7 million on the transaction within other non-operating income fiscal year <em style="font: inherit;">2019</em> in the consolidated st</span>atements of earnings and comprehensive income, which represented the adjustment of our historical investment to its fair value. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is <em style="font: inherit;">not</em> deductible for income tax purposes. The business became part of the Protein Sciences segment in the <em style="font: inherit;">fourth</em> quarter of fiscal year <em style="font: inherit;">2019.</em> Purchase accounting remained opened as disclosed in our prior year <em style="font: inherit;">10</em>-K/A for working capital adjustments and our income tax assessment of acquired net operating losses (NOLs) with the completion of the stub period tax returns. Our purchase accounting was finalized in fiscal <em style="font: inherit;">2020</em> with an immaterial adjustment of $0.3 million to deferred tax amounts and goodwill. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible asset acquired in fiscal <em style="font: inherit;">2019</em> is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is <em style="font: inherit;">not</em> deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">B-MoGen</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Biotechnologies</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exosome</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Diagnostics</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Quad</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Technologies</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,611</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">269</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,212</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">228</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Intangible assets:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">105,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,256</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Trade name</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">58,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,131</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">105,362</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,481</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,304</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">275,485</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,001</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,716</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">296</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,051</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">943</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">251,623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,462</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Additional consideration<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,594</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,300</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>)</sup>Additional consideration for the B-MoGen acquisition includes a previously held investment of $1.4 million and a gain of approximately $3.7 million recorded on the transaction. The remaining additional consideration for B-MoGen, ExosomeDx, and Quad relate to the opening balance sheet value of contingent consideration.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are <em style="font: inherit;">not</em> deductible for income tax purposes, and the future tax benefit of net operating loss and tax credit carryforwards which will be deductible by the Company in future periods. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.476 9800000 9000000.0 6000000 15800000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Preliminary<br/> Allocation at<br/> Acquisition<br/> Date</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="background-color:#ffffff;">Adjustments to Fair Value</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="background-color:#ffffff;">Final Allocation at June 30, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,145</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,145</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,639</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,639</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Intangible assets:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,778</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,133</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,133</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,811</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,848</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,506</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,543</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,436</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,320</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,357</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,765</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,765</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Fair value of noncontrolling interest in Eminence</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,985</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,750</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Preliminary allocation at acquisition date and at June <span style="background-color:#ffffff;">30, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,422</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,762</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Intangible assets:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">107,000</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">In-process research and development</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,700</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,700</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Tradenames</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,000</td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Non-competition agreement</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">94,970</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">253,554</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,003</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,664</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">233,887</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">215,587</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Contingent consideration payable</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,300</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">233,887</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">B-MoGen</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Biotechnologies</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exosome</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Diagnostics</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Quad</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Technologies</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets, net of cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,611</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and other long-term assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">269</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,212</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">228</td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Intangible assets:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">105,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,256</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Trade name</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">58,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,131</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">105,362</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,481</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,304</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">275,485</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,001</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,716</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">296</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,051</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">943</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid, net of cash acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">251,623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,462</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Additional consideration<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,594</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,300</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,762</td></tr> </tbody></table> 3145000 3145000 1639000 1639000 6778000 6778000 2133000 2133000 8811000 -963000 7848000 22506000 -963000 21543000 1436000 1436000 2320000 -963000 1357000 18750000 18750000 9765000 9765000 8985000 8985000 18750000 18750000 -1000000.0 P13Y P10Y 216000000 105000000.0 7100000 -3400000 10422000 3762000 107000000 22700000 11700000 2000000 1000000 94970000 253554000 4003000 15664000 233887000 215587000 18300000 233887000 P14Y P16Y P5Y P3Y 20500000 51000000.0 P14Y 251600000 325000000.0 P15Y P14Y 7200000 17500000 38000000.0 1400000 3700000 300000 P14Y 504000 2611000 36000 269000 2212000 228000 14000000 105000000 12256000 58000000 400000 2300000 16131000 105362000 14481000 31304000 275485000 27001000 211000 3716000 296000 3051000 16346000 943000 28042000 255423000 25762000 17448000 251623000 20462000 10594000 3800000 5300000 28042000 255423000 25762000 1400000 3700000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Note </i></b><b><em style="font: inherit;">5.</em></b><b><i> Fair Value Measurements:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into <em style="font: inherit;">three</em> levels. Level <em style="font: inherit;">1</em> inputs are quoted prices in active markets for identical assets or liabilities. Level <em style="font: inherit;">2</em> inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are <em style="font: inherit;">not</em> active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level <em style="font: inherit;">3</em> inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least <em style="font: inherit;">one</em> significant model assumption or input is unobservable. Level <em style="font: inherit;">3</em> <em style="font: inherit;"> may </em>also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>carrying</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>value as of</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 1</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 2</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 3</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Derivative instruments - cash flow hedges</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,657</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Derivative instruments - cash flow hedges</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,776</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>carrying</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>value as of</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2020</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 1</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 2</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 3</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">87,842</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79,846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">7,996</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">124,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">7,996</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;">$</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">6,137</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Derivative instruments - cash flow hedges</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">17,331</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">17,331</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:3.3%;"> </td><td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>) Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020 </em>was $6.6 million and $6.6 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.4 million as of <em style="font: inherit;"> June </em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021.</em> The fair value of the warrant as of <em style="font: inherit;"> June 30, 2020 </em>was $8.0 million </p> </td></tr> <tr><td style="vertical-align:middle;width:3.3%;"> </td><td style="vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">2</em>) Included in available-for-sale investments on the balance sheet.  The certificate of deposits have contractual maturity dates within <em style="font: inherit;">one</em> year.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Fair value measurements of available for sale securities</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Available for sale securities excluding warrants are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level <i><em style="font: inherit;">1</em></i> assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level <i><em style="font: inherit;">2</em></i> asset. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Fair value measurements of derivative instruments</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> October</em><i> </i><em style="font: inherit;">2018</em><i>,</i> the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note <em style="font: inherit;">6</em> to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount. The notional amount decreased by $100 million in  <em style="font: inherit;"> October </em><em style="font: inherit;">2020</em> and will further decrease by $80 million in  <em style="font: inherit;"> October 2021 </em>and $200 million in  <em style="font: inherit;"> October 2022. </em>In  <em style="font: inherit;"> June 2020, </em>the Company de-designated $80 million of the notional amount set to expire in <em style="font: inherit;"> October 2020. </em>The net loss associated with the <em style="font: inherit;"> June 2020 </em>de-designated portion of the derivative instrument was <em style="font: inherit;">not</em> reclassified into earnings based on the amount of probable variable interest payments to occur within a <em style="font: inherit;">two</em> month time period of the forecasted hedged transaction. In <em style="font: inherit;"> December 2020, </em>the Company de-designated an additional $80 million of notional amount set to expire in <em style="font: inherit;"> October 2021. </em>During fiscal year <em style="font: inherit;">2021,</em> the Company recorded a loss in other non-operating income related to variable interest debt payments in certain months on a portion of the de-designated derivative that is <em style="font: inherit;">not</em> expected to occur. The remaining variable interest payments for the portion of the de-designated derivative were considered probable of occurring and therefore remain in accumulated other comprehensive income as of <em style="font: inherit;"> June 30, 2021. </em>The fair value of the portion of the de-designated derivative was $0.8 million as of <em style="font: inherit;"> June 30, 2021, </em>which is recorded within short-term liabilities on the Consolidated Balance Sheet. The fair value of the designated derivative instrument is $7.6 million as of <em style="font: inherit;"> June 30, 2021 </em>and is recorded within other long-term liabilities on the Consolidated Balance Sheet. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> May 2021, </em>the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt. The forward starting swap reduces the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swap, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on $200 million of notional principal amount. The effective date of the swap is <em style="font: inherit;"> November 2022 </em>with the full swap maturing in <em style="font: inherit;"> November 2025. </em>The fair value of the derivative instrument was $0.3 million as of <em style="font: inherit;"> June 30, 2021 </em>which is recorded within other long-term assets on the Consolidated Balance Sheet.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Changes in the fair value of the designated hedged instrument are reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $8.6 million to interest expense, $0.5 million to non-operating income for the portion of de-designated variable payments considered probable to <em style="font: inherit;">not</em> occur, and related tax benefits of $2.1 million during the fiscal year ended <em style="font: inherit;"> June 30, 2021 </em>relating to the cash flow hedge entered into in <em style="font: inherit;"> October 2018. </em><em style="font: inherit;">No</em> amounts were reclassified relating to the cash flow hedge entered into in <em style="font: inherit;"> May 2021 </em>as they will be recorded within the effective period of the cash flow hedge.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company reclassified $3.5 million, net of taxes, to interest expense during the fiscal year ended <em style="font: inherit;"> June 30, 2020. </em>The change in the fair value of the de-designated notional hedged amount was <em style="font: inherit;">not</em> material as of <em style="font: inherit;"> June 30, 2020. </em>The instruments were valued using observable market inputs in active markets and therefore are classified as Level <em style="font: inherit;">2</em> liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company did <em style="font: inherit;">not</em> reclassify any amounts out of other comprehensive income into interest expense during the fiscal year ended <em style="font: inherit;"> June 30, 2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>Fair value measurements of contingent consideration</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has $29.4 million, which is the fair value, of contingent consideration related to the Asuragen, Quad, and B-MoGen acquisitions. The Company is required to make contingent consideration payments of up to $105.0 million, $51.0  million, and $38.0 million, respectively, as part of these acquisition agreements. The contingent agreement with Asuragen was based on achieving certain revenue thresholds, the contingent agreement with Quad is based on meeting certain product development milestones and revenue thresholds, and the contingent agreement with B-MoGen is based on meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the Asuragen acquisition was $18.3 million as discussed in Note <em style="font: inherit;">4.</em> The preliminary fair value of the revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors.   </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the <em style="font: inherit;">fourth</em> quarter of fiscal <em style="font: inherit;">2020,</em> the Company's obligation for potential contingent consideration payments related to the ExosomeDx acquisition were relieved as part of the Company's escrow settlement with the former shareholders of ExosomeDx. As the result of this settlement, the Company reversed an accrual for the fair value of the contingent liability at the date of settlement.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The ultimate settlement of contingent consideration liabilities for the Asuragen, Quad, and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level <em style="font: inherit;">3</em> financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level <em style="font: inherit;">3</em>) (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value at the beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchase price contingent consideration (Note 4)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gain on escrow settlement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">(1,200</td><td style="font-family: Times New Roman; font-size: 10pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(905</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Contingent consideration payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Fair value measurements of other financial instruments </i>– The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility  and long-term debt approximates fair value because our interest rate is variable and reflects current market rates. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>carrying</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>value as of</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 1</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 2</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 3</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Derivative instruments - cash flow hedges</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">32,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">31,081</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,657</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Derivative instruments - cash flow hedges</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37,776</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>carrying</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>value as of</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Fair Value Measurements Using</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Inputs Considered as</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2020</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 1</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 2</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Level 3</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Equity securities (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">87,842</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79,846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">7,996</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Certificates of deposit (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,426</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">124,268</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116,272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">7,996</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;">$</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">-</em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">6,137</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Derivative instruments - cash flow hedges</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">17,331</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">23,468</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">17,331</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 19963000 18581000 1382000 0 12500000 12500000 0 0 275000 0 275000 0 32738000 31081000 1657000 0 29400000 0 0 29400000 8376000 0 8376000 0 37776000 0 8376000 29400000 87842000 79846000 0 36426000 36426000 124268000 116272000 0 6137000 17331000 0 23468000 6137000 6600000 6600000 1400000 8000000.0 380000000 100000000 80000000 200000000 80000000 80000000 800000 7600000 200000000 300000 8600000 -500000 -2100000 3500000 29400000 105000000.0 51000000.0 38000000.0 18300000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value at the beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchase price contingent consideration (Note 4)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gain on escrow settlement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">(1,200</td><td style="font-family: Times New Roman; font-size: 10pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(905</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Contingent consideration payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,137</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 6137000 12600000 18300000 0 337000 4358000 -0 1200000 -5300000 905000 29400000 6137000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Note </i></b><b><em style="font: inherit;">6</em></b><b><i>. Debt and Other Financing Arrangements:</i></b> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> August 1, 2018, </em>the Company entered into a new uncollateralized revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement <em style="font: inherit;"> may </em>be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined for the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 12.5 basis points. The Company has recorded $12.5 million of our outstanding borrowings under the Credit Agreement as a current liability in our Consolidated Balance sheet, which represents our required quarterly debt payments to be made in fiscal year <em style="font: inherit;">2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Credit Agreement matures on <em style="font: inherit;"> August 1, 2023 </em>and contains customary restrictive and financial covenants and customary events of default. At the closing on <em style="font: inherit;"> August 1, 2018 </em>the company borrowed $250.0 million under the term loan and $330.0 million under the revolving credit facility. As of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;">2020,</em> the outstanding balance under the Credit Agreement was $341 million and $357 million respectively. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/> 600000000.0 200000000.0 250000000.0 0.00125 12500000 250000000.0 330000000.0 341000000 357000000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Note <em style="font: inherit;">7.</em> Leases:</i></b> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> and related standards (collectively ASC <em style="font: inherit;">842,</em> <i>Leases</i>), which replaced previous lease accounting guidance, on <em style="font: inherit;"> July 1, 2019. </em></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During fiscal year <em style="font: inherit;">2021,</em> the Company recognized $3.6 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income.  During fiscal year <em style="font: inherit;">2021,</em> the Company also recognized $32.5 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income. </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The following table summarizes the balance sheet classification of the Company’s operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%; border-bottom: 1px solid black;"><i>Balance Sheet Classification</i></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>As of: </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Operating lease right of use assets<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;">Right of Use Asset</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 14%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current operating lease liabilities<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;">Operating lease liabilities current</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,602</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Noncurrent operating lease liabilities<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;">Operating lease liabilities</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,625</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total operating lease liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 14%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average remaining lease term (in years):</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 14%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average discount rate:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>) The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in <em style="font: inherit;"> June 2021 </em>for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal <em style="font: inherit;">2022</em> after construction is completed by the landlord. As the lease has <em style="font: inherit;">not</em> commenced as of <em style="font: inherit;"> June 30, 2021, </em>the related asset and liability were <em style="font: inherit;">not</em> recorded.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended  <em style="font: inherit;"> June 30, 2021 (</em>in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>For the year</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>ended June</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>30,</i> <i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash amounts paid on operating lease liabilities(1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,492</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use assets obtained in exchange for lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">(<em style="font: inherit;">1</em>) Total cash paid for the Company's operating leases during the year ended <em style="font: inherit;"> June 30, 2021 </em>include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The following table summarizes payments by date for the Company’s operating leases, which is then reconciled to our total lease obligation (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 30, 2021</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,840</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">92,791</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Amounts representing interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">13,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease obligations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Certain leases include <em style="font: inherit;">one</em> or more options to renew, with terms that extend the lease term up to <span style="-sec-ix-hidden:c76649010">five</span> years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is <em style="font: inherit;">not</em> reasonably certain to exercise such options.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> 3600000 32500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%; border-bottom: 1px solid black;"><i>Balance Sheet Classification</i></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>As of: </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30,</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Operating lease right of use assets<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;">Right of Use Asset</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 14%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current operating lease liabilities<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;">Operating lease liabilities current</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,602</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Noncurrent operating lease liabilities<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;">Operating lease liabilities</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">67,625</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total operating lease liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 14%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average remaining lease term (in years):</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 14%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average discount rate:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr> </tbody></table> 73834000 11602000 67625000 79227000 P7Y11M19D 0.0393 25000 P25Y 300000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>For the year</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>ended June</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>30,</i> <i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash amounts paid on operating lease liabilities(1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,492</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use assets obtained in exchange for lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,144</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 13492000 12144000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 30, 2021</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Operating</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Leases</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,840</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">92,791</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Amounts representing interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">13,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease obligations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 14349000 13371000 11840000 10780000 10120000 32331000 92791000 13564000 79227000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">8.</em></b><b><i> Supplemental Equity and</i></b> <b><i>Accumulated Other Comprehensive Income (loss):</i></b> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Supplemental Equity </i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company has declared cash dividends per share of $<span style="background-color:#ffffff;">1.28 </span>in each of the full fiscal years ended <em style="font: inherit;"> June 30, 2021, </em><em style="font: inherit;"> June 30, 2020, </em>and <em style="font: inherit;"> June 30, 2019. </em>During the years ended <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020, </em>the Company repurchased 120,000 shares at an average share <span style="color:#000000;">price of $359.81 <span style="background-color:#ffffff;">and </span><em style="font: inherit;">2</em></span><span style="-sec-ix-hidden:c76649042">79,381</span> shares at an average share price of $179.37, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the amounts within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise options due to net settlement stock options exercises were <em style="font: inherit;">not</em> material.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Accumulated Other Comprehensive Income (loss)</i> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Changes in accumulated other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Unrealized</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Gains</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(Losses)</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>on</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Available-</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>for-Sale </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Investments</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Foreign </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Currency</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Translation </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Adjustments</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Unrealized</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Gains</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(Losses) on</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Derivatives</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Instruments</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2018 </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,682</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(69,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(44,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cumulative effect adjustment for adoption for ASU 2018-02</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cumulative effect adjustment for adoption for ASU 2016-01</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,487</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,537</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,024</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(73,983</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,537</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(83,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7,179</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="background-color:#ffffff;">Reclassification from loss on derivatives to interest expense, net of taxes</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,464</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,464</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(83,946</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(97,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Other comprehensive income (loss) before reclassifications<sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,848</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,948</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Reclassification from loss on derivatives to interest expense, net of taxes<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">6,960</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">6,960</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Balance June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(6,193</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,291</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">(<em style="font: inherit;">1</em>) Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable <em style="font: inherit;">not</em> to occur as further discussed in Note <em style="font: inherit;">5</em> for the fiscal year ended <em style="font: inherit;"> June 30, 2021. </em>The Company also recorded a related tax benefit of $2,150 during fiscal <em style="font: inherit;">2021.</em> The Company had deferred tax benefits of $<span style="background-color:#ffffff;">1,908 and </span>$4,058 included in the accumulated other comprehensive income loss as of <em style="font: inherit;"> June 30, 2021 </em>and <em style="font: inherit;"> June 30, 2020</em><i>,</i> respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">(<em style="font: inherit;">2</em>) Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1.28 120000 359.81 179.37 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Unrealized</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Gains</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(Losses)</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>on</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Available-</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>for-Sale </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Investments</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Foreign </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Currency</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Translation </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Adjustments</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Unrealized</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Gains</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(Losses) on</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Derivatives</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Instruments</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Total</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2018 </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,682</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(69,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(44,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cumulative effect adjustment for adoption for ASU 2018-02</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cumulative effect adjustment for adoption for ASU 2016-01</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(27,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,487</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,537</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,024</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(73,983</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,537</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(83,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income (loss) before reclassifications</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7,179</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(17,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="background-color:#ffffff;">Reclassification from loss on derivatives to interest expense, net of taxes</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,464</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,464</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(83,946</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(97,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Other comprehensive income (loss) before reclassifications<sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,848</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32,948</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Reclassification from loss on derivatives to interest expense, net of taxes<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">6,960</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">6,960</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Balance June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(6,193</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(57,291</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 24682000 -69496000 0 -44814000 2371000 0 0 2371000 -27053000 0 0 -27053000 0 -4487000 -9537000 -14024000 0 -73983000 -9537000 -83521000 0 -9963000 -7179000 -17142000 -0 -0 -3464000 -3464000 0 -83946000 -13253000 -97199000 0 32848000 100000 32948000 -0 -0 -6960000 -6960000 0 -51098000 -6193000 -57291000 8598000 512000 2150000 -1908000 -4058000 103000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">9.</em></b><b><i> Earnings Per Share:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2020</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2019</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Net earnings, including noncontrolling interest</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Less net earnings attributable to noncontrolling interest</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(825</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,324</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">229,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,324</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">229,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Dilutive effect of stock options and restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average common shares outstanding – diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,401</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have <em style="font: inherit;">not</em> yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was <em style="font: inherit;">0</em><span style="background-color:#ffffff;"><span style="-sec-ix-hidden:c76649115">.6</span> </span>million, 0.9 million, and 1.3 million for the fiscal years ended <em style="font: inherit;"> June 30, 2021, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2020</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2019</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – basic:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Net earnings, including noncontrolling interest</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139,585</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 18pt;">Less net earnings attributable to noncontrolling interest</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(825</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,324</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">229,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.62</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Earnings per share – diluted:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,410</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">229,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income allocated to participating securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(224</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Income available to common shareholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">140,324</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">229,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average shares outstanding – basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,747</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,201</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Dilutive effect of stock options and restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,736</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted-average common shares outstanding – diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,401</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Earnings per share – diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 139585000 229296000 96072000 -825000 0 0 140410000 229296000 96072000 86000 224000 105000 140324000 229072000 95967000 38747000 38201000 37781000 3.62 6.00 2.54 140410000 229296000 96072000 86000 224000 105000 140324000 229072000 95967000 38747000 38201000 37781000 1736000 1200000 1111000 40483000 39401000 38892000 3.47 5.82 2.47 900000 1300000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">10.</em></b> <b><i>Share-based Compensation and Other Benefit Plans:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Equity incentive plan:</i> The Company's Second Amended and Restated <em style="font: inherit;">2010</em> Equity Incentive Plan (the Second A&amp;R <em style="font: inherit;">2010</em> Plan) provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There were 7.5 million shares of common stock authorized for grant under the Second A&amp;R <em style="font: inherit;">2010</em> Plan. In <em style="font: inherit;"> October 2020, </em>the shareholders approved an amended and restated incentive plan - the <em style="font: inherit;">2020</em> Equity Incentive Plan. The maximum aggregate number of shares of common stock reserved and available for awards under the Amended Plan is 2,484,202 shares, which includes an additional 1,300,000 shares authorized by the <em style="font: inherit;">2020</em> Equity Incentive Plan. Shares issued after the shareholder meeting are issued under the <em style="font: inherit;">2020</em> Equity Incentive Plan. At <em style="font: inherit;"> June 30, 2021, </em>there were 1.1 million shares of common stock available for grant under the <em style="font: inherit;">2020</em> Equity Incentive Plan. The maximum term of incentive options granted under the <em style="font: inherit;">2020</em> Equity Incentive Plan is <span style="-sec-ix-hidden:c76649179">ten</span> years. The <em style="font: inherit;">2020</em> Equity Incentive Plan replaced the Company's <em style="font: inherit;">second</em> A&amp;R <em style="font: inherit;">2010</em> Plan, which had previously amended and restated the Company's Amended and Restate <em style="font: inherit;">2010</em> Equity Incentive Plan (the A&amp;R <em style="font: inherit;">2010</em> Plan). The A&amp;R <em style="font: inherit;">2010</em> Plan had previously replaced the Company's <em style="font: inherit;">1998</em> Nonqualified Stock Option Plan (the <em style="font: inherit;">1998</em> Plan). The Second A&amp;R <em style="font: inherit;">2010</em> Plan and the <em style="font: inherit;">1998</em> Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of  <em style="font: inherit;"> June 30, 2021 </em>under the <em style="font: inherit;">2020</em> Equity Incentive Plan were 3.7 million.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0.24%</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0.67%</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0.74%</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">30%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">22%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">23%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.2%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.3%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.9%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.5%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.0%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected lives (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">4.4</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.0</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Stock option activity under the Plans for the <em style="font: inherit;">three</em> years ended <em style="font: inherit;"> June 30, 2021, </em>consists of the following (shares in thousands): </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Number of </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Shares (in</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>thousands)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted</i><br/> <i>Average</i><br/> <i>Exercise</i><br/> <i>Price</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Aggregate</i><br/> <i>Intrinsic</i><br/> <i>Value</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(millions)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Contractual</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Life (years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td style="width: 15px;"> </td><td style="width: 177px;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">105.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">917</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">173.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(330</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">129.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(383</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">95.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95.97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(743</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">157.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,609</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">140.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Granted</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">763</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">277.75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Forfeited</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">214.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Exercised</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(627</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">112.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Outstanding at June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,717</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">172.63</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,031.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td style="width: 15px;"> </td><td style="width: 177px;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2019:</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">98.70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2020:</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">112.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Exercisable at June 30, 2021:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">126.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">571.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The weighted average fair value of options granted during fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> was $59.75, $37.01, and $34.66 respectively. The total intrinsic value of options exercised during fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> <span style="background-color:#ffffff;">and <em style="font: inherit;">2019</em> were $145.6 m</span>illion, $99.3 million, and $159.0 million, respectively. The total fair value of options vested during fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019</em> were $70.5 million, $71.1 million, and $31.7 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Restricted common stock activity under the Plans for the <em style="font: inherit;">three</em> years ended <em style="font: inherit;"> June 30, 2021, </em>consists of the following (units in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Number of </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Shares (in </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>thousands)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average Grant</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Date Fair </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Value</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Remaining</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Contractual</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Term</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">177.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">116.76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">147.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">193.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142.12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">177.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Granted</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">264.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Vested</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">171.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Forfeited</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Unvested at June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">226.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The total fair value of restricted shares that vested was $2.8 million for fiscal <em style="font: inherit;">2021,</em> $2.5 million for fiscal <em style="font: inherit;">2020,</em> and $2.3 million for fiscal <em style="font: inherit;">2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Restricted stock unit activity under the Plans for the <em style="font: inherit;">three</em> years ended <em style="font: inherit;"> June 30, 2021, </em>consists of the following (units in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Number of </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Units</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(in thousands)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average Grant</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Date Fair </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Value</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Remaining</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Contractual</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Term</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">170.96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">110.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">143.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">134.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">111.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">155.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">159.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Granted</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">300.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Vested</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Forfeited</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Outstanding at June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">220.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The total fair value of restricted stock units that vested was $<span style="background-color:#ffffff;">6.7 </span>million for fiscal <em style="font: inherit;">2021,</em> $5.7 million for fiscal <em style="font: inherit;">2020,</em> and $3.1 million for fiscal <em style="font: inherit;">2019.</em> The restricted stock units vest over a <span style="-sec-ix-hidden:c76649226">three</span>-year period.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Stock-based compensation cost, inclusive of payroll taxes, of $46.4 million, $32.4 million, and $32.3 million was included in selling, general and administrative expense in fiscal <em style="font: inherit;">2021,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively. Additionally, stock-based compensation costs, inclusive of payroll taxes, of $1.6 million was included in cost of goods sold in <em style="font: inherit;">2021.</em> As of <em style="font: inherit;"> June 30, 2021, </em>there was $37.1 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal <em style="font: inherit;">2022</em> through <em style="font: inherit;">2024</em> using a 4.6% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Employee stock purchase plan:</i> In fiscal year <em style="font: inherit;">2015,</em> the Company established the Bio-Techne Corporation <em style="font: inherit;">2014</em> Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on <em style="font: inherit;"> October 30, 2014, </em>and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.9 million, $0.4 million, and $0.5 million for the ESPP in fiscal <span style="background-color:#ffffff;"><em style="font: inherit;">2021</em></span>, <em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Profit sharing and savings plans: </i>The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for <em style="font: inherit;">401</em>(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $3.4 million, $3.2 million, and $2.8 million for the years ended <em style="font: inherit;"> June 30, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019,</em> respectively. The Company operates defined contribution pension plans for its U.K. employees. The Company has recorded an expense for contributions to the plans of $1.6 million for year ended <em style="font: inherit;"> June 30, 2021 </em>an<span style="background-color:#ffffff;">d $1.4 million for each of the years ended <em style="font: inherit;"> June 30,  </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019.</em></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Performance incentive programs: </i>In fiscal <em style="font: inherit;">2021,</em> under certain employment agreements, a Management Incentive Plan, and a business incentive plan, available to executive officers, certain management personnel, and certain other professional employees, the Company recorded cash bonuses of $<span style="background-color:#ffffff;">21.1 m</span>illion, granted options for 762,761 shares of common stock, issued 11,803 restricted common shares and 30,823 restricted stock units. In fiscal <em style="font: inherit;">2020</em> and fiscal <em style="font: inherit;">2019,</em> the Company recorded cash bonuses of $10.5 million and $9.3 million, granted options for 751,499 and 618,898 shares of common stock, and issued 15,398 and 11,279 restricted common stock shares and 30,858 and 25,903 restricted stock, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 7500000 2484202 1300000 1100000 3700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 47%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 46%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 5%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0.24%</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0.67%</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0.74%</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">30%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">22%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">23%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.2%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.3%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.9%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.5%</td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.0%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected lives (years)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">4.4</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.0</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="width: 5%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 5%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> </tbody></table> 0.0024 0.0067 0.0074 0.25 0.30 0.22 0.24 0.20 0.23 0.002 0.007 0.013 0.019 0.025 0.030 P4Y4M24D P4Y P4Y1M6D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Number of </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Shares (in</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>thousands)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted</i><br/> <i>Average</i><br/> <i>Exercise</i><br/> <i>Price</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Aggregate</i><br/> <i>Intrinsic</i><br/> <i>Value</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(millions)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Contractual</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Life (years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td style="width: 15px;"> </td><td style="width: 177px;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">105.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">917</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">173.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(330</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">129.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(383</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">95.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,656</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190.80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95.97</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(743</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">157.45</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,609</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">140.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Granted</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">763</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">277.75</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Forfeited</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">214.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Exercised</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(627</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">112.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Outstanding at June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,717</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">172.63</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,031.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td style="width: 15px;"> </td><td style="width: 177px;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2019:</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,467</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">98.70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 15px;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 177px;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at June 30, 2020:</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">112.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Exercisable at June 30, 2021:</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">126.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 15px; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 177px; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">571.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 3452000 105.17 917000 173.89 330000 129.93 383000 95.29 3656000 121.16 752000 190.80 56000 95.97 743000 157.45 3609000 140.28 763000 277.75 28000 214.33 627000 112.53 3717000 172.63 1031900000 P4Y1M6D 1467000 98.70 1564000 112.60 1764000 126.44 571300000 P3Y 59.75 37.01 34.66 145600000 99300000 159000000.0 70500000 71100000 31700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Number of </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Shares (in </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>thousands)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average Grant</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Date Fair </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Value</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Remaining</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Contractual</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Term</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">177.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">116.76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">147.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">193.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142.12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">177.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Granted</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">264.73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Vested</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">171.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Forfeited</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Unvested at June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">23</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">226.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Number of </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Units</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(in thousands)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average Grant</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Date Fair </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Value</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Weighted </i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Average</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Remaining</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Contractual</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Term</i></i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>(years)</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2018</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">117.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">170.96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">110.86</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">143.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">134.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">192.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">111.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">155.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at June 30, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">159.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Granted</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">300.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Vested</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Forfeited</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">Outstanding at June 30, 2021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px solid black;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px solid black;">220.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 35000 117.39 15000 177.93 20000 116.76 -0 0 30000 147.94 15000 193.48 18000 142.12 -0 0 28000 177.20 12000 264.73 17000 171.64 -0 0 23000 226.07 P6Y25D 2800000 2500000 2300000 148000 117.95 56000 170.96 28000 110.86 36000 143.72 139000 134.17 31000 192.08 51000 111.07 3000 155.60 116000 159.25 31000 300.78 51000 130.18 -0 0 96000 220.53 P5Y4M9D 6700000 5700000 3100000 46400000 32400000 32300000 1600000 37100000 0.046 P2Y1M6D 200000 900000 400000 500000 3400000 3200000 2800000 1600000 1400000 21100000 762761 11803 30823 10500000 9300000 751499 618898 15398 11279 30858 25903 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">11.</em></b><b><i> Income Taxes:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Income before income taxes was comprised of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,662</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">245,365</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64,081</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">52,513</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,112</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,934</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Income before income taxes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">148,175</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">276,477</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,015</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The provision for income taxes consisted of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i><span style="background-color:#ffffff;">2021</span></i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Taxes on income consist of:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Currently tax provision:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,179</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,976</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,090</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,681</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,018</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">544</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,743</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,580</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current tax provision</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,603</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,574</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29,963</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax provision:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(20,812</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,074</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(6,903</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,962</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,055</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,977</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c76649561">(2,239</span></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,522</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,142</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax provision</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28,013</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,607</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,021</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total income tax provision</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="background-color:#ffffff;">$</span></td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: medium double rgb(0, 0, 0); padding: 0px;"> <div style="background-color: rgb(255, 255, 255);"> 8,590 </div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,181</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,943</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company’s effective income tax rate for fiscal <em style="font: inherit;">2021</em> was <span style="background-color:#ffffff;">5.8</span>% vs 17.1% in the prior year. The change in the effective tax rate for fiscal <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was driven by changes in net discrete tax benefits<span style="background-color:#ffffff;"> of $28.1 </span>million and $19.4 million for fiscal year <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The Company's effective income tax rate for fiscal <em style="font: inherit;">2020</em> was 17.1% for fiscal <em style="font: inherit;">2020</em> vs 14.2% in the prior year. The change in the effective tax rate for fiscal <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> were driven by the changes in the net discrete tax benefits $19.4 million and $12.7 million, respectively. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company's discrete tax benefits in fiscal <em style="font: inherit;">2021</em> primarily related to share-based compensation excess tax benefits of <span style="background-color:#ffffff;">$28.1 </span>million.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company's discrete tax benefits in fiscal <em style="font: inherit;">2020</em> primarily related to share-based compensation excess tax benefits of $17.7 million.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company's discrete tax benefits in fiscal <em style="font: inherit;">2019</em> primarily related to share-based compensation excess tax benefits of $7.2 million, $3.2 million related to fiscal <em style="font: inherit;">2019</em> acquisitions, and $2.0 million for tax refunds relating to certain state apportionments. </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company continues to monitor newly enacted regulations, clarifications, and changes in guidance the Tax Cuts and Jobs Act “Tax Act”, which was enacted on <em style="font: inherit;"> December 22, 2017. </em>The Company recognizes changes in legislation in the period enacted, which <em style="font: inherit;"> may </em>have a material impact on our effective tax rate in future periods.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense at federal statutory rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.3</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development tax credit</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent consideration adjustment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.4</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differences</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Option exercises</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16.9</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. taxation of foreign earnings</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.9</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign derived intangible income</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.9</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Executive compensation limitations</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.4</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other, net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Effective tax rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17.1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Inventory</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,730</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,769</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryovers</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,345</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,707</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax credit carryovers</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,486</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,568</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Excess tax basis in equity investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,429</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,423</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred compensation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,108</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,755</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Derivative - cash flow hedge</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,908</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,058</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,016</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,526</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,340</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,665</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,523</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax assets</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,883</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,353</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net unrealized gain on available-for-sale investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,159</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(19,102</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible asset amortization</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(150,765</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(128,279</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Depreciation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,099</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(10,764</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,868</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,118</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,117</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,180</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(180,008</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(174,443</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net deferred tax liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(93,125</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(101,090</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">A deferred tax valuation allowance is required when it is more likely than <em style="font: inherit;">not</em> that all or a portion of deferred tax assets will <em style="font: inherit;">not</em> be realized. The valuation allowance as of <em style="font: inherit;"> June 30, </em><em style="font: inherit;">20</em><span style="background-color:#ffffff;"><em style="font: inherit;">21</em> was $6.7 mil</span>lion compared to $7.5 million in the prior year. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">As of <em style="font: inherit;"> June 30, 2021, </em>the <span style="background-color:#ffffff;">$6.7 </span>million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Quad, ExosomeDx, ACD, Novus, ProteinSimple and CyVek as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than <em style="font: inherit;">not</em> that these tax carryovers will <em style="font: inherit;">not</em> be realized.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">As of <em style="font: inherit;"> June 30, 2021, </em>the Company has federal operating loss carryforwards of approximately <span style="background-color:#ffffff;">$92.1 m</span>illion and state operating loss carryforwards of <span style="background-color:#ffffff;">$129.6 m</span>illion from its acquisitions of Asuragen (refer to note <em style="font: inherit;">4</em>), Quad, ExosomeDx, ACD, ProteinSimple and CyVek, which are <em style="font: inherit;">not</em> limited under IRC Section <em style="font: inherit;">382.</em> As of <em style="font: inherit;"> June 30, 2021, </em>the Company has foreign net operating loss carryforwards of <span style="background-color:#ffffff;">$13.9 </span>million. <span style="background-color:#ffffff;">The net operating loss carryforwards expire between fiscal <em style="font: inherit;">2022</em> and <em style="font: inherit;">2036.</em> The Company has a deferred tax asset of $26.6 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of <em style="font: inherit;"> June 30, 2021, </em>the Company has federal and state tax credit carryforwards of $10.1 </span><span style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">million and $4.4 m</span>illion, respectively. The federal tax credit carryforwards expire between <em style="font: inherit;">2028</em> and <em style="font: inherit;">2038.</em> The majority of the state credit carryforwards have <em style="font: inherit;">no</em> expiry date. The Company has a deferred tax asset of $12.6 million, net of the valuation allowance discussed above, related to the tax credit carryovers.</p> <p>The Company has <em style="font: inherit;">not</em> recognized a deferred tax liability for unremitted foreign earnings of approxi<span style="background-color:#ffffff;">mately $223 mill</span>ion from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitel<span style="background-color:#ffffff;">y. The transition tax included as part of the Tax Act resulted in the previously untaxed foreign earnings being included in the federal and state fiscal <em style="font: inherit;">2018</em> taxable income. The <em style="font: inherit;">one</em>-time transition tax was based on certain foreign earnings for which earnings have been previously indefinitely reinvested as well as the amount of earnin</span>gs held in cash and other specified assets.   <em style="font: inherit;">No</em> additional income taxes have been provided for cumulative unremitted foreign earnings as at this time our intention with respect to unremitted foreign earnings is to continue to indefinitely reinvest outside the U.S. those earnings needed for working capital or additional foreign investment. If there are policy changes, we would record applicable taxes at that time.</p> <p>We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.  In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes. Therefore, it is <em style="font: inherit;">not</em> practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.</p> <p>The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,297</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,032</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,947</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to acquisitions</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">900</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions for tax positions of prior year</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,038</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">306</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,185</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Decrease in unrecognized tax benefits for prior year positions</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(778</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,041</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Settlements</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(286</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Ending balances</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,271</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,297</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,032</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Included in the balance of unrecognized tax benefits at <em style="font: inherit;"> June 30, 2021 </em>are potential benefits of $5.2 million that, if recognized, would affect the effective tax rate on income from continuing operations. The amount of interest and penalties recognized on the balance sheet as of <em style="font: inherit;"> June 30, 2021 </em>is <em style="font: inherit;">not</em> material. The Company does <em style="font: inherit;">not</em> believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next <em style="font: inherit;">twelve</em> months. It is reasonably possible that the unrecognized tax benefits <em style="font: inherit;"> may </em>decrease by $2.6 million as a result of ongoing discussions with the German tax authorities regarding a historical local matter. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for <em style="font: inherit;">2017</em> and subsequent years. State and foreign income tax returns are generally subject to examination for a period of <em style="font: inherit;">three</em> to <em style="font: inherit;">five</em> years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to <em style="font: inherit;">one</em> year after formal notification to the states.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95,662</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">245,365</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64,081</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">52,513</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,112</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,934</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Income before income taxes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">148,175</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">276,477</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,015</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i><span style="background-color:#ffffff;">2021</span></i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Taxes on income consist of:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Currently tax provision:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,179</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,976</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,090</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,681</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,018</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">544</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,743</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,580</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current tax provision</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,603</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,574</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29,963</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax provision:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(20,812</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,074</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(6,903</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,962</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,055</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,977</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Foreign</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c76649561">(2,239</span></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,522</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,142</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax provision</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28,013</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,607</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,021</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total income tax provision</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="background-color:#ffffff;">$</span></td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: medium double rgb(0, 0, 0); padding: 0px;"> <div style="background-color: rgb(255, 255, 255);"> 8,590 </div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,181</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,943</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> </tbody> </table> 95662000 245365000 64081000 52513000 31112000 47934000 148175000 276477000 112015000 15179000 18976000 16090000 6681000 6018000 544000 14743000 8580000 13329000 36603000 33574000 29963000 -20812000 14074000 -6903000 -4962000 2055000 -3977000 -2522000 -3142000 -28013000 13607000 -14021000 8590000 47181000 15943000 0.058 0.171 28100000 19400000 0.171 0.142 19400000 12700000 28100000 17700000 7200000 -3200000 -2000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense at federal statutory rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.3</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development tax credit</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent consideration adjustment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.4</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax rate differences</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Option exercises</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(16.9</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. taxation of foreign earnings</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.9</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign derived intangible income</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5.1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.9</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Executive compensation limitations</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.4</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other, net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1.0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Effective tax rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17.1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14.2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td> </tr> </tbody> </table> 0.210 0.210 0.210 0.006 0.023 -0.015 0.018 0.007 0.016 0.008 -0.002 -0.004 0.008 -0.002 0.002 -0.169 -0.057 -0.058 -0.001 0.009 0.037 -0.051 -0.009 -0.020 0.065 0.016 0.004 0.000 -0.010 0.002 0.058 0.171 0.142 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>June 30</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Inventory</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,730</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,769</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryovers</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,345</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,707</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax credit carryovers</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,486</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,568</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Excess tax basis in equity investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,429</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,423</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred compensation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,108</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,755</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Derivative - cash flow hedge</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,908</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,058</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,016</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,526</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,340</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,665</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(7,523</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax assets</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">86,883</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">73,353</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net unrealized gain on available-for-sale investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,159</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(19,102</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible asset amortization</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(150,765</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(128,279</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Depreciation</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(9,099</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(10,764</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,868</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,118</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,117</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,180</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(180,008</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(174,443</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net deferred tax liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(93,125</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(101,090</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> </tbody> </table> 6730000 7769000 31345000 25707000 14486000 9568000 2429000 2423000 11108000 10755000 1908000 4058000 17016000 16256000 8526000 4340000 6665000 7523000 86883000 73353000 3159000 19102000 150765000 128279000 9099000 10764000 15868000 15118000 1117000 1180000 180008000 174443000 93125000 101090000 6700000 7500000 6700000 92100000 129600000 13900000 26600000 10100000 4400000 12600000 223000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,297</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,032</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,947</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions due to acquisitions</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">900</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions for tax positions of prior year</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,038</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">306</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,185</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Decrease in unrecognized tax benefits for prior year positions</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(778</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,041</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Settlements</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(286</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Ending balances</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,271</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,297</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,032</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 4297000 5032000 1947000 0 0 900000 4038000 306000 2185000 778000 1041000 -0 286000 -0 -0 7271000 4297000 5032000 5200000 2600000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">12.</em></b><b><i> Segment Information:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company's Protein Sciences segment is comprised of the reagent solutions and analytical solutions. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than <em style="font: inherit;">10%</em> of the segment’s net sales for the years ended <em style="font: inherit;"> June 30, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company's Diagnostics and Genomics segment is comprised of diagnostics reagents, genomics, and our Exosome and Asuragen acquisitions. Diagnostics reagents develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. Genomics, Exosome, and Asuragen consists of Genomics and Exosome products and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than <em style="font: inherit;">10%</em> of the segment’s net sales for the fiscal years ended <em style="font: inherit;"> June 30, 2021, </em><em style="font: inherit;">2020,</em> and <em style="font: inherit;">2019.</em> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">There are <em style="font: inherit;">no</em> concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Following is financial information relating to the operating segments (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">704,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">555,352</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">543,159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">227,744</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184,549</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">171,674</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intersegment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated net sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">931,032</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating Income:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">328,837</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">234,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">240,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,079</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Segment operating income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">367,262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">249,894</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,998</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Costs recognized upon sale of acquired inventory</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amortization of acquired intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(64,239</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(60,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(58,550</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Gain on escrow settlement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,169</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Acquisition related expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7,114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(416</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restructuring costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(87</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation, inclusive of employer taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(51,846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(34,262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(33,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Corporate general, selling and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated operating income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">237,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">157,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,719</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by operating segment has <em style="font: inherit;">not</em> been provided and is <em style="font: inherit;">not</em> available, since the Company does <em style="font: inherit;">not</em> produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment’s operating results, it is <em style="font: inherit;">not</em> discretely identifiable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note <em style="font: inherit;">2.</em> The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note <em style="font: inherit;">2.</em> The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) :</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Consumables revenue - Protein Sciences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">557,037</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">431,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">430,655</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Consumables revenue - Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">194,948</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">158,324</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total consumable revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">751,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">602,642</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">588,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following is financial information relating to geographic areas (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">162,039</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,457</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,670</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">207,907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176,829</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">594,512</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499,875</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,369</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,321</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">615,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.</p> 2 0 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">704,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">555,352</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">543,159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">227,744</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">184,549</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">171,674</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intersegment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated net sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">931,032</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">738,691</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">714,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating Income:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Protein Sciences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">328,837</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">234,929</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">240,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38,425</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,965</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,079</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Segment operating income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">367,262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">249,894</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,998</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Costs recognized upon sale of acquired inventory</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,739</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amortization of acquired intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(64,239</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(60,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(58,550</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Gain on escrow settlement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,169</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Acquisition related expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7,114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(416</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,282</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restructuring costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(87</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation, inclusive of employer taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(51,846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(34,262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(33,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Corporate general, selling and administrative expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Consolidated operating income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">237,296</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">157,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">146,719</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year Ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i><span style="background-color:#ffffff;">2021</span></i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2019</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Consumables revenue - Protein Sciences</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">557,037</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">431,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">430,655</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Consumables revenue - Diagnostics and Genomics</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">194,948</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">158,324</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total consumable revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">751,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">602,642</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">588,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>Year ended June 30,</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i><i>2021</i></i></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><i><i>2020</i></i></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190,501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">162,039</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,120</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,457</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,670</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">207,907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176,829</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States and Canada</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">594,512</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">499,875</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,369</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Asia</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,321</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">615,968</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">516,545</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 704564000 555352000 543159000 227744000 184549000 171674000 -1276000 -1210000 -827000 931032000 738691000 714006000 328837000 234929000 240919000 38425000 14965000 10079000 367262000 249894000 250998000 1565000 -0 3739000 64239000 60865000 58550000 0 7169000 0 7114000 416000 2282000 142000 87000 -0 51846000 34262000 33057000 5060000 4015000 6651000 237296000 157419000 146719000 557037000 431052000 430655000 194948000 171590000 158324000 751985000 602642000 588979000 190501000 162039000 13949000 13120000 3457000 1670000 207907000 176829000 594512000 499875000 9369000 12349000 12087000 4321000 615968000 516545000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Note </i></b><b><em style="font: inherit;">13.</em></b><b><i> Subsequent Events:</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><em style="font: inherit;">None</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired. Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5. Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2021 and June 30, 2020 was $6.6 million and $6.6 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.4 million as of June 30, 2021. The fair value of the warrant as of June 30, 2020 was $8.0 million Total cash paid for the Company's operating leases during the year ended June 30, 2021 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity. Finished goods inventory of $5,456 and $4,646 is included within other long-term assets in the June 30, 2021 and June 30, 2020 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date. Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year. Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company had deferred tax benefits of $1,908 and $4,058 included in the accumulated other comprehensive income loss as of June 30, 2021 and June 30, 2020, respectively. Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence. $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021. The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded. XML 25 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information - USD ($)
 12 Months Ended
Jun. 30, 2021
Aug. 20, 2021
Dec. 31, 2020
Document Information [Line Items]      
Entity Central Index Key 0000842023    
Entity Registrant Name BIO-TECHNE Corp    
Amendment Flag false    
Current Fiscal Year End Date --06-30    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Jun. 30, 2021    
Document Transition Report false    
Entity File Number 0-17272    
Entity Incorporation, State or Country Code MN    
Entity Tax Identification Number 41-1427402    
Entity Address, Address Line One 614 McKinley Place N.E.    
Entity Address, City or Town Minneapolis    
Entity Address, State or Province MN    
Entity Address, Postal Zip Code 55413    
City Area Code 612    
Local Phone Number 379-8854    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol TECH    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 12,400,000,000
Entity Common Stock, Shares Outstanding   39,079,539  
ICFR Auditor Attestation Flag true    
XML 26 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Earnings and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Net sales $ 931,032 $ 738,691 $ 714,006
Cost of sales 298,182 255,497 240,515
Gross margin 632,850 483,194 473,491
Operating expenses:      
Selling, general and administrative 324,951 260,583 264,359
Research and development 70,603 65,192 62,413
Total operating expenses 395,554 325,775 326,772
Operating income 237,296 157,419 146,719
Other income (expense):      
Interest expense (13,952) (19,197) (21,705)
Interest income 473 605 569
Other non-operating income (expense), net (75,642) 137,650 (13,568)
Total other income (expense), net (89,121) 119,058 (34,704)
Earnings before income taxes 148,175 276,477 112,015
Income taxes (benefit) 8,590 47,181 15,943
Net earnings, including noncontrolling interest 139,585 229,296 96,072
Net earnings (loss) attributable to noncontrolling interest (825) 0 0
Net earnings attributable to Bio-Techne 140,410 229,296 96,072
Other comprehensive income (loss):      
Foreign currency translation adjustments 32,951 (9,963) (4,487)
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8. 7,060 (3,715) (9,537)
Other comprehensive income (loss) 40,011 (13,678) (14,024)
Other comprehensive income (loss) attributable to noncontrolling interest 103 0 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total 39,908 (13,678) (14,024)
Comprehensive income attributable to Bio-Techne $ 180,318 $ 215,618 $ 82,048
Earnings per share:      
Basic (in dollars per share) $ 3.62 $ 6.00 $ 2.54
Diluted (in dollars per share) $ 3.47 $ 5.82 $ 2.47
Weighted average common shares outstanding:      
Basic (in shares) 38,747 38,201 37,781
Diluted (in shares) 40,483 39,401 38,892
XML 27 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Current assets:    
Cash and cash equivalents $ 199,091 $ 146,625
Short-term available-for-sale investments 32,463 124,268
Accounts receivable, less allowance for doubtful accounts of $1,229 and $775, respectively 145,385 122,534
Inventories 116,748 103,152
Other current assets 16,919 24,341
Total current assets 510,606 520,920
Property and equipment, net 207,907 176,829
Right of use asset 73,834 [1] 71,465
Goodwill 843,067 728,308
Intangible assets, net 615,968 516,545
Other assets 11,575 13,522
Total assets 2,262,957 2,027,589
Current liabilities:    
Trade accounts payable 29,384 23,090
Salaries, wages and related accruals 51,294 31,087
Accrued expenses 15,282 9,093
Contract liabilities 18,995 13,049
Income taxes payable 5,336 2,376
Operating lease liabilities - current 11,602 [1] 9,535
Contingent consideration payable 4,000 5,938
Current portion of long-term debt obligations 12,500 12,500
Other current liabilities 3,891 0
Total current liabilities 152,284 106,668
Deferred income taxes 93,125 101,090
Long-term debt obligations 328,827 344,243
Long-term contingent consideration payable 25,400 199
Operating lease liabilities 67,625 [1] 67,248
Other long-term liabilities 24,462 26,949
Bio-Techne's shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,955,484 and 38,453,046 shares, respectively 390 385
Additional paid-in capital 534,411 420,536
Retained earnings 1,085,461 1,057,470
Accumulated other comprehensive loss (57,291) (97,199)
Total Bio-Techne shareholders' equity 1,562,971 1,381,192
Noncontrolling interest 8,263 0
Total shareholders' equity 1,571,234 1,381,192
Total liabilities and shareholders’ equity $ 2,262,957 $ 2,027,589
[1] The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.
XML 28 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Accounts receivable, allowance for doubtful accounts $ 1,229 $ 775
Undesignated capital stock, no par (in dollars per share) $ 0 $ 0
Undesignated capital stock, shares authorized (in shares) 5,000,000 5,000,000
Undesignated capital stock, shares issued (in shares) 0 0
Undesignated capital stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 38,955,484 38,453,046
Common stock, shares outstanding (in shares) 38,955,484 38,453,046
XML 29 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Additional Paid-in Capital [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Retained Earnings [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
AOCI Attributable to Parent [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Noncontrolling Interest [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Total
Balances (in shares) at Jun. 30, 2018             37,608,000          
Balances at Jun. 30, 2018 $ 25,276 $ (24,682) $ 594 $ 376 $ 246,568 $ 876,931 $ (44,814) $ 0 $ 1,079,061
Net earnings             96,072 96,072
Other comprehensive income (loss)             (14,024) (14,024)
Share repurchases (in shares)             (95,000)          
Share repurchases             $ (1) (15,404) $ (15,405)
Common stock issued for exercise of options (in shares)             382,000         383,000
Common stock issued for exercise of options             $ 4 36,272 $ 36,276
Common stock issued for restricted stock awards (in shares)             29,000          
Common stock issued for restricted stock awards             $ 0 (2,575) (2,575)
Cash dividends             (48,366) (48,364)
Stock-based compensation expense             31,775 31,775
Common stock issued to employee stock purchase plan (in shares)             10,000          
Common stock issued to employee stock purchase plan             $ 0 1,676 1,676
Employee stock purchase plan expense             505 505
Balances (in shares) at Jun. 30, 2019             37,934,000          
Balances at Jun. 30, 2019 (879) (879) $ 379 316,797 931,934 (83,521) 0 1,165,589
Net earnings             229,296 229,296
Other comprehensive income (loss)             (13,678) $ (13,678)
Share repurchases (in shares)             (279,000)         (279,381)
Share repurchases             $ (3) (50,109) $ (50,112)
Common stock issued for exercise of options (in shares)             730,000         743,000
Common stock issued for exercise of options             $ 7 69,461 (1,642) $ 67,826
Common stock issued for restricted stock awards (in shares)             56,000          
Common stock issued for restricted stock awards             $ 1 (1) (2,229) (2,228)
Cash dividends             (48,902) (48,902)
Stock-based compensation expense             31,932 31,932
Common stock issued to employee stock purchase plan (in shares)             14,000          
Common stock issued to employee stock purchase plan             $ 0 2,312 2,312
Employee stock purchase plan expense             435 435
Surrender and retirement of stock to exercise option (in shares)             (2,000)          
Surrender and retirement of stock to exercise option             $ 0 (400) $ (400)
Balances (in shares) at Jun. 30, 2020             38,453,000         38,453,046
Balances at Jun. 30, 2020 $ (276) $ (276) $ 385 420,536 1,057,470 (97,199) 0 $ 1,381,192
Net earnings             140,410 (825) 139,585
Other comprehensive income (loss)             39,908 103 $ 40,011
Share repurchases (in shares)             (120,000)         (120,000)
Share repurchases             $ (1) (43,177) $ (43,178)
Common stock issued for exercise of options (in shares)             573,000         627,000
Common stock issued for exercise of options             $ 6 62,102 (12,287) $ 49,821
Common stock issued for restricted stock awards (in shares)             38,000          
Common stock issued for restricted stock awards             $ 0 (0) (7,057) (7,057)
Cash dividends             (49,622) (49,622)
Stock-based compensation expense             48,065 48,065
Common stock issued to employee stock purchase plan (in shares)             11,000          
Common stock issued to employee stock purchase plan             $ 0 2,791 2,791
Employee stock purchase plan expense             917 917
Non-controlling interest in Eminence             8,985 $ 8,985
Balances (in shares) at Jun. 30, 2021             38,955,000         38,955,484
Balances at Jun. 30, 2021             $ 390 $ 534,411 $ 1,085,461 $ (57,291) $ 8,263 $ 1,571,234
XML 30 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Cash flows from operating activities:      
Net earnings, including non-controlling interest $ 139,585 $ 229,296 $ 96,072
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 87,747 82,737 78,171
Costs recognized on sale of acquired inventory 1,565 0 3,739
Deferred income taxes (27,431) 13,130 (13,582)
Stock-based compensation expense 48,982 32,367 32,280
Fair value adjustment to contingent consideration payable 5,300 (905) (2,000)
Contingent consideration payments (337) (958) 0
(Gain) Loss on investment, net 0 0 (3,702)
Fair value adjustment on available for sale investments 67,879 (137,527) 16,067
Leases, net 75 225 0
Gain on escrow settlement 0 (7,170) 0
Other operating activity (464) (732) 2,325
Change in operating assets and liabilities, net of acquisitions:      
Trade accounts and other receivables (15,549) 6,556 (15,000)
Inventories (7,140) (14,861) (13,647)
Prepaid expenses (1,101) (2,605) (698)
Trade accounts payable and accrued expenses 19,091 10,343 6,101
Salaries, wages and related accruals 20,536 2,552 5,013
Income taxes payable 13,426 (7,231) (9,520)
Net cash provided by operating activities 352,164 205,217 181,619
Cash flows from investing activities:      
Proceeds from sale and maturities of available-for-sale investments 66,377 147,120 21,579
Purchase of available-for-sale investments (39,684) (70,187) (43,475)
Additions to property and equipment (44,301) (51,744) (25,411)
Acquisitions, net of cash acquired (225,352) 0 (289,492)
Investment in unconsolidated entity, net (556) 1,906 0
Other investing activities 0 0 0
Net cash provided by (used in) investing activities (243,516) 27,095 (336,799)
Cash flows from financing activities:      
Cash dividends (49,622) (48,902) (48,364)
Proceeds from stock option exercises 65,092 70,983 37,950
Re-purchases of common stock (43,178) (50,112) (15,405)
Borrowings under line-of-credit agreement 256,000 40,000 580,000
Payments on line-of-credit (271,500) (188,500) (413,500)
Contingent consideration payments 0 (3,400) 0
Other financing activities (19,343) (3,872) (6,297)
Net cash provided by (used in) financing activities (62,551) (183,802) 134,384
Effect of exchange rate changes on cash and cash equivalents 6,369 (2,771) (308)
Net change in cash and cash equivalents 52,466 45,739 (21,104)
Cash and cash equivalents at beginning of year 146,625 100,886 121,990
Cash and cash equivalents at end of year $ 199,091 $ 146,625 $ 100,886
XML 31 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Note 1 - Description of Business and Summary of Significant Accounting Policies
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]

Note 1. Description of Business and Summary of Significant Accounting Policies:

 

Description of business: Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (the Company), develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

 

Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.

 

Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. The Company consolidated our partial acquisition of Eminence in our consolidated financial statements on a one month lag. Refer to Note 4 for additional discussion regarding Eminence.

 

Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.

 

Revenue recognition: The Company adopted ASC 606 - Revenue from Contracts with Customers on July 1, 2018 using the modified retrospective transition approach. ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note 2 for additional information regarding our revenue recognition policy under ASC 606.

 

Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.

 

Advertising costs: Advertising expenses were $4.7 million, $4.2 million, and $4.1 million for fiscal 2021, 2020, and 2019 respectively. The Company expenses advertising expenses as incurred.

 

Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note 11 for additional information regarding income taxes.

 

Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.

 

Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.

 

Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to six months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on available-for-sale securities are included within other income (expense) in accordance with ASU 2018-02, which the Company adopted on  July 1, 2018. 

 

Trade accounts receivable and allowances: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. The Company adopted ASU 2016-13 on July 1, 2020, which reflects the expected credit losses on financial instruments within its scope, including trade receivables. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables. Refer to the Recently Adopted Accounting Pronouncements section of Note 1 for further details.

 

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration.

 

For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 - Inventory.

 

Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.

 

Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income.

 

Intangible assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.

 

In conjunction with the Asuragen acquisition that occurred in fiscal year 2021, the Company reassessed the useful life of a tradename from a previous acquisition due to the planned integration and cobranding strategy developed with the most recent transaction.  As a result, the Company accelerated the amortization of the trade name to be consistent with the life used for the Asuragen trade name.  The accelerated amortization resulted in a $1.4 million impact in fiscal 2021, a $5.7 million impact in fiscal years 2022 through 2025, and a $4.3 impact in fiscal year 2026.

 

In fiscal year 2020, the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal 2020 and $0.6 million in fiscal 2021.

 

Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.

 

The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. No other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2019, 2020, and 2021.

 

Impairment of goodwill: We evaluate the carrying value of goodwill during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2021, 2020, and 2019 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment. Further, the Company elected April 1 as the annual goodwill impairment assessment date for the Asuragen acquisition, acquired on April 6, 2021.

 

2021 Goodwill Impairment Analyses

 

In completing our 2021 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017-04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2021. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2021, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2020 Goodwill Impairment Analyses

 

The Company elected to perform a quantitative assessment for all of our reporting units in our 2020 goodwill impairment analysis. The quantitative assessment completed utilized a consistent process and methodology to the 2021 goodwill impairment assessment. The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2020. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2020, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.

 

Because our quantitative analysis performed as of January 1, 2019 included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was not impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.

 

The quantitative assessments completed as of January 1, 2019 indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test on April 1, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

 

Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, no triggering events or items beyond the realignment discussed above were identified in the year ended June 30, 2019 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.

 

 

Other Significant Accounting Policies

 

The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:

 

Policy

 

Note

 

Fair value measurements

  5 

Earnings per share

  9 

Share-based compensation

  10 

Operating segments

  12 

 

 

Recently Adopted Accounting Pronouncements

 

In  February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic 842) through ASU No. 2018-10 and ASU 2019-01. Additionally, the FASB issued ASU 2018-11, allowing an entity to elect a transition method where they do not recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU 2018-11 when adopting Leases (Topic 842). The Company adopted the standard effective  July 1, 2019 and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC 840 - Leases into operating lease liabilities upon adoption of Topic 842. In adopting ASC 842, the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note 7 for additional information on leases.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendment in this update replaced the previous incurred loss impairment methodology with a methodology that reflects expected credit losses on financial instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted this standard on July 1, 2020 using a modified retrospective transition approach with a cumulative impact of $0.3 million to retained earnings. The adoption of this ASU did not have a material impact on the Company's financial statements as the Company's primary financial instruments impacted by the ASU were trade accounts receivable, where we have high historical and expected future collections due to the length of receivables and the credit quality of our customers.

 

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is not affected by the new standard. The Company adopted this standard on a prospective basis on July 1, 2020. Accordingly, as of July 1, 2020, the Company will record eligible costs to be capitalized within prepaid assets or other non-current assets depending on the nature of the duration of the asset.

 

In  March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting and in January 2021 issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope. These ASUs provide expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in 2021, to a new reference rate. The provisions of the ASUs impact contract modifications and other changes that occur while LIBOR is phased out. The Company adopted the optional relief guidance provided within these ASUs in the fourth quarter of fiscal 2021 and continues to monitor its debt and derivative instruments that utilize LIBOR as the reference rate. The adoption of the standard did not impact our financial results for fiscal 2021.

 
XML 32 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue Recognition
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

Note 2. Revenue Recognition:

 

Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at a point in time. Prior to fiscal year 2021, the Company has not recognized revenue upon completion of the performance obligation for laboratory services, but rather upon cash receipt, which was subsequent to the performance obligation being satisfied. The Company accounted for these services based on cash receipts as we did not have significant historical experience collecting payments from Medicare or other insurance providers and considered the variable consideration for such services to be constrained as it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. Given Medicare coverage for our laboratory services became effective on December 1, 2019, the Company considered that it had sufficient data to estimate variable consideration as of July 1, 2020 for laboratory services that are reimbursed by Medicare. The amount of cash received in fiscal year 2021 for laboratory services reimbursed by Medicare that were performed prior to July 1, 2020 was approximately $0.5 million. The Company continues to record revenue based on cash receipts for laboratory services not reimbursed by Medicare, as the variable consideration remains constrained. We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date.

 

The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance.  The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of June 30, 2021 and June 30, 2020.

 

Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.

 

Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.

 

Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over the contract period. Contract assets as of June 30, 2021 are not material.

 

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of June 30, 2021 and June 30, 2020 were approximately $20.0 million and $14.2 million, respectively. Contract liabilities as of June 30, 2020 subsequently recognized as revenue during the year ended June 30, 2021 were approximately $10.6 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the balance sheet. 

 

Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.

 

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.

 

The following tables present our disaggregated revenue for the periods presented.

 

Revenue by type is as follows:

 

  

Year ended June 30,

     
  

2021

  2020  2019 

Consumables

 $751,985  $602,642  $588,979 

Instruments

  93,782   71,462   67,538 

Services

  66,416   47,459   38,050 

Total product and services revenue, net

  912,183  $721,563   694,567 

Royalty revenues

  18,849   17,128   19,439 

Total revenues, net

 $931,032  $738,691  $714,006 

 

Revenue by geography is as follows:

 

  

Year Ended June 30,

 
  2021  2020  2019 

Net sales:

            

United States

 $502,080  $404,407  $391,191 

EMEA, excluding U.K.

  204,264   155,289   155,821 

U.K.

  40,945   30,411   34,975 

APAC, excluding Greater China

  69,013   60,362   52,913 

Greater China

  87,556   68,792   57,799 

Rest of world

  27,174   19,430   21,307 

Total external sales

 $931,032  $738,691  $714,006 

 
XML 33 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

Note 3. Supplemental Balance Sheet and Cash Flow Information:

 

Available-For-Sale Investments:

 

The fair value of the Company's available-for-sale equity investments as of June 30, 2021 and June 30, 2020 were $20.0 million and $87.8 million, respectively. The decrease was due to year-over-year decrease in the stock price of CCXI, which was $13.39 per share at June 30, 2021 compared to $57.54 per share at June 30, 2020. The amortized cost basis of the Company's investment in CCXI was $6.6 million and $6.6 million as of June 30, 2021 and 2020, respectively. The Company's available-for-sale debt securities as of June 30, 2021 and June 30, 2020 were $12.5 million and $36.4 million, respectively. The decrease is due to the timing of debt maturities and cash balances at the balance sheet date. 

 

Inventories:

 

Inventories consist of (in thousands):

 

  

June 30,

 
  

2021

  2020 
         

Raw materials

 $55,096  $51,530 

Finished goods(1)

  67,108   56,268 

Inventories, net

 $122,204  $107,798 

 

(1) Finished goods inventory of $5,456 and $4,646 is included within other long-term assets in the June 30, 2021 and June 30, 2020 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.  

 

Property and Equipment:

 

Property and equipment consist of (in thousands):

 

  

June 30,

 
  

2021

  2020 

Cost:

        

Land

 $8,612  $8,516 

Buildings and improvements

  190,661   184,430 

Machinery, equipment and other

  198,483   153,704 

Property and equipment

  397,756   346,650 

Accumulated depreciation and amortization

  (189,849

)

  (169,821

)

Property and equipment, net

 $207,907  $176,829 

 

Intangibles assets were comprised of the following (in thousands):

 

        

June 30,

 
  

Useful Life

(years)

  

2021

  2020 
               

Developed technology

  9-15  $552,160  $434,653 

Trade names

  2-20   147,640   146,713 

Customer relationships

  7-16   232,493   211,750 

Patents

   10    2,926   2,475 
Other intangibles(1)  5-15   6,316   - 

Definite-lived intangible assets

        941,535   795,591 

Accumulated amortization

        (348,267

)

  (279,046

)

Definite-lived intangibles assets, net

        593,268   516,545 
In process research and development        22,700   - 
Total intangible assets, net       $615,968  $516,545 

 

(1) Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired.

 

Changes to the carrying amount of net intangible assets consist of (in thousands):

 

   

June 30,

 
   2021  2020 
          

Beginning balance

  $516,545  $579,429 

Acquisitions (Note 4)

   153,311   - 

Other additions

   5,912   311 

Amortization expense

   (64,940

)

  (61,095

)

Currency translation

   5,140

 

  (2,100

)

Ending balance

  $615,968  $516,545 

 

Amortization expense related to developed technologies included in cost of sales was $36.5 million, $34.5 million, and $33.3 million in fiscal 2021, 2020, and 2019, respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was $28.4 million, $26.6 million, and $25.4 million, in fiscal 2021, 2020, and 2019 respectively.

 

The estimated future amortization expense for intangible assets as of June 30, 2021, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows (in thousands):

 

2022

 $74,482 

2023

  72,649 

2024

  69,780 

2025

  66,523 

2026

  62,739 

Thereafter

  247,095 

Total

 $593,268 

 

Changes in goodwill by segment and in total consist of (in thousands):

 

  

Protein

Sciences

  

Diagnostics &

Genomics

  

Total

 

June 30, 2019

 $377,407  $355,260  $732,667 

Acquisitions (Note 4)

  (326

)

  -   (326

)

Currency Translation

  (4,000

)

  (31

)

  (4,031

)

June 30, 2020

 $373,081  $355,229  $728,310 
Acquisitions (Note 4)  7,848   94,970   102,818 
Currency translation  11,788   151   11,939 
June 30, 2021 $392,717  $450,350  $843,067 

 

Supplemental Cash Flow Information:

 

Supplemental cash flow information was as follows (in thousands):

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Income taxes paid

 $20,952  $41,992  $36,814 

Interest paid

  13,576   18,615   21,497 

Non-cash activities:

            

Acquisition-related liabilities(1)

  23,600

 

  (2,105)  12,600 
Other intangibles(2)  4,000   -   - 

 

 

(1) Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.

(2) $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021. 

 
XML 34 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Note 4 - Acquisitions
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

Note 4. Acquisitions:

 

We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.

 

2021 Acquisitions

 

Eminence Biotechnology

 

On October 20, 2020, the Company acquired 47.6% of the outstanding equity shares of Changzhou Eminence Biotechnology Co., Ltd. (Eminence) for approximately $9.8 million, net of cash acquired. The fair value of the noncontrolling interest of $9.0 million included in the consolidated balance sheet was a non-cash activity within the statement of cash flows. Eminence is considered a variable interest entity as it is an early stage biotechnology company that required additional funding through a subsequent equity investment, which was used to fund Eminence’s expansion and GMP manufacturing capabilities within China. On April 2, 2021, the Company invested approximately $6 million of additional funding into Eminence, increasing our percentage of outstanding equity shares to 57.4%. The Company was considered the primary beneficiary at the time of initial acquisition given the Company was the largest shareholder coupled with its ability to exercise significant influence over the entity. As of June 30, 2021, the Company’s investment at risk is limited to its $15.8 million in investments.

 

As Eminence met the criteria for consolidation, the transaction was accounted for in accordance with ASC 805, Business Combinations. In applying ASC 805 to the transaction, the Company has elected to include Eminence in our consolidated financial statements on a one month lag.

 

The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The fair value of the noncontrolling interest in Eminence was calculated utilizing cash flow projections discounted to the acquisition date and control premiums calculated using market data. Acquired goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences reportable segment in the second quarter of fiscal year 2021.

 

The allocation of purchase consideration related to Eminence was completed in the fourth quarter of fiscal year 2021. The fair values of the assets acquired and liabilities assumed at acquisition date and the updated final amounts as of June 30, 2021 are as follows (in thousands):

 

  

Preliminary
Allocation at
Acquisition
Date

  

Adjustments to Fair Value

  

Final Allocation at June 30, 2021

Current assets, net of cash

 $3,145  $-  $3,145

Equipment and other long-term assets

  1,639   -   1,639
Intangible assets:           

Developed technology

  6,778   -   6,778

Customer relationships

  2,133   -   2,133

Goodwill

  8,811   (963)  7,848

Total assets acquired

  22,506   (963)  21,543

Liabilities

  1,436   -   1,436

Deferred income taxes, net

  2,320   (963)  1,357

Net assets acquired

 $18,750  $-  $18,750
            

Cash paid, net of cash acquired

  9,765   -   9,765
Fair value of noncontrolling interest in Eminence  8,985   -   8,985

Net assets acquired

 $18,750  $-  $18,750

 

As summarized in the table, there were adjustments totaling $1.0 million to goodwill during the measurement period. These adjustments relate to refinements within our deferred tax amounts based on factors existing on the acquisition date.


Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 13 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 10 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.

 

Asuragen, Inc.
 

On April 6, 2021, the Company acquired all of the ownership interests of Asuragen, Inc. for approximately $216 million, net of cash acquired, plus contingent consideration of up to $105.0 million, subject to certain revenue thresholds. The Asuragen acquisition adds a leading portfolio of best in-class molecular diagnostic and research products, including genetic screening, oncology testing kits, molecular controls, a GMP compliant manufacturing facility, and a CLIA-certified laboratory. The transaction was accounted for in accordance with ASC 805, Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’ product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the fourth quarter of fiscal year 2021. 

 

The allocation of purchase consideration related to Asuragen Inc is considered preliminary with provisional amounts primarily rel ated to goodwill and income tax assessment of acquired net operating losses. The Company expects to finalize the allocation of purchase price within the one-year measurement-period following the acquisition. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations in fiscal year 2021 were approximately $7.1 million and $ 3.4 million, respectively. The preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date and at June  30, 2021 are as follows (in thousands):

 

    

Preliminary allocation at acquisition date and at June 30, 2021

Current assets, net of cash

   $10,422

Equipment and other long-term assets

    3,762
Intangible assets:     

Developed technology

    107,000
In-process research and development    22,700

Customer relationships

    11,700
Tradenames    2,000
Non-competition agreement    1,000

Goodwill

    94,970

Total assets acquired

    253,554
      

Liabilities

    4,003

Deferred income taxes, net

    15,664

Net assets acquired

   $233,887
      

Cash paid, net of cash acquired

    215,587
Contingent consideration payable    18,300

Net assets acquired

   $

233,887

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology, in-process research and development, and customer relationships was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 16 years.  The amount recorded for tradenames and the non-competition agreement is being amortized with the expense reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for tradenames and the non-competition agreement is estimated to be 5 years and 3 years, respectively. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the preliminary calculation of acquired NOLs.

 

 

2019 Acquisitions

 

Quad Technologies

 

On July 2, 2018, the Company acquired QT Holdings Corporation (Quad) for approximately $20.5 million, net of cash acquired, plus contingent consideration of up to $51.0 million, subject to certain product development milestones and revenue thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019.

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible assets acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for our calculation of acquired net operating losses (NOLs).

 

Exosome Diagnostics

 

On August 1, 2018, the Company acquired Exosome Diagnostics, Inc. (ExosomeDx) for approximately $251.6 million, net of cash acquired, plus contingent consideration of up to $325.0 million, subject to certain EBITA thresholds. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Genomics operating segment in the first quarter of fiscal year 2019. Purchase accounting was finalized during fiscal 2019. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multiperiod excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The amortization periods for intangible assets acquired in fiscal 2019 are 15 years for developed technology and trade names, and 14 years for customer relationships. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.

 

Note: As part of the ExosomeDx acquisition, a certain amount of the cash payment was held in escrow. As part of the finalization of the outstanding amounts held in escrow, the Company recognized a gain of $7.2 million during fiscal year 2020 related to returned proceeds and a relief of any future contingent payments as described in Note 5. The gain was recorded within selling, general, and administrative costs in the Consolidated Statement of Comprehensive Income. 

 

B-MoGen Biotechnologies

 

On June 4, 2019, the Company acquired the remaining interest in B-MoGen Biotechnologies Inc. (B-MoGen) for approximately $17.5 million, net of cash acquired, plus contingent consideration of up to $38.0 million, subject to certain product development milestones and revenue thresholds. The Company previously held an investment of $1.4 million in B-MoGen and recognized a gain of approximately $3.7 million on the transaction within other non-operating income fiscal year 2019 in the consolidated statements of earnings and comprehensive income, which represented the adjustment of our historical investment to its fair value. 

 

The goodwill recorded as result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences segment in the fourth quarter of fiscal year 2019. Purchase accounting remained opened as disclosed in our prior year 10-K/A for working capital adjustments and our income tax assessment of acquired net operating losses (NOLs) with the completion of the stub period tax returns. Our purchase accounting was finalized in fiscal 2020 with an immaterial adjustment of $0.3 million to deferred tax amounts and goodwill. 

 

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows and using a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology asset is being amortized with the expense reflected in cost of goods sold in the Consolidated Statement of Earnings and Comprehensive Income. The amortization period for the developed technology intangible asset acquired in fiscal 2019 is 14 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes offset by the deferred tax asset for the calculation of acquired NOLs.

 

  

B-MoGen

Biotechnologies

  

Exosome

Diagnostics

  

Quad

Technologies

Current assets, net of cash

 $504  $2,611  $36

Equipment and other long-term assets

  269   2,212   228
Intangible assets:           

Developed technology

  14,000   105,000   12,256

Trade name

  -   58,000   -

Customer relationships

  400   2,300   -

Goodwill

  16,131   105,362   14,481

Total assets acquired

  31,304   275,485   27,001
            

Liabilities

  211   3,716   296

Deferred income taxes, net

  3,051   16,346   943

Net assets acquired

 $28,042  $255,423  $25,762
            

Cash paid, net of cash acquired

  17,448   251,623   20,462

Additional consideration(1)

  10,594   3,800   5,300

Net assets acquired

 $28,042  $255,423  $25,762

 

(1)Additional consideration for the B-MoGen acquisition includes a previously held investment of $1.4 million and a gain of approximately $3.7 million recorded on the transaction. The remaining additional consideration for B-MoGen, ExosomeDx, and Quad relate to the opening balance sheet value of contingent consideration.  

 

Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management's assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management's forecasted cash inflows and outflows and using a relief-from-royalty and multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of good sold in the Consolidated Statements of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statements of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes, and the future tax benefit of net operating loss and tax credit carryforwards which will be deductible by the Company in future periods. 

 
XML 35 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Fair Value Measurements
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]

Note 5. Fair Value Measurements:

 

The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt.

 

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

 

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

 

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

 

  

Total

carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30,

2021

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $19,963  $18,581  $1,382  $- 

Certificates of deposit (2)

  12,500   12,500   -   - 
Derivative instruments - cash flow hedges  275   -   275   - 

Total Assets

 $32,738  $31,081  $1,657  $- 
                 

Liabilities

                

Contingent consideration

 $29,400  $-  $-  $29,400 

Derivative instruments - cash flow hedges

  8,376   -   8,376   - 

Total Liabilities

 $37,776  $-  $8,376  $29,400 

 

 

  

Total

carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30,

2020

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $87,842  $79,846  $7,996  $- 

Certificates of deposit (2)

  36,426   36,426   -   - 

Total Assets

 $124,268  $116,272  $7,996  $- 
                 

Liabilities

                

Contingent consideration

  6,137  $-   -   6,137 

Derivative instruments - cash flow hedges

  17,331   -   17,331   - 

Total Liabilities

 $23,468  $-  $17,331  $6,137 

 

 

(1) Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2021 and June 30, 2020 was $6.6 million and $6.6 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.4 million as of June 30, 2021. The fair value of the warrant as of  June 30, 2020 was $8.0 million 

 

(2) Included in available-for-sale investments on the balance sheet.  The certificate of deposits have contractual maturity dates within one year.

 

Fair value measurements of available for sale securities

 

Available for sale securities excluding warrants are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets. The Company's warrant to purchase additional shares at a specified future price was valued using a Black-Scholes model with observable inputs in active markets and therefore was classified as a Level 2 asset. 

 

Fair value measurements of derivative instruments

 

In October 2018, the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note 6 to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on an initial $380 million of notional principal amount. The notional amount decreased by $100 million in   October 2020 and will further decrease by $80 million in   October 2021 and $200 million in   October 2022. In   June 2020, the Company de-designated $80 million of the notional amount set to expire in  October 2020. The net loss associated with the  June 2020 de-designated portion of the derivative instrument was not reclassified into earnings based on the amount of probable variable interest payments to occur within a two month time period of the forecasted hedged transaction. In  December 2020, the Company de-designated an additional $80 million of notional amount set to expire in  October 2021. During fiscal year 2021, the Company recorded a loss in other non-operating income related to variable interest debt payments in certain months on a portion of the de-designated derivative that is not expected to occur. The remaining variable interest payments for the portion of the de-designated derivative were considered probable of occurring and therefore remain in accumulated other comprehensive income as of  June 30, 2021. The fair value of the portion of the de-designated derivative was $0.8 million as of  June 30, 2021, which is recorded within short-term liabilities on the Consolidated Balance Sheet. The fair value of the designated derivative instrument is $7.6 million as of June 30, 2021 and is recorded within other long-term liabilities on the Consolidated Balance Sheet. 

 

In May 2021, the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt. The forward starting swap reduces the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swap, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on $200 million of notional principal amount. The effective date of the swap is November 2022 with the full swap maturing in November 2025. The fair value of the derivative instrument was $0.3 million as of June 30, 2021 which is recorded within other long-term assets on the Consolidated Balance Sheet.

 

Changes in the fair value of the designated hedged instrument are reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $8.6 million to interest expense, $0.5 million to non-operating income for the portion of de-designated variable payments considered probable to not occur, and related tax benefits of $2.1 million during the fiscal year ended  June 30, 2021 relating to the cash flow hedge entered into in October 2018. No amounts were reclassified relating to the cash flow hedge entered into in May 2021 as they will be recorded within the effective period of the cash flow hedge.

 

The Company reclassified $3.5 million, net of taxes, to interest expense during the fiscal year ended  June 30, 2020. The change in the fair value of the de-designated notional hedged amount was not material as of June 30, 2020. The instruments were valued using observable market inputs in active markets and therefore are classified as Level 2 liabilities.

 

The Company did not reclassify any amounts out of other comprehensive income into interest expense during the fiscal year ended June 30, 2019.

 

Fair value measurements of contingent consideration

 

The Company has $29.4 million, which is the fair value, of contingent consideration related to the Asuragen, Quad, and B-MoGen acquisitions. The Company is required to make contingent consideration payments of up to $105.0 million, $51.0  million, and $38.0 million, respectively, as part of these acquisition agreements. The contingent agreement with Asuragen was based on achieving certain revenue thresholds, the contingent agreement with Quad is based on meeting certain product development milestones and revenue thresholds, and the contingent agreement with B-MoGen is based on meeting certain product development milestones and revenue thresholds. The preliminary fair value of the liabilities for the Asuragen acquisition was $18.3 million as discussed in Note 4. The preliminary fair value of the revenue milestone payments was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors.   

 

During the fourth quarter of fiscal 2020, the Company's obligation for potential contingent consideration payments related to the ExosomeDx acquisition were relieved as part of the Company's escrow settlement with the former shareholders of ExosomeDx. As the result of this settlement, the Company reversed an accrual for the fair value of the contingent liability at the date of settlement.

 

The ultimate settlement of contingent consideration liabilities for the Asuragen, Quad, and B-Mogen acquisitions could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.

 

The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

 

  

June 30,

 
  

2021

  2020 
         

Fair value at the beginning of period

 $6,137  $12,600 

Purchase price contingent consideration (Note 4)

  18,300   - 

Payments

  (337

)

  (4,358)

Gain on escrow settlement

  -

 

  (1,200)

Change in fair value of contingent consideration

  5,300

 

  (905

)

Contingent consideration payable

 $29,400  $6,137 

 

Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.

 

Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.

 

Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility  and long-term debt approximates fair value because our interest rate is variable and reflects current market rates. 

 
XML 36 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Note 6 - Debt and Other Financing Arrangements
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Debt Disclosure [Text Block]

Note 6. Debt and Other Financing Arrangements: 

 

On August 1, 2018, the Company entered into a new uncollateralized revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $600.0 million, which can be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the Eurodollar Loans term for which the interest rate is calculated as the sum of LIBOR plus an applicable margin. The applicable margin is determined for the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 12.5 basis points. The Company has recorded $12.5 million of our outstanding borrowings under the Credit Agreement as a current liability in our Consolidated Balance sheet, which represents our required quarterly debt payments to be made in fiscal year 2022.

 

The Credit Agreement matures on August 1, 2023 and contains customary restrictive and financial covenants and customary events of default. At the closing on August 1, 2018 the company borrowed $250.0 million under the term loan and $330.0 million under the revolving credit facility. As of June 30, 2021 and 2020, the outstanding balance under the Credit Agreement was $341 million and $357 million respectively. 

 
XML 37 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Leases
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

Note 7. Leases: 

 

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company adopted ASU No. 2016-02 and related standards (collectively ASC 842, Leases), which replaced previous lease accounting guidance, on July 1, 2019. 

 

The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During fiscal year 2021, the Company recognized $3.6 million in variable lease expense in the Consolidated Statements of Earnings and Comprehensive Income.  During fiscal year 2021, the Company also recognized $32.5 million relating to fixed lease expense in the Consolidated Statements of Earnings and Comprehensive Income. 

 

The following table summarizes the balance sheet classification of the Company’s operating leases, amounts of right of use assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):

 

  Balance Sheet Classification 

As of:

June 30,

2021

 

Operating leases:

      

Operating lease right of use assets(1)

 Right of Use Asset $73,834 
       

Current operating lease liabilities(1)

 Operating lease liabilities current $11,602 

Noncurrent operating lease liabilities(1)

 Operating lease liabilities  67,625 

Total operating lease liabilities

   $79,227 
       

Weighted average remaining lease term (in years):

    7.97 
       

Weighted average discount rate:

    3.93

%

(1) The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.

 

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the year ended  June 30, 2021 (in thousands):

 

  

For the year

ended June

30, 2021

 

Cash amounts paid on operating lease liabilities(1)

 $13,492 
     

Right of use assets obtained in exchange for lease liabilities

  12,144 

 

(1) Total cash paid for the Company's operating leases during the year ended June 30, 2021 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.  

 

The following table summarizes payments by date for the Company’s operating leases, which is then reconciled to our total lease obligation (in thousands):

 

  

June 30, 2021

Operating

Leases

 

2022

 $14,349 

2023

  13,371 

2024

  11,840 

2025

  10,780 

2026

  10,120 

Thereafter

  32,331 

Total

 $92,791 

Less: Amounts representing interest

  13,564 

Total lease obligations

  79,227 

 

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. The Company includes option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, the Company is not reasonably certain to exercise such options.

 

 
XML 38 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Comprehensive Income (Loss) Note [Text Block]

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss): 

 

Supplemental Equity

 

The Company has declared cash dividends per share of $1.28 in each of the full fiscal years ended  June 30, 2021, June 30, 2020, and June 30, 2019. During the years ended June 30, 2021 and June 30, 2020, the Company repurchased 120,000 shares at an average share price of $359.81 and 279,381 shares at an average share price of $179.37, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year 2021, 2020 and 2019, the amounts within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise options due to net settlement stock options exercises were not material.

 

 

Accumulated Other Comprehensive Income (loss) 

 

Changes in accumulated other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows (in thousands):

 

  

Unrealized

Gains

(Losses)

on

Available-

for-Sale

Investments

  

Foreign

Currency

Translation

Adjustments

  

Unrealized

Gains

(Losses) on

Derivatives

Instruments

  

Total

 

Balance June 30, 2018 

 $24,682  $(69,496

)

 $-  $(44,814

)

Cumulative effect adjustment for adoption for ASU 2018-02

  2,371   -   -   2,371 

Cumulative effect adjustment for adoption for ASU 2016-01

  (27,053

)

  -   -   (27,053

)

Other comprehensive income (loss) before reclassifications

  -   (4,487

)

  (9,537

)

  (14,024

)

Balance June 30, 2019

 $-  $(73,983

)

 $(9,537

)

 $(83,521

)

Other comprehensive income (loss) before reclassifications

  -   (9,963

)

  (7,179

)

  (17,142

)

Reclassification from loss on derivatives to interest expense, net of taxes

  -   -   3,464   3,464 

Balance June 30, 2020

 $-  $(83,946

)

 $(13,253

)

 $(97,199

)

Other comprehensive income (loss) before reclassifications(2)  -   32,848   100   32,948 
Reclassification from loss on derivatives to interest expense, net of taxes(1)  -   -   6,960   6,960 
Balance June 30, 2021 $-  $(51,098) $(6,193) $(57,291)

 

(1) Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company had deferred tax benefits of $1,908 and $4,058 included in the accumulated other comprehensive income loss as of June 30, 2021 and June 30, 2020, respectively.

(2) Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence. 

 
XML 39 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Earnings Per Share
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Earnings Per Share [Text Block]

Note 9. Earnings Per Share:

 

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

 

  

Year Ended June 30,

 
  

2021

  

2020

  

2019

 

Earnings per share – basic:

            
Net earnings, including noncontrolling interest  139,585   229,296   96,072 
Less net earnings attributable to noncontrolling interest  (825)  -   - 

Net income

 $140,410  $229,296  $96,072 

Income allocated to participating securities

  (86

)

  (224

)

  (105

)

Income available to common shareholders

 $140,324  $229,072  $95,967 

Weighted-average shares outstanding – basic

  38,747   38,201   37,781 

Earnings per share – basic

 $3.62  $6.00  $2.54 
             

Earnings per share – diluted:

            

Net income

 $140,410  $229,296  $96,072 

Income allocated to participating securities

  (86

)

  (224

)

  (105

)

Income available to common shareholders

 $140,324  $229,072  $95,967 

Weighted-average shares outstanding – basic

  38,747   38,201   37,781 

Dilutive effect of stock options and restricted stock units

  1,736   1,200   1,111 

Weighted-average common shares outstanding – diluted

  40,483   39,401   38,892 

Earnings per share – diluted

 $3.47  $5.82  $2.47 

 

Basic net income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares of our stock result from dilutive common stock options and restricted stock units. We use the treasury stock method to calculate the weighted-average shares used in the diluted earnings per share computation. Under the treasury stock method, the proceeds from exercise of an option, the amount of compensation cost, if any, for future service that we have not yet recognized, and the amount of estimated tax benefits that would be recorded in paid-in capital, if any, when the option is exercised are assumed to be used to repurchase shares in the current period.

 

The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.6 million, 0.9 million, and 1.3 million for the fiscal years ended June 30, 2021, 2020 and 2019, respectively.

 
XML 40 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Share-based Compensation and Other Benefit Plans
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

Note 10. Share-based Compensation and Other Benefit Plans:

 

The cost of employee services received in exchange for the award of equity instruments is based on the fair value of the award at the date of grant. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. Stock option exercises and stock awards are satisfied through the issuance of new shares. 

 

Equity incentive plan: The Company's Second Amended and Restated 2010 Equity Incentive Plan (the Second A&R 2010 Plan) provides for the granting of incentive and nonqualified stock options, restricted stock, restricted stock units, performance shares, performance units and stock appreciation rights. There were 7.5 million shares of common stock authorized for grant under the Second A&R 2010 Plan. In October 2020, the shareholders approved an amended and restated incentive plan - the 2020 Equity Incentive Plan. The maximum aggregate number of shares of common stock reserved and available for awards under the Amended Plan is 2,484,202 shares, which includes an additional 1,300,000 shares authorized by the 2020 Equity Incentive Plan. Shares issued after the shareholder meeting are issued under the 2020 Equity Incentive Plan. At June 30, 2021, there were 1.1 million shares of common stock available for grant under the 2020 Equity Incentive Plan. The maximum term of incentive options granted under the 2020 Equity Incentive Plan is ten years. The 2020 Equity Incentive Plan replaced the Company's second A&R 2010 Plan, which had previously amended and restated the Company's Amended and Restate 2010 Equity Incentive Plan (the A&R 2010 Plan). The A&R 2010 Plan had previously replaced the Company's 1998 Nonqualified Stock Option Plan (the 1998 Plan). The Second A&R 2010 Plan and the 1998 Plan (collectively, the Plans) are administered by the Board of Directors and its Executive Compensation Committee, which determine the persons who are to receive awards under the Plans, the number of shares subject to each award and the term and exercise price of each award. The number of shares of common stock subject to outstanding awards as of  June 30, 2021 under the 2020 Equity Incentive Plan were 3.7 million.

 

The fair values of options granted under the Plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

 

  

Year Ended June 30,

 
  

2021

  2020  2019 
                   

Dividend yield

   0.24%     0.67%     0.74%  

Expected volatility

  25%-30%   22%-24%   20%-23% 

Risk-free interest rates

  0.2%-0.7%   1.3%-1.9%   2.5%-3.0% 

Expected lives (years)

   4.4     4.0     4.1  

 

The dividend yield is based on the Company's historical annual cash dividend divided by the market value of the Company's common stock. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rates with a term consistent with the expected life of the options granted.

 

Stock option activity under the Plans for the three years ended June 30, 2021, consists of the following (shares in thousands): 

 

  

Number of

Shares (in

thousands)

  

Weighted
Average
Exercise
Price

  

Aggregate
Intrinsic
Value

(millions)

  

Weighted

Average

Contractual

Life (years)

 
                 

Outstanding at June 30, 2018

  3,452  $105.17         

Granted

  917   173.89         

Forfeited

  (330

)

  129.93         

Exercised

  (383

)

  95.29         

Outstanding at June 30, 2019

  3,656  $121.16         

Granted

  752   190.80         

Forfeited

  (56

)

  95.97         

Exercised

  (743

)

  157.45         

Outstanding at June 30, 2020

  3,609  $140.28         
Granted  763   277.75         
Forfeited  (28)  214.33         
Exercised  (627)  112.53         
Outstanding at June 30, 2021  3,717  $172.63  $1,031.9   4.1 
                 

Exercisable at June 30, 2019:

  1,467   98.70         

Exercisable at June 30, 2020:

  1,564   112.60         
Exercisable at June 30, 2021:  1,764   126.44  $571.3   3.0 

 

The weighted average fair value of options granted during fiscal 2021, 2020, and 2019 was $59.75, $37.01, and $34.66 respectively. The total intrinsic value of options exercised during fiscal 2021, 2020, and 2019 were $145.6 million, $99.3 million, and $159.0 million, respectively. The total fair value of options vested during fiscal 2021, 2020, and 2019 were $70.5 million, $71.1 million, and $31.7 million, respectively.

 

Restricted common stock activity under the Plans for the three years ended June 30, 2021, consists of the following (units in thousands):

 

  

Number of

Shares (in

thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Unvested at June 30, 2018

  35  $117.39     

Granted

  15   177.93     

Vested

  (20

)

  116.76     

Forfeited

  -   -     

Unvested at June 30, 2019

  30  $147.94     

Granted

  15   193.48     

Vested

  (18

)

  142.12     

Forfeited

  -   -     

Unvested at June 30, 2020

  28  $177.20     
Granted  12   264.73     
Vested  (17)  171.64     
Forfeited  -   -     
Unvested at June 30, 2021  23  $226.07   6.07 

 

The total fair value of restricted shares that vested was $2.8 million for fiscal 2021, $2.5 million for fiscal 2020, and $2.3 million for fiscal 2019.

 

Restricted stock unit activity under the Plans for the three years ended June 30, 2021, consists of the following (units in thousands):

 

  

Number of

Units

(in thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Outstanding at June 30, 2018

  148  $117.95     

Granted

  56   170.96     

Vested

  (28

)

  110.86     

Forfeited

  (36

)

  143.72     

Outstanding at June 30, 2019

  139  $134.17     

Granted

  31   192.08     

Vested

  (51

)

  111.07     

Forfeited

  (3

)

  155.60     

Outstanding at June 30, 2020

  116  $159.25     
Granted  31   300.78     
Vested  (51)  130.18     
Forfeited  -   -     
Outstanding at June 30, 2021  96  $220.53   5.36 

 

The total fair value of restricted stock units that vested was $6.7 million for fiscal 2021, $5.7 million for fiscal 2020, and $3.1 million for fiscal 2019. The restricted stock units vest over a three-year period.

 

Stock-based compensation cost, inclusive of payroll taxes, of $46.4 million, $32.4 million, and $32.3 million was included in selling, general and administrative expense in fiscal 2021, 2020 and 2019, respectively. Additionally, stock-based compensation costs, inclusive of payroll taxes, of $1.6 million was included in cost of goods sold in 2021. As of June 30, 2021, there was $37.1 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock which will be expensed in fiscal 2022 through 2024 using a 4.6% forfeiture rate. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years.

 

Employee stock purchase plan: In fiscal year 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. The Company recorded expense of $0.9 million, $0.4 million, and $0.5 million for the ESPP in fiscal 2021, 2020, and 2019, respectively.

 

Profit sharing and savings plans: The Company has profit sharing and savings plans for its U.S. employees, which conform to IRS provisions for 401(k) plans. The Company makes matching contributions to the Plan. The Company has recorded an expense for contributions to the plans of $3.4 million, $3.2 million, and $2.8 million for the years ended June 30, 2021, 2020, and 2019, respectively. The Company operates defined contribution pension plans for its U.K. employees. The Company has recorded an expense for contributions to the plans of $1.6 million for year ended June 30, 2021 and $1.4 million for each of the years ended June 30,  2020 and 2019.

 

Performance incentive programs: In fiscal 2021, under certain employment agreements, a Management Incentive Plan, and a business incentive plan, available to executive officers, certain management personnel, and certain other professional employees, the Company recorded cash bonuses of $21.1 million, granted options for 762,761 shares of common stock, issued 11,803 restricted common shares and 30,823 restricted stock units. In fiscal 2020 and fiscal 2019, the Company recorded cash bonuses of $10.5 million and $9.3 million, granted options for 751,499 and 618,898 shares of common stock, and issued 15,398 and 11,279 restricted common stock shares and 30,858 and 25,903 restricted stock, respectively.

 
XML 41 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Income Taxes
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

Note 11. Income Taxes:

 

Income before income taxes was comprised of the following (in thousands):

 

   

Year Ended June 30,

  
   

2021

     2020     2019  

Domestic

   $ 95,662     $ 245,365     $ 64,081  

Foreign

     52,513       31,112       47,934  

Income before income taxes

   $ 148,175     $ 276,477     $ 112,015  

 

The provision for income taxes consisted of the following (in thousands):

 

   

Year Ended June 30,

  
    2021     2020     2019  

Taxes on income consist of:

                        

Currently tax provision:

                        

Federal

   $ 15,179     $ 18,976     $ 16,090  

State

     6,681       6,018       544  

Foreign

     14,743       8,580       13,329  

Total current tax provision

     36,603       33,574       29,963  

Deferred tax provision:

                        

Federal

     (20,812 )     14,074

 

     (6,903

)

State

     (4,962 )     2,055

 

     (3,977

)

Foreign

     (2,239 )     (2,522

)

     (3,142

)

Total deferred tax provision

     (28,013 )     13,607

 

     (14,021

)

Total income tax provision

   $
8,590
    $ 47,181     $ 15,943

 

 

The Company’s effective income tax rate for fiscal 2021 was 5.8% vs 17.1% in the prior year. The change in the effective tax rate for fiscal 2021 and 2020 was driven by changes in net discrete tax benefits of $28.1 million and $19.4 million for fiscal year 2021 and 2020, respectively.

 

The Company's effective income tax rate for fiscal 2020 was 17.1% for fiscal 2020 vs 14.2% in the prior year. The change in the effective tax rate for fiscal 2020 and 2019 were driven by the changes in the net discrete tax benefits $19.4 million and $12.7 million, respectively. 

 

The Company's discrete tax benefits in fiscal 2021 primarily related to share-based compensation excess tax benefits of $28.1 million.

 

The Company's discrete tax benefits in fiscal 2020 primarily related to share-based compensation excess tax benefits of $17.7 million.

 

The Company's discrete tax benefits in fiscal 2019 primarily related to share-based compensation excess tax benefits of $7.2 million, $3.2 million related to fiscal 2019 acquisitions, and $2.0 million for tax refunds relating to certain state apportionments. 

 

The Company continues to monitor newly enacted regulations, clarifications, and changes in guidance the Tax Cuts and Jobs Act “Tax Act”, which was enacted on  December 22, 2017. The Company recognizes changes in legislation in the period enacted, which may have a material impact on our effective tax rate in future periods.

 

The following is a reconciliation of the federal tax calculated at the statutory rate of to the actual income taxes provided:

 

   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Income tax expense at federal statutory rate

     21.0

%

     21.0

%

     21.0

%

State income taxes, net of federal benefit

     0.6

 

     2.3

 

     (1.5

)

Research and development tax credit

     (1.8

)

     (0.7

)

     (1.6

)

Contingent consideration adjustment

     0.8

 

     (0.2

)

     (0.4

)

Foreign tax rate differences

     0.8

 

     (0.2

)

     0.2

 

Option exercises

     (16.9

)

     (5.7

)

     (5.8

)

U.S. taxation of foreign earnings

     (0.1 )     0.9

 

     3.7

 

Foreign derived intangible income

     (5.1 )     (0.9

)

     (2.0 )

Executive compensation limitations

     6.5       1.6

 

     0.4  

Other, net

     0.0       (1.0

)

     0.2

 

Effective tax rate

     5.8

%

     17.1

%

     14.2

%

 

Deferred taxes on the Consolidated Balance Sheets consisted of the following temporary differences (in thousands):

 

   

June 30

  
   

2021

     2020  
                 

Inventory

   $ 6,730     $ 7,769  

Net operating loss carryovers

     31,345       25,707  

Tax credit carryovers

     14,486       9,568  

Excess tax basis in equity investments

     2,429       2,423  

Deferred compensation

     11,108       10,755  

Derivative - cash flow hedge

     1,908       4,058  

Lease liability

     17,016       16,256  

Other

     8,526       4,340  

Valuation allowance

     (6,665

)

     (7,523

)

Deferred tax assets

     86,883       73,353  
                 

Net unrealized gain on available-for-sale investments

     (3,159

)

     (19,102

)

Intangible asset amortization

     (150,765

)

     (128,279

)

Depreciation

     (9,099

)

     (10,764

)

Right of use asset

     (15,868

)

     (15,118 )

Other

     (1,117

)

     (1,180

)

Deferred tax liabilities

     (180,008

)

     (174,443

)

Net deferred tax liabilities

   $ (93,125 )   $ (101,090

)

 

A deferred tax valuation allowance is required when it is more likely than not that all or a portion of deferred tax assets will not be realized. The valuation allowance as of June 30, 2021 was $6.7 million compared to $7.5 million in the prior year. 

 

As of June 30, 2021, the $6.7 million valuation allowance relates to certain foreign and state tax net operating loss and state credit carryforwards that existed at the date the Company acquired Quad, ExosomeDx, ACD, Novus, ProteinSimple and CyVek as well as immaterial amounts generated after the acquisitions. The Company believes it is more likely than not that these tax carryovers will not be realized.

 

As of June 30, 2021, the Company has federal operating loss carryforwards of approximately $92.1 million and state operating loss carryforwards of $129.6 million from its acquisitions of Asuragen (refer to note 4), Quad, ExosomeDx, ACD, ProteinSimple and CyVek, which are not limited under IRC Section 382. As of June 30, 2021, the Company has foreign net operating loss carryforwards of $13.9 million. The net operating loss carryforwards expire between fiscal 2022 and 2036. The Company has a deferred tax asset of $26.6 million, net of the valuation allowance discussed above, related to the net operating loss carryovers. As of June 30, 2021, the Company has federal and state tax credit carryforwards of $10.1 million and $4.4 million, respectively. The federal tax credit carryforwards expire between 2028 and 2038. The majority of the state credit carryforwards have no expiry date. The Company has a deferred tax asset of $12.6 million, net of the valuation allowance discussed above, related to the tax credit carryovers.

The Company has not recognized a deferred tax liability for unremitted foreign earnings of approximately $223 million from its foreign operations because its subsidiaries have invested or will invest the undistributed earnings indefinitely. The transition tax included as part of the Tax Act resulted in the previously untaxed foreign earnings being included in the federal and state fiscal 2018 taxable income. The one-time transition tax was based on certain foreign earnings for which earnings have been previously indefinitely reinvested as well as the amount of earnings held in cash and other specified assets.   No additional income taxes have been provided for cumulative unremitted foreign earnings as at this time our intention with respect to unremitted foreign earnings is to continue to indefinitely reinvest outside the U.S. those earnings needed for working capital or additional foreign investment. If there are policy changes, we would record applicable taxes at that time.

We continue to analyze our global working capital requirements and the potential tax liabilities that would be incurred if the non-U.S. subsidiaries distribute cash to the U.S. parent, which include local country withholding tax and potential U.S. state taxation.  In addition, we anticipate that further guidance from the IRS and US Treasury related to the Tax Act could impact the amount of any related taxes. Therefore, it is not practical to estimate the amount of the deferred income tax liabilities related to investments in these foreign subsidiaries.

The following is a reconciliation of the beginning and ending balance of unrecognized tax benefits (in thousands):

 

   

Year Ended June 30,

  
   

2021

     2020     2019  

Beginning balance

   $ 4,297     $ 5,032     $ 1,947  

Additions due to acquisitions

     -       -       900  

Additions for tax positions of prior year

     4,038       306       2,185  

Decrease in unrecognized tax benefits for prior year positions

     (778

)

     (1,041 )     -  
Settlements     (286 )     -       -  

Ending balances

   $ 7,271     $ 4,297     $ 5,032  

 

Included in the balance of unrecognized tax benefits at June 30, 2021 are potential benefits of $5.2 million that, if recognized, would affect the effective tax rate on income from continuing operations. The amount of interest and penalties recognized on the balance sheet as of June 30, 2021 is not material. The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase in the next twelve months. It is reasonably possible that the unrecognized tax benefits may decrease by $2.6 million as a result of ongoing discussions with the German tax authorities regarding a historical local matter. The Company files income tax returns in the U.S. federal and certain state tax jurisdictions, and several jurisdictions outside the U.S. The Company's federal returns are subject to tax assessment for 2017 and subsequent years. State and foreign income tax returns are generally subject to examination for a period of three to five years after filing of the respective return. The state impact of any federal changes remains subject to examination by various states for a period of up to one year after formal notification to the states.

 
XML 42 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information:

 

The Company operates under two operating segments, Protein Sciences and Diagnostics and Genomics.

 

The Company's Protein Sciences segment is comprised of the reagent solutions and analytical solutions. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2021, 2020, and 2019.

 

The Company's Diagnostics and Genomics segment is comprised of diagnostics reagents, genomics, and our Exosome and Asuragen acquisitions. Diagnostics reagents develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. Genomics, Exosome, and Asuragen consists of Genomics and Exosome products and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment’s net sales for the fiscal years ended June 30, 2021, 2020, and 2019. 

 

There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term.

 

Following is financial information relating to the operating segments (in thousands):

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Net sales:

            

Protein Sciences

 $704,564  $555,352  $543,159 

Diagnostics and Genomics

  227,744   184,549   171,674 

Intersegment

  (1,276

)

  (1,210

)

  (827

)

Consolidated net sales

 $931,032  $738,691  $714,006 
             

Operating Income:

            

Protein Sciences

 $328,837  $234,929  $240,919 

Diagnostics and Genomics

  38,425   14,965   10,079 

Segment operating income

  367,262   249,894   250,998 

Costs recognized upon sale of acquired inventory

  (1,565)  -

 

  (3,739

)

Amortization of acquired intangible assets

  (64,239

)

  (60,865

)

  (58,550

)

Gain on escrow settlement

  -   7,169   - 

Acquisition related expenses

  (7,114

)

  (416

)

  (2,282

)

Restructuring costs

  (142

)

  (87)  -

 

Stock-based compensation, inclusive of employer taxes

  (51,846

)

  (34,262

)

  (33,057

)

Corporate general, selling and administrative expenses

  (5,060

)

  (4,015

)

  (6,651

)

Consolidated operating income

 $237,296  $157,419  $146,719 

 

The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by operating segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each operating segment’s operating results, it is not discretely identifiable.

 

The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. The Company has disclosed dis-aggregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) :

 

  

Year Ended June 30,

 
  

2021

  2020  2019 

Consumables revenue - Protein Sciences

 $557,037  $431,052  $430,655 

Consumables revenue - Diagnostics and Genomics

  194,948   171,590   158,324 

Total consumable revenue

 $751,985  $602,642  $588,979 

 

The following is financial information relating to geographic areas (in thousands):

 

  

Year ended June 30,

 

Long-lived assets:

 

2021

  2020 

United States and Canada

 $190,501  $162,039 

Europe

  13,949   13,120 

Asia

  3,457   1,670 

Total long-lived assets

 $207,907  $176,829 

Intangible assets:

        

United States and Canada

 $594,512  $499,875 

Europe

  9,369   12,349 

Asia

  12,087   4,321 

Total intangible assets

 $615,968  $516,545 

 

Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.
XML 43 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Note 13 - Subsequent Events
 12 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Subsequent Events [Text Block]

Note 13. Subsequent Events:

 

None

 
XML 44 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies (Policies)
 12 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block] Use of estimates: The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock-based compensation and income taxes. Actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block] Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. The Company consolidated our partial acquisition of Eminence in our consolidated financial statements on a one month lag. Refer to Note 4 for additional discussion regarding Eminence.
Foreign Currency Transactions and Translations Policy [Policy Text Block] Translation of foreign financial statements: Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.
Revenue [Policy Text Block] Revenue recognition: The Company adopted ASC 606 - Revenue from Contracts with Customers on July 1, 2018 using the modified retrospective transition approach. ASC 606 provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Refer to Note 2 for additional information regarding our revenue recognition policy under ASC 606.
Research and Development Expense, Policy [Policy Text Block] Research and development: Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.
Advertising Cost [Policy Text Block] Advertising costs: Advertising expenses were $4.7 million, $4.2 million, and $4.1 million for fiscal 2021, 2020, and 2019 respectively. The Company expenses advertising expenses as incurred.
Income Tax, Policy [Policy Text Block] Income taxes: The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Refer to Note 11 for additional information regarding income taxes.
Comprehensive Income, Policy [Policy Text Block] Comprehensive income: Comprehensive income includes charges and credits to shareholders' equity that are not the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on cash flow hedges, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.
Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents: Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of three months or less.
Marketable Securities, Policy [Policy Text Block] Available-for-sale investments: Available-for-sale investments consist of debt instruments with original maturities of generally three months to six months and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value. Unrealized gains and losses on available-for-sale securities are included within other income (expense) in accordance with ASU 2018-02, which the Company adopted on  July 1, 2018. 
Accounts Receivable [Policy Text Block] Trade accounts receivable and allowances: Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do not bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. The Company adopted ASU 2016-13 on July 1, 2020, which reflects the expected credit losses on financial instruments within its scope, including trade receivables. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer. The Company does not have material long-term customer receivables. Refer to the Recently Adopted Accounting Pronouncements section of Note 1 for further details.
Inventory, Policy [Policy Text Block]

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration.

 

For certain proteins, antibodies, and chemically based manufactured products, the Company produces larger batches of established products than current sales requirements due to economies of scale through a highly controlled manufacturing process. Accordingly, the manufacturing process for these products has and will continue to produce quantities in excess of forecasted usage. The Company forecasts usage for its products based on several factors including historical demand, current market dynamics, and technological advances. The Company forecasts product usage on an individual product level for a period that is consistent with our ability to reasonably forecast inventory usage for that product. There have been no material changes to the Company’s estimates of the net realizable value for excess and obsolete inventory or other types of inventory reserves and inventory cost adjustments in the fiscal years presented. Additionally, current and historical reserves recorded to reduce the cost of inventory to its net realizable value become part of the new cost basis for the inventory item in accordance with ASC 330 - Inventory.
Property, Plant and Equipment, Policy [Policy Text Block] Property and equipment: Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of 3 to 5 years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of 5 to 40 years.
Contingent Consideration, Policy [Policy Text Block] Contingent Consideration: Contingent Consideration relates to the potential payment for an acquisition that is contingent upon the achievement of the acquired business meeting certain product development milestones and/or certain financial performance milestones. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred. For potential payments related to financial performance milestones, we use a real option model in calculating the fair value of the contingent consideration liabilities. The assumptions utilized in the calculation based on financial performance milestones include projected revenue and/or EBITDA amounts, volatility and discount rates. For potential payments related to product development milestones, we estimated the fair value based on the probability of achievement of such milestones. The assumptions utilized in the calculation of the acquisition date fair value include probability of success and the discount rates. Contingent consideration involves certain assumptions requiring significant judgment and actual results may differ from assumed and estimated amounts. Contingent consideration is remeasured each reporting period, and subsequent changes in fair value, including accretion for the passage of time, are recognized within selling, general and administrative in the consolidated statement of earnings and comprehensive income.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible assets: Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from 1 year to 20 years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life.

 

In conjunction with the Asuragen acquisition that occurred in fiscal year 2021, the Company reassessed the useful life of a tradename from a previous acquisition due to the planned integration and cobranding strategy developed with the most recent transaction.  As a result, the Company accelerated the amortization of the trade name to be consistent with the life used for the Asuragen trade name.  The accelerated amortization resulted in a $1.4 million impact in fiscal 2021, a $5.7 million impact in fiscal years 2022 through 2025, and a $4.3 impact in fiscal year 2026.

 

In fiscal year 2020, the Company accelerated the amortization of a certain trade name based on the Company's planned integration of the products under that acquired trade name into a legacy brand. The accelerated amortization resulted in $1.3 million in additional amortization expense in fiscal 2020 and $0.6 million in fiscal 2021.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Impairment of long-lived assets and amortizable intangibles: We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount may not be recoverable. Such circumstances could include, but are not limited to, (1) a significant decrease in the market value of an asset, (2) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (3) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are not available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.

 

The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. No other triggering events were identified and no impairments were recorded for property, plant, and equipment or amortizable intangibles during fiscal years 2019, 2020, and 2021.

 

Impairment of goodwill: We evaluate the carrying value of goodwill during the fourth quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, (3) an adverse action or assessment by a regulator, or (4) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.

 

To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form one reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business. The Company had five reporting units for our 2021, 2020, and 2019 goodwill impairment assessment performed on April 1 of each of the respective fiscal years, the date of our annual goodwill impairment assessment. Further, the Company elected April 1 as the annual goodwill impairment assessment date for the Asuragen acquisition, acquired on April 6, 2021.

 

2021 Goodwill Impairment Analyses

 

In completing our 2021 annual goodwill impairment analyses, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU 2017-04, a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit’s financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value- weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.

 

The result of our quantitative assessment indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2021. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2021, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2020 Goodwill Impairment Analyses

 

The Company elected to perform a quantitative assessment for all of our reporting units in our 2020 goodwill impairment analysis. The quantitative assessment completed utilized a consistent process and methodology to the 2021 goodwill impairment assessment. The result of our quantitative assessment, where we compared the discounted cash flows of each reporting unit to its carrying value, indicated that all of the reporting units had a substantial amount of headroom as of April 1, 2020. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units. The Company did not identify any triggering events after our annual goodwill impairment through June 30, 2020, the date of our consolidated balance sheet, that would require an additional goodwill impairment assessment to be performed. 

 

2019 Goodwill Impairment Analyses

 

At the beginning of the quarter ended March 31, 2019, the Company realigned the management of certain business processes between reporting units within the same segment. A goodwill allocation was performed between the impacted reporting units based on the relative fair value of the processes realigned. In conjunction with the realignment, a quantitative goodwill impairment assessment was performed both prior to and subsequent to the realignment. The quantitative assessment indicated that all of the impacted reporting units had substantial headroom both prior to and subsequent to the realignment.

 

Because our quantitative analysis performed as of January 1, 2019 included all of our reporting units, except for Exosome a recent acquisition that was a separate reporting unit that was not impacted by the business process realignment, the summation of the calculated reporting units’ fair values combined with the fair value of the Exosome acquisition, was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.

 

The quantitative assessments completed as of January 1, 2019 indicated that all tested reporting units had a substantial amount of headroom. Changes in the reporting unit’s results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.

 

In conducting our annual goodwill impairment test on April 1, we elected to perform a qualitative assessment to determine whether changes in events or circumstances since our most recent quantitative test for goodwill impairment indicated that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

 

Based on its annual analysis, the Company determined there was no indication of impairment of goodwill. Further, no triggering events or items beyond the realignment discussed above were identified in the year ended June 30, 2019 that would require an additional goodwill impairment assessment beyond our required annual goodwill impairment assessment.
New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements

 

In  February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. The FASB has issued narrow codification improvements to Leases (Topic 842) through ASU No. 2018-10 and ASU 2019-01. Additionally, the FASB issued ASU 2018-11, allowing an entity to elect a transition method where they do not recast prior periods presented in the financial statements in the period of adoption. The Company has elected the transition method allowed for under ASU 2018-11 when adopting Leases (Topic 842). The Company adopted the standard effective  July 1, 2019 and correspondingly recorded incremental operating lease liabilities of $80.6 million, a right-of-use lease asset of $79.5 million, retained earnings of $0.8 million and a deferred tax adjustment of $0.3 million. Additionally, the Company reclassified $4.0 million of deferred rent recorded within accrued expenses under ASC 840 - Leases into operating lease liabilities upon adoption of Topic 842. In adopting ASC 842, the Company elected the package of available practical expedients and to use hindsight in determining the lease term for all existing leases. Further, as part of our adoption of ASC 842, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments. Refer to Note 7 for additional information on leases.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendment in this update replaced the previous incurred loss impairment methodology with a methodology that reflects expected credit losses on financial instruments within its scope, including trade and loan receivables and available-for-sale debt securities. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted this standard on July 1, 2020 using a modified retrospective transition approach with a cumulative impact of $0.3 million to retained earnings. The adoption of this ASU did not have a material impact on the Company's financial statements as the Company's primary financial instruments impacted by the ASU were trade accounts receivable, where we have high historical and expected future collections due to the length of receivables and the credit quality of our customers.

 

In August 2018, the FASB issued ASU No. 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is not affected by the new standard. The Company adopted this standard on a prospective basis on July 1, 2020. Accordingly, as of July 1, 2020, the Company will record eligible costs to be capitalized within prepaid assets or other non-current assets depending on the nature of the duration of the asset.

 

In  March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting and in January 2021 issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope. These ASUs provide expedients and exceptions to existing guidance on contract modifications and hedge accounting that is optional to facilitate the market transition from a reference rate, including LIBOR which is being phased out in 2021, to a new reference rate. The provisions of the ASUs impact contract modifications and other changes that occur while LIBOR is phased out. The Company adopted the optional relief guidance provided within these ASUs in the fourth quarter of fiscal 2021 and continues to monitor its debt and derivative instruments that utilize LIBOR as the reference rate. The adoption of the standard did not impact our financial results for fiscal 2021.
XML 45 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue Recognition (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Disaggregation of Revenue [Table Text Block]
  

Year ended June 30,

     
  

2021

  2020  2019 

Consumables

 $751,985  $602,642  $588,979 

Instruments

  93,782   71,462   67,538 

Services

  66,416   47,459   38,050 

Total product and services revenue, net

  912,183  $721,563   694,567 

Royalty revenues

  18,849   17,128   19,439 

Total revenues, net

 $931,032  $738,691  $714,006 
  

Year Ended June 30,

 
  2021  2020  2019 

Net sales:

            

United States

 $502,080  $404,407  $391,191 

EMEA, excluding U.K.

  204,264   155,289   155,821 

U.K.

  40,945   30,411   34,975 

APAC, excluding Greater China

  69,013   60,362   52,913 

Greater China

  87,556   68,792   57,799 

Rest of world

  27,174   19,430   21,307 

Total external sales

 $931,032  $738,691  $714,006 
XML 46 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
  

June 30,

 
  

2021

  2020 
         

Raw materials

 $55,096  $51,530 

Finished goods(1)

  67,108   56,268 

Inventories, net

 $122,204  $107,798 
Property, Plant and Equipment [Table Text Block]
  

June 30,

 
  

2021

  2020 

Cost:

        

Land

 $8,612  $8,516 

Buildings and improvements

  190,661   184,430 

Machinery, equipment and other

  198,483   153,704 

Property and equipment

  397,756   346,650 

Accumulated depreciation and amortization

  (189,849

)

  (169,821

)

Property and equipment, net

 $207,907  $176,829 
Schedule of Intangible Assets and Goodwill [Table Text Block]
        

June 30,

 
  

Useful Life

(years)

  

2021

  2020 
               

Developed technology

  9-15  $552,160  $434,653 

Trade names

  2-20   147,640   146,713 

Customer relationships

  7-16   232,493   211,750 

Patents

   10    2,926   2,475 
Other intangibles(1)  5-15   6,316   - 

Definite-lived intangible assets

        941,535   795,591 

Accumulated amortization

        (348,267

)

  (279,046

)

Definite-lived intangibles assets, net

        593,268   516,545 
In process research and development        22,700   - 
Total intangible assets, net       $615,968  $516,545 
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   

June 30,

 
   2021  2020 
          

Beginning balance

  $516,545  $579,429 

Acquisitions (Note 4)

   153,311   - 

Other additions

   5,912   311 

Amortization expense

   (64,940

)

  (61,095

)

Currency translation

   5,140

 

  (2,100

)

Ending balance

  $615,968  $516,545 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

2022

 $74,482 

2023

  72,649 

2024

  69,780 

2025

  66,523 

2026

  62,739 

Thereafter

  247,095 

Total

 $593,268 
Schedule of Goodwill [Table Text Block]
  

Protein

Sciences

  

Diagnostics &

Genomics

  

Total

 

June 30, 2019

 $377,407  $355,260  $732,667 

Acquisitions (Note 4)

  (326

)

  -   (326

)

Currency Translation

  (4,000

)

  (31

)

  (4,031

)

June 30, 2020

 $373,081  $355,229  $728,310 
Acquisitions (Note 4)  7,848   94,970   102,818 
Currency translation  11,788   151   11,939 
June 30, 2021 $392,717  $450,350  $843,067 
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
  

Year Ended June 30,

 
  

2021

  2020  2019 

Income taxes paid

 $20,952  $41,992  $36,814 

Interest paid

  13,576   18,615   21,497 

Non-cash activities:

            

Acquisition-related liabilities(1)

  23,600

 

  (2,105)  12,600 
Other intangibles(2)  4,000   -   - 
XML 47 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Note 4 - Acquisitions (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
  

Preliminary
Allocation at
Acquisition
Date

  

Adjustments to Fair Value

  

Final Allocation at June 30, 2021

Current assets, net of cash

 $3,145  $-  $3,145

Equipment and other long-term assets

  1,639   -   1,639
Intangible assets:           

Developed technology

  6,778   -   6,778

Customer relationships

  2,133   -   2,133

Goodwill

  8,811   (963)  7,848

Total assets acquired

  22,506   (963)  21,543

Liabilities

  1,436   -   1,436

Deferred income taxes, net

  2,320   (963)  1,357

Net assets acquired

 $18,750  $-  $18,750
            

Cash paid, net of cash acquired

  9,765   -   9,765
Fair value of noncontrolling interest in Eminence  8,985   -   8,985

Net assets acquired

 $18,750  $-  $18,750
    

Preliminary allocation at acquisition date and at June 30, 2021

Current assets, net of cash

   $10,422

Equipment and other long-term assets

    3,762
Intangible assets:     

Developed technology

    107,000
In-process research and development    22,700

Customer relationships

    11,700
Tradenames    2,000
Non-competition agreement    1,000

Goodwill

    94,970

Total assets acquired

    253,554
      

Liabilities

    4,003

Deferred income taxes, net

    15,664

Net assets acquired

   $233,887
      

Cash paid, net of cash acquired

    215,587
Contingent consideration payable    18,300

Net assets acquired

   $

233,887

  

B-MoGen

Biotechnologies

  

Exosome

Diagnostics

  

Quad

Technologies

Current assets, net of cash

 $504  $2,611  $36

Equipment and other long-term assets

  269   2,212   228
Intangible assets:           

Developed technology

  14,000   105,000   12,256

Trade name

  -   58,000   -

Customer relationships

  400   2,300   -

Goodwill

  16,131   105,362   14,481

Total assets acquired

  31,304   275,485   27,001
            

Liabilities

  211   3,716   296

Deferred income taxes, net

  3,051   16,346   943

Net assets acquired

 $28,042  $255,423  $25,762
            

Cash paid, net of cash acquired

  17,448   251,623   20,462

Additional consideration(1)

  10,594   3,800   5,300

Net assets acquired

 $28,042  $255,423  $25,762
XML 48 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Fair Value Measurements (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
  

Total

carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30,

2021

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $19,963  $18,581  $1,382  $- 

Certificates of deposit (2)

  12,500   12,500   -   - 
Derivative instruments - cash flow hedges  275   -   275   - 

Total Assets

 $32,738  $31,081  $1,657  $- 
                 

Liabilities

                

Contingent consideration

 $29,400  $-  $-  $29,400 

Derivative instruments - cash flow hedges

  8,376   -   8,376   - 

Total Liabilities

 $37,776  $-  $8,376  $29,400 
  

Total

carrying

value as of

  

Fair Value Measurements Using

Inputs Considered as

 
  

June 30,

2020

  

Level 1

  

Level 2

  

Level 3

 

Assets

                

Equity securities (1)

 $87,842  $79,846  $7,996  $- 

Certificates of deposit (2)

  36,426   36,426   -   - 

Total Assets

 $124,268  $116,272  $7,996  $- 
                 

Liabilities

                

Contingent consideration

  6,137  $-   -   6,137 

Derivative instruments - cash flow hedges

  17,331   -   17,331   - 

Total Liabilities

 $23,468  $-  $17,331  $6,137 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

June 30,

 
  

2021

  2020 
         

Fair value at the beginning of period

 $6,137  $12,600 

Purchase price contingent consideration (Note 4)

  18,300   - 

Payments

  (337

)

  (4,358)

Gain on escrow settlement

  -

 

  (1,200)

Change in fair value of contingent consideration

  5,300

 

  (905

)

Contingent consideration payable

 $29,400  $6,137 
XML 49 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Leases (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Lessee, Operating Lease, Asset and Liabilities [Table Text Block]
  Balance Sheet Classification 

As of:

June 30,

2021

 

Operating leases:

      

Operating lease right of use assets(1)

 Right of Use Asset $73,834 
       

Current operating lease liabilities(1)

 Operating lease liabilities current $11,602 

Noncurrent operating lease liabilities(1)

 Operating lease liabilities  67,625 

Total operating lease liabilities

   $79,227 
       

Weighted average remaining lease term (in years):

    7.97 
       

Weighted average discount rate:

    3.93

%
Lessee, Operating Lease, Cash Flow Information [Table Text Block]
  

For the year

ended June

30, 2021

 

Cash amounts paid on operating lease liabilities(1)

 $13,492 
     

Right of use assets obtained in exchange for lease liabilities

  12,144 
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
  

June 30, 2021

Operating

Leases

 

2022

 $14,349 

2023

  13,371 

2024

  11,840 

2025

  10,780 

2026

  10,120 

Thereafter

  32,331 

Total

 $92,791 

Less: Amounts representing interest

  13,564 

Total lease obligations

  79,227 
XML 50 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
  

Unrealized

Gains

(Losses)

on

Available-

for-Sale

Investments

  

Foreign

Currency

Translation

Adjustments

  

Unrealized

Gains

(Losses) on

Derivatives

Instruments

  

Total

 

Balance June 30, 2018 

 $24,682  $(69,496

)

 $-  $(44,814

)

Cumulative effect adjustment for adoption for ASU 2018-02

  2,371   -   -   2,371 

Cumulative effect adjustment for adoption for ASU 2016-01

  (27,053

)

  -   -   (27,053

)

Other comprehensive income (loss) before reclassifications

  -   (4,487

)

  (9,537

)

  (14,024

)

Balance June 30, 2019

 $-  $(73,983

)

 $(9,537

)

 $(83,521

)

Other comprehensive income (loss) before reclassifications

  -   (9,963

)

  (7,179

)

  (17,142

)

Reclassification from loss on derivatives to interest expense, net of taxes

  -   -   3,464   3,464 

Balance June 30, 2020

 $-  $(83,946

)

 $(13,253

)

 $(97,199

)

Other comprehensive income (loss) before reclassifications(2)  -   32,848   100   32,948 
Reclassification from loss on derivatives to interest expense, net of taxes(1)  -   -   6,960   6,960 
Balance June 30, 2021 $-  $(51,098) $(6,193) $(57,291)
XML 51 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Earnings Per Share (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Year Ended June 30,

 
  

2021

  

2020

  

2019

 

Earnings per share – basic:

            
Net earnings, including noncontrolling interest  139,585   229,296   96,072 
Less net earnings attributable to noncontrolling interest  (825)  -   - 

Net income

 $140,410  $229,296  $96,072 

Income allocated to participating securities

  (86

)

  (224

)

  (105

)

Income available to common shareholders

 $140,324  $229,072  $95,967 

Weighted-average shares outstanding – basic

  38,747   38,201   37,781 

Earnings per share – basic

 $3.62  $6.00  $2.54 
             

Earnings per share – diluted:

            

Net income

 $140,410  $229,296  $96,072 

Income allocated to participating securities

  (86

)

  (224

)

  (105

)

Income available to common shareholders

 $140,324  $229,072  $95,967 

Weighted-average shares outstanding – basic

  38,747   38,201   37,781 

Dilutive effect of stock options and restricted stock units

  1,736   1,200   1,111 

Weighted-average common shares outstanding – diluted

  40,483   39,401   38,892 

Earnings per share – diluted

 $3.47  $5.82  $2.47 
XML 52 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Share-based Compensation and Other Benefit Plans (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  

Year Ended June 30,

 
  

2021

  2020  2019 
                   

Dividend yield

   0.24%     0.67%     0.74%  

Expected volatility

  25%-30%   22%-24%   20%-23% 

Risk-free interest rates

  0.2%-0.7%   1.3%-1.9%   2.5%-3.0% 

Expected lives (years)

   4.4     4.0     4.1  
Share-based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of

Shares (in

thousands)

  

Weighted
Average
Exercise
Price

  

Aggregate
Intrinsic
Value

(millions)

  

Weighted

Average

Contractual

Life (years)

 
                 

Outstanding at June 30, 2018

  3,452  $105.17         

Granted

  917   173.89         

Forfeited

  (330

)

  129.93         

Exercised

  (383

)

  95.29         

Outstanding at June 30, 2019

  3,656  $121.16         

Granted

  752   190.80         

Forfeited

  (56

)

  95.97         

Exercised

  (743

)

  157.45         

Outstanding at June 30, 2020

  3,609  $140.28         
Granted  763   277.75         
Forfeited  (28)  214.33         
Exercised  (627)  112.53         
Outstanding at June 30, 2021  3,717  $172.63  $1,031.9   4.1 
                 

Exercisable at June 30, 2019:

  1,467   98.70         

Exercisable at June 30, 2020:

  1,564   112.60         
Exercisable at June 30, 2021:  1,764   126.44  $571.3   3.0 
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
  

Number of

Shares (in

thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Unvested at June 30, 2018

  35  $117.39     

Granted

  15   177.93     

Vested

  (20

)

  116.76     

Forfeited

  -   -     

Unvested at June 30, 2019

  30  $147.94     

Granted

  15   193.48     

Vested

  (18

)

  142.12     

Forfeited

  -   -     

Unvested at June 30, 2020

  28  $177.20     
Granted  12   264.73     
Vested  (17)  171.64     
Forfeited  -   -     
Unvested at June 30, 2021  23  $226.07   6.07 
  

Number of

Units

(in thousands)

  

Weighted

Average Grant

Date Fair

Value

  

Weighted

Average

Remaining

Contractual

Term

(years)

 

Outstanding at June 30, 2018

  148  $117.95     

Granted

  56   170.96     

Vested

  (28

)

  110.86     

Forfeited

  (36

)

  143.72     

Outstanding at June 30, 2019

  139  $134.17     

Granted

  31   192.08     

Vested

  (51

)

  111.07     

Forfeited

  (3

)

  155.60     

Outstanding at June 30, 2020

  116  $159.25     
Granted  31   300.78     
Vested  (51)  130.18     
Forfeited  -   -     
Outstanding at June 30, 2021  96  $220.53   5.36 
XML 53 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Income Taxes (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
   

Year Ended June 30,

  
   

2021

     2020     2019  

Domestic

   $ 95,662     $ 245,365     $ 64,081  

Foreign

     52,513       31,112       47,934  

Income before income taxes

   $ 148,175     $ 276,477     $ 112,015  
   

Year Ended June 30,

  
    2021     2020     2019  

Taxes on income consist of:

                        

Currently tax provision:

                        

Federal

   $ 15,179     $ 18,976     $ 16,090  

State

     6,681       6,018       544  

Foreign

     14,743       8,580       13,329  

Total current tax provision

     36,603       33,574       29,963  

Deferred tax provision:

                        

Federal

     (20,812 )     14,074

 

     (6,903

)

State

     (4,962 )     2,055

 

     (3,977

)

Foreign

     (2,239 )     (2,522

)

     (3,142

)

Total deferred tax provision

     (28,013 )     13,607

 

     (14,021

)

Total income tax provision

   $
8,590
    $ 47,181     $ 15,943

 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   

Year Ended June 30,

  
   

2021

     2020     2019  
                         

Income tax expense at federal statutory rate

     21.0

%

     21.0

%

     21.0

%

State income taxes, net of federal benefit

     0.6

 

     2.3

 

     (1.5

)

Research and development tax credit

     (1.8

)

     (0.7

)

     (1.6

)

Contingent consideration adjustment

     0.8

 

     (0.2

)

     (0.4

)

Foreign tax rate differences

     0.8

 

     (0.2

)

     0.2

 

Option exercises

     (16.9

)

     (5.7

)

     (5.8

)

U.S. taxation of foreign earnings

     (0.1 )     0.9

 

     3.7

 

Foreign derived intangible income

     (5.1 )     (0.9

)

     (2.0 )

Executive compensation limitations

     6.5       1.6

 

     0.4  

Other, net

     0.0       (1.0

)

     0.2

 

Effective tax rate

     5.8

%

     17.1

%

     14.2

%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   

June 30

  
   

2021

     2020  
                 

Inventory

   $ 6,730     $ 7,769  

Net operating loss carryovers

     31,345       25,707  

Tax credit carryovers

     14,486       9,568  

Excess tax basis in equity investments

     2,429       2,423  

Deferred compensation

     11,108       10,755  

Derivative - cash flow hedge

     1,908       4,058  

Lease liability

     17,016       16,256  

Other

     8,526       4,340  

Valuation allowance

     (6,665

)

     (7,523

)

Deferred tax assets

     86,883       73,353  
                 

Net unrealized gain on available-for-sale investments

     (3,159

)

     (19,102

)

Intangible asset amortization

     (150,765

)

     (128,279

)

Depreciation

     (9,099

)

     (10,764

)

Right of use asset

     (15,868

)

     (15,118 )

Other

     (1,117

)

     (1,180

)

Deferred tax liabilities

     (180,008

)

     (174,443

)

Net deferred tax liabilities

   $ (93,125 )   $ (101,090

)
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
   

Year Ended June 30,

  
   

2021

     2020     2019  

Beginning balance

   $ 4,297     $ 5,032     $ 1,947  

Additions due to acquisitions

     -       -       900  

Additions for tax positions of prior year

     4,038       306       2,185  

Decrease in unrecognized tax benefits for prior year positions

     (778

)

     (1,041 )     -  
Settlements     (286 )     -       -  

Ending balances

   $ 7,271     $ 4,297     $ 5,032  
XML 54 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information (Tables)
 12 Months Ended
Jun. 30, 2021
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

Year Ended June 30,

 
  

2021

  2020  2019 

Net sales:

            

Protein Sciences

 $704,564  $555,352  $543,159 

Diagnostics and Genomics

  227,744   184,549   171,674 

Intersegment

  (1,276

)

  (1,210

)

  (827

)

Consolidated net sales

 $931,032  $738,691  $714,006 
             

Operating Income:

            

Protein Sciences

 $328,837  $234,929  $240,919 

Diagnostics and Genomics

  38,425   14,965   10,079 

Segment operating income

  367,262   249,894   250,998 

Costs recognized upon sale of acquired inventory

  (1,565)  -

 

  (3,739

)

Amortization of acquired intangible assets

  (64,239

)

  (60,865

)

  (58,550

)

Gain on escrow settlement

  -   7,169   - 

Acquisition related expenses

  (7,114

)

  (416

)

  (2,282

)

Restructuring costs

  (142

)

  (87)  -

 

Stock-based compensation, inclusive of employer taxes

  (51,846

)

  (34,262

)

  (33,057

)

Corporate general, selling and administrative expenses

  (5,060

)

  (4,015

)

  (6,651

)

Consolidated operating income

 $237,296  $157,419  $146,719 
  

Year Ended June 30,

 
  

2021

  2020  2019 

Consumables revenue - Protein Sciences

 $557,037  $431,052  $430,655 

Consumables revenue - Diagnostics and Genomics

  194,948   171,590   158,324 

Total consumable revenue

 $751,985  $602,642  $588,979 
  

Year ended June 30,

 

Long-lived assets:

 

2021

  2020 

United States and Canada

 $190,501  $162,039 

Europe

  13,949   13,120 

Asia

  3,457   1,670 

Total long-lived assets

 $207,907  $176,829 

Intangible assets:

        

United States and Canada

 $594,512  $499,875 

Europe

  9,369   12,349 

Asia

  12,087   4,321 

Total intangible assets

 $615,968  $516,545 
XML 55 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Jul. 01, 2020
Jul. 01, 2019
Advertising Expense $ 4,700 $ 4,200 $ 4,100    
Amortization of Intangible Assets, Total 64,940 61,095      
Operating Lease, Liability, Total 79,227        
Operating Lease, Right-of-Use Asset 73,834 [1] 71,465      
Retained Earnings (Accumulated Deficit), Ending Balance 1,085,461 1,057,470      
Deferred Income Tax Liabilities, Net, Total 93,125 101,090      
Accounting Standards Update 2016-02 [Member]          
Operating Lease, Liability, Total         $ 80,600
Operating Lease, Right-of-Use Asset         79,500
Retained Earnings (Accumulated Deficit), Ending Balance         800
Deferred Income Tax Liabilities, Net, Total         (300)
Deferred Rent Credit         $ 4,000
Accounting Standards Update 2016-13 [Member]          
Retained Earnings (Accumulated Deficit), Ending Balance       $ (300)  
Trade Names [Member]          
Amortization of Intangible Assets, Total 1,400 1,300      
Finite-Lived Intangible Asset, Expected Amortization, Year One 5,700 $ 600      
Finite-Lived Intangible Asset, Expected Amortization, Year Five $ 4,300        
Minimum [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 1 year        
Minimum [Member] | Trade Names [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 2 years        
Maximum [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 20 years        
Maximum [Member] | Trade Names [Member]          
Finite-Lived Intangible Asset, Useful Life (Year) 20 years        
Equipment [Member] | Minimum [Member]          
Property, Plant and Equipment, Useful Life (Year) 3 years        
Equipment [Member] | Maximum [Member]          
Property, Plant and Equipment, Useful Life (Year) 5 years        
Building, Building Improvements and Leasehold Improvements [Member] | Minimum [Member]          
Property, Plant and Equipment, Useful Life (Year) 5 years        
Building, Building Improvements and Leasehold Improvements [Member] | Maximum [Member]          
Property, Plant and Equipment, Useful Life (Year) 40 years        
[1] The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.
XML 56 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue Recognition (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Proceeds from Laboratory Services Reimbursed by Medicare $ 0.5  
Contract with Customer, Liability, Total 20.0 $ 14.2
Contract with Customer, Liability, Revenue Recognized $ 10.6  
XML 57 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Revenues, net $ 931,032 $ 738,691 $ 714,006
UNITED STATES      
Revenues, net 502,080 404,407 391,191
EMEA, excluding U.K. [Member]      
Revenues, net 204,264 155,289 155,821
UNITED KINGDOM      
Revenues, net 40,945 30,411 34,975
APAC, excluding Greater China [Member]      
Revenues, net 69,013 60,362 52,913
CHINA      
Revenues, net 87,556 68,792 57,799
Rest of World [Member]      
Revenues, net 27,174 19,430 21,307
Consumables [Member]      
Revenues, net 751,985 602,642 588,979
Instruments [Member]      
Revenues, net 93,782 71,462 67,538
Service [Member]      
Revenues, net 66,416 47,459 38,050
Product and Services [Member]      
Revenues, net 912,183 721,563 694,567
Royalty [Member]      
Revenues, net $ 18,849 $ 17,128 $ 19,439
XML 58 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Available-for-sale Securities, Total   $ 20,000 $ 87,800  
Debt Securities, Available-for-sale, Total   12,500 36,400  
Finite-lived Intangible Assets Acquired   153,311 0  
Amortization of Intangible Assets, Total   64,940 61,095  
Noncash or Part Noncash Acquisition, Intangible Assets Acquired [1]   4,000 0 $ 0
Patented Technology [Member]        
Finite-lived Intangible Assets Acquired $ 5,000      
Noncash or Part Noncash Acquisition, Intangible Assets Acquired   4,000    
Developed Technology Rights [Member] | Cost of Sales [Member]        
Amortization of Intangible Assets, Total   36,500 34,500 33,300
Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member] | Selling, General and Administrative Expenses [Member]        
Amortization of Intangible Assets, Total   28,400 26,600 $ 25,400
Other Noncurrent Assets [Member]        
Inventory, Finished Goods, Net of Reserves, Non-current   5,456 4,646  
ChemoCentryx, Inc (CCXI) [Member]        
Available-for-sale Equity Securities, Amortized Cost Basis, Total   $ 6,600 $ 6,600  
ChemoCentryx, Inc (CCXI) [Member]        
Share Price (in dollars per share)   $ 13.39 $ 57.54  
[1] $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.
XML 59 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Raw materials $ 55,096 $ 51,530
Finished goods [1] 67,108 56,268
Inventories, net $ 122,204 $ 107,798
[1] Finished goods inventory of $5,456 and $4,646 is included within other long-term assets in the June 30, 2021 and June 30, 2020 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.
XML 60 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Property and equipment, cost $ 397,756 $ 346,650
Accumulated depreciation and amortization (189,849) (169,821)
Property and equipment, net 207,907 176,829
Land [Member]    
Property and equipment, cost 8,612 8,516
Building and Building Improvements [Member]    
Property and equipment, cost 190,661 184,430
Machinery and Equipment [Member]    
Property and equipment, cost $ 198,483 $ 153,704
XML 61 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Definite-lived intangibles assets $ 941,535 $ 795,591
Accumulated amortization (348,267) (279,046)
Total 593,268 516,545
Total intangible assets, net 615,968 516,545
In Process Research and Development [Member]    
In process research and development $ 22,700 0
Minimum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 1 year  
Maximum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 20 years  
Developed Technology Rights [Member]    
Definite-lived intangibles assets $ 552,160 434,653
Developed Technology Rights [Member] | Minimum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 9 years  
Developed Technology Rights [Member] | Maximum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 15 years  
Trade Names [Member]    
Definite-lived intangibles assets $ 147,640 146,713
Trade Names [Member] | Minimum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 2 years  
Trade Names [Member] | Maximum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 20 years  
Customer Relationships [Member]    
Definite-lived intangibles assets $ 232,493 211,750
Customer Relationships [Member] | Minimum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 7 years  
Customer Relationships [Member] | Maximum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 16 years  
Patents [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 10 years  
Definite-lived intangibles assets $ 2,926 2,475
Other Intangible Assets [Member]    
Definite-lived intangibles assets [1] $ 6,316 $ 0
Other Intangible Assets [Member] | Minimum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) [1] 5 years  
Other Intangible Assets [Member] | Maximum [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) [1] 15 years  
[1] Increase in other intangibles assets is primarily due to $5.0 million recognized in intangible assets in the first quarter of fiscal 2021 for certain third party patented technology acquired.
XML 62 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Beginning balance $ 516,545 $ 579,429
Finite-lived Intangible Assets Acquired 153,311 0
Other additions 5,912 311
Amortization expense (64,940) (61,095)
Currency translation 5,140 (2,100)
Ending balance $ 615,968 $ 516,545
XML 63 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
2022 $ 74,482  
2023 72,649  
2024 69,780  
2025 66,523  
2026 62,739  
Thereafter 247,095  
Total $ 593,268 $ 516,545
XML 64 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Balance $ 728,308 $ 732,667
Acquisitions (Note 4)   (326)
Currency Translation 11,939 (4,031)
Acquisitions (Note 4) 102,818  
Balance 843,067 728,308
Protein Sciences [Member]    
Balance 373,081 377,407
Acquisitions (Note 4)   (326)
Currency Translation 11,788 (4,000)
Acquisitions (Note 4) 7,848  
Balance 392,717 373,081
Diagnostics and Genomics [Member]    
Balance 355,229 355,260
Acquisitions (Note 4)   0
Currency Translation 151 (31)
Acquisitions (Note 4) 94,970  
Balance $ 450,350 $ 355,229
XML 65 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Income taxes paid $ 20,952 $ 41,992 $ 36,814
Interest paid 13,576 18,615 21,497
Acquisition-related liabilities [1] 23,600 (2,105) 12,600
Other intangibles [2] $ 4,000 $ 0 $ 0
[1] Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.
[2] $4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.
XML 66 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Note 4 - Acquisitions (Details Textual) - USD ($)
$ in Thousands
 8 Months Ended 12 Months Ended
Apr. 06, 2021
Apr. 02, 2021
Oct. 20, 2020
Jun. 04, 2019
Aug. 01, 2018
Jul. 02, 2018
Jun. 30, 2021
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Payments to Acquire Businesses, Net of Cash Acquired, Total               $ 225,352 $ (0) $ 289,492
Gain (Loss) on Escrow Settlement               (0) 7,170 $ (0)
Changzhou Eminence Biotechnology [Member]                    
Business Acquisition, Percentage of Voting Interests Acquired     47.60%              
Business Combination, Consideration Transferred, Total     $ 9,800              
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value     8,985       $ 8,985 8,985    
Payments to Acquire Businesses, Gross   $ 6,000                
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total   57.40%                
Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment             15,800 15,800    
Goodwill, Purchase Accounting Adjustments             (963)      
Payments to Acquire Businesses, Net of Cash Acquired, Total     $ 9,765       9,765      
Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)     13 years              
Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)     10 years              
Acquisition of Asuragen, Inc. [Member]                    
Business Combination, Consideration Transferred, Total $ 233,887                  
Payments to Acquire Businesses, Net of Cash Acquired, Total 215,587                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 105,000           105,000 105,000    
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual 7,100                  
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual $ (3,400)                  
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 14 years                  
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 16 years                  
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 5 years                  
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 3 years                  
QT Holdings Corporation [Member]                    
Payments to Acquire Businesses, Net of Cash Acquired, Total           $ 20,500     20,462  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High           $ 51,000 51,000 51,000    
QT Holdings Corporation [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)           14 years        
Exosome Diagnostics, Inc [Member]                    
Payments to Acquire Businesses, Net of Cash Acquired, Total         $ 251,600       251,623  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High         325,000          
Gain (Loss) on Escrow Settlement         $ 7,200          
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)         15 years          
Exosome Diagnostics, Inc [Member] | Trade Names [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)         15 years          
B-MoGen [Member]                    
Goodwill, Purchase Accounting Adjustments                 300  
Finite-Lived Intangible Asset, Useful Life (Year)         14 years          
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 17,500         $ 17,448  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       38,000     $ 38,000 $ 38,000    
Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value       1,400            
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain       $ 3,700            
B-MoGen [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)       14 years            
XML 67 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($)
$ in Thousands
 8 Months Ended 12 Months Ended
Apr. 06, 2021
Oct. 20, 2020
Jun. 04, 2019
Aug. 01, 2018
Jul. 02, 2018
Jun. 30, 2021
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Goodwill           $ 843,067 $ 843,067 $ 728,308 $ 732,667
Payments to Acquire Businesses, Net of Cash Acquired, Total             225,352 (0) $ 289,492
Changzhou Eminence Biotechnology [Member]                  
Current assets, net of cash   $ 3,145       3,145 3,145    
Equipment and other long-term assets   1,639       1,639 1,639    
Goodwill   8,811       7,848 7,848    
Goodwill, Purchase Accounting Adjustments           (963)      
Total assets acquired   22,506       21,543 21,543    
Total assets acquired, adjustments           (963)      
Liabilities   1,436       1,436 1,436    
Deferred income taxes, net   2,320       1,357 1,357    
Deferred income taxes, net, adjustments           (963)      
Net assets acquired   18,750       18,750 18,750    
Payments to Acquire Businesses, Net of Cash Acquired, Total   9,765       9,765      
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value   8,985       8,985 8,985    
Net assets acquired   18,750       18,750      
Net assets acquired   9,800              
Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member]                  
Intangible assets   6,778       6,778 6,778    
Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member]                  
Intangible assets   $ 2,133       $ 2,133 $ 2,133    
Acquisition of Asuragen, Inc. [Member]                  
Current assets, net of cash $ 10,422                
Equipment and other long-term assets 3,762                
Goodwill 94,970                
Total assets acquired 253,554                
Liabilities 4,003                
Deferred income taxes, net 15,664                
Net assets acquired 233,887                
Payments to Acquire Businesses, Net of Cash Acquired, Total 215,587                
Contingent consideration payable 18,300                
Net assets acquired 233,887                
Acquisition of Asuragen, Inc. [Member] | In Process Research and Development [Member]                  
In-process research and development 22,700                
Acquisition of Asuragen, Inc. [Member] | Developed Technology Rights [Member]                  
Intangible assets 107,000                
Acquisition of Asuragen, Inc. [Member] | Customer Relationships [Member]                  
Intangible assets 11,700                
Acquisition of Asuragen, Inc. [Member] | Trade Names [Member]                  
Intangible assets 2,000                
Acquisition of Asuragen, Inc. [Member] | Noncompete Agreements [Member]                  
Intangible assets $ 1,000                
B-MoGen [Member]                  
Current assets, net of cash               504  
Equipment and other long-term assets               269  
Goodwill               16,131  
Goodwill, Purchase Accounting Adjustments               300  
Total assets acquired               31,304  
Liabilities               211  
Deferred income taxes, net               3,051  
Net assets acquired               28,042  
Payments to Acquire Businesses, Net of Cash Acquired, Total     $ 17,500         17,448  
Net assets acquired               28,042  
Contingent consideration payable               10,594  
B-MoGen [Member] | Developed Technology Rights [Member]                  
Intangible assets               14,000  
B-MoGen [Member] | Customer Relationships [Member]                  
Intangible assets               400  
Exosome Diagnostics, Inc [Member]                  
Current assets, net of cash               2,611  
Equipment and other long-term assets               2,212  
Goodwill               105,362  
Total assets acquired               275,485  
Liabilities               3,716  
Deferred income taxes, net               16,346  
Net assets acquired               255,423  
Payments to Acquire Businesses, Net of Cash Acquired, Total       $ 251,600       251,623  
Net assets acquired               255,423  
Contingent consideration payable               3,800  
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]                  
Intangible assets               105,000  
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]                  
Intangible assets               2,300  
Exosome Diagnostics, Inc [Member] | Trade Names [Member]                  
Intangible assets               58,000  
QT Holdings Corporation [Member]                  
Current assets, net of cash               36  
Equipment and other long-term assets               228  
Goodwill               14,481  
Total assets acquired               27,001  
Liabilities               296  
Deferred income taxes, net               943  
Net assets acquired               25,762  
Payments to Acquire Businesses, Net of Cash Acquired, Total         $ 20,500     20,462  
Net assets acquired               25,762  
Contingent consideration payable               5,300  
QT Holdings Corporation [Member] | Developed Technology Rights [Member]                  
Intangible assets               $ 12,256  
XML 68 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Oct. 31, 2022
Oct. 31, 2021
Oct. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
May 31, 2021
Apr. 06, 2021
Dec. 31, 2020
Jun. 04, 2019
Oct. 31, 2018
Jul. 02, 2018
Interest Expense, Total       $ 13,952 $ 19,197 $ 21,705            
Nonoperating Income (Expense), Total       (89,121) 119,058 (34,704)            
Income Tax Expense (Benefit), Total       8,590 47,181 $ 15,943            
Business Combination, Contingent Consideration, Liability, Total       29,400                
Acquisition of Asuragen, Inc. [Member]                        
Business Combination, Contingent Consideration, Liability, Total       18,300                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       105,000       $ 105,000        
QT Holdings Corporation [Member]                        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       51,000               $ 51,000
B-MoGen [Member]                        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       38,000           $ 38,000    
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]                        
Interest Expense, Total       8,598                
Nonoperating Income (Expense), Total       512                
Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]                        
Interest Expense, Total       8,600 3,500              
Nonoperating Income (Expense), Total       (500)                
Income Tax Expense (Benefit), Total       (2,100)                
Forward Starting Swap [Member] | Other Current Liabilities [Member] | Not Designated as Hedging Instrument [Member]                        
Derivative Liability, Current       800                
Forward Starting Swap [Member] | Cash Flow Hedging [Member]                        
Derivative, Notional Amount                     $ 380,000  
Derivative Notional Amount, Decrease in Period     $ 100,000                  
Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Other Noncurrent Liabilities [Member]                        
Derivative Notional Amount, Dedesignated         80,000       $ 80,000      
Hedging Liabilities, Noncurrent       7,600                
Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Forecast [Member]                        
Derivative Notional Amount, Decrease in Period $ 200,000 $ 80,000                    
New Forward Starting Swap [Member] | Cash Flow Hedging [Member]                        
Derivative, Notional Amount             $ 200,000          
New Forward Starting Swap [Member] | Cash Flow Hedging [Member] | Other Noncurrent Assets [Member]                        
Hedging Assets, Noncurrent, Total       300                
CCXI [Member]                        
Investments, Total       6,600 6,600              
Investments, Fair Value Disclosure, Total       $ 1,400 $ 8,000              
XML 69 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Business Combination, Contingent Consideration, Liability, Total $ 29,400  
Fair Value, Recurring [Member]    
Derivative instruments - cash flow hedges 275  
Total Assets 32,738 $ 124,268
Business Combination, Contingent Consideration, Liability, Total 29,400 6,137
Derivative instruments - cash flow hedges 8,376 17,331
Total Liabilities 37,776 23,468
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Derivative instruments - cash flow hedges 0  
Total Assets 31,081 116,272
Business Combination, Contingent Consideration, Liability, Total 0  
Derivative instruments - cash flow hedges 0  
Total Liabilities 0  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Derivative instruments - cash flow hedges 275  
Total Assets 1,657 0
Business Combination, Contingent Consideration, Liability, Total 0  
Derivative instruments - cash flow hedges 8,376 0
Total Liabilities 8,376 6,137
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Derivative instruments - cash flow hedges 0  
Total Assets 0  
Business Combination, Contingent Consideration, Liability, Total 29,400  
Derivative instruments - cash flow hedges 0  
Total Liabilities 29,400  
Equity Securities [Member] | Fair Value, Recurring [Member]    
Investments, Fair Value Disclosure [1] 19,963 87,842
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [1] 18,581 79,846
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [1] 1,382 0
Equity Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [1] 0  
Certificates of Deposit [Member] | Fair Value, Recurring [Member]    
Investments, Fair Value Disclosure [2] 12,500 36,426
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [2] 12,500 $ 36,426
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [2] 0  
Certificates of Deposit [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [2] $ 0  
[1] Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at June 30, 2021 and June 30, 2020 was $6.6 million and $6.6 million respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $1.4 million as of June 30, 2021. The fair value of the warrant as of June 30, 2020 was $8.0 million
[2] Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.
XML 70 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Fair value at the beginning of period $ 6,137 $ 12,600
Purchase price contingent consideration (Note 4) 18,300 0
Payments (337) (4,358)
Gain on escrow settlement 0 (1,200)
Change in fair value of contingent consideration 5,300 (905)
Contingent consideration payable $ 29,400 $ 6,137
XML 71 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Note 6 - Debt and Other Financing Arrangements (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Aug. 01, 2018
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Proceeds from Long-term Lines of Credit   $ 256.0 $ 40.0 $ 580.0
Credit Agreement [Member]        
Long-term Debt, Total   $ 341.0 $ 357.0  
Credit Agreement [Member] | Term Loan [Member]        
Debt Instrument, Face Amount $ 250.0      
Proceeds from Issuance of Long-term Debt, Total 250.0      
Revolving Credit Facility [Member] | Credit Agreement [Member]        
Line of Credit Facility, Maximum Borrowing Capacity 600.0      
Line of Credit Facility, Additional Borrowing Capacity $ 200.0      
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.125%      
Line of Credit, Current $ 12.5      
Proceeds from Long-term Lines of Credit $ 330.0      
XML 72 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Leases (Details Textual)
$ in Millions
 12 Months Ended
Jun. 30, 2021
USD ($)
ft²
Variable Lease, Cost $ 3.6
Fixed Lease, Cost $ 32.5
Lessee, Operating Lease, Lease Not yet Commenced, Area of Property (Square Foot) | ft² 25,000
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract (Year) 25 years
Lessee, Operating Lease, Lease Not yet Commenced, Annunal Rental Impact $ 0.3
Maximum [Member]  
Lessee, Operating Lease, Renewal Term (Year) 5 years
XML 73 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Leases - Balance Sheet Classification (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Operating Lease, Right-of-Use Asset $ 73,834 [1] $ 71,465
Current operating lease liabilities 11,602 [1] 9,535
Noncurrent operating lease liabilities 67,625 [1] $ 67,248
Total operating lease liabilities $ 79,227  
Weighted average remaining lease term (in years): (Year) 7 years 11 months 19 days  
Weighted average discount rate: 3.93%  
[1] The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.
XML 74 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Leases - Cash Paid (Details)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
USD ($)
Cash amounts paid on operating lease liabilities $ 13,492 [1]
Right of use assets obtained in exchange for lease liabilities $ 12,144
[1] Total cash paid for the Company's operating leases during the year ended June 30, 2021 include cash amounts paid on operating lease liabilities and variable lease expenses. Cash flow impacts from right of use assets and lease liabilities are presented net on the cash flow statement in changes in other operating activity.
XML 75 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)
$ in Thousands
Jun. 30, 2021
USD ($)
2022 $ 14,349
2023 13,371
2024 11,840
2025 10,780
2026 10,120
Thereafter 32,331
Total 92,791
Less: Amounts representing interest 13,564
Total lease obligations $ 79,227
XML 76 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 1.28 $ 1.28 $ 1.28
Stock Repurchased During Period, Shares (in shares) 120,000 279,381  
Stock Repurchased During Period, Average Share Price (in dollars per share) $ 359.81 $ 179.37  
Interest Expense, Total $ 13,952 $ 19,197 $ 21,705
Nonoperating Income (Expense), Total (89,121) 119,058 (34,704)
Deferred Income Tax Expense (Benefit), Total (28,013) 13,607 $ (14,021)
Changzhou Eminence Biotechnology [Member]      
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest 103    
AOCI Attributable to Parent [Member]      
Deferred Income Tax Expense (Benefit), Total (1,908) $ (4,058)  
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]      
Interest Expense, Total 8,598    
Nonoperating Income (Expense), Total 512    
Reclassification from AOCI, Current Period, Tax, Total $ 2,150    
XML 77 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Balance $ 1,381,192    
Balance 1,562,971 $ 1,381,192  
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]      
Balance 0 0 $ 24,682
Other comprehensive income (loss) before reclassifications 0 [1] 0 0
Reclassification from loss on derivatives to interest expense, net of taxes [2] 0 0  
Balance 0 0 0
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     2,371
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     (27,053)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]      
Balance (83,946) (73,983) (69,496)
Other comprehensive income (loss) before reclassifications 32,848 [1] (9,963) (4,487)
Reclassification from loss on derivatives to interest expense, net of taxes [2] 0 0  
Balance (51,098) (83,946) (73,983)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     0
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     0
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]      
Balance (13,253) (9,537) 0
Other comprehensive income (loss) before reclassifications 100 [1] (7,179) (9,537)
Reclassification from loss on derivatives to interest expense, net of taxes [2] 6,960 3,464  
Balance (6,193) (13,253) (9,537)
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     0
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     0
AOCI Attributable to Parent [Member]      
Balance (97,199) (83,521) (44,814)
Other comprehensive income (loss) before reclassifications 32,948 [1] (17,142) (14,024)
Reclassification from loss on derivatives to interest expense, net of taxes [2] 6,960 3,464  
Balance $ (57,291) $ (97,199) (83,521)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     2,371
AOCI Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]      
Balance     $ (27,053)
[1] Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence.
[2] Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company had deferred tax benefits of $1,908 and $4,058 included in the accumulated other comprehensive income loss as of June 30, 2021 and June 30, 2020, respectively.
XML 78 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Earnings Per Share (Details Textual) - shares
shares in Millions
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 0.6 0.9 1.3
XML 79 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Net earnings $ 139,585 $ 229,296 $ 96,072
Net earnings (loss) attributable to noncontrolling interest (825) 0 0
Net income 140,410 229,296 96,072
Income allocated to participating securities (86) (224) (105)
Income available to common shareholders $ 140,324 $ 229,072 $ 95,967
Basic (in shares) 38,747 38,201 37,781
Basic (in dollars per share) $ 3.62 $ 6.00 $ 2.54
Income allocated to participating securities $ (86) $ (224) $ (105)
Income available to common shareholders $ 140,324 $ 229,072 $ 95,967
Dilutive effect of stock options and restricted stock units (in shares) 1,736 1,200 1,111
Diluted (in shares) 40,483 39,401 38,892
Diluted (in dollars per share) $ 3.47 $ 5.82 $ 2.47
XML 80 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Oct. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2010
Oct. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)   3,717,000 3,609,000 3,656,000 3,452,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)   $ 59.75 $ 37.01 $ 34.66      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value   $ 145.6 $ 99.3 $ 159.0      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value   70.5 71.1 31.7      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 37.1          
Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate   4.60%          
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)   2 years 1 month 6 days          
US Profit Sharing and Savings Plan [Member]              
Defined Contribution Plan, Cost   $ 3.4 3.2 2.8      
GB Profit Sharing and Savings Plan [Member]              
Defined Contribution Plan, Cost   1.6 1.4 1.4      
Selling, General and Administrative Expenses [Member]              
Share-based Payment Arrangement, Expense   46.4 32.4 32.3      
Cost of Sales [Member]              
Share-based Payment Arrangement, Expense     1.6        
Restricted Stock [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value   2.8 2.5 2.3      
Restricted Stock Units (RSUs) [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value   $ 6.7 5.7 3.1      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         3 years    
Equity Incentive Plan 2010 [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)           7,500,000  
The 2020 Equity Incentive Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) 2,484,202            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) 1,300,000            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)   1,100,000          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)   3,700,000          
The 2020 Equity Incentive Plan [Member] | Maximum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)           10 years  
Employee Stock Purchase Plan 2014 [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)             200,000
Share-based Payment Arrangement, Expense   $ 0.9 0.4 0.5      
Performance Incentive Programs [Member] | Executive Officer [Member]              
Salary and Wage, Officer, Excluding Cost of Good and Service Sold   $ 21.1 $ 10.5 $ 9.3      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)   762,761 751,499 618,898      
Performance Incentive Programs [Member] | Restricted Stock [Member] | Executive Officer [Member]              
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)   11,803 15,398 11,279      
Performance Incentive Programs [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]              
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)   30,823 30,858 25,903      
XML 81 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Dividend yield 0.24% 0.67% 0.74%
Expected lives (years) (Year) 4 years 4 months 24 days 4 years 4 years 1 month 6 days
Minimum [Member]      
Expected volatility 25.00% 22.00% 20.00%
Risk-free interest rates 0.20% 1.30% 2.50%
Maximum [Member]      
Expected volatility 30.00% 24.00% 23.00%
Risk-free interest rates 0.70% 1.90% 3.00%
XML 82 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Outstanding, shares (in shares) 3,609 3,656 3,452
Outstanding, weighted average exercise price (in dollars per share) $ 140.28 $ 121.16 $ 105.17
Granted, shares (in shares) 763 752 917
Granted, weighted average exercise price (in dollars per share) $ 277.75 $ 190.80 $ 173.89
Forfeited, shares (in shares) (28) (56) (330)
Forfeited, weighted average exercise price (in dollars per share) $ 214.33 $ 95.97 $ 129.93
Exercised, shares (in shares) (627) (743) (383)
Exercised, weighted average exercise price (in dollars per share) $ 112.53 $ 157.45 $ 95.29
Outstanding, shares (in shares) 3,717 3,609 3,656
Outstanding, weighted average exercise price (in dollars per share) $ 172.63 $ 140.28 $ 121.16
Outstanding, aggregate intrinsic value $ 1,031.9    
Outstanding, weighted average contractual life (Year) 4 years 1 month 6 days    
Exercisable, shares (in shares) 1,764 1,564 1,467
Exercisable, weighted average exercise price (in dollars per share) $ 126.44 $ 112.60 $ 98.70
Exercisable, aggregate intrinsic value $ 571.3    
Exercisable, weighted average contractual life (Year) 3 years    
XML 83 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) - $ / shares
shares in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Restricted Stock [Member]      
Balance, shares (in shares) 28 30 35
Balance, weighted average exercise price (in dollars per share) $ 177.20 $ 147.94 $ 117.39
Granted, shares (in shares) 12 15 15
Granted, weighted average exercise price (in dollars per share) $ 264.73 $ 193.48 $ 177.93
Vested, shares (in shares) (17) (18) (20)
Vested, weighted average exercise price (in dollars per share) $ 171.64 $ 142.12 $ 116.76
Forfeited, shares (in shares) 0 0 0
Forfeited, weighted average exercise price (in dollars per share) $ 0 $ 0 $ 0
Balance, weighted average contractual life (Year) 6 years 25 days    
Balance, shares (in shares) 23 28 30
Balance, weighted average exercise price (in dollars per share) $ 226.07 $ 177.20 $ 147.94
Restricted Stock Units (RSUs) [Member]      
Balance, shares (in shares) 116 139 148
Balance, weighted average exercise price (in dollars per share) $ 159.25 $ 134.17 $ 117.95
Granted, shares (in shares) 31 31 56
Granted, weighted average exercise price (in dollars per share) $ 300.78 $ 192.08 $ 170.96
Vested, shares (in shares) (51) (51) (28)
Vested, weighted average exercise price (in dollars per share) $ 130.18 $ 111.07 $ 110.86
Forfeited, shares (in shares) 0 (3) (36)
Forfeited, weighted average exercise price (in dollars per share) $ 0 $ 155.60 $ 143.72
Balance, weighted average contractual life (Year) 5 years 4 months 9 days    
Balance, shares (in shares) 96 116 139
Balance, weighted average exercise price (in dollars per share) $ 220.53 $ 159.25 $ 134.17
XML 84 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Effective Income Tax Rate Reconciliation, Percent, Total 5.80% 17.10% 14.20%
Income Tax Expense (Benefit), Discrete Tax Items $ 28,100 $ 19,400 $ 12,700
Excess Tax Benefit from Share-based Compensation, Operating Activities 28,100 17,700 7,200
Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions     (3,200)
Income Tax Expense (Benefit) Discrete Tax Items State Apportionments     $ (2,000)
Deferred Tax Assets, Valuation Allowance, Total 6,665 7,523  
Deferred Tax Assets, Net of Valuation Allowance, Total 86,883 $ 73,353  
Undistributed Earnings of Foreign Subsidiaries 223,000    
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 5,200    
Decrease in Unrecognized Tax Benefits is Reasonably Possible 2,600    
Operating Loss Carryforwards [Member]      
Deferred Tax Assets, Net of Valuation Allowance, Total 26,600    
Tax Credit Carryforwards [Member]      
Deferred Tax Assets, Net of Valuation Allowance, Total 12,600    
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]      
Operating Loss Carryforwards, Total 92,100    
Tax Credit Carryforward, Amount 10,100    
State and Local Jurisdiction [Member]      
Operating Loss Carryforwards, Total 129,600    
Tax Credit Carryforward, Amount 4,400    
Foreign Tax Authority [Member]      
Operating Loss Carryforwards, Total $ 13,900    
XML 85 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Domestic $ 95,662 $ 245,365 $ 64,081
Foreign 52,513 31,112 47,934
Earnings before income taxes 148,175 276,477 112,015
Federal 15,179 18,976 16,090
State 6,681 6,018 544
Foreign 14,743 8,580 13,329
Total current tax provision 36,603 33,574 29,963
Federal (20,812) 14,074 (6,903)
State (4,962) 2,055 (3,977)
Foreign (2,239) (2,522) (3,142)
Total deferred tax provision (28,013) 13,607 (14,021)
Total income tax provision $ 8,590 $ 47,181 $ 15,943
XML 86 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Income tax expense at federal statutory rate 21.00% 21.00% 21.00%
State income taxes, net of federal benefit 0.60% 2.30% (1.50%)
Research and development tax credit (1.80%) (0.70%) (1.60%)
Contingent consideration adjustment 0.80% (0.20%) (0.40%)
Foreign tax rate differences 0.80% (0.20%) 0.20%
Option exercises (16.90%) (5.70%) (5.80%)
U.S. taxation of foreign earnings (0.10%) 0.90% 3.70%
Foreign derived intangible income (5.10%) (0.90%) (2.00%)
Executive compensation limitations 6.50% 1.60% 0.40%
Other, net 0.00% (1.00%) 0.20%
Effective tax rate 5.80% 17.10% 14.20%
XML 87 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Inventory $ 6,730 $ 7,769
Net operating loss carryovers 31,345 25,707
Tax credit carryovers 14,486 9,568
Excess tax basis in equity investments 2,429 2,423
Deferred compensation 11,108 10,755
Derivative - cash flow hedge 1,908 4,058
Lease liability 17,016 16,256
Other 8,526 4,340
Valuation allowance (6,665) (7,523)
Deferred tax assets 86,883 73,353
Net unrealized gain on available-for-sale investments (3,159) (19,102)
Intangible asset amortization (150,765) (128,279)
Depreciation (9,099) (10,764)
Right of use asset 15,868 15,118
Other 1,117 1,180
Deferred tax liabilities (180,008) (174,443)
Net deferred tax liabilities $ (93,125) $ (101,090)
XML 88 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Balance $ 4,297 $ 5,032 $ 1,947
Additions due to acquisitions 0 0 900
Additions for tax positions of prior year 4,038 306 2,185
Decrease in unrecognized tax benefits for prior year positions (778) (1,041) 0
Settlements (286) 0 0
Ending balances $ 7,271 $ 4,297 $ 5,032
XML 89 R65.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information (Details Textual)
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Number of Reportable Segments 2    
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Protein Sciences [Member]      
Number of Major Customers 0 0 0
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member] | Diagnostics and Genomics [Member]      
Number of Major Customers 0 0 0
XML 90 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Revenues, net $ 931,032 $ 738,691 $ 714,006
Operating income 237,296 157,419 146,719
Costs recognized upon sale of acquired inventory (1,565) 0 (3,739)
Gain on escrow settlement (0) 7,170 (0)
Corporate general, selling and administrative expenses (324,951) (260,583) (264,359)
Total long-lived assets 207,907 176,829  
Total intangible assets 615,968 516,545 579,429
United States and Canada [Member]      
Total long-lived assets 190,501 162,039  
Total intangible assets 594,512 499,875  
Europe [Member]      
Total long-lived assets 13,949 13,120  
Total intangible assets 9,369 12,349  
Asia [Member]      
Total long-lived assets 3,457 1,670  
Total intangible assets 12,087 4,321  
Consumables [Member]      
Revenues, net 751,985 602,642 588,979
Protein Sciences [Member] | Consumables [Member]      
Revenues, net 557,037 431,052 430,655
Diagnostics and Genomics [Member] | Consumables [Member]      
Revenues, net 194,948 171,590 158,324
Operating Segments [Member]      
Operating income 367,262 249,894 250,998
Costs recognized upon sale of acquired inventory (1,565) 0 (3,739)
Amortization of acquired intangible assets (64,239) (60,865) (58,550)
Gain on escrow settlement 0 7,169 0
Acquisition related expenses (7,114) (416) (2,282)
Restructuring costs (142) (87) 0
Stock-based compensation, inclusive of employer taxes (51,846) (34,262) (33,057)
Operating Segments [Member] | Protein Sciences [Member]      
Revenues, net 704,564 555,352 543,159
Operating income 328,837 234,929 240,919
Operating Segments [Member] | Diagnostics and Genomics [Member]      
Revenues, net 227,744 184,549 171,674
Operating income 38,425 14,965 10,079
Intersegment Eliminations [Member]      
Revenues, net (1,276) (1,210) (827)
Corporate, Non-Segment [Member]      
Corporate general, selling and administrative expenses $ (5,060) $ (4,015) $ (6,651)
EXCEL 91 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 92 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 93 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 369 491 1 true 96 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.bio-techne.com/20210630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Statements of Earnings and Comprehensive Income Sheet http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income Consolidated Statements of Earnings and Comprehensive Income Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets Sheet http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 3 false false R4.htm 003 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies Sheet http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies Note 1 - Description of Business and Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Revenue Recognition Sheet http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition Note 2 - Revenue Recognition Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information Note 3 - Supplemental Balance Sheet and Cash Flow Information Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Acquisitions Sheet http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions Note 4 - Acquisitions Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Fair Value Measurements Sheet http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements Note 5 - Fair Value Measurements Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Debt and Other Financing Arrangements Sheet http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements Note 6 - Debt and Other Financing Arrangements Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Leases Sheet http://www.bio-techne.com/20210630/role/statement-note-7-leases Note 7 - Leases Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Sheet http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Earnings Per Share Sheet http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share Note 9 - Earnings Per Share Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans Sheet http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans- Note 10 - Share-based Compensation and Other Benefit Plans Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Income Taxes Sheet http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes Note 11 - Income Taxes Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Segment Information Sheet http://www.bio-techne.com/20210630/role/statement-note-12-segment-information Note 12 - Segment Information Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Subsequent Events Sheet http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events Note 13 - Subsequent Events Notes 19 false false R20.htm 019 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies 20 false false R21.htm 020 - Disclosure - Note 2 - Revenue Recognition (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables Note 2 - Revenue Recognition (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition 21 false false R22.htm 021 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information 22 false false R23.htm 022 - Disclosure - Note 4 - Acquisitions (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables Note 4 - Acquisitions (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions 23 false false R24.htm 023 - Disclosure - Note 5 - Fair Value Measurements (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables Note 5 - Fair Value Measurements (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements 24 false false R25.htm 024 - Disclosure - Note 7 - Leases (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables Note 7 - Leases (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-7-leases 25 false false R26.htm 025 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss 26 false false R27.htm 026 - Disclosure - Note 9 - Earnings Per Share (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables Note 9 - Earnings Per Share (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share 27 false false R28.htm 027 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables Note 10 - Share-based Compensation and Other Benefit Plans (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans- 28 false false R29.htm 028 - Disclosure - Note 11 - Income Taxes (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables Note 11 - Income Taxes (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes 29 false false R30.htm 029 - Disclosure - Note 12 - Segment Information (Tables) Sheet http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables Note 12 - Segment Information (Tables) Tables http://www.bio-techne.com/20210630/role/statement-note-12-segment-information 30 false false R31.htm 030 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual) Details 31 false false R32.htm 031 - Disclosure - Note 2 - Revenue Recognition (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual Note 2 - Revenue Recognition (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables 32 false false R33.htm 032 - Disclosure - Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) Details 33 false false R34.htm 033 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables 34 false false R35.htm 034 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details) Details http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables 35 false false R36.htm 035 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details) Details 36 false false R37.htm 036 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details) Details 37 false false R38.htm 037 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details) Details 38 false false R39.htm 038 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details) Details 39 false false R40.htm 039 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details) Details 40 false false R41.htm 040 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details) Details 41 false false R42.htm 041 - Disclosure - Note 4 - Acquisitions (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual Note 4 - Acquisitions (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables 42 false false R43.htm 042 - Disclosure - Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) Details 43 false false R44.htm 043 - Disclosure - Note 5 - Fair Value Measurements (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual Note 5 - Fair Value Measurements (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables 44 false false R45.htm 044 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 45 false false R46.htm 045 - Disclosure - Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) Details 46 false false R47.htm 046 - Disclosure - Note 6 - Debt and Other Financing Arrangements (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual Note 6 - Debt and Other Financing Arrangements (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements 47 false false R48.htm 047 - Disclosure - Note 7 - Leases (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual Note 7 - Leases (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables 48 false false R49.htm 048 - Disclosure - Note 7 - Leases - Balance Sheet Classification (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details Note 7 - Leases - Balance Sheet Classification (Details) Details 49 false false R50.htm 049 - Disclosure - Note 7 - Leases - Cash Paid (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details Note 7 - Leases - Cash Paid (Details) Details 50 false false R51.htm 050 - Disclosure - Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details) Details 51 false false R52.htm 051 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables 52 false false R53.htm 052 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Details http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables 53 false false R54.htm 053 - Disclosure - Note 9 - Earnings Per Share (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-details-textual Note 9 - Earnings Per Share (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables 54 false false R55.htm 054 - Disclosure - Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) Details 55 false false R56.htm 055 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables 56 false false R57.htm 056 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details) Details 57 false false R58.htm 057 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details) Details 58 false false R59.htm 058 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details) Details 59 false false R60.htm 059 - Disclosure - Note 11 - Income Taxes (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual Note 11 - Income Taxes (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables 60 false false R61.htm 060 - Disclosure - Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details Note 11 - Income Taxes - Components of Provision for Income Taxes (Details) Details 61 false false R62.htm 061 - Disclosure - Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details) Details 62 false false R63.htm 062 - Disclosure - Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details) Details 63 false false R64.htm 063 - Disclosure - Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 64 false false R65.htm 064 - Disclosure - Note 12 - Segment Information (Details Textual) Sheet http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual Note 12 - Segment Information (Details Textual) Details http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables 65 false false R66.htm 065 - Disclosure - Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) Sheet http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) Details 66 false false All Reports Book All Reports tech20200630b_10k.htm ex_248803.htm ex_248804.htm ex_248805.htm ex_248806.htm ex_248807.htm ex_248808.htm ex_248809.htm ex_248810.htm ex_248811.htm ex_248812.htm ex_248813.htm ex_248814.htm ex_248815.htm ex_248816.htm ex_248817.htm ex_248818.htm tech-20210630.xsd tech-20210630_cal.xml tech-20210630_def.xml tech-20210630_lab.xml tech-20210630_pre.xml grph01.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://xbrl.sec.gov/country/2021 http://fasb.org/srt/2021-01-31 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tech20200630b_10k.htm": { "axisCustom": 0, "axisStandard": 38, "contextCount": 369, "dts": { "calculationLink": { "local": [ "tech-20210630_cal.xml" ] }, "definitionLink": { "local": [ "tech-20210630_def.xml" ] }, "inline": { "local": [ "tech20200630b_10k.htm" ] }, "labelLink": { "local": [ "tech-20210630_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "tech-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "tech-20210630.xsd" ], "remote": [ "https://xbrl.sec.gov/country/2021/country-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 663, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 21, "http://www.bio-techne.com/20210630": 12, "http://xbrl.sec.gov/dei/2021": 6, "total": 39 }, "keyCustom": 48, "keyStandard": 443, "memberCustom": 31, "memberStandard": 63, "nsprefix": "tech", "nsuri": "http://www.bio-techne.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Acquisitions", "role": "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "shortName": "Note 4 - Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Fair Value Measurements", "role": "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "shortName": "Note 5 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Debt and Other Financing Arrangements", "role": "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "shortName": "Note 6 - Debt and Other Financing Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Leases", "role": "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "shortName": "Note 7 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)", "role": "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Earnings Per Share", "role": "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share", "shortName": "Note 9 - Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans", "role": "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Income Taxes", "role": "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "shortName": "Note 11 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Segment Information", "role": "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "shortName": "Note 12 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Subsequent Events", "role": "http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events", "shortName": "Note 13 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Statements of Earnings and Comprehensive Income", "role": "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "shortName": "Consolidated Statements of Earnings and Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 2 - Revenue Recognition (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables", "shortName": "Note 2 - Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 4 - Acquisitions (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables", "shortName": "Note 4 - Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 5 - Fair Value Measurements (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables", "shortName": "Note 5 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 7 - Leases (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables", "shortName": "Note 7 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 9 - Earnings Per Share (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables", "shortName": "Note 9 - Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 11 - Income Taxes (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables", "shortName": "Note 11 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets", "role": "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 12 - Segment Information (Tables)", "role": "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables", "shortName": "Note 12 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:AdvertisingCostsPolicyTextBlock", "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AdvertisingCostsPolicyTextBlock", "p", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-5", "first": true, "lang": null, "name": "tech:ProceedsFromLaboratoryServicesReimbursedByMedicare", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 2 - Revenue Recognition (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual", "shortName": "Note 2 - Revenue Recognition (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-5", "first": true, "lang": null, "name": "tech:ProceedsFromLaboratoryServicesReimbursedByMedicare", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 2 - Revenue Recognition - Disaggregation of Revenue (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "shortName": "Note 2 - Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30_StatementGeographicalAxis-US", "decimals": "-4", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-7", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "lang": null, "name": "tech:FinitelivedIntangibleAssetsOtherAdditions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-3", "lang": null, "name": "tech:GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxesPaidNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 4 - Acquisitions (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "shortName": "Note 4 - Acquisitions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-10-20_BusinessAcquisitionAxis-ChangzhouEminenceBiotechnologyMember", "decimals": "3", "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "shortName": "Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-10-20_BusinessAcquisitionAxis-ChangzhouEminenceBiotechnologyMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 5 - Fair Value Measurements (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "shortName": "Note 5 - Fair Value Measurements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30_BusinessAcquisitionAxis-AcquisitionOfAsuragenIncMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "shortName": "Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:DerivativeLiabilityFairValueGrossAsset", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "shortName": "Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2019-06-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-5", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 6 - Debt and Other Financing Arrangements (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "shortName": "Note 6 - Debt and Other Financing Arrangements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30_DebtInstrumentAxis-CreditAgreementMember", "decimals": "-6", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 7 - Leases (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual", "shortName": "Note 7 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:VariableLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 7 - Leases - Balance Sheet Classification (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details", "shortName": "Note 7 - Leases - Balance Sheet Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2018-06-30_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Shareholders' Equity", "role": "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2018-06-30_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 7 - Leases - Cash Paid (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details", "shortName": "Note 7 - Leases - Cash Paid (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "shortName": "Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "shortName": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2018-06-30_StatementEquityComponentsAxis-AccumulatedNetUnrealizedInvestmentGainLossMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 9 - Earnings Per Share (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-details-textual", "shortName": "Note 9 - Earnings Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2019-07-01_2020-06-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "shortName": "Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2018-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2020-06-30_AwardTypeAxis-RestrictedStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "shortName": "Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2018-06-30_AwardTypeAxis-RestrictedStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 11 - Income Taxes (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "shortName": "Note 11 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-5", "lang": null, "name": "tech:IncomeTaxExpenseBenefitDiscreteTaxItems", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 11 - Income Taxes - Components of Provision for Income Taxes (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "shortName": "Note 11 - Income Taxes - Components of Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "shortName": "Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "shortName": "Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2019-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "shortName": "Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2017-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 12 - Segment Information (Details Textual)", "role": "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "shortName": "Note 12 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)", "role": "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "shortName": "Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "i_2021-06-30", "decimals": "-3", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies", "role": "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "shortName": "Note 1 - Description of Business and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Revenue Recognition", "role": "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition", "shortName": "Note 2 - Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Supplemental Balance Sheet and Cash Flow Information", "role": "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "shortName": "Note 3 - Supplemental Balance Sheet and Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "tech20200630b_10k.htm", "contextRef": "d_2020-07-01_2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 96, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r797" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r799" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r794", "r795", "r796" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r792" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r793" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r144", "r305", "r310", "r318", "r583", "r584", "r592", "r593", "r676", "r789" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r144", "r305", "r310", "r318", "r583", "r584", "r592", "r593", "r676", "r789" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r144", "r206", "r219", "r220", "r221", "r222", "r224", "r226", "r230", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r315", "r317", "r318" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r144", "r206", "r219", "r220", "r221", "r222", "r224", "r226", "r230", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r313", "r315", "r317", "r318" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r149", "r156", "r162", "r261", "r489", "r490", "r491", "r534", "r535", "r613", "r616", "r618", "r619", "r802" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r149", "r156", "r162", "r261", "r489", "r490", "r491", "r534", "r535", "r613", "r616", "r618", "r619", "r802" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r149", "r156", "r162", "r261", "r489", "r490", "r491", "r534", "r535", "r613", "r616", "r618", "r619", "r802" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r323", "r353", "r444", "r450", "r686", "r687", "r688", "r689", "r690", "r691", "r693", "r743", "r746", "r790", "r791" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r323", "r353", "r444", "r450", "r686", "r687", "r688", "r689", "r690", "r691", "r693", "r743", "r746", "r790", "r791" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r233", "r368", "r372", "r695", "r742", "r744" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r233", "r368", "r372", "r695", "r742", "r744" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r323", "r353", "r399", "r444", "r450", "r686", "r687", "r688", "r689", "r690", "r691", "r693", "r743", "r746", "r790", "r791" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r323", "r353", "r399", "r444", "r450", "r686", "r687", "r688", "r689", "r690", "r691", "r693", "r743", "r746", "r790", "r791" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r157", "r445" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r157", "r162", "r445" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r234", "r235", "r368", "r373", "r745", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r234", "r235", "r368", "r373", "r745", "r776", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r157", "r162", "r302", "r445", "r681" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r239", "r675" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_APACExcludingGreaterChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the APAC, excluding Greater China.", "label": "APAC, excluding Greater China [Member]" } } }, "localname": "APACExcludingGreaterChinaMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_AcquisitionOfAsuragenIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding the acquisition of Asuragen, Inc.", "label": "Acquisition of Asuragen, Inc. [Member]" } } }, "localname": "AcquisitionOfAsuragenIncMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_AcquisitionRelatedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-cash change in the liability related to acquisition.", "label": "Acquisition-related liabilities" } } }, "localname": "AcquisitionRelatedLiabilities", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details" ], "xbrltype": "monetaryItemType" }, "tech_AmortizationOfAcquiredIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of amortization of acquired intangible assets.", "label": "tech_AmortizationOfAcquiredIntangibleAssets", "negatedLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangibleAssets", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "tech_BMoGenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to B-MoGen Biotechnologies.", "label": "B-MoGen [Member]" } } }, "localname": "BMoGenMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_BuildingBuildingImprovementsAndLeaseholdImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to building, building improvements and leasehold improvements.", "label": "Building, Building Improvements and Leasehold Improvements [Member]" } } }, "localname": "BuildingBuildingImprovementsAndLeaseholdImprovementsMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to assets acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "terseLabel": "Total assets acquired, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to deferred income taxes, after deferred tax assets, assumed in connection with a business combination for which the initial accounting was incomplete.", "label": "tech_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxesNet", "terseLabel": "Deferred income taxes, net, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxesNet", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired, including goodwill, at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 2.0, "parentTag": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of equipment and other long-term assets acquired at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "terseLabel": "Equipment and other long-term assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities excluding deferred income taxes assumed at the acquisition date.", "label": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "terseLabel": "Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "tech_BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages, before remeasurement to fair value.", "label": "tech_BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Before Remeasurement to Fair Value" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeBeforeRemeasurementToFairValue", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_CCXIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the CCXI investment.", "label": "CCXI [Member]" } } }, "localname": "CCXIMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_ChangzhouEminenceBiotechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition of Changzhou Eminence Biotechnology Co, Ltd.", "label": "Changzhou Eminence Biotechnology [Member]" } } }, "localname": "ChangzhouEminenceBiotechnologyMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "tech_ChemoCentryxIncCCXIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer primarily focused on orphan and rare diseases.", "label": "ChemoCentryx, Inc (CCXI) [Member]" } } }, "localname": "ChemoCentryxIncCCXIMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "tech_ConsumablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to consumables products.", "label": "Consumables [Member]" } } }, "localname": "ConsumablesMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities that are contingent on agreed-upon conditions that arise from business combinations.", "label": "Contingent Consideration [Member]" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "tech_ContingentConsiderationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for contingent consideration.", "label": "Contingent Consideration, Policy [Policy Text Block]" } } }, "localname": "ContingentConsiderationPolicyPolicyTextBlock", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "tech_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to credit agreement.", "label": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "tech_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from lease liabilities.", "label": "tech_DeferredTaxAssetsLeaseLiabilities", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "tech_DerivativeNotionalAmountDecreaseInPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease during the period in the notional amount of the derivative.", "label": "tech_DerivativeNotionalAmountDecreaseInPeriod", "terseLabel": "Derivative Notional Amount, Decrease in Period" } } }, "localname": "DerivativeNotionalAmountDecreaseInPeriod", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_DerivativeNotionalAmountDedesignated": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of dedesignated derivative notional amount.", "label": "tech_DerivativeNotionalAmountDedesignated", "terseLabel": "Derivative Notional Amount, Dedesignated" } } }, "localname": "DerivativeNotionalAmountDedesignated", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_DiagnosticsAndGenomicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consist of the ACD operating segment and the Diagnostics operating segment.", "label": "Diagnostics and Genomics [Member]" } } }, "localname": "DiagnosticsAndGenomicsMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "domainItemType" }, "tech_EMEAExcludingUKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa, excluding the United Kingdom.", "label": "EMEA, excluding U.K. [Member]" } } }, "localname": "EMEAExcludingUKMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to contingent consideration adjustments.", "label": "tech_EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment", "terseLabel": "Contingent consideration adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationAdjustment", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "tech_EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Global Intangible Low-Taxed Income (GILTI) and Foreign-Derived Intangible Income (FDII).", "label": "tech_EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent", "terseLabel": "Foreign derived intangible income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGILTIAndFDIIPercent", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "tech_EffectiveIncomeTaxRateReconciliationOptionExercises": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to option exercises.", "label": "tech_EffectiveIncomeTaxRateReconciliationOptionExercises", "terseLabel": "Option exercises" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOptionExercises", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "tech_EmployeeStockPurchasePlan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2014 Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan 2014 [Member]" } } }, "localname": "EmployeeStockPurchasePlan2014Member", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_EquityIncentivePlan2010Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2010 Equity Incentive Plan.", "label": "Equity Incentive Plan 2010 [Member]" } } }, "localname": "EquityIncentivePlan2010Member", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_ExosomeDiagnosticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about Exosome Diagnostics, Inc.", "label": "Exosome Diagnostics, Inc [Member]" } } }, "localname": "ExosomeDiagnosticsIncMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "tech_FairValueAdjustmentOnAvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fair value adjustment made on available for sale securities during the period.", "label": "Fair value adjustment on available for sale investments" } } }, "localname": "FairValueAdjustmentOnAvailableForSaleSecurities", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_FairValueAdjustmentToContingentConsiderationPayable": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value adjustment to contingent consideration payable" } } }, "localname": "FairValueAdjustmentToContingentConsiderationPayable", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of gain on escrow settlement of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "tech_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement", "negatedLabel": "Gain on escrow settlement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainOnEscrowSettelement", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "tech_FairValueWriteUpOfAcquiredInventory": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting.", "label": "Costs recognized on sale of acquired inventory", "negatedLabel": "Costs recognized upon sale of acquired inventory" } } }, "localname": "FairValueWriteUpOfAcquiredInventory", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "tech_FinitelivedIntangibleAssetsOtherAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other additions lacking physical substance with a definite life.", "label": "tech_FinitelivedIntangibleAssetsOtherAdditions", "terseLabel": "Other additions" } } }, "localname": "FinitelivedIntangibleAssetsOtherAdditions", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "tech_FixedLeaseCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of fixed lease cost.", "label": "tech_FixedLeaseCost", "terseLabel": "Fixed Lease, Cost" } } }, "localname": "FixedLeaseCost", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_ForwardStartingSwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents forward starting swap.", "label": "Forward Starting Swap [Member]" } } }, "localname": "ForwardStartingSwapMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_GBProfitSharingAndSavingsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the GB Profit Sharing and Savings Plan", "label": "GB Profit Sharing and Savings Plan [Member]" } } }, "localname": "GBProfitSharingAndSavingsPlanMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_GainLossOnEscrowSettlement": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) during the period on escrow settlement.", "label": "Gain on escrow settlement", "negatedLabel": "Gain on escrow settlement", "terseLabel": "Gain (Loss) on Escrow Settlement" } } }, "localname": "GainLossOnEscrowSettlement", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from new acquisitions and adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "tech_GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements", "terseLabel": "Acquisitions (Note 4)" } } }, "localname": "GoodwillAcquiredDuringPeriodAndPurchaseAccountingAdjustements", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitDiscreteTaxItems": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the income tax expense (benefit) related to discrete tax items.", "label": "tech_IncomeTaxExpenseBenefitDiscreteTaxItems", "terseLabel": "Income Tax Expense (Benefit), Discrete Tax Items" } } }, "localname": "IncomeTaxExpenseBenefitDiscreteTaxItems", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents income tax expense (benefit) for discrete tax items relating to acquisitions.", "label": "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions", "terseLabel": "Income Tax Expense (Benefit), Discrete Tax Items, Acquisitions" } } }, "localname": "IncomeTaxExpenseBenefitDiscreteTaxItemsAcquisitions", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents income tax expense (benefit) for discrete tax items relating to certain state appointments.", "label": "tech_IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments", "terseLabel": "Income Tax Expense (Benefit) Discrete Tax Items State Apportionments" } } }, "localname": "IncomeTaxExpenseBenefitDiscreteTaxItemsStateApportionments", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_InstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to instruments which typically consist of longer-lived assets.", "label": "Instruments [Member]" } } }, "localname": "InstrumentsMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_InventoryFinishedGoodsNetOfReservesCurrentAndNonCurrent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "order": 1.0, "parentTag": "tech_InventoryNetCurrentAndNonCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. Includes both current and non-current amounts.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReservesCurrentAndNonCurrent", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details" ], "xbrltype": "monetaryItemType" }, "tech_InventoryFinishedGoodsNetOfReservesNonCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "tech_InventoryFinishedGoodsNetOfReservesNonCurrent", "terseLabel": "Inventory, Finished Goods, Net of Reserves, Non-current" } } }, "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_InventoryNetCurrentAndNonCurrent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory, net of reserves, including both current and non-current portions.", "label": "tech_InventoryNetCurrentAndNonCurrent", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNetCurrentAndNonCurrent", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details" ], "xbrltype": "monetaryItemType" }, "tech_InvestmentInUnconsolidatedEntity": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of investment in unconsolidated entity.", "label": "tech_InvestmentInUnconsolidatedEntity", "negatedLabel": "Investment in unconsolidated entity, net" } } }, "localname": "InvestmentInUnconsolidatedEntity", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for asset and liabilities of operating leases of the lessee.", "label": "Lessee, Operating Lease, Asset and Liabilities [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "tech_LesseeOperatingLeaseCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash flow information of operating leases of the lessee.", "label": "Lessee, Operating Lease, Cash Flow Information [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseCashFlowInformationTableTextBlock", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "tech_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentalImpact": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The annual rental impact of an operating lease not yet commenced.", "label": "tech_LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentalImpact", "terseLabel": "Lessee, Operating Lease, Lease Not yet Commenced, Annunal Rental Impact" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentalImpact", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of property under an operating lease not yet commenced.", "label": "tech_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfProperty", "terseLabel": "Lessee, Operating Lease, Lease Not yet Commenced, Area of Property (Square Foot)" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAreaOfProperty", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "areaItemType" }, "tech_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The element representing the additional borrowing capacity under a line of credit.", "label": "tech_LineOfCreditFacilityAdditionalBorrowingCapacity", "terseLabel": "Line of Credit Facility, Additional Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_NewForwardStartingSwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the new forward starting swap.", "label": "New Forward Starting Swap [Member]" } } }, "localname": "NewForwardStartingSwapMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_NoncashPortionOfLeaseExpense": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of noncash portion of lease expense during the period.", "label": "Leases, net" } } }, "localname": "NoncashPortionOfLeaseExpense", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "tech_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "tech_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "tech_OperatingLossCarryforwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information for deferred tax assets related to operating loss carryforwards.", "label": "Operating Loss Carryforwards [Member]" } } }, "localname": "OperatingLossCarryforwardsMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "tech_PerformanceIncentiveProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Performance Incentive Programs.", "label": "Performance Incentive Programs [Member]" } } }, "localname": "PerformanceIncentiveProgramsMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_ProceedsFromLaboratoryServicesReimbursedByMedicare": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the cash received from laboratory services reimbursed by Medicare.", "label": "tech_ProceedsFromLaboratoryServicesReimbursedByMedicare", "terseLabel": "Proceeds from Laboratory Services Reimbursed by Medicare" } } }, "localname": "ProceedsFromLaboratoryServicesReimbursedByMedicare", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_ProductAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the product and services provided by the company.", "label": "Product and Services [Member]" } } }, "localname": "ProductAndServicesMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_ProteinSciencesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment.", "label": "Protein Sciences [Member]" } } }, "localname": "ProteinSciencesMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "domainItemType" }, "tech_QTHoldingsCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about QT Holdings Corporation.", "label": "QT Holdings Corporation [Member]" } } }, "localname": "QTHoldingsCorporationMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "tech_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of the geographical locations in the world.", "label": "Rest of World [Member]" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the forfeiture rate used under share-based compensation arrangement by share-based payment award.", "label": "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-vested, Forfeiture Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedForfeitureRate", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "tech_StockRepurchasedDuringPeriodAverageSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "tech_StockRepurchasedDuringPeriodAverageSharePrice", "terseLabel": "Stock Repurchased During Period, Average Share Price (in dollars per share)" } } }, "localname": "StockRepurchasedDuringPeriodAverageSharePrice", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "perShareItemType" }, "tech_SurrenderAndRetirementOfStockToExerciseOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares of stock surrendered and retired to exercise options during the period.", "label": "Surrender and retirement of stock to exercise option (in shares)" } } }, "localname": "SurrenderAndRetirementOfStockToExerciseOptionsShares", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "tech_SurrenderAndRetirementOfStockToExerciseOptionsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value of stocks surrendered and retired to exercise options.", "label": "Surrender and retirement of stock to exercise option" } } }, "localname": "SurrenderAndRetirementOfStockToExerciseOptionsValue", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "tech_TaxCreditCarryforwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information for deferred assets related to tax credit carryforwards.", "label": "Tax Credit Carryforwards [Member]" } } }, "localname": "TaxCreditCarryforwardsMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "tech_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about term loan.", "label": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "tech_The2020EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2020 Equity Incentive Plan.", "label": "The 2020 Equity Incentive Plan [Member]" } } }, "localname": "The2020EquityIncentivePlanMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to trade names, customer relationships, non-compete agreements and patents.", "label": "Trade Names, Customer Relationships, Non-Compete Agreements, and Patents [Member]" } } }, "localname": "TradeNamesCustomerRelationshipsNoncompeteAgreementsAndPatentsMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "tech_USProfitSharingAndSavingsPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the US Profit Sharing and Savings Plan.", "label": "US Profit Sharing and Savings Plan [Member]" } } }, "localname": "USProfitSharingAndSavingsPlanMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "tech_UndesignatedCapitalStockNoParValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the no par value for undesignated capital stock.", "label": "Undesignated capital stock, no par (in dollars per share)" } } }, "localname": "UndesignatedCapitalStockNoParValue", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "tech_UndesignatedCapitalStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares authorized for undesignated capital stock.", "label": "Undesignated capital stock, shares authorized (in shares)" } } }, "localname": "UndesignatedCapitalStockSharesAuthorized", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "tech_UndesignatedCapitalStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares issued for undesignated capital stock.", "label": "Undesignated capital stock, shares issued (in shares)" } } }, "localname": "UndesignatedCapitalStockSharesIssued", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "tech_UndesignatedCapitalStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares outstanding for undesignated capital stock.", "label": "Undesignated capital stock, shares outstanding (in shares)" } } }, "localname": "UndesignatedCapitalStockSharesOutstanding", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "tech_UndesignatedCapitalStockValue": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value of undesignated capital stock as of the balance sheet date.", "label": "Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding" } } }, "localname": "UndesignatedCapitalStockValue", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "tech_UnitedStatesAndCanadaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Geographical location of the United States and Canada.", "label": "United States and Canada [Member]" } } }, "localname": "UnitedStatesAndCanadaMember", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "tech_VariableInterestEntityPrimaryBeneficiaryMaximumLossExposurePortionStemmingFromInitialInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the amount of maximum exposure to loss from involvement with consolidated variable interest entity (VIE) stemming from the reporting entity's initial investment in the VIE.", "label": "tech_VariableInterestEntityPrimaryBeneficiaryMaximumLossExposurePortionStemmingFromInitialInvestment", "terseLabel": "Variable Interest Entity, Primary Beneficiary, Maximum Loss Exposure, Portion Stemming from Initial Investment" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMaximumLossExposurePortionStemmingFromInitialInvestment", "nsuri": "http://www.bio-techne.com/20210630", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans - Assumptions Used in Black-Scholes Option-Pricing Model (Details)" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans - Restricted Stock and Restricted Stock Units Activity (Details)" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Share-based Compensation and Other Benefit Plans" } } }, "localname": "statement-statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Components of Provision for Income Taxes (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Reconciliation of Federal Tax Calculated at Statutory Rate (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes" } } }, "localname": "statement-statement-note-11-income-taxes-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Temporary Differences Comprising Deferred Taxes on Consolidated Balance Sheets (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details)" } } }, "localname": "statement-statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-12-segment-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information" } } }, "localname": "statement-statement-note-12-segment-information-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-2-revenue-recognition-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Revenue Recognition - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-2-revenue-recognition-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Revenue Recognition" } } }, "localname": "statement-statement-note-2-revenue-recognition-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes in Carrying Amount of Goodwill (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Changes to Carrying Amount of Net Intangible Assets (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Estimated Future Amortization Expense for Intangible Assets (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Intangible Assets (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Inventories (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Property and Equipment (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information - Supplemental Cash Flow Information (Details)" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Supplemental Balance Sheet and Cash Flow Information" } } }, "localname": "statement-statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)" } } }, "localname": "statement-statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-4-acquisitions-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Acquisitions" } } }, "localname": "statement-statement-note-4-acquisitions-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)" } } }, "localname": "statement-statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details)" } } }, "localname": "statement-statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-5-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Fair Value Measurements" } } }, "localname": "statement-statement-note-5-fair-value-measurements-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-balance-sheet-classification-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Balance Sheet Classification (Details)" } } }, "localname": "statement-statement-note-7-leases-balance-sheet-classification-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-cash-paid-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Cash Paid (Details)" } } }, "localname": "statement-statement-note-7-leases-cash-paid-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases - Fair Value of the Lease Liability by Payment Date (Details)" } } }, "localname": "statement-statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-7-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Leases" } } }, "localname": "statement-statement-note-7-leases-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)" } } }, "localname": "statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "statement-statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)" } } }, "localname": "statement-statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-note-9-earnings-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Earnings Per Share" } } }, "localname": "statement-statement-note-9-earnings-per-share-tables", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "tech_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.bio-techne.com/20210630", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201601Member": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.", "label": "Accounting Standards Update 2016-01 [Member]" } } }, "localname": "AccountingStandardsUpdate201601Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201802Member": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.", "label": "Accounting Standards Update 2018-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201802Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Trade accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r27", "r240", "r241" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, less allowance for doubtful accounts of $1,229 and $775, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r21", "r705", "r727" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r66", "r67", "r68", "r73", "r82", "r83", "r84" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r73", "r82", "r83", "r84", "r609" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.", "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r70", "r72", "r73", "r729", "r754", "r758" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r69", "r73", "r82", "r83", "r84", "r146", "r147", "r148", "r591", "r749", "r750", "r804" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r65", "r73", "r82", "r83", "r84", "r591", "r646", "r647", "r648", "r649", "r651" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r28" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r146", "r147", "r148", "r489", "r490", "r491", "r618" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r150", "r151", "r152", "r153", "r162", "r250", "r251", "r258", "r259", "r260", "r261", "r262", "r263", "r304", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r532", "r533", "r534", "r535", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r674", "r697", "r698", "r699", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r800", "r801", "r802", "r803", "r804" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.", "label": "Employee stock purchase plan expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r451", "r453", "r495", "r496" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "us-gaap_AdvertisingExpense", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r453", "r481", "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "negatedLabel": "Stock-based compensation, inclusive of employer taxes", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r34", "r246", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r124", "r278", "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "negatedTerseLabel": "Amortization expense", "terseLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r139", "r214", "r221", "r228", "r256", "r305", "r306", "r307", "r309", "r310", "r311", "r312", "r314", "r316", "r318", "r319", "r583", "r592", "r634", "r677", "r679", "r703", "r726" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r56", "r139", "r256", "r305", "r306", "r307", "r309", "r310", "r311", "r312", "r314", "r316", "r318", "r319", "r583", "r592", "r634", "r677", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleEquitySecuritiesAmortizedCostBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the cost of equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments for other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "us-gaap_AvailableForSaleEquitySecuritiesAmortizedCostBasis", "terseLabel": "Available-for-sale Equity Securities, Amortized Cost Basis, Total" } } }, "localname": "AvailableForSaleEquitySecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "us-gaap_AvailableForSaleSecurities", "terseLabel": "Available-for-sale Securities, Total" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Short-term available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r252", "r254", "r265", "r710" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "terseLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r454", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r601", "r605" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r440", "r446" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r440", "r446", "r555", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired", "terseLabel": "Business Acquisition, Percentage of Voting Interests Acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "terseLabel": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r550" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "negatedLabel": "Acquisition related expenses" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r568", "r569", "r572" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred, Total", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "auth_ref": [ "r552", "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.", "label": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "terseLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r566", "r568", "r569", "r574" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "terseLabel": "Contingent consideration payable" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r123", "r577" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Contingent consideration payments" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r576" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r567", "r570", "r575" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability, Total" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r567", "r571" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r567", "r571" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Long-term contingent consideration payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "terseLabel": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r558" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 1.0, "parentTag": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "terseLabel": "Current assets, net of cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r558" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "terseLabel": "Deferred income taxes, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r558" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 4.0, "parentTag": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "terseLabel": "In-process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r557", "r558" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 3.0, "parentTag": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r558" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r145", "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r39", "r126" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r120", "r126", "r132" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r120", "r644" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "us-gaap_CommonStockDividendsPerShareDeclared", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r146", "r147", "r618" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,955,484 and 38,453,046 shares, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r77", "r79", "r80", "r91", "r715", "r737" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income attributable to Bio-Techne" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r90", "r103", "r714", "r736" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r195", "r196", "r237", "r632", "r633", "r777" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r195", "r196", "r237", "r632", "r633", "r760", "r777" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r195", "r196", "r237", "r632", "r633", "r760", "r777" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r195", "r196", "r237", "r632", "r633", "r777" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r133", "r585" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r357", "r358", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r357", "r358", "r369" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r219", "r220", "r221", "r222", "r224", "r230", "r232" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r97", "r695" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r140", "r528", "r538" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r140", "r528" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r528", "r538", "r540" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current tax provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r140", "r528", "r538" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r194", "r237" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r137", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r337", "r344", "r345", "r346", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r138", "r144", "r320", "r321", "r322", "r323", "r324", "r325", "r327", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r348", "r349", "r350", "r351", "r656", "r704", "r707", "r724" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r320", "r348", "r349", "r654", "r656", "r657" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r49", "r138", "r144", "r320", "r321", "r322", "r323", "r324", "r325", "r327", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r348", "r349", "r350", "r351", "r656" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r529", "r538" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r529", "r538" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r140", "r529", "r538", "r539", "r540" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "terseLabel": "Deferred Income Tax Expense (Benefit), Total", "totalLabel": "Total deferred tax provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r23", "r24", "r520", "r706", "r723" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r506", "r507" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred income taxes", "terseLabel": "Deferred Income Tax Liabilities, Net, Total" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r125" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r658", "r673" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized.", "label": "us-gaap_DeferredRentCredit", "terseLabel": "Deferred Rent Credit" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r140", "r529", "r538" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsDerivativeInstruments": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.", "label": "Derivative - cash flow hedge" } } }, "localname": "DeferredTaxAssetsDerivativeInstruments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.", "label": "Excess tax basis in equity investments" } } }, "localname": "DeferredTaxAssetsEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r522" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryovers" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r525", "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Tax credit carryovers" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r521" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedTerseLabel": "Valuation allowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r507", "r522" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "negatedLabel": "Intangible asset amortization" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "verboseLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "us-gaap_DeferredTaxLiabilitiesOther", "verboseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains in other comprehensive income.", "label": "us-gaap_DeferredTaxLiabilitiesOtherComprehensiveIncome", "negatedLabel": "Net unrealized gain on available-for-sale investments" } } }, "localname": "DeferredTaxLiabilitiesOtherComprehensiveIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r526", "r527" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedTerseLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r438" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r124", "r209" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r57", "r61", "r62", "r603", "r692" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "us-gaap_DerivativeFairValueOfDerivativeLiability", "terseLabel": "Derivative instruments - cash flow hedges" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r61", "r602", "r604", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r600", "r602", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "us-gaap_DerivativeLiabilitiesCurrent", "terseLabel": "Derivative Liability, Current" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r58", "r60", "r63", "r603" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "us-gaap_DerivativeLiabilityFairValueGrossAsset", "terseLabel": "Derivative instruments - cash flow hedges" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r597", "r598" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "us-gaap_DerivativeNotionalAmount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "us-gaap_DividendsCommonStockCash", "negatedLabel": "Cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r92", "r154", "r155", "r156", "r157", "r158", "r163", "r166", "r177", "r180", "r181", "r185", "r186", "r619", "r620", "r716", "r738" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r92", "r154", "r155", "r156", "r157", "r158", "r166", "r177", "r180", "r181", "r185", "r186", "r619", "r620", "r716", "r738" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r182", "r183", "r184", "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r644" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r509" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r142", "r509", "r542" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Income tax expense at federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r509", "r542" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "terseLabel": "U.S. taxation of foreign earnings" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r509", "r542" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "terseLabel": "Foreign tax rate differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r509", "r542" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "terseLabel": "Executive compensation limitations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r509", "r542" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments", "terseLabel": "Other, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r509", "r542" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "terseLabel": "State income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r509", "r542" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "negatedTerseLabel": "Research and development tax credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Salaries, wages and related accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bio-Techne's shareholders' equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r82", "r83", "r84", "r146", "r147", "r148", "r151", "r159", "r161", "r189", "r261", "r354", "r355", "r489", "r490", "r491", "r534", "r535", "r618", "r645", "r646", "r647", "r648", "r649", "r651", "r749", "r750", "r751", "r804" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r16", "r20", "r255", "r725", "r773", "r774", "r775" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r497" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "terseLabel": "Excess Tax Benefit from Share-based Compensation, Operating Activities" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r621", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r335", "r348", "r349", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r436", "r622", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r621", "r622", "r623", "r624", "r630" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r335", "r400", "r401", "r406", "r436", "r622", "r683" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r335", "r348", "r349", "r400", "r401", "r406", "r436", "r622", "r684" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r335", "r348", "r349", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r436", "r622", "r685" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r625", "r629" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r626" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r627" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Purchase price contingent consideration (Note 4)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "negatedLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r625" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Contingent consideration payable", "periodStartLabel": "Fair value at the beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r335", "r348", "r349", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r436", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r628", "r630" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r286" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "verboseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "verboseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "verboseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "verboseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r279", "r282", "r286", "r290", "r696", "r700" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "negatedTerseLabel": "Currency translation" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r286", "r700" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsGross", "terseLabel": "Definite-lived intangibles assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r279", "r285" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r286", "r696" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "us-gaap_FinitelivedIntangibleAssetsAcquired1", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainOnSaleOfInvestments": { "auth_ref": [ "r94", "r95", "r124", "r711", "r739" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.", "label": "us-gaap_GainOnSaleOfInvestments", "negatedLabel": "(Gain) Loss on investment, net" } } }, "localname": "GainOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r270", "r271", "r679", "r702" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "us-gaap_GoodwillAcquiredDuringPeriod", "terseLabel": "Acquisitions (Note 4)" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillForeignCurrencyTranslationGainLoss", "terseLabel": "Currency Translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r274", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillPurchaseAccountingAdjustments", "terseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r96", "r139", "r214", "r220", "r224", "r227", "r230", "r256", "r305", "r306", "r307", "r310", "r311", "r312", "r314", "r316", "r318", "r319", "r634" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingAssetsNoncurrent": { "auth_ref": [ "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the asset arising from a financial instrument or a contract used to hedge price changes in underlying assets, and which are expected to be converted into cash or otherwise disposed of after a year or beyond the normal operating cycle, if longer.", "label": "us-gaap_HedgingAssetsNoncurrent", "terseLabel": "Hedging Assets, Noncurrent, Total" } } }, "localname": "HedgingAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r600", "r608" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingLiabilitiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability arising from a financial instrument or contract used to mitigate a specified risk (hedge), expected to be settled after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_HedgingLiabilitiesNoncurrent", "terseLabel": "Hedging Liabilities, Noncurrent" } } }, "localname": "HedgingLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r141", "r541" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r88", "r214", "r220", "r224", "r227", "r230", "r701", "r712", "r718", "r740" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Earnings before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r141", "r541" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r294", "r297" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r142", "r510", "r518", "r524", "r536", "r543", "r545", "r546", "r548" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r143", "r160", "r161", "r212", "r508", "r537", "r544", "r741" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes (benefit)", "terseLabel": "Income Tax Expense (Benefit), Total", "totalLabel": "Total income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r81", "r504", "r505", "r518", "r519", "r523", "r530" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables", "negatedLabel": "Trade accounts and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Trade accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "verboseLabel": "Salaries, wages and related accruals" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r167", "r168", "r169", "r181" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r281", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r289" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "In process research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r281", "r289" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r277", "r284" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Total intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "us-gaap_IntangibleAssetsNetIncludingGoodwill", "totalLabel": "Total intangible assets, net" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r87", "r208", "r653", "r655", "r717" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r118", "r121", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r206", "r219", "r220", "r221", "r222", "r224", "r226", "r230" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r53", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r54", "r134", "r188", "r266", "r267", "r269", "r694" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r35", "r268" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details": { "order": 0.0, "parentTag": "tech_InventoryNetCurrentAndNonCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r99", "r101" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Investments": { "auth_ref": [ "r734" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "us-gaap_Investments", "terseLabel": "Investments, Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "us-gaap_InvestmentsFairValueDisclosure", "terseLabel": "Investments, Fair Value Disclosure, Total", "verboseLabel": "Investments, Fair Value Disclosure" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "terseLabel": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract (Year)" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r670" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r670" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r670" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r670" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r670" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r670" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r670" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r670" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r670" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: Amounts representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r139", "r256", "r634", "r679", "r709", "r732" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r48", "r139", "r256", "r305", "r306", "r307", "r310", "r311", "r312", "r314", "r316", "r318", "r319", "r584", "r592", "r593", "r634", "r677", "r678", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r621" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "us-gaap_LiabilitiesFairValueDisclosure", "totalLabel": "Total Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r19", "r704" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "us-gaap_LinesOfCreditCurrent", "terseLabel": "Line of Credit, Current" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r334", "r347", "r348", "r349", "r707", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-term Debt, Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r22" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term debt obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt obligations" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r49", "r303" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r52", "r139", "r256", "r305", "r310", "r311", "r312", "r318", "r319", "r634", "r708", "r731" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r120", "r122", "r125" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r75", "r78", "r84", "r89", "r125", "r139", "r150", "r154", "r155", "r156", "r157", "r160", "r161", "r174", "r214", "r220", "r224", "r227", "r230", "r256", "r305", "r306", "r307", "r310", "r311", "r312", "r314", "r316", "r318", "r319", "r620", "r634", "r713", "r735" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "us-gaap_NetIncomeLoss", "totalLabel": "Net earnings attributable to Bio-Techne", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r75", "r78", "r84", "r160", "r161", "r587", "r595" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net earnings (loss) attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r154", "r155", "r156", "r157", "r163", "r164", "r176", "r181", "r214", "r220", "r224", "r227", "r230" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Income available to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r165", "r170", "r171", "r172", "r173", "r176", "r181" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "totalLabel": "Income available to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r129", "r130", "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "terseLabel": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "verboseLabel": "Other intangibles" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "auth_ref": [ "r356", "r559", "r589" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from a business combination.", "label": "Non-controlling interest in Eminence" } } }, "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r146", "r147", "r148", "r355", "r579" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "us-gaap_NoncurrentAssets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r100" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "terseLabel": "Nonoperating Income (Expense), Total", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r73", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "us-gaap_OfficersCompensation", "terseLabel": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r214", "r220", "r224", "r227", "r230" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating income", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r661" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "terseLabel": "Operating Lease, Liability, Total", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total lease obligations" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r661" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities - current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r661" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liabilities", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r662", "r666" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash amounts paid on operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r660" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r669", "r671" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate:" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r668", "r671" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term (in years): (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r525" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r219", "r220", "r221", "r222", "r224", "r230" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r55", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r581", "r582", "r590" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.", "label": "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r581", "r582", "r590" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r70" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8." } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r76", "r79", "r82", "r83", "r85", "r90", "r354", "r645", "r650", "r651", "r714", "r736" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r76", "r79", "r581", "r582", "r590" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other comprehensive income (loss) attributable to noncontrolling interest" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r76", "r79", "r581", "r582", "r590" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r47", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other non-operating income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other operating activity" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentedTechnologyMember": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law.", "label": "Patented Technology [Member]" } } }, "localname": "PatentedTechnologyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities", "negatedLabel": "Contingent consideration payments" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r106", "r110" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "us-gaap_PaymentsForProceedsFromOtherInvestingActivities", "negatedLabel": "Other investing activities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r114" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Re-purchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r114" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Cash dividends" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecurities": { "auth_ref": [ "r107", "r253" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.", "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecurities", "negatedLabel": "Purchase of available-for-sale investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r108", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "us-gaap_PaymentsToAcquireBusinessesGross", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 }, "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "negatedLabel": "Acquisitions, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r109" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r454", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r112" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "us-gaap_ProceedsFromIssuanceOfLongTermDebt", "terseLabel": "Proceeds from Issuance of Long-term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r112" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Borrowings under line-of-credit agreement", "terseLabel": "Proceeds from Long-term Lines of Credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r104", "r105", "r253" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from sale and maturities of available-for-sale investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r113", "r117" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r111", "r484" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r75", "r78", "r84", "r119", "r139", "r150", "r160", "r161", "r214", "r220", "r224", "r227", "r230", "r256", "r305", "r306", "r307", "r310", "r311", "r312", "r314", "r316", "r318", "r319", "r581", "r586", "r588", "r595", "r596", "r620", "r634", "r718" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net earnings", "terseLabel": "Net earnings, including non-controlling interest", "totalLabel": "Net earnings, including noncontrolling interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r293" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r293", "r679", "r720", "r733" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r293", "r778", "r779" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r293" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r291" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r73", "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "negatedLabel": "Reclassification from loss on derivatives to interest expense, net of taxes" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r71", "r74", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "us-gaap_ReclassificationFromAociCurrentPeriodTax", "terseLabel": "Reclassification from AOCI, Current Period, Tax, Total" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r115", "r138" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "us-gaap_RepaymentsOfLinesOfCredit", "negatedLabel": "Payments on line-of-credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r501" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r124", "r296", "r299", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "us-gaap_RestructuringCharges", "negatedLabel": "Restructuring costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r355", "r492", "r679", "r730", "r753", "r758" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings", "terseLabel": "Retained Earnings (Accumulated Deficit), Ending Balance" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r146", "r147", "r148", "r151", "r159", "r161", "r261", "r489", "r490", "r491", "r534", "r535", "r618", "r749", "r751" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r205", "r206", "r219", "r225", "r226", "r233", "r234", "r237", "r367", "r368", "r695" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net sales", "verboseLabel": "Revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r371", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r135", "r136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r667", "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right of use assets obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueSegmentMember": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Segment Benchmark [Member]" } } }, "localname": "SalesRevenueSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r73", "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r279", "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r36", "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r214", "r217", "r223", "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r460", "r471", "r474" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r517", "r531" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r201", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r230", "r237", "r298", "r301", "r742" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r201", "r203", "r204", "r214", "r218", "r224", "r228", "r229", "r230", "r231", "r233", "r236", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative", "negatedLabel": "Corporate general, selling and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedTerseLabel": "Forfeited, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "terseLabel": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Granted, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Balance, shares (in shares)", "periodStartLabel": "Balance, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Balance, weighted average exercise price (in dollars per share)", "periodStartLabel": "Balance, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "terseLabel": "Balance, weighted average contractual life (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedTerseLabel": "Vested, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Vested, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rates" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "terseLabel": "Exercisable, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r462", "r483" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r452", "r458" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r477", "r493" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected lives (years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r5", "r201", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r224", "r225", "r226", "r227", "r228", "r230", "r237", "r275", "r295", "r298", "r301", "r742" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r51", "r82", "r83", "r84", "r146", "r147", "r148", "r151", "r159", "r161", "r189", "r261", "r354", "r355", "r489", "r490", "r491", "r534", "r535", "r618", "r645", "r646", "r647", "r648", "r649", "r651", "r749", "r750", "r751", "r804" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r146", "r147", "r148", "r189", "r695" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets-parentheticals", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-cash-flows", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-assumptions-used-in-blackscholes-optionpricing-model-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-restricted-stock-and-restricted-stock-units-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-components-of-provision-for-income-taxes-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-federal-tax-calculated-at-statutory-rate-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-temporary-differences-comprising-deferred-taxes-on-consolidated-balance-sheets-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-financial-information-relating-to-reportable-segments-details", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-disaggregation-of-revenue-details", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-in-carrying-amount-of-goodwill-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-changes-to-carrying-amount-of-net-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-estimated-future-amortization-expense-for-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-inventories-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-property-and-equipment-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-supplemental-cash-flow-information-details", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-liability-measured-at-fair-value-on-a-recurring-basis-using-significant-unobservable-inputs-details", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements", "http://www.bio-techne.com/20210630/role/statement-note-6-debt-and-other-financing-arrangements-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-balance-sheet-classification-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-cash-paid-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-fair-value-of-the-lease-liability-by-payment-date-details", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables", "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r25", "r26", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Common stock issued to employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)", "verboseLabel": "Common stock issued for restricted stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r354", "r355", "r465" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued for exercise of options (in shares)", "negatedLabel": "Exercised, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r25", "r26", "r354", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Common stock issued to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r25", "r26", "r354", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Common stock issued for restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r51", "r354", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued for exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r25", "r26", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "us-gaap_StockRepurchasedDuringPeriodShares", "negatedLabel": "Share repurchases (in shares)", "terseLabel": "Stock Repurchased During Period, Shares (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r25", "r26", "r354", "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "us-gaap_StockRepurchasedDuringPeriodValue", "negatedLabel": "Share repurchases" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r139", "r248", "r256", "r634", "r679" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Bio-Techne shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r83", "r139", "r146", "r147", "r148", "r151", "r159", "r256", "r261", "r355", "r489", "r490", "r491", "r534", "r535", "r579", "r580", "r594", "r618", "r634", "r645", "r646", "r651", "r750", "r751", "r804" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "periodEndLabel": "Balances", "periodStartLabel": "Balances", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-balance-sheets", "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r680", "r682" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-13-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-10-sharebased-compensation-and-other-benefit-plans-tables", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-tables", "http://www.bio-techne.com/20210630/role/statement-note-12-segment-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-2-revenue-recognition-tables", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-tables", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-tables", "http://www.bio-techne.com/20210630/role/statement-note-5-fair-value-measurements-tables", "http://www.bio-techne.com/20210630/role/statement-note-7-leases-tables", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-tables", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r525" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r242", "r243", "r244", "r245", "r247", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-3-supplemental-balance-sheet-and-cash-flow-information-intangible-assets-details", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-4-acquisitions-preliminary-and-final-fair-value-of-assets-and-liabilities-assumed-details" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r150", "r151", "r152", "r153", "r162", "r250", "r251", "r258", "r259", "r260", "r261", "r262", "r263", "r304", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r532", "r533", "r534", "r535", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r674", "r697", "r698", "r699", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r800", "r801", "r802", "r803", "r804" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies", "http://www.bio-techne.com/20210630/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual", "http://www.bio-techne.com/20210630/role/statement-note-8-supplemental-equity-and-accumulated-other-comprehensive-income-loss-changes-in-accumulated-other-comprehensive-income-loss-net-of-tax-details" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r175", "r178", "r179" ], "calculation": { "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "negatedLabel": "Income allocated to participating securities", "negatedTerseLabel": "Income allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r502", "r547", "r722", "r759" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "us-gaap_UndistributedEarningsOfForeignSubsidiaries", "terseLabel": "Undistributed Earnings of Foreign Subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r503", "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Ending balances", "periodStartLabel": "Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "negatedLabel": "Decrease in unrecognized tax benefits for prior year positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "negatedLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Additions due to acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Additions for tax positions of prior year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r190", "r191", "r192", "r193", "r197", "r198", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes", "http://www.bio-techne.com/20210630/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r665", "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "us-gaap_VariableLeaseCost", "terseLabel": "Variable Lease, Cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-note-7-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r165", "r181" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r163", "r181" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income", "http://www.bio-techne.com/20210630/role/statement-note-9-earnings-per-share-shares-used-in-the-earnings-per-share-computations-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.bio-techne.com/20210630/role/statement-consolidated-statements-of-earnings-and-comprehensive-income" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11374-113907" }, "r498": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28200-109314" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r548": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r578": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r631": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL75039408-165497" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r652": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r672": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r682": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r792": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r793": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r794": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r795": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r796": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r797": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r798": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r799": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123457312&loc=SL116659633-172590" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 98 0001437749-21-020980-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-020980-xbrl.zip M4$L#!!0 ( ,Z%&5-HY;90F0P #Q& - 97A?,C0X.# S+FAT;>U< MZW/;QA'_;/\55Z5U[!F2HF0[ED19,]3#L>O85B6V7SL'X$A<#-PA=P=2[%_? MW;W#4\^D29N4\HS'!'"/O<7N;Y_P8>KR[.@P%3PY.LR%XRQ.N;'"O=TJW7RX MMQ7N*IZ+MUMS;7+NAHEP(G92JRT6:^6$@M%.9*)(M1)OE89)?QH.V?=""<.= M2%BT9K.T5(DPISH7[%P;QS,V9'O;NZ^W=\>[.^S-P>ZK@U?[[/P3&PZ/GCXY M=-)EXDA<_7/WU=[>^.4(Z#S<]C>?/GEZN$T4/SV,=+)FUJTSHDZYH97_$@=L M9URX":,;9R5Q8]EFLV(7.N?(W)ZS@22+5XH"-I6+CT8Y4 M$Q:7QFISP'CI]&0+]BHZ&SUHW9M)6G(CN7('3"$_LPG+N5E(!;OC$">NW)!G M<@$WC%RD#C8_C([.KE(92<=>C78.MZ.CP^WBZ.DM-'W;H^;;24,'D=&A(A 1 M:,#'6T?/5&2+R5U[L-X>#SYK^W@QB(XPG?/7?X<[13CYZ=GER<6'\]F'+Y_9 MEW?LY,NG3_#K#)+!4S*,KT"F66VS&'LFNDY M<_ @UGFN%9"BXZ\#$&S#ECPK!?OS>#3>884PS(*&"_8$:FX=YO) V;$'%Z%TS1M7F89*4:USNW'Q+4]70,6:9?BB%4J MXY3A2Q4>)"PN3#Q4"M@*AX3Y#CD-1\A![(8?<82?YU)X%>VSP"7/K(:MJO4& MM"T2]DDJ):P&BW!<6@D_;4["]O5JM1D8 P[09Y6JTT,MM?"VE$W8[EDYLOQSO3D>;I^F'\FA:NE0;6"1A MEZBXEAUNRPT%O8 U)$8-6T"2I;4 <66!OW?&KP?C\1C_>JBSE?2!LV*E=:15 MS1CT2RR8(T(!/X'$?<<_;ZV#\]I:/&)3NO?7$O#QY7C T)49D)Y4E*8\82_W M!ONO7P]>[;WRG+MY,7^&)$"5 _%7Z))LH-"'-]WF#/%4JVS=9@V+,VZ)CV3L M*NP,K!\Q7.=8'(J#?BLVMC>L"[@X^BVA>I*&9J**),60!=>.!B#7 /F M$A7X/L&R"B/]FPWO>&YT3KO=)F2PZEQ>T1 C,@#1I?!.7V5%T$P(%?M5!0[,>2.@&BB#@[JE<#M\_$@F< *XU7 C$N#?4[\>#Q5$@P0M MP2J /$I%4M,2]=M\AC,$<3_N!A^@HQ!H9F!'T81M7A&N4Z&TBLN\]!9DQ&Y5 MVQZ-]Z@N;2:N8E&@(C%;B!A"M)@TQHB?2HFS( @19B6MMQU>>=#WAR B W8Z MAWO9,LJE<_Y8E1;2B2IJ\!2@MW:>\-+:$P2CPO"@R4$(T5AE?#2KH$4L0_9ZA0U]VY\T$)+=AY* / AT$ M6DG0VJAKEWW"J#!@H3E$_E(1;MRR4S"X78,*VSLC(_\B^1P@ 0[[E30S 1SA M3C0)D\8"2XO)Z 4I?R(B!ZJHP?]>D'P$GR"3/)*@3,&=;1MY?.SWN@'U&@^X MC7=]+$PY^N/>+?$N=-:2T)9WOIGJ^@7AU*N@XZ$>OE/D. #V2J2KLJ 4N7KJ M$;7BK"2E(_"J"*X))"B(N)6T*XXIC(Q%8\IIM4 S,@>X4#$@(4(KYB1X]#XK MQ7P.EI:0Q\-;$W3@7$!88''D6?]:Y5-[ZLG.C8Y&4FYN0OFQ'+S%7,(>X(_ B01_! M@VX3581HC$!HQ-[K%;AL@,F\'0BQO+0N5/=H-$^6A#^ % A_1<-VPMK$QYZ7 M?@O/B=W1SKB"<5\K&K$/BBVH'I\-B"B.3AP5AT*,=",=/FR#)RN#T9NJJ*C M7-4"41VN[PY6M2LR148XK%0",F8"8Z7OQBP!7:;D)1I#RJ<"Z9C"?'].;I(>#2.7$/7OHC*+5!"?V<((#>'XFJFNUS[W:0JJD6J+<1Z@5Z M5%0R@\5\2H77"97*&ZI]&:S-R'D/0SR,V=\UCG6TM&;0'P[-?B8]'XRJ MH3\;BC83BWZ0(&E!G8#W)R&LP?!/.:.S#06FDR"7W;Z8=J_+H"4[K883S"0C MD&$V2)>&+R"\343&UQ3,0LA,:2]$)K,@;RH&";72&T\8$0*L^C7$_C5T U ( M!Q8IX]6PH*&YR"-QK6)%Q=WQ3I49PC%43"%-9=8>?CDZ=/GARZ.B3#[ $6 :IPR.F" M1N&@I+_H7H=.E]P]CAX^3";[(GD_K[[9_^[-OF<6;G,[,57'YV](S+1K#0.L MHBSYF.$Z'//,@W7;7#\/$,RNH^^+:P>%?XWOG25!>93*1ZGL$X/.A4^GURZ) MSYAAU0&;)EL"U@C?_FCG4?8>9>\WE#V?]ZZRN^T&*7R7*(3@(G?3ZSX[7?V:A#45$-R4@OKEGY5T*;K.;33F!5IYV.]Y<%S8R[XG\RC_C_+_LXEI MQ0U4R:G+O9TPB_J@OWM3 RZZQP.24_ AL#^C[OD(/2)-V8(<8^/#;%YU/ 9O M.-1 6KYSZ()\E.1'2?XE2 X825\.4!1VGS2_[$HS7-3IB5CG49UA-EQ9'KII MI%KJ;.E[E"IAEEA8\GTT+<0.DNQWK,+*JKI)*21LKY*:VH3G^-4$)F!L:!V@ M-#?(#%8',1&#^7PLV6*]$8BC-EY6;=S>=L!*E5&&!9E152)KZX%ES0@C8I%, MT!X]ZMFCGOT"/-6Y ]%>IIA;SG"=@ M-)CC7X5>4COCG+*^IJ-C00_NZ@(FJ:-22];LKZB$[^!$DCH.,48&U<%TC_?D M@J4+6=4.$0_7OM'O1/,>Z_"/=?@'?Q.&L7@>"I8/^59P,W/.LU[;7Z=EE[XH M:K7^W8)ZU %(**-7_H/-)A%R*^?[S48T90 8JPM'26DC"@$PU$YXVV[+=M8J M(UA!#5X.'1'ZK#-D8-HY%Q.XAW7, MUB>>E+*I6,EK5IJ:E3U'HR[,=+ZWV#Q>4Q'25M%_1[\W4_AF]\@("ELF*6Z$ M6Y^GEZ?3O[4^9K'K/-)9%63.SD[>CT),^;]IT_QA>CD;-O[8-7?IW>RB=R^= M#XU>7;^)P1SS'N*-GE//CX(?^/^M@ 31_QKS;U!+ P04 " #.A1E3.2EA MTF<< GHP #0 &5X7S(T.#@P-"YH=&WM/6MSVS:VG]M?@>M.6Z1I\8REB-'DF$VY&LL49L='"O&^Z/)$ MCN&"DN-) 9.?#$_[[R=R* L89^_HY.'P].1A?OKE J"^;8#S[7$%",%1 \-" M88' VSNGWZ1#G1\OFX,UYEA[L>'Z(J >H6H(\/]V#W*[].O^S>#Z_&S0?\EN M!I=G/[#>+[WKEZSW^KK?_[%_,2!T#!62P^GNX/S'/OL9WCB_>/U@%:(^].Y5 MP#_=/#2^.+_L#OIG;R[Z[.SR^NKRNCPK[.E+V.L> M_,:M[\'&;Q"4A_L'^ZS_/S^=#_[)SB_.@/[.?^ZSJ[>]U:C\-*CMMU(7W?L,=G0]PO^% MG;,!NV!]=@/_].'WFV=;DE]&\K^\Z5_W>S<=%M 5 \I$PHS!-F(3H030// " M9^_$C(EIGF0S(3K "2,9"=5AL53 'YE"WH#_@LFERZ2@@13C\:T$(X45&8UI MJ1SO@"V&;\A"LYMRJ&4L87U"'R/A;S=LY8:%V+R3>@( 8['"O'.F1*Z4#)" MXU876?2.\3NN8GPBW&BPEYD&>UJ07'.CP9]3(($;>B\'&[/$9^T&!B+N1L!6 MQZ&D8[VI '!CDEW7 )9UT8=_5[*8L;.4^1DE*57":\+0+S@1-J6"-8G@EX\ ME:F$[>:6!_$B87<"^@I\@TFF *B8KAOZ@(?6))'E*/BL-^'B\I<.&^!.O+J\ M[G<8^&4H^F0L+#/8K_KS@<2A\ZJ@#@!,@=UYJ@:\,!1@4ND1,E-&$&1B1@1H81; /_G&L*;QC M+&(STB1+ZN^6H%02(.&C7)/'2IX9TP\!MF<%MY"#L$ M F8/#3.W^S@!O"C&&4[97+<''U>TD,("^NC,<8_=6=P!_&%0-IX4VJ@KXAG< M=YCD3@)& (0\@,TAO50.X;E0,J-UW4TD$D;U%&(AH&S@\=/CZ;88,C\BVC(G+!IM82+N66"**TQCN%("V85GP84*<$+SU M.;AQ_Z8T/UPMS=\BTY(T=VSVJF(S9)"FE#]F R!1F7INN1:&<_1$YB3\M_LQ MMQ^/'Q%TN_S!:O5*T?6D4J.6]70H4E"@D18TS ^6$E@_X2.!K#0BWH@A-'^0 M-5'5ZIJ^^QFV&>^\Q#M5,,5+N6+"BYK8,7-JY]A2,J#AJ:(=75AB@0?,DR2# MBXG*RO$$:*< )Y@N<2_F>)XG,B).#Z'")VIRW4O=W>$#\VXHYY>2X0<.HX.< M8E'"M7Z^<_7ZQ0\[;LH[&1<3I*K]KQVI=!,Q*FP^P%XA>4B7,!=1&^OBIQ_] M8&UAG6"""B08 8&:*/?F5>]UO_L"/)\?NKU7@_[U,Q"N=WRFC]DP4Z 7D,93 M41OM&&P9 ]9A_OX8=%&""9.O]NE_\!Z/WHUA"].X6[\UMX(W+Z];5X!H6 :_ M7\;?E@;YP',8U85VADU)/=_!':6>8K-C)%H'F$/)48LXNR\58DKL MBR^_^.*D4!\:%AP9!X[=P+<")0I/'%E,91PG%2D>(<@?>/)[ZZ65"%Z=^J,H M*PAWE&,HV7UP%0%Z6,3W1,NCCQ@M*Z+3'E56[5D-\ &0]H%IR3&W@0/^5*>? M),_4U_GW$>F_#<=VWS=?*-0%@(_8;$7D A'Y(3"TY8O-IX0M7VSY8LL76[[8 M\L66+[9\\?GRQ9?P)\://OZZX-61\YW3\Y%)AYD$%;QU,OHVG03"Y@Z7M MZ9B2&%@'H+($T0N[AFD]C$-K"?!S9>H *-@LWHNH+*J@=1C8=IFX()"-Y8H, MJ^.KQ(=]L59$0K4,@D<3%G$MJF1O(Q_BQ'61X1Q\X/=T8-:ZGEY;N+/ M_'>;$EJ4H@LRQ933M%GMY74&)928IK=\H0V?U%& M/LCZ5AFD>LV4XPAAB@;2#:%%X.127-A7#B*)"]^(>O9/4[+NQI;8%^6K$(VQ+=H>&0Z>Y3L3W?VBM-2.G9=I0W8>%1C4.&V%[F*=G24BF1&O B'FF1;:UQ^$10D=5UQ1;8JM MK&!3 6JW)A=@@(!=%\LORYDI,?"HP-*Q FM?4?9Q,/L>/[9V PPF2")Z@AUA M7=7NXP<@=+C2SEX&YLA*M"[4K01[>:6@./:ZH<8OC?(03U"1$C'5S-' +1-F MJ<,EU9WY4C0C!L,Q ;U*C$LPY>$-'4U$7%JCYBY3[]CA/L(ZS5!(9B @<$!V M)\2[/?:J5(A!OR&$1+<700$=KEMS4"VX/X0[G'*4"*I_(L]C1OH.N#7ALJ\C5@S?69 M[F22@-?@W Z-+27X?)JE74 )-?O:.>LO/3Y0)%03+-.)8R5#,8 02UOEDIM%UIHV!-< O X,1OT ET/K 9*X M-7:G;81),]-^C'(>"'>N:G&H)-B98%0 :X(Y3'6% DS//_Y(+*)&BI= G2BQ M8]"3"IQ_>-P2\D@DF2%KYQ<&$!C!F&0(<\+O8$FW67)+E# DOH-U2&UU8QU[ M( ?(4"=3'JB.>G6&R)IHX<"RQ=@@ O8 >!I^C^E>815 +E+=-(",*=(W*DO- MFT.=VC*4"2W87J)<*A[-$!J0!5-I[";R,#GWAWCL^-]^N-JX4$+M(Q2#SB$LN:L#?H,)51X1AL*<%; M.B?AY=@*1(M,?RN5=6K67,CF:,O-J$7KLD/6W9:B?5R1MU9CYVA5#?'P]-?! M)7O19S_=]%^R\XNJ$_B&_7(^>,/Z_]L_^XE:J2]?O3H_ZU_?/&.FL1_K?-YD M"56+7XO?2VLD^6*?(3BG%UF!"@"U&#T'? >&%OQP;0_8L94Y8];K86M74T"0 M!&6K<:+,I&1#4&_$X_VOG0B[ ,_,NGFV)CWV=:N!Y6R"([7102[JD;0"Q/2L M9'L!&3*2) MYV#+*=J,UN#$N[7*7$4A!6P?L%&L8$#;8Q' A%MK_178X3DKV-J%>\P]!_8: M/%<-Z:\?X'7J22@F8(3/[5:]![/:,3!HP.ZH!PQ243A-9IL1D.HF(K$^.?[% M4FK!WU/7P6?1'[U> _F)//WNN\OK[[X[>2A//V',W*_<'Q!S3L?H2#3WP+#( MIFC>QWO_^H11] %4SJ,UFA!-EP2[0E=48S1SVWJR7NL)J_\!N.R'GBF[)/=N M/D@\J.O7*K\ *A;S!R!3Z]'?F6WT:KIO-@3@+/*:7TRO&0=3!1 L#$JTG(/0 M0:R1BP"WP$@ Z07@">^\\UDUF@&P$7-&9>%"H4:;U4$, 2/SI+)&6C T)!M$ M%ZHT;8,1..TF*E/S\HV=$E6!'T27!'4?$S#^I)05B[]TZ(G/%;#NX[AG>)V*HLFFN* M- ZO\8CQ[!!I[5MC$-X'1L\PWP_6)4:>M!$U&.TD85,_ MN 0C) 5_9TF&F]@5YCX*%L.6:YQ)9;DRB9V,B5279"9SD\9)P436FOPBA"NT M;JG$P NF+DD[E$*X[KDVW,"J1C.\,IE5-B5AQ*?@F0-)YGQ&[S2:!.(1)_$S>< ->N>QR%!V;%9-+AP2XH$0^CS23U[+ '%5RD5F7,/D)L<8YRT M @;\!3,Y_V9MA-420]B[SX-H[XKC"%J3B[7>NJ^C[.\:#OQ M!&Y2&!H5J,X O['4H)U,/-726*JJ9<9RFV3S M)[Z$N >6%Y+,$ZSPZ=2:U\,^?/:*2\5^Y.H=N)4_\Z0483J8\G<4_3>TA9^23&3 L2G+,*CA/J&,G2*D:C<[@ZSC*F(JE*9?$__O2VOZT6$U(.G1X],98]'VN:8%YL2_#[:!K\_[N"WLP[C MU=;A!;EN5$3'*4LZ,^;A*TS-92S)3!J9Q.IR[43\E\R, ^$-J_G#'5K*@MI4 MD2W^<\ I3-C[%"]*C$3$XRJM#:@%X=!2$=NJS3>'YS>/:,3"4(L]^N^>Q_U5 MGJ>A"$&GXD1."=7<2UD5936/(#15QIAPSRER8A.O[L2[(<872,%6'FG#.$)X MI7:6,]H%Y@A#(B)O$GBOLQDSDK6".1HL-45*)CJDS5%!%C&^\G7^O*7Z85FT M@C$H984E-?4I82!?:P'>0.J#_+^7&/Y'K;K'N=&HN@7J,'" M1VA\3LJ$9UJJ=/&FX5 #-!8RN +,*J/5K,3*KF(=$;6+6"Q5W<5I.XFIZ\! ]C8YANCK[T( S6(%DEB2TI,A)+*6\PU>VHJQAYS9^8/2W-*K:=?<"MI5H :%0=9 MKDG2C+JN5H2=9=X[+IQ"I^[T,@0= Q_ 62 S#I[L@YGM!(GQ(*?VT%BQ,"&X;4LORJC_$ASIM/:0- M.X=-(R-?_?H(;" :H[HP:CFC:W$IZ0@L$(I89FA# T29TL*E?$Q]VC)L50:P M$B3?9'H+.Q\;'1ZX^TL!WC+"8D:8K,$(8&B2///[O223.)26ZF1J]QWI:RA2 M,9)S*3IZKM!5],/$,HQS8WXWS=9ZL 1=L^K=1G&\B7T6;>:U Y[8!WZ(]R@[ M-98C!X8MQMC:&KC\*<6UVB5K!S=-Q<8B?$@MX S;Q=B>>#3$GTAQ6P][DP8T MD2EW2*<-E+6 O.6 Q1P@5W- 3PUEH0(SLP=4B(H>=PU@HC)Q5-VF\#DT.>9] M#XIM8A4Q$J8M_483LN-N3OD[:U($FMF[<,^U(GY M@%)K$==\&P.^B2>;4[;1B0-7!HPNH$V@)C"M,F4X02DZRA5/UK='=VM1%(E= MTRBH-J9.59#_VG;BI/6R/QO?<+B+>&JC&\!^67*+"J3V@%^$F8]8&44,)6RJ M7=EC_UW&8X+&!_ZYC;J@WJCBO.XEJ[Q-4R4]8,,G458J.@@9I_@-S'4=VYKR MPGP+PM@!P3A53)DI:A!Q62RXYU);OP%XP@1[,0"?J53,,!9#'GN.=J;$.("N M' 14A:7&0D!TIPN;DC'V@VL$0=MP]V#?-H+XE)O;4(M=86 M@^%-^-["WH,GP(A(:P#T0*' :R:'5J8);D(8^57.M(8!XRJ2$6=1:6H#:(E>4,3"=2T %?R4.F8*IK , MI1W5#ZD UN,3&PC2\-3^D%" 3/&MP+,)>70!/_CRT/-29F.;=-- MGT:ZZ;?5-N5+,!(Q]@Y&?=4J>N.K!6V+DO E2F'X,G1= H?E+(L#3WC_:<\K MPB7G/5BMWNC/Y*[#LJI?=+W]KMW2V0^3JLN2HAD-&&Q_M#$JS$IM4V%C6B_T MM !Q8ZT==')<@VE-GO9A+,@1C#(]2I MZ@Y1-QFW]DDW1T9M'I&_6TWDU^X3$90I6_A)&5M+Z;Y98M^AD'C3@7)!TC;" M<6'2>B^^KY%C1/I:*I<2"^LZVHHO%_-3K: /*!(H101!A]V193\4]2))Q&^$5BA6<9ED%YFB_MVG3Y^&4_GS1H33IH$! MZDI6;<$?%B_"(O X+E^6:%+'I ?0#,8],,5G)IUF@+3]\?!NFK'<-*Q[7\A/ M.Q1&I?C5!"LQ6[]H$<=F-JIUM9>K[PW9^MN.\_DH3<^CB* DYV&N)+ECG2?J MG:=&^*HRV4JK]3#=L4M?^H4J:M;+"Q=FP/["+HXYY. C^[JU,79-8#2A*N[# M2HIL*J.*7=HX9"Z09%G/;*+&936WQ(]G/5Z AM"S?!?V;)6'=8A6L5K#80J. M43)QE/IA<[YW,UABR ^- LGZF4S!M![K*"MS00+3Y:4M47 DQMJWU:KKU6=A M[B8FC^S=PSJ\8>L+>*I:VGX'%X'SL;9E*!K91+$[8L4VA5%=57CLB@U[DBCF M2>2K&3W27!2_+D'(O W6C+L]Q9+ZT.D%?3O-;9D()A$P4?9>3KF/YT="F7-" M:A6DEDU,& S[_M)@U$X8*Z7^I%R)8G[(@#O# (M=A39R$Z>9(T6+J,$*!-M3 MK4J83D^< U10NP@4SH_P708P A!*$FW(M&OM(H!RJ!3@G#?3WR3=%57Q@>N"J-Q-3B4:K44179Q/0(2 @5UTN:2/"EYI0=;>:GDIV) MH'-WS-E45%E760$WA2W5J4*!'\7QHEL(_K*S"'Z]@2__: M&/1L@B9!K?']5FM\W%K#'I;0.SN[O'YY?O'Z[3];/WY-^30Z[VXN)F8/Q'1G M8?O3)4V!#1WX8@*CYE/,MJKPK_RPXE_W83Y#WL]W]G<:W^AK?J&O]?M\S?UO M &1HEY@EY&Q>%MEQC;'I2O7YO54GT1=9[AGC^X.OV[^2!5P'T*?/=XYVUAKG MZZ7']*]8Z4K4GPQ/7YQ?=@?]LS<7?0:D>W5YW1N<7UZT?=TM^"K$!T'%&N\> M_3VOMKR[^8L?9D6133_4VQN$@@]*_H&,)R:O\\.+63OL85;@M4^'N[N=QC^_\$QN^=>;S[%_6=WJK8QYX6^ST=!FMS,&EM$ M$?"6/=KD#WYLB**M63W[==NS9H7-P;OB:RLMBK:%U^QTAT!NY&>/X2[L]HZ! M ]3JDZ^;=&AU.CQ% -N_.E+87_]S,2T@@P*]ZET/SL_.KWH7@U7?1'4L^F01 M] >'?RWT>*75A+[_YCGBPAOW,1U6;NBGB9$6%."GBQ;@X/%G@X0M;]R3-Q:K MZ_7(:N7[*W9D;:/EJTI$%A\^[V?R^-I.4M.CJ=*QB?',U5* M$4UE853Y8JJ5%&ILW1'1%E:JA3N+E6B\FF6 MJA=I!@_]J=\7;U2J"EFJ6(SFXGI:I;$J7F4S)=YG12D3T1=/'AX?S\T3,Q^$'T^R=??W5__@K^<_R0 M8/[Z>)3%4+PI67?Z'^JY^)@/R^/!%T8RYE.YL_%M[]567ETK6?*B'-U M*RZSF4SYXI'(91SK=/)<[.M4[.\=Z/1(1%5ALN*YD%69'>W N_+&BS9:MQND M&UEHF9;/18H838[$3!83G<+;\992W95]F>@)7"CT9%K"RX]')\.[J1[I$M;9 M>WS\<'1R_# _^7H)4']I@?.7HQH0@J,!AH7" H%?[YQ\FXY,?K3J':+UCHTW M&^XO NY110,!_K_]@]QN_7)X=7UY=GH]?"6NKB]._R8&/P\N7XG!F\OA\(?A M^36A8U0@.YSLOA]>OKZX_&%P?CH4/\ ^=O'JS#UZG'Y_N)R<'UV<;X61?\^ *^&IQ?G0%X@[2L@^0 ^(P<,@/[W",K# M_8-],?SO'\^N_R[.@-G.K\]^&HKW[P;K4?EY<-NOE2GU>+X"3WR[!LV/:SSZ MGJ"[?GMV58NNT :>CY50XS%:E1LEI!'96/SR[9^???_79T?_Z*']D"F8$57> M*I6*ESKK7ZMHFBIQFA5Y!D8&C%%/2/E-E,C1C]1=BMYPJ\>V?GQX>[A^= M9K-L"Y",K4#;@?\'S,E52TD*%D/&-!E]%E!FM:;D:C,%@ #'DP+Q+D6A3%GH"'U<4V;1!R%O M91'C'2&AP6T6!MQJ17K-K0;_SH %KNBY'%S-"N^U! Q4W)4"4L>AIA.#F0)P M8])=EP ".=ELCGZK=#D79RE*,NK2]XEL*D"\X%3:E@DV9X)!/-.I!G)+*X-X MD; [!7L%(<(T*P"HF*XS?\!-&[+(:A1\T40XO_BY)ZZ1$N#4#WL"PC-4?3I6 M5A@L*?)"S;0!*%$H[+595580:$;9C4H!+D-JEAM RR(5 MP.$C$3).'RZSFT:1>BVG0HXR=!V7R5NH NG%3@>2=@X<0/_QP3J='2YY1;?Z M-2V(X$O-F"%1A6MD5Q. ;+D1OS?5Z%>P[KA=&2,Q0,.7#:MPQ2D7$K)7 ="@FN56CS@? $^QHK759%2!EZ(7@V Y0KVM=4 JD2F1L5-S2(CV /P@!FKPA.5$ A("&&*E8D*/=+I9"DLI!+@RV+)BJM@S8OL1F-J MB!@%WQ!)L*Y)XK5/ [E$&M@$O-4"@';:V&7@,[S!D?(0* 0*9@\=,T=]? $\ MJ"89OK*];P\^[F@IAP7\T5N0'DM9I !^8)1-IJ5AP M.:17A4-XK@J=T;YNIQH9H[X+L1!P-I*F21E4YU%2$7KQ;5E5BD3/=&DC.@\= M/GZ3H< CLJU@XK;!)U;:[B76B.(TAF]*0-NH*N4H(4D(GOH2PKA_49L?KM?F M[U!H29L[,7M=BQD*2%O+'XEK8%&=>FFY5"PY9JIS4OY;>BS0X\EC@FY7/EAO M7BG)GM1FM$O_.;R7K=[(R.CJ58WK%R=[Z8**BV 7A49/0PBW58R M_@Y6. !##Q7K*$/CWS8X+E<^J#?I-'JOUL7E%#89*D?P(<$O-"[\ILI%(Y[N MQH5LF1"OX'='#WB/(0![XGVP&T<;ORM+"##>ZD8F%<5VJ.FPZH*2Q%#A%6O) M309*+M9@!57H$#<"%K;J(19=,HVLR!38@HP]WC63=WI6S40"5$I@9Z#^]5C# M:S./5V:_@045'JZ2$L&YL8A!KR:*LB*F5Y$=(4@CB: V-K(86Y'_X=&Y\%)F M<^MWM2AA'3"/U)"S1XHN@?9112._*.S-Y%!FH1EKPN7(8>VM K898]BPAJ'! M.8$W:AE2>@DO=^U:P(;/F$SP$O0%EPAYG('N*5F %TPW(H!0.Q>:OCP MRMA8Z_S''_QB79G:X 4U2+ " C4MW)/O!V^&_9>7P\'?^H/7U\/+YX#76SDW M1Z ^"W#UT&REJK':$6AW!NLPOSL"]S+!4NB?]^G_X#D9?9@4697&_>97"SMX M^^JR

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Ð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end

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ȱU:1=81E)'S667@&?!TL/"2'[CKG;A[]! MAAQ"NN^EW5P&$;9K]: !6N[ @7)*"&(-AFEA'E"DCBW3Q7>8H^QTA4GD-WQ% M5599N6VQK?LA:7R75G/;J1>J[A\ 8"?%!4">(DXP8)?U4OC7:QK>IRN)*7>E MI2-%]:;2]A0V/,Y__:XQN6:AZB)'7,=0U MZ&>2A*CAJO94Y;-!95Q3!_Q4D2MT?;K0:F6$*&259KEM]Q-*("]3"0366KLM MC4( <0%8'R^7ZZ^!TKUJ2_,R"DG?)CL C1RH=#4U-*0@-<5?9W2-?*K#DBC^ MZ8/O5BZ\ZGRMLY,E#LP^B8PH=?A;W7Z:-\,LZK*+%/YG@9XDM\3MP2O@')A4 M-+_0 %8&G =D2 9XZ"Z.$JM4#R W QP8XT7G1[CSL8XRJOJ"+FI>1@K\7@$E MQ!.B(8]6N5N=KF"?=Y\'8@&/WW%61%E_8!@8'M&20PN/.MAT'<[?03;0E,\(WC*>'&6[:D1\?= M=&.AE%FXI/(C[TL[G-5E$Y^D/H)?0DLREBT.'ZUE?R7 M1,+$0U\>HDCXA02V17KC8:^ S #$Q"P\P)9/0\$'!9==*MW- *LD1&FO M#_5'I'7U1^00T8]B*LS8L;U+$.V)S*(#/U9*Y:1R_<6/?J5@%F(Q0TR[RNP^ M*S)<5G #+>>CW7.C)([[8'I _;=MQN168??Y'(,^2L=S'-M"@-AG<]8OJ?D/ M-KP7@X7<<-72%OGW\&0O-(3'IB;^/E[6_-+6X3%I6>8 L-S^HG?N.^!W5WZVT =9;YWY M9*:RF)1+S>KOF\\.?Y %F"UJ%%['>>!E//;3 WU[!@?6B>/\'2.??8]_>-]9 MV'^!:JM56&*;PNFQ5[O:UMZYK(]=?8]L$+%,J&NLD8H%12LJ._3GUT_G*R%^ M(@0COREI%CP#20?<2_0"2ZU3%C3C3L;*8'+K9C!T$U$7 X1Z1!==\OG*GW/S M!AL>6A9?\!RF5ROYA*]_P9L-5@[^H\*J!Z_;I7O\:8UR%GZ54R]=@-K,?H)K M?XP$N4[#&SZ'\OWZ>;),HPDK+*B?&_Z 3;32HD?LWA2B/1P(K6^[N _SX!/URY?YG@.& M?)5O$AZQ6*20#^V!C59&, MLUN#7.(;KL0V/ER]M!5#N;_(3=:R+5Y@HL_'1B,EFCZSH4UTZ_W5&5H ^DW5 MMO*",WC);/;F2V/FWDJC+4>$11*5"[C]4L7HE\[R? BO!8@FH21M#@?.RHH? M%5E=R1P+?WGU8&KM-V&&X(K&B+E,(PI1:,IRB:51UT;.[;A!DM3,]IR.!N\H M0T$#2L1L_H>(07&53W<#'_3QX=+H6YJ\/0/Q%Y+U=>5)$I=JL;._TF'EM.\B M!V>8';O#TJDP;4'-7R&\1X'>%L02OGX(,V7;*5(0VGSE;UO-_T/A'V]K!!LN MU$\GUT$W!V_\HX@C]CQ5?F=&JCQ2)[]96I9SRU[+$ MPZ^XX40(%/9U9TZX\T\$ZI*7'+7Q9#,)0C=P( (3L@H]8C@>,JT:B0SUC3@X;AQ+)7^.5W"$Z3FZCJ3MY?QQ9( M,'CXIZ7=U]G9?_/"'[$F89>GR6;I!SJ7=SZO;D\9YQ/=_D]^O /0?>2H7J?! M4K.1,O&&J.($ZQ8D71D%A9;21D0'.&B,A10BF,42\_-\[K:6=%VE](/1^/NK MFE-A1:]DF=S8&CO5U.?5 BP-_3:K_NW*?JI!HG*>S3,L6O$&]\Z+E)V(ULBWMJ#V]T]:, M,E&V1@3*00]O!JRH4 #VF@JF>7P\%M]%:7QO;-5#4Z2/_$8KC]?XQ=HAT"TH MK)XWP^M/Q.Q)[;HOWH!YXK0Z=C(N8*UV]VSUEW #^?6!.$GX .[8!_--9VPC M+ V'Y.#?^U)_M/]QQ!!E3JJMGX[?1Q79:I1 )5N\+E<4!64=\+C Z&I$8XB&J2$[WV8M M"!A;SF]K?;TWT7B:+[02PO5[>?IZ5>,-#6O++DU]/S!_[1-"(T1(\:7>%QZ_ M)JVM3[K1#1 Z[QGMT]=.VEW2=_H)@23"9&,8T]+HU+TAV92Z7M)W==F;D844 M&6$P)2\,,2F?,Z?:S19[L'<84ZE-GPH#/D4$"1(7+[.[.!'XQ BXTSA;]^0 M:\Z=X5;MM[4DD_Z B<59S?%+;.U-C5TU97F-<8E??DSMV@3%)&)N4S_:=J/< MM-GB?M&/9^:5-;'S+U@-3VHE)&+[6<8#XZ^ @#"E#R]XKP LR)/_:*#WP:T2 MVU[ *V =)PM07_*098AMM&2[QC";=1,KEP&QTU^!3QA+&2ET7]A%V/"H8!?F MQ'BIK91G"_=F'(%*L?Y9&27HB\HM))A,+Q=;W:9@?@4\,=@S/OGY>/<14>9? ML'/LO[Q\+7[!I0@*OK\^M[P.BKR]A7&^ A*%HZX+D ZRK"I+#GC/;?V4,RR@ M(Y.^\.N*7*'=B(8#:+C%.2'(RG[S?@%\T(BY U*L"'5"2=;E1QQCN?4F(<+> MT-]O]N?!7=/;_DGM9;]Y:1O\#^JPMA#DQ/3%F@+,Q9X"?)(^M5"F9RDZ49V_ M9S -/@.)8\7U9M@6+Q[TJD$@D2OYHBPB@DR;N=X6C.G+/9@KE.Y9Z51HO8C] M1X.!'@VK[SY&X!+/+XALLQ";!BY"]/^:%)2Z4KZG8)]!@Z_>G7@'=PN,_2P'R@66_YPF]%&OL=9)KLTEP#1*, M==&_Y+R<1ZENTX8L 5P3FY-A=R&4>W_DV(OFZ+HT*$;TP) ><;^ZH;O0:X#V M24:X,&?9\)[NO?^GL$\[0^DQ'?GJB\-/1PZ JC?Q<-WPS0"74?6=;I,SS M5X!J9^Q0.E@'6@3!QG53""P8T*%[XSI)X">4C]O1*%]^+ZO48)MHD7*GAGIR M^E%-=/L5\.;)OKHH1*"PW*?G[$74\X1/1>54U[9_);A[)SG\KZ"H_25-?R5X MR*"/]+;P$..B1>/>('I I+JT*(3#41ACT__]E_/?O$#^5T#ZE21]QLMC .1( MQ[,37NF",(8-5+V<66/)I$\'VA*0Q6RU>!=)HGDNJS#]=\"D>YTV>&.]597G M6G=@0L^JP7.U06>N>9I[).PR;>(M>:($;2'/S/2_[J@FB*GP8>F!=3YEM-5' M@OV/?KCN&1HN2M,EA0!&N?[&X502!AZJB$ 6:2B81;MYZGI4A'=U96A:;[F& M:4P<,5H5R04P^;WZ_RA4R/)T\.%TN/>35QPUI\UB]TZ%SVI^546RR".=VDL9 MWID^5ESDM)=YY+):24W]OKT[#+A8P)^\EP'/\0W\#69-KH0D_+FM!29T[#&B M&*NVFBL*T.N/^:3,=NS^Y"A:^9H(F)S "_1%S,7Y66"[KB4==RJ)KIDOG.JN MY"P_S)]_!^_DL,VJ]R)3<3(FELS7XL-]!7I>VV.WU<:5!!C[IF.T!?D5XH:2 M#%8$!;[GO8_1OL\$#Q-#_F!?EH@7BUU.G0KP#XH+///\8]0/?:CS\,P7(3O$?&B^X#R6\K,,_F]^SC'6];K[YJO@,+@TJ& 7_D/MH\_,^(]5B?W M]6=5D;1? =B$#6."IAJO *J?G30>791>&6BXHGTOGU(0 M202NB-SVXSUH\_7G_[)3!=_P/E7V?'KVQ"G]]!!*/FQK62;T7*RX9&>,(-_E%N!L(W$_;R.+2&,E7%=)LR M N7_-\M,/CH)XVE1)R1%ZTA&QI?F""KE"O21_CQKH?00U[ZX*Z'&I(RW3.;# M@VVSCLYH*W1GN-S3UA!^*4)#6ZAX*6D_URV6H=L^7V M1FR*,2L!/82^GT:J?GHB2 \@2^0]S0P5\07O4T7C$E R,"E[" M&UU*RGBVAGEM)RRW7,7^H8P%7*J0<\<\!O",9MUA#/TUH:@EV=-QT) MW]Z;SC$9"U>*KEM#-,W)*>GS8[2738N"/<3;+?)WXWY&^'![+5VH M%QV45"_#V7W5'I%6H%,V)\L4:P33 0/XG5OB/W/^SA%8MC6*508'042QA[I/ M9?W-OSZ9HG^YD@P?5/U@7"H-<*$Z#[>K+Y4MFT2.J&/=2AY)7K6=F2"XB'^Z MHIPKRB**Q?VC.)O?,^S)?)SB6CRZ)WC]RUF,SH6E[J\8?FVXJ&);O G&DNF* M*QY/>GY?'A@WL/]BOD9%=8>0\PHX6?7XJHK,]YR_K7'7(5N$=<=_Q?(9ON_T\3IZTSUF7$@O8>P4T=*@'W<714)W:VHAEDXI]#Y +NHNW_GMY MCK6'\1]X_MK&O;;UX %8T=_8DD61\VF3.[CG?07?GS.2^S"5)P25YS=P1O3X M<'\];@\QV7-P=(<$^W,?:O!O.)N_0H$EZWQS1SHW^.RYP$XPP.,+%&8OM+O5R9 7QJBTFRD!580QC7!]HT/>2\@62D(787'^M0: M7AMA,Y1N/N,*W;7]R.T:?3/44),Z3$/ME2"/&E\]%;B&Q-)8%$*"CF-0-D0C ME_%848 %S?\O[R+[UZ#M]?^'[NI_ 91$93Z] [<9:P(SS4++P\**!!V-!W_4 M=6L:(FDXR9;E?B"JRD44FZJ,$5]2"3;ZM.O\:&L^/TELKX'9L0"/3"8K#/3( MOI&2>7A$HTSUJ,7'+I%E5ZP(>;;DHPI36,'*QED"_+ZQT*E_VGVG 4Z+MKZ3 M]R=X<;U-+9D/37-+[!J,)Y8XF<)Q.LAC2PN7*20?$'Y%;E"*RIOBN9HDAD69F#S2\@%9<)^_%HE9NW=7 !9 MP7/DHU3'G'-MW2E]QZ6%3\^R9/ST,+;%>TY??'+<@C?=9B&4M=4'Q3I0ZP8^ M;R]C&^+6QF_]K!;8$MJ4VX4(.,D2"+%;W&?A?LKYF\M"*,U&"BSW"'E.E4[F M\I:XDM^'VO5("%!EB0'H";'>UG0A7GZ8W[/.(JY7[?CSB,^.M]IUD\:&*.!/ MMBM)!@F4!S4CR<:E=\*>6.]HY"87&84R1A+<[_AWY9Z8![(#"Y96RB,]VH_P MVV9.II&R*7HR36.T)'<_M&*4^M*VWE2K';9YU-N!3&#MQM4B534CGPX+"-]/ MC@%HZ3R&"E""(4"Q_;17P O:_BM@B^EE!?P*R/O+]WOV_%= =/GB499RN:^W M;=FAEW<&KTKC(9G_%]"& ZAYEKQR!!2>& 6M5T7ROMTM?[K\^0KX]3?9>I*F M6D[/OQIY!;P"$*]> 1<$Q=( ZV G_>!)EK]/B29? 7UJSS]L7P'"?_.._$Q(M3PKE7MD&_U7]V[4!J#!RWIY6(L]P]R@GP"*9Z4WN1"?I1XSF MVNND/6IF!T9B]6[.Q]P,QO/*?YYIYC[2M(2A%MZ%]"NTUH!'9S8M9T&QC/U/ M5)E!GCNN5UAJ>A!C[O/FA$[P71?]],EFNPK7FGS]EG2FGY.DP1[E5@CP7Q.B M4YC%DNVS#P'11VIAD8.^6WK24H<)A@G-_(87>G2;>?$U>05L= 6_T"2=C*H\ M[ :_ L(>_G(]]F\2\^'GOY2)6E*F?PL451Q'64H##;P@Y\JET4J#LH>:E$U2 MFX6DS&2*[H#18:H^$9LW'8+7CJQ;]@8[TLDHWW25O>OF!!YS OJC-M5? ?\T MO9K3=C"/29OD==C00@.XI9!!W0D;H,@HQ@&706?A)F('_& R?0-I52+3:I@E M70J; +*I:^ (=#N6G A3=D6&X/T;S-?_&RB867+]N*/)[ T.J,;$-1>5.4I# MS.^$V%0V=7B ZO^A0\9_8#US*!@BLZ.X[QGA6?O@4OM9]=/B7V13?9T9869\ MV YI*MG8RYE$^9DRUW\5@[VB /45\,\JB?_/JJ#!<"$:[FAO[>E:>]!@L)X, M9/!OG6-[^YN6;K,M,;-6 3#QWQ%6_$]$_>.TBK-_)DSLGXABD8G]=T412^'' MF^[*4WM),X3PB951:,$NYWE"]'/O>36VO9_6?+UHFF/ETGC%,MO#\7:K3!;] M=KJX&_*88.+V?!'D@C?EJ55L$* 62=9EG@O MA.*_LT&R_VQ(Y>U$_#_C9#,*2EJS5S;,W3,LY_4 #5#9E8_-5 SAJ!QPFO*DFV9\=WP^A?5EX6Z(7+ M:.W,O#H2KAO.QR:QQOCMTX4=(%KHZ?'.C\\G!%6R")S=X??F"%&F@NG6PK#M,UE,:X*L3&? A<$L%(\Z$P#;E -1?)&&]H]_C*#P.);$4KPRI.DQF*=JN MKJ= #&21G2N_%]MP1EVQA8!D UE5#X?.!;\Y3G$G-KI>(C-53GSX27&T8%. M\%%W6S-!DB:$0-,4[O=[FW_1UGB^C$9%\!L6<=+9F;"[N]7R?:JL@9*_=T?[-F0FZR9YJ)TSVQ8_MJ>;KD=BG4 M0?SWZ-3/B[.;R^26F9/0_!X@\\N@(="S9&V93I^^LP-J;" /:/ZF^.Z13N@[ M?8S$4'#N#Q)0(^!FY%]NYH /O\\H7U]9\[&ZA1K\!K*R[_A77C]*>'*_*P 1 MS.,F_4R'!G&G?96%_O+7DO M">%Q.9@ #M?U;E#'/?"T0VW=^E@>F<]VVJ^)/50XL5R#?]TJ*LS^:>9)IV34 MTQ(Q;7=\*4DK439;D=(H)W5".(:Z%854_/&N=6T1U0W/IA9#N\=1=@M!$#.[ M:,VF33E6>)&=%EHV4>[C.,:9+T*[""K*(;(BZ89/U%EB*L "WNN5F?RJ-ICD MS?8M_V6YF2"F\,.@VCM\K#VFA!W,0=:-+NJ:[.VBPG.H^2_R"QHL=)I84NT./;=\EQ]KN>*LH@"+(G);;T:8],]\ M]49+UVP-]S*9$)!F79F!NY4DK4132TA+43JE>)<3FT,6OZX#A^X5@-4AY"'6 MS".BO6 8>VCY2-'?QMJX6I,Z!%PE:*E@A2?H-LSCLE_^_5^_'>I_P_\"D+B' MT-:A'3#*+V$=SOZ\)HF@8WM^0?0])GB)L% M5E-LMDP5A-*\/G>;IF/DY.R%,*M<4 9^>,$5"@Q6:FAHGZHU:P,5=Z7;6\G+ MHV428AP&:70GM >1_3S/]?'T!$--5-^<[!D$1%MPQ&1ZHWQ:#FAX1X']W7R0 M? &QXHEUGH>"L>]<5]\FB").>^9S4[CB3+E7,U=-1)8O2@3'8L]Y5.AP]>!F M5_.^2DE<-M6Q4&T@S[!3?&-@I9PEJ%#W]F1W%O!XKW$G7X"9NH45Q\..<&^W M;P2& CU96/CO5E@A)PCAK/@(;Q@Q%GZ8#-2LWC>R8QW:[DFQ5Q"S_K4#/1)XZQN^L%?3C7KJY_XIWO$$'ZP5OH6\$<;37;)]=@-KO- MT=<14%Z5FG>=)W)N^3<@;:Y%TX5:R.0K/'YT=/@3T1^=QB#.Q1#.5JJ'OTUL M*L>_%<)M=9^P*<=&'=$%3C>50.S;&J4NS!LC>=_WA"/'K\R0[,XV1:H"4:_1^XS1N[\04GT MTDOXYZNVO>M^Y\ R;[1#ZFA\NBU^O3BT$F,6U$_W$^,F?9:^5;&:NGZ;J7GS M<7!R:9ZC5/1L?>-B9BU$,)=J"RO2\T1AK5=QEM(@#L09(E(S7=.EX9C,TH;X MN;P"F9_Z>J_&YH7G_.5GI4AB:H7O586782\-W4A2 XS1$HU)FY@>#6"?>+[0 MZV@NTW$>#]'1_I0%'*BDGXK5&:V=-B=6^6H1'[]/?))E @C@[#@O*RW/E3J& M(1R MN1#2'T[/$FILH&_,$U 21@4 J=7GLIH5QQ-N?.! ;JCB$Z5:N'8F/B(]B]!0ZB1=X43+#I39/'F**32* M/APF.U,O1Y0S="1VDB/V6^@]P[/#]8EEJN?.I+W0:@8+IHWZ-I!I)P1 ;#X_ MW(7E$N2ZK,KCPT&/@G$[6#:/CAY%#%3SWH-W$A5_443T5;]I?2#)Q [!JO.[ MF*^%W6_W0KRR&;0]XU_.+9S\?N>%O5 MN[D>[=V"G7U1HWLPI6=@P#+J$A#>?%GHOT/Y86J?H+8J0&"^0X4JUHFG/9M, M:%4?!H7-L>ZDZ,XXT#/%0NV'M NIVSL/CO54;2-A>* MEH*?&D?:BY%P0[O-AAQ;A3=F(2;8 0*6WAC-=QG6]('BA#0=%->" M- 4 6.QD.<>_D/G$]>4!6W_*@Y?;35J65I;D UW9,TU!!!^D<1$L33@*Z'\A M;"-0H@!6SE\!_11B?6X'GZ%+)S+%P>[6I,8ETW)K?>;PV5B@+7CB7P"/:_3^ MC8QS'#V,C%^NQA)]T<8)NE.=1\SA=(E(R**WZ^W"UC>=VKAS623RCE1(K;ZP MZX]LTB=/>D!+8HA!"EL<1=JL4J+'Z'"IXA0+44^NFZ\ ?",R1\*;O>SC2I]* M>O#WLXAA-)J'V/8,ZOCXC7ARTO5ZL7/OD!L3+)\XF:[.5K"/@S 0,X&YYUA1 M.06)%4X5U9R?$1G6^>;_$L_5U-_+LG:,[E_="*^_H:>"0?@-Z2* M& M!3WSG)?SA\RO%AZI+H,4_-7S\[8V3;Y8G!\4H U9UAGH@7QXS8'XIIC=JLCO M-I*B->Z7]GXT06E(U<%#$([UFE29H5U)I;=:-DNS3@ B8N&LJ,W]OLWM59G+ M.8_Z1C1_CWP_0Y)/TB4@] ]OXG85>*UM5E $)LDWEP-8YJTN/$];H+9!%.WM MW]N;?W1,E68\<\G[)%J%AN"D/>YC]D$$SK2>R,Y_]HL27Z1G5^B/EQWHLW)* M4;RDFE4H7ZP.)0O+N*'+P5L,*.1$4CAN28 MD9J"XSYKB+7+;H3V.7O/HPK608N;_>CMJO+$Y=8>+J1IV!E/.%$KA>@=04\7 M%S;YSGZGVGW,^8S.A7,,6[,1PRT4JE;<[VC)FOAKLRWQQ%IG4PXM8L!7^/I, M_.WF9/RY3]C>!68V1KRJ/2_, G?2Z^06)."86/B._S,^=CFJ^VB]/@QRGUMR M:,PU#0;B4/X!*IZ$UGL-X\HX7N1FI^*&+6>XM(6+GM"_!_=]M'N%L-D^05V8G]N!D=1OIMNSD>I/8;9'^01Q[ZL"9AE MJ0CN"7RG_1P!D &@APSF)"N[ 33[C,W"3]LZ\"9Z1'+S5]^R:%]<-QI,/PD ME=P:WS ,\"P7ZW-&ZR]#>VA^^_G+>@)_2;I&3;6;S"9.=-EYGQM7<<5-G0+[ MF_O3P)-^,/Z$AXGU^A==LOY'6I88E 2%"FK+BT3WT!Q5Y 8;OY?L+2&B M=B@;J^7C=DR-PBR>OW^'9R(GV6;F'_I8T/(-](,&;Y M@SUE-S-F4@%P:+)E 9( ?H5]8ME"N?EV[?H94M(-'0J3#A8:'5)AI\MG%U#G MG,I+ZC&F4R&PH7EV?!GE=A]U='?^&9S&JJPVRXNTF3;$3X+@@@6?D+$YT>!* M!SM.,&T[\@FC, ,2;HZW+&Y=?F0P8?=2('1\,5GK'D!2T=IPQIC<#,;DJ3T& M#?NZ>XN<#']))1UFC1BII,9%$A^&YY] ^LM(P?_3\%3=W7+::7/I&PH?D(<@ MV?O'4">;[D?%5[,K]ZDBQI97V<&"XCX[\]@/.9ST(EXQ!!8T\*.*R!\C,S2\ M C;AH6+[5WU4]VJ'5$]!U3YG/7>D3W[2_2G,L%-@6WV,FD*7+A-,E(L M"4O(A3N4/PHPHQ3GP,]V?<:V?,EK!NDL>Y*/(:8NFG]P5BBE#>NP?OU-[@8R M _VK[90"'=T]?=AHP7&&'9G8S,Q)W.!OF8DKN=WQ9K[P>>6:4ZPW,87IIXZ2 MO%&G<4H*6TLJ @_IC*KKT=QPN=OUQ%(;^5B#E2KX;IEUF^"DB>SA&'V9@0,Z MV#*.C+R0BG):1MV3>,?Y?GB-9X+!QTB8?_MU$PM# 4:-Q*AC;AT.&0XVW(HJ M^7<$S.;F;2##E<'YT<&MMKYR0:I"V-ZD-M;.)*';"(F;>5!\??-W3=<5WSX3 M)$^4 &#I02H:A>3(I&K7#T&,\>NB>?YR;=TYALNE..D4*>(!?5EARV10BS9X=A2'XXQ?IK1^R)0=%0BP_/7FJ#[U.WK+?", MXVG/F,_R?T3"[A_^XEKD.?FST>A5QHJ!;U!) M(O//)^;[=ZZTIHB.K>3- "^8 M24*J^KEH>7U@W&@K]&6.8BX_MY5U?C>\(+ C3"=R>2H166&SKDNL%[DWEZ6O MX=ZWI/UGA[^MQUF+^9 6&>0ASX36_J,K.+B&_&+2J-B'[4KYWK?V $_)R1-H M5N]$SS1FEF@0-FCSF4O+&R['8B,',VU?APK.\P?WXS?S6>Y+$YFFYC &T%/K MZ90!ZV7@V&;ZG+B(LN^;$)&//G=R$,A<'8_0-[,HI=F!K* )ABS9M!9'I3S5 MSSNM#QH^@T)M6RJ(/@/L)+!#".]MV1H+AK(] FM?YD>S(#?42DGOP)FA?C>( M&"9/SJ&.UP(AT/L5\%;?_E9-GJ7&C::H,%$&52&%[Q(>X'53*X9RSVX$_3R[ M,^O9\CWKT:!U%@9D&4T1P#7ZEC VE;YM2\6VUAD( -J\<,T+BS?8Z;-'X1Z) M9QT4)/X^A&,S(HCE[B$4;^>#3UIS8OX H0,:MMV';V8#U>W1:B6VLPA!%"_# MG%\Z7#,I$ IY/U2%*42RH9DYR?Q7;0EBW[N,L+Z/S-V!"BL/">X8,9OV,?!EN>N2=7]L^H70*F.0+)G,=X/43X M\17P;I#X8*@4^D)LK.L#-1A-:EP]^+GL;H\]RE;H9-W.&-G=82$P7)X=?V>8!5[)-YS+PZHXAYV*2CLO M]C(*%Y<@L1_;M*YOR_;LZ1/J\I:(R);&WH5(,Y)-$!U "R]> 9%U'5JER[9' MI3:PSE!0UN&,1HHNV6ER$OIT-?&JO, #IA1.VMF8C0E6@,XFRK5_)^FCTAP/ MBQ'\(XWSR?O21/Y%.8N$J:H&3_5^WMPO5?4LB_"5D/N(HFP1A20ZG"%Y:+AA\W[/N-WIQ/-N9U/*38=RU@X:1M]M)1=*.J_D049$ M-)N$T?V#K_"L]E]-:=9EU5XB7A'UZGF$PGR.>KUA M&U"'FX]9OX<^:\NM]%PB8)KKM3PX;,I]#HV#6X[=,SMWCKD66J75FK* UC63 M!6/*%JW(!@I7XK9ACW*E21HZK::]>TO\$*$Y+4IT*.@=I[16<*LS;ZZ;H6L0 MV=FAK499-N?51*S_46^A7(,H2J=.LK@AX3BGL5?4@*8LNT1;O_%Z]W*XIP"5X %.$\-UE*,!S?$R,I MNM^LG\CX9>GCIY8Q0@%2Q%;+E7=7M]%WH.FWZ#[;.1HE%S^CBA8&$A@*XWKY MFR=3&;\RLK1*6BWOQJ#\CH!0\N_HT(OUUEHICG9RLK'*1/ANT2]8_. :OBT5 M^A*)0[G:T19"%8RJ,J*$]R0X;]'1/H.[U6>CDT=CY*68RIIOI]$J9X9SLCQ: M 7=W7O)4,H7XS+)U&RH:ZEAQ% ^SR,!P"XC>3M\?C25Y2F5I9!S*7+[B15+F M%?LX,W^GEIM.0D$;+X4W=ME.SEQ$S;ISTQ/>S5C T!&YO3'Q\SF\ M_)?='WV[ECC?VT#UM9>]^:WAW59; M"T',A+0#LA36ZX]VG%#RM!6*#6OHMB MQ@'\N%B>LG;(^#-RR[HE3OT+"RM(($&WJD6"UE8C'ENBX.WR%F.D]J!*.]&5 M7-;7E%X[D)[RI3R=WEJ>?J%+K^V#'')L:76 QOE$_N;BC:)0;P59KJBCY 2Q MV=>'A@$!-DFJ]][8[3D S$"4.O]>*G3/7)(G9B<+Z+2'H_;+I_47 MW5\24]\W-@#\#$T>KX O+TQ083&"YMSY5%=OT5#O(J.'F9&&/KH\>?,4+EKZ M[W34E6A3IEF ZR,L['[/C6QG7$/QJ7ZV',@9*L5QK#DN 7)"'Z:0U8\SM"=Y M(_.>)I\,@Z8FZ+7>MS11)W&FP_0Y M1US**S6.."J<\N3Q%1OA*YKS>0+G-\>$*?\H%QYDG)1+DZ/=) MUGS3O;^KXT70=C^&)YXMD&Q%PGKB_LSB8ZR\GSD24_=13L.&-Z#!\4*Q-UPV M[$Z]*Y$W^P2K<8(E+ADD]2YAQ^%C333*;J9D> XNDKWZ_J Q6?,\[0S]'/:* MW#NAXH0UNBOW7>0TS2*B7S"24"?.G-C- +[S_?X\S#P*6=D,F?99C+2YKZ!5 M%2XIRL?RO/=PFO0-'9&?V%Q[O:L%ZWN>954OTHLKE/_:#/V.= VC&&=GX#QC MJ)8!X737L,1B?/N*@]@:?#+FB!BYCY\)'L4;H4M/N \&)X_">7IIJG+3,5X/ MECW)"I%#UU6D^WTL6!CW;48LNDG'MQPVXU7CP3_R3?%8#82;U576)R2>A.;Q M_QJ,.)/8J#X_AQ9](S!D7.2XA<^]\&TM6Q72WSO((K ]XB]K30:;BFG_!J7)Y(?%OBW.P$>45M\$?UINS-V M7,Q+AM+VW$K6'-GC&93J-=)\71O=E5K4B;* .0JB+:_4BM]M9=5!M6;VEC6B MJ9@$NRD'OU2S/[_]Z4_X"M#&!X7_=HVI#N"=/PU0JSQ*U^%ED*JT]8N(QQVE MJK^J+O+B09)>/CO&T$4_W+V0K M@$:JL8R1P$2JKSBHFWB]T%%O'MTY6Z)7F>EVD;\U-%AB)(K3O9'QWPAD>J/P M7WW"]_^&_S6 A:H?HXXM=K#GB,SDS) U&H5EQ:(Q)/#A>E" /*VK: <;5G_6K&:; ,_;5//'=>7QY ^J=G4 MU16+MG*N;'3XA7ZA83(F.^">OKF[?89E&P'><0O58%5<8I5@OT6,;SZNIO?UWOGM9LX':K&G8V3G)#<33W4 M2&Q?:9TQ<;T2J=F3@;?C25M!S57]%D"/:B.N74\#?G;'O0YS5K41DEAA9]2A MI"^GV7+4Q1!^P(T"RSCW*R"NZ9#4W5AV,ZX_\;?$<_IITR!%KQ*7-.DP:S(S M+14GV9V5&E@ X82L&6Q"N*Y_;]VO/QAKOO2J$3[C1&E_]$:C#S1T&MM#T,(L?O2C6O#D&8XNK-/O=R6MC2( M@ S3J(-\\>T./4T867;FN+GEH:0X,.M M3!O[EA[!)NIO*8A4YDX_SVK;S_CS%EIBY:)^?(, ,F=@,+WJZRZ#1W@%^%7 M[+MHV^:)>J!'?/,ZSE7R)&UYL*6Z[1;"+CLG6.0;O5[3JOQDT\VF$"RUHH[' MWA?F"^08CU&66I%CZ*8',9N3]D<&I-;'E/]].O,*JT=W .T@RD1!?+ '9)?JP.H RZK((]Q/",#ZF67>STQ5M^ M3N]H^OL;Y(-9?Q7JZ=@32+5C01 \*>3V0@0%649-[S-J[29+T )Y)U5 -]&U M[!O^ [:T"86@$6YGU&&RA*@S:F2TYF^<+%[K6VDK\[=N?%'3!KIA+ DDTK=! M4RF?0$G\#\$_:,<3HBFM$;_+$U-3QDG[[N3Q+0 #?"V+UVW#UK;^#'_T KJ4 M(7Q58K+%Z);T KONRJSV)?-6KNA8]XMRMDTYYRTH0W74_!U%C13.QMHN><6_ MH#..+*\\+6J SJ^#Q5@5L7N=8AL9>=C#U_G&$\+) M0Q$B.;<5_SOPFG^PHX@T,:+K#A5.;Y]TA% -*V M*W&MY7V&+V$FXD3QYH]:RKWC@_F+D?:/O2 0F@L3+HP')%LR\C2!P4E:( MR)O8\07VTID.EHKU[^]YFK\VX:#%1VH"+YO>4\@B5%(6-[NVY./5(8X%VT]W MSQ!>>#PX!RVU.7,OQ>6NJ<:_-R3')7;SP8?[_54GVZY+^ *C);OPT)M4T+;E MSEN12>X4ZNH)KV_YAQ\A#R%Q%DR>3Y_&!;]TG^34F0.><[ M8L@("@!361 =-&(0H-4V=]WJM" YZ_'HGWFL/[^KKJ5'D[7'?]LT[H3GM037 M9R4N\;=T.G^'S< ZJ8Y<\,>FVI@S$WJ'.7$0[CN,D2--P+M1>]2L\01O[?R="ELJ41]Z]H> M@B5=U-';)X9W8^ 3(&MK6%C?OEAHRKJ M;3O-;#!.+X3X0_^ K8%/K/0>3W.4@H4E',(T MQZR*8%\*+C=$*NP S?F9GK;2 M_L@D9W/6K*!"T6P/YP H1DTU?OSOS]UBHKLDIHMP+3L;\/-,=<&&%TB%9?(E MBWJVR4:'L$R7[YU+L2BW,D;#&:-6M 54#/*TU.C;^>?>L^3LK*D\)\G5--,R+8GH+R M3L%_]&/8%E^*)5]ZP\"Q,>UNR[ !$Q^ZF.%E&RRISS?>*UG*C(Z(YI3?N<^; M)5N;;]B!:"\!4OUROH^6IA'V%N$?1:V_RJ.AGGBYK/=C)B 7]T@Z[W8$]CY@ MO\WD>>O&RM%*M]) M:N#IA2"Z9F[(!9K9*\#Z6-0QLKTE4UX#_/)"-?.4('PH:-DY/CI69KB"4F+3 M)XVRO#M29>(BE 1/Q>-\SSAP==^X=;MVIT"J-5XD<^9PAS!.^93;V/<[,1Z M3,W%>Y:VC R@\/S_: L(R9_Y'V:;)\+&=BERR>!*U =5^0_M[8Y:;TF;<.7A M0PU/TTI]S#4O5!<82>;6]N2)1)K@+&=F=[02>:ZF[RXCW1$(3^7>Y3SC][W=&43>Z4L]R#_8VUGP-DV87)MC(\.3,(K>$A+A;8V>7%*RT]199 M:Y*;0ENSW98Y+PM6-+4OQ$([U*J/LDYVZZ.V(PVJ'16F%.&:$YR*4W@)CTV\ MLX[E5-?,F2N9"%S0 %@Z\P$\Q3Y93!/UMK>EV,.X01%=JZ'..L'1X)V?)Q&1DB@5X OJP0!63TQ3D%W-S5Y>&J>_192WDQ+%&+. M*&9EQ5ONE*K><7O;9-_CXJ[QZ(??'/Z@')\GK!K8T\?6VMI!4K!VM+Y,I,V@V'A$&RZ<]RFQLL%H M/7W9WEHW \C+U/F*5PO? JG%G=<[1YH0XM*O$T7\W\*RC<37C)9\/@?] M/@QBN)=\-&J%*N5&3!26Z1L8?O1XI&J(U#.P_GK?ID$,8*G;)5MP6?YE)DZ! M'HS9 <3G4V/+&A"J>&I,\OR HBKVC9#\YZFX"S'*[485Z$Z&$#K3*XAF>&^' MP@"JCX*QU>[HG8[UF.\2@;*])%@B65T$&.$96DON?6O*ZAE*TD/L1FNZ+^R2 M!.4Y(*1^O;2^^2S8%AB@9D7/Y7CMH+0-"JMU-6A)RWD#='[:HZ\CN%FR9T_7 M26J<'[;3HI,['N5TE,P%=^!%B71^F^4(FQ^1HF\>695FO7-7H@9]MLE@.]6M M*OZ.*J_6NF%5^PKHX2P)[A%X#K\5NT^_C1H+J%SOX @X12?;0\>4 (1QL R6 MGP/7(P-H[5T]S:S+E]DR'+*@H][H;_T.?/&XN>1TWP,IK]$'G<\&:H(7HW+'^#+!U/CL8JF@@,,OSEKY9DQ!4#<-2J2+=)F^MO1S&K MK^('QQ9E?C=*-F$3F^*!]&!8O0GZ$QALIT>R"3R*[SVD]9X6QY+[T3GIA[0Q MNA]TL47/J?HXQ2FKRW[K.X'0+VQ;8ASQ'_F*\"!O2?L*T)\*:)@ IJYY):E# MH[;G?^Z&SZ]'Z5QM"5.6&?3W4++6@$6ZGQ[0!-F(_ A=TX2BD)J"2'P^Z)R? M=O),U#L'9"#!Y.J=Z=/'I((YO^(PUW#&6 RA+^^9'G7$4XQ]S&,[G^_<&M<_ M75M6S/Z$819L27^]4 D$7RB2L4KRWQ'*LJGE=H W2;SY?U%38(?W!./4D,"( M.F)12II]=N5KC;DS\;\S+1,C*97@"IJ&&X!L8 $ZI/%'#J4W7&57OJQ-9@CF MS&Z+=Q#R3/NKK.DE:LS=&&M)9W8?LSJ@&W%,=(%:7S1*W.AW$&,![\X22 MT!1D$_'_UMMY_K/]?WW\$S6J=NV:E=A*;4HIM6+3VK-&"6+5+&W5WD6(47O3 M2FLEL;5&C:^H42NA-BT)L3IT7+Z_>]?C<=V]?G_ N76>KW/C_3CG^>9=QL2H MJ_DT1X9A;D!L9!VK9WPXKX[Q"UIKKL@CER[=7"S!/MQ F%ST,6$M=IOK9(XV MD,UUV=CXNL!T]1O32N+,.8!,?9B MZD83_\!D^M1:5YKV2EFGHO45++^>9<@/\>CFEAI@A@[26_@Y&C;CY MVN@>;ZHH#7(Q&GEM+6E@=Q0_6MSA[79A^"7)N:0-2[?>7B86\I,>VJZ',UHJ MRB3'>-)W*1'!DJE( 2#"GZOFQ;Z-35P!X M/A028D[M\1@B,F#>W%WDVV6TWY **TG5<[<=HY9R**G> 2-%7@VL+E,#E9( MQ?ZH/I]TE%C"[PB*/O8F+ MB(?/W@FG%?%ZC@NW=\\ M>JU\Y0-+?-$=L( @(5#\;;3284_[1<07""#!F,@Z,R^TL\. MCL/4L<].732I;N" WO:'P,,9PQ^,+[B5Y9KI$3WOBY&JO_X6Z[6,JF] M'/9[Y+9KH8.W'%G3LD/V> \48M=-CH&]6R@ZCX204)JLGE>]E3'BT*I%H] Z MPCCCCS;BYX?!FWZ$ETS ZE;$CF(&_/#@_=G+^%N^\,^L0CVSN+?)-5Z$/_)%CK:&OP:"C? M*DS:,TQ>GSF!MU46$F^NBGM<7.H;G IL]ZTY1[C_@WE0VY(66"ZT;'CU3@LW MLT$%>HQ]X2TC#R79TFS5C(&PD*9ZLGRV1_4):Z9A=AHNS1]4LOBCX%)I%5JR MHC)&+M2,_LOCB;PF= 4O20JW%YE#LMU))XH9%-I""91K5'77K/#;0>-W ,SK(T5AG2&'VM=N) M1V[9588(-AT9M.(QV'JI')0.BM7J48X[X2:]\?>&60:CT,JD/##3[V+@QO68,H MB."M(=O60[WG;GL0CF"%,4\1&*H&J2_7^"H_W UG6)G>K'(%& JX(&CREV0? M/=U+:+YIJ)+;YS'=K@+] H!%7O ):@S@*6!]'FNPW@1[RC@5 N,WN4677!+O MP_W&*SB%6QCLA L;IM7LJ1;! #*,;&9/LV0=VP]=TZK7_)1PJ=&SB%>-V!#>7*S2_790,'_V6A.I>N* MRB^Y@1(J;-H\JK4ER*:<)2XM[ :.!48Q1TWQ+7?/LVK1DZ&*'13>G]YYCW+S M)%EDCTSZ ,C4\3ZR1ES-XD!XP]YC>$G;OK4X2GHC P*NMX90Z*E9C9=HX\;- MHL['L3?V-\QD2<*Y4CY]*U*FP+=R.C9K"[)-TG");SU?N#&'34ZD];RFWXOQ MDB.]6;^U3"TNWD,?%R)1X#S@G.?<^L/Y/?^#M[]KU'^YJQX==W'MU!D"'RLK M4[^N1-8F+\3=7R=SI&FTB[R@;GX@4L$BK[KW:9GS_)CV-MM7S=_M:!Y8?0;JZ5)]ZY@O/[-9?CF4- MB2+7T"I?Z_@NG]0K3+@;SS5MENG-PA4ONV<-'MGC6AI5@#QAZ#L@\]:1&,46 M>S9G6K2J1DM(_1$ [_N6 MV@:44A6/"EBA;F8&C_/3?DP1KBRPJ'+ MJSMG2EK(MR#;(X=YM5/R*GOJ*9#GQ_]=(T\18+.PXK2:P5O#Q0.(F979D<2' M(BZJ[CCE7%S8YO-B]R( H^ME'Y&F,ZL(.^EB<'N_9XXF>+4E?N&W163^K22_-8,3E7*&6Y*:4#)UQIL/ MD"*.)O>&:AVI#*]@!*5HN3!TZ.;W?.UK!V?7Y]K(KT+.09UFFB327\"FY'/X M]I>9(F"FLK*]"],38^:E;L/"X7E59RTW3]C6(YR2^J+TMFAF4:#)YLR"_=:-HE9 MJCG=AL)(=[8YYZ:"BE@;(SF9GMH%\_M>Y0>HT:>4/3O(53S(*7FM. M-J%+@K*=7$^BC$I%_E<>EU7+^.TF0LOQHWS%1?$G\(+@.)+N.^)?^!6&6>(JCVEHGLK]A\:5_!X MZ9\+[R;KO0E5:BC7?P M5SFK8D:V^6J+._SL0:'K\KU#)'734(NJUTOJ+.J;*0Q;_6C?\AZF7"&FG:"! M@!\QPRMU BDU28/V\-**AE&1U-+[W?GN3JR=1DJZ-G6?D0;:%00_J0**7+[QV>K MMALRCAU&)MX::"]LOHY-CFJM5:DH)L6?[WTQ])UJ&.Z]W)5BQ-[COJ00,V:I MN\Y3^XJRC,;:9Y]$CH[3B01&^>'3+BPN-9RW$?)]G_UPG\!DY!$N.%M>:N94X?(]1<&V#1.C(:6N5#V M)8BGN_CV3?P[J8$@5.S\:#=9!%&U @M'!WWAE"4H#!A@)9]$7)?P.(Y_:C^L MG.6(WGF0R?;03*\R1N4O0+D;=Y?,F;8>BW/PA;:+>3ZOIH_^M72WYQM&VNB ML A![Q=O=Q3L>USKON6<[=XXZBO\>YP 6T+ECD@9)UI^XY@?8;^?LZ]_ '&# M '[O+GVJ+V>B:C-C68IP>!]F[URV+BE^LD='\ZCE>PJ765IRNNMKW[?B([D: MFY[WC5WGTN>M6F?;D_],1@86Q4Y<:\IUE8\75T^U,Z0@I3+2E>53 M^35%.X66/\'<1PS&>ONUQ6,S5?W!B =_@1?3R=7^^9=R0$&_5-PGVR_ #%]+ M?G-R $24FJB9S$I[1N$[_."G*M5V*.;Z1:R!%1Y\/BCOOGT]15%@( #SY><$ MJ6 .TP)[:MF.;HAR#Z*<5V-GT_/5WD MJ(ED*,WC3*F;M9S]@L/(18;KV8X4C,:D:QGDL'IW--YW:;><26SZY(F1/9DJ 5GQ M%Z"E/1Q 5[L9=:45%!D\\MUJ>N<&$>S +K44YVY01;RZ%KU4FD96-B\EF?C M)51(D()1]K%WL*MB$A0EA\:7Z=X.M%@<4S,@/]3-"*>JKD5X97BDZDKL[N6Y M1@C&S9K3B).O;.]Z<\ >!#R36'9JA-Y.Z5CV>\D7GXX<--S#BBV][GX[#C & ML?ZY*O)=JQQ5KO@\#(&O;=J,K/PV8ASLPO MJ/]\*RQH[Q"/?SFAM\234*34Z=EKQZ%L/;R=(SA^''S7X]LKY;->R5+:6FPW MF:K(Q4XW2BQ1LG"HJP>OF=TB"J5>^-7V@(41F 2KGDF(71KRVR1'(T>6XODA M<:9'"N2PE!N#B&3=B8]9P^^L+8>B8Q+P,IUGEYTGZ7M%[7M5. MD]7U1:%Y!,<.]%4QU1PSR8!1$=NX8XK'49YLH*'O?P&BB\^T^@'QS;[CY-GD MOJ8FD3\@_[SXAT#WXK>?T5UH__7Z7XI3IU$W7*QZR1";M 8G.]A? )8#4!S$):^/Q(=AWG^,<@Y01>(%"E:*LV/]*5)"'FB]]MOHS.BC1AE<.1@',1; M+:7\W(I++3<]9AIIO=P'RGC0A&P52#CMX32:/J5[R7TRFSEWM&'8D0B?*OC5 MY2+^PRI=(5Y9;8"*WHZK+/QB5B_S#'0F8%*DVY6T)\C,U722-?^ZI:.LTQXJ8XGGDKS3T5%6SW135L@9_/5Z+]]'[*MJ!Z7EP1:DL& 7">N6GW"PF M$@*U@;TR;7(?/E2&8:@6QJ%',K'W>#X-)^L(GA^EV(*Y!O2:!"0_]0]'H/Z] MW^YCWOT#1L["Y'>502>[BI?7SJ]"@VA3O3!("%2]?;F-,YVA_,]>W[WE[T>3 MUCWS;6MUT,::MEO.5?)/8F'NUE@7P7[>83W3<.*]^6TNL%!7T052#[KGFD+A M$K=]GK'H-CKYA!T.HV;2H/"G(UP5DZ2T VLIS;E-@=4)S[J$TY0GV@YQ[T*K[&\.IWY4!C7A+4MU-3 3+>BARB(?)Q*^H%L[/C:, 5=1N.8P=] 5*F1U;5N)]> M>$"FL1&6XLTWK8H:?,28$T,EMH_,NFPD4HSY*D4B_F/YLIIU'PDMTQ0MQ/:_ MXB#P4U-%9;"!MFZARC9X].9"2JZ86%5.-Z&DV_8:I"%Y*'L/"UZ'Y5:PG@F. MO6"#N10[Q'/Y=.3/Z-GY9S;'7;KH;3UTA_PX?X; MCW^E@XG9XUZ'>W=F_(FH)E13R'B05#C' ;?V_8PZ,$_B3!X-.'T#?-OI_^_3 M.IJ_B_\#4$L#!!0 ( ,Z%&5-_8@O:Y!< &4F 0 1 =&5C:"TR,#(Q M,#8S,"YX<_9I M"B(A"7-(@@.2MG5^_70#)$5*($5)4$Q%?$EDLH'N1G]H-!H7?O[KL^]9CU1$ MC =GO9/7QSV+!@YW63 YZST,[?YP<'75LZ*8!"[Q>$#/>@'O_?77__R/S_]E MVU]I0 6)J6N-9M;]- E<*BZX3ZW?S^^N+=LZ?O/I[GUT]O7G,Q.3H]/CXY M^OW;]5#2]E)BAR=!+&9Y@>>1\%Y'U'D]X8]'ZA30JR2^+H ;P^@A?8YEC^_C$GI>DS\Y4SP/?E)AX+/A#7S^T MT)LC?#TB$E E%G!..2322_.'AD;+MB?VF2+K0 M*,4"ZI6N6!R*"EG@34F8F!8:#UMDQ+B-#P/ZVN&^I#U^_^8XHT\B>T)(N"Q/ M^D(C#;RIT"%[HRF$4KMQ68G43N^.U,LB*:NQ*@NPWSFY59^74)#VDI./'S\> MR;<]B\2Q8*,DIE^X\"_HF"0>2),$_TJ(Q\:,NM##/>K3("X1%%['1$QH_)WX M- J)0QLU,C@$RY*]FODA%[$5+!6OZ:3*$UQSA\32#V&)J*Y(]H>-?[P&MKVC M=24H]H-&_.<%U,_U>-=95\=>6P3_LK-R-CZR3TX!>XVEJ 5];2MH2QY1+XZR M)_:\KO7E6?0BS63)2BDYT+%L($.%_MF&<>_AF M?%-R_+$!UR4WV!#X60%$_+O-%"T,J(TTS>GEK_5TK1\EMNAELK*M(;X0[33S MO<4R^5];>$!M5%0ERJJ2\N]H(Z>SL8&67<_&UEF$^\HDG M1*D4=I6/.#B?B'"0 M3WT4@TA3D:RQ* \"DH]H0CU MKN?B9671"F>]"!K;HZG6/UP=AWCKJ@-%G,235FFI4BX=KZL4%&$!:[%.H:#K MZ@1%(HB=-[(45G /!!:#N2X$<;$,PVV7.XG\ 7-L&_YG\ZE&RMJSG;ST<+ MO);$2"+JW@2_RM\+?2,MG%+4%2SCKWFY11OK2Z9/,Z,VL[7#@XA[S)4^.G\< MV7QL4R("%DPB:2JP*4@QI4'$'BE8#/ZF6P%A*\:F4'("T!AFO.'WH"#4_$5D M\;%UF0IE@5! 5Q *@(1"=1B2IAP13TX&HRFE<60.(@OUFD+ :1T"SA5/:RAY M=@;6&,(."83>\93&##3>F;T7V9@R_YOFYK=>W99D^)\.#QK?'4VAD:;<#HFF]MCC3P:]1"4'4T!X MUQP( ^!N?4'NAVM^F,E3^\1V:>0(%B(#M,LHB5A (Q7018GO$S&3/9A- C8& M;XKS 4>FT"'$LD-H8 >F3%O!Q*PDIN#T'N;- M8_)L)/>X4*$IDU>D$#&&3!W]/?([='.>VA&=R+^-)H(JZC5E7'TN4,:10\6V M2^3,;8%9N5$$\1H^PERIBI7].O2@7;O^ L/JR#,Q4-?6;LCXI_I<7\4BC_7J7G(_=+MO MMNIB#!C;L3>%''UR<-.UGPY:ND4;8Y#15VL*"OITXN*24&?B%0LXQJR]DH,I MP^MS@C4K11T&RAE]8R9?K-"4A?5)OOE*06=0@[EZ8V@P*HTI*.ES@L86$#HD M5N?\C0&KKG)3.-$G$O7K"IW1-\[UFX+$YJQ- :8B.;G)8D.')^TB@3FPZ.LU MA82*-.;B&D1GY;I% W/&KJW>E,WU^Q&KEB8ZTYL]@0#5Q(1YT)/I50W:#TPG!<(98I9.JSV%L@\S:56Q)=9G)W(-W6.<4DF#"8ZMLD MBO"FEI?&9[5$IJ"I3YQOY30SD:V^%+E#Y788<*9X. Z"-0X$0LSDR3T?$P X M9PAHW$+<;B.S*63K,_Q;('N@E+)B#B1**:LOE<(ITG<:=]@WC7T:QA O1U:2H5J MDU8O!N@U1#0$YK?Z5:,MP%PJ5I]T.W0@+^Q^-IZZ75&_*0CIEXR6MUEWJ=8Z MZP [C_DLP%5D]!!XAXI7W# -0UH:NN%KCY$1\QA>E8Z/$Q^"0&/N:W>BF<)< MPZW]F,;*99=N"Z^$\8K;P&&$38-&?'T]EQT?H^R=NUJY?=^XYVK.RA2@-C@R MT/FSAC:K\ TIC6OCEDQ3,(,SJUW)) /!.S>V$@\9"&9S")"X-,[I (&[J2:E75])P$<1%8^XHP^"]S Q MF2IZ6?%-H5Z_7%6/^@SJLSG025P:RG6P?T#]2GO;'@KZP;P$]>LZQWI7^9D? M\3=E; J0^D6JQG<*=M% U<$_XTBIK-D4%/2K.L6SA9VM]18IY[D<#P(LZ73- M)M?68V<*%?KUC0(J[(4DV: D3S?"+%I/YC=#P@SF+6KJ-@4#??*_! .9]+P% MYIW-%^U2SAG!>*I>%$+7T0SL-E-;I*".'6!CB=/N=>PE Y005"JE>% M&'@T XQ)(:T+$++#FM$SYL:CEMV(90J1^A2^P3/P7<2T S04UK_7*89[H]#S MD6=SWK5M"IGJ&/IU!G,=H[3XOU;1O\CM8# XW)/GSOG7W0-AW)/"^%1#-RA(W+FHS>\E,7^6?7L93 '/X(WLG??;WLQROT:H?$SFCT8>B5,H][#FJ9 ^53M:- MNH3B5BEE?4.E.@>[.8BBF$/K*J3 S"-FCSA[>4E8UTMD"K;B9@>==.@K4-9V71X!5+@,(_E MUQZ-J4L%\62*.%-?;8_#JI*8BYDMC"XW[D F4TC4+_;HD'A7$AK1^$4)+9/. M@UQHW(LR.@S?9XH ?:Z(6EB1BE@7J2)I"1!D4%"D MO*FG\[G-_5L2I%?1_:E DLT5=@C:380PA4C].DTSK_I0D%*ZUG06TL%MQ9V] MYB<4S?B8 HU^V:7ZDN!N>M'$6NG6<8BMBD\%1=5AY(HY_(8Q05[XG%5@TBOM M0BI3B*M8;ZE"G)WM=X>8K_C\+A4;;ZJYR\7.JC@,O_7YZ#ER/Y$P1'O*9^F3 M &! U)4".N_M&_[0\NGQTO<:%5OPH*B!*# M*;3]-^J/J.A9 ?'I66\U&?,\-$7& +_-&3.(S$&&PL;?T6?7.X3%ES!.U2T9RG:D K&W7M%FPBI6^]H'>WFAW)OQGU 'IG0 M (;%!>564;VD;CI=9"^@;N$,GD85+=$FFJ@G/@^@:XG9HAYIP'W6S*?4.%7;I:'U]*Z%Z_HU_I4$9F O/6MG%SA/F MH5/(_K_R,;FE3B?U U=N'YYRSRT^7]!RFQI:T36SF^UA=C<"GXCT>?J,>(7Q MZPK'"N+-;[F7(7KHT9CVW7\F48SUEI&^H[K;UB]VU);9)%M-A>1,Z#N-=].V ME;S:ZW0U#7"7SPBO7*!E8T9R?YKY6>R5\V$EO:]"D8#R:9"07A]5T]8[8/42 ML&8!!.)!_,,:.K\4%][*Q<-K'DP@'O-7.HX=LCR$AB\\R6-A3:>_ARA\)[!? MD_^+N)T-;3*,:5B(7=6^=@CG**[B7P5IL]!S"BZ9WM'"_0/W',\LR2-+-6UN MJO[6N?+*N&PP^/VJ'&>5GK0REI1G$OZ<\N32!P-"JYPS+K,?W..3V8(VS6A; MJB?U^0!(Q.P9.J[&5#4$[=2(!^"BY*?$%C31O&BK!AC8 0V*S'"Y$>M8TJ:6 MJ!6SD0HAY?>T9NI?S..>>]SY8X5B566VTS/.:C)O1.E#^Q-PY4BX8+R*EZTP M6C:.PPBN(@$Y[=5D>)H0MC48NP#Z1VB+1_J=QW*.I:Z;O: P^($65\&MK'&N M:V/ZU@W,#91V*5Y_A$FZU0J7:-L6V57VQPM&)@$'X1S,Y'RE ??A9[E;KJ!I MY6!QP9TDG0Y=@N/$4#+/%>1ZU=-L;D/< QI,C.MT^>VRGT\K'OZW;*2JEZWP MG9?C,<4ML#2?!.%6H/)R=\4 -\_>Y)H:JFR[EH$V<*">'](T7Z^N[Z\ I5\N MKJYN%=]U&D-??'_45P<'+I^!)8OFX^QF15]4[>JN[8<>GU$J-XW?)L*9PN") M.\U/CT_>+G3T1J2M=,K9I!Z;$.R6"GV\H-\*HG9J]LPCP&!AI%Q:PZPG:86; MSO,H%B2#PZQ&L42P'O^L5:N[:A4>6>5TV]R R5J&F%!D7; MWQ*%NS9_8_&T>$>FNB*S[''S6S;E)9OYK41? 9\WP67D"/XTI'&<\EMJO%US M:W][_P:]A#Z$Q35S]27(V5)CU9*V5U/-HV^2M'/'#K3T2X0V")'F[X1,+R>%='T,HQ_.OYK>!C M%N-90! 8 N8A><2+*S $*>O6C+058SJZ0KP6J.@.R[ZWEJ*]69ML33GS?1<) MFD*EF\ @660\WQ&@QF6U.R77?.XP5/0&%\@X[P= MFI/ON\;%KX"LJ?U"T7UO"3R71?LA;M&%&DO=8JL:VM8NE0[_*H 7B6:_F^Y% M*YQY'M]A2!1-J8O^"_E/>8W2/XB^M"V]:^(47B&N5QWNR\=N A?68YLHW*=QFY>4_WWG\_]!9N>_C MQAD(18.$>'<4KQ2]\D,8S.I:H'$-;5NE7+]=!"4W8YB+ >7<&6Q<>CM8$*BN M#A&-%&GP\<9J<@TZ-_]]F9 MW$SKAM2M6Y!'R2.=Z%%1MTJ*/=*GGQ99K5>!\J7TF^N3H >X&7\C_^1BD$0Q M3&K%W#95;S>7FP4QG5!AW##SL8Q'D?P2^%CYNX6):P.Z5J9>;ZF0P1KXHOG" MK^ 30?P%#1M1ML+A@U0.I6[T17#_FHPX%($IV!"FE\RAT1UE_B@1$77/9]]@ MO'0@>LAUW*3DW@P.H)V;.#@]R31:L'#U^W9B5X O9,'08?("F25EM"];J7MU/4DKM<(K&6_&OW'AN65=="]:X3GD993G>!=E\2K* MPD<%SV=SDO13/WWT\A _8AJ$NA -CRG(+2ANB9LW.I =Y1V.F]DKW MI'S&MQ'E[@?5)EG7*E'5"-A/XBD7>!I\E6H:^EV.G=NK=A5%25.ULWJ25OC$OX/7 M5AN4U6T%:LD9Y@T^M*3:.N,P^/F-/#,_\3$W=_DX.;^;V*+_UA(V6:%LG3ND4%DVVSW7=/S-MJ2WE^:ENM^'22 M>6.L8OA3M[:\974GS9K7O$?MM_7'158UX_8,]KMWM0AK"B] M/^UP"A9]I$%"[=3/2T5<%I')1-!)/@YD5$T!MGF]^]YV#2&THO#^M,(;.TK" M4!4'QU'RR'(^@;M9[;''GTI]Q<&+(<&C,_B)*Y+H7XB\10MA,4F/9#;&VX^2 MXF#L KY>TR(!18^7';_'--4ZH_^+B/336XR"/KZ,AL8)[LK!MLF_NF!3M7,\ MG87^8,N9$>VGM^ /M\N!M[8Z"I(=VV M"7YZ>S2<"FQ;^_ZTXUN;%*[/@!Y+/>:S /,_J">F'SQ[3)BP M'W$7 X9WZ?B$K[WY26:U0 IQ15,\[Y+SWK9_0WQ6E=H?O=\535OX:D149>24 MQL6$(\$9NKI@#OIFQ)I'#3MC^S.T?*;W;*XUB4M=4-<&B0[-UPTYAF-G^M/)'FQ(1X+$:&YBH?7#JW_E&6_2<&BILAR16YY(: M]PCS_/:\K1L"M+[L7K1!<1I \KMC[1 _TX63O>Q'75NL4<ILG>$U>9 MD.F7_<,/'_?W>!K*2*2/7_;O;X/CVY.+B_V]+&=IQ!*9\B_[J=S_VU__\S]^ M^Z\@^,93KEC.H[V'U[V[R3R-N#J54[[WCZ\WEWO!WL>C7W_Z?/U][_[N9._3 MQT^'P<>_!)]^#H*__I:(]%^_ZA\/+.-[0$2:%7]^V9_D^>S7@X/GY^>CHNSAY\^?#XJWRZ*9 MJ"L(C1X>_./[Y6TXX5,6B%1S)-2T9.+7K'AX*4.6%VQLA;!G+*'_"A;% OTH M./P4'!U^>,FB?>#ZWE[).B43?L/C/?W__7 49//9+"F>L"1X8(F&%603SO, ^CP(638)XD0^ M ^98JFD!,>!9+J:ZXX-XGL\5#]A4JES\7KU]F?$4R(?R4 L8]2@>$BB393S/ M@HCG3"09L*Y ,E$\_K*OZ0T6E&JP?R)':/XZ ^G/Q!2HV#]8ZXN0)>$\*5J\ MA+^KXIK;.]PM)5K^DG,8U)7H+0 G,MSH/ TR6PS!F&4/A3S/L^"1L5D!]( G M>;9X$I2JX+ 2ZS]5C_]Y+E*1\TOQQ*.+)7G'!77':SC.2A@_@+8;F0 9CW?/ M/'GBWV6:3Y;T)^R!)U_V!VF[Y$VBQ[M4E2B0XDU%^W&<<_6_G*ESJ-<+8YH: MWA6N#,&0G>:%G*O>>;'6YB[QX@[(Z%TP-AK=*6X\R]YYL6J2%B=^\-P>ZUJE M)C1K!L*Q"O>D C/YRSZ8VL]%Q_>6@A81OSTSACQ MQCS ,N+G]\.(!B-ZQ8W?#NIQ )U.69?CR?@@OJYN8;OQ(8'!>^EO6 MZR?__#K/1,JS[$1.'X >3>D-#^5C*GX':8X BXB!D*4\:T"*1\=I=+FB[[@D MKRQRD8;)7$<0OTD9/8LDV3*LQOZLC:$Y I/.X-U,RPB\OE"=I(U_H.NFJN'W7'WM H#6XXB_J)!@.JHDXSC?:] M'>?A0C6 4EA[.0(SFS^\XUR] (,G-IO=([ 72<'.\WD!:QR>OOG:[O!O87?6 M(C/'%P?^F@?^&>Q^TVL/%%ZS5VT"@XU6L7/1"5R[^%?Q"C]7H3;:"=@F3S&XMO0$_L0$HT* MI3FHZ> /+O<207)0W3O->E]^,86%N?>CK"T<9>(*O#W\*?MP$2@8PGUQH<] MJH>%T3\'"6?08UOK=&#ME2^6RW2OP<-K,"N[/(B@#<<5T/X^..929]]4CYIY M?*G')+^:%1*9/EYJ@A>R^+H8Q:=S4V:@;74/ 0\LB9B4X4YM$<:ND]D0J>1= MFR/,@9XZ?H?ZO"4!VK49XHB;TIR=VZ&.V9C,[-@*K6"N\UPD>V($)9-U#"8T MJW<*(=:Q1<(]JW.,/-_1!H9[VO<86;YCL &5V>H_SW>T<>$YOS<$;ULF(BHV MABX?9]H]6VXCM7!2K9H;R05UH*E3TNPY.+G_HWW9LV7[^0)3&(@R/#[1G &1%F3@P2 ;:9/$'\' M_O#[V56\B*1=I$_P>:E>&XENK]8#D=^82"]EEEVE9QGHI>=;GN?EINXZVMI+ M]T"2AEEVUD5ZGZZ/FS/HN;R6:=@Z/9#W0Z9ZP%[K31,RO8H+Q5KMFZ@C#5.> M1@:1860<*\7@::&N3B;ZUXOT>"KGJ8X/UU=9SC-V:;N#?=T#?W7D7/_3"_!/ MH">!_!L0425"$,HBK)Y&FP_62EYS):1>9U-:6$YY^?]R6>3L)2PX<0,"?A;' M/#0E;ODAP@.W:Y8F 1K\?P(/A3'9$EO-"Z*9XJ$H!!I^3W@Q&-)H?;>6$16^ MJ@=DI;!L"=)5V$M6E4)Z*;"8SEGQ3K!'H9JOK%>:0T:TQ@5])J\-2U>[Q1T:($$SC/P4>4K!V\[T::M2]^V-T$" MZ<+5L8%64X<$EFO%9TQ$]2Z";34/B'[P7,]JUTH^@8D=?7V]S_1(.0>[/0WU M+O$P%T]-4FC? !V4Y>36 65# W10+J.$KB@;&O" LIBJ:TC2E)\G\OEV$7XS M@+2N[V]_R+E4;5XP?J#VTJ;'O3) . AFR'F4G2LY+;H1/X =6_&+]X;/Y@K< ME8SK<,AT*M/;7(;_:H?84M$CJJOX5&CEDD89'E%S)0K[M]"Q]PXM4,#I?Y_: M6$A!2\ )ZS87[/<:X/%V=J #Y1KJD_O%;KC:GJI>P/ZH0B*FA>7@UHIGO,4<<34K0F]G M+UR%(C,K*6P]/YABD>N%.3/Q6P4\4'FS'!)7,4:CM);W@.%VPF!Z J,I BM# M.^9--?ZBP.J7$O6YPG>.PE++VW%C0/<&& M4LI>!Q[@TR,H)>9UDWO3=(Q%^ M=36:5)H3%^V?R/>H8,<0RX"_D&6"?P;HPV7N@:?VY9BVC@8^S&Z"K[-EE$:."C')#0M^ ;%V'1L(]V$7;3 M8BT:.5U+S<:C1<.E:Z?UDSR.9L0O9!G19XX0FAWTK3WWM!J'LT-&5X)-:YV^ MC@ZAQ@2'30<[$+;!]GS_2QX. 1UJ(M%+&H%#4(DLIQZ2A[4*4WPYV'PFCE*8\3]LF92?_E-R,29:+O]832ZC:' \M[@8?SEYRQ<#J+NZ-O@![)M-9G5!3E?>(7Z0Y5X"K/S[9?G$W^%AI MM?[8M-6@-RY@544'K> O6C2&^,H!M JE6!%]'M8.)5)!2YRI+AU]+TK2X@S5 MQN0G%01T[EN4'TI)C+&F<$W^K8W+0TF<.T"VMZDIB767OK9P "F)MP/4G9-G M>S5E"7'\F[4>6,+2D ?9A/,\"!.692(68P)'#3P;CK@W MN!@MI7V<5E5/434T[&!L5:*#1MOF+H#>UJ/I!+:)E73K.DIJO3M$4V>.J]DW M;F+8T&VN5TS4-^+C8HDF2CI=)W$/-3,PN%BQC#T3.4N*U*9BA\S6D,97\*"? MMC:N-&O9YL(>J5_M)]7K_R@,357\(-DZZ:$51G-Y?QC6=ON@,)C+^\$PG\Z+ M74M%4K;>V*?X!*QP\<17<;)B2P^PW8S,I14?>*-(:,W+DFLF0)PJW=1^TB"^ MH@]4&_=4;U->IM-"/K4?ZKA>D]]&]P=W@0JO7TDN; MGFZG*7;I;20D'N1DGN4P M6RKD2+2I2B$=9LWV 6, FPY37\O'W37&?=[-W82NY^/F%RFC9Y$D!M*W7WM) M(LA9^BCT.0.%E0 R5?J,V)3&!V MR_0D8 RW8JOY1=0\>$F-UL5.PE/^D!>S<.&%%'&VJX=$/&[NF-A&8E79,[J6 M3C&7]$#W=Y%*L/9?6S+=3,7HQ.G_6'4@8Z-OTG:CH_M7\7U63F0H/(8ZOFYD MP80!S 7]4MTN24UE?=&.GN):2A.@']?]Z'V=[#5/%R>GO.1,JC M,Z92T"_96L07W#41-ASCCJWHXSQWK!U+RG)]2\QRTVAUCO)QGBOQ,,]U0/). M6F7C]]LXS=7Z^@E&.D=S*2W3MV-#+PA2RA5LA67VDREM&&^%T68 .1P3XP^, M0ZB84K+FUL*9; N*T5,#]0/%-B1&3P^TC)SV1",JFJ!60>_2Z*\#@#=A'8Z M\B%9>*^:DOIJ\.?6=;3U"A(E-8?#B$P>HJ3G<,"&R"4=0_GAT/659D!):^*0 MMT:W*2E.]!ALS:7$HAKCQ'3D ,0$SK"PQCCY' ?+VRL9H2^@(TQ MG3>$H#:!N6=B4IK9<7";LW@H3>C([K/,,J4TJ>,0VL:#:0_!3K%1B>+=#HS, MOKC0O#Y.21+0>2T&HPZ;?4&IWUTP]Y@@2TF9N[#">5.(=22BCAQ> M!)!KU$2]NU:(V^FXX?&I]5(O8*[.B[>)>/BV-R>659!BR-BA-T ME_Y/=6;N@F[+;;Z.7_&Q#[@3J>,>&_S6/VW9:XBHX64/1P8TZ/6S8GAQ]21" MGMW""#/":*O@8R^ DEE67D]M(+NFQ&X*%).<&:Q'0F7'GB7S^;QX]\F],I(6NB4&?W/#-@];* M&^6=&-K]0\2XUN(@$#^!!$->]S3N@;ZR2_QR'BP[H$]L)WQ<)3\[9,"%:)@X MWQ;PLOLEXTR%.IGYE#_Q1!;IC!7WEMFSB^O.+]+B[D^]ZF$!5+H,^.HZE(19;KP?34,O;L M*M/<,5,7]I$]]J;#.N=PEZ*V@,5&[BBM5YN=)ME-4"DM4*- ]J9X';IW.)%M M2G=F,R!B/IC3ZFH)YV\O#0R?L#2>#/:(N;0.[R,JC4R3$EZ:KSQ;O=JN2V2 MDIKW,#S9H2MJZM?Q9"->>IW2BJ+C\AZE'K.R&Q&6V @K,)3T?=_LZVN]9==$ M#-/Y[\?;\<21,3VCX>XS1*3PF50U73UBB:K7%:AQDV^+^\&.@FP^FR7%$Y9L MW1)69)J"#@QB4(*!2,'J6_"O.J='\,SQYK3^/SSFM6I#4=_I>I_EX4GG.MX[ MX5$1W2ZD4,=+U=,RP1VF*] V]:<)]M&4S>).&YC5N59XJEOJ^#PC^H8]?P=1 M4H(EF_PTK#OA*]):<[+KD+HCP)" *4P>UF#[&V2[-&^'%MZ<7X+E$VT?2K:V*_QXJHV@WPL8!DWGWI '?=Y ;+&898]Q MHQHM1.8$=UPE+_-MQ&,SY<79:( N,4"I4]W5L "L*8RX6I<#DO$F";F&$A&-30=3B$QS'<=6O)R M_9H23T7NWCET:'$ PU6\>M@&UK:ZWTNBBQ,I!9( RY<)9KF"I+V;D?P MT)W [.&[";&'2>SSZIR&&5?@T#/%RY]9,,] N8HTR">\KI0^TV&>EQD6CK/7 M0%\?<]H:%,*H\]7N;K=>W)MQ)]>.+*S.F?D*UD"(08-OA33>4Y',P3?JC'BK M'0^8[]-([P+02Y"K@QL+NI."#AX5JY*Y",6L2&5;W9?2U.E]-4MSIG85Z<$6 MOD=*MG*#VJ\L4(HZN _T=RT)#6"'DH713+G#P^I@K2#7.:[:(Y9I"&9FR3X9 M!S'71G>BWP<+>L!"87EQ=-=<+^T%8)1S1VMN. +&-.B&1M$I9>(LCGF8+[-V M[MC+#7SH9H-$@Y^URINL2T7HM>$>TBDP]'R[N+R[.$ZC\].+BVNNP@[0&IH: M"X&/B[?'T'1MQH/Y5D]M77J^P5"S;X ,RLT^.<[/2XUQNU /&X6M MX#NU3)0O)Q,&VN0B/4M9F!?;LSNRH[E!HERH\MXW2IP*J*AS9P0SK8'VV311 MSOR0>IZ<0S&PYJJ-++?'Y M7?#"SA4F$+V'=S.IF'H-HHK,$)[JE $E,IWF%E77I%3E@;\;EW%L;-%PS<\8 MERB?4?XQD'6*_"]NQ0'9+5-@-R[T$O418W0E+VF"YFM^C*F![54\(EER>97H M=9%FN9HWQ6'L*E- 5][<])WG$QFM3MI"XVNI3@'A<"'/?J4"T;R'8-4N""SETNZ4L2^:QM'"Q<E2%V^#TF*2,W9$#(W2 M4E ;3I=8+J7-**BX;7U_6EN"%*V';KC1[AFE#)M^H".M88KV1C?@K6XJ1:NC MA^%-7X?AX;6O4I':1&SVQ7E=O=]L3TWI&Z56N/JE(CJ>R9\](!D1I1?L&6]+O_.KN[^2[X[L./__;G7VZ_?/?MX?R[3Q\^?0P^ M_!Q\^BD(_M>_)W'Z^[^I_WDD@GXGB4A%\<^_?;_(LM6__?##\_/SGUX>>?(G MQN<_?/KPX<F;KE=P&(EZN$OK]#]V)BMB2Q&FP MI,M'REN25SF&=4+C)4W520G*S[6EM688V^0NY'@\S!]IL/MB2XHU(_4XQW1& M\B3K/LFOQZDE>$OM,:GJ6X\Q"S(:+E+ZIY M?U"\[,-??OSP0T&R9 49E5_+ M@I1E-/CX8R#R1T'_E:M?T2?YO^(U"#52L!VCH-9@B%KZ)O,2B@K": M%JUIFA'Q6!RW7 1S0E8E833)Q/8W07G%?]Q<5_]S\^M_7,0B3)C(.7V0^^5, M?N7WR:/(. FS([H->CC <;\]'?)\T6OYX_&T-S=T2?4#>4QH$\6O&KF@=L=O M+@MVLUO_.L*;VNLP[#GFA(??,2ZEU[]]+R7@\B[Y-[4%:239-<]W4[*YIEH* M-3/.EJ!MPEJGQ$&8+= 1!^M+\WK M^ZC5VE1?:ET1;7[)TDQNZLNDF%JF6M ^ $S M9I![F/_^0X4T:5=,CEB8%S^0- IHL=>D1CUC?%DHT'!A&3C0,"*S$3&]",X3 M^?E(D7"5D'F%2%CY]QZ%U'/%7C@EYRPZ%CSJ_MPG-3GG"KL\/R3Y;TKX91I= MR,6KHJRA:8]47FQVT21-%5S/SRT/!27(M!;N7 M_Z#K6C)KVO5/'ULN67J?2>G_?D'D3$WSK/#LQ6F5N COU#_EI4!6?O5Q2/I=+\YFSYVPA-]F*I/4G1MNZ=UJOXH1^S0]5 M\C<$OFTR"%7\7'*Z.>/U,U?9JG?:KM.0<7GX"N&O8,?G+)=,;ZV]:D"]!J ] MH\J:$C]1*162#2_1$*UKWCNUM_EC$H=7"2/U)%:TZ9VN.SJ/E54JS;Z29?V2 M5S?KG;K[!4V2)J93U:A_RI8D2,L'ZV:QIUSM]O\G]]1^IE/SO*1$LI=&U$+EF/AO:GY2[ M&4 34V:EA9R'VFU8UZ1'JNYIF',Y"1\_/3[$6:5]I*[) %1=OH0+DLYI#4_6 M->N1N@=.E#9QOUX^LJ2"K,J_OZ7G?U@AYCJ<\4D>Q7+429919=^7G*O&HM[< MV)G_^=WX9T$F1^^E;;-2/7MI:U;NILI7"SDV'32 M/A#:C^B@:;RJ0$Q_1H<)Y@ %POL)'3R@:Q*([R_(\=4X-8'H_HH6W5O_$Q#2 MSV@AU;OS@=!^00M-XVJ%WMC]!UFUWHI:)RT4'U:1I,ZX#<6%51PQL#=#H>(3 M3PQ,<5"0^.05H-\?"A"?Q (*&8#"PR>PP-WW4(SXQ!9H. 44(3XIICZ@$XH) MG_BB-R%#]7%\DHO>" W%A4]BT=B*H:#PB2O-=GDH-JSR"9-$9-0*'A$U# 7)0 SL^6:4I M' >*#)^TTA"?!06&3V(QC1W>(OT?.ICX[G6H_W^_D .D5Y:U.X*(BI#'*_6- M@,V"QPW?*](31;Y<2CE$_5[$\[2P"JG,Q3!4!C"Y.L&*R2T94^/*)98_.V2U MDUY(]Q52'(69.ZR0(GAV4/%"_NNXVH7\U3^^D)=XF2^_O.)"&^IJ_SX4;?)H M:6FK^OM M-TI!;AB12O_-B1-M;-5\5=L='4YEV_O!/6;?YSE<:+N^>U_KY6S;4:0P' M6+?J\,5>]I'GZ8#8C5335(BI]3B^(%EK')?_RN.5VD3:TU;3R@&]5TIBIS?Q M$XVN4WGRY_%C0B="T$R*VI M$NUQ2T:^HCQ;WR9$A6Y%NY-VME:Q:9I];- 3$RY%FW8-#7J>&BX$^]$7J.R? M6N5?+OROU3B!5"F9YJ3=/Q46YR(GTI4)]JU@"DVL#$&FP\ MF!!TTTV9"9_ "-M$Z&(=9!J,V-LH3LR2+C+L?%BHY]M:2A]XY9OO%9.]RX F M V@LI_7M794FV__9[J?^\>![6N,>0;-KZRY2UNAU0K4GH8("AIW5837J_9-H M(+1D@U8]3M#(,C2@ PI_*_(9N7W]H2!0P.UHXQ8*0O@ X?MOO^PG;?;1S177D:KB1#.V=I0%/IEVMU[QMUZQKVOT_LZO7SMY>M3EJ_;W4G#B]7JA>W5JMP( M) D>24+2D 9B06GYD&!(Q"*8)>RYW0N)%CXRH&!N@U ON9^RY%Z3;'2^H$M6 M5,Y=OURGX?GY?UW7YQ(U-K9 T-Y?L&4Y=S0I=JM8Q"OQE:7R,*QH1B=S3G=. MI5MY&K1I4!:'=9%K4I[G>W6<55VEXC*I#Y)N:HX$@39PN+G#N%$@B'H^9R*; MSNY)TA"26]O.A>5 BB<)6]'H0=V,+&'S]5T\7]0WA+B,Y0P9NR\-[P( M>*.J<+ND>W6P^=(%],"#0[M:H#ZG@ 7%/GNBI>4M?4%J60X52#Q\F5%4]$@D[<:P_N/3C*S\O[ ]'>H<.XUA<8B%&V& M\)XR[RFSD:*QBYD8AC#@A^@%K)81C1/M^TN:@JU\KOK/VXO&[]7P/4VJW MDI$R,V>(=^4[WW10%1K-WFO!#L:\*VWSR$[;%E\Z&! M\G#;M$I@D+OZ/;K]A)*A8V[&.[^#-\('AH\D,+R]BV#XX/ _!R3\5QZ7#TN; MOL12W7G 8&X= 3Y(^QT&:4_VVV$ZF\BC1N8TE4RZ/MP9UL,":6=?F.3ZFN\9*EG16^L*,PDSO>/N-<3!6CN(A)[4P;@8*,7/TJ)2Q^0#>UW2I@01!]5 MT:A)8-"W=DC_.5L^QFDI#K^5GQK@P#J[R 2H4F3T.0'-/7QV@,\.:&]"]-D! M/CL ;79 E8U'RV*:._C8S).,S>SQU0L?8^EC+*$QE@WR=$5]-:""A!'M^XD] MM!EE E&YT-FPX;N5M;8 H?3;V3S1&%SN/N[$C)&Y##+PX2?./;06=@;8@H,. MO#G3-W&'G%*\ DR]&#;"MT M=*'LON"E,2(?US1P07D3Y]SP$4T_!3,2\^"))#F5Z(DBKKC4MH0!@YL:QQDP MS@E(BP]Y.N60IVH[N^#9@8U=_NO8OJX>4KL/:4IXS*X8IR$16:6%O;GAP-1^ M2\6*AO$LIE'E@H/:CHEF^_XZ&.U;9K,EK&(/-[;SP7M]!._IB\SV4556GOQG MPB.YUKQXNNF9K.HI:&QL@:"O]-F()DA['QM82G23,,R7>2*/=52DE4K);L7I M0HG\3[3,;= Z8XW[(ZE$ZRL"CQH%@K@6'U7KHVH'C3LE8G&5L.>_TV@N;Q%] MQ*FNK9-84QX_%>EMVW=2HRGBOQ_BX6OVL.!Z0+ M$B3BLYSE&R;$V7IS& Y]>(88X8,Y02_B>:H$L8G84+>GO"&F&]S3QW6WQJ&> M@\_62CYFJ9Q7+N^&:FH\7 8)34W'/0:#4MQ\S!@3KX6O@^QKX@^7M1#O!L"EA MIZZE [I+,V19&N\F)H]Q(K7WAI024!]76$[@'8(CJHR6!=#- :([&JK NG@6 MEV;):9Y-9P!CN(9CVQAR1#.AO8+M#.IG XG4TA: ECO8&=1E5N:1JJS+Z0;U M\7FQ_LU[GV4ZBKS+CN9E9JQQ8YR$!LO36Y --AZ,&&&,FQG9?C'B?"]/TX!\ M7ZRJ?9,?$R/:]Y4,;T4#8_UH,1CGZQ0>ZM$C;0YZ9491R*,M>? NWH/Q#\", MOJ !/#0%W8X%20K,+.X:Y=:U*4)AJ*/?\_8UC3I"M[&;-=3#4@O-H8NCV=26 M%?H3>?,(F$B$9AO#Q#L&3Y]#M7^[2[B=MB6^1WC>XQ-R#9Y55!O6KL$)@_C; MS^K"PAF 2']"=TPA48OH#FFC&?MU51Y]5 W*4]G=I#^2$VFDK<$S4H?57/J^ M5SH_3?H7='S'7I0..NYDR5QM8;)&P^YP>0Q&PCI-;D'CW"0@VK^B8RP&$3[H M.(?>9WT \I3.OAW/?J9K;IYRSN*=&G:VB!D ?*ES>, M: K/5;=P4<&HF(HK$BI_1-62-3=T3K4V3TO7='R4(\@;NY#<&%Z=HZ&U(_KW MYBIMM:&ZALZI;GR2LJGY>!%@. $G4OWHAJ7S3%Y$:JH;*E?HFB*@7+N3](W' M23V"4W!'GUCR),7PU_=40WHPH(_/F/49LSYC=A3)1AH1B9D*(QCQ:90>9J)B M8,2FO=*9V?4Y+#Z+KK$FK1:=95.[UUBKFQ:5X;W[R@2KOZT]_F>LL^WPTMZ7\A+O,R7M<\K5OY](-KN M5 !#S-,@PJC1>ZHT[$BNO-$=X<@=4< M82*E#6^5^#D0^6I5+C]) EKDZ151X&2?K[B)" \/,Q:#N$A9#.1,F)HTK'YS M0'M(#W1[8XHWIE0JX>%Q4=]FY=6D6 M"RFF_;%@^>527IUI2,]B5G JEK!Y=?R?<3\'6G;7IT_&\,I)!4U?Y1HTV7.@ MW;R=S;]$.]*7:/W;85W)]F^'^;?#_-MA_NTP[R'Q'I+WY2%IU'.9F6Z)"9\9 MOQK_DUFXB@>.W*]F7Q)&9W/W]3E]?4Y,1\U7K!S9:4!0L1)/5@G<:X!F\P(% M.];:"(YJU]H1=WVNB0_N\,$=O09WF+ELA@_O^"6@A*>JBFL@SV$@%H3OI@T8 MK:$;8L#@BV8R?"S%^XNE>+^.S,UAN*7\7AV%)M]R8WMO!/=&<&\$'[\QT$O+ M7EK&*BT#+Z'AQ>2/'TJ!\I'(Z2IB=^6F+:R1R@ZB[R'. M$KG1K],H?HJCG"0UZZIMYXK6W^)LZ1"8-N%HB4LO.,\:5ZF'8_(YS-.5F*>AKA MO2R0^+"@\IB.4V>JVCA)CQ'9 M='9/DN-WV=_DP]2T>9;EP^N;C18#@1-_31 XZ_TQ3RDDBE8-)M(S36,DW2I&Y?%&R78.\ MVVH,%UAW$NFAS#HY>"7T;/U&:BV4C[T&DD8@SMWGI_S,F7X*PSGS,2-HO+\^ M9@1#S,CX2TM"4P:UXA]"%>=7L.&;NGT,5?-CNP&'(9.V^9F;^MM'EZ?I2TZ=5 M:AI/[BS F8IFAPTB1S$C4S6JK>M4$!W)/>)H[^A#;1L:1&*Q]K&[B' MD@%U-W^.A.V U]4X[G98N:$[ S(-V@7B^PD-_P&F-J!A/5V,E0R>WH2*__1E MQ>W$C?Z"9@O[=&MC1#[=>JB'L&U&E^\G8["D[(_;=Y,R\F+\;G9-[R&3J744 M^$3I4TZ4KLD\VC\"QX0X)YROI7RGK&2:S"UH'QMY6^3EG-,HSH"D0=J[2$VA M,\HE79*\B1!4_U"*OO$XJ4<0IG MIQ#2=4V=)0"I39UG"\:K636L,0KJ 9E+]-LQ,P48(V: H/8F'@,B#HT#*QRG>XS6 ZCTNAXZJWWCFC C M&P(JAY*]'8HA.J'7G3J27 \0IV0MY?^1[-VV-PF&/6R9(1FI0^@B_$R0-MM MAX5GD1FU4TO0L:8&496U\IBA9$GV!?J1L";@$L,]C\/&_/F (A]0=,(!17## MM8-HH4_!9L6#."W"9K.#TP<-&M(.,F3L$( 0'T+T#D.(+F(R3YDR$0@IE7^F M*5O*'^MC="#M+9!UR^6NC=/[,%:/K>H*4>L:.C#XG[,BLIZ7@9&Q^/U,TK58 M$OZ[UBD)[78ZB!"X6M^2N-X1J7'*0+OA0-10A!+0 P..QE*.@!YCQX'AQ.0B MDQ(;?T.EONXZK)Y:;N)@Q@8;N>E M@_MI?$2#CV@P0^PC&FHC&HQ-98,&-HAXGL:S."3R9Q*&*C)1TABL6!)+%B]V M/VQ);(YR,!UQF)"'=E3Y^(=W&/\@956U-^2ND3^).**EU'JK=LBZ_-\Z\WCK M_@Y,M)/=*;C=[/T&/U=S!Q9%L2G]^ACV2C^N2F["(/9>3P'<_"9L>@Y3E1I\>LT(^D\EL)I$3,N MCO]=$EV#O?4X+BHT+%O^2R1@<0?$-S)PB>Y%HP#EV^AN8.$'PA_'>:*0WRGH8YEZH#U1_,Y@X. M4'RESP>2%F>I_#$LG\$P.5YMAW& ^(B2!C&TH;4+^CE;27%RK6IM9Y+)*^%K M5507!ZV4:7<'".^HH(2'2KJ\H$\T805]FQ"DG MNV[O5#<:?>@6Z&[!%"$SHK M[^;Q;IXQN7F:> $SMXRBPP@@G,&8/CI?N!DT MN!5NV)@4ZT MV>&&C1"P/@N&\CL0K:57UWI :ZB# ?%:>N7).EXC[PX0JZ7G M@*QCA1D2@2#_BA1D.\\/$/3/6$&;>_. B']!BAAJCH7*&ECEJ!86 "ADK/(5 MS%L 18E5N&IGR86BQB9,=0QV@<+&*E5U].I"X6,5LGIWWT(G"*MDULT!-V@0 M:%$/ZE/ 2ZU(_G>G%@7%=6SZ,!YDJ $K7<')\?&>IQSO::]"")G/N:1'[:/I M;&-,*&R:38Y#H[[>>7B:SD/(1C'?$:-PL.E@>;^:]ZMYO]K)^]5J6 #K=$D. M+R[_&(A\M2H7GB3!(TE4#>U +"C- I)&04C$(I@E[/FPO&H[>=K*MP84N"W2 MZR5R+Y&W#\!L'7J)0A8/%S3*$SJ=*1_ E3PM]P>G:I]&*D "9SC%<3S5JOS EE"S]3,>R3'NC=>C#+?(C,%" MNCM$R'3GZ2K/)#N9+%76^Q_%!;^).#":!9N?\/84;T_Q]A1O3_'V%&]/>4_V ME'82!;J(WF:@INHL[5L)0JCB]PUP=Q2?4,7OPO';%_^11?<:[(!&O1; M=,&\)M@ZV&6&-W__.2"AY*ZB^(9H9];6CC&@N1I AS=#>S.T@>%GDUCRAV39 MD=QF\2S>1L1-U$[C\E]I=!.3QS@IHISEW_*E>I+4R#YD]2O>..*-(]XXXHTC MWCCBC2/OTSC2PW4ZO%S^4S C,0^>2))3.3-$J0Y%S'D[$1TZW(#2NAE)7G#W M@GMSL4NYH7Y5^^G@='\I=U8T3>]4,B*/T_D9$;'XEK)'07F1J7>=KO),L8TT ME+T* TQC'